0.28076172.12042316.html.plaintext.txt	0	apolipoprotein e apoe isoform dependent lipid release astrocyte prepared human apoenum apoenum knock mouse jian sheng gong mariko kobayashi hideki hayashi kun zou naoya sawamura shinobu c
0.28076172.12042316.html.plaintext.txt	1	fujita katsuhiko yanagisawa makoto michikawa
0.28076172.12042316.html.plaintext.txt	2	department dementia research national institute longevity science num num gengo morioka obu aichi num num japan organization pharmaceutical safety research japan tokyo num num japan mitsubishi kagaku institute life science num minamiooya machida tokyo num num japan japan society promotion science jsps tokyo num num japan
0.28076172.12042316.html.plaintext.txt	3	received publication april num num revised form may num num
0.28076172.12042316.html.plaintext.txt	4	previous epidemiological study show elevated serum cholesterol level risk factor development alzheimers disease adnum num num statin therapy reduces frequency ad num dementia num
0.28076172.12042316.html.plaintext.txt	5	decreased level cellular cholesterol shown reduce production vitro num vivo num
0.28076172.12042316.html.plaintext.txt	6	previous study also shown association cholesterol accumulation mature senile plaque num neurofibrillary tangle bearing neuron num
0.28076172.12042316.html.plaintext.txt	7	additionally recent study num suggested increased cholesterol level membrane facilitates amyloid fibril formation formation gmnum ganglioside bound putative endogenous seed
0.28076172.12042316.html.plaintext.txt	8	finding suggest increased cellular cholesterol level induce high amyloid protein production subsequent ad development
0.28076172.12042316.html.plaintext.txt	9	however several study num num shown opposing evidence indicating cholesterol level serum cell membrane brain cerebrospinal fluid decreased ad patient compared control
0.28076172.12042316.html.plaintext.txt	10	previous study shown increased dietary cholesterol level reduce secretion num increased cellular cholesterol level inhibit mediated cell toxicity num num
0.28076172.12042316.html.plaintext.txt	11	hand effect cellular cholesterol metabolism also investigated num
0.28076172.12042316.html.plaintext.txt	12	recent study shown monomeric oligomeric affect cholesterol metabolism num eventually reduces cellular cholesterol level num
0.28076172.12042316.html.plaintext.txt	13	addition cholesterol deficiency shown promote tau phosphorylation vitro num num vivo num
0.28076172.12042316.html.plaintext.txt	14	finding suggest involvement cholesterol pathogenesis ad dualistic
0.28076172.12042316.html.plaintext.txt	15	elevated level cellular cholesterol contribute ad development elevating secretion however increasing amount oligomerized reduces cellular cholesterol level turn may promote progression ad pathology
0.28076172.12042316.html.plaintext.txt	16	animal mouse expressing human apoenum place mouse apoe generated gene targeting technique taking advantage homologous recombination embryonic stem cell knock described previously num
0.28076172.12042316.html.plaintext.txt	17	apoenum knock mouse produced manner except transgene carried apoenum cdna place apoenum cdna
0.28076172.12042316.html.plaintext.txt	18	detail generation apoenum mouse described elsewhere
0.28076172.12042316.html.plaintext.txt	19	postnatal day num mouse posse homozygous num numnum num numnum allele correctly expressing human apoenum apoenum protein respectively used study
0.28076172.12042316.html.plaintext.txt	20	cell culture highly astrocyte rich culture prepared according method described previously num num
0.28076172.12042316.html.plaintext.txt	21	brief brain postnatal day num mouse removed anesthesia
0.28076172.12042316.html.plaintext.txt	22	cerebral cortex mouse brain dissected freed meninges diced small piece cortical fragment incubated num
0.28076172.12042316.html.plaintext.txt	23	num trypsin num mgml dnase phosphate buffered saline pb num
0.28076172.12042316.html.plaintext.txt	24	num mm khnumponum num mm nacl num
0.28076172.12042316.html.plaintext.txt	25	fragment dissociated single cell pipetting
0.28076172.12042316.html.plaintext.txt	26	dissociated cell seeded num cmnum dish cell density num x num dmem containing num fbs
0.28076172.12042316.html.plaintext.txt	27	num day incubation vitro astrocyte monolayer trypsinized num
0.28076172.12042316.html.plaintext.txt	28	num reseeded onto num well dish
0.28076172.12042316.html.plaintext.txt	29	astrocyte rich culture maintained dmem containing num fbs use
0.28076172.12042316.html.plaintext.txt	30	neuron rich culture prepared rat cerebral cortex described previously num
0.28076172.12042316.html.plaintext.txt	31	dissociated cell suspended feeding medium plated onto poly d lysine coated num well plate cell density num x numcmnum
0.28076172.12042316.html.plaintext.txt	32	feeding medium consisted dulbeccos modified eagle medium nutrient mixture dmemf num numnum nnum supplement
0.28076172.12042316.html.plaintext.txt	33	num cultured cell identified neuron immunocytochemical analysis using monoclonal antibody microtubule associated protein num neuron specific marker day num culture num
0.28076172.12042316.html.plaintext.txt	34	quantification released intracellular cholesterol phosphatidylcholines astrocyte num well plate washed dmem three time incubated num ml dmem num num num day num degree c
0.28076172.12042316.html.plaintext.txt	35	conditioned culture medium removed processed lipid extraction
0.28076172.12042316.html.plaintext.txt	36	astrocyte monolayer washed pb three time air dried room temperature
0.28076172.12042316.html.plaintext.txt	37	lipid conditioned culture medium extracted according method reported previously num num modification
0.28076172.12042316.html.plaintext.txt	38	num ml conditioned culture medium transferred clean glass tube containing num
0.28076172.12042316.html.plaintext.txt	39	num ml chloroformmethanol numnum vv
0.28076172.12042316.html.plaintext.txt	40	organic phase separated aqueous phase washed twice vigorous mixing num ml water re separated aqueous phase centrifugation dried nnum gas
0.28076172.12042316.html.plaintext.txt	41	extraction intracellular lipid dried cell incubated hexaneisopropyl alcohol numnum vv num h room temperature
0.28076172.12042316.html.plaintext.txt	42	solvent plate removed dried nnum gas
0.28076172.12042316.html.plaintext.txt	43	organic phase redissolved num microl chloroform num microl sample transferred onto num well polypropylene plate corning glass dried air flow
0.28076172.12042316.html.plaintext.txt	44	dried lipid dissolved num microl isopropyl alcohol content cholesterol phospholipid determined using cholesterol wako osaka japan phospholipid kyowa medix tokyo japan determiner kit respectively
0.28076172.12042316.html.plaintext.txt	45	determination amount numcacetate incorporated cholesterol phosphatidylcholine astrocyte cultured dmem plus num fbs washed pb three time recultured dmem
0.28076172.12042316.html.plaintext.txt	46	culture treated num kbqml numcacetate perkinelmer life science num num num day
0.28076172.12042316.html.plaintext.txt	47	indicated time point culture medium quickly removed cell washed three time cold pb dried room temperature
0.28076172.12042316.html.plaintext.txt	48	num ml conditioned culture medium transferred clean glass tube containing num
0.28076172.12042316.html.plaintext.txt	49	num ml chloroformmethanol numnum vv
0.28076172.12042316.html.plaintext.txt	50	extraction intracellular lipid dried cell incubated hexaneisopropyl alcohol numnum vv num h room temperature
0.28076172.12042316.html.plaintext.txt	51	solvent plate removed dried nnum gas
0.28076172.12042316.html.plaintext.txt	52	organic phase redissolved num microl chloroform num microl sample spotted activated silica gel high performance thin layer chromatography plate merck lipid separated sequential one dimensional chromatography using chloroformmethanolacetic acidwater numnumnumnum vv followed another run hexanediethyl etheracetic acid numnumnum
0.28076172.12042316.html.plaintext.txt	53	numccholesterol numcphosphatidylcholine used standard
0.28076172.12042316.html.plaintext.txt	54	chromatography plate exposed radiosensitive film lipid visualized quantified basnum fuji film tokyo japan
0.28076172.12042316.html.plaintext.txt	55	determination protein concentration astrocyte cultured num ml distilled water containing num
0.28076172.12042316.html.plaintext.txt	56	num naoh num h num microl sample processed determination protein concentration using bca kit
0.28076172.12042316.html.plaintext.txt	57	density gradient ultracentrifugation incubation dmem num day astrocyte culture medium collected centrifuged numnum x g num min num ml plastic tube exclude cell debris adjusted discontinuous sucrose gradient
0.28076172.12042316.html.plaintext.txt	58	discontinuous sucrose gradient prepared num x num mm ultracentrifuge tube ultraclear beckman instrument palo alto ca bottom top num ml sucrose density num
0.28076172.12042316.html.plaintext.txt	59	sample sucrose gradient centrifuged swnum ti swing rotor beckman instrument palo alto ca num degree c num h numnum x gav
0.28076172.12042316.html.plaintext.txt	60	following density gradient centrifugation num num
0.28076172.12042316.html.plaintext.txt	61	num ml fraction collected micropipette top gradient
0.28076172.12042316.html.plaintext.txt	62	density fraction determined measuring weight num microl fraction using micropipette
0.28076172.12042316.html.plaintext.txt	63	final fraction stirred resuspend pellet
0.28076172.12042316.html.plaintext.txt	64	lipid content fraction determined described
0.28076172.12042316.html.plaintext.txt	65	density fraction determined using density meter dmanumn anton paar graz austria
0.28076172.12042316.html.plaintext.txt	66	immunoblot analysis sample fraction dissolved sampling buffer consisting num mm tris hcl ph num
0.28076172.12042316.html.plaintext.txt	67	num num glycerol num sd num mercaptoethanol num
0.28076172.12042316.html.plaintext.txt	68	num bromphenol blue analyzed num
0.28076172.12042316.html.plaintext.txt	69	num tristricine sd page reported previously num
0.28076172.12042316.html.plaintext.txt	70	separated protein transferred onto immobilon membrane semidry electrophoretic transfer apparatus nihon eido tokyo japan using transfer buffer num
0.28076172.12042316.html.plaintext.txt	71	num m glycine num methanol
0.28076172.12042316.html.plaintext.txt	72	blot probed num h room temperature goat anti apoe polyclonal antibody abnum numnumnum chemicon temecula ca goat anti apoj antibody num numnum rockland gilbertsville pa
0.28076172.12042316.html.plaintext.txt	73	band detection carried ecl kit amersham bioscience
0.28076172.12042316.html.plaintext.txt	74	determination concentration apoe released culture medium signal corresponding apoe sample immunoblot membrane quantified densitometry nih image software varying concentration synthetic apoe protein wako tokyo japan standard
0.28076172.12042316.html.plaintext.txt	75	standard signal demonstrated linear range apoe protein amount num num microg per lane
0.28076172.12042316.html.plaintext.txt	76	apoe concentration conditioned culture medium within range used analysis
0.28076172.12042316.html.plaintext.txt	77	detection oligomeric apoe protein conditioned culture medium western blot analysis performed nonreducing condition
0.28076172.12042316.html.plaintext.txt	78	aliquot conditioned culture medium apoenum apoenum expressing astrocyte mixed volume num x nonreducing laemmli buffer consisting num mm tris hcl ph num
0.28076172.12042316.html.plaintext.txt	79	num num glycerol num sd num
0.28076172.12042316.html.plaintext.txt	80	num bromphenol blue mercaptoethanol analyzed western blotting described
0.28076172.12042316.html.plaintext.txt	81	size determination lipoprotein particle conditioned culture medium astrocyte expressing human apoenum apoenum concentrated num fold using centriprep ymnum tube millipore bedford ma centrifugation ja num rotor using beckman j numi ultracentrifuge num degree c num min numnum x g
0.28076172.12042316.html.plaintext.txt	82	centrifugation sample subjected density gradient ultracentrifugation discontinuous sucrose gradient described
0.28076172.12042316.html.plaintext.txt	83	two milliliter hdl fraction fraction number num centricon ymnum tube millipore concentrated num microl ja num
0.28076172.12042316.html.plaintext.txt	84	num rotor using beckman j numi ultracentrifuge num degree c num h numnum x g
0.28076172.12042316.html.plaintext.txt	85	concentrated conditioned culture medium subjected nondenaturing num num tbe ph num
0.28076172.12042316.html.plaintext.txt	86	num buffered page evaluate particle size heterogeneity apoe fraction
0.28076172.12042316.html.plaintext.txt	87	ten microliters apoe lipid particle unboiled nonreduced containing num sucrose num
0.28076172.12042316.html.plaintext.txt	88	num bromphenol blue applied onto num num gradient gel
0.28076172.12042316.html.plaintext.txt	89	native high molecular weight protein standard amersham bioscience used size standard num
0.28076172.12042316.html.plaintext.txt	90	electrophoresis performed num degree c prerun num min num v entry sample stacking gel followed migration num v num h
0.28076172.12042316.html.plaintext.txt	91	separated apoe migrated lipid apoe complex transferred onto immobilon membrane semidry electrophoretic transfer apparatus nihon eido tokyo japan using transfer buffer num
0.28076172.12042316.html.plaintext.txt	92	num m glycine num methanol
0.28076172.12042316.html.plaintext.txt	93	separated protein probed num h room temperature goat anti apoe polyclonal antibody abnum chemicon temecula ca numnum
0.28076172.12042316.html.plaintext.txt	94	apoe protein detected using ecl kit amersham bioscience
0.28076172.12042316.html.plaintext.txt	95	mean apoe lipid particle size obtained based migration size standard stained num
0.28076172.12042316.html.plaintext.txt	96	num ponceau sigma num acetic acid distilled water
0.28076172.12042316.html.plaintext.txt	97	apoenum apoenum expressing astrocyte became confluent num day replating appeared morphologically comparable
0.28076172.12042316.html.plaintext.txt	98	time dependent curve release cholesterol phospholipid cultured astrocyte expressing human apoenum apoenum shown fig
0.28076172.12042316.html.plaintext.txt	99	found amount cholesterol fig
0.28076172.12042316.html.plaintext.txt	100	numb released cell genotype increased time dependent manner amount lipid released apoenum expressing astrocyte significantly higher apoenum expressing astrocyte day num num compared basis cellular protein
0.28076172.12042316.html.plaintext.txt	101	contrast level numcacetate incorporation cholesterol phosphatidylcholine apoenum apoenum expressing astrocyte similar time point fig
0.28076172.12042316.html.plaintext.txt	102	similarly total amount cellular cholesterol phospholipid genotype astrocyte similar time point fig
0.28076172.12042316.html.plaintext.txt	103	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	104	characterization lipid metabolism cultured astrocyte prepared human apoenum apoenum knock mouse brain
0.28076172.12042316.html.plaintext.txt	105	astrocyte rich culture prepared described experimental procedure
0.28076172.12042316.html.plaintext.txt	106	three week cultured astrocyte washed three time dmem incubated dmem
0.28076172.12042316.html.plaintext.txt	107	time point indicated lipid released medium intracellular lipid extracted analyzed described experimental procedure b e f
0.28076172.12042316.html.plaintext.txt	108	determination synthesis rate cholesterol phospholipid cultured astrocyte washed three time dmem followed incubation numcacetate num h num degree c
0.28076172.12042316.html.plaintext.txt	109	cell washed cold pb three time amount numcacetate incorporated cholesterol phosphatidylcholine determined described experimental procedure c d
0.28076172.12042316.html.plaintext.txt	110	amount cholesterol phospholipid b apoenum expressing astrocyte significantly greater apoenum expressing astrocyte respectively significant difference cellular cholesterolphospholipids concentration e f rate cholesterolphosphatidylcholine synthesis c d apoenum apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	111	data mean plus minus
0.28076172.12042316.html.plaintext.txt	112	num versus apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	113	six independent experiment show similar result
0.28076172.12042316.html.plaintext.txt	114	next determined amount apoenum apoenum released culture medium
0.28076172.12042316.html.plaintext.txt	115	western blot analysis conditioned culture medium apoenum apoenum expressing astrocyte culture day num num num show total amount apoe released culture medium apoenum apoenum expressing astrocyte increased culture time fig
0.28076172.12042316.html.plaintext.txt	116	densitometric analysis signal show comparative amount apoe released apoenum apoenum expressing astrocyte fig
0.28076172.12042316.html.plaintext.txt	117	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	118	amount apoe protein released conditioned culture medium apoenum apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	119	astrocyte rich culture prepared described experimental procedure
0.28076172.12042316.html.plaintext.txt	120	experiment cell washed three time dmem cultured dmem
0.28076172.12042316.html.plaintext.txt	121	time point indicated lipid released medium extracted analyzed described experimental procedure
0.28076172.12042316.html.plaintext.txt	122	aliquot num microl sample subjected immunoblot analysis using polyclonal anti apoe antibody abnum primary antibody
0.28076172.12042316.html.plaintext.txt	123	intensity band quantified densitometric analysis using nih imaging software macintosh b
0.28076172.12042316.html.plaintext.txt	124	amount apoe released culture medium apoenum expressing astrocyte similar apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	125	four independent experiment show similar result
0.28076172.12042316.html.plaintext.txt	126	characteristic lipid particle released serum free medium cultured astrocyte examined
0.28076172.12042316.html.plaintext.txt	127	result density gradient ultracentrifugation cultured medium apoenum apoenum expressing astrocyte shown fig
0.28076172.12042316.html.plaintext.txt	128	num indicate lipid distribution sample contains two peak
0.28076172.12042316.html.plaintext.txt	129	show cholesterol phospholipid distributed similarly fraction density num
0.28076172.12042316.html.plaintext.txt	130	also show smaller amount cholesterol phospholipid distributed fraction density num
0.28076172.12042316.html.plaintext.txt	131	result show major part cholesterol phospholipid present lighter density fraction num num minor part lipid present heavier density fraction num num density corresponded hdl
0.28076172.12042316.html.plaintext.txt	132	next performed immunoblot analysis fraction using anti apoe anti apoj antibody
0.28076172.12042316.html.plaintext.txt	133	apoenum apoenum detected mainly fraction num num sample conditioned culture medium apoenum apoenum expressing astrocyte consistent major peak lipid distribution shown fig
0.28076172.12042316.html.plaintext.txt	134	contrast apoj sample conditioned culture medium apoenum apoenum expressing astrocyte detected fraction num num distinct containing apoe fig
0.28076172.12042316.html.plaintext.txt	135	distribution apoe apoj across fraction sample quantified densitometric analysis shown fig
0.28076172.12042316.html.plaintext.txt	136	numc indicating difference distribution apoe apoj
0.28076172.12042316.html.plaintext.txt	137	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	138	density gradient analysis lipid particle released astrocyte
0.28076172.12042316.html.plaintext.txt	139	three week cultured astrocyte plated num well dish maintained dmem containing num fbs num microgml cholesterol
0.28076172.12042316.html.plaintext.txt	140	astrocyte rinsed three time fresh dmem incubated dmem num day
0.28076172.12042316.html.plaintext.txt	141	culture medium collected centrifuged numnum x g num min exclude cell debris
0.28076172.12042316.html.plaintext.txt	142	supernatant collected subjected initial discontinuous density gradient prepared sucrose solution described experimental procedure
0.28076172.12042316.html.plaintext.txt	143	centrifugation fraction collected analyzed cholesterol phospholipid b content
0.28076172.12042316.html.plaintext.txt	144	density fraction also determined using density meter dmanumn
0.28076172.12042316.html.plaintext.txt	145	apoenum ast apoenum expressing astrocyte apoenum ast apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	146	six independent experiment showed similar result
0.28076172.12042316.html.plaintext.txt	147	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	148	distribution apoenum apoenum across fraction separated density gradient ultracentrifugation
0.28076172.12042316.html.plaintext.txt	149	twelve fraction obtained culture medium apoenum apoenum expressing astrocyte described fig
0.28076172.12042316.html.plaintext.txt	150	num used determination distribution apoe apoj
0.28076172.12042316.html.plaintext.txt	151	aliquot num microl fraction mixed volume sample buffer subjected sd page
0.28076172.12042316.html.plaintext.txt	152	separated protein culture medium apoenum apoenum expressing astrocyte b immunoblotted anti apoe antibody anti apoj antibody
0.28076172.12042316.html.plaintext.txt	153	determine distribution pattern apoe apoj across fraction immunoblot membrane subjected scanning intensity band determined densitometric analysis using computer software c
0.28076172.12042316.html.plaintext.txt	154	apoenum ast apoenum expressing astrocyte apoenum ast apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	155	six independent experiment show similar result
0.28076172.12042316.html.plaintext.txt	156	addition found neuron synthesize secrete apoj form hdl like particle without secretion apoe characterized apoj mediated lipid release neuron compare astrocyte
0.28076172.12042316.html.plaintext.txt	157	apoj mediated lipid release conditioned medium cultured neuron found distributed across fraction density num
0.28076172.12042316.html.plaintext.txt	158	num gml similar apoj mediated lipid release astrocyte culture fig
0.28076172.12042316.html.plaintext.txt	159	distribution peak apoj fig
0.28076172.12042316.html.plaintext.txt	160	numc across fraction density found identical num
0.28076172.12042316.html.plaintext.txt	161	result show apoj containing lipoprotein conditioned medium cultured neuron astrocyte heavier generated apoe conditioned medium cultured astrocyte characteristic apoj containing lipoprotein generated neuron astrocyte examined study comparable
0.28076172.12042316.html.plaintext.txt	162	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	163	comparison distribution pattern apolipoproteins lipid conditioned medium cultured astrocyte neuron
0.28076172.12042316.html.plaintext.txt	164	density gradient ultracentrifugation conditioned culture medium neuron performed obtain num fraction
0.28076172.12042316.html.plaintext.txt	165	neuron cultured serum free nnum supplemented dmemf num medium nnum medium num day washed fresh dmem incubated nnum medium another num day
0.28076172.12042316.html.plaintext.txt	166	culture medium centrifuged numnum x g num min supernatant collected subjected initial discontinuous density gradient analysis using sucrose solution described experimental procedure
0.28076172.12042316.html.plaintext.txt	167	centrifugation fraction collected analyzed cholesterol phospholipid content
0.28076172.12042316.html.plaintext.txt	168	aliquot num microl fraction mixed volume sample buffer subjected sd page
0.28076172.12042316.html.plaintext.txt	169	separated protein immunoblotted anti apoe antibody anti apoj antibody
0.28076172.12042316.html.plaintext.txt	170	apoe signal detected conditioned culture medium neuron
0.28076172.12042316.html.plaintext.txt	171	intensity apoj signal detected western blotting determined densitometric analysis described experimental procedure
0.28076172.12042316.html.plaintext.txt	172	comparison result distribution apoenum lipid across fraction conditioned culture medium astrocyte used
0.28076172.12042316.html.plaintext.txt	173	value parameter expressed term density fraction x axis
0.28076172.12042316.html.plaintext.txt	174	distribution apoenum apoj across density conditioned culture medium astrocyte apoj conditioned culture medium neuron shown
0.28076172.12042316.html.plaintext.txt	175	distribution cholesterol phospholipid astrocyte culture medium shown open circle b c neuronal culture medium shown closed circle b c
0.28076172.12042316.html.plaintext.txt	176	astro cm conditioned culture medium astrocyte neuron cm conditioned culture medium neuron
0.28076172.12042316.html.plaintext.txt	177	result indicate apoe lipid complex isoform dependent stoichiometry lipid apoe
0.28076172.12042316.html.plaintext.txt	178	thus next determined molar weight ratio cholesterol phospholipid apoe
0.28076172.12042316.html.plaintext.txt	179	quantification apoe given fraction carried western blot analysis followed densitometric analysis using recombinant human apoenum apoenum standard
0.28076172.12042316.html.plaintext.txt	180	shown table molar ratio cholesterol apoe apoenum lipid particle num
0.28076172.12042316.html.plaintext.txt	181	num fold greater apoenum lipid particle
0.28076172.12042316.html.plaintext.txt	182	hand weight ratio phospholipid apoe apoenum lipid particle num
0.28076172.12042316.html.plaintext.txt	183	num fold greater apoenum lipid particle
0.28076172.12042316.html.plaintext.txt	184	value comparable difference amount lipid released apoenum apoenum expressing astrocyte fig
0.28076172.12042316.html.plaintext.txt	185	view table table molar weight ratio cholesterol phospholipid apoe associated lipid complex released cultured medium culture medium astrocyte expressing human apoenum apoenum changed dmem without serum
0.28076172.12042316.html.plaintext.txt	186	culture incubated num day conditioned medium culture collected
0.28076172.12042316.html.plaintext.txt	187	conditioned culture medium fractionated density gradient ultracentrifugation amount cholesterol phospholipid hdl fraction fraction number num determined described experimental procedure
0.28076172.12042316.html.plaintext.txt	188	amount apoe fraction determined quantitative western blot analysis described experimental procedure
0.28076172.12042316.html.plaintext.txt	189	result show ability apoenum form lipid particle greater apoenum indicating lipid particle generated stable form apoenum le number apoe molecule apoenum
0.28076172.12042316.html.plaintext.txt	190	determined compared size particle associated apoenum apoenum
0.28076172.12042316.html.plaintext.txt	191	size apoe lipid particle hdl fraction num analyzed nondenaturing gradient gel electrophoresis
0.28076172.12042316.html.plaintext.txt	192	sample conditioned culture medium apoenum apoenum expressing astrocyte separated electrophoresis subsequently analyzed apoe western blotting fig
0.28076172.12042316.html.plaintext.txt	193	two population prominent apoe lipid particle diameter num
0.28076172.12042316.html.plaintext.txt	194	num nm present fraction num conditioned culture medium apoenum apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	195	equivalent amount aliquot used western blot analysis anti apoj antibody signal detected data shown
0.28076172.12042316.html.plaintext.txt	196	apoe lipid particle size determined calculation size band based size standard
0.28076172.12042316.html.plaintext.txt	197	particle size apoenum expressing astrocyte similar apoenum expressing astrocyte table ii
0.28076172.12042316.html.plaintext.txt	198	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	199	native nondenaturing gradient gel electrophoresis apoenum apoenum expressing astrocyte lipoprotein particle followed western blot analysis
0.28076172.12042316.html.plaintext.txt	200	apoe rich fraction num conditioned culture medium apoenum apoenum expressing astrocyte nondenaturing nonreducing condition electrophoresed nondenaturing num num tbe gradient gel followed western blot analysis using anti apoe antibody
0.28076172.12042316.html.plaintext.txt	201	amersham bioscience native high molecular weight standard used hydrated diameter assessment
0.28076172.12042316.html.plaintext.txt	202	lane num num sample fraction num different conditioned culture medium apoenum expressing astrocyte lane num num sample fraction num different conditioned culture medium apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	203	four independent experiment showed similar result
0.28076172.12042316.html.plaintext.txt	204	view table table ii particle size apoe lipid complex conditioned culture medium mouse astrocyte expressing human apoenum apoenum conditioned culture medium astrocyte expressing human apoenum apoenum concentrated num fold using centriprep num millipore bedford ma prior fractionation
0.28076172.12042316.html.plaintext.txt	205	two milliliter hdl fraction fraction number num concentrated num microl using centricon ymnum millipore
0.28076172.12042316.html.plaintext.txt	206	sample electrophoresed nondenaturing num num gradient gel separated protein transferred onto polyvinylidene difluoride membrane millipore probed anti apoe antibody abnum
0.28076172.12042316.html.plaintext.txt	207	num apoe associated hdl like particle visualized separated band size determined comparison migration standard protein known diameter hmw calibration kit amersham bioscience
0.28076172.12042316.html.plaintext.txt	208	significant difference size lipid particle obtained apoenum apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	209	suggested disulfide linked dimeric apoa ii exhibit stronger ability promote lipid release monomeric apoa ii increased number helical segment num
0.28076172.12042316.html.plaintext.txt	210	apoenum contains cysteine residue num apoenum higher ability apoenum promote lipid release may caused increased number helical segment due formation disulfide linked dimer
0.28076172.12042316.html.plaintext.txt	211	examine possibility performed immunoblot analysis conditioned culture medium apoenum apoenum expressing astrocyte reducing nonreducing condition
0.28076172.12042316.html.plaintext.txt	212	absence mercaptoethanol conditioned culture medium apoenum expressing astrocyte contained oligomers mainly dimer le amount tetramers addition monomer whereas apoenum expressing astrocyte contained monomer fig
0.28076172.12042316.html.plaintext.txt	213	obviously band representing apoenum dimer higher expected one mr numnum
0.28076172.12042316.html.plaintext.txt	214	known serum apoenum form homodimers migrate anomalously sd gel nonreducing condition num may also case apoenum dimer conditioned culture medium
0.28076172.12042316.html.plaintext.txt	215	oligomers found conditioned culture medium apoenum expressing astrocyte found monomer sample incubated num mercaptoethanol fig
0.28076172.12042316.html.plaintext.txt	216	demonstrate apoe isoform dependent lipid release cultured astrocyte prepared apoenum apoenum knock mouse
0.28076172.12042316.html.plaintext.txt	217	although found apoe isoform dependent difference size apoenum apoenum lipid particle total amount released apoe apoenum apoenum astrocyte apoenum specific enhancement lipid release cell observed
0.28076172.12042316.html.plaintext.txt	218	result indicate apoenum higher ability generate apoe lipid particle le number apoe molecule per particle apoenum suggesting apoenum expressing astrocyte could supply cholesterol neuron apoenum expressing astrocyte thereby supporting neuronal plasticity promoting neuronal regeneration
0.28076172.12042316.html.plaintext.txt	219	reported apolipoproteins multiple helix segment num num amino acid residue hydrophobic hydrophilic residue aligned opposite side axis induce cholesterol efflux cell added culture medium num num num
0.28076172.12042316.html.plaintext.txt	220	apoe one apolipoproteins effect apoe cholesterol release examined various cell system num num
0.28076172.12042316.html.plaintext.txt	221	apolipoprotein mediated cholesterol release result generation pre hdl contains apolipoproteins cellular cholesterol phosphatidylcholine
0.28076172.12042316.html.plaintext.txt	222	recent study num num demonstrated hdl like particle association exogenous endogenous apoe also generated cultured medium central nervous system cell astrocyte neuron
0.28076172.12042316.html.plaintext.txt	223	addition found addition exogenous apoe promotes lipid release central nervous system cell generating hdl like particle apoe isoform dependent manner num
0.28076172.12042316.html.plaintext.txt	224	consistent previous finding using exogenous apoe present study also show amount lipid released apoenum apoenum expressing astrocyte apoe isoform dependent order potency apoenum apoenum
0.28076172.12042316.html.plaintext.txt	225	however mechanism underlying isoform dependent cholesterol release remains undetermined
0.28076172.12042316.html.plaintext.txt	226	therefore next question addressed mechanism underlying apoe isoform dependent cholesterol release
0.28076172.12042316.html.plaintext.txt	227	found amount lipid released apoenum expressing astrocyte num
0.28076172.12042316.html.plaintext.txt	228	num fold greater apoenum expressing astrocyte whereas amount apoenum released similar apoenum
0.28076172.12042316.html.plaintext.txt	229	one possible explanation may particle contains equal amount apoe protein however particle containing apoenum contain num
0.28076172.12042316.html.plaintext.txt	230	num fold greater amount lipid containing apoenum
0.28076172.12042316.html.plaintext.txt	231	another possible explanation may particle contains equal amount lipid apoenum containing particle contain lower number apoe molecule apoenum containing particle
0.28076172.12042316.html.plaintext.txt	232	implies apoenum ability form lipid particle lower number apoe molecule apoenum thus generate num
0.28076172.12042316.html.plaintext.txt	233	num fold greater number apoe lipid particle apoenum number apoe molecule
0.28076172.12042316.html.plaintext.txt	234	two possibility experiment favor latter shown fig
0.28076172.12042316.html.plaintext.txt	235	num table ii size particle conditioned culture medium apoenum apoenum expressing astrocyte similar
0.28076172.12042316.html.plaintext.txt	236	apoe isoform dependent difference association lipoprotein particle may explained term mechanism underlying apoe isoform specific formation apoe oligomers apoenum protein form dimer apoenum
0.28076172.12042316.html.plaintext.txt	237	difference may apoenum cysteine position num n terminal domain whereas apoenum arginine position
0.28076172.12042316.html.plaintext.txt	238	previous study shown number length amphiphilic helix responsible determining ability given apolipoprotein promote lipid release num num num
0.28076172.12042316.html.plaintext.txt	239	interestingly human apoa ii known form disulfide linked dimer exhibit stronger ability promote lipid release monomeric apoa ii num
0.28076172.12042316.html.plaintext.txt	240	line evidence allow u postulate higher ability apoe dimer apoe monomer promote lipid release may explain greater amount lipid released conditioned culture medium apoenum expressing astrocyte apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	241	based assumption propose model isoform dependent association apoe lipid particle fig
0.28076172.12042316.html.plaintext.txt	242	consistent present result previous study revealed conformational adaptability apoe n terminal domain function lipid availability num presence competitor apolipoproteins review see ref
0.28076172.12042316.html.plaintext.txt	243	study model two possible conformation apoe spherical lipid particle proposed high apoe concentration n terminal domain displaced lipid surface form helix bundle closed conformation whereas low concentration surface four helix bundle n terminal domain open conformation helix contact lipid surface
0.28076172.12042316.html.plaintext.txt	244	based line evidence together finding apoenum containing hdl like particle contains approximately one half number apoe molecule compared apoenum containing particle may possible apoe isoform dependent conformational change occurs surface lipid particle n terminal domain apoenum open conformation whereas apoenum closed helix bundle conformation
0.28076172.12042316.html.plaintext.txt	245	view larger version numk fig
0.28076172.12042316.html.plaintext.txt	246	model apoe lipid particle generated apoenum apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	247	present data indicate apoenum ability generate similarly sized apoe lipid particle le number apoe molecule apoenum
0.28076172.12042316.html.plaintext.txt	248	based finding propose model showing one apoenum containing lipid particle contains num fold number apoe molecule compared apoenum containing lipid particle
0.28076172.12042316.html.plaintext.txt	249	another possible explanation may preferential association apoe isoforms lipoprotein apoenum preferentially associate low density lipoprotein whereas apoenum associate hdl
0.28076172.12042316.html.plaintext.txt	250	assumption based fact n terminal domain modulates lipid binding preference elicited c terminal domain num num interaction n c terminal domain responsible isoform preference num num
0.28076172.12042316.html.plaintext.txt	251	suggested apoenum interaction arginine num glutamic acid num may stabilize extended helical structure carboxyl terminus best accommodated le curved low density lipoprotein surface whereas interaction exist apoenum therefore lack stability shorter helix preference hdl num num
0.28076172.12042316.html.plaintext.txt	252	based line evidence apoenum may preferentially bind hdl particle lower number apoe molecule stabilize particle whereas apoenum le binding efficacy hdl particle requires higher number apoe molecule stabilize particle
0.28076172.12042316.html.plaintext.txt	253	physical property apoe assumed influence function
0.28076172.12042316.html.plaintext.txt	254	associate lipid particle stabilizes apoe isoform dependent difference stability among num kda n terminal fragment apoe num may involved isoform dependent binding efficacy apoe hdl particle
0.28076172.12042316.html.plaintext.txt	255	previous study num num num demonstrated various cell generate cholesterol rich hdl like particle exogenous apolipoproteins
0.28076172.12042316.html.plaintext.txt	256	however case astrocyte researcher found generation hdl endogenous apoe exogenous apoe differently regulated cultured astrocyte hdl like particle generated exogenous apolipoproteins low amount cholesterol num num whereas hdl like particle generated endogenous apoe cholesterol rich num
0.28076172.12042316.html.plaintext.txt	257	support finding present study shown apoe lipid particle generated endogenously synthesized released apoe cholesterol rich compared generated addition exogenous apoe num
0.28076172.12042316.html.plaintext.txt	258	amount apoe free lipid particle cultured medium csf detection limit see ref
0.28076172.12042316.html.plaintext.txt	259	num b result suggest physiological condition cholesterol rich lipid particle associated endogenous apoe major cholesterol source neuron central nervous system
0.28076172.12042316.html.plaintext.txt	260	regard interest note apoenum expressing astrocyte could supply cholesterol form apoe lipid particle cell including neuron comparable level apoe secretion apoenum expressing astrocyte
0.28076172.12042316.html.plaintext.txt	261	steady state condition lipid metabolism central nervous system appear similar brain apoenum apoenum knock mouse concentration free esterified cholesterol postnuclear supernatant plasma membrane endoplasmic reticulum brain homogenate similar num
0.28076172.12042316.html.plaintext.txt	262	however different condition recovery phase brain injury cell damage endogenous apoe mediated generation hdl like particle could play critical role cholesterol delivery neuron essential material axonal regeneration synapse formation num num
0.28076172.12042316.html.plaintext.txt	263	actually previous study num num demonstrated traumatic brain injury robust environmental risk factor development ad
0.28076172.12042316.html.plaintext.txt	264	line evidence may allow u postulate apoe isoform dependence development ad may explained apoe isoform dependent ability cholesterol supply neuron injury cell damage leading neuroregeneration
0.28076172.12042316.html.plaintext.txt	265	work supported research grant longevity science numa num program promotion fundamental study health science organization pharmaceutical safety research research brain science ministry health welfare crest japan
0.28076172.12042316.html.plaintext.txt	266	cost publication article defrayed part payment page charge
0.28076172.12042316.html.plaintext.txt	267	article must therefore hereby marked advertisement accordance num u
0.28076172.12042316.html.plaintext.txt	268	section num solely indicate fact
0.28076172.12042316.html.plaintext.txt	269	correspondence addressed dept
0.28076172.12042316.html.plaintext.txt	270	dementia research national institute longevity science num num gengo morioka obu aichi num num japan
0.28076172.12042316.html.plaintext.txt	271	num num num num fax num num num num e mail michinils
0.28076172.12042316.html.plaintext.txt	272	published jbc paper press may num num doi num
0.28076172.12042316.html.plaintext.txt	273	abbreviation used ad alzheimers disease hdl high density lipoprotein apoe apolipoprotein e apoa ii apolipoprotein ii csf cerebrospinal fluid dmem dulbeccos modified eagle medium fbs fetal bovine serum pb phosphate buffered saline tricine n num hydroxy numnum bishydroxymethylethylglycine amyloid protein
0.28076172.12042316.html.plaintext.txt	274	copyright num american society biochemistry molecular biology inc
0.28218916.14764623.html.plaintext.txt	0	alzheimers disease one disorder many gene lars bertram rudolph e
0.28218916.14764623.html.plaintext.txt	1	genetics aging research unit department neurology massgeneral institute neurodegenerative disease massachusetts general hospital harvard medical school charlestown ma usa
0.28218916.14764623.html.plaintext.txt	2	received january num num accepted january num num
0.28218916.14764623.html.plaintext.txt	3	overview concordant linkageassociation region observed full genome screen published num disease specific characteristic together advent relatively inexpensive powerful high throughput genotyping technology near completion human genome sequence led steep increase number laboratory studying genetics ad worldwide
0.28218916.14764623.html.plaintext.txt	4	date le num full genome screen using linkage association based methodology published ad using overlapping identical sample employing different set genetic marker andor analytic strategy num num table num
0.28218916.14764623.html.plaintext.txt	5	hand number locus specific candidate gene based ad association study become nearly intractable
0.28218916.14764623.html.plaintext.txt	6	course num num gene reported show either positive negative evidence association different ad phenotype per month peer reviewed journal listed ncbis pubmed
0.28218916.14764623.html.plaintext.txt	7	despite vast effort single gene yet emerged attain nearly degree replication consistency observed literally hundred laboratory studying association apoe num ad
0.28218916.14764623.html.plaintext.txt	8	review present discus finding genetic ad association study published num excluding explicitly searching cause early onset familial ad case
0.28218916.14764623.html.plaintext.txt	9	using data example attempt pinpoint methodological difficulty likely underlie remarkable failure replicate genetic finding using current approach
0.28218916.14764623.html.plaintext.txt	10	candidate gene study searching pubmed www
0.28218916.14764623.html.plaintext.txt	11	govpubmed keywords alzheimer association associated paper published january num december num num retrieved total num study december num num num directly deal genetic association candidate polymorphism ad
0.28218916.14764623.html.plaintext.txt	12	seen table num study examined total num genetic locus locus set marker within num mb genomic interval num different chromosome
0.28218916.14764623.html.plaintext.txt	13	total num analyzed gene within locus found positive judged author num tested negative
0.28218916.14764623.html.plaintext.txt	14	interestingly even num year discovery largest number nnum report focusing single gene dealt association apoe ad using new polymorphism new samplesethnic group new phenotype
0.28218916.14764623.html.plaintext.txt	15	study considered total num positive num negative paper remained
0.28218916.14764623.html.plaintext.txt	16	overview chromosomal locus tested genetic association ad num num represents one prolific vintage late onset ad genetic study next pressing question large quantity study also dilute quality product perhaps even making unpalatable quaff answer opinion yes least majority case
0.28218916.14764623.html.plaintext.txt	17	growing consensus success rate reliability genetic association study complex disease depend fulfillment several criterion numnum three discussed detail
0.28218916.14764623.html.plaintext.txt	18	addition classic requirement least plausible biological andor positional candidacy investigated locus well direct proof pathophysiological consequence positive disease association
0.28218916.14764623.html.plaintext.txt	19	former criterion fulfilled vast majority ad candidate gene investigated thus far latter condition elusive
0.28218916.14764623.html.plaintext.txt	20	due several factor generally bedevil study genetic association complex disease linkage disequilibrium actual functionally relevant disease modifying variant small effect size impede detection significant effect using basic molecular biochemical assay possibly involvement yet unknown pathophysiological mechanism
0.28218916.14764623.html.plaintext.txt	21	situation apoe num ad serf good example genetic association per se extremely well established past decade still consensus association translates pathophysiologically numnum
0.28218916.14764623.html.plaintext.txt	22	thus attempting uncover functional consequence putative new disease association propose emphasis must placed criterion allow better distinction false positive well false negative finding prior initial publication
0.28218916.14764623.html.plaintext.txt	23	power sample size structure enable investigator detect effect size moderate small extent obvious concern report negative outcome power study also governs rate false positive finding
0.28218916.14764623.html.plaintext.txt	24	probability observed significant association indeed genuine observed chance num num
0.28218916.14764623.html.plaintext.txt	25	factor influencing ability detect meaningful effect include attributable risk polymorphism overall genetic variance degree linkage disequilibrium ld associated allele actual disease predisposing variant mode inheritance lesser extent disease prevalence
0.28218916.14764623.html.plaintext.txt	26	variable course difficult estimate true disease gene unknown power given sample size fairly easily calculated variety possible plausible scenario
0.28218916.14764623.html.plaintext.txt	27	practice however still remains exception
0.28218916.14764623.html.plaintext.txt	28	recent study estimated minimal number case control sufficient achieve num power num
0.28218916.14764623.html.plaintext.txt	29	num usually far greater num actual disease allele tested directly even favorable circumstance num
0.28218916.14764623.html.plaintext.txt	30	interesting regardless estimate num study published num still used smaller sample size thus probably suitable use reaching reliable conclusion
0.28218916.14764623.html.plaintext.txt	31	replicability result validatedreplicated independent sample sufficient size report significant association putative candidate gene ad every chromosome human genome past num year num none finding exception apoe num yet replicated consistently
0.28218916.14764623.html.plaintext.txt	32	many seemingly positive result could validated independent dataset prior first publication several author long suggesting guideline proper quality control genetic association finding numnumnumnumnum
0.28218916.14764623.html.plaintext.txt	33	current inflation probable false positive report may avoided independent replication sought earlier
0.28218916.14764623.html.plaintext.txt	34	independent sample found house establishment least temporary consortium collaborative laboratory test others positive signal prior publication would represent easy effective mean restore credibility
0.28218916.14764623.html.plaintext.txt	35	upon review num ad genetics literature le num study either referred finding two independent sample published tandem independent report investigating candidate gene andor genetic variant
0.28218916.14764623.html.plaintext.txt	36	haplotype structure author made attempt elucidate structure underlying haplotype architecture current systematic assessment haplotype structure various region throughout genome past num num year emphasized importance performing haplotype systematic ld analysis searching novel complex disease gene numnum especially effect size expected lower conferred apoe num
0.28218916.14764623.html.plaintext.txt	37	addition increasing power analysis approach also reduces number statistical test need performed lead decrease false positive finding
0.28218916.14764623.html.plaintext.txt	38	several recently published complex disease association would impossible observe without thorough assessment underlying haplotype architecture num num
0.28218916.14764623.html.plaintext.txt	39	along line recent study apoe shown locus would easily identified mean haplotype analysis alone even without prior knowledge num polymorphism numnum
0.28218916.14764623.html.plaintext.txt	40	yet num one third study investigated one polymorphism per locus
0.28218916.14764623.html.plaintext.txt	41	half carried le thorough assessment haplotype structure
0.28218916.14764623.html.plaintext.txt	42	four polymorphism per gene
0.28218916.14764623.html.plaintext.txt	43	num paper published num topic genetic association candidate gene different ad phenotype num num fulfilled least two criterion
0.28218916.14764623.html.plaintext.txt	44	likely many observed discrepancy across study could explained lack methodological thoroughness
0.28218916.14764623.html.plaintext.txt	45	nonetheless three locus addition apoe tested positive across least three study chromosome numpnum numqnum numqnum table num
0.28218916.14764623.html.plaintext.txt	46	locus covered remainder review
0.28218916.14764623.html.plaintext.txt	47	chromosome numpnum chromosomal region implicated harboring putative ad gene early num based association finding variant highly polymorphic major histocompatibility complex region hla num mb ad small case control study num
0.28218916.14764623.html.plaintext.txt	48	two potential ad candidate map within num mb interval gene encoding hereditary haemochromatosis protein hfe num mb tumor necrosis factor alpha tnfa num mb
0.28218916.14764623.html.plaintext.txt	49	num two study reported significant evidence association latter two gene numnum two study confirm finding numnum
0.28218916.14764623.html.plaintext.txt	50	another candidate gene located region hapanumb found associated certain neuropsychological variable num disease risk num
0.28218916.14764623.html.plaintext.txt	51	finally one study investigated variation onset age function hla anum allele small sample ad patient find significant effect num
0.28218916.14764623.html.plaintext.txt	52	literature search association study gene including year num yielded least num positive study num report found evidence genetic involvement factor
0.28218916.14764623.html.plaintext.txt	53	evidence direct involvement tnfa as production toxicity num direct proof pathogenetic relevance genesproteins remains seen
0.28218916.14764623.html.plaintext.txt	54	furthermore full genome screen ad gene consistently yielded signal numpnum residing num num mb whereas associated gene map num mb proximal
0.28218916.14764623.html.plaintext.txt	55	thus increasing evidence supporting existence putative ad locus numpnum general possibility actual disease gene yet identified excluded despite overlapping positive result year past study
0.28218916.14764623.html.plaintext.txt	56	chromosome numqnum six candidate locus analyzed region numqnum numqnum num three reported associated ad phenotype across multiple sample
0.28218916.14764623.html.plaintext.txt	57	cdcnumvrnum tnfrsfnumide gstonumnum
0.28218916.14764623.html.plaintext.txt	58	locus found associated one group investigator located num num mb encompasses gene tnfrsfnum num mb idekiffnumhhex num num
0.28218916.14764623.html.plaintext.txt	59	probably best candidate biological ground ide encoding insulin degrading enzyme protein ide
0.28218916.14764623.html.plaintext.txt	60	metalloprotease shown degrade monomeric as aggregate oligomeric form ultimately s amyloid plaque num
0.28218916.14764623.html.plaintext.txt	61	several issue proposed mode action still remain controversial e
0.28218916.14764623.html.plaintext.txt	62	precise cellular location as cleavage relevance ide functiondysfunction development ad number animal model available showing predicted effect vivo num num
0.28218916.14764623.html.plaintext.txt	63	num two paper published showing allelic association microsatellite marker region numnum two report find association ide variant nearby marker ad numnum
0.28218916.14764623.html.plaintext.txt	64	note data one negative study num actually largely overlap positive paper edland et al
0.28218916.14764623.html.plaintext.txt	65	num important exception author first paper account potential interaction ide apoe num status
0.28218916.14764623.html.plaintext.txt	66	may crucial since latter study found significant effect ide ad risk individual lacking apoe num allele
0.28218916.14764623.html.plaintext.txt	67	clearly study independent sample sufficient size necessary elucidate potential role ide variant development ad general population
0.28218916.14764623.html.plaintext.txt	68	addition ide locus total four gene long arm chromosome num found associated ad
0.28218916.14764623.html.plaintext.txt	69	two cdcnum vrnum map num mb proximal ide two gstonumnum prssnum map num num mb distal
0.28218916.14764623.html.plaintext.txt	70	none association yet confirmed independent ad sample noteworthy two gene also found associated neurodegenerative illness frontotemporal dementia cdcnum num parkinson disease gstonumnum num potentially suggesting common pathway leading neuronal cell death across syndrome
0.28218916.14764623.html.plaintext.txt	71	cdcnum encodes cell division cycle num protein involved phosphorylation tau app found neuron bearing neurofibrillary tangle
0.28218916.14764623.html.plaintext.txt	72	gstonum num encode glutathione transferase omega num num involved physiological response oxidative stress may particular responsible regulating expression inflammatory cytokine like ilnum s
0.28218916.14764623.html.plaintext.txt	73	thus plausible ad candidate gene positional well biologicalbiochemical ground study still necessary elucidate proposed role influencing risk andor age onset ad general population
0.28218916.14764623.html.plaintext.txt	74	chromosome numqnum region near tip long arm chromosome num implicated one full genome screen published date num therefore appear table num
0.28218916.14764623.html.plaintext.txt	75	yet total three study showing significant association ad candidate gene num bace encoding s site app cleaving enzyme s secretase num num
0.28218916.14764623.html.plaintext.txt	76	protein excellent ad candidate biochemical ground s secretase cleavage app as liberated precursor via secretase cleavage
0.28218916.14764623.html.plaintext.txt	77	interestingly contrast putative ad association discussed appears high degree consistency respect site allelic nature underlying finding positive study including initial report nowotny colleague published num num observe representation g allele synonymous snp located codon num exon num ad case compared healthy control
0.28218916.14764623.html.plaintext.txt	78	furthermore study observed effect pronounced carrier apoe num allele yielding significantly elevated odds ratio ranging num num
0.28218916.14764623.html.plaintext.txt	79	contrast four positive association equal number study literature showing apparent effect bace polymorphism ad
0.28218916.14764623.html.plaintext.txt	80	however must pointed one studied early onset familial ad case num remaining study account potential interaction apoe num allele num num
0.28218916.14764623.html.plaintext.txt	81	unless done similar situation encountered variant tested ide see firm conclusion reached whether exon num polymorphism bace genetic risk factor ad sample
0.28218916.14764623.html.plaintext.txt	82	thus three known app cleaving enzyme associated protein adamnumnum num s bace bacenum secretase psennum aphnuma ncstn pennum already tested genetic association ad phenotype bace currently show promise genuine relevant risk factor late onset ad
0.28218916.14764623.html.plaintext.txt	83	case putative ad gene study using sufficiently sized sample appropriate analytic strategy need performed general conclusion reached
0.28218916.14764623.html.plaintext.txt	84	note first study examining putative genetic role bace late onset ad num also report significant effect exon num polymorphism case control sample chinese origin num
0.28218916.14764623.html.plaintext.txt	85	footnote correspondence addressed genetics aging research unit department neurology massachusetts general hospital num numth street charlestown ma num usa
0.28218916.14764623.html.plaintext.txt	86	tel num num fax num num email tanziathelix
0.28218916.14764623.html.plaintext.txt	87	num role heredity late onset alzheimer disease vascular dementia
0.28218916.14764623.html.plaintext.txt	88	num number trait locus late onset alzheimer disease
0.28218916.14764623.html.plaintext.txt	89	num genetics adult onset neuropsychiatric disease complexity conundra science num num num
0.28218916.14764623.html.plaintext.txt	90	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.28218916.14764623.html.plaintext.txt	91	num diagnostic accuracy alzheimers disease neuropathological study
0.28218916.14764623.html.plaintext.txt	92	num accuracy clinical diagnosis alzheimer disease clinical feature patient non alzheimer disease neuropathology
0.28218916.14764623.html.plaintext.txt	93	num result high resolution genome screen num alzheimers disease family
0.28218916.14764623.html.plaintext.txt	94	num complete genomic screen late onset familial alzheimer disease
0.28218916.14764623.html.plaintext.txt	95	evidence new locus chromosome num
0.28218916.14764623.html.plaintext.txt	96	num genome survey novel alzheimer disease risk locus result num cm resolution
0.28218916.14764623.html.plaintext.txt	97	num full genome scan late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	98	num identification novel gene late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	99	num novel method two locus linkage analysis applied genome scan late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	100	num genome wide linkage disequilibrium mapping late onset alzheimers disease finland
0.28218916.14764623.html.plaintext.txt	101	num age onset two common neurodegenerative disease genetically controlled
0.28218916.14764623.html.plaintext.txt	102	num full genome screen alzheimer disease stage ii analysis
0.28218916.14764623.html.plaintext.txt	103	num second locus late onset alzheimer disease genome scan reveals linkage nump epistasis nump amyloid precursor protein region
0.28218916.14764623.html.plaintext.txt	104	num identification multiple locus alzheimer disease consanguineous israeli arab community
0.28218916.14764623.html.plaintext.txt	105	num ordered subset linkage analysis detects novel alzheimer disease locus chromosome numqnum numqnum
0.28218916.14764623.html.plaintext.txt	106	num genetic association study gene search disease
0.28218916.14764623.html.plaintext.txt	107	num association study design complex disease
0.28218916.14764623.html.plaintext.txt	108	num apolipoprotein e alzheimers disease
0.28218916.14764623.html.plaintext.txt	109	num role apoeabeta interaction pathogenesis alzheimers disease cerebral amyloid angiopathy
0.28218916.14764623.html.plaintext.txt	110	num predictive value single diagnostic test unselected population
0.28218916.14764623.html.plaintext.txt	111	num replication validity genetic association study
0.28218916.14764623.html.plaintext.txt	112	num sample size calculation population family based case control association study marker genotype
0.28218916.14764623.html.plaintext.txt	113	num replication refutation status alzheimers disease genetic research
0.28218916.14764623.html.plaintext.txt	114	num proposed guideline paper describing dna polymorphism disease association
0.28218916.14764623.html.plaintext.txt	115	num opinion candidate gene approach studying complex genetic trait practical consideration
0.28218916.14764623.html.plaintext.txt	116	num structure haplotype block human genome
0.28218916.14764623.html.plaintext.txt	117	num using haplotype block map human complex trait locus
0.28218916.14764623.html.plaintext.txt	118	num genetic evidence involvement tau progressive supranuclear palsy
0.28218916.14764623.html.plaintext.txt	119	num genetic variation gene encoding calpain num associated type num diabetes mellitus
0.28218916.14764623.html.plaintext.txt	120	num genetic variation numqnum cytokine gene cluster confers susceptibility crohn disease
0.28218916.14764623.html.plaintext.txt	121	num snping away complex disease analysis single nucleotide polymorphism around apoe alzheimer disease
0.28218916.14764623.html.plaintext.txt	122	num genetic analysis casecontrol data using estimated haplotype frequency application apoe locus variation alzheimers disease
0.28218916.14764623.html.plaintext.txt	123	num histocompatibility antigen alzheimers disease
0.28218916.14764623.html.plaintext.txt	124	num tumour necrosis factor alpha gene polymorphism alzheimers disease
0.28218916.14764623.html.plaintext.txt	125	num association hfe mutation neurodegeneration oxidative stress alzheimers disease correlation apoe
0.28218916.14764623.html.plaintext.txt	126	num association hfe mutation unsuccessful ageing study alzheimers disease patient northern italy
0.28218916.14764623.html.plaintext.txt	127	num tumor necrosis factor alpha polymorphism c numt associated alzheimers disease vascular dementia italian population
0.28218916.14764623.html.plaintext.txt	128	num hspnum num hspanumb associated noncognitive symptom late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	129	num joint analysis candidate gene related alzheimers disease spanish population
0.28218916.14764623.html.plaintext.txt	130	num association anum allele hla system age onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	131	num inflammation alzheimers disease
0.28218916.14764623.html.plaintext.txt	132	num insulin degrading enzyme ide genetic variant risk alzheimers disease evidence effect modification apolipoprotein e apoe
0.28218916.14764623.html.plaintext.txt	133	num evidence role promoter variant tnfrsfnum gene alzheimer disease
0.28218916.14764623.html.plaintext.txt	134	num genetic variation haplotype block spanning ide influence alzheimer disease
0.28218916.14764623.html.plaintext.txt	135	num insulin degrading enzyme regulates extracellular level amyloid beta protein degradation
0.28218916.14764623.html.plaintext.txt	136	num insulin degrading enzyme regulates level insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivo
0.28218916.14764623.html.plaintext.txt	137	num amyloid beta peptide level brain inversely correlated insulysin activity level vivo
0.28218916.14764623.html.plaintext.txt	138	num enhanced proteolysis beta amyloid app transgenic mouse prevents plaque formation secondary pathology premature death
0.28218916.14764623.html.plaintext.txt	139	num evidence genetic linkage alzheimers disease chromosome numq
0.28218916.14764623.html.plaintext.txt	140	num confirmation association dnumsnum alzheimers disease case control sample
0.28218916.14764623.html.plaintext.txt	141	num substantial linkage disequilibrium across insulin degrading enzyme locus association late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	142	num polymorphism insulin degrading enzyme gene associated alzheimers disease
0.28218916.14764623.html.plaintext.txt	143	num increased frequency new polymorphism cell division cycle num cdcnum gene patient alzheimers disease frontotemporal dementia
0.28218916.14764623.html.plaintext.txt	144	num glutathione transferase omega num modifiesage onset alzheimer disease parkinson disease
0.28218916.14764623.html.plaintext.txt	145	num specific bacenum genotype provide additional risk late onset alzheimer disease apoe epsilon num carrier
0.28218916.14764623.html.plaintext.txt	146	num polymorphism bace gene influence risk alzheimers disease
0.28218916.14764623.html.plaintext.txt	147	num association study alzheimers disease gene involved abeta biosynthesis aggregation degradation suggestive result bacenum
0.28218916.14764623.html.plaintext.txt	148	num association study using novel polymorphism bacenum bacenum
0.28218916.14764623.html.plaintext.txt	149	num amyloid beta secretase gene bace neither mutated associated early onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	150	num bace gene genomic structure candidate gene study late onset alzheimers disease
0.28218916.14764623.html.plaintext.txt	151	num mutation open reading frame beta site app cleaving enzyme bace locus common cause alzheimers disease
0.28218916.14764623.html.plaintext.txt	152	num association beta site app cleaving enzyme bace cnumg polymorphism alzheimers disease
0.28218916.14764623.html.plaintext.txt	153	num numgc polymorphism exon num bacenum gene may associated sporadic alzheimers disease chinese han
0.29108343.15269218.html.plaintext.txt	0	deficiency abcanum impairs apolipoprotein e metabolism brain veronica hirsch reinshagen steven zhou braydon l
0.29108343.15269218.html.plaintext.txt	1	burgess lise bernier sean
0.29108343.15269218.html.plaintext.txt	2	department pathology laboratory medicine university british columbia vancouver vnumz numhnum canada clinical research institute montreal montreal hnumw numrnum canada centre molecular medicine therapeutic university british columbia vancouver vnumz numhnum canada
0.29108343.15269218.html.plaintext.txt	3	received publication july num num
0.29108343.15269218.html.plaintext.txt	4	abcanum abundant liver macrophage expression induced agonist liver x receptorretinoid x receptor lxrrxr pathway num num
0.29108343.15269218.html.plaintext.txt	5	abcanum also expressed glia neuron central nervous system cns particularly abundant purkinje cell large pyramidal cortical neuron num num num
0.29108343.15269218.html.plaintext.txt	6	similar non cns cell abcanum induced lxrrxr stimulation primary neuron astrocyte microglia num num
0.29108343.15269218.html.plaintext.txt	7	importance lipid homeostasis cns underscored fact brain cholesterol rich organ body contains num total body cholesterol num total body weight num
0.29108343.15269218.html.plaintext.txt	8	nearly brain cholesterol synthesized situ quantitative analysis show essentially cholesterol cross blood brain barrier num
0.29108343.15269218.html.plaintext.txt	9	contrast brain degrade cholesterol excess cholesterol must delivered peripheral circulation eventual excretion via liver
0.29108343.15269218.html.plaintext.txt	10	approximately num num mg cholesterol leaf human brain day conversion nums hydroxycholesterol easily traverse blood brain barrier num num
0.29108343.15269218.html.plaintext.txt	11	glial cell play crucial role regulating lipid homeostasis cns
0.29108343.15269218.html.plaintext.txt	12	astrocyte microglia cell within cns synthesize secrete apolipoproteins transport lipid within brain cerebrospinal fluid csf num num
0.29108343.15269218.html.plaintext.txt	13	apolipoprotein e apoe major apolipoprotein brain also component several lipoprotein peripheral circulation including hdl low density lipoprotein vldl chylomicron num num
0.29108343.15269218.html.plaintext.txt	14	human apoe exists one three allelic variant contain either cysteine arginine residue amino acid num num num
0.29108343.15269218.html.plaintext.txt	15	liver transplantation experiment human shown allelic variant apoe plasma converted donor whereas apoe csf retains allelic identity recipient illustrating cns non cns apoe pool synthesized independently num
0.29108343.15269218.html.plaintext.txt	16	additionally brain perfusion experiment guinea pig shown radiolabeled apoe administered peripheral circulation demonstrates low blood brain transport num providing additional support independent regulation cns non cns apoe pool
0.29108343.15269218.html.plaintext.txt	17	apoj second major cns lipoprotein unlike apoe easily traverse blood brain barrier associate hdl periphery num num num
0.29108343.15269218.html.plaintext.txt	18	apoe apoj synthesized secreted astrocyte microglia expression apoe apoj induced response cns injury disease num num
0.29108343.15269218.html.plaintext.txt	19	apoe thought coordinate mobilization redistribution cholesterol repair maintenance neuronal membrane myelin num num whereas apoj may function cytoprotective extracellular chaperone num
0.29108343.15269218.html.plaintext.txt	20	contrast apoe apoj apoa primarily taken brain outside cns believed involved maturation lipoprotein particle csf num num
0.29108343.15269218.html.plaintext.txt	21	num apoe discovered important genetic risk factor alzheimers disease ad finding replicated num study
0.29108343.15269218.html.plaintext.txt	22	inheritance apoenum increase risk ad dosage specific manner may act decreasing age onset ad num num
0.29108343.15269218.html.plaintext.txt	23	contrast inheritance apoenum appears protect ad associated later age onset num
0.29108343.15269218.html.plaintext.txt	24	many hypothesis proposed explain apoe participates pathogenesis ad including role apoe formation deposition clearance peptide constitute amyloid plaque num num
0.29108343.15269218.html.plaintext.txt	25	example apoe bind vivo required amyloid deposition num num
0.29108343.15269218.html.plaintext.txt	26	furthermore apoe affect deposition isoform specific manner mouse expressing human apoenum develop least num
0.29108343.15269218.html.plaintext.txt	27	num fold deposit mouse expressing human apoenum per unit area num num num num
0.29108343.15269218.html.plaintext.txt	28	interestingly replacement murine apoe human apoe isoforms completely suppresses deposition compared wild type mouse expressing endogenous murine apoe num num suggesting distinction human murine apoe may play important role deposition andor clearance
0.29108343.15269218.html.plaintext.txt	29	compared apoe role apoj ad le well understood although known apoj also bind suggested play major role transporting across blood brain barrier num num
0.29108343.15269218.html.plaintext.txt	30	abcanum apoe shown induced response lxrrxr stimulation num num num num num repressed znnum num peripheral macrophage
0.29108343.15269218.html.plaintext.txt	31	previous work demonstrated apoe robust acceptor lipid abcanum num num raising question whether abcanum mediated lipid efflux may play important role brain apoe predominant apolipoprotein
0.29108343.15269218.html.plaintext.txt	32	furthermore antisense inhibition abcanum observed inhibit secretion apoe monocyte derived macrophage num raising second question whether abcanum may also regulate apoe synthesis secretion apoe producing cell astrocyte microglia
0.29108343.15269218.html.plaintext.txt	33	address two question sought determine relationship abcanum cholesterol efflux apoe metabolism specifically glia
0.29108343.15269218.html.plaintext.txt	34	study report abcanum deficient primary astrocyte microglia impaired ability efflux lipid exogenous apoe result lipid accumulation normal culture condition
0.29108343.15269218.html.plaintext.txt	35	furthermore lack abcanum expression decrease apoe secretion glial cell vitro
0.29108343.15269218.html.plaintext.txt	36	vivo impairment apoe secretion astrocyte microglia result decrease apoe level num whole brain lysates abcanum deficient mouse hippocampus striatum severely affected region
0.29108343.15269218.html.plaintext.txt	37	observation show abcanum play key role cholesterol transport apoe metabolism cns
0.29108343.15269218.html.plaintext.txt	38	animal tissue murine brain harvested immediately sacrifice dissected individual region indicated stored num degree c use
0.29108343.15269218.html.plaintext.txt	39	tissue homogenized buffer containing num glycerol num triton x num protease inhibitor roche applied science phosphate buffered saline pb
0.29108343.15269218.html.plaintext.txt	40	protein concentration determined lowry assay
0.29108343.15269218.html.plaintext.txt	41	culture primary astrocyte microglia primary mixed glial culture prepared postnatal day num num mouse
0.29108343.15269218.html.plaintext.txt	42	brain individual animal placed ice cold hank buffered salt solution canadian life technology containing num mgml glucose num mm hepes
0.29108343.15269218.html.plaintext.txt	43	meninges removed frontal cortex dissected cell dissociated repeated passage series wide fine bored pipette
0.29108343.15269218.html.plaintext.txt	44	dissociated cell plated dulbeccos modified eagle medium dmem canadian life technology num fetal bovine serum num horse serum num mm l glutamine canadian life technology num unitsml penicillin streptomycin canadian life technology one tnum flask per mouse
0.29108343.15269218.html.plaintext.txt	45	cell cultured presence num conum num day num medium change
0.29108343.15269218.html.plaintext.txt	46	reaching confluence microglia isolated gently tapping culture flask collecting medium detached cell
0.29108343.15269218.html.plaintext.txt	47	subsequently attached microglia separated astrocyte mild trypsinization previously described num added previously isolated cell
0.29108343.15269218.html.plaintext.txt	48	microglia enriched astrocyte reseeded needed
0.29108343.15269218.html.plaintext.txt	49	immunofluorescence cell seeded poly d lysine coated coverslips washed twice pb fixed num paraformaldehyde pb num min room temperature washed twice permeabilized num
0.29108343.15269218.html.plaintext.txt	50	num triton x num pb num min room temperature
0.29108343.15269218.html.plaintext.txt	51	washing three time pb cell blocked num normal goat serum pb num min room temperature stained astrocyte marker gfap cynum numnum sigma microglial marker fnumnum numnum serotec num h
0.29108343.15269218.html.plaintext.txt	52	fnumnum stained cell visualized incubation alexa num conjugated secondary antibody transduction laboratory num min
0.29108343.15269218.html.plaintext.txt	53	finally cell nucleus stained numnum diamidine num phenylindole dihydrochloride dapi coverslips mounted vectashield vector laboratory
0.29108343.15269218.html.plaintext.txt	54	percentage stained cell determined least num cell
0.29108343.15269218.html.plaintext.txt	55	cell viewed zeiss axioplan num microscope image captured using ccd camera equipped metamorph universal imaging corporation imaging software
0.29108343.15269218.html.plaintext.txt	56	western blotting equal amount protein electrophoresed num
0.29108343.15269218.html.plaintext.txt	57	num num sd polyacrylamide gel electrophoretically transferred polyvinylidene fluoride membrane millipore immunodetected using monoclonal anti abcanum antibody raised second nucleotide binding domain nbdnum abcanum num murine specific apoe antibody santa cruz biotechnology numnum polyclonal antibody murine apoj numnum generously provided dr
0.29108343.15269218.html.plaintext.txt	58	david holtzman washington university school medicine anti gapdh antibody chemicon numnumnum loading control
0.29108343.15269218.html.plaintext.txt	59	blot developed using enhanced chemiluminescence amersham bioscience according manufacturer recommendation
0.29108343.15269218.html.plaintext.txt	60	band quantitated densitometry using nih image j
0.29108343.15269218.html.plaintext.txt	61	applicable apoe apoj abcanum level normalized gapdh level control protein loading
0.29108343.15269218.html.plaintext.txt	62	purification recombinant apoe protein apoe isoforms purified escherichia coli harboring recombinant glutathione transferase gst apoenum apoenum apoenum fusion protein described num
0.29108343.15269218.html.plaintext.txt	63	briefly logarithmic phase cell induced num
0.29108343.15269218.html.plaintext.txt	64	num mm isopropyl num thio d galactopyranoside num h harvested centrifugation lysed sonication num
0.29108343.15269218.html.plaintext.txt	65	num triton x num num glycerol pb num microgml lysozyme cleared centrifugation
0.29108343.15269218.html.plaintext.txt	66	gst apoe fusion protein cleared lysates purified glutathione sepharose numb bead eluted upon cleavage gst moiety precision protease amersham bioscience
0.29108343.15269218.html.plaintext.txt	67	indicated purified apoe protein delipidated num m urea followed dialysis several change pb
0.29108343.15269218.html.plaintext.txt	68	cholesterol efflux microglia enriched astrocyte seeded numnum cellswell num well plate labeled num microciml numh cholesterol perkinelmer life science num num h
0.29108343.15269218.html.plaintext.txt	69	labeled cell washed equilibrated dmemfnum num h num microgml lipid free apoa calbiochem recombinant apoenum apoenum apoenum added num h
0.29108343.15269218.html.plaintext.txt	70	medium collected centrifuged num rpm num min
0.29108343.15269218.html.plaintext.txt	71	cell lysed addition num microl num
0.29108343.15269218.html.plaintext.txt	72	num sd followed incubation room temperature num min
0.29108343.15269218.html.plaintext.txt	73	num microl medium cell lysate added scintillation vial quantified
0.29108343.15269218.html.plaintext.txt	74	percent cholesterol efflux calculated total count medium divided sum count medium plus cell lysate previously described num
0.29108343.15269218.html.plaintext.txt	75	lipid staining cell seeded num well plate poly d lysine coated coverslips numnum cellswell microglia numnum cellswell astrocyte
0.29108343.15269218.html.plaintext.txt	76	least num h dmem containing num fetal bovine serum num horse serum cell air dried fixed neutral buffered formalin stained oil red o
0.29108343.15269218.html.plaintext.txt	77	nucleus counterstained hematoxylin
0.29108343.15269218.html.plaintext.txt	78	cell photographed zeiss axioplan num microscope using ccd camera equipped metamorph universal imaging corporation imaging software
0.29108343.15269218.html.plaintext.txt	79	measurement apolipoprotein secretion microglia astrocyte seeded num well plate numnum cellswell numnum cellswell respectively
0.29108343.15269218.html.plaintext.txt	80	num h cell washed pb cultured serum free dmemfnum canadian life technology num h microglia num h astrocyte
0.29108343.15269218.html.plaintext.txt	81	conditioned medium collected centrifuged numnum rpm num min supernatant stored num degree c use
0.29108343.15269218.html.plaintext.txt	82	cell scraped lysed buffer containing num glycerol num triton x num protease inhibitor roche applied science pb centrifuged numnum rpm num min
0.29108343.15269218.html.plaintext.txt	83	supernatant stored num degree c use
0.29108343.15269218.html.plaintext.txt	84	medium cell lysate sample analyzed apoe apoj abcanum gapdh expression western blot described
0.29108343.15269218.html.plaintext.txt	85	intracellular gapdh level used normalize measurement cellular secreted apoe
0.29108343.15269218.html.plaintext.txt	86	statistical analysis one way anova newman keuls post test two tailed unpaired student test used statistical analysis
0.29108343.15269218.html.plaintext.txt	87	student test analysis welchs correction unequal variance applied variance significantly different group
0.29108343.15269218.html.plaintext.txt	88	indicated apoe abcanum level correlated using linear regression analysis
0.29108343.15269218.html.plaintext.txt	89	statistical analysis performed using graphpad prism version num
0.29108343.15269218.html.plaintext.txt	90	num graphpad software science inc
0.29108343.15269218.html.plaintext.txt	91	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	92	cholesterol efflux impaired abcanum glial cell
0.29108343.15269218.html.plaintext.txt	93	abcanum expression wild type abcanum primary astrocyte left microglia right first determined western blotting using abcanum specific antibody
0.29108343.15269218.html.plaintext.txt	94	gapdh lower panel served control equal protein loading
0.29108343.15269218.html.plaintext.txt	95	efflux num h presence absence num microgml exogenous apoanum apoenum apoenum apoenum evaluated wild type abcanum astrocyte b microglia c
0.29108343.15269218.html.plaintext.txt	96	least two independent experiment least six individual mouse per genotype
0.29108343.15269218.html.plaintext.txt	97	one way anova newman keuls post test used determine significant increase cholesterol efflux baseline
0.29108343.15269218.html.plaintext.txt	98	role glial abcanum cholesterol efflux exogenous apoa apoe isoforms apoenum apoenum apoenum determined primary wild type abcanum astrocyte microglia
0.29108343.15269218.html.plaintext.txt	99	cholesterol efflux measured absence apolipoprotein acceptor presence recombinant human apoa apoenum apoenum apoenum num h
0.29108343.15269218.html.plaintext.txt	100	preliminary experiment mixed glial culture showed difference cholesterol efflux presence either native delipidated apoenum data shown native apoe protein used subsequent experiment
0.29108343.15269218.html.plaintext.txt	101	effect different apolipoprotein acceptor cholesterol efflux wild type abcanum astrocyte microglia illustrated fig
0.29108343.15269218.html.plaintext.txt	102	expected abcanum required astrocyte efflux cholesterol exogenous apoa
0.29108343.15269218.html.plaintext.txt	103	experimental condition wild type astrocyte displayed num
0.29108343.15269218.html.plaintext.txt	104	num fold increase cholesterol efflux upon apoa addition whereas abcanum astrocyte show higher efflux apoa compared baseline p num
0.29108343.15269218.html.plaintext.txt	105	wild type astrocyte addition apoenum apoenum apoenum resulted num
0.29108343.15269218.html.plaintext.txt	106	num fold increase cholesterol efflux similar magnitude elicited apoa
0.29108343.15269218.html.plaintext.txt	107	contrast cholesterol efflux elicited apoe isoform num le abcanum cell compared wild type astrocyte corrected difference baseline efflux table
0.29108343.15269218.html.plaintext.txt	108	observation suggest abcanum astrocyte facilitates lipid efflux exogenous apoe
0.29108343.15269218.html.plaintext.txt	109	however abcanum absolutely required efflux cholesterol apoe residual efflux activity num
0.29108343.15269218.html.plaintext.txt	110	num fold remained absence abcanum
0.29108343.15269218.html.plaintext.txt	111	observation suggest gene addition abcanum also contribute cholesterol efflux astrocyte
0.29108343.15269218.html.plaintext.txt	112	comparison among apoe isoforms suggested apoenum le effective cholesterol acceptor apoenum apoenum wild type abcanum astrocyte whereas significant difference observed efflux apoenum apoenum fig
0.29108343.15269218.html.plaintext.txt	113	compared wild type astrocyte abcanum astrocyte significantly impaired ability efflux cholesterol apoa apoe isoform p num
0.29108343.15269218.html.plaintext.txt	114	view table table cholesterol efflux different apolipoproteins wt abcanum glia
0.29108343.15269218.html.plaintext.txt	115	noted fold increase cholesterol efflux apoa consistently greater wild type astrocyte compared microglia cultured animal num
0.29108343.15269218.html.plaintext.txt	116	experiment conducted absence lxrrxr stimulation order selectively examine effect abcanum cholesterol efflux possible condition astrocyte express component pathway necessary efficient cholesterol efflux apoa whereas additional factor may required elicit strong efflux response apoa microglia
0.29108343.15269218.html.plaintext.txt	117	although surprisingly low efflux exogenous apoa num
0.29108343.15269218.html.plaintext.txt	118	num fold observed primary wild type microglia cell display significant cholesterol efflux apoenum num
0.29108343.15269218.html.plaintext.txt	119	wild type microglia showed poor efflux presence apoenum num
0.29108343.15269218.html.plaintext.txt	120	num fold reach statistical significance baseline fig
0.29108343.15269218.html.plaintext.txt	121	deficiency abcanum microglia blocked efflux apoa impaired cholesterol efflux num apoenum apoenum p num
0.29108343.15269218.html.plaintext.txt	122	num compared wild type cell
0.29108343.15269218.html.plaintext.txt	123	apoe isoform still able elicit residual efflux activity num
0.29108343.15269218.html.plaintext.txt	124	num fold abcanum microglia fig
0.29108343.15269218.html.plaintext.txt	125	numc table suggesting microglia also contain abcanum independent pathway efflux lipid apoe
0.29108343.15269218.html.plaintext.txt	126	wild type abcanum microglia apoenum tended best acceptor although statistically significant difference observed among apoe isoform tested
0.29108343.15269218.html.plaintext.txt	127	taken together result suggest abcanum facilitates cholesterol efflux apoe required cholesterol efflux apoa astrocyte microglia
0.29108343.15269218.html.plaintext.txt	128	additionally astrocyte microglia appear contain abcanum independent pathway efflux cholesterol apoe
0.29108343.15269218.html.plaintext.txt	129	astrocyte apoe good cholesterol acceptor apoa whereas apoe appears preferred acceptor microglia
0.29108343.15269218.html.plaintext.txt	130	lack abcanum result lipid accumulation astrocyte microglia determine elimination abcanum dependent efflux pathway result cellular lipid accumulation glia subjected wild type abcanum primary astrocyte microglia oil red o staining
0.29108343.15269218.html.plaintext.txt	131	normal culture condition lipid accumulate efflux competent wild type astrocyte fig
0.29108343.15269218.html.plaintext.txt	132	numa small lipid droplet observed wild type microglia fig
0.29108343.15269218.html.plaintext.txt	133	contrast abcanum astrocyte microglia accumulated numerous cytoplasmic lipid droplet particularly abundant microglia fig
0.29108343.15269218.html.plaintext.txt	134	observation suggest abcanum required prevent excessive accumulation lipid glial cell even absence cholesterol loading
0.29108343.15269218.html.plaintext.txt	135	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	136	abcanum deficient glia accumulate lipid
0.29108343.15269218.html.plaintext.txt	137	primary wild type wt abcanum astrocyte b microglia c d stained oil red o reveal accumulated neutral lipid nucleus counterstained hematoxylin blue
0.29108343.15269218.html.plaintext.txt	138	image taken xnum magnification
0.29108343.15269218.html.plaintext.txt	139	b compared wild type astrocyte abcanum astrocyte show increased intracellular level neutral lipid red droplet
0.29108343.15269218.html.plaintext.txt	140	c d microglia showing marked accumulation lipid droplet absence abcanum compared wild type cell
0.29108343.15269218.html.plaintext.txt	141	abcanum facilitates apoe secretion astrocyte microglia antisense inhibition abcanum expression previously reported reduce apoe secretion peripheral macrophage num
0.29108343.15269218.html.plaintext.txt	142	ass role abcanum apoe secretion glial cell first determined level intracellular apoe well level apoe secreted conditioned medium
0.29108343.15269218.html.plaintext.txt	143	initial experiment conducted using medium conditioned num h difference secreted apoe level observed wild type abcanum glia data shown
0.29108343.15269218.html.plaintext.txt	144	astrocyte microglia express apoe receptor known take resecrete apoe hypothesized num h apoe medium may arisen newly synthesized apoe well resecreted apoe
0.29108343.15269218.html.plaintext.txt	145	therefore examined apoe secretion astrocyte microglia num num h respectively order minimize effect resecreted apoe
0.29108343.15269218.html.plaintext.txt	146	well intracellular gapdh level used control small variation total number cell per well
0.29108343.15269218.html.plaintext.txt	147	intracellular level apoe equivalent wild type abcanum astrocyte fig
0.29108343.15269218.html.plaintext.txt	148	contrast abcanum conditioned medium contained num le apoe wild type fig
0.29108343.15269218.html.plaintext.txt	149	well proportion total apoe released num h conditioned medium primary wild type abcanum astrocyte determined
0.29108343.15269218.html.plaintext.txt	150	value defined apoe medium divided sum intracellular extracellular apoe thus correcting variation intracellular apoe level
0.29108343.15269218.html.plaintext.txt	151	proportion total apoe secreted conditioned medium reduced num abcanum compared wild type astrocyte fig
0.29108343.15269218.html.plaintext.txt	152	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	153	abcanum facilitates apoe secretion astrocyte
0.29108343.15269218.html.plaintext.txt	154	apoe level conditioned medium upper panel whole cell lysates middle panel wild type abcanum primary astrocyte determined using polyclonal antibody murine apoe
0.29108343.15269218.html.plaintext.txt	155	intracellular gapdh lower panel detected control equal protein loading normalize small variation cell number measurement secreted apoe
0.29108343.15269218.html.plaintext.txt	156	band quantitated densitometry
0.29108343.15269218.html.plaintext.txt	157	graph illustrate four independent experiment n indicating number culture prepared individual mouse
0.29108343.15269218.html.plaintext.txt	158	apoe level whole cell lysates b conditioned medium c astrocyte well proportion total apoe secreted medium d
0.29108343.15269218.html.plaintext.txt	159	student test used determine significant difference apoe level
0.29108343.15269218.html.plaintext.txt	160	welchs correction applied necessary
0.29108343.15269218.html.plaintext.txt	161	abcanum pronounced effect apoe metabolism microglia
0.29108343.15269218.html.plaintext.txt	162	compared wild type microglia deficiency abcanum resulted num decrease intracellular apoe level fig
0.29108343.15269218.html.plaintext.txt	163	num num decrease secreted apoe level fig
0.29108343.15269218.html.plaintext.txt	164	num resulted num overall reduction proportion total apoe secreted conditioned medium fig
0.29108343.15269218.html.plaintext.txt	165	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	166	abcanum microglia impaired apoe secretion
0.29108343.15269218.html.plaintext.txt	167	apoe level conditioned medium upper panel whole cell lysates middle panel wild type abcanum primary microglia determined using polyclonal antibody murine apoe
0.29108343.15269218.html.plaintext.txt	168	intracellular gapdh lower panel detected control equal protein loading normalize variation total cell number measurement secreted apoe
0.29108343.15269218.html.plaintext.txt	169	band quantitated densitometry
0.29108343.15269218.html.plaintext.txt	170	graph illustrate least two independent experiment n indicates number culture prepared individual mouse
0.29108343.15269218.html.plaintext.txt	171	apoe level microglial whole cell lysates b conditioned medium c well proportion total apoe secreted medium d
0.29108343.15269218.html.plaintext.txt	172	student test used determine significant difference apoe level
0.29108343.15269218.html.plaintext.txt	173	welchs correction applied necessary
0.29108343.15269218.html.plaintext.txt	174	apoe secretion wild type microglia correlate abcanum expression level despite consistent culture condition noted wild type microglia cultured individual animal displayed surprisingly large variability apoe level particularly apoe secreted medium
0.29108343.15269218.html.plaintext.txt	175	abcanum previously shown affect apoe secretion macrophage num hypothesized abcanum expression level may influence extent apoe secreted microglia derived lineage peripheral macrophage
0.29108343.15269218.html.plaintext.txt	176	ass possibility abcanum expression level microglia determined immunoblotting
0.29108343.15269218.html.plaintext.txt	177	basal abcanum protein level wild type microglia found highly variable among equivalent amount wild type microglia prepared individual mouse
0.29108343.15269218.html.plaintext.txt	178	furthermore abcanum level correlated highly apoe secretion rnum num
0.29108343.15269218.html.plaintext.txt	179	numa apoe intracellular level rnum num
0.29108343.15269218.html.plaintext.txt	180	contrast microglia intracellular medium apoe level abcanum expression level far consistent among independent primary culture wild type astrocyte
0.29108343.15269218.html.plaintext.txt	181	however slight variation level abcanum protein positively correlated medium rnum num
0.29108343.15269218.html.plaintext.txt	182	taken together result provide support role abcanum secretion apoe particularly microglia
0.29108343.15269218.html.plaintext.txt	183	finally microglia showed far greater range abcanum apoe level medium cell compared astrocyte fig
0.29108343.15269218.html.plaintext.txt	184	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	185	abcanum expression correlated secreted intracellular apoe level wild type glia
0.29108343.15269218.html.plaintext.txt	186	abcanum apoe level wild type microglia b astrocyte c d normalized intracellular gapdh level correlated using linear regression analysis
0.29108343.15269218.html.plaintext.txt	187	graph secreted c intracellular b d apoe represent pooled data least three independent experiment n indicating number culture prepared individual mouse
0.29108343.15269218.html.plaintext.txt	188	apoe level reduced brain abcanum deficient mouse result presented led u hypothesize abcanum may play prominent role regulation apoe homeostasis murine brain
0.29108343.15269218.html.plaintext.txt	189	ass impact abcanum deficiency apoe level vivo first compared apoe protein level whole brain extract prepared age sex matched abcanum mouse wild type littermate control dbanumj genetic background
0.29108343.15269218.html.plaintext.txt	190	genetic strain profound effect murine lipid lipoprotein num num whole brain extract age sex matched apoe deficient wild type control pure cnumblnum genetic background also prepared additional control
0.29108343.15269218.html.plaintext.txt	191	western blot analysis showed apoe level whole brain male abcanum mouse reduced num compared wild type dbanumj littermate control p num
0.29108343.15269218.html.plaintext.txt	192	num well age sex matched wild type cnumblnum mouse p num
0.29108343.15269218.html.plaintext.txt	193	significant difference total brain apoe level wild type dbanumj cnumblnum mouse fig
0.29108343.15269218.html.plaintext.txt	194	identical result obtained mouse evaluated num
0.29108343.15269218.html.plaintext.txt	195	num month well num month age data shown
0.29108343.15269218.html.plaintext.txt	196	compared wild type mouse abcanum mouse also num le apoe plasma data shown similar result reported warhle et al
0.29108343.15269218.html.plaintext.txt	197	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	198	apoe level reduced brain abcanum deficient mouse
0.29108343.15269218.html.plaintext.txt	199	b male mouse wt dbanumj abcanum dbanumj apoe cnumblnum wt cnumblnum sacrificed num
0.29108343.15269218.html.plaintext.txt	200	gel representative total protein lysates prepared whole brain two individual mouse per genotype
0.29108343.15269218.html.plaintext.txt	201	tissue blot immunodetected abcanum upper panel apoe second panel gapdh third panel apoj fourth panel
0.29108343.15269218.html.plaintext.txt	202	gapdh level used control equal protein loading
0.29108343.15269218.html.plaintext.txt	203	band quantitated densitometry graph represents pooled data least four mouse per genotype measured duplicate
0.29108343.15269218.html.plaintext.txt	204	one way anova newman keuls post test used determine significant difference brain apoe level
0.29108343.15269218.html.plaintext.txt	205	apoj second major brain lipoprotein synthesized secreted astrocyte microglia
0.29108343.15269218.html.plaintext.txt	206	ass whether loss abcanum also affected metabolism apoj total brain extract wild type abcanum mouse immunoblotted apoj
0.29108343.15269218.html.plaintext.txt	207	contrast apoe apoj level indistinguishable among abcanum wild type dbanumj littermate control well apoe deficient wild type littermate cnumblnum control fig
0.29108343.15269218.html.plaintext.txt	208	numa lower panel demonstrating abcanum selectively influence apoe metabolism vivo
0.29108343.15269218.html.plaintext.txt	209	determine abcanum affected apoe level region specific manner individual brain region age sex matched abcanum mouse wild type littermate control examined fig
0.29108343.15269218.html.plaintext.txt	210	lack abcanum affected apoe level severely hippocampus striatum apoe level reduced num num respectively fig
0.29108343.15269218.html.plaintext.txt	211	apoe level reduced num thalamus num cortex fig
0.29108343.15269218.html.plaintext.txt	212	contrast abcanum least impact cerebellum apoe level reduced num abcanum compared wild type mouse fig
0.29108343.15269218.html.plaintext.txt	213	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	214	abcanum deficiency affect brain apoe level region specific manner
0.29108343.15269218.html.plaintext.txt	215	male mouse wt dbanumj abcanum dbanumj sacrificed num month age individual brain region dissected
0.29108343.15269218.html.plaintext.txt	216	abcanum upper panel apoe middle panel detected region western blot quantitated densitometry normalized gapdh lower panel internal protein loading control
0.29108343.15269218.html.plaintext.txt	217	b graph represents mean
0.29108343.15269218.html.plaintext.txt	218	two micegenotype measured duplicate
0.29108343.15269218.html.plaintext.txt	219	student test used determine significant difference regional apoe level
0.29108343.15269218.html.plaintext.txt	220	abcanum mouse used study lack circulating hdl apoa loss peripheral abcanum activity num formally possible change apoe level observed brain abcanum mouse simply due loss hdl apoa primarily taken brain peripheral circulation num
0.29108343.15269218.html.plaintext.txt	221	address possibility apoe level compared total brain extract prepared age sex matched wild type apoa deficient mouse model characterized absent hdl apoa
0.29108343.15269218.html.plaintext.txt	222	deficiency apoa impact apoe level brain fig
0.29108343.15269218.html.plaintext.txt	223	num demonstrating lack circulating hdl apoa abcanum mouse sufficient alter brain apoe level vivo
0.29108343.15269218.html.plaintext.txt	224	view larger version numk fig
0.29108343.15269218.html.plaintext.txt	225	apoe level affected apoa deficiency
0.29108343.15269218.html.plaintext.txt	226	total brain lysates num month old male mouse wt cnumblnum apoanum cnumblnum apoe cnumblnum immunodetected apoe upper panel gapdh lower panel control equal protein loading
0.29108343.15269218.html.plaintext.txt	227	western blot representative two micegenotype single apoe control
0.29108343.15269218.html.plaintext.txt	228	study provide evidence lack glial abcanum activity result num decrease apoe level vivo likely due reduced apoe secretion astrocyte microglia diminished pool intracellular apoe microglia
0.29108343.15269218.html.plaintext.txt	229	additionally show abcanum facilitates cholesterol efflux exogenous apoe primary astrocyte microglia efflux reduced absence abcanum cell type
0.29108343.15269218.html.plaintext.txt	230	however astrocyte microglia may also contain abcanum independent pathway efflux cholesterol apoe residual efflux remains abcanum cell
0.29108343.15269218.html.plaintext.txt	231	finding agreement previous study showing macrophage abcanum facilitates cholesterol efflux exogenous apoe num num
0.29108343.15269218.html.plaintext.txt	232	experimental condition used efflux study observe marked apoe isoform specificity pattern consistent astrocyte microglial culture
0.29108343.15269218.html.plaintext.txt	233	astrocyte culture apoenum slightly le potent acceptor apoenum apoenum trend observed microglial culture significant difference observed efflux among apoe isoforms
0.29108343.15269218.html.plaintext.txt	234	finding contrast previous study suggesting apoenum elicits cholesterol efflux apoenum apoenum num
0.29108343.15269218.html.plaintext.txt	235	reason finding differ previous work clear may due subtle difference culture preparation efflux protocol
0.29108343.15269218.html.plaintext.txt	236	study show abcanum play critical role secretion apoe astrocyte microglia
0.29108343.15269218.html.plaintext.txt	237	observation confirm extend previous study abcanum found facilitate apoe secretion human monocyte derived macrophage num
0.29108343.15269218.html.plaintext.txt	238	also demonstrate abcanum positively correlated steady state level intracellular apoe well apoe secreted medium measure dynamic process
0.29108343.15269218.html.plaintext.txt	239	steady state intracellular apoe level reflect balance apoe synthesis degradation newly synthesized recycled apoe whereas secreted apoe level reflect balance apoe released cell coupled reuptake apoe apoe receptor expressed astrocyte microglia
0.29108343.15269218.html.plaintext.txt	240	although mechanism abcanum affect apoe metabolism glial cell yet understood clear lack abcanum impairs proportion total apoe secreted medium astrocyte microglia
0.29108343.15269218.html.plaintext.txt	241	several potential mechanism abcanum may affect apoe metabolism may may linked functionally lipid efflux
0.29108343.15269218.html.plaintext.txt	242	abcanum known cycle plasma membrane late endosomal compartment num addition plasma membrane suggested abcanum may efflux cholesterol late endosomes lysosome num
0.29108343.15269218.html.plaintext.txt	243	moreover apoa recently reported internalized resecreted abcanum mediated cholesterol efflux num
0.29108343.15269218.html.plaintext.txt	244	increasing body evidence indicates internalized apoe undergo complete degradation resecreted num num
0.29108343.15269218.html.plaintext.txt	245	example nascent lipoprotein recovered liver apoe mouse transplanted wild type bone marrow model circulating apoe derived exclusively macrophage showed num internalized apoe may reutilized physiological condition num
0.29108343.15269218.html.plaintext.txt	246	recently hdlnum shown stimulate recycling internalized apoe act extracellular acceptor recycled apoe hepatoma cell num
0.29108343.15269218.html.plaintext.txt	247	study apoe recycling accompanied cholesterol efflux involved internalization hdlnum derived apoa targeting endosomes containing cholesterol apoe num
0.29108343.15269218.html.plaintext.txt	248	taken together observation suggest possibility apoe secretion recycling may coupled cholesterol efflux abcanum may play role process
0.29108343.15269218.html.plaintext.txt	249	also possible speculate abcanum could influence apoe secretion affecting trafficking secretory recycling pathway
0.29108343.15269218.html.plaintext.txt	250	respect plasma membrane associated abcanum may distinct function compared intracytoplasmic abcanum
0.29108343.15269218.html.plaintext.txt	251	example plasma membrane associated abcanum may function transport cholesterol phospholipid various extracellular apolipoprotein acceptor whereas intracytoplasmic abcanum may primarily participate intracellular lipid trafficking
0.29108343.15269218.html.plaintext.txt	252	additionally known apoe requires prenylation order efficiently secreted num suggesting possibility impact abcanum prenylation pathway might also affect apoe secretion
0.29108343.15269218.html.plaintext.txt	253	although much remains learned result provide support role abcanum apoe secretion
0.29108343.15269218.html.plaintext.txt	254	reported nascent particle released conditioned medium abcanum astrocyte contain le cholesterol wild type particle suggesting abcanum affect secretion lipidation apoe cns
0.29108343.15269218.html.plaintext.txt	255	vivo total apoe level reduced num whole brain abcanum compared wild type animal indicating critical role abcanum maintaining normal apoe homeostasis cns physiological condition
0.29108343.15269218.html.plaintext.txt	256	loss abcanum affect apoe level severely hippocampus striatum whereas cortex thalamus moderately affected abcanum deficiency
0.29108343.15269218.html.plaintext.txt	257	apoe level cerebellum minimally reduced abcanum mouse compared wild type control
0.29108343.15269218.html.plaintext.txt	258	hypothesize defective secretion apoe astrocyte microglia key factor underlies reduced apoe level vivo
0.29108343.15269218.html.plaintext.txt	259	absence abcanum astrocyte microglia secrete le apoe intracellular pool microglial apoe available secretion also lower
0.29108343.15269218.html.plaintext.txt	260	interestingly elimination abcanum effect apoj level suggesting abcanum selectively regulates apoe metabolism rather general effect brain derived apolipoproteins
0.29108343.15269218.html.plaintext.txt	261	knowledge whether deficiency human abcanum result change cns csf level apoe determined
0.29108343.15269218.html.plaintext.txt	262	vivo reduction brain apoe level coupled reduced ability abcanum glia maintain normal level cholesterol efflux apoe secretion vitro suggests abcanum deficiency may impair normal brain function particularly response injury disease
0.29108343.15269218.html.plaintext.txt	263	apoe expression known induced glial cell response neuronal injury believed participate lipid transport process involved repairing neuronal membrane num num
0.29108343.15269218.html.plaintext.txt	264	abcanum deficiency result region specific reduction apoe level brain possible speculate abcanum may play role recovery variety neurological insult facilitating lipid mobilization via apoe
0.29108343.15269218.html.plaintext.txt	265	observation abcanum mouse significant reduction apoe level brain creates paradox prediction role abcanum ad
0.29108343.15269218.html.plaintext.txt	266	study provide first direct evidence glial abcanum affect apoe metabolism vivo vitro
0.29108343.15269218.html.plaintext.txt	267	reduced level apoe abcanum brain may predict greater susceptibility neuronal injury due decreased lipid mediated repair pathway yet lower level apoe may also delay amyloid deposition
0.29108343.15269218.html.plaintext.txt	268	addition glial abcanum neuronal abcanum may also participate ad affecting generation
0.29108343.15269218.html.plaintext.txt	269	present controversial whether abcanum increase decrease generation two vitro study reported increased abcanum expression reduced production num num whereas third study reported opposite finding num
0.29108343.15269218.html.plaintext.txt	270	genetic variation abcanum reported alter susceptibility ad num num although additional study necessary fully validate result
0.29108343.15269218.html.plaintext.txt	271	clearly understanding contribution abcanum ad require vivo study contribution glial neuronal abcanum pathogenesis ad evaluated appropriate physiological context
0.29108343.15269218.html.plaintext.txt	272	summary demonstrate glial abcanum key participant apoe metabolism
0.29108343.15269218.html.plaintext.txt	273	show selective disruption abcanum reduces cholesterol efflux exogenous apoe impairs apoe secretion astrocyte microglia
0.29108343.15269218.html.plaintext.txt	274	result abcanum glia accumulate lipid normal culture condition
0.29108343.15269218.html.plaintext.txt	275	vivo abcanum required maintain normal level apoe brain
0.29108343.15269218.html.plaintext.txt	276	effect abcanum specific apoe independent hdl apoa level
0.29108343.15269218.html.plaintext.txt	277	taken together observation provide clear direct link abcanum apoe metabolism brain
0.29108343.15269218.html.plaintext.txt	278	footnote cost publication article defrayed part payment page charge
0.29108343.15269218.html.plaintext.txt	279	article must therefore hereby marked advertisement accordance num u
0.29108343.15269218.html.plaintext.txt	280	section num solely indicate fact
0.29108343.15269218.html.plaintext.txt	281	supported british columbia research institute childrens woman health bcricwh
0.29108343.15269218.html.plaintext.txt	282	supported operating grant canadian institute health research cihr cihrpfizer investigator salary award
0.29108343.15269218.html.plaintext.txt	283	hold canada research chair human genetics supported grant heart stroke foundation bc yukon hsfbcy cihr
0.29108343.15269218.html.plaintext.txt	284	supported cihr new investigator salary award operating grant cihr alzheimers society canadacihrastrazeneca
0.29108343.15269218.html.plaintext.txt	285	correspondence addressed dept
0.29108343.15269218.html.plaintext.txt	286	pathology laboratory medicine university british columbia num w
0.29108343.15269218.html.plaintext.txt	287	vancouver bc vnumz numhnum canada
0.29108343.15269218.html.plaintext.txt	288	num fax num num num e mail cherylatcmmt
0.29108343.15269218.html.plaintext.txt	289	num abbreviation used hdl high density lipoprotein ad alzheimers disease pb phosphate buffered saline dmem dulbeccos modified eagle medium gst glutathione transferase anova analysis variance gapdh glyceraldehyde num phosphate dehydrogenase cns central nervous system apoe apolipoprotein e wt wild type
0.29108343.15269218.html.plaintext.txt	290	acknowledgment thank omar francone providing abcanum deficient mouse dave holtzman john cirrito apoj antibody anita kwok yu zhou yang hayden laboratory abcanum antibody leonardo basso member research group many insightful comment suggestion throughout course work
0.29569125.7721816.html.plaintext.txt	0	num american society biochemistry molecular biology inc
0.29569125.7721816.html.plaintext.txt	1	purification apolipoprotein e attenuates isoform specific binding amyloid
0.29569125.7721816.html.plaintext.txt	2	apolipoprotein e apoe particularly enum allele genetically linked incidence alzheimers disease
0.29569125.7721816.html.plaintext.txt	3	vitro apoe shown bind amyloid amyloidogenic peptide aggregate form primary component senile plaque
0.29569125.7721816.html.plaintext.txt	4	previous work demonstrated apoenum tissue culture medium bind greater avidity apoenum ladu m
0.29569125.7721816.html.plaintext.txt	5	contrast data using purified apoe isoforms substrate strittmatter w
0.29569125.7721816.html.plaintext.txt	6	resolve apparent discrepancy demonstrating preferential binding apoenum attenuated even abolished purification process includes delipidation denaturation
0.29569125.7721816.html.plaintext.txt	7	compared binding capacity unpurified apoe isoforms tissue culture medium intact human low density lipoprotein apoe purified two source
0.29569125.7721816.html.plaintext.txt	8	interaction human num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num peptide apoe analyzed nonreducing sd polyacrylamide gel electrophoresis followed western immunoblotting either apoe immunoreactivity
0.29569125.7721816.html.plaintext.txt	9	level apoenuma complex num fold greater compared apoenuma complex unpurified conditioned medium apoenum apoenum purified medium bound comparable avidity
0.29569125.7721816.html.plaintext.txt	10	moreover using endogenous apoe low density lipoprotein plasma apoenumnum apoenumnum homozygote apoenum better substrate apoenum
0.29569125.7721816.html.plaintext.txt	11	however apoe purified plasma lipoprotein exhibited little isoform specificity binding
0.29569125.7721816.html.plaintext.txt	12	result suggest native preparation apoe may physiologically relevant substrate binding purified apoe underscore importance subtle difference apoe conformation biological activity
0.29569125.7721816.html.plaintext.txt	13	apolipoprotein e apoe component several class lipoprotein act ligand lipoprotein receptor thus regulating lipid transport clearance
0.29569125.7721816.html.plaintext.txt	14	apoe also expressed brain num response injury peripheral num central nervous num system
0.29569125.7721816.html.plaintext.txt	15	human apoe three major isoforms enum cys cys enum cys arg enum arg arg product three allele single gene locus
0.29569125.7721816.html.plaintext.txt	16	presence cysteine apoenum apoenum allow isoforms form disulfide linked dimer
0.29569125.7721816.html.plaintext.txt	17	recently demonstrated apoe enum allele present increased frequency patient sporadic num late onset familial num alzheimers disease ad
0.29569125.7721816.html.plaintext.txt	18	due primarily genetic linkage role apoe pathogenesis ad actively pursued
0.29569125.7721816.html.plaintext.txt	19	major neuropathological feature ad presence extracellular senile plaque composed predominantly aggregated amyloid peptide
0.29569125.7721816.html.plaintext.txt	20	physiological mechanism apoe contributes ad pathology may mean isoform specific interaction
0.29569125.7721816.html.plaintext.txt	21	apoe colocalize senile plaque num synthetic peptide bind vitro apoe tissue culture medium num cerebrospinal fluid num num num well purified apoe num num
0.29569125.7721816.html.plaintext.txt	22	however study involving apoe isoform specificity binding limited contradictory
0.29569125.7721816.html.plaintext.txt	23	previous work demonstrated apoenum tissue culture medium bind greater avidity apoenum num
0.29569125.7721816.html.plaintext.txt	24	contrast data strittmatter et al
0.29569125.7721816.html.plaintext.txt	25	num used apoe isoforms purified human plasma substrate
0.29569125.7721816.html.plaintext.txt	26	resolve apparent discrepancy study demonstrating previously observed preferential association apoenum attenuated abolished purification process includes delipidation denaturation
0.29569125.7721816.html.plaintext.txt	27	expression human apoe cultured cell human apoenum apoenum expressed hek num cell stably transfected human apoenum apoenum product enum enum allele respectively cdna described previously num
0.29569125.7721816.html.plaintext.txt	28	conditioned medium containing apoe concentrated centriprep amicon inc
0.29569125.7721816.html.plaintext.txt	29	num fold prior binding reaction purification
0.29569125.7721816.html.plaintext.txt	30	purification apoe human plasma screened apoe genotype using modification method hixson vernier num
0.29569125.7721816.html.plaintext.txt	31	intermediate low density lipoprotein vldl particle d num
0.29569125.7721816.html.plaintext.txt	32	num gml isolated num plasma individual homozygous apoenum apoenum
0.29569125.7721816.html.plaintext.txt	33	unpurified preparation vldl used within num week isolation
0.29569125.7721816.html.plaintext.txt	34	purification apoe lipoprotein fraction concentrated conditioned medium carried according standard procedure num
0.29569125.7721816.html.plaintext.txt	35	briefly conditioned medium lipoprotein dialyzed num
0.29569125.7721816.html.plaintext.txt	36	num edta lyophilized delipidated chclmeoh numnum
0.29569125.7721816.html.plaintext.txt	37	delipidated protein pelleted meoh solubilized num m guanidine num
0.29569125.7721816.html.plaintext.txt	38	protein fractionated sephacryl num column pharmacia biotech inc
0.29569125.7721816.html.plaintext.txt	39	equilibrated num m guanidine num
0.29569125.7721816.html.plaintext.txt	40	fraction containing apoe dialyzed num m m nhhco lyophilized resuspended num
0.29569125.7721816.html.plaintext.txt	41	unpurified purified apoe protein quantified sd polyacrylamide gel electrophoresis protein staining densitometry molecular dynamic inc
0.29569125.7721816.html.plaintext.txt	42	serial dilution apoe containing sample using purified apoe standard
0.29569125.7721816.html.plaintext.txt	43	apoea complex formation detection binding reaction synthetic human num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num num peptide purified high performance liquid chromatography resuspended num m m num meso
0.29569125.7721816.html.plaintext.txt	44	apoe num microgml num n m incubated num h except noted legend fig
0.29569125.7721816.html.plaintext.txt	45	num room temperature num micro m ph num
0.29569125.7721816.html.plaintext.txt	46	control reaction without contained num meso
0.29569125.7721816.html.plaintext.txt	47	reaction stopped addition num nonreducing laemmli buffer num num sd num mercaptoethanol frozen num degree c
0.29569125.7721816.html.plaintext.txt	48	sample boiled num min electrophoresed num num sd tricine gel transferred immobilon p membrane millipore corp
0.29569125.7721816.html.plaintext.txt	49	probed antibody apoe numnum dilution
0.29569125.7721816.html.plaintext.txt	50	monoclonal antibody numgnum amino acid num num provided drs
0.29569125.7721816.html.plaintext.txt	51	apoe antiserum obtained immunizing rabbit apoe purified human serum
0.29569125.7721816.html.plaintext.txt	52	protein western blot visualized enhanced chemiluminescence amersham corp
0.29569125.7721816.html.plaintext.txt	53	quantified densitometry
0.29569125.7721816.html.plaintext.txt	54	figure num time course binding apoe isoforms purified human plasma
0.29569125.7721816.html.plaintext.txt	55	shown western blot apoea binding reaction assayed condition described legend fig
0.29569125.7721816.html.plaintext.txt	56	num probed numgnum antibody apoe antiserum b
0.29569125.7721816.html.plaintext.txt	57	apoe purified human plasma apoenumnum lane num num apoenumnum lane num num homozygote
0.29569125.7721816.html.plaintext.txt	58	lane num num apoe alone lane num num num num apoe num min num min num h num h num h respectively
0.29569125.7721816.html.plaintext.txt	59	genetic data defined presence enum allele apoe major risk factor occurrence sporadic num late onset familial num alzheimers disease
0.29569125.7721816.html.plaintext.txt	60	however physiological mechanism apoe isoform specificity contributes pathogenesis disease unknown
0.29569125.7721816.html.plaintext.txt	61	previously using unpurified apoe conditioned medium showed amount apoenuma complex much greater compared apoenuma complex num
0.29569125.7721816.html.plaintext.txt	62	result contrast data published strittmatter et al
0.29569125.7721816.html.plaintext.txt	63	using apoe purified human plasma reported apoenum bind rapidly apoenum
0.29569125.7721816.html.plaintext.txt	64	however level binding apoenum apoenum several hour incubation comparable
0.29569125.7721816.html.plaintext.txt	65	major difference two study source apoe plasma versus secreted cultured cell whether apoe protein purified prior use binding assay
0.29569125.7721816.html.plaintext.txt	66	study examined whether difference could account discrepancy two report regarding apoe isoform specific binding
0.29569125.7721816.html.plaintext.txt	67	compared binding capacity unpurified apoe conditioned medium intact human vldl plasma apoenumnum apoenumnum homozygote binding capacity apoe purified two source
0.29569125.7721816.html.plaintext.txt	68	purification procedure num used used strittmatter et al
0.29569125.7721816.html.plaintext.txt	69	first examined effect purification apoe conditioned medium formation apoea complex
0.29569125.7721816.html.plaintext.txt	70	apoenum apoenum purified medium transfected hek num cell binding material compared binding unpurified apoe medium fig
0.29569125.7721816.html.plaintext.txt	71	prior purification amount apoenuma complex fig
0.29569125.7721816.html.plaintext.txt	72	num b lane num num fold greater compared apoenuma complex lane num
0.29569125.7721816.html.plaintext.txt	73	result consistent previous data demonstrated preferential binding apoenum maintained time ph range concentration apoe num
0.29569125.7721816.html.plaintext.txt	74	purification apoe isoforms medium resulted decrease binding apoenum fig
0.29569125.7721816.html.plaintext.txt	75	num b lane num increase binding apoenum lane num
0.29569125.7721816.html.plaintext.txt	76	determine whether auxiliary component influence isoform specificity apoe binding present medium hek num cell reconstituted purified apoe mock transfected conditioned medium
0.29569125.7721816.html.plaintext.txt	77	isoform specificity apoe binding restored pre purification level indicating purification remove component present medium confers preferential binding apoenum compare fig
0.29569125.7721816.html.plaintext.txt	78	figure num apoea binding effect purifying apoe isoforms conditioned medium
0.29569125.7721816.html.plaintext.txt	79	shown western blot binding reaction using num microgml apoe num n m incubated lane num num num num without lane num num num num num micro m num num peptide num h room temperature
0.29569125.7721816.html.plaintext.txt	80	source apoe follows conditioned medium transfected cell apoenum lane num num apoenum lane num num purified conditioned medium apoenum lane num num apoenum lane num num
0.29569125.7721816.html.plaintext.txt	81	sample run nonreducing laemmli buffer num num sd tricine gel transferred immobilon p membrane probed numgnum antibody apoe antiserum b
0.29569125.7721816.html.plaintext.txt	82	examine binding unpurified plasma apoe isoforms vldl isolated plasma apoenumnum apoenumnum homozygote used binding reaction
0.29569125.7721816.html.plaintext.txt	83	similar result using unpurified apoe conditioned medium observed num fold difference amount apoenuma complex fig
0.29569125.7721816.html.plaintext.txt	84	num b lane num compared apoenuma complex lane num using intact vldl particle source apoe
0.29569125.7721816.html.plaintext.txt	85	purification apoe medium purification apoe vldl fraction human plasma attenuated preferential binding apoenum fig
0.29569125.7721816.html.plaintext.txt	86	level binding apoenum apoenum dimer increased purification apoe plasma
0.29569125.7721816.html.plaintext.txt	87	apoenumnum plasma apoe immunoreactive specie migrating slightly higher apoea complex num kda apoenum apolipoprotein ii heterodimer fig
0.29569125.7721816.html.plaintext.txt	88	autoradiograph shown fig
0.29569125.7721816.html.plaintext.txt	89	num num representative several experiment similar result using different apoe containing preparation
0.29569125.7721816.html.plaintext.txt	90	variation purification mediated loss preferential apoenum binding observed general purification apoe medium plasma abolished isoform specific binding
0.29569125.7721816.html.plaintext.txt	91	figure num apoea binding effect purifying apoe isoforms human plasma
0.29569125.7721816.html.plaintext.txt	92	shown western blot apoea binding reaction assayed condition described legend fig
0.29569125.7721816.html.plaintext.txt	93	source apoe follows intact vldl apoenumnum lane num num apoenumnum lane num num homozygote purified vldl apoenumnum lane num num apoenumnum lane num num homozygote
0.29569125.7721816.html.plaintext.txt	94	sample run described legend fig
0.29569125.7721816.html.plaintext.txt	95	num probed numgnum antibody apoe antiserum b
0.29569125.7721816.html.plaintext.txt	96	apoenum vldl total protein num ng microl triglyceride num ng microl
0.29569125.7721816.html.plaintext.txt	97	apoenum vldl total protein num ng microl triglyceride num ng microl
0.29569125.7721816.html.plaintext.txt	98	num used apoe purified plasma show bind apoenum monomer faster rate apoenum monomer
0.29569125.7721816.html.plaintext.txt	99	however contribution apoenum complex time course data difficult discern since blot probed apoe immunoreactivity simultaneously num
0.29569125.7721816.html.plaintext.txt	100	therefore repeated time course study using purified plasma apoe isoforms probed fig
0.29569125.7721816.html.plaintext.txt	101	num b immunoreactivity individually
0.29569125.7721816.html.plaintext.txt	102	similar result obtained strittmatter et al
0.29569125.7721816.html.plaintext.txt	103	num apoenum monomer form complex faster rate compared apoenum monomer
0.29569125.7721816.html.plaintext.txt	104	however apoenum dimer complex taken account total binding apoenum apoenum remained comparable across time
0.29569125.7721816.html.plaintext.txt	105	several possibility could account loss isoform specificity binding purified apoe
0.29569125.7721816.html.plaintext.txt	106	purification may result change oxidative state apoe influence binding
0.29569125.7721816.html.plaintext.txt	107	although apoe isoforms subject condition undergoing purification oxidation could specific cysin apoenum
0.29569125.7721816.html.plaintext.txt	108	could affect conformation dependent binding apoe either directly via interaction amino acid residue
0.29569125.7721816.html.plaintext.txt	109	however apoenum dimer particularly purified form readily bind indicating least oxidation cysteine seem adversely affect apoenum complex formation
0.29569125.7721816.html.plaintext.txt	110	addition oxidation provides obvious explanation increase binding purified apoenum monomer
0.29569125.7721816.html.plaintext.txt	111	another likely explanation apoe acquires conformation lipid associated confers isoform specific binding
0.29569125.7721816.html.plaintext.txt	112	purification includes delipidation may increase binding apoenum dimer apoenum monomer disrupting endogenous conformation apoe specie
0.29569125.7721816.html.plaintext.txt	113	unpurified preparation used apoe lipid associated
0.29569125.7721816.html.plaintext.txt	114	apoe human plasma vldl fraction majority apoe conditioned medium high density lipid fraction
0.29569125.7721816.html.plaintext.txt	115	purified apoe shown require lipid restore biological activity assay system presumably allowing denatured protein refold functional conformation
0.29569125.7721816.html.plaintext.txt	116	apoe activity assay include diverse function receptor binding modulation neuritic growth
0.29569125.7721816.html.plaintext.txt	117	purified apoe unable displace labeled low density lipoprotein ldl ldl receptor num high affinity binding restored apoe added presence variety lipid particle including phospholipid vesicle num
0.29569125.7721816.html.plaintext.txt	118	similarly binding purified apoe ldl receptor related protein enhanced addition migrating vldl num
0.29569125.7721816.html.plaintext.txt	119	primary dorsal root ganglion culture purified apoenum apoenum effect neuritic growth
0.29569125.7721816.html.plaintext.txt	120	however added presence migrating vldl apoe isoforms affect neuritic growth apoenum increasing neuritic extension decreasing branching apoenum decreasing branching extension num
0.29569125.7721816.html.plaintext.txt	121	experiment progress using assay system described determine nature interaction lipid associated apoe using endogenous lipoprotein reconstituted lipid vesicle
0.29569125.7721816.html.plaintext.txt	122	data presented consistent function apoe pathogenesis ad sequestering
0.29569125.7721816.html.plaintext.txt	123	avid binding apoenum soluble neuropil could lead enhanced clearance altered fibril formation could prevent conversion neurotoxic specie
0.29569125.7721816.html.plaintext.txt	124	since lipid associated apoenum apoenum bind ldl receptor ldl receptor related protein equal affinity num efficient uptake clearance may depend preferential binding apoenum
0.29569125.7721816.html.plaintext.txt	125	alternatively purified apoenum apoenum known differ respect effect fibril formation num num num suggesting native apoe may play even greater isoform specific role extracellular aggregation due difference binding characteristic
0.29569125.7721816.html.plaintext.txt	126	finally evidence induced toxicity hippocampal neuron attenuated addition rabbit apoe num leading intriguing possibility human apoe may contribute induced toxicity isoform specific manner
0.29569125.7721816.html.plaintext.txt	127	summary using unpurified apoe tissue culture medium intact vldl particle apoenuma complex num fold abundant apoenuma complex
0.29569125.7721816.html.plaintext.txt	128	isoform specificity attenuated abolished apoe purified two source used binding reaction
0.29569125.7721816.html.plaintext.txt	129	apoe apolipoprotein endogenous conformation requires lipid
0.29569125.7721816.html.plaintext.txt	130	therefore surprising type apoe preparation used affect result
0.29569125.7721816.html.plaintext.txt	131	avidity binding apoenum compared apoenum demonstrated may involved isoform specific effect underlying genetic correlation apoe enum allele ad
0.29569125.7721816.html.plaintext.txt	132	physiological relevance complex plaque formation neurodegeneration awaits investigation
0.29569125.7721816.html.plaintext.txt	133	work supported part national institute health grant hlnum specialized center research atherosclerosis abbott laboratory
0.29569125.7721816.html.plaintext.txt	134	cost publication article defrayed part payment page charge
0.29569125.7721816.html.plaintext.txt	135	article must therefore hereby marked advertisement accordance num u
0.29569125.7721816.html.plaintext.txt	136	section num solely indicate fact
0.29569125.7721816.html.plaintext.txt	137	supported national institute health grant numfnum hlnum num
0.29569125.7721816.html.plaintext.txt	138	correspondence addressed dept
0.29569125.7721816.html.plaintext.txt	139	pathology mc num university chicago num
0.29569125.7721816.html.plaintext.txt	140	num num num fax num num num
0.29569125.7721816.html.plaintext.txt	141	present address woman health research inst
0.29569125.7721816.html.plaintext.txt	142	wyeth ayerst research num king prussia rd
0.29569125.7721816.html.plaintext.txt	143	abbreviation used apoe apolipoprotein e ad alzheimers disease amyloid vldl low density lipoprotein tricine n num hydroxy numnum bishydroxymethylethylglycine ldl low density lipoprotein
0.29569125.7721816.html.plaintext.txt	144	falduto unpublished observation
0.29569125.7721816.html.plaintext.txt	145	reardon unpublished observation
0.29569125.7721816.html.plaintext.txt	146	thank warren wade richard perner synthesis peptide randy metzger genotyping plasma source john lukens lipoprotein isolation
0.29569125.7721816.html.plaintext.txt	147	also thank brad hyman bill rebeck helpful discussion providing apoenumnum plasma
0.29722524.9461617.html.plaintext.txt	0	minimally lipidated form cell derived apolipoprotein e exhibit isoform specific stimulation neurite outgrowth absence exogenous lipid lipoprotein ronald b
0.29722524.9461617.html.plaintext.txt	1	department pharmacological science university medical center state university new york stony brook new york num department immunology vascular biology scripps research institute la jolla california num
0.29722524.9461617.html.plaintext.txt	2	within central nervous system apolipoprotein e apoe synthesis increased response nerve injury finding may reflect role apoe neuronal remodeling
0.29722524.9461617.html.plaintext.txt	3	recent study show apoenum promotes apoenum inhibits neurite outgrowth cultured neuronal cell
0.29722524.9461617.html.plaintext.txt	4	interestingly isoform specific effect observed apoe presented cell presence exogenous lipid source rabbit low density lipoprotein vldl making difficult discern biologically active form apoe understand role lipid source
0.29722524.9461617.html.plaintext.txt	5	present study tested whether cell derived lipidated form apoe alter neurite outgrowth absence vldl constructing neuro numa cell line expressing high level apoe
0.29722524.9461617.html.plaintext.txt	6	result showed endogenous apoenum stimulated neurite outgrowth whereas endogenous apoenum isoform neutral
0.29722524.9461617.html.plaintext.txt	7	furthermore vldl antagonized stimulatory effect endogenous apoenum
0.29722524.9461617.html.plaintext.txt	8	characterization secreted apoenum indicated neurite outgrowth stimulating activity could recovered culture medium anti apoe immunoaffinity column present poorly lipidated particle density num
0.29722524.9461617.html.plaintext.txt	9	result indicated biological activity apoenum stimulating neurite outgrowth inherent cell derived apoe particle dependent either interaction apoenum artificial lipid source b independent action apoenum vldl
0.29722524.9461617.html.plaintext.txt	10	apolipoprotein e apoenum num amino acid glycoprotein num first identified num constituent human low density lipoprotein vldl subsequently found lipoprotein class
0.29722524.9461617.html.plaintext.txt	11	apoe play key role cholesterol homeostasis mediating hepatic clearance plasma cholesteryl ester rich vldl chylomicron remnant
0.29722524.9461617.html.plaintext.txt	12	contrast apolipoproteins synthesized liver gut apoe expressed variety tissue cell type including abundant expression steroidogenic cell astrocyte brain num num
0.29722524.9461617.html.plaintext.txt	13	apoe present cerebrospinal fluid csf num num microgml approximately num num plasma concentration num num
0.29722524.9461617.html.plaintext.txt	14	endogenous lipoprotein csf predominantly hdl like particle arise astrocyte derived apoe addition apoai presumably cross blood brain barrier num num
0.29722524.9461617.html.plaintext.txt	15	role brain apoe known although expression appears correlated nerve injury neuronal remodeling num num
0.29722524.9461617.html.plaintext.txt	16	three common isoforms human apoe result cysteine arginine interchange residue num num num
0.29722524.9461617.html.plaintext.txt	17	apoenum contains cysteine residue num arginine residue num
0.29722524.9461617.html.plaintext.txt	18	apoenum contains num cysteine whereas apoenum contains arginine residue
0.29722524.9461617.html.plaintext.txt	19	correlation apoe num allele late onset familial alzheimers disease identified num num
0.29722524.9461617.html.plaintext.txt	20	however role apoe pathology alzheimers disease still unknown
0.29722524.9461617.html.plaintext.txt	21	evidence apoe interacts protein component pathologic feature alzheimers disease amyloid plaque neurofibrillary tangle isoform specific manner num num
0.29722524.9461617.html.plaintext.txt	22	addition purified delipidated apoe stimulate isoform specific difference neurite outgrowth added neuronal cell culture num num num
0.29722524.9461617.html.plaintext.txt	23	murine neuroblastoma cell line neuro numa exposed delipidated apoenum significantly longer neurite extension compared either control cell cell treated apoenum num
0.29722524.9461617.html.plaintext.txt	24	delipidated apoenum isoform inhibitory effect neurite outgrowth correlate destabilization microtubular array num
0.29722524.9461617.html.plaintext.txt	25	interestingly isoform specific difference observed exogenous lipid source rabbit vldl added along delipidated apoe isoforms
0.29722524.9461617.html.plaintext.txt	26	neither rabbit vldl contains abundant rabbit apoe human apoe alone alters neurite outgrowth
0.29722524.9461617.html.plaintext.txt	27	neuro numa cell line expressing low quantity apoe isoforms display similar isoform specific difference presence rabbit vldl yet indistinguishable control cell lack apoe expression absence exogenous lipid source num
0.29722524.9461617.html.plaintext.txt	28	multiple lipid source vldl triglyceride rich emulsion hdl hdl like csf lipoprotein substitute vldl propagate similar isoform specific difference num num
0.29722524.9461617.html.plaintext.txt	29	however puzzling aspect study csf lipoprotein fail induce difference neuritogenesis unless enriched exogenous human apoe num even though csf hdl like particle already contain apoe num num
0.29722524.9461617.html.plaintext.txt	30	importantly study identify physiologically significant biologically active form apoe require artificial lipid source observe apoe induced stimulated neurite outgrowth
0.29722524.9461617.html.plaintext.txt	31	apoe mediated alteration neurite outgrowth relevant neuronal remodeling event vivo likely biologically active form apoe cell derived lipidated complex act absence vldl artificial lipid source
0.29722524.9461617.html.plaintext.txt	32	test possibility constructed neuro numa cell line secrete higher level apoe isoforms
0.29722524.9461617.html.plaintext.txt	33	cell produced minimally lipidated apoenum stimulated neurite outgrowth absence exogenous lipid
0.29722524.9461617.html.plaintext.txt	34	identical condition apoenum effect neurite outgrowth indicating enum isoform neutral inhibitory
0.29722524.9461617.html.plaintext.txt	35	furthermore exogenous vldl antagonized stimulatory effect cell derived apoenum
0.29722524.9461617.html.plaintext.txt	36	thus study identified minimally lipidated form apoe biologically active promoting neurite outgrowth
0.29722524.9461617.html.plaintext.txt	37	high expression apoenum vector constructed inserting pcr generated apoenum cdna pcdnanum invitrogen
0.29722524.9461617.html.plaintext.txt	38	apoenum insert produced following pcr condition num ng template phenum generous gift john taylor david walker gladstone institute cardiovascular disease num unit taq polymerase num microm dntps num
0.29722524.9461617.html.plaintext.txt	39	num gelatin num menumso num mm kcl num mm tris hcl ph num
0.29722524.9461617.html.plaintext.txt	40	num num microm high annealing temperature primer incorporating unique num restriction enzyme site
0.29722524.9461617.html.plaintext.txt	41	translational enhancer alpha mosaic virus expression plasmid pcmvnum num inserted num base upstream apoenum cdna yield pcnumenum
0.29722524.9461617.html.plaintext.txt	42	apoenum expression vector pcnumenum made substituting sacii fsei fragment pcnumenum corresponding fragment apoenum sequence plasmid pfe num
0.29722524.9461617.html.plaintext.txt	43	pcr insert junction verified standard sequencing technique
0.29722524.9461617.html.plaintext.txt	44	production stable apoenum apoenum transfected neuro numa cell line
0.29722524.9461617.html.plaintext.txt	45	neuro numa cell maintained num degree c humidified num air num conum incubator medium dulbeccos modified eagle mediumhams fnum numnum supplemented num heat inactivated fetal bovine serum fbs atlanta biologicals num mm glutamine num unitsml penicillin num unitsml streptomycin sulfate num
0.29722524.9461617.html.plaintext.txt	46	neuro numa cell plated num
0.29722524.9461617.html.plaintext.txt	47	num x num cell num ml medium per num cm dish transfected num microg plasmid using standard calcium phosphate precipitation protocol num
0.29722524.9461617.html.plaintext.txt	48	stable integrants selected maintained medium b medium plus num microgml gnum life technology inc
0.29722524.9461617.html.plaintext.txt	49	characterization parental apoenum apoenum neuro numa cell line
0.29722524.9461617.html.plaintext.txt	50	northern blotting analysis total rna isolated confluent num cm plate parental apoenum apoenum cell line using stat num tel test reagent protocol
0.29722524.9461617.html.plaintext.txt	51	total rna num microg denatured subjected electrophoresis num
0.29722524.9461617.html.plaintext.txt	52	num m formaldehyde transferred nylon membrane overnight capillary transfer
0.29722524.9461617.html.plaintext.txt	53	membrane probed nump random primed apoe fragment nucleotide num num hybridization visualized molecular dynamic phosphorimager
0.29722524.9461617.html.plaintext.txt	54	western blotting analysis cell plated num
0.29722524.9461617.html.plaintext.txt	55	num x num cell num ml medium per num cm dish incubated overnight num degree c washed twice medium incubated additional num h num ml fresh medium
0.29722524.9461617.html.plaintext.txt	56	conditioned medium removed cell washed num time pb solubilized num
0.29722524.9461617.html.plaintext.txt	57	num ml num sd pb total protein determination
0.29722524.9461617.html.plaintext.txt	58	conditioned medium run num sd polyacrylamide gel electrophoretically transferred nitrocellulose blocked num h room temperature num mm tris hcl ph num
0.29722524.9461617.html.plaintext.txt	59	num num mm nacl tb containing num nonfat milk num
0.29722524.9461617.html.plaintext.txt	60	blocked membrane incubated affinity purified polyclonal goat anti human apoe antibody biodesign international num microgml overnight room temperature tb containing num nonfat milk num
0.29722524.9461617.html.plaintext.txt	61	membrane washed three time tb containing num
0.29722524.9461617.html.plaintext.txt	62	num tween num incubated horseradish peroxidase conjugated anti goat igg sigma num h room temperature tb containing num nonfat milk num
0.29722524.9461617.html.plaintext.txt	63	band visualized enhanced chemiluminescence amersham corp
0.29722524.9461617.html.plaintext.txt	64	neuro numa cell plated onto num mm glass circle coverslips num well tissue culture plate num
0.29722524.9461617.html.plaintext.txt	65	num x num cell num ml medium per well allowed adhere overnight num degree c
0.29722524.9461617.html.plaintext.txt	66	cell washed twice pb fixed ice cold pb containing num paraformaldehyde num min
0.29722524.9461617.html.plaintext.txt	67	cell washed twice pb permeabilized ice cold pb containing num
0.29722524.9461617.html.plaintext.txt	68	num triton x num num min blocked pb containing num fbs num
0.29722524.9461617.html.plaintext.txt	69	num triton x num additional num min num degree c
0.29722524.9461617.html.plaintext.txt	70	cell incubated affinity purified polyclonal goat anti human apoe antibody num microgml pb containing num fbs num
0.29722524.9461617.html.plaintext.txt	71	num triton x num num h num degree c
0.29722524.9461617.html.plaintext.txt	72	cell washed three time pb containing num
0.29722524.9461617.html.plaintext.txt	73	num triton x num incubated rhodamine conjugated donkey anti goat igg antibody jackson immuno research numnum pb containing num fbs num
0.29722524.9461617.html.plaintext.txt	74	num triton x num num h num degree c
0.29722524.9461617.html.plaintext.txt	75	glass slip washed three time pb containing num
0.29722524.9461617.html.plaintext.txt	76	num triton x num mounted slowfade molecular probe analyzed bio rad mrc num scanning confocal system mounted nikon diaphot inverted microscope
0.29722524.9461617.html.plaintext.txt	77	image saved bio rad pic file subsequently converted tif file
0.29722524.9461617.html.plaintext.txt	78	apoe concentration conditioned medium determined elisa follows num well plate coated num microl affinity purified goat anti human apoe antibody num microgml pb overnight num degree c
0.29722524.9461617.html.plaintext.txt	79	plate washed twice pb blocked num microl pb containing num non fat milk num h num degree c washed twice
0.29722524.9461617.html.plaintext.txt	80	coated plate incubated num degree c num h num microl conditioned medium washed twice num microl biotin labeled affinity purified goat anti human apoe polyclonal diluted numnum pb containing num
0.29722524.9461617.html.plaintext.txt	81	num non fat milk added incubated num degree c num min
0.29722524.9461617.html.plaintext.txt	82	washing four time num microl streptavidinhorseradish peroxidase life technology inc
0.29722524.9461617.html.plaintext.txt	83	diluted numnum pb containing num
0.29722524.9461617.html.plaintext.txt	84	num non fat milk added plate incubated num degree c num min
0.29722524.9461617.html.plaintext.txt	85	plate washed six time num microl numnumnumnum tetramethylbenzidine liquid substrate sigma added color development monitored num nm
0.29722524.9461617.html.plaintext.txt	86	standard curve generated purified human apoe panvera concentration ranging num num ng
0.29722524.9461617.html.plaintext.txt	87	sample assayed triplicate
0.29722524.9461617.html.plaintext.txt	88	parental apoenum apoenum neuro numa cell line trypsinized plated low cell density day num num
0.29722524.9461617.html.plaintext.txt	89	time num cell trypsinized exactly num min subsequently plated medium density num
0.29722524.9461617.html.plaintext.txt	90	num h num degree c medium removed dish washed twice basal medium medium lacking fbs freshly made basal medium plus nnum growth supplement life technology inc
0.29722524.9461617.html.plaintext.txt	91	either without rabbit vldl num microg cholesterolml added
0.29722524.9461617.html.plaintext.txt	92	cell incubated num h num degree c num medium change num h
0.29722524.9461617.html.plaintext.txt	93	num h cell fixed pb containing num
0.29722524.9461617.html.plaintext.txt	94	num glutaraldehyde num min room temperature nonspecifically stained num
0.29722524.9461617.html.plaintext.txt	95	num acridine orange pb num min
0.29722524.9461617.html.plaintext.txt	96	cell washed three time pb coverslipped
0.29722524.9461617.html.plaintext.txt	97	image captured num x objective filter group specific rhodamine fluorescence system stated
0.29722524.9461617.html.plaintext.txt	98	image converted tif format analyzed uthscsa image tool program developed university texas health science center san antonio tx
0.29722524.9461617.html.plaintext.txt	99	num every cell contained process longer cell diameter measured longest neurite
0.29722524.9461617.html.plaintext.txt	100	initial sample contained microsphere calibration standard duke scientific corp
0.29722524.9461617.html.plaintext.txt	101	affinity purification apolipoprotein e lipid particle
0.29722524.9461617.html.plaintext.txt	102	affinity chromatography isolation procedure utilizing human apoe specific monoclonal antibody nume employed
0.29722524.9461617.html.plaintext.txt	103	purified nume antibody coupled cnbr activated sepharose numb sigma incubating num mg antibody num
0.29722524.9461617.html.plaintext.txt	104	num m nacl num ml pre swelled cnbr activated sepharose numb rotary shaker overnight num degree c
0.29722524.9461617.html.plaintext.txt	105	gel washed num ml num
0.29722524.9461617.html.plaintext.txt	106	num m nacl remaining active group blocked num h num m ethanolamine ph num
0.29722524.9461617.html.plaintext.txt	107	gel washed three cycle alternating ph using num ml num
0.29722524.9461617.html.plaintext.txt	108	coupled gel packed glass column conditioned medium cell secreting apoenum recycled num mlmin overnight num degree c
0.29722524.9461617.html.plaintext.txt	109	column washed num ml pb apoenum containing particle eluted num ml num mm triethylamine ph num
0.29722524.9461617.html.plaintext.txt	110	num immediately neutralized num ml num m sodium phosphate ph num
0.29722524.9461617.html.plaintext.txt	111	apoenum particle dialyzed concentrated pb subsequently basal medium using centriprep num concentrators amicon
0.29722524.9461617.html.plaintext.txt	112	final apoenum preparation sterilized filtration pre blocked num bovine serum albumin pb num
0.29722524.9461617.html.plaintext.txt	113	num microm filter schleicher schuell
0.29722524.9461617.html.plaintext.txt	114	apoenum preparation analyzed western blotting quantified elisa described
0.29722524.9461617.html.plaintext.txt	115	trans addition analysis affinity purified apoe particle
0.29722524.9461617.html.plaintext.txt	116	parental neuro numa cell plated density num
0.29722524.9461617.html.plaintext.txt	117	num x num cell per well num well tissue culture plate costar medium
0.29722524.9461617.html.plaintext.txt	118	num h num degree c medium removed dish washed twice basal medium medium lacking fbs incubation continued num h num degree c either basal medium plus nnum supplement alone immunopurified apoenum num microgml basal medium plus nnum supplement
0.29722524.9461617.html.plaintext.txt	119	cell fixed stained analyzed stated
0.29722524.9461617.html.plaintext.txt	120	microscopy experiment coded confocal image analysis neurite measurement using double blind coding procedure
0.29722524.9461617.html.plaintext.txt	121	preparation rabbit vldl described num except protease inhibitor omitted
0.29722524.9461617.html.plaintext.txt	122	rabbit vldl stored num degree c nitrogen used within num week isolation
0.29722524.9461617.html.plaintext.txt	123	num gml isolated standard ultracentrifugation technique num
0.29722524.9461617.html.plaintext.txt	124	lipidation state apoe secreted neuro numa cell determined ultracentrifugation using kbr density adjustment
0.29722524.9461617.html.plaintext.txt	125	conditioned medium num ml adjusted num
0.29722524.9461617.html.plaintext.txt	126	num gml underlaid num ml num
0.29722524.9461617.html.plaintext.txt	127	num gml overlaid num ml num
0.29722524.9461617.html.plaintext.txt	128	gradient centrifuged numnum rpm swnum rotor num h num degree c
0.29722524.9461617.html.plaintext.txt	129	fraction collected top tube density measured weight apoe content determined elisa
0.29722524.9461617.html.plaintext.txt	130	secreted apoe delipidated diethyl etherethanol described num
0.29722524.9461617.html.plaintext.txt	131	protein measured igg standard num
0.29722524.9461617.html.plaintext.txt	132	statistical significance determined student test
0.29722524.9461617.html.plaintext.txt	133	high capacity expression vector stable expression human apoe constructed incorporating alpha mosaic virus translational enhancer apoe num untranslated region within pcdnanum vector expression driven strong cytomegalovirus promoterenhancer invitrogen
0.29722524.9461617.html.plaintext.txt	134	multiple cell line apoe isoform isolated characterized apoe production
0.29722524.9461617.html.plaintext.txt	135	num show similar level apoenum apoenum mrna representative cell line expressing transfected apoe cdna whereas apoe mrna detected parental cell line
0.29722524.9461617.html.plaintext.txt	136	conditioned medium cell line analyzed western blotting using affinity purified apoe polyclonal antibody shown fig
0.29722524.9461617.html.plaintext.txt	137	parent neuro numa cell line completely devoid apoe immunoreactivity whereas apoenum apoenum cell line showed expected num kda apoe band
0.29722524.9461617.html.plaintext.txt	138	quantification apoe accumulation conditioned medium showed high level expression apoenum apoenum cell line table
0.29722524.9461617.html.plaintext.txt	139	value approximately num fold greater previously reported apoe expressing neuro numa cell line num
0.29722524.9461617.html.plaintext.txt	140	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	141	northern blotting apoe mrna stably transfected cell line
0.29722524.9461617.html.plaintext.txt	142	total rna num microglane prepared parental neuro numa line apoenum expressing apoenum expressing neuro numa cell line denatured separated electrophoresis num
0.29722524.9461617.html.plaintext.txt	143	transfer nylon membrane rna visualized ethidium bromide staining verify equal amount intact rna present
0.29722524.9461617.html.plaintext.txt	144	membrane probed nump random primed apoe fragment nucleotide num num hybridization visualized molecular dynamic phosphorimager b
0.29722524.9461617.html.plaintext.txt	145	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	146	western blotting apoe secreted stably transfected cell line
0.29722524.9461617.html.plaintext.txt	147	conditioned medium num microg protein separated sd num polyacrylamide gel electrophoresis electroblotted nitrocellulose membrane
0.29722524.9461617.html.plaintext.txt	148	membrane probed affinity purified polyclonal goat anti human apoe antibody
0.29722524.9461617.html.plaintext.txt	149	incubation horseradish peroxidase conjugated anti goat igg band visualized enhanced chemiluminescence
0.29722524.9461617.html.plaintext.txt	150	slight difference mobility apoenum apoenum band due curvature running front seen experiment
0.29722524.9461617.html.plaintext.txt	151	view table table apolipoprotein e secretion apoe concentration measured two clone expressing apoe isoform parental neuro numa cell
0.29722524.9461617.html.plaintext.txt	152	cell line plated num
0.29722524.9461617.html.plaintext.txt	153	num x num cell per num mm dish medium incubated num degree c num h
0.29722524.9461617.html.plaintext.txt	154	plate washed basal medium num ml medium b basal nnum supplement added plate incubated num degree c num h
0.29722524.9461617.html.plaintext.txt	155	triplicate plate cell line analyzed apoe accumulation medium elisa total cell protein determined num h
0.29722524.9461617.html.plaintext.txt	156	triplicate plate cell line also allowed continue another num h fresh medium b prior measurement apoe total cell protein
0.29722524.9461617.html.plaintext.txt	157	apoe value mean plus minus standard deviation
0.29722524.9461617.html.plaintext.txt	158	neurite extension measured cell line described legend fig
0.29722524.9461617.html.plaintext.txt	159	immunocytochemical localization neuro numa associated apoe showed punctate staining pattern throughout entire cell exception nucleus devoid staining fig
0.29722524.9461617.html.plaintext.txt	160	apoe staining particularly concentrated within growth cone extending neurites apoenum apoenum expressing cell
0.29722524.9461617.html.plaintext.txt	161	analysis indicated detectable apoe expression parental cell line importantly similar level apoe expression apoenum apoenum cell line
0.29722524.9461617.html.plaintext.txt	162	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	163	immunocytochemical detection apoe stably transfected cell line
0.29722524.9461617.html.plaintext.txt	164	neuro numa parental cell b neuro numa apoenum secreting cell c neuro numa apoenum secreting cell d grown glass coverslips
0.29722524.9461617.html.plaintext.txt	165	apoe localization detected affinity purified polyclonal goat anti human apoe antibody rhodamine conjugated secondary antibody c d
0.29722524.9461617.html.plaintext.txt	166	white arrow highlight concentrated localization apoe growth cone domain apoe isoform expressing neuro numa cell
0.29722524.9461617.html.plaintext.txt	167	b transmitted light image parental neuro numa cell found black arrow highlight num neuro numa cell
0.29722524.9461617.html.plaintext.txt	168	image collected confocal microscopy num x oil immersion lens
0.29722524.9461617.html.plaintext.txt	169	cell line analyzed neurite extension assay
0.29722524.9461617.html.plaintext.txt	170	numa show representative confocal image three cell line conclusion num h assay absence vldl
0.29722524.9461617.html.plaintext.txt	171	strikingly cell secreting apoenum substantially longer neurite extension either apoenum control cell
0.29722524.9461617.html.plaintext.txt	172	quantify difference multiple image saved three independent experiment analyzed neurite length
0.29722524.9461617.html.plaintext.txt	173	numa demonstrates apoenum secreting cell line significantly longer neurites num p num
0.29722524.9461617.html.plaintext.txt	174	num versus control either control set num apoenum secreting cell num absence vldl
0.29722524.9461617.html.plaintext.txt	175	data analyzed ascertain whether observed mean difference indicative uniform behavior within cell population due minor subpopulation cell dramatically longer neurites
0.29722524.9461617.html.plaintext.txt	176	numb illustrates distribution neurite length shifted throughout cell population apoenum secreting cell whereas apoenum secreting cell nearly indistinguishable control cell
0.29722524.9461617.html.plaintext.txt	177	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	178	cell derived apoe isoform effect neurite outgrowth absence presence vldl
0.29722524.9461617.html.plaintext.txt	179	cell grown num h nnum supplemented basal medium alone presence vldl num microg cholesterolml b
0.29722524.9461617.html.plaintext.txt	180	cell fixed permeabilized nonspecifically stained acridine orange conclusion num h assay
0.29722524.9461617.html.plaintext.txt	181	confocal image captured using num x objective filter group specific rhodamine fluorescence
0.29722524.9461617.html.plaintext.txt	182	figure show negative image transformed image tool program
0.29722524.9461617.html.plaintext.txt	183	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	184	quantification cell derived apoe isoform effect neurite outgrowth absence presence vldl
0.29722524.9461617.html.plaintext.txt	185	cell grown num h nnum supplemented basal medium alone presence vldl num microg cholesterolml
0.29722524.9461617.html.plaintext.txt	186	cell fixed permeabilized nonspecifically stained acridine orange
0.29722524.9461617.html.plaintext.txt	187	multiple confocal image treatment three cell line captured using num x objective analyzed image tool program
0.29722524.9461617.html.plaintext.txt	188	neurite extension determined measuring longest neurite outgrowth num num responsive cell cell containing neurite least num cell diameter length
0.29722524.9461617.html.plaintext.txt	189	show average neurite extension three independent experiment absence presence vldl error bar indicate standard error
0.29722524.9461617.html.plaintext.txt	190	level significance difference calculated apoenum secreting cell compared control neuro numa cell absence vldl p num
0.29722524.9461617.html.plaintext.txt	191	num apoenum secreting cell absence vldl compared apoenum secreting cell presence vldl p num
0.29722524.9461617.html.plaintext.txt	192	data analyzed determine percentage total cell n expressing neurites defined length absence vldl b presence vldl c
0.29722524.9461617.html.plaintext.txt	193	error bar b c indicate standard deviation
0.29722524.9461617.html.plaintext.txt	194	error bar shown within area symbol
0.29722524.9461617.html.plaintext.txt	195	apoe concentration medium num num h extension assay measured two clonal line expressing apoe isoform
0.29722524.9461617.html.plaintext.txt	196	table show variation secreted apoe yet neurite extension result clone consistent isoform specific modulation relatively unaffected small difference secreted apoe
0.29722524.9461617.html.plaintext.txt	197	example numc numenumc clone showed identical apoe concentration num h numenumc apoe concentration differed numc concentration num num h
0.29722524.9461617.html.plaintext.txt	198	nevertheless apoenum expressing numc clone showed stimulation neurite outgrowth p num
0.29722524.9461617.html.plaintext.txt	199	num whereas apoenum expressing numenumc clone
0.29722524.9461617.html.plaintext.txt	200	data indicate cell derived apoenum stimulated neurite outgrowth absence vldl whereas identical condition apoenum neutral
0.29722524.9461617.html.plaintext.txt	201	numb show image cell line num h exposure vldl
0.29722524.9461617.html.plaintext.txt	202	surprisingly addition vldl extension assay reduced apoenum neurite extension compared apoenum extension absence vldl
0.29722524.9461617.html.plaintext.txt	203	numa vldl reduced neurite outgrowth apoenum expressing cell num control num control p num
0.29722524.9461617.html.plaintext.txt	204	num whereas vldl significant effect p num
0.29722524.9461617.html.plaintext.txt	205	num neurite outgrowth control neruo numa apoenum expressing cell line
0.29722524.9461617.html.plaintext.txt	206	numc vldl appeared normalize neurite length distribution three cell line
0.29722524.9461617.html.plaintext.txt	207	thus vldl inhibited neurite outgrowth apoenum expressing cell p num
0.29722524.9461617.html.plaintext.txt	208	num effect control apoenum expressing cell p num
0.29722524.9461617.html.plaintext.txt	209	important question result whether effect apoenum neurite outgrowth reflected extracellular action secreted protein
0.29722524.9461617.html.plaintext.txt	210	alternative possibility effect due intracellular apoe indirect result high level apolipoprotein secretion might perturb lipid homeostasis within cell
0.29722524.9461617.html.plaintext.txt	211	test possibility isolated secreted apoenum conditioned medium affinity chromatography monoclonal antibody nume
0.29722524.9461617.html.plaintext.txt	212	series five trans addition experiment performed isolated apoenum num microgml incubated parental neuro numa cell num h extension assay
0.29722524.9461617.html.plaintext.txt	213	numa illustrates immunopurified apoenum maintained ability stimulate significant increase average neurite length num control p num
0.29722524.9461617.html.plaintext.txt	214	furthermore population distribution neurite length cell treated purified apoenum closely resembled distribution seen transfected apoenum cell line absence vldl fig
0.29722524.9461617.html.plaintext.txt	215	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	216	effect immunopurified apoenum neurite outgrowth neuro numa cell
0.29722524.9461617.html.plaintext.txt	217	neuro numa cell incubated nnum supplemented basal medium alone presence num microgml cell derived apoenum num h
0.29722524.9461617.html.plaintext.txt	218	cell fixed permeabilized nonspecifically stained acridine orange
0.29722524.9461617.html.plaintext.txt	219	multiple confocal image either treatment captured using num x objective analyzed image tool program
0.29722524.9461617.html.plaintext.txt	220	average neurite extension determined measuring longest neurite num num responsive cell five independent experiment
0.29722524.9461617.html.plaintext.txt	221	error bar indicate standard error
0.29722524.9461617.html.plaintext.txt	222	level significance difference p num
0.29722524.9461617.html.plaintext.txt	223	data analyzed determine percentage neuro numa cell n expressing neurites defined length b
0.29722524.9461617.html.plaintext.txt	224	error bar indicate standard deviation
0.29722524.9461617.html.plaintext.txt	225	previous study shown apoe secreted non hepatic cell poorly lipidated num num
0.29722524.9461617.html.plaintext.txt	226	therefore lipidation state apoe secreted neuro numa cell determined density gradient ultracentrifugation
0.29722524.9461617.html.plaintext.txt	227	secreted apoe isoforms floated density num
0.29722524.9461617.html.plaintext.txt	228	num gml indicating poorly lipidated particle fig
0.29722524.9461617.html.plaintext.txt	229	none secreted apoe density typical apoe containing plasma hdl fig
0.29722524.9461617.html.plaintext.txt	230	numc secreted apoe shifted higher density upon delipidation fig
0.29722524.9461617.html.plaintext.txt	231	result indicate physiologically relevant lipid poor form secreted apoenum enhanced neurite outgrowth
0.29722524.9461617.html.plaintext.txt	232	view larger version numk fig
0.29722524.9461617.html.plaintext.txt	233	density distribution neuro numa derived apoe
0.29722524.9461617.html.plaintext.txt	234	cell derived apoe isoforms analyzed density distribution density gradient ultracentrifugation
0.29722524.9461617.html.plaintext.txt	235	conditioned medium apoenum apoenum expressing neuro numa cell centrifuged kbr density gradient num h fraction taken top tube
0.29722524.9461617.html.plaintext.txt	236	fraction assayed elisa apoe content density determined weight
0.29722524.9461617.html.plaintext.txt	237	graph show percent total apoenum apoenum b apoe hdlnum c delipidated apoenum comparison apoenum conditioned medium d per fraction
0.29722524.9461617.html.plaintext.txt	238	produced high expressing apoenum apoenum neuro numa cell line test whether cell derived apoe could exhibit isoform specific stimulation neurite outgrowth absence exogenous lipid source
0.29722524.9461617.html.plaintext.txt	239	apoenum stimulated neurite outgrowth absence vldl exogenous lipid source
0.29722524.9461617.html.plaintext.txt	240	furthermore cell derived lipidated apoenum isolated immunoaffinity chromatography active promoting neurite outgrowth parental neuro numa cell
0.29722524.9461617.html.plaintext.txt	241	num discovered co addition purified delipidated apoe vldl neuro numa cell elicits isoform specific difference neurite outgrowth effect also seen cell line primary neuronal culture num num num
0.29722524.9461617.html.plaintext.txt	242	interestingly isoform specific effect could duplicated apoe addition alone
0.29722524.9461617.html.plaintext.txt	243	similarly neuro numa cell line express low amount apoe isoforms also required vldl elicit effect neurite outgrowth num
0.29722524.9461617.html.plaintext.txt	244	unclear study whether apoenum stimulates neurite outgrowth independently concert exogenous lipid whether active form apoe formed combined exogenous lipid source
0.29722524.9461617.html.plaintext.txt	245	result indicated biological activity apoenum stimulating neurite outgrowth inherent cell derived lipidated particle dependent either interaction apoenum artificial lipid source b independent action apoenum vldl neuro numa cell
0.29722524.9461617.html.plaintext.txt	246	demonstrated cell derived apoenum neutral challenged neurite extension assay absence vldl
0.29722524.9461617.html.plaintext.txt	247	although study implicated apoenum inhibitory neurite outgrowth presence artificial lipid source num num study support conclusion apoenum neutral
0.29722524.9461617.html.plaintext.txt	248	num showed apoenum enhancement neurite outgrowth neuronal cell line gtnum num trknum presence vldl nerve growth factor significant difference apoenum treated cell control condition
0.29722524.9461617.html.plaintext.txt	249	experiment gtnum num trknum cell give similar result hdl sized particle human csf substituted vldl num
0.29722524.9461617.html.plaintext.txt	250	study puttfarcken et al
0.29722524.9461617.html.plaintext.txt	251	num showed bulk conditioned medium hek num cell stably expressing either apoenum apoenum isoforms moderately stimulatory primary hippocampal culture
0.29722524.9461617.html.plaintext.txt	252	experiment num num well present result argue apoenum isoform devoid neurite stimulating activity inhibitory presented cell alone combination exogenous lipid cell derived lipidated particle
0.29722524.9461617.html.plaintext.txt	253	present neurite extension assay vldl antagonized stimulatory effect apoenum effect detected previous study vldl required effect delipidated apoe num num num num
0.29722524.9461617.html.plaintext.txt	254	may experiment delipidated apoe vldl act lipid source facilitate formation active apoe particle time antagonizes action lipidated apoe
0.29722524.9461617.html.plaintext.txt	255	case level apoenum stimulated neurite outgrowth would depend balance two factor
0.29722524.9461617.html.plaintext.txt	256	furthermore unlikely antagonism observed present study nonspecific cytotoxic effect vldl alone modestly stimulated neurite outgrowth num effect also observed others num num num
0.29722524.9461617.html.plaintext.txt	257	antagonism vldl may reflect sequestration secreted apoe competition cellular receptor site
0.29722524.9461617.html.plaintext.txt	258	cell derived apoe occurred poorly lipidated particle density num
0.29722524.9461617.html.plaintext.txt	259	minimally lipidated form apoe biologically active absence exogenous lipid source unlikely neurite outgrowth stimulation reflects action apoe simply deliver lipid cell membrane formation
0.29722524.9461617.html.plaintext.txt	260	speculate apoe acted extracellularly direct neurite extension paracrine factor stimulate neurite growth
0.29722524.9461617.html.plaintext.txt	261	lipidated apoenum particle stimulate neurite outgrowth although apoenum remains neutral ldl receptor ldl receptor related protein lrp bind apoe containing lipoprotein expressed neuronal cell num num
0.29722524.9461617.html.plaintext.txt	262	evidence several study implicate lrp apoe isoform specific stimulation neurite outgrowth num num num
0.29722524.9461617.html.plaintext.txt	263	particular inhibition apoenum effect neurite outgrowth anti lrp antibody provides strong evidence involvement lrp
0.29722524.9461617.html.plaintext.txt	264	however binding study lrp show isoform specific difference apoenum apoenum num
0.29722524.9461617.html.plaintext.txt	265	discrepancy may resolved recent report apoe receptor
0.29722524.9461617.html.plaintext.txt	266	new apoe receptor described localizes neuron high homology ldl receptor num
0.29722524.9461617.html.plaintext.txt	267	additional brain specific receptor high homology lrp num ldl receptor num also identified
0.29722524.9461617.html.plaintext.txt	268	present finding cell derived form apoenum active stimulating neurite outgrowth permit physical characterization particle analysis isoform specific interaction recently described neuronal receptor
0.29722524.9461617.html.plaintext.txt	269	thank miguel berrios william theurkauf advice confocal microscopy david colflesh katherine richards anna demian technical assistance
0.29722524.9461617.html.plaintext.txt	270	work supported grant hl num hl num nhlbi national institute health
0.29722524.9461617.html.plaintext.txt	271	cost publication article defrayed part payment page charge
0.29722524.9461617.html.plaintext.txt	272	article must therefore hereby marked advertisement accordance num u
0.29722524.9461617.html.plaintext.txt	273	section num solely indicate fact
0.29722524.9461617.html.plaintext.txt	274	correspondence addressed dept
0.29722524.9461617.html.plaintext.txt	275	pharmacological science university medical center state university new york stony brook ny num
0.29722524.9461617.html.plaintext.txt	276	num num num fax num num num e mail daveatpharm
0.29722524.9461617.html.plaintext.txt	277	num abbreviation used apoe apolipoprotein e vldl low density lipoprotein ldl low density lipoprotein hdl high density lipoprotein csf cerebrospinal fluid pb phosphate buffered saline tb tris buffered saline elisa enzyme linked immunosorbent assay lrp ldl receptor related protein fbs fetal bovine serum pcr polymerase chain reaction
0.29722524.9461617.html.plaintext.txt	278	num available internet anonymous ftp ftpmaxradnum
0.29722524.9461617.html.plaintext.txt	279	copyright num american society biochemistry molecular biology inc
0.30754375.9787187.html.plaintext.txt	0	apolipoprotein e num allele genetic risk factor left ventricular failure homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	1	effrosini economou petersen athanassios aessopos athina kladi panagiota flevari fotis karabatsos christina fragodimitri peter nicolaidis helen vrettou dimitris vassilopoulos markissia karagiorga lagana dimitrios th
0.30754375.9787187.html.plaintext.txt	2	hellenic red cross hospital athens eginition university hospital athens laiko university hospital athens onassis cardiac surgery center piraeus aghia sophia childrens hospital athens mitera maternity hospital athens institute child health athens greece
0.30754375.9787187.html.plaintext.txt	3	homozygous thalassemia organ damage mainly attributed excessive iron deposition formation oxygen free radical
0.30754375.9787187.html.plaintext.txt	4	despite appropriate transfusion chelation therapy low ferritin level patient still develop organ failure heart failure main cause death
0.30754375.9787187.html.plaintext.txt	5	study designed determine whether decreased antioxidant activity apolipoprotein e apoe num allele could represent genetic risk factor development left ventricular failure lvf thalassemia homozygote
0.30754375.9787187.html.plaintext.txt	6	total num greek thalassemia homozygote studied
0.30754375.9787187.html.plaintext.txt	7	patient divided three group group n num cardiac impairment group c n num lvf num patient lv dilatation normal lv systolic function constituted group b
0.30754375.9787187.html.plaintext.txt	8	dna obtained patient polymerase chain reaction used analyze polymorphism apoe locus
0.30754375.9787187.html.plaintext.txt	9	apoe allele frequency compared greek control sample num healthy blood donor
0.30754375.9787187.html.plaintext.txt	10	patient cardiac impairment apoe num allele frequency num
0.30754375.9787187.html.plaintext.txt	11	num different population control num
0.30754375.9787187.html.plaintext.txt	12	num patient lvf significantly higher frequency apoe num num
0.30754375.9787187.html.plaintext.txt	13	apoe num allele may represent important genetic risk factor development organ damage homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	14	num american society hematology
0.30754375.9787187.html.plaintext.txt	15	hemoglobinopathy common monogenic disorder world population first disease analyzed recombinant dna technology
0.30754375.9787187.html.plaintext.txt	16	num num known molecular pathology genetic disease possible trace almost diverse pathophysiologic feature back primary molecular defect single gene
0.30754375.9787187.html.plaintext.txt	17	num monogenic disorder phenotypic variability expected due allelic heterogeneity although sibling genotype show big phenotypic difference
0.30754375.9787187.html.plaintext.txt	18	molecular basis difference clinical expression yet fully understood
0.30754375.9787187.html.plaintext.txt	19	homozygous thalassemia characterized severe hemolytic anemia associated chronic tissue damage disease treatment related organ failure premature death
0.30754375.9787187.html.plaintext.txt	20	heart failure remains main cause death traditionally attributed iron overload regular transfusion increased iron intestinal absorption ineffective erythropoiesis life span patient
0.30754375.9787187.html.plaintext.txt	21	numnum last two decade striking improvement life quality life expectancy observed mainly due proper transfusion effective chelation therapy prevent secondary hemosiderosis
0.30754375.9787187.html.plaintext.txt	22	regular chelation therapy deferoxamine mesylate naturally occurring trihydroxamic acid produced streptomyces pilosus increase urinary fecal iron excretion resulting amelioration cardiac dysfunctionnumnum increased survival
0.30754375.9787187.html.plaintext.txt	23	num although many patient benefit therapy others continue organ dysfunction die sometimes despite intensive treatment deferoxamine
0.30754375.9787187.html.plaintext.txt	24	num thus hypothesized either deferoxamine therapy effective patient reduced defense mechanism iron overload
0.30754375.9787187.html.plaintext.txt	25	present study designed test hypothesis whether postulated genetically determined decreased antioxidant iron binding activity patient homozygous thalassemia could represent independent risk factor development heart failure
0.30754375.9787187.html.plaintext.txt	26	apolipoprotein e apoe plasma protein known function cholesterol transport metabolism alzheimers disease
0.30754375.9787187.html.plaintext.txt	27	numnum apoe gene located chromosome num polymorphism exists apoe locus three common allele designated num num num corresponding three isoforms apoe protein
0.30754375.9787187.html.plaintext.txt	28	num recently shown apoe physiologic level isoform specific effect protecting rat neuronal cell line oxidative cell death effect correlated apoes antioxidant activity vitro assay ranked enum enum enum
0.30754375.9787187.html.plaintext.txt	29	num demonstrated metal binding ability including iron apoe postulated one mechanism accounting antioxidant property
0.30754375.9787187.html.plaintext.txt	30	num hypothesized decreased antioxidant activity apoenum thalassemia homozygote might genetic risk factor development left ventricular failure lvf
0.30754375.9787187.html.plaintext.txt	31	tested hypothesis comparing frequency apoe allele num thalassemia major patient divided three group according cardiac status num frequency greek control sample
0.30754375.9787187.html.plaintext.txt	32	clinical laboratory cardiac evaluation included medical history clinical examination electrocardiographic ecg well echocardiographic study
0.30754375.9787187.html.plaintext.txt	33	echocardiographic examination performed follows two dimensional m mode echocardiogram obtained using instrument num mhz transducer
0.30754375.9787187.html.plaintext.txt	34	two dimensional study first performed identify overall cardiac anatomy motion
0.30754375.9787187.html.plaintext.txt	35	long axis parasternal short axis view midventricular level used derive following m mode measurement left ventricular end systolic end diastolic dimension left atrial right ventricular cavity dimension thickness interventricular septum posterior left ventricular wall according recommendation american society echocardiography
0.30754375.9787187.html.plaintext.txt	36	num four two chamber apical view used estimate ventricular systolic diastolic volume calculated using disc method
0.30754375.9787187.html.plaintext.txt	37	num left ventricular ejection fraction lvef calculated end diastolic volume minus end systolic volume divided end diastolic volume multiplied num
0.30754375.9787187.html.plaintext.txt	38	patient divided three group according severity heart disease based clinical evaluation echocardiographic finding
0.30754375.9787187.html.plaintext.txt	39	group patient symptom sign heart failure echocardiographic study within normal limit
0.30754375.9787187.html.plaintext.txt	40	group c patient symptom sign lvf concomitant echocardiographic finding
0.30754375.9787187.html.plaintext.txt	41	patient exhibited dyspnea exertion new york heart association nyha functional class iv fulfilled least two major framingham criterion heart failure diagnosis
0.30754375.9787187.html.plaintext.txt	42	finally patient group b asymptomatic exhibited lv dilatation lv end diastolic diameter index lveddi higher num mmmnum without left ventricular systolic dysfunction lv fractional shortening f higher num assessed echocardiographically
0.30754375.9787187.html.plaintext.txt	43	patient group receive treatment
0.30754375.9787187.html.plaintext.txt	44	another type heart failure thalassemia major associated right ventricular dilatation
0.30754375.9787187.html.plaintext.txt	45	patient kind excluded study right ventricular failure thalassemia major due different pathophysiologic reason
0.30754375.9787187.html.plaintext.txt	46	genomic dna extracted edta blood sample salting procedure
0.30754375.9787187.html.plaintext.txt	47	num genotyping polymorphic apoe allele done polymerase chain reaction amplification genomic dna digestion hha restriction enzyme agarose gel electrophoresis described previously
0.30754375.9787187.html.plaintext.txt	48	numnum control sample data apoe genotype available consisted random sample num voluntary healthy greek blood donor
0.30754375.9787187.html.plaintext.txt	49	num blood donor num men num woman mean age num
0.30754375.9787187.html.plaintext.txt	50	num year range num num year
0.30754375.9787187.html.plaintext.txt	51	used analysis variance anova multiple group ass difference regarding echocardiographic measurement three patient group num test compare num allele frequency different patient group population control
0.30754375.9787187.html.plaintext.txt	52	num patient studied num belonged group num group b num group c
0.30754375.9787187.html.plaintext.txt	53	three case excluded study presented clinical picture congestive heart failure echocardiographic finding profound right ventricular dilatation good lv function pulmonary hypertension doppler study
0.30754375.9787187.html.plaintext.txt	54	hematologic hemosiderosis parameter patient shown table num
0.30754375.9787187.html.plaintext.txt	55	statistically significant difference found hemoglobin ferritin level patient group
0.30754375.9787187.html.plaintext.txt	56	hematologic characteristic patient thalassemia major stratified cardiac status
0.30754375.9787187.html.plaintext.txt	57	cardiologic characteristic three patient group depicted table num
0.30754375.9787187.html.plaintext.txt	58	twenty eight patient group c severe cardiac failure nyha class iii iv num class ii
0.30754375.9787187.html.plaintext.txt	59	patient group b c lv dilatation lveddi higher num mmmnum
0.30754375.9787187.html.plaintext.txt	60	group b good lv function significant difference fractional shortening ejection fraction group c table num
0.30754375.9787187.html.plaintext.txt	61	num patient group c receiving treatment angiotensin converting enzyme ace inhibitor diuretic plus minus digitalis
0.30754375.9787187.html.plaintext.txt	62	num patient group b num patient group cardiac failure echocardiographically normal lv function
0.30754375.9787187.html.plaintext.txt	63	clinical echocardiographic characteristic patient thalassemia major
0.30754375.9787187.html.plaintext.txt	64	table num give apoe allele frequency three patient group well control
0.30754375.9787187.html.plaintext.txt	65	apoe num allele highest frequency three patient group num allele frequency num
0.30754375.9787187.html.plaintext.txt	66	num group c show statistical difference control group
0.30754375.9787187.html.plaintext.txt	67	apoe num allele frequency thalassemia homozygote without cardiac impairment num
0.30754375.9787187.html.plaintext.txt	68	num different frequency population control num
0.30754375.9787187.html.plaintext.txt	69	num frequency patient heart failure num
0.30754375.9787187.html.plaintext.txt	70	num significantly higher control num num
0.30754375.9787187.html.plaintext.txt	71	num num frequency group b patient num
0.30754375.9787187.html.plaintext.txt	72	taking patient group b c together num frequency num
0.30754375.9787187.html.plaintext.txt	73	num significantly higher control num num
0.30754375.9787187.html.plaintext.txt	74	thalassemia homozygote irrespective cardiac diagnosis num frequency num
0.30754375.9787187.html.plaintext.txt	75	num different population healthy blood donor num num
0.30754375.9787187.html.plaintext.txt	76	four patient homozygous num allele three belonged group c one group b
0.30754375.9787187.html.plaintext.txt	77	apoe allele frequency patient thalassemia major control stratified cardiac status
0.30754375.9787187.html.plaintext.txt	78	severity iron toxicity thalassemia major seems related magnitude body iron burden
0.30754375.9787187.html.plaintext.txt	79	numnum exact mechanism iron overload toxicity uncertain many year
0.30754375.9787187.html.plaintext.txt	80	via iron driven fenton haber wei reaction nontransferrin plasma iron bivalent trivalent form high toxicity formation hydroxyl radical oh
0.30754375.9787187.html.plaintext.txt	81	num lead peroxidative damage membrane lipid protein
0.30754375.9787187.html.plaintext.txt	82	imbalance production oxygen free radical antioxidant defense mechanism result oxidative stress human disease
0.30754375.9787187.html.plaintext.txt	83	num heart imbalance free radical antioxidant mechanism manifested impaired function mitochondrial inner membrane respiratory chain resulting abnormal energy metabolism expressed clinically fatal cardiomyopathy
0.30754375.9787187.html.plaintext.txt	84	apart iron overload recently shown group myocarditis appears involved pathogenesis lvf certain number patient homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	85	num shown animal model oxygen free radical may also contribute pathogenesis infectious myocarditis
0.30754375.9787187.html.plaintext.txt	86	present study categorized patient three group according severity heart disease
0.30754375.9787187.html.plaintext.txt	87	normal case group severely affected case group c clear clinical echocardiographic characteristic easily distinguished
0.30754375.9787187.html.plaintext.txt	88	patient group b characterized lv dilatation good lv function
0.30754375.9787187.html.plaintext.txt	89	case lv left atrial la dilatation could possibly represent first step lv dysfunction without overt lv decreased contractility compensatory mechanism due anemia
0.30754375.9787187.html.plaintext.txt	90	patient eventually develop lvf
0.30754375.9787187.html.plaintext.txt	91	result functional polymorphism apoe locus study suggest num allele may genetic risk factor development lvf organ damage homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	92	represents first demonstration genetic factor unlinked globin gene cluster contributing clinical manifestation disease
0.30754375.9787187.html.plaintext.txt	93	num allele could represent predictive marker development lvf patient thalassemia major lv dilatation patient group b suggesting closer follow patient
0.30754375.9787187.html.plaintext.txt	94	apoe num frequency found num
0.30754375.9787187.html.plaintext.txt	95	num patient homozygous thalassemia lvf obvious genetic environmental factor instance number transfusion iron overload chelation therapy viral myocardial inflammation play role development organ damage
0.30754375.9787187.html.plaintext.txt	96	fact patient group b c shown table num either higher ferritin level transfused inadequately without cardiac impairment support role apoe num allele genetic risk factor lvf development
0.30754375.9787187.html.plaintext.txt	97	furthermore patient group num allele could still develop lvf
0.30754375.9787187.html.plaintext.txt	98	additional evidence relationship num allele heart disease come analysis patient homozygous num allele three lvf one lv dilatation number category small
0.30754375.9787187.html.plaintext.txt	99	increase num allele frequency among patient cardiac disease come reduction num rather num allele frequency num allele frequency already low greek populationnum factor may influence level allele
0.30754375.9787187.html.plaintext.txt	100	apoe num allele found patient advanced age cardiac impairment presence num allele guarantee development lvf thalassemia
0.30754375.9787187.html.plaintext.txt	101	addition num patient lvf carry num allele neither necessary prerequisite development lvf
0.30754375.9787187.html.plaintext.txt	102	equivalent association apoe num alzheimers disease association confirmed almost num study around world
0.30754375.9787187.html.plaintext.txt	103	num consensus statement apoe genotyping alzheimers disease concluded apoe genotyping used adjunct diagnostic test prospective investigation dementia function apoe genotype needednum something similar might apply thalassemia
0.30754375.9787187.html.plaintext.txt	104	allelic variation apoe locus studied many population
0.30754375.9787187.html.plaintext.txt	105	significant difference observed caucasian chinese japanese black race
0.30754375.9787187.html.plaintext.txt	106	also among caucasian population significant variation allele frequency
0.30754375.9787187.html.plaintext.txt	107	num average allele frequency caucasian show num allele frequency num
0.30754375.9787187.html.plaintext.txt	108	low num frequency greek populationnum agreement gradient found frequency allele europe supported similar low frequency num
0.30754375.9787187.html.plaintext.txt	109	num finding association apoe num allele lvf greek thalassemia homozygote need confirmation population using appropriate population control
0.30754375.9787187.html.plaintext.txt	110	well known isoform specific influence apoe plasma cholesterol level atherosclerosisnum explain association found apoe allele num lvf thalassemia homozygote atherosclerosis general feature pathophysiology disorder
0.30754375.9787187.html.plaintext.txt	111	recognized severity monogenic disorder may modified second locus depending genetic background
0.30754375.9787187.html.plaintext.txt	112	num gene involved pathogenic pathway represent candidate modifier gene
0.30754375.9787187.html.plaintext.txt	113	num boundary monogenic polygenic disorder might always clear cut previously thoughtnum gene gene interaction become known progress human genome project
0.30754375.9787187.html.plaintext.txt	114	finding increased frequency apoe num allele thalassemia homozygote lvf provides additional evidence theory oxygen free radical contributing organ damage due recently demonstrated antioxidant iron binding activity apoe
0.30754375.9787187.html.plaintext.txt	115	num suggests several genetic locus could potential relevance oxidative damage organ thalassemia
0.30754375.9787187.html.plaintext.txt	116	locus include gene modulating genesis oxygen free radical ie cytochrome c oxidase gene scavenger enzyme superoxide dismutases catalase gene regulating mitochondrial dna replication structural gene membrane lipoprotein gene involved dna repair mechanism
0.30754375.9787187.html.plaintext.txt	117	num noteworthy mutant mouse lacking mn superoxide dismutase enzyme suffer neonatal lethality due dilated cardiomyopathy
0.30754375.9787187.html.plaintext.txt	118	num functional polymorphism gene could examined association organ failure thalassemia
0.30754375.9787187.html.plaintext.txt	119	also believed genetic susceptibility majority common disease associated relatively common allele one several locus
0.30754375.9787187.html.plaintext.txt	120	submitted september num num accepted june num num
0.30754375.9787187.html.plaintext.txt	121	address reprint request effrosini economou petersen md hellenic red cross hospital num alkibiadou gr num athens greece
0.30754375.9787187.html.plaintext.txt	122	publication cost article defrayed part page charge payment
0.30754375.9787187.html.plaintext.txt	123	article must therefore hereby marked advertisement accordance num u
0.30754375.9787187.html.plaintext.txt	124	section num solely indicate fact
0.30761042.15010453.html.plaintext.txt	0	defective endoplasmic reticulum resident membrane protein clnnum affect lysosomal degradation endocytosed arylsulfatase claudia heine bettina koch stephan storch alfried kohlschutter david n
0.30761042.15010453.html.plaintext.txt	1	department biochemistry childrens hospital university hamburg d num hamburg germany animal food science division lincoln university canterbury num new zealand
0.30761042.15010453.html.plaintext.txt	2	received publication january num num revised form march num num
0.30761042.15010453.html.plaintext.txt	3	newly synthesized palmitoyl protein thioesterase num tripeptidylpeptidase num transported lysosome man num p dependent manner num num
0.30761042.15010453.html.plaintext.txt	4	binding man num p specific receptor mprnum mprnum allows segregation secretory pathway transport trans golgi network endosomal compartment
0.30761042.15010453.html.plaintext.txt	5	low ph receptor ligand complex dissociate enzyme delivered lysosome
0.30761042.15010453.html.plaintext.txt	6	soluble enzyme escape binding mpr trans golgi network secreted partially endocytosed binding mpr localized cell surface transported lysosome num
0.30761042.15010453.html.plaintext.txt	7	clnnum clnnum clnnum localized lysosome endoplasmic reticulum erer golgi intermediate compartment respectively num num
0.30761042.15010453.html.plaintext.txt	8	subcellular localization clnnum known
0.30761042.15010453.html.plaintext.txt	9	transport lysosomal membrane protein requires tyrosine dileucine based sorting signal num
0.30761042.15010453.html.plaintext.txt	10	recently lysosomal targeting motif identified clnnum protein num whereas localization clnnum er mediated kkxx er retrieval signal num
0.30761042.15010453.html.plaintext.txt	11	clnnum gene encodes highly conserved num amino acid protein six seven predicted membrane spanning domain
0.30761042.15010453.html.plaintext.txt	12	deduced amino acid sequence contains putative n glycosylation site classical lysosomal sorting signal
0.30761042.15010453.html.plaintext.txt	13	furthermore sequence homology protein described num num
0.30761042.15010453.html.plaintext.txt	14	various mutation clnnum gene identified leading variant late infantile form ncl num num num num
0.30761042.15010453.html.plaintext.txt	15	naturally occurring ncls south hampshire merino sheep oclnum nclf mouse localized clnnum num num
0.30761042.15010453.html.plaintext.txt	16	severe progressive neurodegeneration cerebral cortex accompanied astrocytosis elevated expression radical scavenger protein mn sod num num
0.30761042.15010453.html.plaintext.txt	17	furthermore difference fatty acid profile brain phosphatidylethanolamine observed oclnum affected sheep num
0.30761042.15010453.html.plaintext.txt	18	study expressed human clnnum bhknum cell investigate subcellular localization
0.30761042.15010453.html.plaintext.txt	19	furthermore transport lysosomal enzyme via biosynthetic endocytic pathway examined fibroblast clnnum patient oclnum nclf mouse
0.30761042.15010453.html.plaintext.txt	20	data indicate clnnum er resident protein
0.30761042.15010453.html.plaintext.txt	21	clnnum cloning full length clnnum cdna amplified using forward primer num cgggatccgcgatggaggcgacgcggagg num reverse primer num cccaagcttggggtgccgactgctgacgtg num image clone imag pnumenum template vector pcmvsportnum
0.30761042.15010453.html.plaintext.txt	22	pcr product subcloned frame c terminal myc tag vector pcdnanum
0.30761042.15010453.html.plaintext.txt	23	nummyc invitrogen bamhihindiii restriction site
0.30761042.15010453.html.plaintext.txt	24	untagged clnnum wild type construct amplified reverse primer num cccaagcttgggtcagtgccgactgctgac num
0.30761042.15010453.html.plaintext.txt	25	expression glutathione transferase clnnum fusion protein cdna coding aa num num amplified primer num numfor num ggaattcctgctcttcagtggctac num num numrev num ggaattcctcaccacatgcagtgacccag num subcloned ecori restriction site vector pgex numt num amersham bioscience
0.30761042.15010453.html.plaintext.txt	26	ilenumser introduced pcr using quick change site directed mutagenesis kit stratagene primer ilenumserfor num gagaaccccagcatcaagaat num ilenumserrev num attcttgatgctggggttctc num
0.30761042.15010453.html.plaintext.txt	27	clone sequenced rule pcr introduced mutation verify reading frame fusion protein
0.30761042.15010453.html.plaintext.txt	28	antibody polyclonal antibody mouse ctsd human ctsd purified mouse liver human placenta human mprnum raised rabbit num num
0.30761042.15010453.html.plaintext.txt	29	polyclonal anti myc antibody obtained santa cruz biotechnology or santa cruz ca
0.30761042.15010453.html.plaintext.txt	30	monoclonal anti myc antibody gift j
0.30761042.15010453.html.plaintext.txt	31	blanz zmnh hamburg germany produced hybridoma cell line purchased lgc promochem teddington united kingdom monoclonal antibody protein disulfide isomerase pdi purchased stressgene biotechnology corp
0.30761042.15010453.html.plaintext.txt	32	victoria british columbia canada
0.30761042.15010453.html.plaintext.txt	33	polyclonal anti clnnum antibody raised rabbit peptide sequence num num num num eurogentech seraing belgium purified sequential affinity chromatography glutathione transferase glutathione transferase clnnum num num fusion protein matrix
0.30761042.15010453.html.plaintext.txt	34	anti mouse igg cynum anti rabbit igg fluorescein isothiocyanate conjugate obtained sigma peroxidase conjugated goat anti rabbit igg jackson immunoresearch laboratory west grove pa
0.30761042.15010453.html.plaintext.txt	35	isolation culture mouse fibroblast clnnum defective mouse bnum
0.30761042.15010453.html.plaintext.txt	36	cg nclf obtained jackson laboratory bar harbor
0.30761042.15010453.html.plaintext.txt	37	age matched cnumblnum mouse served control
0.30761042.15010453.html.plaintext.txt	38	animal maintained killed according institutional guideline animal facility university hospital hamburg eppendorf
0.30761042.15010453.html.plaintext.txt	39	fibroblast prepared lung biopsy num month old mouse described previously num
0.30761042.15010453.html.plaintext.txt	40	cell culture cell transfection skin fibroblast affected south hampshire age matched control sheep well clnnum patient described previously num
0.30761042.15010453.html.plaintext.txt	41	cell cultured dulbeccos modified eagle medium invitrogen containing num fetal calf serum paa laboratory linz austria num penicillinstreptomycin humidified atmosphere containing num conum num onum num degree c
0.30761042.15010453.html.plaintext.txt	42	bhknum cell cultured condition dmemfetal calf serum transiently transfected described previously num
0.30761042.15010453.html.plaintext.txt	43	control cell transfected pcdnanum
0.30761042.15010453.html.plaintext.txt	44	metabolic labelings immunoprecipitation cell labeled numsmethionine num microciml num h followed chase indicated time
0.30761042.15010453.html.plaintext.txt	45	ctsd immunoprecipitated cell extract medium described previously num analyzed sd page fluorography
0.30761042.15010453.html.plaintext.txt	46	cell surface biotinylation mprnum immunoprecipitation cell surface protein biotinylated sulfo nh s biotin num degree c described previously num
0.30761042.15010453.html.plaintext.txt	47	washing cell incubated presence absence num mm mesna num mm tris buffer ph num
0.30761042.15010453.html.plaintext.txt	48	num containing num mm nacl num mm mgclnum num
0.30761042.15010453.html.plaintext.txt	49	num mm caclnum followed immunoprecipitation mprnum cell extract described previously num
0.30761042.15010453.html.plaintext.txt	50	ligand internalization internalization numiasa examined described previously num
0.30761042.15010453.html.plaintext.txt	51	internalized numitransferrin determined num h incubation num degree c
0.30761042.15010453.html.plaintext.txt	52	cell washed cell surface bound numitransferrin displaced acidic wash num
0.30761042.15010453.html.plaintext.txt	53	cell solubilized analyzed sd page autoradiography
0.30761042.15010453.html.plaintext.txt	54	sd page western blotting solubilized protein transfected non transfected cell separated sd page transferred nitrocellulose membrane examined clnnum myc immunoreactivity described previously num
0.30761042.15010453.html.plaintext.txt	55	cross link experiment clnnum overexpressing bhknum cell permeabilized num
0.30761042.15010453.html.plaintext.txt	56	num saponin num mm me buffer ph num
0.30761042.15010453.html.plaintext.txt	57	num containing num mm nacl num
0.30761042.15010453.html.plaintext.txt	58	num bovine serum albumin num min num degree c cross linked bsnum ds indicated concentration
0.30761042.15010453.html.plaintext.txt	59	protein analyzed western blotting num num
0.30761042.15010453.html.plaintext.txt	60	method protein concentration determined using bradford protein assay bovine serum albumin standard
0.30761042.15010453.html.plaintext.txt	61	num num microg iodinated iodo gen described previously num
0.30761042.15010453.html.plaintext.txt	62	deglycosylation experiment total bhknum extract solubilized incubated presence absence num milliunit peptide n glycosidase f pngase f num milliunits endoglycosidase h endo h roche applied science according manufacturer protocol
0.30761042.15010453.html.plaintext.txt	63	sample separated sd page followed western blot analysis
0.30761042.15010453.html.plaintext.txt	64	double immunofluorescence microscopy performed transfected bhknum cell described previously num using anti myc numnum anti pdi numnum anti mouse ctsd antibody numnum indicated
0.30761042.15010453.html.plaintext.txt	65	hexosaminidase asa activity determined described previously num num
0.30761042.15010453.html.plaintext.txt	66	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	67	overexpression clnnum bhknum cell
0.30761042.15010453.html.plaintext.txt	68	cell extract vector transfected wild type clnnum wild type clnnummychis tag expressing bhknum cell separated sd page transferred nitrocellulose membrane analyzed peptide specific clnnum antibody
0.30761042.15010453.html.plaintext.txt	69	b western blot analysis carried nitrocellulose using antibody myc tag
0.30761042.15010453.html.plaintext.txt	70	position molecular mass marker kda indicated
0.30761042.15010453.html.plaintext.txt	71	clnnum er resident protein deduced amino acid sequence predicted protein structure clnnum revealed neither potential n glycosylation site sequence nxst x amino acid classical lysosomal sorting motif
0.30761042.15010453.html.plaintext.txt	72	hand n terminal rrr sequence amino acid residue num num detected er type ii membrane protein glucosidase num whereas n terminal segment clnnum encoded exon num amino acid residue num num suggested function putative targeting signal mitochondrion num
0.30761042.15010453.html.plaintext.txt	73	investigate subcellular localization n glycosylation site introduced predicted second luminal loop
0.30761042.15010453.html.plaintext.txt	74	ile residue num substituted ser p
0.30761042.15010453.html.plaintext.txt	75	ilenumser site directed mutagenesis clnnum cdna changing sequence asn x ile asn x ser
0.30761042.15010453.html.plaintext.txt	76	ilenumser expressed bhknum cell western blot analysis revealed additional band num kda disappeared deglycosylation pngase f endo h fig
0.30761042.15010453.html.plaintext.txt	77	data demonstrate nascent clnnum polypeptide translocated lumen er became accessible glycosylation machinery
0.30761042.15010453.html.plaintext.txt	78	confirmed double immunofluorescence microscopy
0.30761042.15010453.html.plaintext.txt	79	clnnummyc protein colocalized er marker protein pdi lysosomal marker enzyme cathepsin d fig
0.30761042.15010453.html.plaintext.txt	80	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	81	extract bhknum cell overexpressing either wild type mutant clnnum p
0.30761042.15010453.html.plaintext.txt	82	ilenumser vector transfected cell incubated presence absence pngase f endo h num h num degree c
0.30761042.15010453.html.plaintext.txt	83	sample separated sd page analyzed western blot using anti myc antibody
0.30761042.15010453.html.plaintext.txt	84	position molecular mass marker protein kda indicated
0.30761042.15010453.html.plaintext.txt	85	b bhknum cell transfected clnnum wild type fixed permeabilized num h transfection
0.30761042.15010453.html.plaintext.txt	86	cell double stained myc green pdi b red myc d red ctsd e green
0.30761042.15010453.html.plaintext.txt	87	red green channel merged adjustment fluorescence signal similar level c f
0.30761042.15010453.html.plaintext.txt	88	clnnum form dimer capability clnnum form oligomeric structure membrane examined cross linkage experiment
0.30761042.15010453.html.plaintext.txt	89	semi intact bhknum cell overexpressing clnnum cross linked non cleavable reagent bsnum ds
0.30761042.15010453.html.plaintext.txt	90	immunoblot analysis showed amount num kda immunoreactive band increased cross linkage concentration dependent manner whereas intensity num kda clnnum band decreased fig
0.30761042.15010453.html.plaintext.txt	91	result indicate clnnum partially exists dimer vivo
0.30761042.15010453.html.plaintext.txt	92	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	93	chemical cross linkage overexpressed clnnum ds bsnum
0.30761042.15010453.html.plaintext.txt	94	clnnummyc fusion protein overexpressing bhknum cell permeabilized treated indicated concentration cross linker bsnum ds
0.30761042.15010453.html.plaintext.txt	95	cell extract separated sd page followed western blot analysis using anti myc antibody
0.30761042.15010453.html.plaintext.txt	96	defective clnnum mouse impair sorting processing newly synthesized cathepsin d examine whether clnnum critical transport processing man num p containing lysosomal protein secretion proteolytic modification newly synthesized ctsd determined fibroblast clnnum patient oclnum sheep nclf mouse corresponding control cell
0.30761042.15010453.html.plaintext.txt	97	human fibroblast ctsd synthesized num kda precursor form num
0.30761042.15010453.html.plaintext.txt	98	small fraction ctsd precursor study bordernumnum total secreted fig
0.30761042.15010453.html.plaintext.txt	99	majority precursor protein bind mprs trans golgi network transported prelysosomalendosomal compartment processed num kda intermediate form within num h synthesis num
0.30761042.15010453.html.plaintext.txt	100	intermediate ctsd form delivered lysosome processed mature num num kda form within num h synthesis fig
0.30761042.15010453.html.plaintext.txt	101	south hampshire sheep fibroblast labeled num h numsmethionine num kda polypeptide immunoprecipitated anti human ctsd antibody fig
0.30761042.15010453.html.plaintext.txt	102	chase period num h num num total ctsd recovered num kda mature form cell num kda form medium respectively fig
0.30761042.15010453.html.plaintext.txt	103	metabolic labeling primary mouse fibroblast followed immunoprecipitation anti mouse ctsd antibody predominant num kda polypeptide observed num
0.30761042.15010453.html.plaintext.txt	104	small amount num total synthesized ctsd detected num num kda band medium fig
0.30761042.15010453.html.plaintext.txt	105	numc suggesting variable extent glycosylation
0.30761042.15010453.html.plaintext.txt	106	result show sorting processing newly synthesized ctsd affected fibroblast clnnum patient oclnum sheep nclf mouse
0.30761042.15010453.html.plaintext.txt	107	additionally specific activity two lysosomal enzyme hexosaminidase asa comparable control human sheep mouse clnnum defective cell
0.30761042.15010453.html.plaintext.txt	108	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	109	immunoprecipitation ctsd affected fibroblast
0.30761042.15010453.html.plaintext.txt	110	fibroblast control co clnnum patient control oclnum sheep fibroblast b control nclf mouse fibroblast c metabolically labeled num h numsmethionine
0.30761042.15010453.html.plaintext.txt	111	ctsd immunoprecipitated cell extract medium
0.30761042.15010453.html.plaintext.txt	112	sample separated sd page visualized fluorography
0.30761042.15010453.html.plaintext.txt	113	position molecular mass marker kda precursor p intermediate mature m ctsd form indicated
0.30761042.15010453.html.plaintext.txt	114	accumulation endocytosed arylsulfatase clnnum defective fibroblast examine whether defective clnnum affect endocytic pathway lysosome fibroblast clnnum patient oclnum sheep nclf mouse respective control incubated numiasa num h
0.30761042.15010453.html.plaintext.txt	115	mprnum function endocytosis lysosomal enzyme num uptake asa mediated mprnum
0.30761042.15010453.html.plaintext.txt	116	asa uptake specific shown complete inhibition presence excess man num p fig
0.30761042.15010453.html.plaintext.txt	117	densitometric evaluation autoradiograph several experiment n num num showed average amount numiasa detectable human clnnum oclnum nclf cell num num num fold higher respectively control cell
0.30761042.15010453.html.plaintext.txt	118	effect specific mprnum mediated uptake amount internalized numitransferrin comparable control clnnum defective cell fig
0.30761042.15010453.html.plaintext.txt	119	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	120	man num p mnump dependent uptake numi labeled protein
0.30761042.15010453.html.plaintext.txt	121	fibroblast affected human clnnum mouse nclf sheep oclnum fibroblast corresponding control co incubated numiasa numnum cpmplate num h num degree c presence absence num mm man num p
0.30761042.15010453.html.plaintext.txt	122	removal medium displacement cell surface bound material man num p cell solubilized separated sd page
0.30761042.15010453.html.plaintext.txt	123	internalized numiasa visualized autoradiography
0.30761042.15010453.html.plaintext.txt	124	densitometric evaluation represented autoradiograph revealed num
0.30761042.15010453.html.plaintext.txt	125	num mouse num ovine fold increased amount numiasa clnnum defective cell
0.30761042.15010453.html.plaintext.txt	126	b clnnum defective cell control incubated numi labeled transferrin num h num degree c presence absence excess unlabeled transferrin
0.30761042.15010453.html.plaintext.txt	127	cell surface bound material removed acidic wash followed solubilization cell sd page autoradiography
0.30761042.15010453.html.plaintext.txt	128	increased intracellular amount numiasa clnnum defective cell could result increased rate endocytosis numiasa caused elevated concentration mprnum cell surface rapid mprnum kinetics cycling decreased degradation endocytosed numiasa
0.30761042.15010453.html.plaintext.txt	129	concentration mprnum cell surface control oclnum sheep fibroblast shown
0.30761042.15010453.html.plaintext.txt	130	determined control affected sheep fibroblast showing significant difference intracellular numiasa content endocytosis cell surface biotinylation followed immunoprecipitation mprnum western blot analysis fig
0.30761042.15010453.html.plaintext.txt	131	even cell amount mprnum cell surface control oclnum fibroblast similar indicating increased amount intracellular numiasa oclnum cell result increased concentration mprnum cell surface
0.30761042.15010453.html.plaintext.txt	132	specificity procedure shown effect mesna cleaved biotin label linkage
0.30761042.15010453.html.plaintext.txt	133	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	134	cell surface biotinylation mprnum
0.30761042.15010453.html.plaintext.txt	135	control co oclnum sheep fibroblast chilled num degree c cell surface biotinylated followed incubation presence absence reducing agent mesna
0.30761042.15010453.html.plaintext.txt	136	mprnum immunoprecipitated cell extract separated sd page num acrylamide transferred nitrocellulose membrane visualized streptavidin hrp enhanced chemiluminescence
0.30761042.15010453.html.plaintext.txt	137	examine whether degradation endocytosed numiasa inhibited clnnum defective fibroblast cell incubated numiasa fornumhatnum degree c
0.30761042.15010453.html.plaintext.txt	138	removal radioactive medium cell either harvested chased num h
0.30761042.15010453.html.plaintext.txt	139	solubilized cell analyzed sd page autoradiography fig
0.30761042.15010453.html.plaintext.txt	140	densitometry autoradiograph revealed amount intracellular numiasa detected cell clnnum patient num
0.30761042.15010453.html.plaintext.txt	141	num fold control cell num h endocytosis
0.30761042.15010453.html.plaintext.txt	142	following chase period num h intracellular numiasa remaining control cell reduced num whereas num remained fibroblast clnnum patient
0.30761042.15010453.html.plaintext.txt	143	data indicate degradation endocytosed numiasa strongly inhibited clnnum defective cell
0.30761042.15010453.html.plaintext.txt	144	view larger version numk fig
0.30761042.15010453.html.plaintext.txt	145	degradation endocytosed numiasa reduced clnnum defective fibroblast
0.30761042.15010453.html.plaintext.txt	146	fibroblast control co affected clnnum patient incubated numiasa numnum cpmml num h num degree c
0.30761042.15010453.html.plaintext.txt	147	removal medium cell either harvested chased additional num h num degree c
0.30761042.15010453.html.plaintext.txt	148	cell solubilized separated sd page internalized numiasa visualized autoradiography
0.30761042.15010453.html.plaintext.txt	149	autoradiograph quantified densitometric scanning expressed percentage total numiasa detectable control cell
0.30761042.15010453.html.plaintext.txt	150	experiment repeated twice similar result
0.30761042.15010453.html.plaintext.txt	151	several line evidence imply translocation localization clnnum protein er
0.30761042.15010453.html.plaintext.txt	152	first clnnum antigenic site found colocalize pdi established er marker ci golgi marker gmnum lysosome stained ctsd
0.30761042.15010453.html.plaintext.txt	153	secondly clnnum protein undergo proteolytic processing step
0.30761042.15010453.html.plaintext.txt	154	thirdly although contains potential n glycosylation site replacement residue isoleucine num serine located second proposed luminal loop amino acid residue num num resulted addition oligosaccharide chain could removed pngase f treatment
0.30761042.15010453.html.plaintext.txt	155	mutant clnnum also completely sensitive endo h removing high mannose er type oligosaccharide chain complex golgi type oligosaccharide
0.30761042.15010453.html.plaintext.txt	156	data strongly support concept clnnum residency er
0.30761042.15010453.html.plaintext.txt	157	er residency membrane protein achieved retention andor retrieval mechanism requiring signal structure targeting motif within protein
0.30761042.15010453.html.plaintext.txt	158	thus er resident type transmembrane protein contain dileucine motif c terminal cytoplasmic domain whereas arginine containing signal structure function targeting signal type ii membrane protein num num num
0.30761042.15010453.html.plaintext.txt	159	recent study revealed additional er retention signal rxr r arginine x large neutral positively charged residue num num
0.30761042.15010453.html.plaintext.txt	160	furthermore oligomerization protein mediated transmembrane andor luminal domain forming large homodimeric heteromeric protein complex might prevent package transport vesicle export er num num num
0.30761042.15010453.html.plaintext.txt	161	signal structure responsible retention polytopic clnnum er known
0.30761042.15010453.html.plaintext.txt	162	n c terminal domain harbor potential rrr rkk retention motif
0.30761042.15010453.html.plaintext.txt	163	however replacement motif lysine leucine residue respectively alter er localization mutant clnnum
0.30761042.15010453.html.plaintext.txt	164	num also possible dimerization reported study assembly clnnum oligomeric complex prevents export er
0.30761042.15010453.html.plaintext.txt	165	function clnnum defined
0.30761042.15010453.html.plaintext.txt	166	however comparable rate synthesis sorting proteolytic processing ctsd clnnum defective control cell well similar specific activity two lysosomal enzyme hexosaminidase asa suggest clnnum limit transport least three enzyme lysosome
0.30761042.15010453.html.plaintext.txt	167	hand study show capability degrade exogenous arylsulfatase strikingly impaired clnnum defective cell
0.30761042.15010453.html.plaintext.txt	168	whereas half life newly synthesized asa reported num day num internalized human asa rapidly degraded ref
0.30761042.15010453.html.plaintext.txt	169	probable acidic ph dependent octamerization completed endocytosed asa resulting increased lysosomal instability num
0.30761042.15010453.html.plaintext.txt	170	taking endocytosed asa index delayed degradation clnnum defective cell result indicate either specific lysosomal protease absent andor inactive lysosomal parameter ph presence cofactor affected
0.30761042.15010453.html.plaintext.txt	171	interest incubation nnume
0.30761042.15010453.html.plaintext.txt	172	num neuroblastoma cell amyloid protein fragment suspected neurotoxic mediator alzheimers disease led increased expression acetylcholinesterase slowed lysosomal degradation
0.30761042.15010453.html.plaintext.txt	173	data suggest lysosomal acidification impaired num
0.30761042.15010453.html.plaintext.txt	174	lysosomal dysfunction attributed defective er resident membrane protein without precedent
0.30761042.15010453.html.plaintext.txt	175	clnnum another polytopic er membrane protein defective progressive epilepsy mental retardation belonging group ncl disorder num
0.30761042.15010453.html.plaintext.txt	176	remains investigated whether reduced capability lysosomal degradation protein demonstrated study specific clnnum common clnnum clnnum defective cell
0.30761042.15010453.html.plaintext.txt	177	footnote work supported deutsche forschungsgemeinschaft grant br numnum num werner otto foundation hamburg germany national institute health grant nsnum d
0.30761042.15010453.html.plaintext.txt	178	cost publication article defrayed part payment page charge
0.30761042.15010453.html.plaintext.txt	179	article must therefore hereby marked advertisement accordance num u
0.30761042.15010453.html.plaintext.txt	180	section num solely indicate fact
0.30761042.15010453.html.plaintext.txt	181	correspondence addressed childrens hospital biochemistry university hospital hamburg martinistr
0.30761042.15010453.html.plaintext.txt	182	num num num num fax num num num num e mail braulkeatuke
0.30761042.15010453.html.plaintext.txt	183	num abbreviation used ncl neuronal ceroid lipofuscinosis mpr mannose num phosphate receptor er endoplasmic reticulum oclnum ovine ncl mesna num mercaptoethanesulfonic acid bsnum bissulfosuccinimidyl suberate ds disuccinimidylsuberate asa arylsulfatase ctsd cathepsin d pdi protein disulfide isomerase endo h endoglycosidase h me num morpholineethanesulfonic acid pngase f peptide n glycosidase f
0.30876386.9218423.html.plaintext.txt	0	targeted replacement mouse apolipoprotein e gene common human apoenum allele enhances diet induced hypercholesterolemia atherosclerosis
0.30876386.9218423.html.plaintext.txt	1	received publication december num num revised form april num num
0.30876386.9218423.html.plaintext.txt	2	sullivan hafid mezdour yasuaki aratani chris knouff jamila najib robert l
0.30876386.9218423.html.plaintext.txt	3	apolipoprotein apo e constituent several lipoprotein ligand low density lipoprotein receptor interaction important maintaining cholesterol triglyceride homeostasis
0.30876386.9218423.html.plaintext.txt	4	used gene replacement strategy generate mouse express human apoenum isoform place mouse protein
0.30876386.9218423.html.plaintext.txt	5	level apoe mrna various tissue virtually human apoenum homozygous numnum mouse littermates wild type mouse allele
0.30876386.9218423.html.plaintext.txt	6	total cholesterol triglyceride level fasted plasma numnum mouse different mouse maintained normal low fat chow diet
0.30876386.9218423.html.plaintext.txt	7	found however notable difference distribution plasma lipoprotein apolipoprotein e two group migrating lipoprotein plasma apobnum level decreased numnum mouse apoe distribution shifted high density lipoprotein larger lipoprotein particle
0.30876386.9218423.html.plaintext.txt	8	addition fractional catabolic rate exogenously administered remnant particle without apoe num fold slower numnum mouse compared mouse
0.30876386.9218423.html.plaintext.txt	9	numnum animal fed high fathigh cholesterol diet numnum animal responded dramatic increase num fold total cholesterol compared mouse num
0.30876386.9218423.html.plaintext.txt	10	num fold num week diet numnum animal developed significantly least num fold larger atherosclerotic plaque aortic sinus area animal
0.30876386.9218423.html.plaintext.txt	11	thus structural difference human apoenum mouse apoe protein sufficient cause increased susceptibility dietary induced hypercholesterolemia atherosclerosis numnum mouse
0.30876386.9218423.html.plaintext.txt	12	apolipoprotein aponum e important transport cholesterol triglyceride throughout body
0.30876386.9218423.html.plaintext.txt	13	amphipathic protein stabilizes structure lipoprotein particle via ability bind lipid function ligand lipoprotein receptor low density lipoprotein receptor ldlr low density lipoprotein receptor related protein num num
0.30876386.9218423.html.plaintext.txt	14	apoe major protein component chylomicron remnant low density lipoprotein vldl intermediate density lipoprotein idl present low density lipoprotein ldl
0.30876386.9218423.html.plaintext.txt	15	apoe also enriched subclass high density lipoprotein hdl function effective ligand binding ldlr num
0.30876386.9218423.html.plaintext.txt	16	human apoe gene located chromosome num num part apolipoprotein cluster also includes gene encoding apoci apocii apociv num
0.30876386.9218423.html.plaintext.txt	17	multiple tissue specific enhancer negative element identified region proximal gene num
0.30876386.9218423.html.plaintext.txt	18	distal enhancer hepatic control region required liver expression located num kb downstream gene num num
0.30876386.9218423.html.plaintext.txt	19	liver synthesizes approximately num apoe found body num found brain remainder synthesized several tissue including spleen lung heart ovary testis kidney skin num num
0.30876386.9218423.html.plaintext.txt	20	three major apoe allele num num num occur human frequency num
0.30876386.9218423.html.plaintext.txt	21	three allele distinguished coding difference position num num num
0.30876386.9218423.html.plaintext.txt	22	common isoform apoenum cysteine position num arginine position num apoenum isoform cysteine position whereas apoenum isoform arginine position
0.30876386.9218423.html.plaintext.txt	23	functionally three isoforms differ affinity ldlr apoenum enum exhibiting num binding apoenum displaying num normal binding affinity num
0.30876386.9218423.html.plaintext.txt	24	despite lower affinity apoenum ldlr individual homozygous num typically lower normal plasma cholesterol level except fraction homozygote num num develop type iii hyperlipoproteinemia num
0.30876386.9218423.html.plaintext.txt	25	individual homozygous num higher total plasma cholesterol ldl cholesterol compared num homozygote increased risk developing coronary artery disease num
0.30876386.9218423.html.plaintext.txt	26	num allele also associated development alzheimers disease num num
0.30876386.9218423.html.plaintext.txt	27	apoe isoform specific effect important etiology atherosclerosis disease appropriate animal model rigorously investigate effect currently lacking
0.30876386.9218423.html.plaintext.txt	28	date transgenic animal made pronuclear injection human dna used study effect method produce mouse varying level transgene expression due difference chromosomal location copy number expression endogenous mouse apoe complicates interpretation data num num num
0.30876386.9218423.html.plaintext.txt	29	overcome difficulty used targeted gene replacement generate mouse express human apoenum isoform level physiological range
0.30876386.9218423.html.plaintext.txt	30	mouse coding sequence mouse apoe replaced sequence coding human apoenum without disturbing known regulatory sequence
0.30876386.9218423.html.plaintext.txt	31	replacement result animal expression human apoe mrna identical tissue distribution level mouse apoe mrna wild type animal
0.30876386.9218423.html.plaintext.txt	32	describe essentially normal cholesterol triglyceride level mouse homozygous human apoenum numnum maintained normal low fat mouse chow diet show markedly susceptible diet induced atherosclerosis wild type littermates
0.30876386.9218423.html.plaintext.txt	33	targeting construct made inserting ppnt vector num num
0.30876386.9218423.html.plaintext.txt	34	num kb saci human genomic fragment isolated plasmid pheg num num kindly provided dr
0.30876386.9218423.html.plaintext.txt	35	john taylor university california san francisco
0.30876386.9218423.html.plaintext.txt	36	fragment contains num part intron num num base pair exon num num human apoenum gene num
0.30876386.9218423.html.plaintext.txt	37	num kb ecori saci strain num mouse genomic fragment containing sequence upstream mouse apoe gene including exon num num part intron num num base pair inserted num human apoenum fragment
0.30876386.9218423.html.plaintext.txt	38	num kb pvui kpni strain num mouse genomic fragment containing num half exon num num flanking sequence inserted downstream neomycin resistant gene ppnt see fig
0.30876386.9218423.html.plaintext.txt	39	replacement mouse apoe gene human apoenum gene
0.30876386.9218423.html.plaintext.txt	40	genomic organization mouse apoe gene containing exon num num black box
0.30876386.9218423.html.plaintext.txt	41	b apoenum targeting construct containing num num arm mouse homology black line box interrupted human apoenum gene hatched box num num num labeled huenum
0.30876386.9218423.html.plaintext.txt	42	neomycin resistant neo thymidine kinase tk gene selection targeted e cell ppnt plasmid vector
0.30876386.9218423.html.plaintext.txt	43	c resulting chimeric gene encoding human apoenum
0.30876386.9218423.html.plaintext.txt	44	mouse exon num probe probe used detect targeted allele
0.30876386.9218423.html.plaintext.txt	45	size diagnostic fragment shown dashed line
0.30876386.9218423.html.plaintext.txt	46	site follows e ecori saci h hindiii p pvui k kpni x xbai b bamhi
0.30876386.9218423.html.plaintext.txt	47	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	48	generation homozygous human apoenum mouse
0.30876386.9218423.html.plaintext.txt	49	subclone bknum mouse strain num embryonic stem e cell line enumtgnuma cultured electroporated human apoenum targeting construct described previously num
0.30876386.9218423.html.plaintext.txt	50	targeted e cell clone identified southern blot analysis
0.30876386.9218423.html.plaintext.txt	51	chimera generated mated cnumblnumj bnum mouse
0.30876386.9218423.html.plaintext.txt	52	fnum generation mouse used experiment described
0.30876386.9218423.html.plaintext.txt	53	mouse kept normal low fat chow diet consisting num ww fat num
0.30876386.9218423.html.plaintext.txt	54	num ww cholesterol prolab rmh num number numpnum st
0.30876386.9218423.html.plaintext.txt	55	louis mo atherogenic diet contains num
0.30876386.9218423.html.plaintext.txt	56	num ww sodium cholate tk num teklad premier madison wi
0.30876386.9218423.html.plaintext.txt	57	lipid measurement performed mouse age num num week
0.30876386.9218423.html.plaintext.txt	58	animal fasted overnight approximately num h anesthetized avertin num microl blood collected retro orbital sinus tube containing num mm edta num microgml aprotinin boehringer mannheim num microgml gentamycin stored ice
0.30876386.9218423.html.plaintext.txt	59	plasma removed centrifugation numnum x g num min num degree c total cholesterol hdl cholesterol measured using diagnostic cii kit wako richmond va according manufacturer instruction
0.30876386.9218423.html.plaintext.txt	60	triglyceride level measured using enzymatic kit sigma
0.30876386.9218423.html.plaintext.txt	61	within num h blood collection num microl plasma electrophoresed precast num agarose gel ciba corning diagnostics corp
0.30876386.9218423.html.plaintext.txt	62	palo alto ca neutral lipid visualized fat red numb staining sigma
0.30876386.9218423.html.plaintext.txt	63	one ml pooled plasma num mouse num microl separated sequential density ultracentrifugation seven fraction ranging density num
0.30876386.9218423.html.plaintext.txt	64	num gml using procedure described de silva et al
0.30876386.9218423.html.plaintext.txt	65	total lipoprotein isolated plasma density num
0.30876386.9218423.html.plaintext.txt	66	lipoprotein fraction dialyzed num mm tris ph num
0.30876386.9218423.html.plaintext.txt	67	num num mm edta num mm nacl electrophoresis num num denaturing sd page gel num
0.30876386.9218423.html.plaintext.txt	68	plasma num microl either individual pooled sample separated gel filtration chromatography using superose num hrnumnum column pharmacia biotech inc
0.30876386.9218423.html.plaintext.txt	69	immunoblot analysis fplc fraction num microl electrophoresed precast num agarose gel performed antibody described
0.30876386.9218423.html.plaintext.txt	70	total rna extracted several tissue according method chomczynski sacchi num using rnazoltm b tel test friendswood tx
0.30876386.9218423.html.plaintext.txt	71	total rna num microg electrophoresed num agarose gel denaturation glyoxalmenumso mixture num
0.30876386.9218423.html.plaintext.txt	72	rna transferred hybond membrane amersham corp
0.30876386.9218423.html.plaintext.txt	73	hybridized overnight num degree c num formamide num x ssc num x denhardts solution num microg salmon sperm dna num mm sodium phosphate ph num
0.30876386.9218423.html.plaintext.txt	74	num num dextran sulfate probe mouse exon num dna fragment labeled numpdctp
0.30876386.9218423.html.plaintext.txt	75	blot washed num x ssc num
0.30876386.9218423.html.plaintext.txt	76	num sd num min num degree c num
0.30876386.9218423.html.plaintext.txt	77	num sd num min num degree c
0.30876386.9218423.html.plaintext.txt	78	blot exposed preflashed kodak xar film num h
0.30876386.9218423.html.plaintext.txt	79	apoe enzyme linked immunosorbent assay
0.30876386.9218423.html.plaintext.txt	80	human apoe mouse plasma measured sandwich type enzyme linked immunosorbent assay elisa essentially described num
0.30876386.9218423.html.plaintext.txt	81	mouse anti human apoe monoclonal antibody enum hue m num used capture antibody goat anti human apoe antibody hue p calbiochem detecting antibody
0.30876386.9218423.html.plaintext.txt	82	hue p antibody cross reacts mouse apoe low level
0.30876386.9218423.html.plaintext.txt	83	hue m antibody shown react human apoe class lipoprotein particle num cross react mouse apoe
0.30876386.9218423.html.plaintext.txt	84	value determined standard curve made pooled human plasma whose apoe level determined purified recombinant human apoenum number num calbiochem validated international calibrator dr
0.30876386.9218423.html.plaintext.txt	85	rifai childrens hospital boston ma
0.30876386.9218423.html.plaintext.txt	86	mouse apoe measured similar manner using purified rabbit anti mouse apoe antibody mue m num microgml raised mouse apoe peptide residue num num capture antibody
0.30876386.9218423.html.plaintext.txt	87	antibody conjugated horseradish peroxidase used detection chromagen
0.30876386.9218423.html.plaintext.txt	88	mouse peptide residue num num used standard determining concentration mouse apoe
0.30876386.9218423.html.plaintext.txt	89	fasted whole plasma num microl electrophoresed num num denaturing sd page gel num agarose gel transferred immobilon p membrane millipore corp
0.30876386.9218423.html.plaintext.txt	90	bedford ma reacted three anti apoe antibody described
0.30876386.9218423.html.plaintext.txt	91	immunoreactive protein visualized horseradish peroxidase conjugate using enhanced chemiluminescence kit amersham corp
0.30876386.9218423.html.plaintext.txt	92	western blot analysis apob made similarly using num sd page rabbit anti mouse apob serum gift dr
0.30876386.9218423.html.plaintext.txt	93	steven young university california san francisco
0.30876386.9218423.html.plaintext.txt	94	four apoe mouse injected num microg free cholesterol containing num
0.30876386.9218423.html.plaintext.txt	95	num microci num numc labeled cholesterol dispersed egg lecithinfree cholesterol numnum molar ratio mesophase
0.30876386.9218423.html.plaintext.txt	96	apoe vldl fraction isolated num h later centrifugation num
0.30876386.9218423.html.plaintext.txt	97	num tracer cholesterol ester fraction num
0.30876386.9218423.html.plaintext.txt	98	three mouse group apoe numnum injected labeled apoe vldl
0.30876386.9218423.html.plaintext.txt	99	fractional catabolic rate variance determined num h described previously num
0.30876386.9218423.html.plaintext.txt	100	evaluation atherosclerotic lesion
0.30876386.9218423.html.plaintext.txt	101	female mouse fed high fat diet num month sacrificed avertin overdose num h fast
0.30876386.9218423.html.plaintext.txt	102	thoracic cavity opened heart vascular system perfused num paraformaldehyde phosphate buffered saline ph num
0.30876386.9218423.html.plaintext.txt	103	num physiological pressure
0.30876386.9218423.html.plaintext.txt	104	segment proximal aorta aortic sinus embedded sectioned stained described previously num
0.30876386.9218423.html.plaintext.txt	105	morphometric evaluation lesion size made using nih image version num
0.30876386.9218423.html.plaintext.txt	106	significance difference mean tested using two tailed unpaired student test nonparametric mann whitney u test
0.30876386.9218423.html.plaintext.txt	107	replacement mouse apoe gene human apoenum allele
0.30876386.9218423.html.plaintext.txt	108	targeting strategy used replace mouse apoe coding exon num num human counterpart illustrated fig
0.30876386.9218423.html.plaintext.txt	109	homologous recombination targeting construct fig
0.30876386.9218423.html.plaintext.txt	110	numb endogenous mouse apoe locus fig
0.30876386.9218423.html.plaintext.txt	111	numa result chimeric gene fig
0.30876386.9218423.html.plaintext.txt	112	numc mouse coding sequence replaced sequence coding human apoenum
0.30876386.9218423.html.plaintext.txt	113	chimeric locus retains normal mouse regulatory sequence addition non coding mouse exon one
0.30876386.9218423.html.plaintext.txt	114	identification correctly modified embryonic stem e cell southern blot analysis mouse exon num exon num probe data shown e cell dna digested ecori hybridized mouse exon num probe revealed num
0.30876386.9218423.html.plaintext.txt	115	num kb targeted band confirming correct modification num region e cell dna digested hindiii hybridized mouse exon num probe revealed num
0.30876386.9218423.html.plaintext.txt	116	num kb endogenous band num kb targeted band confirming correct modification num region
0.30876386.9218423.html.plaintext.txt	117	modified locus transmitted fnum generation chimera made one targeted cell line
0.30876386.9218423.html.plaintext.txt	118	fnum mating produced normal litter size normal mendelian segregation pattern modified locus
0.30876386.9218423.html.plaintext.txt	119	genotype fnum animal determined using southern blot analysis tail dna digested bamhi fig
0.30876386.9218423.html.plaintext.txt	120	nucleotide sequence codon num tgc codon num cgc numnum mouse confirmed using allele specific pcr num tail dna
0.30876386.9218423.html.plaintext.txt	121	southern western blot analysis
0.30876386.9218423.html.plaintext.txt	122	southern analysis mouse exon num probe identify fnum mouse carrying targeted allele
0.30876386.9218423.html.plaintext.txt	123	num kb hybridizing bamhi fragment indicates presence human apoenum allele
0.30876386.9218423.html.plaintext.txt	124	num kb hybridizing bamhi fragment indicates presence mouse apoe allele
0.30876386.9218423.html.plaintext.txt	125	b fasted whole plasma num microl electrophoresed num num denaturing sd page gel protein transferred immobilon p membrane incubated either anti human apoe antiserum hue p weakly cross reacts mouse apoe top panel anti mouse apoe antibody mue m middle panel anti human apoe monoclonal antibody hue m bottom panel cross react mouse apoe
0.30876386.9218423.html.plaintext.txt	126	c fasted whole plasma num microl electrophoresed num num sd page gel protein transferred immobilon p membrane incubated hue p antiserum presence absence mercaptoethanol
0.30876386.9218423.html.plaintext.txt	127	abbreviation used hu human sample numnum sample homozygous human apoenum mouse num heterozygous sample wild type sample
0.30876386.9218423.html.plaintext.txt	128	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	129	human apoenum level whole plasma
0.30876386.9218423.html.plaintext.txt	130	confirm presence human apoe protein mouse plasma num microl numnum num mouse human hu electrophoresed num num gradient denaturing sd page gel
0.30876386.9218423.html.plaintext.txt	131	western blot analysis anti human apoe antiserum hue p slightly cross reacts mouse apoe showed human apoe num num da numnum plasma migrates rate apoe human plasma slightly slower mouse apoe num num da plasma fig
0.30876386.9218423.html.plaintext.txt	132	absence mouse apoe numnum plasma confirmed western blot analysis anti mouse apoe antibody mu m show mouse apoe present num sample numnum plasma
0.30876386.9218423.html.plaintext.txt	133	contrast anti human apoe monoclonal antibody hue m cross react mouse apoe show human apoe present numnum num human plasma plasma fig
0.30876386.9218423.html.plaintext.txt	134	western blotting plasma two numnum mouse num num nonreducing sd page gel showed human apoenum homodimer present le num monomeric enum fig
0.30876386.9218423.html.plaintext.txt	135	concentration apoe numnum plasma num
0.30876386.9218423.html.plaintext.txt	136	num mgdl determined elisa similar level num
0.30876386.9218423.html.plaintext.txt	137	num mgdl found plasma see table
0.30876386.9218423.html.plaintext.txt	138	plasma lipid profile apoe concentration mouse fed normal high fat diet
0.30876386.9218423.html.plaintext.txt	139	data mean plus minus
0.30876386.9218423.html.plaintext.txt	140	fasted mouse receiving chow c high fat hf diet
0.30876386.9218423.html.plaintext.txt	141	parenthesis show number mouse
0.30876386.9218423.html.plaintext.txt	142	genotype diet tc tg hdl cholesterol human apoenum mouse apoe mgdl mgdl mgdl mgdl mgdl female numnum c num plus minus num num num plus minus num num num plus minus num num num
0.30876386.9218423.html.plaintext.txt	143	num num hf num plus minus num numa num plus minus num num num plus minus num num num
0.30876386.9218423.html.plaintext.txt	144	num numa c num plus minus num num num plus minus num num num plus minus num num num
0.30876386.9218423.html.plaintext.txt	145	num num hf num plus minus num numb num plus minus num num num plus minus num num num
0.30876386.9218423.html.plaintext.txt	146	num num male numnum c num plus minus num numc num plus minus num num num plus minus num num c num plus minus num num num plus minus num num num plus minus num num p num
0.30876386.9218423.html.plaintext.txt	147	num versus numnum female high fat
0.30876386.9218423.html.plaintext.txt	148	tissue distribution apoe mrna
0.30876386.9218423.html.plaintext.txt	149	total rna extracted several tissue including skin sk spleen sp kidney ki small intestine si stomach st heart testis te muscle mu lung lu liver li submandibular gland su brain br numnum male mouse wild type male mouse
0.30876386.9218423.html.plaintext.txt	150	northern blot analysis mouse exon num probe used compare level apoe mrna two type animal fig
0.30876386.9218423.html.plaintext.txt	151	probe hybridizes equally well human gene mouse gene condition used
0.30876386.9218423.html.plaintext.txt	152	actin probe hybridized blot removal apoe probe lower panel fig
0.30876386.9218423.html.plaintext.txt	153	num ass amount mrna loaded group
0.30876386.9218423.html.plaintext.txt	154	agreement previous report num num apoe mrna expression highest liver second brain lesser amount tissue
0.30876386.9218423.html.plaintext.txt	155	apoe mrna detected muscle
0.30876386.9218423.html.plaintext.txt	156	expression apoe mrna numnum animal essentially indistinguishable tissue analyzed exception small intestine reduced level apoe mrna numnum animal compared mouse
0.30876386.9218423.html.plaintext.txt	157	northern blot analysis clearly demonstrates modified locus containing human apoenum coding sequence wild type mouse gene expressed virtually identical level tissue
0.30876386.9218423.html.plaintext.txt	158	northern blot analysis total rna various tissue
0.30876386.9218423.html.plaintext.txt	159	total rna num microg electrophoresed num gel blotted hybridized mouse apoe exon num probe indicated
0.30876386.9218423.html.plaintext.txt	160	filter rehybridized actin probe
0.30876386.9218423.html.plaintext.txt	161	num identifies lane containing rna human apoenum mouse identifies lane containing rna wild type mouse sk skin sp spleen ki kidney si small intestine st stomach heart te testis mu muscle lu lung li liver su submandibular gland br brain
0.30876386.9218423.html.plaintext.txt	162	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	163	plasma lipid lipoprotein mouse fed normal chow
0.30876386.9218423.html.plaintext.txt	164	level total cholesterol tc triglyceride hdl cholesterol female mouse fed normal low fat chow diet determined plasma obtained num h fast table
0.30876386.9218423.html.plaintext.txt	165	difference tc level numnum mouse num plus minus num mgdl n num control num plus minus num mgdl n num striking contrast total cholesterol level previously found apoe deficient mouse diet num plus minus num mgdl num
0.30876386.9218423.html.plaintext.txt	166	tc level male higher female p num
0.30876386.9218423.html.plaintext.txt	167	num difference numnum group
0.30876386.9218423.html.plaintext.txt	168	triglyceride hdl cholesterol level numnum mouse mouse also similar table
0.30876386.9218423.html.plaintext.txt	169	fasted wild type plasma lipoprotein migrate three distinct band designated hdl ldl pre vldl using agarose gel electrophoresis fig
0.30876386.9218423.html.plaintext.txt	170	plasma fasted numnum mouse hand showed increase pre band absence migrating lipoprotein relative sample
0.30876386.9218423.html.plaintext.txt	171	difference observed plasma male female numnum mouse
0.30876386.9218423.html.plaintext.txt	172	amount migrating particle numnum mouse
0.30876386.9218423.html.plaintext.txt	173	result suggest numnum mouse slightly increased amount vldlidl remnant reduction ldl particle
0.30876386.9218423.html.plaintext.txt	174	analysis plasma lipoprotein
0.30876386.9218423.html.plaintext.txt	175	fasted plasma num microl male female maintained normal low fat chow diet electrophoresed num agarose gel stained fat red numb
0.30876386.9218423.html.plaintext.txt	176	position pre lipoprotein indicated
0.30876386.9218423.html.plaintext.txt	177	b western analysis fasted plasma num microl female mouse using denaturing num sd page gel anti apob antiserum
0.30876386.9218423.html.plaintext.txt	178	position apobnum num protein indicated
0.30876386.9218423.html.plaintext.txt	179	sample numnum homozygous human apoenum mouse wild type mouse
0.30876386.9218423.html.plaintext.txt	180	c total lipoprotein density num
0.30876386.9218423.html.plaintext.txt	181	num gml pooled five female numnum four mouse electrophoresed num num sd page gel stained coomassie brilliant blue
0.30876386.9218423.html.plaintext.txt	182	position apolipoproteins indicated
0.30876386.9218423.html.plaintext.txt	183	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	184	determine amount apobnum relative apobnum equal amount whole plasma numnum female mouse separated num sd page gel blotted reacted anti mouse apob serum fig
0.30876386.9218423.html.plaintext.txt	185	densitometric scan autoradiograph showed numnum sample bnumbnum ratio numnum compared bnumbnum ratio numnum
0.30876386.9218423.html.plaintext.txt	186	separate experiment total lipoprotein density num
0.30876386.9218423.html.plaintext.txt	187	num gml isolated pooled plasma five female numnum mouse four mouse electrophoresed num num sd page gel
0.30876386.9218423.html.plaintext.txt	188	coomassie brilliant blue staining gel fig
0.30876386.9218423.html.plaintext.txt	189	numc showed plasma apobnum level numnum mouse greatly reduced compared mouse apobnum level higher numnum mouse compared mouse
0.30876386.9218423.html.plaintext.txt	190	different distribution human mouse apolipoprotein e
0.30876386.9218423.html.plaintext.txt	191	individual plasma sample pooled n num plasma sample separated gel filtration chromatography superose numb column determination cholesterol triglyceride apoe distribution
0.30876386.9218423.html.plaintext.txt	192	distribution cholesterol solid circle fig
0.30876386.9218423.html.plaintext.txt	193	num b nearly identical numnum mouse except small decrease fraction num num numnum group
0.30876386.9218423.html.plaintext.txt	194	decrease ldl cholesterol agrees agarose gel electrophoresis result described
0.30876386.9218423.html.plaintext.txt	195	triglyceride distribution essentially group data shown largest percentage triglyceride present fraction num num
0.30876386.9218423.html.plaintext.txt	196	distribution cholesterol apoe mouse fed normal chow
0.30876386.9218423.html.plaintext.txt	197	b pooled plasma num mouse fractionated gel filtration chromatography superose numb column
0.30876386.9218423.html.plaintext.txt	198	num ml fraction collected cholesterol measured microgfraction
0.30876386.9218423.html.plaintext.txt	199	apoe microgfraction measured using elisa antibody specific human hue m mouse apoe mue m b
0.30876386.9218423.html.plaintext.txt	200	c d western blot analysis fplc fraction c numnum d electrophoresed num agarose gel incubated hue p antiserum cross reacts mouse apoe
0.30876386.9218423.html.plaintext.txt	201	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	202	contrary identical distribution lipid distribution apoe open circle fig
0.30876386.9218423.html.plaintext.txt	203	num b numnum mouse markedly different determined elisa mouse human specific antibody
0.30876386.9218423.html.plaintext.txt	204	majority apoe mouse present hdl region fraction num num minor amount present vldl fraction num num idl ldl region fraction num num fig
0.30876386.9218423.html.plaintext.txt	205	western blot analysis fplc fraction electrophoresed agarose gel using hue p antiserum support result obtained elisa fig
0.30876386.9218423.html.plaintext.txt	206	however numnum mouse majority apoe present two distinct peak vldl fraction num num idl specie fraction num num typically elute fig
0.30876386.9218423.html.plaintext.txt	207	western blot agarose gel fplc fraction agreement apoenum distribution determined elisa fig
0.30876386.9218423.html.plaintext.txt	208	sd page gel electrophoresis lipoprotein fractionated sequential density ultracentrifugation fig
0.30876386.9218423.html.plaintext.txt	209	numa showed apoenum numnum mouse found predominantly lower density fraction d num
0.30876386.9218423.html.plaintext.txt	210	major difference detectable distribution apolipoproteins ai numnum sample apocs sd page fraction separated sequential density ultracentrifugation fig
0.30876386.9218423.html.plaintext.txt	211	distribution apolipoproteins mouse fed either normal high fat diet
0.30876386.9218423.html.plaintext.txt	212	pooled plasma num mouse fed normal chow fractionated sequential density ultracentrifugation fraction electrophoresed denaturing sd page num num gradient gel stained coomassie brilliant blue
0.30876386.9218423.html.plaintext.txt	213	b except mouse fed high fat diet num month
0.30876386.9218423.html.plaintext.txt	214	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	215	idl like peak numnum plasma particularly noteworthy since cholesterol triglyceride fraction low
0.30876386.9218423.html.plaintext.txt	216	idl like particle enriched apoenum likely represent vldlchylomicron remnant since agarose gel electrophoresis fplc fraction followed western blotting hue p antiserum demonstrated majority apoenum associated particle migrating pre position association apoenum large hdl particle position minimal fig
0.30876386.9218423.html.plaintext.txt	217	fplc analysis plasma immunoprecipitation anti mouse apob antibody confirms idl like particle contain apob data shown
0.30876386.9218423.html.plaintext.txt	218	interestingly fplc analysis plasma mouse heterozygous human apoenum num showed shift second apoenum peak fraction num num suggesting co presence mouse apoe reduces size remnant particle apoenum accumulates data shown
0.30876386.9218423.html.plaintext.txt	219	increase mouse apoe associated larger particle also evident heterozygote although approximately half mouse apoe still found associated hdl
0.30876386.9218423.html.plaintext.txt	220	response atherogenic diet
0.30876386.9218423.html.plaintext.txt	221	numnum n num n num female mouse used measure lipid profile normal chow fed atherogenic diet num week ass change response diet two group
0.30876386.9218423.html.plaintext.txt	222	one animal showed significant weight loss yellow colored plasma diet study excluded
0.30876386.9218423.html.plaintext.txt	223	numnum mouse responded num fold increase cholesterol num plus minus num versus num plus minus num mgdl whereas cholesterol control mouse increased num
0.30876386.9218423.html.plaintext.txt	224	num fold num plus minus num versus num plus minus num mgdl table
0.30876386.9218423.html.plaintext.txt	225	triglyceride level numnum mouse reduced num num respectively
0.30876386.9218423.html.plaintext.txt	226	hdl cholesterol level reduced group mouse extent approximately num
0.30876386.9218423.html.plaintext.txt	227	agarose gel electrophoresis plasma type animal showed decrease migrating particle increase pre migrating particle consistent total lipid measurement data shown
0.30876386.9218423.html.plaintext.txt	228	result suggest marked increase remnant particle concurrent reduction hdl response atherogenic diet type mouse extent increase numnum mouse much larger
0.30876386.9218423.html.plaintext.txt	229	elution profile superose num gel filtration column numnum plasma fig
0.30876386.9218423.html.plaintext.txt	230	numa showed majority highly elevated cholesterol vldl idl fraction whereas group modestly increased cholesterol distributed equally vldl hdl fraction fig
0.30876386.9218423.html.plaintext.txt	231	expected mouse distribution apoe followed cholesterol fig
0.30876386.9218423.html.plaintext.txt	232	apoe distribution pattern numnum animal highly unusual similar seen animal fed normal chow diet two distinct class lipoprotein vldl idl range associated human apoe fig
0.30876386.9218423.html.plaintext.txt	233	large increase plasma apoe numnum animal num
0.30876386.9218423.html.plaintext.txt	234	num mgdl compared increase animal num
0.30876386.9218423.html.plaintext.txt	235	num mgdl two diet table
0.30876386.9218423.html.plaintext.txt	236	distribution cholesterol apoe mouse high fat hf diet
0.30876386.9218423.html.plaintext.txt	237	b plasma num mouse pooled group lipoprotein fractionated gel filtration chromatography superose numb column
0.30876386.9218423.html.plaintext.txt	238	num ml fraction collected cholesterol measured microgfraction
0.30876386.9218423.html.plaintext.txt	239	apoe microgfraction measured using elisa antibody specific human hue m mouse apoe mue m b
0.30876386.9218423.html.plaintext.txt	240	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	241	distribution several plasma apolipoproteins also different numnum mouse fed high fat diet fig
0.30876386.9218423.html.plaintext.txt	242	comparison apolipoprotein distribution among density fraction sd page fig
0.30876386.9218423.html.plaintext.txt	243	num normal chow b high fat revealed marked increase high fat diet apoe ai aiv mainly num
0.30876386.9218423.html.plaintext.txt	244	num gml fraction mouse
0.30876386.9218423.html.plaintext.txt	245	contrast numnum mouse showed increase protein whole density range
0.30876386.9218423.html.plaintext.txt	246	particular interest increase apoai num
0.30876386.9218423.html.plaintext.txt	247	num fraction apoaiv num
0.30876386.9218423.html.plaintext.txt	248	amount apobnum increased numnum mouse compared mouse distribution different
0.30876386.9218423.html.plaintext.txt	249	delayed clearance apoe deficient vldl numnum mouse
0.30876386.9218423.html.plaintext.txt	250	marked increase cholesterol rich remnant particle seen numnum animal response atherogenic diet suggests human apoenum effective murine homologue clearance particle mouse
0.30876386.9218423.html.plaintext.txt	251	test possibility injected numc radiolabeled remnant particle num cholesterol ester vldl flotation range prepared apoe deficient mouse mouse fed normal chow measured decay label num h period
0.30876386.9218423.html.plaintext.txt	252	decay numccholesterol rapid mouse virtually complete num min fig
0.30876386.9218423.html.plaintext.txt	253	fractional catabolic rate mouse based single compartment system num
0.30876386.9218423.html.plaintext.txt	254	clearance lipoprotein apoe mouse considerably slower fractional catabolic rate num
0.30876386.9218423.html.plaintext.txt	255	nummin num fold slower mouse rapid apoe mouse
0.30876386.9218423.html.plaintext.txt	256	note however within num h amount label remaining numnum mouse decreased level seen mouse
0.30876386.9218423.html.plaintext.txt	257	plasma clearance apoe remnant particle control numnum mouse
0.30876386.9218423.html.plaintext.txt	258	three mouse group apoe deficient mouse e numnum injected radiolabeled apoe remnant particle clearance measured num h
0.30876386.9218423.html.plaintext.txt	259	data point show mean plus minus
0.30876386.9218423.html.plaintext.txt	260	abbreviation numnum homozygous human apoenum mouse wild type mouse e apoe deficient mouse
0.30876386.9218423.html.plaintext.txt	261	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	262	morphometric evaluation aortic lesion
0.30876386.9218423.html.plaintext.txt	263	num month atherogenic diet numnum animal female evaluated atherosclerotic lesion
0.30876386.9218423.html.plaintext.txt	264	measurement made section proximal aorta near aortic valve attachment site
0.30876386.9218423.html.plaintext.txt	265	six numnum animal developed substantial atherosclerotic lesion logarithmic mean area num
0.30876386.9218423.html.plaintext.txt	266	num x num micromnum ranging num
0.30876386.9218423.html.plaintext.txt	267	contrast four five animal developed fatty streak lesion small logarithmic mean area num
0.30876386.9218423.html.plaintext.txt	268	num x num micromnum ranging num
0.30876386.9218423.html.plaintext.txt	269	observation clearly demonstrate numnum mouse much susceptible diet induced atherosclerosis mouse
0.30876386.9218423.html.plaintext.txt	270	morphometric evaluation atherosclerotic lesion mouse fed atherogenic diet
0.30876386.9218423.html.plaintext.txt	271	mouse fnum female kept atherogenic diet num week sacrifice
0.30876386.9218423.html.plaintext.txt	272	measurement animal made single section proximal aorta near aortic valve attachment site
0.30876386.9218423.html.plaintext.txt	273	logarithmic mean lesion area six numnum mouse four five mouse indicated p num
0.30876386.9218423.html.plaintext.txt	274	view larger version image numk gif file
0.30876386.9218423.html.plaintext.txt	275	successfully replaced coding sequence mouse apoe gene equivalent human apoenum coding region without altering known endogenous regulatory sequence
0.30876386.9218423.html.plaintext.txt	276	expression human apoe mrna liver brain tissue parallel found normally wild type mouse
0.30876386.9218423.html.plaintext.txt	277	thus human apoenum protein functional expressed physiological level modified mouse thereby providing model studying function human apoenum vivo
0.30876386.9218423.html.plaintext.txt	278	date pronuclear injection dna used generate transgenic animal expressing various form human apoe study role lipid metabolism num num num
0.30876386.9218423.html.plaintext.txt	279	three severe limitation approach follows number copy transgene vary wide range marked uncontrolled difference expression transgene different chromosomal location presence endogenous mouse protein complicates interpretation result
0.30876386.9218423.html.plaintext.txt	280	importantly rigorous comparison different isoforms possible variable expression inherent conventional transgenic animal
0.30876386.9218423.html.plaintext.txt	281	mouse made replacement endogenous mouse coding region equivalent region human gene retain natural chromosomal context apoe locus
0.30876386.9218423.html.plaintext.txt	282	thus locus specific sequence enhancer altered except possible intragenic control sequence differ mouse human
0.30876386.9218423.html.plaintext.txt	283	therefore expected tissue specific expression human replacement apoenum gene would closely parallel endogenous mouse apoe gene
0.30876386.9218423.html.plaintext.txt	284	mrna study show expectation indeed fulfilled exception intestinal apoe mrna slightly reduced numnum mouse compared mouse
0.30876386.9218423.html.plaintext.txt	285	significance reduction intestinal expression clear considering intestinal apoe expression low compared tissue chylomicron originating small intestine known contain little apoe num num
0.30876386.9218423.html.plaintext.txt	286	difference numnum mouse consequently highly informative far function apolipoprotein concerned
0.30876386.9218423.html.plaintext.txt	287	thus gene replacement demonstrates advantage pronuclear injection generating transgenic animal
0.30876386.9218423.html.plaintext.txt	288	lipid profile numnum mouse similar mouse maintained chow low fat diet fasting level total cholesterol triglyceride hdl cholesterol essentially identical two animal
0.30876386.9218423.html.plaintext.txt	289	however mouse fed high fat diet numnum animal responded num fold increase total cholesterol compared num
0.30876386.9218423.html.plaintext.txt	290	num fold increase animal
0.30876386.9218423.html.plaintext.txt	291	second num month high fat diet atherosclerotic plaque seen numnum animal num fold larger observed wild type control
0.30876386.9218423.html.plaintext.txt	292	third num fold slower clearance rate remnant lipoprotein particle numnum animal
0.30876386.9218423.html.plaintext.txt	293	accumulation cholesterol delayed clearance remnant particle observed numnum animal likely cause increased susceptibility lesion development
0.30876386.9218423.html.plaintext.txt	294	dramatic delay clearance remnant particle numnum mouse unexpected since previous study using transgenic mouse expressing human apoe revealed normal enhanced clearance kinetics num num
0.30876386.9218423.html.plaintext.txt	295	one possible explanation observed delay clearance human apoenum protein lower affinity mouse ldlr andor receptor mouse apoe specie difference structure
0.30876386.9218423.html.plaintext.txt	296	mouse human apoe differ num amino acid sequence difference amino carboxyl terminus num
0.30876386.9218423.html.plaintext.txt	297	receptor binding domain residue num num highly conserved mouse human apoe since num num residue identical region including seven residue designated critical receptor binding num num
0.30876386.9218423.html.plaintext.txt	298	residue differ conservative substitution e
0.30876386.9218423.html.plaintext.txt	299	methionine leucine affect net charge hydrophobicity protein would predicted substantial effect protein conformation num
0.30876386.9218423.html.plaintext.txt	300	thus must ascribed difference outside receptor binding domain affinity receptor differs mouse human apoe protein
0.30876386.9218423.html.plaintext.txt	301	specie difference receptor interact apoe ldlr low density lipoprotein receptor related protein could also contribute lower affinity
0.30876386.9218423.html.plaintext.txt	302	dysfunctional interaction human apoenum mouse heparan sulfate proteoglycans hspg may also contribute delay clearance
0.30876386.9218423.html.plaintext.txt	303	postulated hspgs involved initial sequestration process enhances uptake apoe containing lipoprotein num num
0.30876386.9218423.html.plaintext.txt	304	interaction apoe hspgs thought occur mainly via electrostatic attraction num
0.30876386.9218423.html.plaintext.txt	305	human apoenum cysteine position num mouse protein arginine equivalent position mouse apoe residue num
0.30876386.9218423.html.plaintext.txt	306	charge difference could significant even though residue num outside known heparin binding domain
0.30876386.9218423.html.plaintext.txt	307	delayed clearance could also due protein protein interaction involving receptor
0.30876386.9218423.html.plaintext.txt	308	several protein known interact apoe play role lipid metabolism
0.30876386.9218423.html.plaintext.txt	309	example interaction apoe hepatic lipoprotein lipase mediatesor enhances catabolism lipoprotein num
0.30876386.9218423.html.plaintext.txt	310	lipoprotein particle containing human apoenum may le efficient type interaction mouse apoe
0.30876386.9218423.html.plaintext.txt	311	would important consequence remodeling processing phase lipoprotein catabolism
0.30876386.9218423.html.plaintext.txt	312	another consideration clearance experiment exogenously introduced remnant particle acquire apoe prior removal receptor
0.30876386.9218423.html.plaintext.txt	313	mouse plasma apoe associated hdl particle presumably source apoe used clear exogenously added remnant
0.30876386.9218423.html.plaintext.txt	314	numnum animal however majority plasma apoenum associated large lipoprotein may transfer easily exogenously added particle
0.30876386.9218423.html.plaintext.txt	315	support others num noted distribution apoe among mouse plasma lipoprotein analyzed fplc ultracentrifugation always agree apoe associated hdl readily lost ultracentrifugation
0.30876386.9218423.html.plaintext.txt	316	although capacity apoenum exchange different class lipoprotein documented decreased ability apoenum transfer large lipoprotein may important implication
0.30876386.9218423.html.plaintext.txt	317	association apoenum larger lipoprotein mouse fig
0.30876386.9218423.html.plaintext.txt	318	num c different observation made human demonstrate preference apoenum hdl num num
0.30876386.9218423.html.plaintext.txt	319	unlikely difference result mutation unexpectedly introduced apoenum gene manipulation worknum observed transgenic apoenum mouse endogenous apoe background virtually identical apoenum distribution pattern seen numnum replacement mouse
0.30876386.9218423.html.plaintext.txt	320	mouse made pronuclear injection human cosmid clone isolated different individual one used make mouse num
0.30876386.9218423.html.plaintext.txt	321	similar finding also reported taylor et al
0.30876386.9218423.html.plaintext.txt	322	num transgenic apoenum mouse also express mouse apoe showed majority human apoenum resided larger lipoprotein particle using sd page immunoblot analysis fraction separated sequential density ultracentrifugation
0.30876386.9218423.html.plaintext.txt	323	work author also found mouse apoe human apoe co distributed among lipoprotein
0.30876386.9218423.html.plaintext.txt	324	different result fplc analysis num heterozygote plasma show approximately half mouse apoe minor fraction human apoenum associated hdl data shown
0.30876386.9218423.html.plaintext.txt	325	known whether observed difference work taylor et al
0.30876386.9218423.html.plaintext.txt	326	result different technique used fractionate plasma lipoprotein result different level human apoe mouse apoe expression two type mouse
0.30876386.9218423.html.plaintext.txt	327	characterization large apoenum rich lipoprotein particle required understand observed delay clearance numnum animal
0.30876386.9218423.html.plaintext.txt	328	reduced clearance rate remnant particle numnum mouse whatever cause eventually prof sufficient cause alteration fasted plasma cholesterol level animal relative littermates animal normal chow diet
0.30876386.9218423.html.plaintext.txt	329	numnum mouse however much susceptible diet induced hyperlipidemia atherosclerosis littermates
0.30876386.9218423.html.plaintext.txt	330	possibly high fat diet postprandial accumulation vldl occurs lead development atherosclerosis suggested zilversmit num
0.30876386.9218423.html.plaintext.txt	331	human apoenum homozygous individual type iii hyperlipoproteinemia abnormal accumulation remnant particle suggested cause accelerated coronary peripheral vascular disease num
0.30876386.9218423.html.plaintext.txt	332	even small change lipid metabolism decrease clearance efficiency lipoprotein likely dramatic effect development atherosclerosis thus numnum animal give u opportunity investigate change important
0.30876386.9218423.html.plaintext.txt	333	conclusion demonstrated use targeted gene replacement generate mouse expressing common human isoform apoenum physiological level
0.30876386.9218423.html.plaintext.txt	334	mouse allow u document behavior human apoenum isoform vivo mouse without co expression mouse apoe
0.30876386.9218423.html.plaintext.txt	335	future experiment comparing mouse mouse expressing human apoenum enum isoforms created identical manner prove invaluable studying disease related different human apoe isoforms
0.30876386.9218423.html.plaintext.txt	336	masahiko watanabe help building targeting construct daniel throckmorton brian oswald denise lee kim kluckman technical help
0.30876386.9218423.html.plaintext.txt	337	taylor apoenum plasmid dr
0.30876386.9218423.html.plaintext.txt	338	fruchart enum antibody dr
0.30876386.9218423.html.plaintext.txt	339	young anti mouse apob serum dr
0.30876386.9218423.html.plaintext.txt	340	rifai validation human apoe standard dr
0.30876386.9218423.html.plaintext.txt	341	kirby reviewing manuscript
0.30876386.9218423.html.plaintext.txt	342	num num num medline order article via infotrieve herz j
0.30876386.9218423.html.plaintext.txt	343	num num num abstract mahley r
0.30876386.9218423.html.plaintext.txt	344	num num num abstract mahley r
0.30876386.9218423.html.plaintext.txt	345	num disturbance lipid lipoprotein metabolism dietschy j
0.30876386.9218423.html.plaintext.txt	346	num num american physiological society bethesda olaisen b
0.30876386.9218423.html.plaintext.txt	347	num num medline order article via infotrieve kardassis d
0.30876386.9218423.html.plaintext.txt	348	num hypertension num num num free full text paik y
0.30876386.9218423.html.plaintext.txt	349	num num num abstractfree full text smith j
0.30876386.9218423.html.plaintext.txt	350	num num num abstractfree full text simonet w
0.30876386.9218423.html.plaintext.txt	351	num num num abstractfree full text blue m
0.30876386.9218423.html.plaintext.txt	352	num num num abstract basu
0.30876386.9218423.html.plaintext.txt	353	num num num free full text hallman d
0.30876386.9218423.html.plaintext.txt	354	num num num medline order article via infotrieve rall
0.30876386.9218423.html.plaintext.txt	355	num num num free full text weisgraber k
0.30876386.9218423.html.plaintext.txt	356	num num num free full text utermann g
0.30876386.9218423.html.plaintext.txt	357	num num num abstract saunders
0.30876386.9218423.html.plaintext.txt	358	num neurology num num num abstract smith j
0.30876386.9218423.html.plaintext.txt	359	num num num abstractfree full text simonet w
0.30876386.9218423.html.plaintext.txt	360	num num num abstractfree full text fazio
0.30876386.9218423.html.plaintext.txt	361	num num num abstract mortimer b
0.30876386.9218423.html.plaintext.txt	362	num num num abstract van den maagdenberg
0.30876386.9218423.html.plaintext.txt	363	num num num abstractfree full text xu p
0.30876386.9218423.html.plaintext.txt	364	num num num crossrefmedline order article via infotrieve tybulewicz v
0.30876386.9218423.html.plaintext.txt	365	num cell num num num medline order article via infotrieve koller b
0.30876386.9218423.html.plaintext.txt	366	num num num abstract de silva h
0.30876386.9218423.html.plaintext.txt	367	num num num abstract chomczynski p
0.30876386.9218423.html.plaintext.txt	368	num num num crossrefmedline order article via infotrieve thomas p
0.30876386.9218423.html.plaintext.txt	369	num num num abstract leroy
0.30876386.9218423.html.plaintext.txt	370	immunoassay num num num medline order article via infotrieve quarfordt
0.30876386.9218423.html.plaintext.txt	371	num num num abstract zhang
0.30876386.9218423.html.plaintext.txt	372	num num num medline order article via infotrieve green e
0.30876386.9218423.html.plaintext.txt	373	num num num abstractfree full text robinson
0.30876386.9218423.html.plaintext.txt	374	acta num num num medline order article via infotrieve imaizumi k
0.30876386.9218423.html.plaintext.txt	375	num num num abstract de silva h
0.30876386.9218423.html.plaintext.txt	376	num num num abstractfree full text yang y
0.30876386.9218423.html.plaintext.txt	377	num num num medline order article via infotrieve wardell m
0.30876386.9218423.html.plaintext.txt	378	num num num medline order article via infotrieve lalazar
0.30876386.9218423.html.plaintext.txt	379	num num num abstractfree full text landis b
0.30876386.9218423.html.plaintext.txt	380	acta num num num medline order article via infotrieve weisgraber k
0.30876386.9218423.html.plaintext.txt	381	num num num abstract taylor j
0.30876386.9218423.html.plaintext.txt	382	num circulation num num num abstract slyper
0.30876386.9218423.html.plaintext.txt	383	num lancet num num num medline order article via infotrieve van vlijmen b
0.30876386.9218423.html.plaintext.txt	384	num num num abstractfree full text num american society biochemistry molecular biology inc
0.3103701.9811940.html.plaintext.txt	0	genetic association alphanum macroglobulin valnumile polymorphism alzheimers disease
0.3103701.9811940.html.plaintext.txt	1	alzheimer research unit neurology service massachusetts general hospital num numth street cny num charlestown ma num usa numuniversity hamburg hamburg germany numirccs
0.3103701.9811940.html.plaintext.txt	2	giovanni de dio fbf brescia italy numuniversity basel basel switzerland
0.3103701.9811940.html.plaintext.txt	3	received july num num revised accepted august num num
0.3103701.9811940.html.plaintext.txt	4	alphanum macroglobulin anumm proteinase inhibitor found association senile plaque sp alzheimers disease ad
0.3103701.9811940.html.plaintext.txt	5	anumm implicated biochemically binding degradation amyloid beta abeta protein accumulates sp
0.3103701.9811940.html.plaintext.txt	6	studied relationship alzheimers disease common anumm polymorphism valnum gtcilenum atc occurs near thiolester active site molecule
0.3103701.9811940.html.plaintext.txt	7	initial exploratory data set num control num alzheimers disease noted increased frequency gg genotype num
0.3103701.9811940.html.plaintext.txt	8	therefore tested hypothesis gg genotype represented alzheimers disease additional independent data set group num control num alzheimers disease patient
0.3103701.9811940.html.plaintext.txt	9	hypothesis testing cohort gg genotype increased num
0.3103701.9811940.html.plaintext.txt	10	num alzheimers disease p num
0.3103701.9811940.html.plaintext.txt	11	odds ratio alzheimers disease associated gg genotype num
0.3103701.9811940.html.plaintext.txt	12	num combination apoenum num
0.3103701.9811940.html.plaintext.txt	13	presence g allele associated increase abeta burden small series
0.3103701.9811940.html.plaintext.txt	14	anumm receptor anumm rlrp multifunctional receptor whose ligand include apolipoprotein e amyloid precursor protein
0.3103701.9811940.html.plaintext.txt	15	four protein genetically linked alzheimers disease suggesting may participate common disease pathway
0.3103701.9811940.html.plaintext.txt	16	alphanum macroglobulin anumm proteinase inhibitor inhibits proteinase class steric trapping mechanism
0.3103701.9811940.html.plaintext.txt	17	tetrameric anumm structure undergoes conformational change upon cleavage peptide bond bait region proteinase conformational change trap proteinase
0.3103701.9811940.html.plaintext.txt	18	anumm implicated several pathophysiological process alzheimers disease
0.3103701.9811940.html.plaintext.txt	19	anumm immunostains senile plaque sp num num bind amyloid beta protein abeta num num high affinity apparent kd num
0.3103701.9811940.html.plaintext.txt	20	moreover recent data suggest serine proteinase anumm complex degrade abeta num trypsin activated anumm efficiently degrades abeta vitro prevents vitro formation thioflavin positive abeta fibril well abeta induced toxicity cultured human cortical neuronal cell num
0.3103701.9811940.html.plaintext.txt	21	activated anumm cleared anumm rlow density lipoprotein receptor related protein anumm rlrp
0.3103701.9811940.html.plaintext.txt	22	anumm rlrp multifunctional receptor interestingly also primary neuronal apolipoprotein e apoe receptor numnum
0.3103701.9811940.html.plaintext.txt	23	lrp also bind clear kunitz proteinase inhibitor containing isoforms amyloid precursor protein app num
0.3103701.9811940.html.plaintext.txt	24	thus anumm potentially impact apoe app metabolism brain
0.3103701.9811940.html.plaintext.txt	25	biological link alzheimers disease studied possible association previously reported polymorphism anumm gene alzheimers disease
0.3103701.9811940.html.plaintext.txt	26	num screened num normal num pulmonary disease patient anumm polymorphism near active site reported three anumm polymorphism
0.3103701.9811940.html.plaintext.txt	27	common occurred num amino acid downstream thiolester site interchanging valnum gtc ilenum atc num
0.3103701.9811940.html.plaintext.txt	28	numbering based cdna sequence includes num amino acid signal peptide corresponds valilenum mature protein
0.3103701.9811940.html.plaintext.txt	29	allele frequency num probands num
0.3103701.9811940.html.plaintext.txt	30	difference anumm serum level associated two allele
0.3103701.9811940.html.plaintext.txt	31	polymorphism especially interesting potential biologically relevant function anumm proteinase inhibitor occurs near thiolester active site molecule
0.3103701.9811940.html.plaintext.txt	32	initial exploratory experiment tested possibility le common form anumm g allele would associated alzheimers disease
0.3103701.9811940.html.plaintext.txt	33	potential error due multiple hypothesis testing planned use initial data set exploratory data set intent formulate specific hypothesis would tested formally second independent data set
0.3103701.9811940.html.plaintext.txt	34	genotyped num non alzheimers individual either undergone screening test blessed dementia scale num whose dna isolated autopsy material demonstrated alzheimers disease num individual either clinical diagnosis alzheimers disease neuropathologically proven alzheimers disease table num
0.3103701.9811940.html.plaintext.txt	35	genotype determined pcr amplification dna restriction enzyme digestion fig
0.3103701.9811940.html.plaintext.txt	36	control series g allele frequency num
0.3103701.9811940.html.plaintext.txt	37	num six num individual contained gg genotype num
0.3103701.9811940.html.plaintext.txt	38	alzheimers disease set g allele frequency num
0.3103701.9811940.html.plaintext.txt	39	noticed gg genotype frequency increased alzheimers group num
0.3103701.9811940.html.plaintext.txt	40	result suggest possible influence anumm polymorphism genetic risk factor alzheimers disease
0.3103701.9811940.html.plaintext.txt	41	electrophoresis pattern restriction digest demonstrating band representing g num bp allele num bp
0.3103701.9811940.html.plaintext.txt	42	representation anumm gg genotype alzheimers disease n g allele gg genotype exploratory data set control num num
0.3103701.9811940.html.plaintext.txt	43	num hypothesis testing data set control num num
0.3103701.9811940.html.plaintext.txt	44	numa combined data set total control num num
0.3103701.9811940.html.plaintext.txt	45	formally test hypothesis gg genotype anumm represented alzheimers disease collected genotyped additional independent group patient control
0.3103701.9811940.html.plaintext.txt	46	power analysis showed num alzheimers disease control individual would necessary num chance showing difference genotype frequency num
0.3103701.9811940.html.plaintext.txt	47	therefore collected case control several site order approximate number sample
0.3103701.9811940.html.plaintext.txt	48	second data set consisted individual met criterion alzheimers disease control hypothesis generating set derived sporadic alzheimers disease patient massachusetts three european center probands multicenter u study sib pair small family
0.3103701.9811940.html.plaintext.txt	49	result second data set supported hypothesis gg genotype frequency num
0.3103701.9811940.html.plaintext.txt	50	num alzheimers disease p num
0.3103701.9811940.html.plaintext.txt	51	num fisher exact test table num
0.3103701.9811940.html.plaintext.txt	52	g allele represented data set control num
0.3103701.9811940.html.plaintext.txt	53	difference age onset gg non gg found second data set
0.3103701.9811940.html.plaintext.txt	54	multivariate analysis showed site collection influence genotype frequency
0.3103701.9811940.html.plaintext.txt	55	also compared rate control subset num clinic based alzheimers disease case gg frequency num
0.3103701.9811940.html.plaintext.txt	56	num subset num familial alzheimers disease sample gg frequency num
0.3103701.9811940.html.plaintext.txt	57	num found essentially equal representation gg
0.3103701.9811940.html.plaintext.txt	58	data support association gg genotype alzheimers disease
0.3103701.9811940.html.plaintext.txt	59	carried series exploratory analysis using pooled data individual num alzheimers disease patient num control
0.3103701.9811940.html.plaintext.txt	60	gg genotype present num
0.3103701.9811940.html.plaintext.txt	61	num alzheimer patient num
0.3103701.9811940.html.plaintext.txt	62	genotype frequency control consistent hardy weinberg equilibrium
0.3103701.9811940.html.plaintext.txt	63	age onset different alzheimers disease patient gg num
0.3103701.9811940.html.plaintext.txt	64	num mean plus minus sd non gg carrier num
0.3103701.9811940.html.plaintext.txt	65	multivariate logistic model controlled presence apoenum allele gender showed odds ratio num
0.3103701.9811940.html.plaintext.txt	66	num presence anumm gg genotype
0.3103701.9811940.html.plaintext.txt	67	presence apoenum model associated odds ratio num
0.3103701.9811940.html.plaintext.txt	68	odds ratio combination gg apoenum num
0.3103701.9811940.html.plaintext.txt	69	num relative neither risk factor
0.3103701.9811940.html.plaintext.txt	70	explore whether gg mediated risk influenced presence absence apoenum stratified sample presence absence apoenum
0.3103701.9811940.html.plaintext.txt	71	similar representation gg genotype seen stratum without apoenum suggesting effect two risk factor independent
0.3103701.9811940.html.plaintext.txt	72	multivariate analysis interaction gg genotype either apoenum gender demonstrated interaction p num
0.3103701.9811940.html.plaintext.txt	73	analysis based mantel haenszel estimator suggested heterogeneity odds ratio stratum without apoenum p num
0.3103701.9811940.html.plaintext.txt	74	num consistent absence interaction anumm apoenum logistic regression model
0.3103701.9811940.html.plaintext.txt	75	next turned attention possible biological effect inheritance anumm gg genotype
0.3103701.9811940.html.plaintext.txt	76	previous study anumm immunohistochemistry alzheimer brain suggested sp different case stained varying intensity num
0.3103701.9811940.html.plaintext.txt	77	explored possibility variability due different genotype immunostaining eight alzheimers disease case known gg aa genotype
0.3103701.9811940.html.plaintext.txt	78	instance anumm immunoreactivity present robustly sp astrocyte neuron qualitative difference observed genotype group
0.3103701.9811940.html.plaintext.txt	79	also explored effect inheritance anumm gg genotype neuropathological phenotype alzheimers disease table num
0.3103701.9811940.html.plaintext.txt	80	previously used stereological technique quantitative image analysis measure amount abeta present amyloid burden neocortical association area surrounding superior temporal sulcus number neurofibrillary tangle present region num
0.3103701.9811940.html.plaintext.txt	81	thirty one previously analyzed alzheimers disease case anumm genotyped selected analysis
0.3103701.9811940.html.plaintext.txt	82	initial inspection data suggested increase abeta individual ag gg difference two group
0.3103701.9811940.html.plaintext.txt	83	statistically significant increase abeta deposition seen comparing g containing case non g containing case num
0.3103701.9811940.html.plaintext.txt	84	effect appears primarily due presence least one g allele difference ag gg genotype observed although sample size limit power comparison
0.3103701.9811940.html.plaintext.txt	85	statistically significant difference neurofibrillary tangle number g allele suggesting specific effect abeta deposition
0.3103701.9811940.html.plaintext.txt	86	neuropathological correlate anumm genotype genotype n amyloid burden neurofibrillary tangle x num aa num num
0.3103701.9811940.html.plaintext.txt	87	exploratory study genetic risk factor run risk type error large number hypothesis either explicitly implicitly tested
0.3103701.9811940.html.plaintext.txt	88	alternatively type ii error occur sample size insufficient
0.3103701.9811940.html.plaintext.txt	89	order overcome difficulty inherent exploratory study genetic risk factor used independent data set first generate test hypothesis gg genotype associated alzheimers disease
0.3103701.9811940.html.plaintext.txt	90	two separate control population gave identical genotype frequency hypothesis testing data set made two group sporadic ad probands multicenter study alzheimers disease sib pair small family gave essentially identical genotype frequency representation gg genotype
0.3103701.9811940.html.plaintext.txt	91	anumm gg effect dependent apoe genotype effect additive substantial odds ratio gg presence apoenum allele showed almost num fold increased risk
0.3103701.9811940.html.plaintext.txt	92	power analysis using size effect observed combined data set using num sample suggests group size num control num alzheimers disease patient would necessary alpha num
0.3103701.9811940.html.plaintext.txt	93	num beta num hypothesis gg genotype increased num
0.3103701.9811940.html.plaintext.txt	94	association gg anumm genotype risk factor alzheimers disease lead several interesting mechanistic interpretation
0.3103701.9811940.html.plaintext.txt	95	previous data shown anumm immunostains sp implicated anumm amyloid precursor protein metabolism num well possible interaction binding abeta num mediation degradation abeta numnum
0.3103701.9811940.html.plaintext.txt	96	anumm abeta complex undergo endocytosis via anumm rlrp receptor num
0.3103701.9811940.html.plaintext.txt	97	anumm associate abeta prevents fibril formation num
0.3103701.9811940.html.plaintext.txt	98	addition anumm viewed subacute phase reactive molecule potent proteinase inhibitor might participate inflammatory response alzheimer brain
0.3103701.9811940.html.plaintext.txt	99	interestingly anumm also implicated trophic factor possibly result binding transporting number polypeptide growth factor cytokine num
0.3103701.9811940.html.plaintext.txt	100	like apoe anumm may serve binding protein targeting various bioactive molecule site action clearing num
0.3103701.9811940.html.plaintext.txt	101	finally fact apoe app two ligand anumm rlrp receptor clearly involved pathophysiology alzheimers disease support plausibility idea anumm polymorphism might contribute risk alzheimers disease
0.3103701.9811940.html.plaintext.txt	102	fact polymorphism anumm rlrp recently reported two study show genetic association alzheimers disease numnum
0.3103701.9811940.html.plaintext.txt	103	although strong biological rationale involvement anumm polymorphism alzheimers disease possibility remains genetic association observe reflects linkage another mutation polymorphism either anumm gene nearby gene chromosome num
0.3103701.9811940.html.plaintext.txt	104	anumm gene resides num cm distal marker dnumsnum yielded maximal lod score recent linkage study suggesting chromosome num contains alzheimer risk factor num
0.3103701.9811940.html.plaintext.txt	105	however likelihood anumm risk factor supported result recent separate study observed association intronic numprime splice site exon num pentanucleotide deletion allele num within anumm gene alzheimers disease sibship analysis alzheimers disease sib pair small alzheimers disease family num
0.3103701.9811940.html.plaintext.txt	106	current result extend observation showing linkage missense mutation case control sample rather family based association
0.3103701.9811940.html.plaintext.txt	107	currently studying two anumm polymorphism relate one another preliminary result consistent hypothesis act independent risk factor
0.3103701.9811940.html.plaintext.txt	108	initial study group evaluated polymorphism suggests g allele inherited num allele num g chromosome examined num gg individual num allele num num allele num compared allele num frequency num p num
0.3103701.9811940.html.plaintext.txt	109	num chinum analysis yates correction
0.3103701.9811940.html.plaintext.txt	110	taken together believe polymorphism anumm gene may contribute risk alzheimers disease
0.3103701.9811940.html.plaintext.txt	111	moreover data focus attention mechanism pathophysiology impact anumm rlrp ligand including clearance mechanism mediated anumm rlrp numnum suggest anumm rlrp ligand may candidate alzheimers disease gene well
0.3103701.9811940.html.plaintext.txt	112	initial hypothesis generating data set established num alzheimers disease patient clinical history probable alzheimers disease num age compatible control individual primarily spouse patient
0.3103701.9811940.html.plaintext.txt	113	second hypothesis testing data set collected several source attempt approximate num patient control estimated power analysis adequately test hypothesis gg genotype represented alzheimers disease
0.3103701.9811940.html.plaintext.txt	114	individual included additional case num sporadic alzheimer disease num control matched site primarily cognitively tested spouse collected massachusetts general hospital memory disorder unit consortium european center university hamburg germany university basel switzerland
0.3103701.9811940.html.plaintext.txt	115	cuore fatebenefratelli hospital brescia italy num probands multicenter study alzheimer disease sib pair small alzheimers disease family num
0.3103701.9811940.html.plaintext.txt	116	genomic dna isolated brain tissue blood amplified pcr presence oligonucleotide sense primer cnum numprime atc cct gaa act gcc acc aa numprime antisense primer asnum numprime gta act gaa acc tac tgg aa numprime num mm tris hcnum num mm kcnum ph num
0.3103701.9811940.html.plaintext.txt	117	num mm mgcnum num mm dntps num pmol primer num
0.3103701.9811940.html.plaintext.txt	118	pcr carried touchdown procedure stepped annealing temperature increase primer specificity follows one cycle num degree c num min four cycle num degree c num num degree c num num degree c num min four cycle num degree c num num degree c num num degree c num min four cycle num degree c num num degree c num num degree c num min num cycle num degree c num num degree c num num degree c num min one cycle num degree c num min
0.3103701.9811940.html.plaintext.txt	119	reaction mixture mboi added amplified product num bp digestion carried num degree c num h producing fragment num g allele num bp allele
0.3103701.9811940.html.plaintext.txt	120	digested product loaded onto num agarose gel treated ethidium bromide num
0.3103701.9811940.html.plaintext.txt	121	num electrophoresed num h constant voltage num v sufficient separate digested product num num bp band distinguished
0.3103701.9811940.html.plaintext.txt	122	electrophoresis dna fragment visualized uv illumination using bio rad gel doc system
0.3103701.9811940.html.plaintext.txt	123	incomplete digestion monitored continued presence num bp product
0.3103701.9811940.html.plaintext.txt	124	immunohistochemical analysis used anti anumm antibody numnum zymed
0.3103701.9811940.html.plaintext.txt	125	goat cynum linked secondary antibody jackson immunoresearch used visualize immunostaining
0.3103701.9811940.html.plaintext.txt	126	instance double immunofluorescence carried abeta counterstain antibody numdnum courtesy dr d
0.3103701.9811940.html.plaintext.txt	127	schenk athena neuroscience using bodipy fluorescein linked secondary antibody molecular probe second fluorochrome
0.3103701.9811940.html.plaintext.txt	128	quantitative neuropathological technique measuring abeta burden neurofibrillary tangle number superior temporal sulcus area previously published num
0.3103701.9811940.html.plaintext.txt	129	comparison anumm allele frequency proportion chromosome allele present genotype frequency proportion individual genotype performed num x num table using fisher exact test significance
0.3103701.9811940.html.plaintext.txt	130	age onset alzheimers disease normally distributed compared test
0.3103701.9811940.html.plaintext.txt	131	multivariate analysis odds alzheimers disease performed logistic regression apoe genotype coded according presence absence apoenum
0.3103701.9811940.html.plaintext.txt	132	similar result obtained group apoenum coded separately heterozygote homozygote allele
0.3103701.9811940.html.plaintext.txt	133	odds ratio presented num confidence interval ci
0.3103701.9811940.html.plaintext.txt	134	analysis performed stata software college park tx
0.3103701.9811940.html.plaintext.txt	135	significance test two tailed
0.3103701.9811940.html.plaintext.txt	136	maschke technical assistance
0.3103701.9811940.html.plaintext.txt	137	thank massachusetts alzheimers research center agnum brain bank dr e
0.3103701.9811940.html.plaintext.txt	138	hedley whyte neuropathological specimen
0.3103701.9811940.html.plaintext.txt	139	additional neurological pathological specimen obtained brain tissue research center mhns num
0.3103701.9811940.html.plaintext.txt	140	work supported nih grant agnum agnum
0.3103701.9811940.html.plaintext.txt	141	num alphanum macroglobulin expression neuritic type plaque patient alzheimers disease
0.3103701.9811940.html.plaintext.txt	142	num multiple diverse senile plaque associated protein ligand apolipoprotein e receptor alpha num macroglobulin receptorlow density lipoprotein receptor related protein
0.3103701.9811940.html.plaintext.txt	143	num alpha num macroglobulin beta amyloid peptide binding plasma protein
0.3103701.9811940.html.plaintext.txt	144	num degradation amyloid beta protein serine protease alpha num macroglobulin complex
0.3103701.9811940.html.plaintext.txt	145	num inhibition alpha num macroglobulinproteinase mediated degradation amyloid beta peptide apolipoprotein e alpha num antichymotrypsin
0.3103701.9811940.html.plaintext.txt	146	num apolipoprotein e sporadic alzheimers disease allelic variation receptor interaction
0.3103701.9811940.html.plaintext.txt	147	num sequence identity alphanum macroglobulin receptor low density lipoprotein receptor related protein suggests molecule multifunctional receptor
0.3103701.9811940.html.plaintext.txt	148	num ldl receptor related protein multifunctional apoe receptor bind secreted beta amyloid precursor protein mediates degradation
0.3103701.9811940.html.plaintext.txt	149	num cloning human alpha num macroglobulin gene detection mutation two functional domain bait region thiolester site
0.3103701.9811940.html.plaintext.txt	150	num association quantitative measure dementia senile change cerebral grey matter elderly subject
0.3103701.9811940.html.plaintext.txt	151	num neuronal loss parallel exceeds tangle formation alzheimers disease
0.3103701.9811940.html.plaintext.txt	152	num alpha num macroglobulin synthesis interleukin num stimulated human neuronal sh synumy neuroblastoma cell
0.3103701.9811940.html.plaintext.txt	153	num alpha num macroglobulin complex mediates endocytosis beta amyloid peptide via cell surface low density lipoprotein receptor related protein
0.3103701.9811940.html.plaintext.txt	154	num alpha num macroglobulin associate beta amyloid peptide prevents fibril formation
0.3103701.9811940.html.plaintext.txt	155	num alphanum macroglobulin multifunctional binding protein targeting characteristic
0.3103701.9811940.html.plaintext.txt	156	num genetic association low density lipoprotein receptor related protein gene lrp apolipoprotein e receptor late onset alzheimers disease
0.3103701.9811940.html.plaintext.txt	157	num confirmation association polymorphism exon num low density lipoprotein receptor related protein gene alzheimers disease
0.3103701.9811940.html.plaintext.txt	158	num complete genomic screen late onset familial alzheimer disease
0.3103701.9811940.html.plaintext.txt	159	evidence new locus chromosome num
0.3103701.9811940.html.plaintext.txt	160	num alpha num macroglobulin genetically associated alzheimers disease
0.3103701.9811940.html.plaintext.txt	161	num apoe num age onset alzheimers disease nimh genetics initiative
0.3103701.9811940.html.plaintext.txt	162	correspondence addressed
0.3103701.9811940.html.plaintext.txt	163	tel num num num num fax num num num num email bhymanhelix
0.3103701.9811940.html.plaintext.txt	164	edu page run oxford university press great clarendon street oxford oxnum numdp part oup journal comment feedback www adminatoup
0.3103701.9811940.html.plaintext.txt	165	uk u d last modification num nov num copyright oxford university press num
0.31053388.15890642.html.plaintext.txt	0	engineering conformational destabilization mouse apolipoprotein e model unique property human apolipoprotein enum danny m
0.31053388.15890642.html.plaintext.txt	1	gladstone institute neurological disease san francisco california num cardiovascular research institute department pathology university california san francisco california num
0.31053388.15890642.html.plaintext.txt	2	received publication april num num revised form may num num
0.31053388.15890642.html.plaintext.txt	3	three isoforms encoded one gene differ one two amino acid sequence position
0.31053388.15890642.html.plaintext.txt	4	apoenum cysteine position num arginine num apoenum cysteine apoenum arginine position num
0.31053388.15890642.html.plaintext.txt	5	sequence difference result structural biophysical property alter function hence likely affect disease
0.31053388.15890642.html.plaintext.txt	6	apoenum two modular domain interact unique manner known domain interaction num num
0.31053388.15890642.html.plaintext.txt	7	arg num apoenum cause arg num side chain adopt different conformation apoenum apoenum allowing form putative salt bridge glu num carboxyl terminal domain num num
0.31053388.15890642.html.plaintext.txt	8	isoforms also differ conformational stability amino terminal domain unfold independently carboxy terminal domain contain isoform specific sequence difference num num
0.31053388.15890642.html.plaintext.txt	9	amino terminal domain apoenum least resistant chemical thermal denaturation apoenum resistant num num
0.31053388.15890642.html.plaintext.txt	10	amino terminal domain apoenum also readily form partially folded intermediate characteristic molten globule state num
0.31053388.15890642.html.plaintext.txt	11	increasing evidence indicates molten globule common mediate wide variety physiological process including translocation across membrane increased affinity membrane binding liposome phospholipid protein trafficking extracellular secretion cell cycle regulation num
0.31053388.15890642.html.plaintext.txt	12	one explanation functional difference among isoforms vivo others suggested partially folded intermediate provide apoe greater conformational adaptability bind phospholipid num num
0.31053388.15890642.html.plaintext.txt	13	previously laboratory introduced domain interaction mouse apoe
0.31053388.15890642.html.plaintext.txt	14	gene targeting used replace threonine mouse equivalent position num arginine tnumr resulted apoenum like lipoprotein binding preference num characteristic domain interaction
0.31053388.15890642.html.plaintext.txt	15	however unlike apoenum tnumr mouse apoe fold highly cooperatively lack apparent folding intermediate
0.31053388.15890642.html.plaintext.txt	16	gain sight difference isoform stability affect phenotype disease sought introduce tnumr mouse apoe reduced folding stability characteristic apoenum
0.31053388.15890642.html.plaintext.txt	17	objective humanize mouse apoe replacing residue apoenum destabilize conformation
0.31053388.15890642.html.plaintext.txt	18	empirical approach taken change urea denaturation curve tnumr mouse apoe resemble apoenum
0.31053388.15890642.html.plaintext.txt	19	crystal structure amino terminal domain wild type mouse apoe determined identify potential structural difference apoenum mouse apoe might result packing difference leading difference urea denaturation curve
0.31053388.15890642.html.plaintext.txt	20	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	21	urea denaturation curve amino terminal domain apoe isoforms
0.31053388.15890642.html.plaintext.txt	22	curve derived fractional change cd ellipticity wavelength num nm num num m urea
0.31053388.15890642.html.plaintext.txt	23	apoenum apoenum wild type mouse apoe tnumr mouse apoe shown
0.31053388.15890642.html.plaintext.txt	24	crystallization x ray diffraction data collection crystal grown hanging drop technique num
0.31053388.15890642.html.plaintext.txt	25	num saturated sodium malonate ph num
0.31053388.15890642.html.plaintext.txt	26	num num mm sodium acetate ph num
0.31053388.15890642.html.plaintext.txt	27	diffraction data collected beam line num num stanford synchrotron radiation laboratory
0.31053388.15890642.html.plaintext.txt	28	data collection statistic summarized table
0.31053388.15890642.html.plaintext.txt	29	space group determined pnum unit cell num
0.31053388.15890642.html.plaintext.txt	30	initial phase obtained using molecular replacement program epmr num structure amino terminal domain apoenum starting model
0.31053388.15890642.html.plaintext.txt	31	decrease model bias resolve num used refine initial phase build preliminary model
0.31053388.15890642.html.plaintext.txt	32	cns num refmac num used subsequent refinement cycle
0.31053388.15890642.html.plaintext.txt	33	view table table data collection refinement statistic
0.31053388.15890642.html.plaintext.txt	34	urea denaturation curve saturated urea solution freshly deionized filtered
0.31053388.15890642.html.plaintext.txt	35	urea concentration determined measurement refractive index described num
0.31053388.15890642.html.plaintext.txt	36	circular dichroism spectrum collected apoe num kda fragment num
0.31053388.15890642.html.plaintext.txt	37	num mgml num num m urea num mm dithiothreitol num mm sodium acetate ph num
0.31053388.15890642.html.plaintext.txt	38	sample preincubated overnight num degree c spectroscopic analysis data collected num degree c using num mm path length cuvette applied biophysics num jasco j num cd spectrometer num m acquisition time
0.31053388.15890642.html.plaintext.txt	39	ellipticity num nm served indicator secondary structure predominately helical folded state data adjusted fraction unfolded assuming protein num unfolded num m urea
0.31053388.15890642.html.plaintext.txt	40	dmpc turbidity clearance assay sample apoe num kda fragment num mgml prepared num mm tris carboxyethylphosphine num mm sodium acetate ph num
0.31053388.15890642.html.plaintext.txt	41	dmpc prepared num mgml buffer incubated num degree c num min extruded num nm pore filter lipex pressure extruder
0.31053388.15890642.html.plaintext.txt	42	resulting large unilamellar vesicle diluted num mgml buffer
0.31053388.15890642.html.plaintext.txt	43	vesicle protein sample spectrophotometer cuvette holding block pre equilibrated num degree c overnight
0.31053388.15890642.html.plaintext.txt	44	sample apoe buffer num microl mixed rapidly vesicle num microl turbidity monitored absorbance num nm num min num degree c
0.31053388.15890642.html.plaintext.txt	45	cuvettes pre equilibrated num degree c num min use
0.31053388.15890642.html.plaintext.txt	46	structural comparison amino terminal domain mouse human apoe crystal structure amino terminal domain wild type mouse apoe determined resolution num
0.31053388.15890642.html.plaintext.txt	47	num used find clue packing difference apoenum may influence folding stability
0.31053388.15890642.html.plaintext.txt	48	x ray diffraction data collection refinement statistic summarized table
0.31053388.15890642.html.plaintext.txt	49	excluding eight additional amino terminal residue human apoe amino terminal domain mouse apoe apoenum differ num sequence position corresponding num sequence identity fig
0.31053388.15890642.html.plaintext.txt	50	overall fold amino terminal domain wild type mouse apoe similar apoenum fig
0.31053388.15890642.html.plaintext.txt	51	except residue num num num num num num residue amino terminal domain mouse apoe clearly visible final electron density map
0.31053388.15890642.html.plaintext.txt	52	although amino terminal domain mouse apoe like apoenum form four helix bundle structural difference
0.31053388.15890642.html.plaintext.txt	53	alignment mouse human structure along helix num num show relative apoenum helix num num amino terminal domain mouse apoe shifted direction roughly parallel helical axis helix num
0.31053388.15890642.html.plaintext.txt	54	addition helix num num num longer mouse apoe apoenum
0.31053388.15890642.html.plaintext.txt	55	crystal contact residue num mouse apoe likely stabilizes extension helix num apoenum contact occurs
0.31053388.15890642.html.plaintext.txt	56	crystal contact residue num mouse apoe seen apoenum likely influence structure loop helix num num residue num num
0.31053388.15890642.html.plaintext.txt	57	two structural difference position num num mediated sequence difference exclusion crystal contact site two key structural difference result sequence difference
0.31053388.15890642.html.plaintext.txt	58	loop helix num num residue num num form tight turn mouse apoe extended relaxed crystal structure human apoe num
0.31053388.15890642.html.plaintext.txt	59	difference reflects ci conformation gly num mouse apoe sterically accommodated thr num apoenum fig
0.31053388.15890642.html.plaintext.txt	60	mouse apoe helix num one helical turn apoenum dipole helix num num le parallel fig
0.31053388.15890642.html.plaintext.txt	61	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	62	sequence alignment amino terminal domain mouse apoe apoenum
0.31053388.15890642.html.plaintext.txt	63	numbering system mouse apoe standardized apoenum sequence apoenum eight additional amino terminal residue
0.31053388.15890642.html.plaintext.txt	64	identical residue highlighted gray
0.31053388.15890642.html.plaintext.txt	65	major structural element noted sequence apoenum black bar mouse apoe gray bar
0.31053388.15890642.html.plaintext.txt	66	major difference residue num mouse apoe contains asparagine apoenum contains glycine fig
0.31053388.15890642.html.plaintext.txt	67	asn num mouse apoe lie straight portion helix num gly num apoenum lie pronounced kink form hydrogen bond arg num formed asn num mouse apoe fig
0.31053388.15890642.html.plaintext.txt	68	result reduced local hydrogen bond network fig
0.31053388.15890642.html.plaintext.txt	69	addition glycine high configurational entropy localized flexibility middle helix num caused gly num may account lower stability greater propensity apoenum form partially folded intermediate
0.31053388.15890642.html.plaintext.txt	70	net effect sequence difference position num num greater stabilization helix num parallel alignment dipole helix num num mouse apoe apoenum fig
0.31053388.15890642.html.plaintext.txt	71	thus data suggest two sequence difference contribute difference human mouse urea denaturation curve
0.31053388.15890642.html.plaintext.txt	72	view table table ii potential hydrogen bond mouse apoe human apoenum near num
0.31053388.15890642.html.plaintext.txt	73	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	74	stereo image overlay crystal structure amino terminal domain mouse apoe apoenum
0.31053388.15890642.html.plaintext.txt	75	carbon trace apoenum blue mouse apoe orange shown
0.31053388.15890642.html.plaintext.txt	76	backbone deviation helix num num crystal form num
0.31053388.15890642.html.plaintext.txt	77	introducing apoenum residue position num num destabilizes tnumr mouse apoe thr num gly num apoenum introduced tnumr mouse apoe prediction would destabilize global conformation
0.31053388.15890642.html.plaintext.txt	78	urea denaturation curve showed mutant unfolded urea readily tnumr mouse apoe mutation additive effect destabilizing conformation fig
0.31053388.15890642.html.plaintext.txt	79	triple mutant mouse apoe tnumr gnumt nnumg apoenum displayed similar denaturation curve range num num
0.31053388.15890642.html.plaintext.txt	80	num m urea suggesting mutation position num num account largest effect difference stability tnumr mouse e apoenum fig
0.31053388.15890642.html.plaintext.txt	81	seven mutant made probe influence structural difference
0.31053388.15890642.html.plaintext.txt	82	introduced apoenum residue qnuml andor hnumq occur site crystal contact apoenum residue mnuml mnuml together correlate difference packing core tnumr mouse apoe
0.31053388.15890642.html.plaintext.txt	83	mutation marginal effect urea denaturation curve data shown
0.31053388.15890642.html.plaintext.txt	84	three mutant made tnumr gnumt nnumg backbone introduced nonconservative sequence difference minimal effect stability
0.31053388.15890642.html.plaintext.txt	85	introducing apoenum residue gnums nnumg group residue nnumg gnums nnumg pnumr gnumv qnuml slightly reduced folding cooperativity stability fig
0.31053388.15890642.html.plaintext.txt	86	introduction apoenum residue
0.31053388.15890642.html.plaintext.txt	87	apoenum sequence without first eight amino acid yielded urea denaturation curve similar apoenum fig
0.31053388.15890642.html.plaintext.txt	88	suggests additional eight residue apoenum play minor role stability
0.31053388.15890642.html.plaintext.txt	89	contrast mutation gnumt nnumg collection seven group mutation minor effect urea denaturation curve
0.31053388.15890642.html.plaintext.txt	90	destabilizing mutation gnumt nnumg increase lipid binding tnumr mouse apoe stability difference amino terminal domain human apoe isoforms correlate inversely lipid binding num num examined lipid binding destabilized mouse apoe
0.31053388.15890642.html.plaintext.txt	91	lipid binding assessed standard apolipoprotein lipid binding assay examines ability apoe remodel large unilamellar vesicle dmpc num
0.31053388.15890642.html.plaintext.txt	92	upon binding dmpc vesicle apoe form smaller apoe dmpc particle thereby decreasing turbidity solution num
0.31053388.15890642.html.plaintext.txt	93	human isoforms apoenum clear turbidity fastest followed apoenum apoenum num
0.31053388.15890642.html.plaintext.txt	94	amino terminal domain apoenum cleared turbidity exponential decay like manner much faster tnumr mouse apoe fig
0.31053388.15890642.html.plaintext.txt	95	destabilizing mutation gnumt nnumg cleared faster tnumr mouse apoe mutation together increased clearance rate fig
0.31053388.15890642.html.plaintext.txt	96	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	97	key structural difference mouse apoe apoenum amino terminal domain
0.31053388.15890642.html.plaintext.txt	98	difference carbon trace overlay mouse apoe yellow apoenum cyan loop helix num num influenced residue num
0.31053388.15890642.html.plaintext.txt	99	b difference helical dipole helix num mouse apoe yellow apoenum cyan helix num num shown
0.31053388.15890642.html.plaintext.txt	100	c difference hydrogen bond network mouse apoe yellow apoenum cyan influenced residue num
0.31053388.15890642.html.plaintext.txt	101	new model apoenum useful testing exploring cooperative additive effect domain interaction lower stability
0.31053388.15890642.html.plaintext.txt	102	furthermore tnumr introduces domain interaction wild type mouse apoe mouse model specific apoenum reduced stability without domain interaction made mutation enuma num
0.31053388.15890642.html.plaintext.txt	103	several protein mutation condition destabilize native conformation also facilitate formation aggregate property amyloid fibril consist ordered polymer strand num num
0.31053388.15890642.html.plaintext.txt	104	thus destabilization compactly folded state apoe although advantageous lipid binding may predispose misfolding amyloid fibril
0.31053388.15890642.html.plaintext.txt	105	could provide basis amyloid formation amyloid plaque brain alzheimer patient show apoe immunoreactivity num num
0.31053388.15890642.html.plaintext.txt	106	apoe isoforms differ ability promote amyloid formation
0.31053388.15890642.html.plaintext.txt	107	vitro co incubation purified apoe promotes fibrillization fibril coated apoe num
0.31053388.15890642.html.plaintext.txt	108	apoenum facilitates formation extensive matrix fibril apoenum assessed electron microscopy num num
0.31053388.15890642.html.plaintext.txt	109	vivo gene dosage apoenum alzheimer patient correlate deposition amyloid num
0.31053388.15890642.html.plaintext.txt	110	mouse model alzheimer disease
0.31053388.15890642.html.plaintext.txt	111	mouse expressing human amyloid precursor protein human apoe isoforms apoenum effective promoting deposition apoenum num num
0.31053388.15890642.html.plaintext.txt	112	furthermore apoe knock mouse expressing human apoe isoforms apoenum drive nucleation aggregation immunopositive deposit greater extent apoenum num
0.31053388.15890642.html.plaintext.txt	113	difference co aggregation apoe isoforms may provide mechanism acceleration nucleation polymerization plaque formation
0.31053388.15890642.html.plaintext.txt	114	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	115	effect mutation urea denaturation curve tnumr mouse apoe compared apoenum
0.31053388.15890642.html.plaintext.txt	116	amino terminal domain tnumr mouse apoe tnumr gnumt mouse apoe tnumr nnumg mouse apoe triple mutant tnumr gnumt nnumg mouse apoe shown
0.31053388.15890642.html.plaintext.txt	117	b amino terminal domain completely humanized mouse apoe num num apoenum apoenum triple mutant tnumrgnumtnnumg mouse apoe multiple mutant tnumrgnumtnnumgnnumggnumsnnumgpnumrgnumvqnuml mouse apoe multiple mutant tnumrgnumtnnumggnumsnnumg mouse apoe shown
0.31053388.15890642.html.plaintext.txt	118	enhanced lipid remodeling property destabilized apoe could also influence cellular functioning result pathologic effect
0.31053388.15890642.html.plaintext.txt	119	apoenum apoenum potentiates induced lysosomal leakage cultured neuronal cell suggesting apoenum destabilizes lysosomal membrane integrity cooperatively num
0.31053388.15890642.html.plaintext.txt	120	result support hypothesis greater phospholipid binding ability destabilized variant apoe account greater permeabilization phospholipid membrane
0.31053388.15890642.html.plaintext.txt	121	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	122	turbidity clearance assay apoe amino terminal domain
0.31053388.15890642.html.plaintext.txt	123	change absorbance followed addition apoe dmpc multilamellar vesicle
0.31053388.15890642.html.plaintext.txt	124	data shown apoenum single mutant tnumr mouse apoe double mutant tnumrgnumt mouse apoe tnumrnnumg mouse apoe triple mutant tnumrgnumtnnumg mouse apoe buffer alone dashed line
0.31053388.15890642.html.plaintext.txt	125	mouse model apoenum conformational stability valuable tool studying potential mechanism
0.31053388.15890642.html.plaintext.txt	126	addition system provide unique model exploring role conformational stability protein function pathology directly vivo
0.31053388.15890642.html.plaintext.txt	127	view larger version numk fig
0.31053388.15890642.html.plaintext.txt	128	urea denaturation curve amino terminal domain human partially humanized mouse apoe mutant
0.31053388.15890642.html.plaintext.txt	129	apoenum apoenum shown
0.31053388.15890642.html.plaintext.txt	130	b tnumr mouse apoe tnumrgnumtnnumg mouse apoe shown
0.31053388.15890642.html.plaintext.txt	131	footnote atomic coordinate structure factor code numyanum deposited protein data bank research collaboratory structural bioinformatics rutgers university new brunswick nj httpwww
0.31053388.15890642.html.plaintext.txt	132	work supported grant pnum agnum rnum agnum national institute health
0.31053388.15890642.html.plaintext.txt	133	cost publication article defrayed part payment page charge
0.31053388.15890642.html.plaintext.txt	134	article must therefore hereby marked advertisement accordance num u
0.31053388.15890642.html.plaintext.txt	135	section num solely indicate fact
0.31053388.15890642.html.plaintext.txt	136	author contributed equally work
0.31053388.15890642.html.plaintext.txt	137	correspondence addressed gladstone institute neurological disease num owen st
0.31053388.15890642.html.plaintext.txt	138	num num num fax num num num e mail kweisgraberatgladstone
0.31053388.15890642.html.plaintext.txt	139	num abbreviation used apo apolipoprotein dmpc dimyristoylphosphatidylcholine amyloid
0.31053388.15890642.html.plaintext.txt	140	acknowledgment thank jon menke maryam tabar yvonne newhouse earl rutenber technical assistance stephen ordway gary howard editorial assistance john carroll jack hull stephen gonzales chris goodfellow graphic assistance karina fantillo manuscript preparation
0.3125666.12588864.html.plaintext.txt	0	characterization heparin binding site human apolipoprotein e hiroyuki saito padmaja dhanasekaran david nguyen faye baldwin karl h
0.3125666.12588864.html.plaintext.txt	1	weisgraber suzanne wehrli michael c
0.3125666.12588864.html.plaintext.txt	2	phillips sissel lund katz
0.3125666.12588864.html.plaintext.txt	3	research institute childrens hospital philadelphia university pennsylvania school medicine philadelphia pennsylvania num num gladstone institute cardiovascular disease cardiovascular research institute department pathology university california san francisco california num
0.3125666.12588864.html.plaintext.txt	4	received publication december num num revised form february num num
0.3125666.12588864.html.plaintext.txt	5	apolipoprotein e apoenum critical ligand several hepatic lipoprotein receptor including low density lipoprotein ldl receptor ldl receptor related protein lrp cell surface heparan sulfate proteoglycans hspg num num
0.3125666.12588864.html.plaintext.txt	6	interaction receptor hspg lrp pathway apoe mediates catabolism remnant lipoprotein num num
0.3125666.12588864.html.plaintext.txt	7	hspg lrp pathway apoe postulated interact initially cell surface hspg transfer lrp internalization num num
0.3125666.12588864.html.plaintext.txt	8	therefore interaction apoe hspg initial step clearance apoe containing lipoprotein plasma
0.3125666.12588864.html.plaintext.txt	9	apoe hspg interaction also involved differential effect apoe isoforms neurite outgrowth num num existence pool newly secreted apoe cell surface num num inhibition platelet derived growth factor stimulated smooth muscle cell proliferation num
0.3125666.12588864.html.plaintext.txt	10	addition several study suggest binding apoe hspg may involved alzheimers disease num num num
0.3125666.12588864.html.plaintext.txt	11	apoe num amino acid single chain protein contains two independently folded functional domain num kda n terminal domain residue num num num kda c terminal domain residue num num num num
0.3125666.12588864.html.plaintext.txt	12	n terminal domain exists lipid free state four helix bundle amphipathic helix contains ldl receptor binding region residue num num helix num num
0.3125666.12588864.html.plaintext.txt	13	amphipathic nature helix containing residue num num critical normal binding ldl receptor num
0.3125666.12588864.html.plaintext.txt	14	recent study using nuclear magnetic resonance nmr demonstrated lys num lys num unusually low pka value local increase positive electrostatic potential associated region surrounding residue num num num num
0.3125666.12588864.html.plaintext.txt	15	c terminal domain also predicted highly helical structure contains major lipid binding region num num
0.3125666.12588864.html.plaintext.txt	16	detailed molecular feature helix c terminal domain poorly understood
0.3125666.12588864.html.plaintext.txt	17	n c terminal domain contain heparin binding site num num
0.3125666.12588864.html.plaintext.txt	18	n terminal domain site located residue num num overlap receptor binding region num
0.3125666.12588864.html.plaintext.txt	19	fact hspg binding activity apoe variant significantly decreased mutation arg num arg num lys num indicating basic amino acid residue contribute heparin binding num
0.3125666.12588864.html.plaintext.txt	20	recent study interaction heparin derived oligosaccharide n terminal domain apoenum found arg num num form salt bridge sulfate group octasaccharide fragment num consistent dramatically reduced binding affinity apoenumrnumc apoenumrnumc mutant hspg num
0.3125666.12588864.html.plaintext.txt	21	study also predicted additional interaction heparin fragment lys num lys num arg num
0.3125666.12588864.html.plaintext.txt	22	recently site directed mutagenesis study showed arg num lys num arg num lys num arg num required high affinity binding heparin lys num participating ionic interaction heparin fragment lys num participating hydrogen bond num
0.3125666.12588864.html.plaintext.txt	23	material numnum dimyristoyl phosphatidylcholine dmpc num palmitoyl num oleoyl phosphatidylcholine popc purchased avanti polar lipid pelham al stock solution stored chloroformmethanol numnum nitrogen num degree c
0.3125666.12588864.html.plaintext.txt	24	purity assayed thin layer chromatography silica gel g plate analtech newark de chloroformmethanolwater numnumnum
0.3125666.12588864.html.plaintext.txt	25	lipid visualized spraying developed thin layer plate num sulfuric acid solution charring num degree c num min num microg quantity gave single spot charring
0.3125666.12588864.html.plaintext.txt	26	heparin sepharose cl numb lot
0.3125666.12588864.html.plaintext.txt	27	num purchased amersham bioscience
0.3125666.12588864.html.plaintext.txt	28	ligand density determined using enzymatic kit heparin diapharma west chester oh num mg heparing dried gel
0.3125666.12588864.html.plaintext.txt	29	sepharose cl numb sigma
0.3125666.12588864.html.plaintext.txt	30	dnumo cambridge isotope laboratory andover ma routinely deoxygenated stored nitrogen
0.3125666.12588864.html.plaintext.txt	31	numcformaldehyde num isotopic enrichment num solution water also obtained cambridge isotope laboratory
0.3125666.12588864.html.plaintext.txt	32	numcformaldehyde num num cimol distilled water purchased perkinelmer life science
0.3125666.12588864.html.plaintext.txt	33	nacnbhnum aldrich milwaukee wi recrystallized methylene chloride use
0.3125666.12588864.html.plaintext.txt	34	salt reagent analytical grade
0.3125666.12588864.html.plaintext.txt	35	bacteriological medium obtained fisher pittsburgh pa
0.3125666.12588864.html.plaintext.txt	36	prokaryotic expression vector petnuma novagen madison wi competent escherichia coli strain blnum star denum invitrogen
0.3125666.12588864.html.plaintext.txt	37	coli strain dhnum invitrogen
0.3125666.12588864.html.plaintext.txt	38	pcr supply qiagen chatsworth ca
0.3125666.12588864.html.plaintext.txt	39	restriction enzyme purchased promega madison wi
0.3125666.12588864.html.plaintext.txt	40	isopropyl d galactopyranoside mercaptoethanol aprotinin ampicillin sigma
0.3125666.12588864.html.plaintext.txt	41	ultrapure guanidine hcl icn pharmaceutical costa mesa ca
0.3125666.12588864.html.plaintext.txt	42	oligonucleotides idt coraville ia dna purification kit qiagen
0.3125666.12588864.html.plaintext.txt	43	expression purification protein mutation knumq knume knumq knume full length apoenum knumq knumq knumq num kda fragment introduced using pcr create dna insert ligated thioredoxin fusion expression vector petnuma described num num
0.3125666.12588864.html.plaintext.txt	44	mutation sequence cdna orientation confirmed restriction enzyme analysis double stranded dna sequencing
0.3125666.12588864.html.plaintext.txt	45	resulting fusion protein expressed e
0.3125666.12588864.html.plaintext.txt	46	coli cleaved purified described num
0.3125666.12588864.html.plaintext.txt	47	c terminal truncated apoenum apoenum num num full length human apoenum num num kda fragment expressed purified described num
0.3125666.12588864.html.plaintext.txt	48	num kda fragment apoenum residue num num prepared thrombin digestion full length apoenum num
0.3125666.12588864.html.plaintext.txt	49	nmr measurement full length apoenum complexed dmpc isolated gel filtration chromatography num
0.3125666.12588864.html.plaintext.txt	50	lysine residue apoenum dmpc complex labeled numc reductive methylation num
0.3125666.12588864.html.plaintext.txt	51	numh numc heteronuclear single quantum coherence hsqc two dimensional nmr spectrum numc labeled full length apoenum dmpc complex obtained bruker dm x num wide bore spectrometer equipped sgi num computer num mm inverse broadband probe num
0.3125666.12588864.html.plaintext.txt	52	two dimensional numh numc hsqc spectrum recorded carbon decoupling acquisition num k
0.3125666.12588864.html.plaintext.txt	53	time proportional phase increment method used obtain phase sensitive spectrum
0.3125666.12588864.html.plaintext.txt	54	chemical shift line width lipid protein complex measured described num num num
0.3125666.12588864.html.plaintext.txt	55	chemical shift numcdimethyl lysine numcdimethyl terminal amino residue complex determined function ph
0.3125666.12588864.html.plaintext.txt	56	pka value numcdimethyl lysine obtained nonlinear regression fitting chemical shift different ph value henderson hasselbalch equation graphpad prism program graphpad software san diego ca num num
0.3125666.12588864.html.plaintext.txt	57	sigmoidal equation y u w x numx xcnumx xc num y chemical shift u lower limit shift w upper limit x ph xc pka
0.3125666.12588864.html.plaintext.txt	58	binding apoe heparin binding apoe heparin assayed using centrifugation method num num
0.3125666.12588864.html.plaintext.txt	59	apoe sample numc labeled specific activity num microcimg protein reductive methylation lysine numcformaldehyde described num num num
0.3125666.12588864.html.plaintext.txt	60	numc labeled lipid free apoe apoe dmpc complex incubated heparin sepharose sepharose gel num
0.3125666.12588864.html.plaintext.txt	61	num mg gelml num h room temperature num microl tris buffer num mm tris hcl num mm nacl num
0.3125666.12588864.html.plaintext.txt	62	mixture centrifuged numnum rpm num min tabletop centrifuge
0.3125666.12588864.html.plaintext.txt	63	radioactivity num microl aliquot top fraction num microl aliquot bottom fraction quantitated amount apoe bound gel calculated subtracting background free apoe concentration bottom fraction
0.3125666.12588864.html.plaintext.txt	64	heparin bound apoe expressed g apoe bound per g dried weight gel dried incubation num h room temperature vacuum oven gel corrected binding sepharose subtraction sepharose gel bound radioactivity obtained parallel incubation
0.3125666.12588864.html.plaintext.txt	65	binding data fitted nonlinear regression one binding site model using graphpad prizm program
0.3125666.12588864.html.plaintext.txt	66	pka value lysine full length apoenum previously used two dimensional nmr spectrum numcdimethyl lysine study microenvironments eight lysine residue num kda apoe dmpc complex num num
0.3125666.12588864.html.plaintext.txt	67	study application higher field num mhz nmr spectrometer enabled u evaluate microenvironments num lysine residue full length apoenum enhanced resolution resonance nmr spectrum
0.3125666.12588864.html.plaintext.txt	68	num show nmr spectrum sequence specific assignment num numcdimethyl lysine resonance full length apoenum dmpc discoidal complex
0.3125666.12588864.html.plaintext.txt	69	addition eight lysine resonance n terminal domain four lysine resonance c terminal domain lys num num num num resolved assigned using selective lysine glutamine mutation technique num
0.3125666.12588864.html.plaintext.txt	70	view larger version numk fig
0.3125666.12588864.html.plaintext.txt	71	phase sensitive num mhz numh numc hsqc nmr spectrum full length apoenum dmpc discoidal complex num degree c
0.3125666.12588864.html.plaintext.txt	72	lysine residue converted numchnumnum lysine reductive methylation
0.3125666.12588864.html.plaintext.txt	73	numnum ww dmpcfull length apoenum discoidal complex num
0.3125666.12588864.html.plaintext.txt	74	num mg proteinml dissolved borate buffer ph num
0.3125666.12588864.html.plaintext.txt	75	spectrum obtained condition similar used previously num
0.3125666.12588864.html.plaintext.txt	76	assignment num lysine resonance indicated
0.3125666.12588864.html.plaintext.txt	77	pka value lysine obtained monitoring chemical shift function ph range ph value num
0.3125666.12588864.html.plaintext.txt	78	titration curve fully reversible across ph range studied data shown pka value lysine full length apoenum listed table
0.3125666.12588864.html.plaintext.txt	79	expected pka value eight lysine n terminal domain full length apoenum num kda fragment apoenum reported previously num
0.3125666.12588864.html.plaintext.txt	80	num similar pka value lys num num located ldl receptorheparin binding region n terminal domain apoenum
0.3125666.12588864.html.plaintext.txt	81	suggests lys num may behave similarly part heparin binding region c terminal domain
0.3125666.12588864.html.plaintext.txt	82	view table table pka value lysine residue full length apoenum discoidal complex dmpc
0.3125666.12588864.html.plaintext.txt	83	heparin binding num kda fragment determine relative heparin binding activity apoe molecule measured binding apoe heparin sepharose gel num num
0.3125666.12588864.html.plaintext.txt	84	binding num kda fragment heparin saturable depended salt concentration fig
0.3125666.12588864.html.plaintext.txt	85	dissociation constant kd calculated num microgml num mm nacl num microgml num mm nacl consistent previous report num
0.3125666.12588864.html.plaintext.txt	86	maximal binding capacity concentration similar corresponded num num g proteing heparin
0.3125666.12588864.html.plaintext.txt	87	contrast apoa bind heparin even low salt concentration
0.3125666.12588864.html.plaintext.txt	88	result indicate interaction num kda fragment heparin electrostatic num num amphipathic characteristic common helical apolipoproteins num responsible heparin binding
0.3125666.12588864.html.plaintext.txt	89	view larger version numk fig
0.3125666.12588864.html.plaintext.txt	90	effect salt concentration apolipoprotein binding heparin
0.3125666.12588864.html.plaintext.txt	91	varying concentration apoe num kda fragment tris buffer ph num
0.3125666.12588864.html.plaintext.txt	92	num containing num mm nacl num mm nacl incubated heparin sepharose gel num h room temperature
0.3125666.12588864.html.plaintext.txt	93	binding data apoa num mm nacl buffer also shown
0.3125666.12588864.html.plaintext.txt	94	point represents mean plus minus
0.3125666.12588864.html.plaintext.txt	95	two independent experiment done duplicate
0.3125666.12588864.html.plaintext.txt	96	binding curve obtained nonlinear regression fitting one binding site model
0.3125666.12588864.html.plaintext.txt	97	basic residue arginine lysine heparin binding region n terminal domain key interaction heparin num num num
0.3125666.12588864.html.plaintext.txt	98	compared heparin binding activity three lysine mutant knumq knumq knumq num kda fragment identify heparin binding site c terminal domain apoe
0.3125666.12588864.html.plaintext.txt	99	num large decrease heparin binding observed num kda knumq variant maximal binding capacity num wild type num kda fragment without change binding affinity kd value num microgml
0.3125666.12588864.html.plaintext.txt	100	four lysine c terminal domain lys num showed relatively low pka value table suggesting unusually basic microenvironment around lys num critical interaction c terminal domain heparin
0.3125666.12588864.html.plaintext.txt	101	view larger version numk fig
0.3125666.12588864.html.plaintext.txt	102	binding isotherm apoe num kda fragment variant heparin
0.3125666.12588864.html.plaintext.txt	103	wild type apoe num kda fragment num kdaknumq num kdaknumq num kdaknumq
0.3125666.12588864.html.plaintext.txt	104	comparison heparin binding full length apoenum num num kda fragment determine relative contribution n c terminal domain heparin binding apoe next compared heparin binding full length apoenum num num kda fragment lipid free lipidated form
0.3125666.12588864.html.plaintext.txt	105	lipid free form full length apoe num kda fragment bound heparin similar affinity whereas num kda fragment bound heparin much lower affinity fig
0.3125666.12588864.html.plaintext.txt	106	complexed dmpc heparin binding num kda fragment completely abolished indicating c terminal binding site masked lipid fig
0.3125666.12588864.html.plaintext.txt	107	instead lipidated num kda fragment bound heparin high affinity rather better full length apoe
0.3125666.12588864.html.plaintext.txt	108	similar result obtained popc physiological phospholipid data shown
0.3125666.12588864.html.plaintext.txt	109	although binding capacity lipidated full length apoenum much lower lipid free form binding affinity full length apoenum state similar kd lipid free lipidated form num num microgml respectively consistent previous observation using surface plasmon resonance analysis num
0.3125666.12588864.html.plaintext.txt	110	view larger version numk fig
0.3125666.12588864.html.plaintext.txt	111	binding isotherm full length apoenum num num kda fragment heparin lipid free form complexed dmpc b
0.3125666.12588864.html.plaintext.txt	112	full length apoenum apoenum num kda fragment apoe num kda fragment
0.3125666.12588864.html.plaintext.txt	113	heparin binding apoe mutant observation suggest two apoe domain contribute differently heparin binding c terminal domain playing dominant role lipid free state n terminal domain lipidated state
0.3125666.12588864.html.plaintext.txt	114	examine hypothesis introduced mutation two lysine full length apoe compared heparin binding activity variant
0.3125666.12588864.html.plaintext.txt	115	mutated protein apoeknumq apoeknume n terminal domain bind defectively heparin num apoenumknumq apoenumknume thought low heparin binding capacity c terminal site
0.3125666.12588864.html.plaintext.txt	116	large decrease heparin binding observed apoeknume lipid free fig
0.3125666.12588864.html.plaintext.txt	117	numa dmpc complexed form fig
0.3125666.12588864.html.plaintext.txt	118	numb indicating lys num contributes greatly heparin binding full length apoe
0.3125666.12588864.html.plaintext.txt	119	num b lipid free apoeknumq exhibited much smaller decrease heparin binding wild type apoenum apoeknumq dmpc complex bound heparin similar manner lipid free form
0.3125666.12588864.html.plaintext.txt	120	disparity apoeknume apoeknumq variant probably ionization state glutamate residue ph num
0.3125666.12588864.html.plaintext.txt	121	num responsible difference heparin binding activity num
0.3125666.12588864.html.plaintext.txt	122	view larger version numk fig
0.3125666.12588864.html.plaintext.txt	123	binding isotherm full length apoe variant heparin lipid free form c complexed dmpc b d
0.3125666.12588864.html.plaintext.txt	124	apoeknumq apoeknume apoenumknumq apoeknume
0.3125666.12588864.html.plaintext.txt	125	data wild type apoenum dotted line also shown comparison
0.3125666.12588864.html.plaintext.txt	126	contrast knumq mutation effect heparin binding activity either lipid free lipidated form
0.3125666.12588864.html.plaintext.txt	127	case apoenumknume variant small decrease heparin binding observed lipid free form complexing dmpc virtually effect heparin binding ability variant fig
0.3125666.12588864.html.plaintext.txt	128	num c d suggesting lys num site unavailable heparin binding full length apoe
0.3125666.12588864.html.plaintext.txt	129	wild type apoe apoeknume apoeknumq variant heparin binding free protein differs protein dmpc complex
0.3125666.12588864.html.plaintext.txt	130	binding dmpc result opening four helix bundle n terminal domain apoe num num
0.3125666.12588864.html.plaintext.txt	131	therefore likely apoe variant subtle difference final conformation dmpc disc may modulate heparin binding property num
0.3125666.12588864.html.plaintext.txt	132	may reason lipidated knumq knume variant bind somewhat heparin wild type apoenum
0.3125666.12588864.html.plaintext.txt	133	explore role c terminal domain heparin binding apoe used apoe num num c terminal truncated variant monomeric rather tetrameric aqueous solution num
0.3125666.12588864.html.plaintext.txt	134	although c terminal heparin binding site conserved variant heparin binding apoe num num significantly lower wild type apoenum close apoenum num kda fragment fig
0.3125666.12588864.html.plaintext.txt	135	indicates tetramerization c terminal domain major influence heparin binding ability lipid free apoe
0.3125666.12588864.html.plaintext.txt	136	also measured binding num kda apoe fragment num heparin investigate whether hinge region play role heparin interaction c terminal domain
0.3125666.12588864.html.plaintext.txt	137	surprisingly heparin binding ability almost disappeared lipid free num kda fragment fig
0.3125666.12588864.html.plaintext.txt	138	num suggesting hinge region may mask heparin binding site c terminal domain
0.3125666.12588864.html.plaintext.txt	139	interaction apoe hspg important several process lipoprotein remnant clearance num num neurite outgrowth num num
0.3125666.12588864.html.plaintext.txt	140	apoe least two heparin binding site located residue num num n terminal receptor binding region num le well defined site c terminal lipid binding region num num
0.3125666.12588864.html.plaintext.txt	141	n terminal site recently characterized using apoenum num kda fragment enzymatically prepared heparin oligosaccharide arg num lys num arg num lys num arg num within site involved interaction heparin fragment num
0.3125666.12588864.html.plaintext.txt	142	study using site directed mutagenesis identified lys num key lysine residue c terminal site also estimated relative contribution site heparin binding full length apoe
0.3125666.12588864.html.plaintext.txt	143	earlier study using either synthetic apoe peptide blocking monoclonal antibody suggested residue num num num num num num contain heparin binding site
0.3125666.12588864.html.plaintext.txt	144	former site factor observed binding c terminal num kda fragment heparin included domain
0.3125666.12588864.html.plaintext.txt	145	also functional num kda fragment bind heparin fig
0.3125666.12588864.html.plaintext.txt	146	presumably small peptide containing residue num num num bind conformation different present part apoe molecule
0.3125666.12588864.html.plaintext.txt	147	possible lys num part heparin binding site identified blocking antibody epitope located residue num num num presence antibody may interfere functionality lys num
0.3125666.12588864.html.plaintext.txt	148	nmr result imply among num lysine full length apoenum lys num num n terminal domain lys num c terminal domain unusually low pka value indicative high positive electrostatic potential around residue
0.3125666.12588864.html.plaintext.txt	149	previous study showed greater positive electrostatic potential around lys num num involved high affinity binding n terminal domain apoe ldl receptor heparin
0.3125666.12588864.html.plaintext.txt	150	study demonstrated residue lys num critical heparin binding c terminal domain fig
0.3125666.12588864.html.plaintext.txt	151	num indicating unusually basic lysine microenvironment c terminal domain also involved heparin interaction
0.3125666.12588864.html.plaintext.txt	152	amphipathic helix spanning region basic residue arg num lys num lys num aligned two turn apart along one side helix
0.3125666.12588864.html.plaintext.txt	153	interesting several acidic residue amino acid sequence near lys num mostly located opposite side amphipathic helix
0.3125666.12588864.html.plaintext.txt	154	consequently reduce positive electrostatic potential around side chain lys num
0.3125666.12588864.html.plaintext.txt	155	comparison heparin binding ability full length apoenum num num kda fragment yield interesting insight
0.3125666.12588864.html.plaintext.txt	156	lipid free state num kda fragment bind heparin higher affinity num kda fragment fig
0.3125666.12588864.html.plaintext.txt	157	contrast heparin binding num kda fragment completely abolished complexed lipid fig
0.3125666.12588864.html.plaintext.txt	158	numb consistent previous observation showing c terminal site available interaction lipid free state num num
0.3125666.12588864.html.plaintext.txt	159	c terminal domain apoe form stable tetramer responsible self association apoe aqueous solution whereas n terminal domain primarily monomeric num
0.3125666.12588864.html.plaintext.txt	160	therefore stronger interaction c terminal domain heparin appears tetramerization
0.3125666.12588864.html.plaintext.txt	161	num heparin binding affinity apoenum num num variant monomeric solution much lower wild type apoenum comparable num kda fragment indicating tetramerization c terminal domain crucial heparin binding ability lipid free apoe
0.3125666.12588864.html.plaintext.txt	162	multiple sequence heparin binding peptide enhance heparin binding cooperativity effect num
0.3125666.12588864.html.plaintext.txt	163	similarly multiple copy receptor binding domain necessary high affinity interaction apoe ldl receptor num num
0.3125666.12588864.html.plaintext.txt	164	regard different binding affinity full length apoenum num kda fragment dmpc disc fig
0.3125666.12588864.html.plaintext.txt	165	numb may explained difference cooperativity arising different number n terminal domain per particle
0.3125666.12588864.html.plaintext.txt	166	despite strong heparin binding ability num kda fragment c terminal site full length apoenum appear involved heparin binding lipid free apoe
0.3125666.12588864.html.plaintext.txt	167	numc small difference heparin binding among lipid free wild type apoenum apoenumknumq apoenumknume variant suggesting even lipid free state n terminal site involved heparin interaction full length apoe
0.3125666.12588864.html.plaintext.txt	168	clear c terminal site lipid free apoe unavailable interaction heparin
0.3125666.12588864.html.plaintext.txt	169	one possible explanation heparin interaction c terminal domain sterically hindered hinge region residue num num act spacer connecting two domain
0.3125666.12588864.html.plaintext.txt	170	indeed num kda fragment contains num kda domain hinge region bound defectively heparin fig
0.3125666.12588864.html.plaintext.txt	171	thus interaction num kda domain hinge region might mask c terminal heparin binding site basic residue around lys num preventing interaction heparin
0.3125666.12588864.html.plaintext.txt	172	recent fluorescence resonance energy transfer study apoenum indicates spatial proximity n c terminal domain lipid free state hinge region tethering n terminal domain close c terminal domain num
0.3125666.12588864.html.plaintext.txt	173	apoe containing high density lipoprotein bind proteoglycan biglycan arterial wall apoe thought act bridging molecule trap particle atherosclerotic intima num
0.3125666.12588864.html.plaintext.txt	174	binding interaction apoe biglycan shown recently occur via c terminal domain charged residue especially lysine arginine residue num num involved binding num num
0.3125666.12588864.html.plaintext.txt	175	result present study suggest unusually basic microenvironment around lys num contributes apoe biglycan interaction
0.3125666.12588864.html.plaintext.txt	176	recent study demonstrated c terminal fragment apoe complexed amyloid brain num num c terminal truncated form apoe occur alzheimers disease num
0.3125666.12588864.html.plaintext.txt	177	presence apoe proteolytic fragment vivo raise possibility c terminal fragment may contribute alzheimers disease interaction hspg brain
0.3125666.12588864.html.plaintext.txt	178	conclusion identified heparin binding site c terminal domain apoe
0.3125666.12588864.html.plaintext.txt	179	data show basic residue around lysine num critical heparin binding c terminal domain unavailable heparin binding full length apoe even lipid free state
0.3125666.12588864.html.plaintext.txt	180	thus seems lipid poor apoe associate cell surface hspg n terminal domain leaving c terminal domain available binding lipoprotein particle
0.3125666.12588864.html.plaintext.txt	181	work supported national institute health grant hlnum
0.3125666.12588864.html.plaintext.txt	182	cost publication article defrayed part payment page charge
0.3125666.12588864.html.plaintext.txt	183	article must therefore hereby marked advertisement accordance num u
0.3125666.12588864.html.plaintext.txt	184	section num solely indicate fact
0.3125666.12588864.html.plaintext.txt	185	present address national institute health science num num num hoenzaka chuo ku osaka num num japan
0.3125666.12588864.html.plaintext.txt	186	correspondence addressed joseph stokes jr
0.3125666.12588864.html.plaintext.txt	187	childrens hospital philadelphia abramson research bldg
0.3125666.12588864.html.plaintext.txt	188	suite num num civic center blvd
0.3125666.12588864.html.plaintext.txt	189	num num num fax num num num e mail katzs email
0.3125666.12588864.html.plaintext.txt	190	published jbc paper press february num num doi num
0.3125666.12588864.html.plaintext.txt	191	abbreviation used apo apolipoprotein hspg heparan sulfate proteoglycan hsqc heteronuclear single quantum coherence ldl low density lipoprotein lrp ldl receptor related protein dmpc numnum dimyristoyl phosphatidylcholine popc num palmitoyl num oleoyl phosphatidylcholine nmr nuclear magnetic resonance
0.3125666.12588864.html.plaintext.txt	192	copyright num american society biochemistry molecular biology inc
0.31263503.15319409.html.plaintext.txt	0	methodological problem genetic association study longevity apolipoprotein e gene example sarah j lewis eric j brunner
0.31263503.15319409.html.plaintext.txt	1	international centre health society department epidemiology public health university college london london uk
0.31263503.15319409.html.plaintext.txt	2	correspondence sarah j lewis department social medicine university bristol canynge hall whiteladies road bristol bsnum numpr uk
0.31263503.15319409.html.plaintext.txt	3	method explored validity assumption reviewed num cross sectional study common apolipoprotein e apoe polymorphism longevity
0.31263503.15319409.html.plaintext.txt	4	result higher relative num frequency lower relative num allele frequency observed elderly versus younger population
0.31263503.15319409.html.plaintext.txt	5	assumption b correct estimate num num allele respectively versus num allele would num
0.31263503.15319409.html.plaintext.txt	6	num elderly versus younger individual
0.31263503.15319409.html.plaintext.txt	7	however association relative num allele frequency control apoe num effect s num
0.31263503.15319409.html.plaintext.txt	8	relation assumption substantial variation relative apoe allele frequency num num considerable heterogeneity evident within geographically proximate population population admixture likely resulted change allele frequency time assumption b apoe related cause death context specific changed considerably last num year
0.31263503.15319409.html.plaintext.txt	9	conclusion validity case control type study genetic basis longevity based assumption questionable especially considerable difference exist allele frequency population gene question interact environmental factor vary time place
0.31263503.15319409.html.plaintext.txt	10	keywords longevity ageing genetic association gene apoe methodology
0.31263503.15319409.html.plaintext.txt	11	twin study longevity suggest around num variation lifespan developed country may inherited
0.31263503.15319409.html.plaintext.txt	12	num understanding heritability consequently biological process involved ageing longevity one greatest scientific challenge time
0.31263503.15319409.html.plaintext.txt	13	post genomic era large dna resource becoming available within epidemiological study better placed ever begin unravel complex problem
0.31263503.15319409.html.plaintext.txt	14	epidemiological study widely used look gene conferring risk common multifactorial disease comparing genotype distribution case control
0.31263503.15319409.html.plaintext.txt	15	num recently case control design used identify difference genotype allele frequency elderly compared younger population
0.31263503.15319409.html.plaintext.txt	16	numnum centenarian typically studied represent survivor may lack disease susceptibility gene gene associated premature mortality
0.31263503.15319409.html.plaintext.txt	17	however specific methodological problem inherent study comparing population across time period although alluded several review adequately addressed study design date
0.31263503.15319409.html.plaintext.txt	18	argue previous claim resulting study may flawed based following assumption initial relative allele frequency different age group similar b risk mortality conferred genotype depend year birth
0.31263503.15319409.html.plaintext.txt	19	due secular trend common disease incidence change pattern exposure environmental risk factor smoking genetic association found study unlikely contribute blueprint future longevity unless improvement made methodology used
0.31263503.15319409.html.plaintext.txt	20	indication type change needed provided concluding section paper
0.31263503.15319409.html.plaintext.txt	21	likely many gene contribute longevity
0.31263503.15319409.html.plaintext.txt	22	candidate gene selected either num gene implicated general process cellular maintenance repair superoxide dismutase num sodnum involved scavenging reactive oxygen specie apoptosis num gene confer increased susceptibility age related disease apolipoprotein e apoe gene involved lipoprotein metabolism proposed risk factor coronary heart disease chd alzheimers disease
0.31263503.15319409.html.plaintext.txt	23	numnum since genetic study longevity date second type paper focus study disease risk gene
0.31263503.15319409.html.plaintext.txt	24	initial gene frequency age cohort represented longevity study likely different necessarily represented frequency youngercontrol population population stratification genetic association study received large amount negative press recently mainly due lack repeatability result opportunity spurious result
0.31263503.15319409.html.plaintext.txt	25	numnum num one reason problem population stratification phenomenon pertinent study longevity
0.31263503.15319409.html.plaintext.txt	26	whilst genuine difference elderly cohort younger individual may exist due role gene longevity artefactual result genetic effect may also arise due variation initial relative allele frequency two comparison group result population admixture
0.31263503.15319409.html.plaintext.txt	27	although novel mutation infrequent diffuse slowly interval human generation long gene pool given population change considerably relatively short period result geographical mobility ethnic admixing selective mating
0.31263503.15319409.html.plaintext.txt	28	migration take britain example last num year mass emigration usa south africa australia new zealand coupled influx individual india pakistan bangladesh china caribbean africa
0.31263503.15319409.html.plaintext.txt	29	recently migration country europe become common result constitutional right established within european union
0.31263503.15319409.html.plaintext.txt	30	scale movement substantial
0.31263503.15319409.html.plaintext.txt	31	respondent decennial census england num population england gave ethnic origin white british num compared num num increase num num year
0.31263503.15319409.html.plaintext.txt	32	num since migration among young adult tends work education net inflow often concentrated city genetic association study may based
0.31263503.15319409.html.plaintext.txt	33	england highest level flow south east
0.31263503.15319409.html.plaintext.txt	34	num resident classified white british irish num census
0.31263503.15319409.html.plaintext.txt	35	num whilst genetic association study usually collect data ethnic group rarely distinguish caucasian hence group together individual different country region origin
0.31263503.15319409.html.plaintext.txt	36	migration within country individual better placed work health care may also played role population mixing last century
0.31263503.15319409.html.plaintext.txt	37	movement region result change genetic structure regional population
0.31263503.15319409.html.plaintext.txt	38	approximately num individual born england scotland wale num num march num resided different region num birth resulted reduction interregional variability abo blood group
0.31263503.15319409.html.plaintext.txt	39	num migration pattern differ widely country time period scale problem depend study population
0.31263503.15319409.html.plaintext.txt	40	risk mortality conferred genotype depend birth year cohort secular trend disease risk migration different gene pool may change genetic risk within given population influence mortality rate time period order decade
0.31263503.15319409.html.plaintext.txt	41	addressing first assumption effect also addressing dynamic
0.31263503.15319409.html.plaintext.txt	42	aside change population genetic structure environmental risk factor disease changed considerably last num year two population born decade apart likely exposed different pattern stressor
0.31263503.15319409.html.plaintext.txt	43	reason population different susceptibility disease regardless genotype
0.31263503.15319409.html.plaintext.txt	44	environmental risk factor unlikely change population distribution genetic variant unless offer strong selection particular allele childhood reproductive year
0.31263503.15319409.html.plaintext.txt	45	therefore secular trend genetic susceptibility disease elderly confounded environment rather environment act effect modifier
0.31263503.15319409.html.plaintext.txt	46	life expectancy doubled first half numth century largely due reduction malnutrition childhood infection
0.31263503.15319409.html.plaintext.txt	47	chronic disease heart disease cancer occur later life became major cause death developed country
0.31263503.15319409.html.plaintext.txt	48	num shift cause mortality epidemiological transition occurred relatively short period
0.31263503.15319409.html.plaintext.txt	49	suggested rise chd cancer incidence western country consequence ageing population
0.31263503.15319409.html.plaintext.txt	50	however increase rate mortality cancer took place among men britain num num largely attributed lung cancer smoking main environmental cause
0.31263503.15319409.html.plaintext.txt	51	num level smoking britain reached peak nums followed steady decline although approximately num adult population continue smoke figure numnum
0.31263503.15319409.html.plaintext.txt	52	similarly national chd mortality rate rose fell past century
0.31263503.15319409.html.plaintext.txt	53	death chd reached peak many westernized country nums declining figure num
0.31263503.15319409.html.plaintext.txt	54	num hence disease risk changed time level exposure major environmental cause changed
0.31263503.15319409.html.plaintext.txt	55	view larger version numk figure num number cigarette smoked per person per day britainnum
0.31263503.15319409.html.plaintext.txt	56	view larger version numk figure num mortality cardiovascular disease seven different countriesnum
0.31263503.15319409.html.plaintext.txt	57	smoking nutrition physical activity sexual behaviour poverty occupation stress education social contact health care pollution war infectious disease factor play part disease risk longevity individual societal level
0.31263503.15319409.html.plaintext.txt	58	pattern availability exposure many changed enormously secular socio economic cultural trend last num year seen case smoking
0.31263503.15319409.html.plaintext.txt	59	treatment disease may also impact mortality rate depend disease year contracted
0.31263503.15319409.html.plaintext.txt	60	apoe longevity possibly extensively studied gene relation longevity apoe
0.31263503.15319409.html.plaintext.txt	61	protein encoded gene ligand low density lipoprotein ldl receptor receptor ldl receptor gene family cell matrix associated heparin sulphate proteoglycans
0.31263503.15319409.html.plaintext.txt	62	gene play important role lipoprotein metabolism shown associated chd risk
0.31263503.15319409.html.plaintext.txt	63	numnum three common polymorphic form apoe known exist num num num
0.31263503.15319409.html.plaintext.txt	64	various apoe isoforms produced result polymorphism interact differently specific lipoprotein receptor ultimately altering circulating level cholesterol
0.31263503.15319409.html.plaintext.txt	65	high ldl cholesterol level associated apoe num low level apoe num apoe num level intermediate two
0.31263503.15319409.html.plaintext.txt	66	num apoe num allele also associated increase risk alzheimers disease
0.31263503.15319409.html.plaintext.txt	67	num although mechanism entirely clear association could due num effect amyloid s metabolism num effect neuron glial cell including neuronal survival neurite extension num effect related atherosclerosis cerebral blood flow blood brain barrier
0.31263503.15319409.html.plaintext.txt	68	num since chd alzheimers disease common disease old age apoe become candidate gene study longevity
0.31263503.15319409.html.plaintext.txt	69	several study comparing apoe genotype elderly versus younger population carried outnum num overview literature gerdes et al
0.31263503.15319409.html.plaintext.txt	70	num found apoe num associated premature death
0.31263503.15319409.html.plaintext.txt	71	determine inaccurate assumption initial apoe allele frequency among elderly population may influence outcome gene association study whether increased risk mortality conferred apoe gene depends year birth determine whether published study addressed problem carried review study comparing apoe allele frequency elderly versus younger population
0.31263503.15319409.html.plaintext.txt	72	statistical method unadjusted odds ratio based published allele frequency calculated proportion num allele num allele elderly versus control population using relative num allele frequency reference
0.31263503.15319409.html.plaintext.txt	73	effect apoe allele shown dependent upon genotype
0.31263503.15319409.html.plaintext.txt	74	numnum however expected relative frequency num num homozygote low around num num
0.31263503.15319409.html.plaintext.txt	75	num respectively stable estimate effect homozygote longevity possible small study
0.31263503.15319409.html.plaintext.txt	76	relative frequency num num homozygote available num num study reviewed
0.31263503.15319409.html.plaintext.txt	77	numnumnum study compare allele frequency combine num homozygote num heterozygote combine num homozygote num heterozygote give estimate num carrier versus num homozygote num carrier versus num homozygote
0.31263503.15319409.html.plaintext.txt	78	using allele frequency weighted effect size genotype frequency
0.31263503.15319409.html.plaintext.txt	79	however analysis genotype instead allele frequency gave similar result shown
0.31263503.15319409.html.plaintext.txt	80	random effect model used calculate summary standard error
0.31263503.15319409.html.plaintext.txt	81	three study provided genotypeallele frequency one age group control populationnumnumnum data different age group study combined give overall estimate age le num
0.31263503.15319409.html.plaintext.txt	82	combined relative risk male female presented
0.31263503.15319409.html.plaintext.txt	83	forest plot constructed logarithmic scale
0.31263503.15319409.html.plaintext.txt	84	ass association frequency num num allele control group log allele frequency elderly population versus control used bayesian random effect meta regression model fitted using bug winbugs num
0.31263503.15319409.html.plaintext.txt	85	num avoids bias caused association allele frequency arises due sampling error
0.31263503.15319409.html.plaintext.txt	86	statistical analysis carried stata version num stata corporation texas
0.31263503.15319409.html.plaintext.txt	87	test funnel plot asymmetrynumnum used investigate publication bias
0.31263503.15319409.html.plaintext.txt	88	study grouped geographical location north america included study usa canada asia included study china japan korea northern europe included finland denmark uk central europe included france southern europe included italy
0.31263503.15319409.html.plaintext.txt	89	view table table num cross sectional study apolipoprotein e apoe polymorphism longevity
0.31263503.15319409.html.plaintext.txt	90	large difference relative apoe allele frequency existed control population num num num num num num
0.31263503.15319409.html.plaintext.txt	91	regional variation apoe allele frequency high relative apoe num northern europe num num intermediate frequency central europe num num asia num num north america num num low frequency southern europe num num
0.31263503.15319409.html.plaintext.txt	92	elderly people num allele frequency converged homogeneous num num
0.31263503.15319409.html.plaintext.txt	93	despite difference num num study reportedly matched geographic origin one study matched ethnicity
0.31263503.15319409.html.plaintext.txt	94	meta analysis including study gave result closer null rr num
0.31263503.15319409.html.plaintext.txt	95	num presence num elderly versus younger population
0.31263503.15319409.html.plaintext.txt	96	four study stated control nationalitynumnumnumnum although necessarily exclude migrant particularly second generation migrant
0.31263503.15319409.html.plaintext.txt	97	regression coefficient association log odds num control group log num allele frequency elderly versus control num
0.31263503.15319409.html.plaintext.txt	98	num providing evidence association two
0.31263503.15319409.html.plaintext.txt	99	finnish studynum frequency num allele num num
0.31263503.15319409.html.plaintext.txt	100	num obtained whereas italian studynum num frequency num num
0.31263503.15319409.html.plaintext.txt	101	significant association num effect size relative num allele frequency control group s num
0.31263503.15319409.html.plaintext.txt	102	meta analysis considering study centenarian gave point estimate num
0.31263503.15319409.html.plaintext.txt	103	num num frequency among centenarian versus control
0.31263503.15319409.html.plaintext.txt	104	whole approach validating laboratory result stated paper
0.31263503.15319409.html.plaintext.txt	105	num reported re genotyping num cohort published schachter numnum finding discordance rate num
0.31263503.15319409.html.plaintext.txt	106	beggs funnel plot figure num egger test standardized effect versus precision provide evidence publication bias p num
0.31263503.15319409.html.plaintext.txt	107	view larger version numk figure num beggs funnel plot cross sectional study apoe num allele longevity
0.31263503.15319409.html.plaintext.txt	108	view larger version numk figure num schematic illustration apoe longevity
0.31263503.15319409.html.plaintext.txt	109	view larger version numk figure num forest plot representing case control study apoe longevity ordered allele frequency control
0.31263503.15319409.html.plaintext.txt	110	apoe num allele longevitya
0.31263503.15319409.html.plaintext.txt	111	b apoe num allele longevitya
0.31263503.15319409.html.plaintext.txt	112	astudies order allele frequency control population low top high bottom
0.31263503.15319409.html.plaintext.txt	113	since genetic study common polygenic disease recent phenomenon impossible determine directly whether initial allele frequency elderly individual represented younger control similarly whether risk mortality associated common genetic variant depends year birth
0.31263503.15319409.html.plaintext.txt	114	however case apoe num clear allele frequency differ widely population even among neighbouring country geographically separated population within country example lapp finn
0.31263503.15319409.html.plaintext.txt	115	num migration pattern differ country substantial internal international migration many country within last num year
0.31263503.15319409.html.plaintext.txt	116	num factor likely produced difference apoe allele frequency age group within given geographical area recent decade
0.31263503.15319409.html.plaintext.txt	117	migration particularly prevalent among younger population large university citiesnum study carried
0.31263503.15319409.html.plaintext.txt	118	whilst almost study showed deficit apoe num allele elderly versus younger population heterogeneity effect size remained even population stratified region
0.31263503.15319409.html.plaintext.txt	119	able make inference based biology epidemiology apoe suggests assumption b invalid longevity effect may subject modification period year decade corresponding age difference elderly control group
0.31263503.15319409.html.plaintext.txt	120	apoe play important role lipoprotein metabolism therefore apoe genotype one influence health effect dietary fat intake
0.31263503.15319409.html.plaintext.txt	121	apoe associated chd risk one mechanism proposed explain association apoe longevity
0.31263503.15319409.html.plaintext.txt	122	last num year chd mortality decreased substantially many country figure num
0.31263503.15319409.html.plaintext.txt	123	factor underlying decrease include change diet smoking treatment chd
0.31263503.15319409.html.plaintext.txt	124	study reviewed size apoe num effect differed population providing evidence num effect context dependant
0.31263503.15319409.html.plaintext.txt	125	appeared association num allele frequency control effect num longevity
0.31263503.15319409.html.plaintext.txt	126	sampling variation important potential explanation
0.31263503.15319409.html.plaintext.txt	127	chance estimated num prevalence true prevalence former tend high within distribution effect size tend extreme due regression mean
0.31263503.15319409.html.plaintext.txt	128	however relative apoe num allele frequency known vary population study reviewed anomalous respect
0.31263503.15319409.html.plaintext.txt	129	among european relative apoe num frequency exhibit north south cline
0.31263503.15319409.html.plaintext.txt	130	num accordingly high relative apoe num allele frequency observed study northern european participant num num low frequency southern european study num num
0.31263503.15319409.html.plaintext.txt	131	furthermore bayesian approach used calculate association control allele frequency effect size avoids bias arise due sampling error
0.31263503.15319409.html.plaintext.txt	132	remains unclear whether sampling younger control population produce valid estimate initial allele frequency corresponding elderly population
0.31263503.15319409.html.plaintext.txt	133	migration population substructure may confound study
0.31263503.15319409.html.plaintext.txt	134	relative allele frequency control population overestimate initial relative allele frequency elderly group spurious estimate longevity effect obtained
0.31263503.15319409.html.plaintext.txt	135	migration likely change relative allele frequency substantially source recipient population different allele frequency
0.31263503.15319409.html.plaintext.txt	136	change allele frequency short term function difference frequency migration rate large difference seen one generation
0.31263503.15319409.html.plaintext.txt	137	num net immigration region relatively high allele frequency overestimate decrease num elderly relative control
0.31263503.15319409.html.plaintext.txt	138	conversely net immigration area relatively low allele frequency underestimate difference
0.31263503.15319409.html.plaintext.txt	139	example canadian studynum relative apoe num allele frequency control group num
0.31263503.15319409.html.plaintext.txt	140	represents allele frequency elderly population birth num
0.31263503.15319409.html.plaintext.txt	141	num good estimate link apoe num longevity
0.31263503.15319409.html.plaintext.txt	142	however num current canadian resident born canada
0.31263503.15319409.html.plaintext.txt	143	num migrant came country relatively high allele frequency num reported among lappsnum migration would result overestimation real initial relative allele frequency num
0.31263503.15319409.html.plaintext.txt	144	num true num effect closer null num
0.31263503.15319409.html.plaintext.txt	145	alternatively migrant came country area low apoe num frequency frequency num reported sardiniansnum real initial frequency would higher around num
0.31263503.15319409.html.plaintext.txt	146	num num effect around num
0.31263503.15319409.html.plaintext.txt	147	simple example international migration occurring within one generation take account second generation migrant born canada internal migration
0.31263503.15319409.html.plaintext.txt	148	involves somewhat unrealistic assumption migration pattern example offer insight migration may influence result genetic association study longevity
0.31263503.15319409.html.plaintext.txt	149	num num study matched ethnicity andor place birth
0.31263503.15319409.html.plaintext.txt	150	remaining study assumed static population identical gene pool elderly younger age group
0.31263503.15319409.html.plaintext.txt	151	meta analysis including study matching origin ethnicity gave result closer null consistent artefactual explanation study failing take account genetic heterogeneity
0.31263503.15319409.html.plaintext.txt	152	remaining study effectively assumed static population identical gene pool elderly younger age group
0.31263503.15319409.html.plaintext.txt	153	explanation apparent association num prevalence magnitude num effect longevity impact greater population higher underlying risk chd
0.31263503.15319409.html.plaintext.txt	154	international comparison suggest apoe num allele frequency may explain geographical variation chd risk
0.31263503.15319409.html.plaintext.txt	155	num japan low chd risk population ratio relative num frequency elderly versus younger population num
0.31263503.15319409.html.plaintext.txt	156	numnum whereas finland high chd risk population ratio found num
0.31263503.15319409.html.plaintext.txt	157	num difference chd risk japan finland could due genetic susceptibility environmental factor likely combination
0.31263503.15319409.html.plaintext.txt	158	example northern europe high apoe num relative allele frequency historically accompanied high level saturated fat intake
0.31263503.15319409.html.plaintext.txt	159	influence genetic variation longevity priori important research question
0.31263503.15319409.html.plaintext.txt	160	proponent genetic epidemiology argue predicting multifactorial disease outcome without consideration epigenetic network increasingly seen naive
0.31263503.15319409.html.plaintext.txt	161	num implication methodology genetic dimension included risk factor model chronic disease extension longevity
0.31263503.15319409.html.plaintext.txt	162	paper reviewed focus single genetic effect main effect apoe longevity represent early attempt develop genetic perspective field dominated environmental explanation
0.31263503.15319409.html.plaintext.txt	163	example know environment broad sense including behavioural factor essential understanding time trend chd rate figure num longevity
0.31263503.15319409.html.plaintext.txt	164	known whether single common genetic variation apoe polymorphism important factor add explanation provided conventional environmental risk factor
0.31263503.15319409.html.plaintext.txt	165	study apoe longevity reviewed consistently showed effect num num allele longevity suggest apoe may part play
0.31263503.15319409.html.plaintext.txt	166	however analysis taking simultaneous account genetic environmental factor needed address question
0.31263503.15319409.html.plaintext.txt	167	assumption initial relative allele frequency different age group similar assumption may hold considerable variation allele frequency population migration resulted change population substructure
0.31263503.15319409.html.plaintext.txt	168	assumption b risk mortality conferred genotype depend year birth
0.31263503.15319409.html.plaintext.txt	169	assumption may invalid mortality risk conferred genotype depends interaction environmental behavioural risk factor pattern exposure risk factor closely related year birth
0.31263503.15319409.html.plaintext.txt	170	whilst study reviewed provide evidence link apoe longevity problem size effect depends population question probably also time period study span
0.31263503.15319409.html.plaintext.txt	171	link size apoe effect relative allele frequency seen review likely result population difference underlying disease susceptibility change population structure time illustrates impact violating assumption
0.31263503.15319409.html.plaintext.txt	172	future case control type study could improved least including comprehensive data birth origin exposure potential confounding factor
0.31263503.15319409.html.plaintext.txt	173	also possible address concern population stratification case control study carrying genome analysis using method genomic control structured association
0.31263503.15319409.html.plaintext.txt	174	cohort study subject assumption hence preferable cross sectional design
0.31263503.15319409.html.plaintext.txt	175	participant selected followed given time period subject age related mortality rate
0.31263503.15319409.html.plaintext.txt	176	cohort study carried date looked apoe longevity tend short follow period typically num yearsnum num hence provide snapshot overall survival
0.31263503.15319409.html.plaintext.txt	177	study reported mixed result documenting null finding apoe num longevitynumnum others showing negative association subgroup
0.31263503.15319409.html.plaintext.txt	178	num num address question adequately cohort study ideally birth cohort long follow required
0.31263503.15319409.html.plaintext.txt	179	cross sectional study longevity assume relative allele frequency different age cohort b risk mortality conferred genotype depend year birth
0.31263503.15319409.html.plaintext.txt	180	population admixture may result considerable population change allele frequency time allele frequency differ substantially population migration high
0.31263503.15319409.html.plaintext.txt	181	mortality risk conferred genotype may differ gene question interacts environmental factor vary time place
0.31263503.15319409.html.plaintext.txt	182	study apolipoprotein e apoe num longevity show effect size estimate associated relative allele frequency control population hence accurately predicting impact apoe longevity depends validity assumption
0.31263503.15319409.html.plaintext.txt	183	apoe associated coronary heart disease chd risk one mechanism proposed explain association apoe longevity
0.31263503.15319409.html.plaintext.txt	184	however chd mortality decreased mortaliy last num year largely due environmental behavioural factor hence effect apoe longevity context dependent
0.31263503.15319409.html.plaintext.txt	185	acknowledgment would like thank dr meena kumari dr mark pearce comment manuscript also drs jonathan sterne nicola welton help statistical analysis using bug
0.31263503.15319409.html.plaintext.txt	186	work funded co op research grant medical research council uk
0.31263503.15319409.html.plaintext.txt	187	num hirschhorn jn lohmueller k byrne e hirschhorn k
0.31263503.15319409.html.plaintext.txt	188	comprehensive review genetic association study
0.31263503.15319409.html.plaintext.txt	189	num heijmans bt westendorp rgj slagboom pe
0.31263503.15319409.html.plaintext.txt	190	common gene variant mortality extreme longevity human
0.31263503.15319409.html.plaintext.txt	191	exp gerontol numnumnum num
0.31263503.15319409.html.plaintext.txt	192	num de benedictis g tan q jeune b et al
0.31263503.15319409.html.plaintext.txt	193	recent advance human gene longevity association study
0.31263503.15319409.html.plaintext.txt	194	mech ageing dev numnumnum num
0.31263503.15319409.html.plaintext.txt	195	searching genetic determinant human aging longevity opportunity challenge
0.31263503.15319409.html.plaintext.txt	196	mech ageing dev numnumnum num
0.31263503.15319409.html.plaintext.txt	197	num schachter f cohen d kirkwood
0.31263503.15319409.html.plaintext.txt	198	prospect genetics human longevity
0.31263503.15319409.html.plaintext.txt	199	num wilson pwf schaefer ej larson mg ordovas jm
0.31263503.15319409.html.plaintext.txt	200	apolipoprotein e allele risk coronary disease meta analysis
0.31263503.15319409.html.plaintext.txt	201	arterioscler thromb vasc biol numnumnum num
0.31263503.15319409.html.plaintext.txt	202	apolipoprotein e genetic variation alzheimers disease
0.31263503.15319409.html.plaintext.txt	203	dement geriatr cogn disord numnumnum num
0.31263503.15319409.html.plaintext.txt	204	num ioannidis jpa ntzani ee trikalinos ta contopoulos ioannidis dg
0.31263503.15319409.html.plaintext.txt	205	replication validity genetic association study
0.31263503.15319409.html.plaintext.txt	206	association study design complex disease
0.31263503.15319409.html.plaintext.txt	207	num colhoun hm mckeigue davey smith g
0.31263503.15319409.html.plaintext.txt	208	problem reporting genetic association complex outcome
0.31263503.15319409.html.plaintext.txt	209	population stratification spurious allelic association
0.31263503.15319409.html.plaintext.txt	210	stationery office ons london num
0.31263503.15319409.html.plaintext.txt	211	international migration united kingdom num num consistency change implication labour market
0.31263503.15319409.html.plaintext.txt	212	popul trend numnumnum num
0.31263503.15319409.html.plaintext.txt	213	effect interregional migration geographic variability biological social trend britain
0.31263503.15319409.html.plaintext.txt	214	num office national statistic
0.31263503.15319409.html.plaintext.txt	215	health adult britain num num
0.31263503.15319409.html.plaintext.txt	216	trend mortality britain num num
0.31263503.15319409.html.plaintext.txt	217	ann nutr metab numnumnum num
0.31263503.15319409.html.plaintext.txt	218	num levi f lucchini f negri e la vecchia c
0.31263503.15319409.html.plaintext.txt	219	trend mortality cardiovascular cerebrovascular disease europe area world
0.31263503.15319409.html.plaintext.txt	220	apolipoproteins aging emerging mechanism
0.31263503.15319409.html.plaintext.txt	221	ageing re rev numnumnum num
0.31263503.15319409.html.plaintext.txt	222	num davignon j bouthillier nestruck c sing cf
0.31263503.15319409.html.plaintext.txt	223	apolipoprotein e polymorphism atherosclerosis insight study octogenarian
0.31263503.15319409.html.plaintext.txt	224	trans clin climatol assoc numnumnum num
0.31263503.15319409.html.plaintext.txt	225	num schachter f faure delanef l guenot f et al
0.31263503.15319409.html.plaintext.txt	226	genetic association human longevity apoe ace locus
0.31263503.15319409.html.plaintext.txt	227	num kervinen k savolainen mj salokannel j et al
0.31263503.15319409.html.plaintext.txt	228	apolipoprotein e b polymorphism longevity factor assessed nonagenarian
0.31263503.15319409.html.plaintext.txt	229	atheroscerosis numnumnum num
0.31263503.15319409.html.plaintext.txt	230	num louhija j miettinen k kontula k tikkanen mj miettinen ta tivlis r
0.31263503.15319409.html.plaintext.txt	231	aging genetic variation plasma apolipoproteins
0.31263503.15319409.html.plaintext.txt	232	relative loss apolipoprotein enum phenotype centenarian
0.31263503.15319409.html.plaintext.txt	233	arterioscler thromb numnumnum num
0.31263503.15319409.html.plaintext.txt	234	num galinsky d tysoe c brayne ce et al
0.31263503.15319409.html.plaintext.txt	235	analysis apo eapo c angiotensin converting enzyme methylenetetrahydrofolate reductase gene candidate affecting human longevity
0.31263503.15319409.html.plaintext.txt	236	atherosclerosis numnumnum num
0.31263503.15319409.html.plaintext.txt	237	num hirose n homma arai y et al
0.31263503.15319409.html.plaintext.txt	238	apolipoprotein e phenotype japanese centenarian living tokyo metropolitan area
0.31263503.15319409.html.plaintext.txt	239	nippon ronen igakkai zasshi numnumnum num
0.31263503.15319409.html.plaintext.txt	240	num bader g zuliani g kostner gm fellin r
0.31263503.15319409.html.plaintext.txt	241	apolipoprotein e polymorphism associated longevity disability sample italian octo nonagenarian
0.31263503.15319409.html.plaintext.txt	242	num jian gang z yong xing m chuan fu w et al
0.31263503.15319409.html.plaintext.txt	243	apolipoprotein e longevity among han chinese population
0.31263503.15319409.html.plaintext.txt	244	mech ageing dev numnumnum num
0.31263503.15319409.html.plaintext.txt	245	num gerdes lu jeune b ranberg ka nybo h vaupel jw
0.31263503.15319409.html.plaintext.txt	246	estimation apolipoprotein e genotype specific relative mortality risk distribution genotype centenarian middle aged men apolipoprotein e gene frailty gene longevity gene
0.31263503.15319409.html.plaintext.txt	247	genet epidemiol numnumnum num
0.31263503.15319409.html.plaintext.txt	248	conum qlinktypedoi crossrefisimedline
0.31263503.15319409.html.plaintext.txt	249	num rea im mcdowell mcmaster d smye m stout r evans
0.31263503.15319409.html.plaintext.txt	250	apolipoprotein e allele nonagenarian subject belfast elderly longitudinal free living ageing study belfast
0.31263503.15319409.html.plaintext.txt	251	mech ageing dev numnumnum num
0.31263503.15319409.html.plaintext.txt	252	num blanche h cabanne l sahbatou m thomas g
0.31263503.15319409.html.plaintext.txt	253	study french centenarian ace apoe associated longevity c r acad sci iii numnumnum num
0.31263503.15319409.html.plaintext.txt	254	num wang x wang g yang c xuan l
0.31263503.15319409.html.plaintext.txt	255	apolipoprotein e gene polymorphism association human longevity uygar nationality xinjiang
0.31263503.15319409.html.plaintext.txt	256	num zubenko g stiffler hughes hb fatigati mj zubenko wn
0.31263503.15319409.html.plaintext.txt	257	genome survey locus influence successful aging sample characterization method validation initial result y chromosome
0.31263503.15319409.html.plaintext.txt	258	j geriatr psychiatry numnumnum num
0.31263503.15319409.html.plaintext.txt	259	num choi yh kim jh kim dk et al
0.31263503.15319409.html.plaintext.txt	260	distribution ace apoe polymorphism relation dementia status korean centenarian
0.31263503.15319409.html.plaintext.txt	261	j gerontol biol sci med sci numnumnum num
0.31263503.15319409.html.plaintext.txt	262	num panza f solfrizzi v colacicco et al
0.31263503.15319409.html.plaintext.txt	263	apolipoprotein e apoe polymorphism influence serum apoe level alzheimers disease patient centenarian
0.31263503.15319409.html.plaintext.txt	264	num schiele f de bacquer d vincent viry m et al
0.31263503.15319409.html.plaintext.txt	265	apolipoprotein e serum concentration polymorphism six european country apoeurope project
0.31263503.15319409.html.plaintext.txt	266	atherosclerosis numnumnum num
0.31263503.15319409.html.plaintext.txt	267	num frikke schmidt r tybjaerg hansen steffensen r jensen g nordestgaard bg
0.31263503.15319409.html.plaintext.txt	268	apolipoprotein e genotype epsilon num woman protected epsilon num epsilon num men susceptible ischemic heart disease
0.31263503.15319409.html.plaintext.txt	269	copenhagen city heart study
0.31263503.15319409.html.plaintext.txt	270	j coll cardiol numnumnum num
0.31263503.15319409.html.plaintext.txt	271	num thomson sg smith tc sharp sj
0.31263503.15319409.html.plaintext.txt	272	investigating underlying risk source heterogeneity meta analysis
0.31263503.15319409.html.plaintext.txt	273	statist med numnumnum num
0.31263503.15319409.html.plaintext.txt	274	conum numlinktypedoi crossrefisi
0.31263503.15319409.html.plaintext.txt	275	operating characteristic rank correlation test publication bias
0.31263503.15319409.html.plaintext.txt	276	biometrics numnumnum num
0.31263503.15319409.html.plaintext.txt	277	num egger m davey smith g schneider m minder c
0.31263503.15319409.html.plaintext.txt	278	bias meta analysis detected simple graphical test
0.31263503.15319409.html.plaintext.txt	279	apolipoprotein e apoe allele distribution world
0.31263503.15319409.html.plaintext.txt	280	apoenum thrifty allele ann hum genet numnumnum num
0.31263503.15319409.html.plaintext.txt	281	num united nation population division department economic social affair
0.31263503.15319409.html.plaintext.txt	282	united nation publication num
0.31263503.15319409.html.plaintext.txt	283	num haddy n de bacquer d chemaly mm et al
0.31263503.15319409.html.plaintext.txt	284	importance plasma apolipoprotein e concentration addition common polymorphism inter individual variation lipid level result apo europe
0.31263503.15319409.html.plaintext.txt	285	eur j hum genet numnumnum num
0.31263503.15319409.html.plaintext.txt	286	estimating effective population size migration rate genetic sample space time
0.31263503.15319409.html.plaintext.txt	287	num lehtinen luoma p lehtimaki nayha hassi j nikkari
0.31263503.15319409.html.plaintext.txt	288	difference genetic variation apolipoprotein lapp finn
0.31263503.15319409.html.plaintext.txt	289	num corbo rm scacchi r mureddu l mulas g alfano g
0.31263503.15319409.html.plaintext.txt	290	apolipoprotein e polymorphism italy investigated native plasma simple polyacrylamide gel isoelectric focusing technique
0.31263503.15319409.html.plaintext.txt	291	comparison frequency data european population
0.31263503.15319409.html.plaintext.txt	292	ann hum genet numnumnum num
0.31263503.15319409.html.plaintext.txt	293	num stengard jh wei km sing cf
0.31263503.15319409.html.plaintext.txt	294	ecological study association coronary heart disease mortality rate men relative frequency common allelic variation gene coding apolipoprotein e
0.31263503.15319409.html.plaintext.txt	295	num sing cf stengard jh kardia slr
0.31263503.15319409.html.plaintext.txt	296	gene environment cardiovascular disease
0.31263503.15319409.html.plaintext.txt	297	arterioscler thromb vasc biol numnumnum num
0.31263503.15319409.html.plaintext.txt	298	mortality difference apoe genotype estimated apoe genotype estimated demographic synthesis
0.31263503.15319409.html.plaintext.txt	299	genet epidemiol numnumnum num
0.31263503.15319409.html.plaintext.txt	300	num tilvis r strandberg te juva k
0.31263503.15319409.html.plaintext.txt	301	apolipoprotein e phenotype dementia mortality prospective population sample
0.31263503.15319409.html.plaintext.txt	302	j geriatr soc numnumnum num
0.31263503.15319409.html.plaintext.txt	303	apolipoprotein e longevity rotterdam study
0.31263503.15319409.html.plaintext.txt	304	j geriatr soc numnumnum num
0.31263503.15319409.html.plaintext.txt	305	num louhija j aguero torres h tilvis r
0.31263503.15319409.html.plaintext.txt	306	survival finnish centenarian relation apolipoprotein e polymorphism
0.31263503.15319409.html.plaintext.txt	307	j geriatr soc numnumnum num
0.31263503.15319409.html.plaintext.txt	308	num stengard jh zerba ke pekkanen j ehnholm c nissinen sing cf
0.31263503.15319409.html.plaintext.txt	309	apolipoprotein e polymorphism predicts death coronary heart disease longitudinal study elderly finnish men
0.31263503.15319409.html.plaintext.txt	310	num stengard jh pekkanen j ehnholm c nissinen sing cf
0.31263503.15319409.html.plaintext.txt	311	genotype apolipoprotein episilon num allele predictor coronary heart disease mortality longitudinal study elderly finnish men
0.31263503.15319409.html.plaintext.txt	312	num corder eh lannfelt l vittanen m et al
0.31263503.15319409.html.plaintext.txt	313	apolipoprotein e genotype determines survival oldest old num year older good cognition
0.31263503.15319409.html.plaintext.txt	314	num lee jh tang mx schupf n et al
0.31263503.15319409.html.plaintext.txt	315	mortality apolipoprotein e hispanic african american caucasian elder
0.31263503.15319409.html.plaintext.txt	316	j med genet numnumnum num
0.31263503.15319409.html.plaintext.txt	317	num vogt mt cauley ja kuller lh
0.31263503.15319409.html.plaintext.txt	318	apolipoprotein e phenotype arterial disease mortality among older woman study osteoporotic fracture
0.31263503.15319409.html.plaintext.txt	319	genet epidemiol numnumnum num
0.31263503.15319409.html.plaintext.txt	320	conum klinktypedoi crossrefisimedline
0.31481948.7615568.html.plaintext.txt	0	num american society biochemistry molecular biology inc
0.31481948.7615568.html.plaintext.txt	1	apolipoprotein e carboxyl terminal fragment complexed amyloid l implication amyloidogenesis alzheimers disease
0.31481948.7615568.html.plaintext.txt	2	received publication february num num revised form may num num
0.31481948.7615568.html.plaintext.txt	3	castao france prelli mordechai pras num blas frangione
0.31481948.7615568.html.plaintext.txt	4	apolipoprotein e apoe immunoreactivity consistently present senile plaque neurofibrillary tangle alzheimers disease ad brain
0.31481948.7615568.html.plaintext.txt	5	vitro apoe particular apoenum isoform bind promote fibrillogenesis amyloid peptide main constituent senile plaque
0.31481948.7615568.html.plaintext.txt	6	finding together strong genetic association late onset ad enum allele apoe strengthened hypothesis apoe may central role pathogenesis ad modulating cerebral accumulation
0.31481948.7615568.html.plaintext.txt	7	however apoe immunoreactivity present cerebral systemic amyloidoses tested tryptic apoe fragment identified association amyloid aa
0.31481948.7615568.html.plaintext.txt	8	order elucidate interaction apoe amyloid purified aa amyloid l al fibril patient familial mediterranean fever primary amyloidosis respectively studied association apoe aa al protein
0.31481948.7615568.html.plaintext.txt	9	case apoe fragment detected western blot co purified amyloid fibril
0.31481948.7615568.html.plaintext.txt	10	microsequencing analysis identified cooh terminal fragment apoe similar num kda fragment produced thrombin digestion contains purported binding region
0.31481948.7615568.html.plaintext.txt	11	vitro co incubation aa purified human apoe resulted formation sd resistant aaapoe complex higher degree polymerization aa peptide
0.31481948.7615568.html.plaintext.txt	12	finding similar result obtained ad senile plaque suggest num carboxyl terminal fragment apoe complexed amyloid fibril resists proteolysis vivo num apoe may promote amyloidogenesis conformation dependent interaction regardless primary structure amyloid precursor
0.31481948.7615568.html.plaintext.txt	13	amyloidosis disorder protein conformation low molecular weight protein soluble physiological condition become deposited accumulate either intact partially digested diverse tissue organ insoluble amyloid fibril
0.31481948.7615568.html.plaintext.txt	14	spite biochemical diversity amyloid protein adopt common secondary structure pleated sheet form fibril similar morphology
0.31481948.7615568.html.plaintext.txt	15	fibril characteristically long straight filament num num nm wide share tinctorial property green birefringence congo red staining specific affinity fluorescent dye thioflavine
0.31481948.7615568.html.plaintext.txt	16	addition feature shared type amyloid several factor consistently associated pathological condition viewed part biochemical setting amyloid deposition arises develops
0.31481948.7615568.html.plaintext.txt	17	include elevated concentration amyloid precursor fluid tissue invariable presence certain amyloid associated protein amyloid p component apnum num sulfated proteoglycans num num num apolipoprotein e apoe num num apolipoprotein j num notorious
0.31481948.7615568.html.plaintext.txt	18	whether amyloid associated protein play active role promoting inhibiting amyloidogenesis inert bystander present unknown
0.31481948.7615568.html.plaintext.txt	19	apoe num kda exchangeable apolipoprotein present type lipoprotein particle involved cholesterol transport well le defined function nerve regeneration injurynum num num num
0.31481948.7615568.html.plaintext.txt	20	recently reported association certain apoe genetic isoforms alzheimers disease ad condition characterized massive deposition brain num num residue amyloid protein anum num num num num num strengthened hypothesis apolipoprotein may directly involved pathogenesis cerebral amyloidosisnum num
0.31481948.7615568.html.plaintext.txt	21	moreover vitro binding experiment using human apoe isolated plasma recombinant human apoe synthetic peptide homologous shown two protein form sd resistant complex promote fibril formation vitronum num num num
0.31481948.7615568.html.plaintext.txt	22	line evidence together immunohistochemical colocalization apoe senile plaque presence intraneuronal amyloid neurofibrillary tanglesnum suggest apoe may play active role pathogenesis ad promoting fibrillogenesis
0.31481948.7615568.html.plaintext.txt	23	however immunohistochemical study shown apoe tightly associated type cerebral amyloidosis including syndrome related hereditary cerebral amyloid angiopathy icelandic type related cystatin c variant spongiform encephalopathy creutzfeldt jakob kuru gerstmann straussler scheinker disease associated prion amyloidnum num num
0.31481948.7615568.html.plaintext.txt	24	furthermore apoe immunohistochemically identified within amyloid deposit systemic form disease secondary amyloidosis familial mediterranean fever related amyloid immunoglobulin related primary amyloidosis al familial amyloidotic polyneuropathy due deposition transthyretin genetic variantsnum
0.31481948.7615568.html.plaintext.txt	25	noteworthy apoe rarely detected nonfibrillar monoclonal deposit light chain deposition disease light heavy chain deposition disease may considered preamyloid form al diseasenum
0.31481948.7615568.html.plaintext.txt	26	widespread association apoe biochemically clinically diverse type amyloidoses suggests apoe may participate general manner process amyloid formation
0.31481948.7615568.html.plaintext.txt	27	order gain insight biochemistry association apoe amyloid protein characterized western blot amino terminal sequence analysis apoe fragment co purified amyloid subunit case systemic amyloidosis aa al
0.31481948.7615568.html.plaintext.txt	28	also studied vitro binding human apoe isolated plasma amyloid protein
0.31481948.7615568.html.plaintext.txt	29	protein purificationamyloid al fibril isolated method pras et al
0.31481948.7615568.html.plaintext.txt	30	num spleen tissue patient familial mediterranean fever coh primary amyloidosis ram
0.31481948.7615568.html.plaintext.txt	31	briefly num g spleen tissue homogenized num
0.31481948.7615568.html.plaintext.txt	32	num m sodium chloride centrifuged numnum g num min num degree c supernatant discarded
0.31481948.7615568.html.plaintext.txt	33	procedure repeated supernatant absorbance le num
0.31481948.7615568.html.plaintext.txt	34	insoluble residue homogenized distilled water centrifuged numnum g num degree c num h
0.31481948.7615568.html.plaintext.txt	35	amyloid fibril appear mucoid mass upper layer dialyzed water lyophilized
0.31481948.7615568.html.plaintext.txt	36	lyophilization aa protein purified high performance liquid chromatography hplc see
0.31481948.7615568.html.plaintext.txt	37	al fibril solubilized num ml num m guanidine hydrochloride num
0.31481948.7615568.html.plaintext.txt	38	num stirred num h room temperature
0.31481948.7615568.html.plaintext.txt	39	num ml num m guanidine hydrochloride num m acetic acid added solution applied column num
0.31481948.7615568.html.plaintext.txt	40	num num cm consisting numnum wt sephadex g num sephadex g num pharmacia biotech inc
0.31481948.7615568.html.plaintext.txt	41	equilibrated num m guanidine hydrochloride num m acetic acid
0.31481948.7615568.html.plaintext.txt	42	al amyloid fragment isolated size exclusion chromatography aa fibril subjected reverse phase chromatography deltapak c column num
0.31481948.7615568.html.plaintext.txt	43	num num cm water gradient num num acetonitrile num
0.31481948.7615568.html.plaintext.txt	44	num vv trifluoroacetic acid ph num
0.31481948.7615568.html.plaintext.txt	45	column eluents monitored num nm protein peak pooled lyophilized
0.31481948.7615568.html.plaintext.txt	46	crude amyloid fibril fraction obtained gel filtration hplc subjected num
0.31481948.7615568.html.plaintext.txt	47	num tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis sd pagenum protein electrophoretically transferred num h num ma num degree c polyvinylidene difluoride membrane immobilon millipore using num mm cap buffer ph num containing num methanol
0.31481948.7615568.html.plaintext.txt	48	membrane blocked num nonfat dry milk num mm tris hcl num mm sodium chloride num
0.31481948.7615568.html.plaintext.txt	49	num num h room temperature incubated overnight num degree c following antibody rabbit polyclonal antibody amyloid anum light chain dako corp
0.31481948.7615568.html.plaintext.txt	50	goat anti human apolipoprotein e fitzgerald monoclonal antibody idnum numcnum raised residue num num num num apoe respectively generous gift dr y
0.31481948.7615568.html.plaintext.txt	51	horseradish peroxidase conjugated sheep anti mouse amersham corp
0.31481948.7615568.html.plaintext.txt	52	goat anti rabbit rabbit anti goat igg biosource international used second antibody dilution numnum
0.31481948.7615568.html.plaintext.txt	53	immunoblots visualized ecl chemiluminescence kit amersham corp
0.31481948.7615568.html.plaintext.txt	54	according manufacturer specification
0.31481948.7615568.html.plaintext.txt	55	anti apoe antiserum adsorbed incubating num microg purified human apoe anti apoe diluted numnum num
0.31481948.7615568.html.plaintext.txt	56	num bovine serum albumin bsa tris buffered saline ph num
0.31481948.7615568.html.plaintext.txt	57	protein sequence analysisautomated edman degradation sequence analysis carried numa proteinpeptide sequenator resulting phenylthiohydantoin amino acid derivative identified using line numa pth analyzer applied biosystems foster city ca
0.31481948.7615568.html.plaintext.txt	58	vitro incubation apoe amyloid peptideshuman apoe purchased cortex biochem bovine ubiquitin bsa purchased sigma
0.31481948.7615568.html.plaintext.txt	59	purity num protein assessed sd page nh terminal sequence analysis
0.31481948.7615568.html.plaintext.txt	60	since human pooled apoe used seems likely major isoform apoenum according statistical distribution normal population
0.31481948.7615568.html.plaintext.txt	61	stock solution amyloid peptide prepared num
0.31481948.7615568.html.plaintext.txt	62	num trifluoroacetic acid num acetonitrile quantitated amino acid analysis using pico tag analyzer water using microbicinchoninic acid assay kit pierce
0.31481948.7615568.html.plaintext.txt	63	apoe stock solution made num
0.31481948.7615568.html.plaintext.txt	64	num aliquot stored num degree c
0.31481948.7615568.html.plaintext.txt	65	aliquot stock solution lyophilized used co incubation experiment describednum
0.31481948.7615568.html.plaintext.txt	66	num microg apoe incubated num microg aa num microg al num microl num
0.31481948.7615568.html.plaintext.txt	67	num indicated time room temperature
0.31481948.7615568.html.plaintext.txt	68	incubation num microl num sd sample buffer added mixture run num
0.31481948.7615568.html.plaintext.txt	69	num sd tricine gel nondenaturing num
0.31481948.7615568.html.plaintext.txt	70	num polyacrylamide gel without sd
0.31481948.7615568.html.plaintext.txt	71	protein transferred immobilon p detected using polyclonal anti apoe anti aa anti al antibody described
0.31481948.7615568.html.plaintext.txt	72	control co incubation experiment ubiquitin molecular mass num kda bsa used instead amyloid peptide apoe respectively
0.31481948.7615568.html.plaintext.txt	73	immunohistochemistrysections spleen tissue case amyloid coh al ram deparaffinized xylene rehydrated ethanol tris buffered saline
0.31481948.7615568.html.plaintext.txt	74	rehydration endogenous peroxidase quenched incubation num
0.31481948.7615568.html.plaintext.txt	75	num hydrogen peroxide methanol num min
0.31481948.7615568.html.plaintext.txt	76	blocking num bsa tris buffered saline section incubated goat anti human apoe fitzgerald numnum dilution overnight num degree c rabbit anti goat labeled horseradish peroxidase biosource international numnum num h
0.31481948.7615568.html.plaintext.txt	77	reaction detected using num
0.31481948.7615568.html.plaintext.txt	78	num numnum diaminobenzidine tetrachloride num
0.31481948.7615568.html.plaintext.txt	79	num hydrogen peroxide num mm tris ph num
0.31481948.7615568.html.plaintext.txt	80	anti apoe antiserum adsorbed purified human apoe described
0.31481948.7615568.html.plaintext.txt	81	immunohistochemistry spleen section patient coh ram showed polyclonal anti human apoe labeled amyloid deposit described previouslynum
0.31481948.7615568.html.plaintext.txt	82	immunoreactivity completely abolished adsorption purified human apoe indicating specificity fig
0.31481948.7615568.html.plaintext.txt	83	figure num immunohistochemistry spleen section patient coh amyloid
0.31481948.7615568.html.plaintext.txt	84	anti apoe antibody label amyloid laden vessel
0.31481948.7615568.html.plaintext.txt	85	b adjacent section adsorption anti apoe human purified apoe
0.31481948.7615568.html.plaintext.txt	86	amyloid l patient ram purified procedure saline water extraction gel chromatography sephadex g num equilibrated num m guanidine
0.31481948.7615568.html.plaintext.txt	87	sd page fraction revealed main amyloid subunit molecular mass num num kda amino terminal sequence analysis showed homology iii iv ig light chain fig
0.31481948.7615568.html.plaintext.txt	88	hplc separation ram al yielded broad peak num num solvent b
0.31481948.7615568.html.plaintext.txt	89	peak divided four fraction b c d rechromatographed fig
0.31481948.7615568.html.plaintext.txt	90	figure num microsequence analysis
0.31481948.7615568.html.plaintext.txt	91	amino terminal sequence amyloid l amyloid protein apoe peptide co purified
0.31481948.7615568.html.plaintext.txt	92	figure num purification ram amyloid l
0.31481948.7615568.html.plaintext.txt	93	reverse phase hplc ram amyloid l deltapak c column num
0.31481948.7615568.html.plaintext.txt	94	num num cm using num num linear gradient acetonitrile num
0.31481948.7615568.html.plaintext.txt	95	ram amyloid l eluted broad peak num num solvent b
0.31481948.7615568.html.plaintext.txt	96	num tricine sd page ram al fibril f hplc fraction b c d
0.31481948.7615568.html.plaintext.txt	97	ram amyloid l subunit mass num num kda k present fraction together minor dimeric component num kda
0.31481948.7615568.html.plaintext.txt	98	num num kda band present fraction c carboxyl terminal truncated fragment al
0.31481948.7615568.html.plaintext.txt	99	c western blot analysis hplc fraction b c d using antibody human apoe developed chemoluminescence showed major num num kda band minor num kda band fraction d
0.31481948.7615568.html.plaintext.txt	100	approximate yield apoe fragment obtained ram amyloid estimated follows
0.31481948.7615568.html.plaintext.txt	101	ratio amyloid apoe fraction d determined densitometry coomassie blue stained num num kda num kda al band num num kda apoe band pdi optical densitometer
0.31481948.7615568.html.plaintext.txt	102	ratio applied area fraction d hplc profile
0.31481948.7615568.html.plaintext.txt	103	proportional area fraction d total area hplc profile determined
0.31481948.7615568.html.plaintext.txt	104	sd page analysis fraction revealed addition major al subunit num num kda num kda component seen fraction
0.31481948.7615568.html.plaintext.txt	105	latter probably corresponded dimer al subunit since recognized anti chain antibody shown
0.31481948.7615568.html.plaintext.txt	106	addition minor band approximately num num kda present fraction c d fig
0.31481948.7615568.html.plaintext.txt	107	western blot analysis fraction using anti apoe antibody visualized chemiluminescence detection revealed major band num num kda minor num kda component fraction d fig
0.31481948.7615568.html.plaintext.txt	108	failure detect apoe direct amino terminal sequence analysis ram fraction d despite positive apoe immunoreactivity fraction indicated present low concentration
0.31481948.7615568.html.plaintext.txt	109	therefore hplc fraction b c d run sd tricine gel transferred immobilon membrane band excised subjected amino terminal sequence analysis
0.31481948.7615568.html.plaintext.txt	110	amino terminal sequence num num kda component fraction c revealed fragment al starting position num shown
0.31481948.7615568.html.plaintext.txt	111	num num kda band hplc fraction d yielded two major fragment apoe starting position num num minor one starting position num addition amyloid protein fig
0.31481948.7615568.html.plaintext.txt	112	estimated relative yield apoe carboxyl fragment extracted amyloid deposit approximately numnum molar ratio apoeamyloid
0.31481948.7615568.html.plaintext.txt	113	purification amyloid subunit coh performed saline water extraction followed separation hplc fig
0.31481948.7615568.html.plaintext.txt	114	procedure yielded broad ill defined peak eluted num num solvent b pooled four fraction b c d rechromatographed analyzed sd page
0.31481948.7615568.html.plaintext.txt	115	major protein band num num kda present fraction minor num kda component may polymer num num kda peptide detected fraction b c fig
0.31481948.7615568.html.plaintext.txt	116	amino terminal sequence analysis hplc fraction revealed one residue per cycle
0.31481948.7615568.html.plaintext.txt	117	sequence identical serum amyloid protein fig
0.31481948.7615568.html.plaintext.txt	118	additional sequence identified
0.31481948.7615568.html.plaintext.txt	119	fraction subjected western blot using anti apoe antibody fluorogram revealed broad band num num kda fraction d fig
0.31481948.7615568.html.plaintext.txt	120	immunoreactivity band completely suppressed adsorption antiserum purified human apoe reflecting specificity reaction
0.31481948.7615568.html.plaintext.txt	121	band corresponding intact apoe num kda suggesting small fragment apoe associated amyloid subunit
0.31481948.7615568.html.plaintext.txt	122	figure num purification coh amyloid protein
0.31481948.7615568.html.plaintext.txt	123	reverse phase hplc coh amyloid deltapak c column num
0.31481948.7615568.html.plaintext.txt	124	num num cm using num num linear gradient acetonitrile num
0.31481948.7615568.html.plaintext.txt	125	coh amyloid eluted broad peak num num solvent b
0.31481948.7615568.html.plaintext.txt	126	num tricine sd page hplc fraction b c d
0.31481948.7615568.html.plaintext.txt	127	major coh amyloid subunit num num kda k present fraction
0.31481948.7615568.html.plaintext.txt	128	minor num kda component possibly polymer former detected fraction b c
0.31481948.7615568.html.plaintext.txt	129	c western blot analysis hplc fraction b c d using antibody human apoe developed chemiluminescence revealed broad num num kda component fraction d
0.31481948.7615568.html.plaintext.txt	130	failure detect apoe direct amino terminal sequence analysis coh fraction d despite positive apoe immunoreactivity indicated present low concentration
0.31481948.7615568.html.plaintext.txt	131	therefore similar approach ram al used protein separated sd tricine gel transferred immobilon membrane
0.31481948.7615568.html.plaintext.txt	132	upper portion num num kda band hplc fraction d yielded two sequence corresponding n terminus amyloid apoe fragment starting position num respectively fig
0.31481948.7615568.html.plaintext.txt	133	order investigate whether intact apoe present crude l amyloid fibril fraction hplc separation performed western blot using monoclonal antibody idnum numcnum specific amino terminal domain apoe
0.31481948.7615568.html.plaintext.txt	134	band corresponding num kda intact apoe observed association coh fibril
0.31481948.7615568.html.plaintext.txt	135	num microgram purified human apoe incubated num microg purified coh amyloid num h room temperature num
0.31481948.7615568.html.plaintext.txt	136	num novel component approximately num kda detected western immunoblot analysis using anti apoe fig
0.31481948.7615568.html.plaintext.txt	137	numa anti aa antibody shown indicating apoe amyloid complex partially resistant sd formed
0.31481948.7615568.html.plaintext.txt	138	nondenaturing condition num
0.31481948.7615568.html.plaintext.txt	139	num polyacrylamide gel complex resulted shift electrophoretic mobility apoe fig
0.31481948.7615568.html.plaintext.txt	140	complex formation detected apoe incubated num microg ubiquitin
0.31481948.7615568.html.plaintext.txt	141	influence apoe upon aa polymerization evaluated detection apoe aa incubation mixture anti aa antibody western blot
0.31481948.7615568.html.plaintext.txt	142	aa alone incubated num h room temperature num
0.31481948.7615568.html.plaintext.txt	143	num showed mainly monomeric form minor polymeric component sd page
0.31481948.7615568.html.plaintext.txt	144	contrast aa co incubated apoe numnum molar ratio apoeamyloid condition resulted appearance gel higher amount aa dimer trimer tetramers higher molecular weight component fig
0.31481948.7615568.html.plaintext.txt	145	aa co incubated bsa showed increment polymerization compared aa alone shown
0.31481948.7615568.html.plaintext.txt	146	experiment done using ram al additional band present
0.31481948.7615568.html.plaintext.txt	147	however amyloid apoe incubation mixture remained top stacking running gel high molecular weight component shown
0.31481948.7615568.html.plaintext.txt	148	result consistent higher degree aggregation amyloid al subunit presence apoe resisted denaturation sd treatment
0.31481948.7615568.html.plaintext.txt	149	figure num vitro co incubation amyloid apoe
0.31481948.7615568.html.plaintext.txt	150	num microg amyloid num microg incubated num
0.31481948.7615568.html.plaintext.txt	151	incubation stopped addition num laemmli sample buffer sample run num
0.31481948.7615568.html.plaintext.txt	152	transferring immobilon p protein detected anti apoe antibody
0.31481948.7615568.html.plaintext.txt	153	lanenum apoe alone lanenum apoe incubated amyloid
0.31481948.7615568.html.plaintext.txt	154	leftmargin indicates molecular mass kilodaltons kd
0.31481948.7615568.html.plaintext.txt	155	e apoe ea apoe amyloid complex
0.31481948.7615568.html.plaintext.txt	156	b apoe amyloid incubated described run nondenaturing num
0.31481948.7615568.html.plaintext.txt	157	protein detected western blot anti apoe antibody
0.31481948.7615568.html.plaintext.txt	158	shift electrophoretic mobility apoe reflects formation amyloid apoe complex
0.31481948.7615568.html.plaintext.txt	159	lanenum apoe alone lanenum apoe incubated amyloid
0.31481948.7615568.html.plaintext.txt	160	c amyloid incubated alone apoe described
0.31481948.7615568.html.plaintext.txt	161	num sd tricine page transferred immobilon p membrane
0.31481948.7615568.html.plaintext.txt	162	protein detected anti aa antibody
0.31481948.7615568.html.plaintext.txt	163	higher degree polymerization amyloid peptide present upon incubation apoe
0.31481948.7615568.html.plaintext.txt	164	lanenum amyloid alone lanenum amyloid incubated apoe
0.31481948.7615568.html.plaintext.txt	165	leftmargin indicates molecular mass kda
0.31481948.7615568.html.plaintext.txt	166	apo e two domain protein modeled two major fragment thrombin digestion
0.31481948.7615568.html.plaintext.txt	167	num kda amino terminal domain residue num num stable globular structure containing sequence mediates low density lipoprotein receptor bindingnum num
0.31481948.7615568.html.plaintext.txt	168	contrast num kda carboxyl terminal fragment le stable bind lipoprotein mediates lipid free apoe tetramerization aqueous solutionsnum
0.31481948.7615568.html.plaintext.txt	169	previously published finding tryptic fragment apolipoprotein e corresponding residue num num association two amyloid proteinsnum
0.31481948.7615568.html.plaintext.txt	170	present data extend observation
0.31481948.7615568.html.plaintext.txt	171	three fragment apoe located within thrombolytic carboxyl fragment apoe co purified ram amyloid l
0.31481948.7615568.html.plaintext.txt	172	slightly larger fragment apoe starting region connecting thrombolytic amino terminal carboxyl terminal domain apoe co purified coh amyloid fig
0.31481948.7615568.html.plaintext.txt	173	similar apoe fragment recently obtained ad senile plaque num
0.31481948.7615568.html.plaintext.txt	174	figure num schematic representation structural domain apolipoprotein e modeled thrombin proteolytic cleavagenum
0.31481948.7615568.html.plaintext.txt	175	alignment apoe carboxyl terminal peptide associated al aa protein shown well representation purported apoe binding domain bnum
0.31481948.7615568.html.plaintext.txt	176	propose apoe fragment co purify aa al bound amyloid protein vivo
0.31481948.7615568.html.plaintext.txt	177	remainder apoe molecule cleaved thrombin andor serine protease situ either amyloid apoe complex formed
0.31481948.7615568.html.plaintext.txt	178	alternatively rule apoe partially degraded purification
0.31481948.7615568.html.plaintext.txt	179	intact apoe apoe fragment determined western blot analysis present crude aa al fibril fraction hplc
0.31481948.7615568.html.plaintext.txt	180	however purification carboxyl terminal apoe fragment co purifies aa al amyloid
0.31481948.7615568.html.plaintext.txt	181	question whether apoe amyloid association precedes tissue deposition remains addressed
0.31481948.7615568.html.plaintext.txt	182	likely initial formation stable apoe amyloid complex requires interaction amino carboxyl terminal domain apoe
0.31481948.7615568.html.plaintext.txt	183	binding low density lipoprotein receptor amino terminal domain apoe requires lipid association largely mediated carboxyl end moleculenum
0.31481948.7615568.html.plaintext.txt	184	interdependence domain apoe reflected effect amino acid substitution within amino terminal region association apoe diverse lipoprotein class
0.31481948.7615568.html.plaintext.txt	185	association known mediated carboxyl terminus apoe num
0.31481948.7615568.html.plaintext.txt	186	apoenum isoform cys position num preferentially bind high density lipoprotein whereas presence arg position favor binding low density intermediate density lipoproteinsnum num
0.31481948.7615568.html.plaintext.txt	187	cooperation domain unique apoe isoform postulated explain selective lipoprotein distributionnum
0.31481948.7615568.html.plaintext.txt	188	whether similar mechanism account higher avidity apoenum isoform ad remains tested
0.31481948.7615568.html.plaintext.txt	189	apoe capable binding synthetic strong interaction resistant sdsnum
0.31481948.7615568.html.plaintext.txt	190	similar interaction apoe dutch variant cerebral amyloid angiopathy rare form familial ad also documented num detail apoe binding published elsewhere
0.31481948.7615568.html.plaintext.txt	191	using set truncated recombinant purported binding region located within carboxyl end apoe amino acid num num num
0.31481948.7615568.html.plaintext.txt	192	finding suggest binding region specific peptide rather reflects hydrophobic interaction apoe carboxyl end common conformation shared different amyloid
0.31481948.7615568.html.plaintext.txt	193	secondary structure prediction indicate putative amphipathic helix high affinity lipid num located within region co purifies amyloid peptide
0.31481948.7615568.html.plaintext.txt	194	possibly exchangeable apolipoproteins sharing similar amphipathic helix also amyloid apolipoprotein interaction
0.31481948.7615568.html.plaintext.txt	195	noteworthy genetic variant apoai form amyloid certain hereditary form human amyloidosis num num saa precursor aa apolipoprotein associated high density lipoproteinnum
0.31481948.7615568.html.plaintext.txt	196	recently found apoai bind promote fibrillogenesis vitro
0.31481948.7615568.html.plaintext.txt	197	presumably way large number amyloidogenic precursor protein end insoluble amyloid fibril also group amyloidogenic apolipoproteins acute phase reactant actively participate process either constituent fibril modulators fibrillogenesis
0.31481948.7615568.html.plaintext.txt	198	finding higher degree polymerization aa al native peptide upon incubation apoe together previous work using synthetic num num num num point general role apoe amyloidogenesis
0.31481948.7615568.html.plaintext.txt	199	molar ratio apoe aa used vitro experiment opposite found plasma normal condition apoe saa
0.31481948.7615568.html.plaintext.txt	200	however saa acute phase reactant concentration plasma capable rising num fold tissue injury inflammationnum
0.31481948.7615568.html.plaintext.txt	201	al turn derived monoclonal light chain known high level circulation case
0.31481948.7615568.html.plaintext.txt	202	therefore believe concentration used vitro resemble closely pathological condition amyloidosis develops physiological level apoe amyloid precursor
0.31481948.7615568.html.plaintext.txt	203	apoe may act one group pathological chaperone promote aggregation amyloidogenic precursor diverse primary structure pleated sheet conformation amyloid fibril
0.31481948.7615568.html.plaintext.txt	204	absence apoe ap nonfibrillar congo red negative monoclonal deposit light chain deposition disease light heavy chain deposition disease considered preamyloid form al diseasenum suggests apoe ap may essential catalyst modulation amyloid generation process
0.31481948.7615568.html.plaintext.txt	205	interaction apoe amyloid may also influenced local acute phase reactant proteoglycans amyloid precursor apoe known bindnum num
0.31481948.7615568.html.plaintext.txt	206	spite putative widespread role apoe amyloid formation seems likely certain specificity exists amyloid precursor apoe genetic isoforms
0.31481948.7615568.html.plaintext.txt	207	thus far preferential association systemic amyloidoses apoe isoforms reported however genetic association ad apoenum vitro higher avidity isoform may reflect specificitynum num
0.31481948.7615568.html.plaintext.txt	208	alternatively apoenum isoform may participate pathogenesis ad different pathway unrelated formation deposition
0.31481948.7615568.html.plaintext.txt	209	recently reported apoe inhibit aggregation vitro concentration similar found normally biological fluidsnum
0.31481948.7615568.html.plaintext.txt	210	apparent discrepancy previous study could due different experimental conditionsnum num num num
0.31481948.7615568.html.plaintext.txt	211	however raise intriguing possibility apoe may dual effect upon fibrillogenesis vivo depending local concentration apoe amyloid precursor site amyloid formation
0.31481948.7615568.html.plaintext.txt	212	within physiological level apoe may protective role amyloid formation sequestering soluble amyloid precursor postulated anum
0.31481948.7615568.html.plaintext.txt	213	however appears associated apolipoproteins
0.31481948.7615568.html.plaintext.txt	214	apolipoprotein j biological fluid vivonum
0.31481948.7615568.html.plaintext.txt	215	yet tissue local membrane repair lipid turnover increased cell injury apoe overexpressed reach higher concentration found normally circulationnum num num num
0.31481948.7615568.html.plaintext.txt	216	circumstance apoe may substantially different effect upon association amyloid precursor
0.31481948.7615568.html.plaintext.txt	217	pathological setting several factor may affect apoe behavior state oxidation lipid association presence amyloidapoe binding protein stage amyloid processnum
0.31481948.7615568.html.plaintext.txt	218	abnormal amyloid response individual determined finally complex process involving critical concentration amyloid precursor set amyloid associated protein apoe apolipoproteins ap antichymotrypsin num proteoglycans
0.31481948.7615568.html.plaintext.txt	219	may act conjunction yet undefined tissue specific factor modulate conformational transition soluble protein insoluble fibril
0.31481948.7615568.html.plaintext.txt	220	better understanding complex interaction amyloid factor modulate formation may open novel strategy treatment systemic cerebral amyloid related disease
0.31481948.7615568.html.plaintext.txt	221	work supported national institute health grant arnum merit agnum lead agnum metropolitan life foundation award medical research num
0.31481948.7615568.html.plaintext.txt	222	part work presented num annual meeting society neuroscience miami beach florida
0.31481948.7615568.html.plaintext.txt	223	cost publication article defrayed part payment page charge
0.31481948.7615568.html.plaintext.txt	224	article must therefore hereby marked advertisement accordance num u
0.31481948.7615568.html.plaintext.txt	225	section num solely indicate fact
0.31481948.7615568.html.plaintext.txt	226	correspondence addressed dept
0.31481948.7615568.html.plaintext.txt	227	pathology new york university medical center num first ave
0.31481948.7615568.html.plaintext.txt	228	num num num fax num num num
0.31481948.7615568.html.plaintext.txt	229	abbreviation used ap amyloid p component hplc high performance liquid chromatography al amyloid l saa serum amyloid precursor aa amyloid ad alzheimers disease cap num cyclohexylaminopropanesulfonic acid bsa bovine serum albumin page polyacrylamide gel electrophoresis
0.31481948.7615568.html.plaintext.txt	230	castao unpublished observation
0.31518275.8817335.html.plaintext.txt	0	alzheimers disease associated mutation presenilin num rare variably penetrant alzheimers disease associated mutation presenilin num rare variably penetrant r
0.31518275.8817335.html.plaintext.txt	1	numcentre research neurodegenerative disease department medicine university toronto department medicine division neurology toronto hospital toronto ontario mnums numanum canada numkarolinska institute department clinical neuroscience geriatric medicine novum kfc num num huddinge sweden numdepartment neurology psychiatry university florence viale morgagni num florence italy numlaboratoire de genetique moleculaire chu rouen num rouen france numdepartment medical molecular genetics university toronto research institute hospital sick child num university avenue toronto ontario canada numdepartment neurology hopital de la salpetriere inserm unum num paris france numsurrey place centre department obstetrics gynaecology dept
0.31518275.8817335.html.plaintext.txt	2	physiology university toronto toronto ontario mnums numanum canada numinserm unum chateau de longchamp num paris france numdepartment neurology university udine udine italy
0.31518275.8817335.html.plaintext.txt	3	received february num num revised accepted april num num
0.31518275.8817335.html.plaintext.txt	4	missense mutation presenilin num p num gene chromosome num sought direct nucleotide sequence analysis open reading frame num pedigree familial alzheimers disease fad
0.31518275.8817335.html.plaintext.txt	5	majority pedigree p num beta amyloid precursor protein betaapp gene mutation excluded
0.31518275.8817335.html.plaintext.txt	6	additional p num pathogenic mutation detected four silent nucleotide substitution alternative splicing nucleotide num num glunum observed
0.31518275.8817335.html.plaintext.txt	7	analysis additional member pedigree known segregate metnumval mutation p num revealed age onset symptom highly variable range num num year
0.31518275.8817335.html.plaintext.txt	8	variability attributable difference apoe genotype
0.31518275.8817335.html.plaintext.txt	9	result suggest contrast mutation p num mutation p num relatively rare cause fad ii genetic environmental factor modify ad phenotype associated p num mutation iii still fad susceptibility gene remain identified
0.31518275.8817335.html.plaintext.txt	10	missense mutation associated early onsetalzheimers disease ad discovered two related gene termed presenilin chromosome num num presenilin ii chromosome num num num
0.31518275.8817335.html.plaintext.txt	11	analysis number large data set revealed missense mutation presenilin p num gene frequent cause early onset familial alzheimers disease fad accounting perhaps much num case early onset fad num num num num
0.31518275.8817335.html.plaintext.txt	12	order determine frequency mutation presenilin ii p num gene undertook survey mutation open reading frame orf p num gene num pedigree fad
0.31518275.8817335.html.plaintext.txt	13	disease family characterized occurrence ad consistent ninds adrda criterion least three closely related subject often one generation
0.31518275.8817335.html.plaintext.txt	14	pedigree age onset range num num year num mean age onset num year num mean age onset num year num insufficient reliable data age onset overlapped observed pedigree known p num mutation onset num num year
0.31518275.8817335.html.plaintext.txt	15	determine penetrance p num mutation also examined several additional member flonum pedigree previously described metnumval missense mutation p num gene num
0.31518275.8817335.html.plaintext.txt	16	data suggest missense mutation p num gene rare cause ad missense mutation may subject modifying action gene environmental influence
0.31518275.8817335.html.plaintext.txt	17	fibroblast transformed lymphoblast peripheral blood sample obtained least one affected member num kindred multiple num family member affected fad ascertained familial alzheimers disease registry university toronto clinic university florence massachusetts alzheimers disease research centre karolinska institute stockholm sweden french university hospital national inserm network france indiana university alzheimers disease dna bank nia sponsored repository coriell institute
0.31518275.8817335.html.plaintext.txt	18	diagnosis ad affected member used ninds adrda criterion similar cerad criterion
0.31518275.8817335.html.plaintext.txt	19	mutation p num beta amyloid precursor protein betaapp gene previously excluded majority pedigree sequencing reverse transcriptase polymerase chain reaction rt pcr product corresponding p num gene genomic pcr product corresponding exon num num betaapp
0.31518275.8817335.html.plaintext.txt	20	analysis nucleotide sequence rt pcr product corresponding orf p num num fad pedigree failed uncover additional mutation beyond two initial mutation asnnumile mutation three related kindred volga german origin metnumval mutation flonum pedigree italian origin previously reported data set num
0.31518275.8817335.html.plaintext.txt	21	specific screening asnnumile metnumval mutation supplemental set genomic dna sample affected probands num swedish fad pedigree also failed identify instance either mutation
0.31518275.8817335.html.plaintext.txt	22	however although pathogenic nucleotide sequence difference observed four silent nucleotide substitution detected c num bpcodon num c num bpcodon num c num bpcodon num g num bpcodon num sequence numbering accession
0.31518275.8817335.html.plaintext.txt	23	substitution occurred third nucleotide position codon would therefore predicted cause change amino acid sequence
0.31518275.8817335.html.plaintext.txt	24	fifth sequence variant variable presence nucleotide num num encoding glunum residuewas found transcript tissue
0.31518275.8817335.html.plaintext.txt	25	transcript without nucleotide num num reflects use alternate splice donor sequence approximately equal abundance brain fibroblast leukocyte
0.31518275.8817335.html.plaintext.txt	26	investigation p num gene several newly ascertained member flonum pedigree segregating metnumval mutation p num identified additional carrier mutation subject iii num table num
0.31518275.8817335.html.plaintext.txt	27	surprisingly subject aged num year evidence cognitive memory impairment serial follow several year age num year noted become mildly demented profoundly demented mini mental status examination score numnum clinical feature sustain diagnosis probable ad ninds adrda criterion
0.31518275.8817335.html.plaintext.txt	28	review clinical data additional member extended pedigree also uncovered two subject direct lineage family either historical evidence late onset ad subject num affected grandfather iii num died num year dementia currently clinical feature consistent probable ad using ninds adrda criterion subject iii num onset num year
0.31518275.8817335.html.plaintext.txt	29	others previously reported genotype apolipoprotein e gene modulate age onset alzheimers disease subject valnumile mutation betaapp num num
0.31518275.8817335.html.plaintext.txt	30	however flonum family metnumval mutation p num apoe genotype correlate age onset table num
0.31518275.8817335.html.plaintext.txt	31	thus elderly symptomatic subject iii num onset num year apoe genotype epsilonnumepsilonnum three affected carrier metnumval mutation developed symptom younger age onset num num year
0.31518275.8817335.html.plaintext.txt	32	moreover affected carrier iv num apoe genotype epsilonnumepsilonnum developed symptom age num year similar affected sibling iv num apoe genotype epsilonnumepsilonnum onset num year table num fig
0.31518275.8817335.html.plaintext.txt	33	sample size small draw reliable conclusion presence absence interaction apoe genotype asnnumile mutation table num
0.31518275.8817335.html.plaintext.txt	34	abbreviated pedigree diagram flonum
0.31518275.8817335.html.plaintext.txt	35	small type face roman numeral pedigree location subject
0.31518275.8817335.html.plaintext.txt	36	solid symbol ad affected subject hatched symbol risk subject open symbol risk
0.31518275.8817335.html.plaintext.txt	37	known age onset age death denoted arabic numeral
0.31518275.8817335.html.plaintext.txt	38	exception subject iii num whose genotype p num apoe unknown biological sample available affected subject carried p num metnumval mutation
0.31518275.8817335.html.plaintext.txt	39	although large cadre fad pedigree reported represent unbiased survey paucity missense mutation p num gene amongst fad pedigree data set suggests contrast mutation orf p num mutation orf gene rare cause fad least caucasian population
0.31518275.8817335.html.plaintext.txt	40	confidently exclude mutation intronic sequence associated rna splice site indeed one mutation affect splicing exon num p num found fad affected subject
0.31518275.8817335.html.plaintext.txt	41	however num utr num utr sequence searched pathogenic mutation exclude formal possibility mutation might exist sequence pedigree
0.31518275.8817335.html.plaintext.txt	42	nevertheless two corollary conclusion p num orf mutation rare
0.31518275.8817335.html.plaintext.txt	43	first unless phenotype uniquely associated least enriched subject p num mutant found screening program mutation orf p num likely low yield
0.31518275.8817335.html.plaintext.txt	44	second importantly yet unidentified fad susceptibility locus must exist
0.31518275.8817335.html.plaintext.txt	45	table num age onset relative genotype apoe p num gene subject
0.31518275.8817335.html.plaintext.txt	46	age symptom onset current age p num mutation carrier displayed along subject apoe genotype
0.31518275.8817335.html.plaintext.txt	47	conclusion drawn data age symptom onset subject p num mutation generally older num num year observed p num mutation num num year highly variable even amongst affected member pedigree
0.31518275.8817335.html.plaintext.txt	48	contrast sharply experience p num mutation age onset generally quite similar amongst affected member family often amongst member different family mutation num num num num
0.31518275.8817335.html.plaintext.txt	49	date subject ad flonum pedigree inherited metnumval mutation unlikely late onset case represent phenocopies andor represents polymorphism linkage disequilibrium nearby pathogenic mutation
0.31518275.8817335.html.plaintext.txt	50	consequently parsimonious explanation single cause disease metnumval mutation phenotype modified genetic environmental factor
0.31518275.8817335.html.plaintext.txt	51	limited number subject asnnumile mutation data set prevents rigorous conclusion interaction apoe genotype mutation
0.31518275.8817335.html.plaintext.txt	52	however analysis larger data set
0.31518275.8817335.html.plaintext.txt	53	schellenberg also reveals obvious interaction genotype apoe p num asnnumile manuscript preparation
0.31518275.8817335.html.plaintext.txt	54	absence close correlation apoe genotype age symptom onset subject p num mutation two implication
0.31518275.8817335.html.plaintext.txt	55	first view parallel observation showing apparent interaction apoe genotype mutation p num num num num together structural amino acid sequence similarity p num p num protein num num likely functional effect p num p num mutation similar either remote functional effect apoe epsilonnum allele affect biochemical pathway leading ad different influenced apoe epsilonnum
0.31518275.8817335.html.plaintext.txt	56	second variation age onset p num mutation carrier argues modifying environmental genetic factor e
0.31518275.8817335.html.plaintext.txt	57	polymorphism within presenilin gene difference gene must exist
0.31518275.8817335.html.plaintext.txt	58	nature factor remains determined
0.31518275.8817335.html.plaintext.txt	59	however modifying factor identified might exploitable therapeutic tool
0.31518275.8817335.html.plaintext.txt	60	subject familially clustered alzheimers disease defined occurrence least three first second degree relative ad recruited patient referred investigation dementia university toronto university florence massachusetts alzheimers disease research centre huddinge hospital karolinska institute french university hospital
0.31518275.8817335.html.plaintext.txt	61	subject provided informed consent using institutionally approved protocol
0.31518275.8817335.html.plaintext.txt	62	diagnosis ad made affected pedigree member direct clinical examination standard laboratory procedure met exceeded stringency nincds adrda criterion num num
0.31518275.8817335.html.plaintext.txt	63	evidence ad deceased family member ascertained investigation medical family record previously described num
0.31518275.8817335.html.plaintext.txt	64	additional fad pedigree sample obtained cornell institute camden nj n num indiana university alzheimers disease dna bank indianapolis n num
0.31518275.8817335.html.plaintext.txt	65	mutation sought orf p num gene numnum pedigree exon num num betaapp gene numnum pedigree using method previously described num num num
0.31518275.8817335.html.plaintext.txt	66	p num gene orf investigated north american italian pedigree isolating complimentary dna fragment amplification using rt pcr oligonucleotide primer sequence reaction condition previously described num
0.31518275.8817335.html.plaintext.txt	67	french family rt pcr performed using primer fnum num caggaaacagctatgaccgagctgaccctcaaatacgg fnum num tgtaaaacgacggccagtgagatcatacacagagatgg recover codon num num primer fnum num caggaaacagctatgacctcaagtacctcccagagtgg fnum num tgtaaaacgacggccagtagcctgtggcacaccatgtc recover codon num num
0.31518275.8817335.html.plaintext.txt	68	nucleotide sequence rt pcr product affected pedigree member determined using fluorescent dye terminator dye primer cycle sequencing
0.31518275.8817335.html.plaintext.txt	69	mutation detected analysis resultant chromatogram heterozygous nucleotidesubstitutions using direct inspection factura ver num
0.31518275.8817335.html.plaintext.txt	70	num sequence navigator ver num
0.31518275.8817335.html.plaintext.txt	71	numbnum software package abi foster city ca
0.31518275.8817335.html.plaintext.txt	72	presence c substitution base pair num p num cdna sequence give rise metnumval mutation assessed genomic dna previously described num
0.31518275.8817335.html.plaintext.txt	73	num familial alzheimers disease kindred missense mutation novel gene chromosome num related alzheimers disease type num gene
0.31518275.8817335.html.plaintext.txt	74	num familial alzheimers disease locus chromosome num
0.31518275.8817335.html.plaintext.txt	75	num molecular genetic analysis familial early onset alzheimers disease linked chromosome numqnum
0.31518275.8817335.html.plaintext.txt	76	num mutation presenilin num gene family early onsetalzheimers disease
0.31518275.8817335.html.plaintext.txt	77	num alzheimers disease collaborative group num structure presenilin gene identification six mutation early onset ad pedigree
0.31518275.8817335.html.plaintext.txt	78	num alzheimers disease possible gene interaction
0.31518275.8817335.html.plaintext.txt	79	num apoe genotype familial alzheimers disease possible influence age onset appnumval ile mutated family
0.31518275.8817335.html.plaintext.txt	80	num apoe genotype modulate age onset family chromosome num encoded alzheimers disease
0.31518275.8817335.html.plaintext.txt	81	num french alzheimers disease collaborative study group num apolipoprotein e genotype affect age onset patient chromosome num encoded alzheimers disease
0.31518275.8817335.html.plaintext.txt	82	num clinical diagnosis alzheimer disease report nincds adrda work group auspex department health human service task force alzheimer disease
0.31518275.8817335.html.plaintext.txt	83	num diagnosis alzheimer disease
0.31518275.8817335.html.plaintext.txt	84	num genetic evidence novel familial alzheimer disease gene chromosome num
0.31518275.8817335.html.plaintext.txt	85	num molecular prospective phenotypic characterization pedigree familial alzheimer disease missense mutation codon num beta amyloid precursor protein app gene
0.31518275.8817335.html.plaintext.txt	86	num pathogenic mutation probable alzheimers disease app gene n terminus beta amyloid
0.31518275.8817335.html.plaintext.txt	87	num association apoliprotein e allele epsilonnum late onset familial sporadic alzheimer disease
0.31518275.8817335.html.plaintext.txt	88	num association alzheimer disease apolipoprotein gene chr num due linkage disequilibrium ann
0.31518275.8817335.html.plaintext.txt	89	correspondence addressed page maintained oup admin
0.31518275.8817335.html.plaintext.txt	90	last updated thu oct num numnumnum gmt num
0.31518275.8817335.html.plaintext.txt	91	part oup journal world wide web service
0.31518275.8817335.html.plaintext.txt	92	copyright oxford university press num
0.31636134.15033916.html.plaintext.txt	0	estrogen facilitates neurite extension via apolipoprotein e cultured adult mouse cortical neuron britto p
0.31636134.15033916.html.plaintext.txt	1	barsukova fei shen mary mcasey robert g
0.31636134.15033916.html.plaintext.txt	2	department biological science b
0.31636134.15033916.html.plaintext.txt	3	eastern illinois university charleston illinois num department obstetrics gynecology m
0.31636134.15033916.html.plaintext.txt	4	center alzheimer disease r
0.31636134.15033916.html.plaintext.txt	5	southern illinois university school medicine springfield illinois num
0.31636134.15033916.html.plaintext.txt	6	address correspondence request reprint robert g
0.31636134.15033916.html.plaintext.txt	7	box num center alzheimer disease related disorder southern illinois university school medicine springfield illinois num num
0.31636134.15033916.html.plaintext.txt	8	apolipoprotein e apoe modifies risk several chronic neurological disease
0.31636134.15033916.html.plaintext.txt	9	human three major isoforms apoe apoenum apoenum apoenum produced three allele num num num single gene locus chromosome num num num
0.31636134.15033916.html.plaintext.txt	10	inheritance num increase risk rate progression late onset alzheimer disease num num num
0.31636134.15033916.html.plaintext.txt	11	individual num allele also appear earlier age onset pd greater risk developing dementia pd num num
0.31636134.15033916.html.plaintext.txt	12	additionally num inheritance increase risk developing dementia head trauma num num num increase severity relapsing remitting multiple sclerosis num num
0.31636134.15033916.html.plaintext.txt	13	neuronal repair may common factor disease
0.31636134.15033916.html.plaintext.txt	14	estradiol apoe independently facilitate neuriteprocess outgrowth vivo vitro
0.31636134.15033916.html.plaintext.txt	15	estradiol increase complexity neuritic growth axonal elongation vitro num num num
0.31636134.15033916.html.plaintext.txt	16	neuronal repair brain lesion rapid presence estradiol num num
0.31636134.15033916.html.plaintext.txt	17	apoe similar estrogen dramatic effect neurite outgrowth variety cultured neuron
0.31636134.15033916.html.plaintext.txt	18	apoenum increase neurite outgrowth whereas absence apoe treatment apoenum either decrease effect neurite outgrowth num num num
0.31636134.15033916.html.plaintext.txt	19	neuropathological study documented deficit dendritic growth plasticity brain apoenum individual num
0.31636134.15033916.html.plaintext.txt	20	apoe appears critical element neuronal growth repair
0.31636134.15033916.html.plaintext.txt	21	apoe level cns vary estrous cycle num several study show estradiol increase apoe vivo num num vitro num num
0.31636134.15033916.html.plaintext.txt	22	sum observation suggest generalized mechanism whereby estrogen could increase apoe level
0.31636134.15033916.html.plaintext.txt	23	apoe level could facilitate process regrowth injury
0.31636134.15033916.html.plaintext.txt	24	tested hypothesis cultured neuron adult mouse
0.31636134.15033916.html.plaintext.txt	25	found presence apoenum apoenum necessary obtain effect estrogen neurite outgrowth
0.31636134.15033916.html.plaintext.txt	26	addition data suggest apoe isoforms differential rate internalizaton lipid transport neuron
0.31636134.15033916.html.plaintext.txt	27	control mouse cnumblnum homozygous apoe knockout ko mouse bred num generation onto cnumblnum background cnumblnum apoe tmiunc obtained jackson laboratory bar harbor
0.31636134.15033916.html.plaintext.txt	28	transgenic tg human apoenum tg human apoenum mouse gift dr
0.31636134.15033916.html.plaintext.txt	29	david holtzman washington university st
0.31636134.15033916.html.plaintext.txt	30	apoenum apoenum transgene inserted glial fibrillary acidic protein gfap promoter region num
0.31636134.15033916.html.plaintext.txt	31	culture preparation experiment num month old female mouse euthanized sodium pentobarbital num mgkg
0.31636134.15033916.html.plaintext.txt	32	entire cerebral cortex dissected brain placed num ml bnumhibernate medium bnumha invitrogen life technology carlsbad ca num
0.31636134.15033916.html.plaintext.txt	33	num mm thickness transferred num ml tube containing num ml bnumha
0.31636134.15033916.html.plaintext.txt	34	warming num min num c slice digested num ml num mgml papain sigma solution bnumha num min num c gyrating water bath
0.31636134.15033916.html.plaintext.txt	35	slice transferred num ml bnumha
0.31636134.15033916.html.plaintext.txt	36	num min room temperature slice triturated num time siliconized num inch pasteur pipette allowed settle num min
0.31636134.15033916.html.plaintext.txt	37	approximately num ml supernatant transferred another tube sediment resuspended num ml bnumha
0.31636134.15033916.html.plaintext.txt	38	step repeated twice total num ml collected
0.31636134.15033916.html.plaintext.txt	39	resultant supernatant subjected density gradient centrifugation num x g num min
0.31636134.15033916.html.plaintext.txt	40	density gradient prepared four num ml layer num num num num optiprep invitrogen life technology bnumha medium volvol
0.31636134.15033916.html.plaintext.txt	41	debris num ml discarded
0.31636134.15033916.html.plaintext.txt	42	rest fraction excluding bottom pellet collected diluted num ml bnumha
0.31636134.15033916.html.plaintext.txt	43	centrifuging twice num x g num min cell pellet resuspended num ml bnumneurobasal medium invitrogen life technology num
0.31636134.15033916.html.plaintext.txt	44	total num x num cell plated num microl aliquot glass cover slip num mm diameter coated overnight poly d lysine num mgml sigma
0.31636134.15033916.html.plaintext.txt	45	num h incubation humidified incubator num c num conum cover slip rinsed twice bnumha transferred num well plate containing num
0.31636134.15033916.html.plaintext.txt	46	num ml bnumneurobasal medium num ngml fibroblast growth factor num invitrogen life technology
0.31636134.15033916.html.plaintext.txt	47	estradiol numss sigma dissolved num ethanol num microm added culture medium num d vitro num div incubation continued num div
0.31636134.15033916.html.plaintext.txt	48	human recombinant apoenum apoenum panvera madison wi dialyzed overnight num
0.31636134.15033916.html.plaintext.txt	49	final concentration estrogen apoe test reagent culture medium varied based experiment
0.31636134.15033916.html.plaintext.txt	50	quantification performed cell num div
0.31636134.15033916.html.plaintext.txt	51	experiment performed three time
0.31636134.15033916.html.plaintext.txt	52	apoe quantification medium num div culture collected centrifuged num min
0.31636134.15033916.html.plaintext.txt	53	apoe immunoprecipitated incubating medium monoclonal anti apoe numhnum heart institute university ottawa ottawa canada numnum dilution medium ice num h
0.31636134.15033916.html.plaintext.txt	54	incubation num protein sepharose cl numb sigma added numnum medium incubated ice num h shaker
0.31636134.15033916.html.plaintext.txt	55	medium centrifuged numnum x g num min num c supernatant discarded
0.31636134.15033916.html.plaintext.txt	56	pellet boiled num min numx lammeli sample buffer electrophoresed num num sodium dodecyl sulfate polyacrylamide gradient gel ecnum mini gel vertical system
0.31636134.15033916.html.plaintext.txt	57	sample run num v separation began num v dye front neared bottom gel
0.31636134.15033916.html.plaintext.txt	58	electrophoresis gel placed transfer buffer num
0.31636134.15033916.html.plaintext.txt	59	num g glycine num ml methanol num ml distilled hnumo shaker num min
0.31636134.15033916.html.plaintext.txt	60	transfer membrane immobilon p transfer membrane millipore bedford ma first soaked methanol num sec washed distilled hnumo num min remove excess methanol
0.31636134.15033916.html.plaintext.txt	61	protein gel transferred membrane using bio rad hercules ca trans blot transfer cell following manufacturer protocol
0.31636134.15033916.html.plaintext.txt	62	membrane blocked tb buffer num mm tris hcl num mm nacl ph num
0.31636134.15033916.html.plaintext.txt	63	num num bsa num c overnight room temperature num h
0.31636134.15033916.html.plaintext.txt	64	blocking membrane washed twice num min tb buffer tb buffer num
0.31636134.15033916.html.plaintext.txt	65	num tween num incubated goat antihuman apoe calbiochem san diego ca numnum dilution tb buffer num h shaker room temperature
0.31636134.15033916.html.plaintext.txt	66	membrane washed four time num min tb buffer incubated horseradish peroxidase conjugated rabbit antigoat igg chemicon temecula ca numnumnum dilution tb buffer num h shaker room temperature
0.31636134.15033916.html.plaintext.txt	67	washing five time num min tb buffer membrane incubated supersignal west pico chemiluminescent substrate pierce rockford il exposed kodak biomax light num film fisher scientific chicago il
0.31636134.15033916.html.plaintext.txt	68	num kda band visualized consistent published molecular mass apoe
0.31636134.15033916.html.plaintext.txt	69	band quantified densitometry scion image frederick md compared band recombinant human apoe
0.31636134.15033916.html.plaintext.txt	70	neurite extension cell prepared described treated varying concentration estradiol
0.31636134.15033916.html.plaintext.txt	71	num nm vehicle estradiol included additional control
0.31636134.15033916.html.plaintext.txt	72	single neurite extension length longest neurite neuron combined neurite length total length neurites neuron measured described previously num
0.31636134.15033916.html.plaintext.txt	73	first technique employed ocular micrometer measure longest neurite
0.31636134.15033916.html.plaintext.txt	74	second technique measured total length neurites
0.31636134.15033916.html.plaintext.txt	75	minimum ten cell per coverslip quantified
0.31636134.15033916.html.plaintext.txt	76	value coverslip averaged yield mean longest length mean total length
0.31636134.15033916.html.plaintext.txt	77	experiment performed three time
0.31636134.15033916.html.plaintext.txt	78	following experiment performed culture system
0.31636134.15033916.html.plaintext.txt	79	experimental study time course apoe level estradiol treatment
0.31636134.15033916.html.plaintext.txt	80	time course apoe level response exogenous estradiol examined
0.31636134.15033916.html.plaintext.txt	81	apoe secretion adult mouse culture evaluated incubating cell num
0.31636134.15033916.html.plaintext.txt	82	incubation medium collected secreted apoe quantified immunoblotting immunoprecipitation
0.31636134.15033916.html.plaintext.txt	83	dose response apoe estradiol treatment
0.31636134.15033916.html.plaintext.txt	84	obtained dose response curve apoe level estradiol addition wild type mouse num d estradiol treatment dosage estradiol ranging num
0.31636134.15033916.html.plaintext.txt	85	cortical cell wild type mouse treated varying concentration estradiol num
0.31636134.15033916.html.plaintext.txt	86	num d amount secreted apoe measured described
0.31636134.15033916.html.plaintext.txt	87	dose response estradiol neurite extension
0.31636134.15033916.html.plaintext.txt	88	second dose response study estradiol performed neurite outgrowth num div
0.31636134.15033916.html.plaintext.txt	89	culture prepared varying concentration estradiol added cell num div
0.31636134.15033916.html.plaintext.txt	90	num div cell evaluated neurite extension described
0.31636134.15033916.html.plaintext.txt	91	apoe replacement neurite extension
0.31636134.15033916.html.plaintext.txt	92	performed apoe replacement study estradiol treated cell culture derived mouse lacking apoe gene apoe ko jackson laboratory
0.31636134.15033916.html.plaintext.txt	93	cell incubated without num pm estradiol ethanol starting num div
0.31636134.15033916.html.plaintext.txt	94	purified recombinant human apoe isoforms added num microgml panvera
0.31636134.15033916.html.plaintext.txt	95	concentration comparable found human cerebrospinal fluid num
0.31636134.15033916.html.plaintext.txt	96	num div combined length neuritic tree obtained described
0.31636134.15033916.html.plaintext.txt	97	estradiol effect neurite outgrowth tg mouse
0.31636134.15033916.html.plaintext.txt	98	tg mouse expressing human apoenum apoenum control glial fibrillary acidic protein promoter num used evaluate effect endogenous apoe estradiol stimulated neurite extension culture
0.31636134.15033916.html.plaintext.txt	99	vivo mouse show apoe protein expression astrocyte ref
0.31636134.15033916.html.plaintext.txt	100	nathan personal observation
0.31636134.15033916.html.plaintext.txt	101	culture prepared evaluation num div
0.31636134.15033916.html.plaintext.txt	102	apoe transfer lipid neuron endocytosis tested rate uptake exogenous apoe lipid neuron culture derived apoe ko mouse
0.31636134.15033916.html.plaintext.txt	103	examined rate apoe uptake rate fatty acid transported cultured neuron
0.31636134.15033916.html.plaintext.txt	104	culture num div apoe ko mouse incubated num h recombinant human apoenum human apoenum prepared immunocytochemical localization apoe
0.31636134.15033916.html.plaintext.txt	105	coverslips fixed num ethanol num h rt rinsed three time tb num
0.31636134.15033916.html.plaintext.txt	106	coverslips rinsed three time tb
0.31636134.15033916.html.plaintext.txt	107	nonspecific binding blocked num bsa num apoe ko mouse serum tb num h rt incubated num h room temperature goat anti apoe antibody chemicon numnum dilution
0.31636134.15033916.html.plaintext.txt	108	washing six time tb coverslips incubated fluorescently labeled antigoat antiserum pierce num min numnum dilution washed five time tb num min
0.31636134.15033916.html.plaintext.txt	109	control coverslips incubated num c
0.31636134.15033916.html.plaintext.txt	110	coverslips mounted anti photobleach medium vectashield vector laboratory burlingame ca stored dark
0.31636134.15033916.html.plaintext.txt	111	digital image num field per coverslip xnum objective containing neuron obtained using fluorescence microscope excitation frequency num nm emission num nm digital camera pixera penguin numcl maintaining identical exposure setting image
0.31636134.15033916.html.plaintext.txt	112	apoe immunofluorescence measured quantifying mean optical fluorescence field using scion image software
0.31636134.15033916.html.plaintext.txt	113	upper lower num bit cut eliminate nonspecific fluorescence mean density pixelsfield within range obtained
0.31636134.15033916.html.plaintext.txt	114	data transformed scale num num statistical analysis
0.31636134.15033916.html.plaintext.txt	115	lipid uptake neuron quantified fluorescently labeled dodecanoic acid numnum difluoro num methyl num bora numanuma diaza indacene num dodecanoic acid accumulation adult cortical neuron
0.31636134.15033916.html.plaintext.txt	116	fluorescence absorption emission num num nm respectively
0.31636134.15033916.html.plaintext.txt	117	cell grown coverslips num d incubated num h num microgml either apoe num apoe num together num microgml fluorescently labeled lipid numnum difluoro num methyl num bora numanuma diaza indacene num dodecanoic acid molecular probe eugene
0.31636134.15033916.html.plaintext.txt	118	incubation coverslips rinsed three time warm num c pb fluorescent image digitized objective magnification xnum described
0.31636134.15033916.html.plaintext.txt	119	od measured using scion image software described
0.31636134.15033916.html.plaintext.txt	120	receptor inhibition apoe uptake
0.31636134.15033916.html.plaintext.txt	121	determine type lipoprotein receptor underlying effect apoe isoforms neuronal internalization lipoprotein three different lipoprotein receptor inhibitor used num receptor associated protein rap num microgml gift dr
0.31636134.15033916.html.plaintext.txt	122	dudley strickland american red cross rockville md num lactoferrin lac num microgml sigma num heparinase num uml sigma
0.31636134.15033916.html.plaintext.txt	123	heparinase depletes cell surface heparan sulfate proteoglycans hspgs bind apoe enriched lipoprotein internalization via lrp whereas rap lac inhibits binding lipoprotein lrp
0.31636134.15033916.html.plaintext.txt	124	cell num div apoe ko mouse preincubated num h medium alone medium containing one three inhibitor
0.31636134.15033916.html.plaintext.txt	125	culture subsequently treated num h recombinant apoenum apoenum prepared immunofluorescent localization apoe
0.31636134.15033916.html.plaintext.txt	126	image num neuron per coverslip digitized analyzed experimental condition
0.31636134.15033916.html.plaintext.txt	127	statistical analysis data experiment analyzed anova
0.31636134.15033916.html.plaintext.txt	128	per cell n num case representing three replication experiment
0.31636134.15033916.html.plaintext.txt	129	appropriate noted significant effect found anova pair wise post hoc testing performed bonferroni corrected test maintain overall type error rate p num
0.31636134.15033916.html.plaintext.txt	130	presence significant interaction data decomposed treated one way analysis bonferroni corrected test
0.31636134.15033916.html.plaintext.txt	131	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	132	time course apoe level culture response num pm numss estradiol added one div sampled num min num h
0.31636134.15033916.html.plaintext.txt	133	apoe level significantly increased num h addition estradiol remain elevated
0.31636134.15033916.html.plaintext.txt	134	data presented mean plus minus sem show variability point
0.31636134.15033916.html.plaintext.txt	135	num h variability among culture apoe level extremely small
0.31636134.15033916.html.plaintext.txt	136	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	137	western blotting apoe mixed cell culture treatment estradiol
0.31636134.15033916.html.plaintext.txt	138	little apoe produced num h exposure estradiol
0.31636134.15033916.html.plaintext.txt	139	dose response apoe level estradiol treatment next examined effect increasing concentration estradiol apoe level culture fig
0.31636134.15033916.html.plaintext.txt	140	anova found overall significance estradiol concentration apoe level fnumnum num
0.31636134.15033916.html.plaintext.txt	141	post hoc testing bonferroni corrected test showed higher dose estradiol significantly increased apoe level lower dose except num pm different num pm estradiol
0.31636134.15033916.html.plaintext.txt	142	dose num nm estrogen exhibited highest response apoe level
0.31636134.15033916.html.plaintext.txt	143	num nm concentration estrogen significantly smaller effect apoe level num pm num nm estradiol
0.31636134.15033916.html.plaintext.txt	144	normal female mouse estradiol concentration num num pm throughout estrous cycle num
0.31636134.15033916.html.plaintext.txt	145	hence data suggest physiological concentration estradiol greatest effect supraphysiologic concentration le effective
0.31636134.15033916.html.plaintext.txt	146	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	147	increasing concentration estradiol significantly increase apoe level culture
0.31636134.15033916.html.plaintext.txt	148	post hoc testing bonferroni corrected test showed higher dose significant lower dose except num pm different num pm
0.31636134.15033916.html.plaintext.txt	149	response num nm estrogen significantly higher dos
0.31636134.15033916.html.plaintext.txt	150	num nm concentration estrogen significantly smaller effect apoe level thannum pm num nm estradiol
0.31636134.15033916.html.plaintext.txt	151	b estradiol stimulates combined neuritic length
0.31636134.15033916.html.plaintext.txt	152	one way anova showed significance p num
0.31636134.15033916.html.plaintext.txt	153	post hoc testing bonferroni corrected test showed num pm num nm estrogen significantly increased neuritic outgrowth compared control condition estradiol ethanol alone
0.31636134.15033916.html.plaintext.txt	154	note peak response estrogen apoe production neuritic outgrowth occurred identical estrogen concentration
0.31636134.15033916.html.plaintext.txt	155	dose response estradiol neurite extension experiment examined effect increasing dos estradiol neurite outgrowth fig
0.31636134.15033916.html.plaintext.txt	156	neuron easily identifiable culture differential interference contrast microscopy fig
0.31636134.15033916.html.plaintext.txt	157	num previously confirmed immunocytochemistry num
0.31636134.15033916.html.plaintext.txt	158	longest neurite combined length correlated highly r num
0.31636134.15033916.html.plaintext.txt	159	num combined length reported
0.31636134.15033916.html.plaintext.txt	160	one way anova showed significance estrogen treatment neurite extension fnumnum num
0.31636134.15033916.html.plaintext.txt	161	post hoc testing indicated num pm num nm estrogen significantly increased neuritic outgrowth compared control condition estradiol ethanol alone whereas response num nm estrogen differ control condition
0.31636134.15033916.html.plaintext.txt	162	therefore neuritic extension showed peak dosage effect estradiol apoe level
0.31636134.15033916.html.plaintext.txt	163	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	164	differential interference contrast digital image two adjacent neuron culture num div
0.31636134.15033916.html.plaintext.txt	165	typical appearance neuron adult mouse culture
0.31636134.15033916.html.plaintext.txt	166	previous study num used antineurofilament antibody confirm conclusion
0.31636134.15033916.html.plaintext.txt	167	note microglia lower left figure
0.31636134.15033916.html.plaintext.txt	168	apoe replacement neurite extension previous study shown apoe isoforms differential effect neurite outgrowth num num num num
0.31636134.15033916.html.plaintext.txt	169	experiment determined combined effect num pm estradiol apoe neurite growth culture apoe ko mouse fig
0.31636134.15033916.html.plaintext.txt	170	anova showed significant main effect estradiol neuritic length fnumnum num
0.31636134.15033916.html.plaintext.txt	171	num apoe isoform f num fnumnum p num
0.31636134.15033916.html.plaintext.txt	172	num interaction estradiol treatment apoe isoform fnumnum num
0.31636134.15033916.html.plaintext.txt	173	decomposition interaction term post hoc one way anova post hoc test showed apoenum apoenum alone increased combined neurite length num compared culture without apoe apoenum fnumnum num
0.31636134.15033916.html.plaintext.txt	174	apoenum differ apoenum post hoc testing
0.31636134.15033916.html.plaintext.txt	175	data replicate previous result num num
0.31636134.15033916.html.plaintext.txt	176	analysis estradiol group also showed isoform specific effect fnumnum num
0.31636134.15033916.html.plaintext.txt	177	bonferroni corrected post hoc testing showed combined neurite length ko group equivalent apoenum replacement group le apoenum p num
0.31636134.15033916.html.plaintext.txt	178	estradiol increased neuritic length combined apoenum num apoenum num absence apoe treatment apoenum
0.31636134.15033916.html.plaintext.txt	179	post hoc testing found difference apoenum apoenum significant p num
0.31636134.15033916.html.plaintext.txt	180	sum estradiol increased neurite outgrowth presence apoenum apoenum estradiol greater effect neurite growth presence apoenum compared apoenum
0.31636134.15033916.html.plaintext.txt	181	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	182	estradiol apoe isoform specific effect neuritic outgrowth culture derived apoe ko mouse
0.31636134.15033916.html.plaintext.txt	183	anova showed overall significant interaction apoe replacement estradiol treatment p num
0.31636134.15033916.html.plaintext.txt	184	post hoc testing found estradiol effect culture lacking apoe supplemented apoenum
0.31636134.15033916.html.plaintext.txt	185	inclusion apoenum apoenum absence estrogen significantly increased neuritic extent compared apoe apoenum
0.31636134.15033916.html.plaintext.txt	186	estradiol increased neurite outgrowth beyond apoe alone apoenum apoenum condition
0.31636134.15033916.html.plaintext.txt	187	addition neuritic extent significantly greater p num
0.31636134.15033916.html.plaintext.txt	188	num apoenum apoenum group line
0.31636134.15033916.html.plaintext.txt	189	estradiol effect neurite outgrowth tg mouse determine whether endogenously produced apoe isoforms differentially modulate estradiol induced neurite outgrowth added estradiol neuronal culture derived tg mouse expressing either apoenum apoenum
0.31636134.15033916.html.plaintext.txt	190	treatment neuronal culture estradiol secreted apoe level fig
0.31636134.15033916.html.plaintext.txt	191	numa comparable genotype fnumnum num
0.31636134.15033916.html.plaintext.txt	192	estradiol num pm significantly increased apoe level num culture genotype fnumnum num
0.31636134.15033916.html.plaintext.txt	193	interaction estradiol treatment apoe level two genotype fnumnum num
0.31636134.15033916.html.plaintext.txt	194	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	195	amount apoe produced estradiol stimulation apoe tg mouse
0.31636134.15033916.html.plaintext.txt	196	treatment num pm numss estradiol increased apoe level apoe tg mouse culture num compared vehicle treated culture
0.31636134.15033916.html.plaintext.txt	197	effect genotype specific
0.31636134.15033916.html.plaintext.txt	198	b neuritic extent apoe tg mouse
0.31636134.15033916.html.plaintext.txt	199	apoenum tg mouse culture greater combined neurite outgrowth apoenum tg mouse
0.31636134.15033916.html.plaintext.txt	200	estradiol increased difference
0.31636134.15033916.html.plaintext.txt	201	estradiol effect neuritic extent apoenum tg culture although increased apoe level equal estradiol treated apoenum tg culture
0.31636134.15033916.html.plaintext.txt	202	combined length neurites fig
0.31636134.15033916.html.plaintext.txt	203	numb significantly greater apoenum tg apoenum tg mouse culture fnumnum num
0.31636134.15033916.html.plaintext.txt	204	estradiol treatment increased total length fnumnum num
0.31636134.15033916.html.plaintext.txt	205	significant interaction genotype estradiol treatment
0.31636134.15033916.html.plaintext.txt	206	effect combined neuritic length apoenum tg mouse culture whereas neuritic extent increased apoenum tg mouse culture fnumnum num
0.31636134.15033916.html.plaintext.txt	207	essence neurites longer culture apoenum tg mouse estradiol increased differential culture apoenum tg mouse
0.31636134.15033916.html.plaintext.txt	208	apoelipid uptake study experiment evaluated rate internalization two apoe isoforms apoenum apoenum adult culture model replicate previous result higher concentration apoe neuroblastoma cell num
0.31636134.15033916.html.plaintext.txt	209	also evaluated rate uptake fluorescently labeled fatty acid function apoe isoform
0.31636134.15033916.html.plaintext.txt	210	le intracellular accumulation apoenum apoenum fig
0.31636134.15033916.html.plaintext.txt	211	apoe like immunoreactivity within neuron incubated apoenum significantly greater fnumnum num
0.31636134.15033916.html.plaintext.txt	212	num apoenum previously reported num
0.31636134.15033916.html.plaintext.txt	213	anova showed neither significant effect time post addition apoe fnumnum num
0.31636134.15033916.html.plaintext.txt	214	num interaction time type apoe fnumnum num
0.31636134.15033916.html.plaintext.txt	215	apoe like immunoreactivity intense cell body extended process vesicular like accumulation fig
0.31636134.15033916.html.plaintext.txt	216	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	217	accumulation apoe isoforms neuron
0.31636134.15033916.html.plaintext.txt	218	anova showed significant effect apoe type p num
0.31636134.15033916.html.plaintext.txt	219	apoenum immunoreactivity found within neuron apoenum
0.31636134.15033916.html.plaintext.txt	220	factor reached statistical significance
0.31636134.15033916.html.plaintext.txt	221	b lipid accumulation num h incubation apoe isoforms absence apoe ko
0.31636134.15033916.html.plaintext.txt	222	recombinant apoenum facilitated fluorescently labeled dodecanoic acid accumulation neuron compared recombinant apoenum
0.31636134.15033916.html.plaintext.txt	223	post hoc testing showed apoenum apoenum apoe ko total lipid uptake
0.31636134.15033916.html.plaintext.txt	224	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	225	immunofluoresence localization apoenum apoenum neuron
0.31636134.15033916.html.plaintext.txt	226	neuronal internalization apoenum le efficient apoenum
0.31636134.15033916.html.plaintext.txt	227	time zero b intensity intracellular immunoreactivity apoenum apoenum roughly comparable
0.31636134.15033916.html.plaintext.txt	228	greater uptake apoe num enum seen num h c d
0.31636134.15033916.html.plaintext.txt	229	apoe also present vesicular like structure neurites
0.31636134.15033916.html.plaintext.txt	230	comparable apoe isoform specific effect fatty acid accumulation neuron present fnumnumnum
0.31636134.15033916.html.plaintext.txt	231	accumulation fluorescent lipid cell cultured apoenum approximately twice p num
0.31636134.15033916.html.plaintext.txt	232	num post hoc test cell treated apoenum displayed vesicular appearance process neuron apoe fig
0.31636134.15033916.html.plaintext.txt	233	apoenum roughly doubled p num
0.31636134.15033916.html.plaintext.txt	234	num post hoc test amount lipid internalized compared absence apoe fig
0.31636134.15033916.html.plaintext.txt	235	apoenum much le effective apoenum intracellular transport lipid although effective apoe treatment
0.31636134.15033916.html.plaintext.txt	236	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	237	uptake fluorescently labeled dodecanoic acid
0.31636134.15033916.html.plaintext.txt	238	uptake absence apoe le apoenum b apoenum c present
0.31636134.15033916.html.plaintext.txt	239	perikaryal size equivalent condition appears greater apoenum fluorescent lipid cell body
0.31636134.15033916.html.plaintext.txt	240	note fluorescence vesicular like neurites
0.31636134.15033916.html.plaintext.txt	241	receptor inhibition apoe uptake experiment performed determine receptor specificity apoe uptake adult neuronal culture
0.31636134.15033916.html.plaintext.txt	242	neither apoenum apoenum like immunoreactivity found neuron treated heparinase therefore statistical analysis performed
0.31636134.15033916.html.plaintext.txt	243	repeated measure anova apoe accumulation neuron rap lac compared inhibitor inhibition condition repeated measure showed significant main effect apoe isoform fnumnum num
0.31636134.15033916.html.plaintext.txt	244	overall le apoenum entered neuron apoenum
0.31636134.15033916.html.plaintext.txt	245	significant effect inhibitor compared inhibitor found fnumnum num
0.31636134.15033916.html.plaintext.txt	246	addition significant interaction isoform inhibitor fnumnum num
0.31636134.15033916.html.plaintext.txt	247	calculating percent inhibition fig
0.31636134.15033916.html.plaintext.txt	248	numb untreated condition showed lac inhibited apoenum uptake num apoenum uptake num
0.31636134.15033916.html.plaintext.txt	249	contrast rap inhibited apoenum uptake num apoenum num
0.31636134.15033916.html.plaintext.txt	250	view larger version numk fig
0.31636134.15033916.html.plaintext.txt	251	inhibition apoe immunoreactivity cell lac rap
0.31636134.15033916.html.plaintext.txt	252	note rap greater effect apoenum apoenum
0.31636134.15033916.html.plaintext.txt	253	roughly equivalent inhibitory effect apoe isoforms shown lac
0.31636134.15033916.html.plaintext.txt	254	b plotting inhibition b emphasizes differential effect rap apoenum v
0.31636134.15033916.html.plaintext.txt	255	previous data suggest glia primary source apoe num num num study apoe tg mouse support
0.31636134.15033916.html.plaintext.txt	256	therefore selected mixed culture derived adult mouse brain evaluate estradiol effect apoe level neuronal process growth
0.31636134.15033916.html.plaintext.txt	257	adult cortical neuronal culture contain microglia astroglia early culture
0.31636134.15033916.html.plaintext.txt	258	previous study showed neuron comprise num total cell astroglia num microglia num num div num
0.31636134.15033916.html.plaintext.txt	259	glial derived factor important synaptogenesis see ref
0.31636134.15033916.html.plaintext.txt	260	num inclusion glia culture may required see broader spectrum effect estrogen neuron vitro
0.31636134.15033916.html.plaintext.txt	261	example previous report shown microglia astroglia must present obtain estrogen induced increase apoe mrna num
0.31636134.15033916.html.plaintext.txt	262	hence monotypic cell culture may give biased interpretation critical estradiol effect interaction exist glia neuron
0.31636134.15033916.html.plaintext.txt	263	data previous study suggest direct relationship apoe neurite outgrowth num num num num num
0.31636134.15033916.html.plaintext.txt	264	found physiological concentration estradiol maximal effect apoe level neurite outgrowth
0.31636134.15033916.html.plaintext.txt	265	data also suggest synergistic effect estradiol apoe estradiol effect neurite outgrowth facilitated apoenum apoenum
0.31636134.15033916.html.plaintext.txt	266	apoenum alone increased neurite extent num
0.31636134.15033916.html.plaintext.txt	267	combined estradiol neuritic growth increased num num
0.31636134.15033916.html.plaintext.txt	268	addition apoenum significantly effective apoenum facilitating neurite outgrowth presence estradiol
0.31636134.15033916.html.plaintext.txt	269	effect corresponds study suggest protective effect apoenum dementia see ref
0.31636134.15033916.html.plaintext.txt	270	addition differential effect apoenum v
0.31636134.15033916.html.plaintext.txt	271	apoenum confirmed using tg mouse expressing apoenum apoenum
0.31636134.15033916.html.plaintext.txt	272	estrogen increased level apoenum apoenum similar extent adult culture derived apoenum apoenum tg mouse however apoenum isoform effective facilitating neurite outgrowth presence estradiol
0.31636134.15033916.html.plaintext.txt	273	partial mechanism differential effect apoenum apoenum suggested uptake study
0.31636134.15033916.html.plaintext.txt	274	procedure used preparing adult culture strip cell process
0.31636134.15033916.html.plaintext.txt	275	next num d extensive neurite sprouting occurs
0.31636134.15033916.html.plaintext.txt	276	estradiol may stimulate neuron extend process concurrently stimulate astroglia perhaps microglia produce apoe
0.31636134.15033916.html.plaintext.txt	277	glial derived apoe supply lipid neuronal membrane synthesis function
0.31636134.15033916.html.plaintext.txt	278	receptor inhibition study suggest apoenum apoenum using low density lipoprotein receptor related protein hspg neurite outgrowth num num
0.31636134.15033916.html.plaintext.txt	279	however neuronal growth slowed disrupted absence apoe presence apoenum
0.31636134.15033916.html.plaintext.txt	280	worth noting apoenum reported show toxic effect culture num disrupt microtubule polymerization although num fold higher concentration used study num
0.31636134.15033916.html.plaintext.txt	281	hence le complex neuritic field seen cell incubated apoenum may represent deficiency lipid combination toxic effect apoenum
0.31636134.15033916.html.plaintext.txt	282	process extension neuronal repair vivo may critical factor rate progression chronic neurological disease
0.31636134.15033916.html.plaintext.txt	283	dementia trauma degeneration repair may dynamic balance
0.31636134.15033916.html.plaintext.txt	284	dementia cognitive decline may occur degenerative process exceed regenerative response
0.31636134.15033916.html.plaintext.txt	285	apoenum may tip scale slower incomplete regeneration accelerate cognitive decline rapidly apoenum apoenum
0.31636134.15033916.html.plaintext.txt	286	interest apoenum shown dominant negative factor mouse expressing apoenum apoenum num num
0.31636134.15033916.html.plaintext.txt	287	ert may le protective num allele previously noted num
0.31636134.15033916.html.plaintext.txt	288	full benefit ert protection chronic neurological disease may compromised presence apoenum
0.31636134.15033916.html.plaintext.txt	289	clinical study evaluate protective effect ert estradiol like compound may need consider apoe genotype obtain optimal efficacy
0.31636134.15033916.html.plaintext.txt	290	acknowledgment gfap apoenum gfap apoenum tg mouse generously provided dr
0.31636134.15033916.html.plaintext.txt	291	holtzman washington university st
0.31636134.15033916.html.plaintext.txt	292	rap generous gift dr
0.31636134.15033916.html.plaintext.txt	293	dudley strickland american red cross rockville md
0.31636134.15033916.html.plaintext.txt	294	footnote research funded illinois department public health alzheimer fund b
0.31636134.15033916.html.plaintext.txt	295	national institute health academic research enhancement award b
0.31636134.15033916.html.plaintext.txt	296	eastern illinois university council faculty research grant b
0.31636134.15033916.html.plaintext.txt	297	southern illinois university school medicine central research committee r
0.31636134.15033916.html.plaintext.txt	298	abbreviation apoe apolipoprotein e div day vitro ert estrogen replacement therapy gfap glial fibrillary acidic protein ha hibernate hspg heparan sulfate proteoglycan ko knockout lac lactoferrin pd parkinson disease rap receptor associated protein tg transgenic
0.31636134.15033916.html.plaintext.txt	299	accepted publication march num num
0.3207539.15509658.html.plaintext.txt	0	apoe mediated cholesterol efflux macrophage separation autocrine paracrine effect dwayne e
0.3207539.15509658.html.plaintext.txt	1	lintonnumnum sergio fazionumnum
0.3207539.15509658.html.plaintext.txt	2	numdepartment pathology numdivision cardiovascular medicine department medicine numdepartment pharmacology vanderbilt university medical center nashville tennessee
0.3207539.15509658.html.plaintext.txt	3	submitted num april num accepted final form num october num
0.3207539.15509658.html.plaintext.txt	4	autocrineparacrine system cholesterol acceptor extracellular space distribution volume
0.3207539.15509658.html.plaintext.txt	5	important challenge atherosclerosis research characterization effect locally synthesized apolipoprotein e apoe within vessel wall
0.3207539.15509658.html.plaintext.txt	6	endogenous synthesis secretion apoe macrophage vessel wall shown protect atherosclerosis num
0.3207539.15509658.html.plaintext.txt	7	arterial macrophage participate inflammation tissue remodeling lipid metabolism
0.3207539.15509658.html.plaintext.txt	8	apoe synthesized hepatocytes adipocytes macrophage mediates lipoprotein metabolism affect cellular cholesterol homeostasis
0.3207539.15509658.html.plaintext.txt	9	apoe macrophage accepts cholesterol cell vessel wall transport back liver cholesterol excreted bile num num
0.3207539.15509658.html.plaintext.txt	10	pathway called reverse cholesterol transport rct system
0.3207539.15509658.html.plaintext.txt	11	effect apoe due cellular extracellular positioning therefore apoe molecule mediate cholesterol efflux macrophage originally secreted autocrine effect surrounding macrophage paracrine effect
0.3207539.15509658.html.plaintext.txt	12	term autocrine paracrine traditionally applied signaling peptide hormone also used describe action mediator broad range function besides signal transduction num num num
0.3207539.15509658.html.plaintext.txt	13	assumed sake cholesterol efflux individual macrophage distinguish apoe secretes apoe derived neighboring cell
0.3207539.15509658.html.plaintext.txt	14	however endogenous synthesis apoe cause high spatial proximity autocrine apoe advantage compared paracrine apoe
0.3207539.15509658.html.plaintext.txt	15	spatial proximity advantage endogenous apoe result temporal sequence autocrine effect occurring paracrine effect concentration gradient autocrine compartment high concentration paracrine compartment low concentration
0.3207539.15509658.html.plaintext.txt	16	making comparison autocrine paracrine effect apoe synthesized macrophage proven difficult
0.3207539.15509658.html.plaintext.txt	17	vitro experiment cultured macrophage exogenously applied apoe used approximate paracrine endocrine apoe num num
0.3207539.15509658.html.plaintext.txt	18	endogenously synthesized apoe used approximate autocrine apoe num num num
0.3207539.15509658.html.plaintext.txt	19	approximation consider single molecule endogenously synthesized mediator series interaction employ combination autocrine paracrine mechanism num
0.3207539.15509658.html.plaintext.txt	20	novel methodology discussed developed separate autocrine paracrine mechanism using simple mathematical model interpret mediator induced biological effect
0.3207539.15509658.html.plaintext.txt	21	study show whereas macrophage apoe autocrine paracrine effect cholesterol efflux autocrine apoe smaller consistent effect paracrine apoe
0.3207539.15509658.html.plaintext.txt	22	whereas macrophage apoe used demonstrate novel methodology concept application separating autocrine paracrine effect many secreted biological mediator including growth factor cytokine carrier protein
0.3207539.15509658.html.plaintext.txt	23	ewtcholesterol efflux efflux apoe macrophage
0.3207539.15509658.html.plaintext.txt	24	ekocholesterol efflux efflux apoe macrophage
0.3207539.15509658.html.plaintext.txt	25	eapoe mediated cholesterol efflux efflux
0.3207539.15509658.html.plaintext.txt	26	vvolume extracellular space ml
0.3207539.15509658.html.plaintext.txt	27	v numrelative concentration ml num apoe extracellular space
0.3207539.15509658.html.plaintext.txt	28	mslope effluxml num linear e v
0.3207539.15509658.html.plaintext.txt	29	intercept efflux linear e v
0.3207539.15509658.html.plaintext.txt	30	ceffective concentration ml num apoe juxtacellular space
0.3207539.15509658.html.plaintext.txt	31	nslope ml numnum h bt v
0.3207539.15509658.html.plaintext.txt	32	fy intercept effluxnum h bt v
0.3207539.15509658.html.plaintext.txt	33	kecoefficient ml num apoe mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	34	kicoefficient ml num apoe mediated cholesterol influx
0.3207539.15509658.html.plaintext.txt	35	lipoprotein preparation chemical modification
0.3207539.15509658.html.plaintext.txt	36	lipoprotein isolated human blood plasma sequential ultracentrifugation density num
0.3207539.15509658.html.plaintext.txt	37	ldl dialyzed num degree c lipoprotein buffer num
0.3207539.15509658.html.plaintext.txt	38	acldl prepared repeated addition acetic anhydride ldl num
0.3207539.15509658.html.plaintext.txt	39	modification reaction acldl dialyzed lipoprotein buffer
0.3207539.15509658.html.plaintext.txt	40	lipoprotein specie modification confirmed electrophoretic mobility agarose gel
0.3207539.15509658.html.plaintext.txt	41	protein concentration determined modified lowry assay num
0.3207539.15509658.html.plaintext.txt	42	modified lipoprotein filtered num
0.3207539.15509658.html.plaintext.txt	43	num microm syringe filter immediately applied cultured cell
0.3207539.15509658.html.plaintext.txt	44	macrophage labeled num microciml numnum numhncholesterol perkin elmer life science boston ma dmem num h num num
0.3207539.15509658.html.plaintext.txt	45	apoe apoe macrophage num
0.3207539.15509658.html.plaintext.txt	46	num microg total cholesterolmg cell protein respectively
0.3207539.15509658.html.plaintext.txt	47	apoe apoe macrophage num
0.3207539.15509658.html.plaintext.txt	48	num cpmmg cell protein respectively
0.3207539.15509658.html.plaintext.txt	49	labeled macrophage rinsed three time dmem num
0.3207539.15509658.html.plaintext.txt	50	efflux period initiated addition dmem acceptor num
0.3207539.15509658.html.plaintext.txt	51	efflux medium removed efflux period num num num num h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	52	remaining cellular numhcholesterol harvested rinsing cell pb lysing cell num
0.3207539.15509658.html.plaintext.txt	53	count cpm medium lysate detected beckman l numic scintillation counter ecolite scintillation fluid icn costa mesa ca
0.3207539.15509658.html.plaintext.txt	54	cholesterol efflux calculated count medium percentage total count medium lysate
0.3207539.15509658.html.plaintext.txt	55	difference cholesterol efflux e apoe ko apoe wt macrophage considered cholesterol efflux specifically mediated apoe
0.3207539.15509658.html.plaintext.txt	56	western blot analysis secreted apoe
0.3207539.15509658.html.plaintext.txt	57	macrophage incubated dmem acceptor num
0.3207539.15509658.html.plaintext.txt	58	num ml num h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	59	apoe extracted total volume culture medium liposorb gel calbiochem san diego ca
0.3207539.15509658.html.plaintext.txt	60	western blot analysis secreted apoe extracted apoe separated num num nupage bi tris gel invitrogen carlsbad ca transferred nitrocellulose membrane
0.3207539.15509658.html.plaintext.txt	61	apoe detected anti murine apoe rabbit antiserum visualized chemiluminescent ecl plus amersham bioscience piscataway nj
0.3207539.15509658.html.plaintext.txt	62	numc labeled adenine release assay cellular toxicity
0.3207539.15509658.html.plaintext.txt	63	cytotoxicity cultured macrophage assayed measuring release numc labeled adenine num
0.3207539.15509658.html.plaintext.txt	64	cell labeled num h dmem num
0.3207539.15509658.html.plaintext.txt	65	num microciml u numcadenine amersham bioscience
0.3207539.15509658.html.plaintext.txt	66	cell rinsed three time dmem
0.3207539.15509658.html.plaintext.txt	67	release period initiated addition dmem
0.3207539.15509658.html.plaintext.txt	68	medium removed release period num h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	69	cellular numcadenine harvested rinsing cell pb lysing cell num
0.3207539.15509658.html.plaintext.txt	70	sample aliquot loaded ecolite scintillation fluid numcadenine count detected beckman l numic scintillation counter
0.3207539.15509658.html.plaintext.txt	71	adenine release calculated medium numcadenine count expressed percentage total count lysate medium
0.3207539.15509658.html.plaintext.txt	72	manipulate extracellular concentration endogenously synthesized biological mediator volume dependence theory take advantage implicit relationship concentration distribution volume
0.3207539.15509658.html.plaintext.txt	73	concentration secreted mediator apoe proportional reciprocal extracellular distribution volume
0.3207539.15509658.html.plaintext.txt	74	increasing distribution volume v cause decrease relative concentration v num secreted mediator
0.3207539.15509658.html.plaintext.txt	75	varying extracellular volume given number cell fig
0.3207539.15509658.html.plaintext.txt	76	numa allows juxtacellular extracellular mechanism synthesized mediator mathematically separated characterized
0.3207539.15509658.html.plaintext.txt	77	theory illustrated graphically follows
0.3207539.15509658.html.plaintext.txt	78	plot biological effect e v
0.3207539.15509658.html.plaintext.txt	79	extracellular volume v extracellular volume increased effect decrease asymptotically plateau represents portion total effect independent extracellular volume fig
0.3207539.15509658.html.plaintext.txt	80	value plateau y intercept b plot biological effect e v
0.3207539.15509658.html.plaintext.txt	81	reciprocal volume v num fig
0.3207539.15509658.html.plaintext.txt	82	dose response curve linear low relative concentration v num fit linear equation
0.3207539.15509658.html.plaintext.txt	83	view larger version numk fig
0.3207539.15509658.html.plaintext.txt	84	theoretical basis separation autocrine paracrine effect apolipoprotein e apoe cholesterol efflux
0.3207539.15509658.html.plaintext.txt	85	experimental design change relative concentration apoe increasing extracellular distribution volume
0.3207539.15509658.html.plaintext.txt	86	b dependence effect apoe distribution volume
0.3207539.15509658.html.plaintext.txt	87	c dependence effect apoe reciprocal volume
0.3207539.15509658.html.plaintext.txt	88	effect apoe depend relative concentration extracellular distribution volume paracrine
0.3207539.15509658.html.plaintext.txt	89	effect occur solely juxtacellular space independent extracellular distribution volume autocrine
0.3207539.15509658.html.plaintext.txt	90	data expressed mean plus minus sd
0.3207539.15509658.html.plaintext.txt	91	mean compared student test
0.3207539.15509658.html.plaintext.txt	92	curve analyzed linear regression
0.3207539.15509658.html.plaintext.txt	93	view larger version numk fig
0.3207539.15509658.html.plaintext.txt	94	volume dependence apoe mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	95	b volume v dependence relative concentration v num dependence b cholesterol efflux apoe apoe macrophage apoe mediated efflux
0.3207539.15509658.html.plaintext.txt	96	value expressed mean plus minus sd num sample efflux apoe apoe macrophage
0.3207539.15509658.html.plaintext.txt	97	statistically significant difference p num
0.3207539.15509658.html.plaintext.txt	98	c linear fit apoe mediated efflux e v
0.3207539.15509658.html.plaintext.txt	99	reciprocal volume num num num num h
0.3207539.15509658.html.plaintext.txt	100	volume independent volume dependent apoe effect contribute cholesterol efflux
0.3207539.15509658.html.plaintext.txt	101	volume dependence apoe secretion
0.3207539.15509658.html.plaintext.txt	102	western blot analysis performed determine whether change apoe secretion related trend efflux
0.3207539.15509658.html.plaintext.txt	103	determine whether macrophage secreted equal mass apoe apoe extracted culture medium
0.3207539.15509658.html.plaintext.txt	104	densitometric analysis macrophage cultured higher medium volume num
0.3207539.15509658.html.plaintext.txt	105	num ml secreted similar amount apoe per cell culture suggesting size distribution volume effect apoe secretion fig
0.3207539.15509658.html.plaintext.txt	106	however macrophage cultured smaller volume num
0.3207539.15509658.html.plaintext.txt	107	num ml secreted apoe per cell culture
0.3207539.15509658.html.plaintext.txt	108	view larger version numk fig
0.3207539.15509658.html.plaintext.txt	109	volume dependence apoe secretion macrophage viability
0.3207539.15509658.html.plaintext.txt	110	secretion apoe per cell culture viability apoe macrophage varying volume b reciprocal volume c shown
0.3207539.15509658.html.plaintext.txt	111	value expressed mean plus minus sd num sample adenine release apoe macrophage
0.3207539.15509658.html.plaintext.txt	112	volume dependence cellular viability
0.3207539.15509658.html.plaintext.txt	113	numcadenine release study performed determine whether change viability related trend efflux apoe secretion
0.3207539.15509658.html.plaintext.txt	114	viability increased smaller distribution volume indicated higher amount numcadenine remaining fig
0.3207539.15509658.html.plaintext.txt	115	viability increased log linear fashion rnum num
0.3207539.15509658.html.plaintext.txt	116	num increasing reciprocal volume fig
0.3207539.15509658.html.plaintext.txt	117	log linear trend viability different linear trend efflux
0.3207539.15509658.html.plaintext.txt	118	model apoe mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	119	limited number assumption mathematical model generated suggests physical model autocrine paracrine effect apoe cholesterol efflux
0.3207539.15509658.html.plaintext.txt	120	num assumes difference primary effect apoe secondary effect change cellular cholesterol homeostasis
0.3207539.15509658.html.plaintext.txt	121	change viability change membrane fluidity
0.3207539.15509658.html.plaintext.txt	122	num assume evaporation extracellular distribution volume negligible
0.3207539.15509658.html.plaintext.txt	123	however evaporation determined num
0.3207539.15509658.html.plaintext.txt	124	evaporation rate affect calculation e calculation v num
0.3207539.15509658.html.plaintext.txt	125	factoring evaporation rate change trend data
0.3207539.15509658.html.plaintext.txt	126	however evaporation correction necessary estimate parameter mathematical model data shown
0.3207539.15509658.html.plaintext.txt	127	extrapolation concentration dependence line common x intercept observed assigned value negative c num
0.3207539.15509658.html.plaintext.txt	128	common x intercept c num line fit eq
0.3207539.15509658.html.plaintext.txt	129	num yield following equation
0.3207539.15509658.html.plaintext.txt	130	num reveals concentration dependence line combined one equation function time rather contained within four unrelated equation
0.3207539.15509658.html.plaintext.txt	131	would expected secretion apoe function time therefore apoe mediated effect would also function time
0.3207539.15509658.html.plaintext.txt	132	y intercept represents autocrine effect result constant rate secretion apoe normalizing y intercept time would reveal constant f
0.3207539.15509658.html.plaintext.txt	133	num normalized y intercept bt however constant time point num
0.3207539.15509658.html.plaintext.txt	134	plot normalized y intercept bt v
0.3207539.15509658.html.plaintext.txt	135	corresponding slope m reveals unexpected relationship linear n num
0.3207539.15509658.html.plaintext.txt	136	num determined linear regression analysis expressed
0.3207539.15509658.html.plaintext.txt	137	num equation num num num combined generate function describe effect apoe cholesterol efflux interpreted mechanistically compartmentalized manner
0.3207539.15509658.html.plaintext.txt	138	num equation num fit experimental data fig
0.3207539.15509658.html.plaintext.txt	139	num express apoe mediated cholesterol efflux product capacity ft system ratio two coefficient efflux coefficient ke v num c influx coefficient ki c nt
0.3207539.15509658.html.plaintext.txt	140	basis mathematical model biological model proposed fig
0.3207539.15509658.html.plaintext.txt	141	view larger version numk fig
0.3207539.15509658.html.plaintext.txt	142	mathematical trend apoe mediated cholesterol efflux data
0.3207539.15509658.html.plaintext.txt	143	common x intercept c num arrow line apoe mediated efflux v
0.3207539.15509658.html.plaintext.txt	144	b kinetics apoe mediated efflux distribution volume num
0.3207539.15509658.html.plaintext.txt	145	experimental data fit eq
0.3207539.15509658.html.plaintext.txt	146	num experimentally estimated value parameter effective apoe concentration c slope n y intercept f
0.3207539.15509658.html.plaintext.txt	147	c correlation experimental theoretical value proposed model apoe mediated efflux eq
0.3207539.15509658.html.plaintext.txt	148	view larger version numk fig
0.3207539.15509658.html.plaintext.txt	149	proposed model apoe mediated cholesterol efflux autocrine paracrine effect
0.3207539.15509658.html.plaintext.txt	150	num compartment secreted apoe distributed juxtacellular space extracellular space
0.3207539.15509658.html.plaintext.txt	151	endogenously synthesized apoe initially distributed juxtacellular space accepts cholesterol autocrine fashion
0.3207539.15509658.html.plaintext.txt	152	apoe eventually distributed extracellular space accepts cholesterol paracrine fashion sensitive volume cell cultured
0.3207539.15509658.html.plaintext.txt	153	determining volume independent effect cholesterol efflux distinguish autocrine action apoe paracrine action
0.3207539.15509658.html.plaintext.txt	154	ke coefficient apoe mediated efflux ki coefficient apoe mediated influx
0.3207539.15509658.html.plaintext.txt	155	study suggests autocrine apoe advantage biologically relevant
0.3207539.15509658.html.plaintext.txt	156	even extracellular space saturated apoe least num num apoe mediated cholesterol efflux result volume independent interaction endogenous apoe table num
0.3207539.15509658.html.plaintext.txt	157	num found apoe deficient cell exogenous application apoe num time concentration normal endogenous apoe secretion increase cholesterol efflux much normal endogenous apoe secretion apoe producing cell
0.3207539.15509658.html.plaintext.txt	158	fundamental importance medium transfer study show exogenous apoe paracrine equivalent endogenous apoe autocrine paracrine
0.3207539.15509658.html.plaintext.txt	159	macrophage endogenously synthesized apoe advantage autocrine apoe may become critical homeostasis challenged cholesterol loading conditioned space large making apoe diluted turnover conditioned space high interstitial flow macrophage isolated macrophage
0.3207539.15509658.html.plaintext.txt	160	interstitial concentration distribution volume turnover macrophage apoe vessel wall known
0.3207539.15509658.html.plaintext.txt	161	factor critical interpretation data vitro cell culture system generalization data biology macrophage vivo
0.3207539.15509658.html.plaintext.txt	162	example trend viability may related change apoe secretion observed low volume fig
0.3207539.15509658.html.plaintext.txt	163	log linear trend viability fig
0.3207539.15509658.html.plaintext.txt	164	numc may due relative concentration confounding mediator like growth factor culture gas e
0.3207539.15509658.html.plaintext.txt	165	conum varying distribution volume
0.3207539.15509658.html.plaintext.txt	166	apoe mediator secreted system necessary subtract effect confounding mediator
0.3207539.15509658.html.plaintext.txt	167	apoe macrophage compared apoe macrophage specific apoe effect calculated apoe mediated cholesterol efflux e
0.3207539.15509658.html.plaintext.txt	168	effect confounding mediator cholesterol efflux minimal fig
0.3207539.15509658.html.plaintext.txt	169	although major role apoe extracellular cholesterol acceptor also possible portion effect apoe cholesterol efflux consequence action apoe receptor proteoglycan binding num intracellular cholesterol routing num even stabilization cytoskeleton num
0.3207539.15509658.html.plaintext.txt	170	irrespective ultimate mechanism combination effect may responsible modulation cholesterol efflux apoe occur either autocrine paracrine event therefore addressed whole study
0.3207539.15509658.html.plaintext.txt	171	although volume dependence apoe secretion viability could explain volume dependent trend apoe mediated efflux fig
0.3207539.15509658.html.plaintext.txt	172	numc data definitely underscore sensitivity biological process vitro culture volume
0.3207539.15509658.html.plaintext.txt	173	higher order characteristic macrophage tissue could overlooked vitro study macrophage
0.3207539.15509658.html.plaintext.txt	174	example aggregate macrophage may become tissue work autocrine efficiency instead sum autocrineparacrine cellular unit
0.3207539.15509658.html.plaintext.txt	175	spatial range autocrine effect num important another cell within range possibility autocrine cooperation
0.3207539.15509658.html.plaintext.txt	176	possibility could explored vitro vivo study effect geometry density cell aggregate apoe mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	177	compared exogenous lipoprotein bound apoe hepatic origin local secretion lipid free apoe macrophage result decreased atherosclerosis due small amount apoe critical location num num
0.3207539.15509658.html.plaintext.txt	178	num wt mouse transplanted apoe bone marrow
0.3207539.15509658.html.plaintext.txt	179	chimeric mouse normal plasma apoe macrophage apoe production vessel wall
0.3207539.15509658.html.plaintext.txt	180	although immunocytochemical staining lesion wt macrophage reveals high apoe level chimeric mouse plasma apoe little apoe lesion
0.3207539.15509658.html.plaintext.txt	181	lack staining plasma derived apoe within artery wall suggests penetration cluster macrophage limited
0.3207539.15509658.html.plaintext.txt	182	macrophage plasma derived apoe primary source apoe rct num num num
0.3207539.15509658.html.plaintext.txt	183	along line paracrine apoe may able fulfill critical action small amount autocrine apoe juxtacellular space possibly even intracellular space
0.3207539.15509658.html.plaintext.txt	184	apoe recycling internalization resecretion apoe num num num reported mediate cholesterol efflux hepatocytes macrophage num
0.3207539.15509658.html.plaintext.txt	185	methodology study unable resolve internal autocrine num intracrine num num mechanism could mediated intracellular apoe
0.3207539.15509658.html.plaintext.txt	186	num macrophage secrete apoe create extracellular sink cellular cholesterol
0.3207539.15509658.html.plaintext.txt	187	capacity concentration compartmentalization sink affect cholesterol efflux fig
0.3207539.15509658.html.plaintext.txt	188	sink capacity ft expands apoe secreted
0.3207539.15509658.html.plaintext.txt	189	sink separated two compartment consequence location apoe juxtacellular extracellular space also described secretion layer bulk layer respectively num num
0.3207539.15509658.html.plaintext.txt	190	dilution apoe move extracellular space diminishes efficacy
0.3207539.15509658.html.plaintext.txt	191	apoe mediated efflux e balance efflux influx cholesterol
0.3207539.15509658.html.plaintext.txt	192	efflux depends sink capacity ft concentration extracellular apoe v num functional concentration juxtacellular apoe c
0.3207539.15509658.html.plaintext.txt	193	influx depends cholesterol apoe sink e functional concentration juxtacellular apoe ki
0.3207539.15509658.html.plaintext.txt	194	decrease functional concentration apoe contribute influx nt may represent change capacitance apoe due accumulation phospholipid stabilize cholesterol proteolytic alteration apoe
0.3207539.15509658.html.plaintext.txt	195	also possible n artifact slight change viability apoe secretion
0.3207539.15509658.html.plaintext.txt	196	many document found literature search term autocrine term autocrine andor paracrine describe proposed mechanism action
0.3207539.15509658.html.plaintext.txt	197	difficult quantitatively separate two mechanism experimentally
0.3207539.15509658.html.plaintext.txt	198	traditional approach problem limitation rely simple qualitative assessment
0.3207539.15509658.html.plaintext.txt	199	traditional methodology used study macrophage apoe include characterizing tissue distribution apoe num measuring effect endogenous synthesis apoe v
0.3207539.15509658.html.plaintext.txt	200	complete absence num measuring effect endogenous synthesis v
0.3207539.15509658.html.plaintext.txt	201	exogenous application apoe num num
0.3207539.15509658.html.plaintext.txt	202	method useful comparative assessment unable simultaneously quantify serial effect mediated apoe secreted biological mediator
0.3207539.15509658.html.plaintext.txt	203	present study performed experiment based theory portion endogenous acceptor mediates autocrine effect diluted
0.3207539.15509658.html.plaintext.txt	204	previous study utilized experimental strategy similar one used study
0.3207539.15509658.html.plaintext.txt	205	num performed volume dependence experiment study whether efflux exogenous acceptor proceeded aqueous diffusion cholesterol acceptor membrane collision
0.3207539.15509658.html.plaintext.txt	206	found certain type acceptor efflux approached volume insensitive plateau proposed type acceptor may site efficient collisional transfer num
0.3207539.15509658.html.plaintext.txt	207	study endogenously synthesized acceptor suggest site may combination binding site membrane enriched aqueous layer around membrane
0.3207539.15509658.html.plaintext.txt	208	num used theoretical model study escape autocrine signaling ligand extracellular space
0.3207539.15509658.html.plaintext.txt	209	found model ligand receptor signaling system varying volume height show little effect ligand concentration
0.3207539.15509658.html.plaintext.txt	210	remains seen whether dilution methodology discussed change mediator concentration large dynamic range many order magnitude log linear dose response curve seen ligand receptor signaling pathway
0.3207539.15509658.html.plaintext.txt	211	summary study separate quantifies autocrine paracrine effect apoe cholesterol efflux macrophage
0.3207539.15509658.html.plaintext.txt	212	data suggest relative importance autocrine paracrine apoe depends size local distribution volume autocrine effect remaining constant even paracrine effect diminished dilution apoe
0.3207539.15509658.html.plaintext.txt	213	footnote address reprint request correspondence
0.3207539.15509658.html.plaintext.txt	214	cardiovascular medicine num preston research bldg
0.3207539.15509658.html.plaintext.txt	215	nashville tn num num e mail sergio
0.3207539.15509658.html.plaintext.txt	216	cost publication article defrayed part payment page charge
0.3207539.15509658.html.plaintext.txt	217	article must therefore hereby marked advertisement accordance num u
0.3207539.15509658.html.plaintext.txt	218	section num solely indicate fact
0.3207539.15509658.html.plaintext.txt	219	basu sk goldstein jl anderson gw brown m
0.3207539.15509658.html.plaintext.txt	220	degradation cationized low density lipoprotein regulation cholesterol metabolism homozygous familial hypercholesterolemia fibroblast
0.3207539.15509658.html.plaintext.txt	221	proc natl acad sci usa num num num num
0.3207539.15509658.html.plaintext.txt	222	basu sk goldstein jl brown m
0.3207539.15509658.html.plaintext.txt	223	independent pathway secretion cholesterol apolipoprotein e macrophage
0.3207539.15509658.html.plaintext.txt	224	batsilas l berezhkovskii shvartsman sy
0.3207539.15509658.html.plaintext.txt	225	stochastic model autocrine paracrine signal cell culture assay
0.3207539.15509658.html.plaintext.txt	226	biophys j num num num num
0.3207539.15509658.html.plaintext.txt	227	blum cb aron l sciacca r
0.3207539.15509658.html.plaintext.txt	228	radioimmunoassay study human apolipoprotein e
0.3207539.15509658.html.plaintext.txt	229	j clin invest num num num num
0.3207539.15509658.html.plaintext.txt	230	brecht wj harris fm chang tesseur yu gq xu q dee fish j wy coray buttini m mucke l mahley rw huang y
0.3207539.15509658.html.plaintext.txt	231	neuron specific apolipoprotein enum proteolysis associated increased tau phosphorylation brain transgenic mouse
0.3207539.15509658.html.plaintext.txt	232	j neurosci num num num num
0.3207539.15509658.html.plaintext.txt	233	coussens lm tinkle cl hanahan d werb z
0.3207539.15509658.html.plaintext.txt	234	mmp num supplied bone marrow derived cell contributes skin carcinogenesis
0.3207539.15509658.html.plaintext.txt	235	lysosomal degradation sorting apolipoprotein e macrophage
0.3207539.15509658.html.plaintext.txt	236	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	237	synthesis secretion apoe thioglycolate elicited mouse peritoneal macrophage effect cholesterol efflux
0.3207539.15509658.html.plaintext.txt	238	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	239	farkas mh swift ll hasty ah linton mf fazio
0.3207539.15509658.html.plaintext.txt	240	recycling apolipoprotein e primary culture mouse hepatocytes
0.3207539.15509658.html.plaintext.txt	241	evidence physiologic connection high density lipoprotein metabolism
0.3207539.15509658.html.plaintext.txt	242	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	243	fazio babaev vr burleigh major hasty ah linton mf
0.3207539.15509658.html.plaintext.txt	244	physiological expression macrophage apoe artery wall reduces atherosclerosis severely hyperlipidemic mouse
0.3207539.15509658.html.plaintext.txt	245	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	246	fazio babaev vr murray ab hasty ah carter kj gleaves la atkinson jb linton mf
0.3207539.15509658.html.plaintext.txt	247	increased atherosclerosis mouse reconstituted apolipoprotein e null macrophage
0.3207539.15509658.html.plaintext.txt	248	proc natl acad sci usa num num num num
0.3207539.15509658.html.plaintext.txt	249	heeren j grewal laatsch rottke d rinninger f enrich c beisiegel u
0.3207539.15509658.html.plaintext.txt	250	recycling apoprotein e associated cholesterol efflux high density lipoprotein internalization
0.3207539.15509658.html.plaintext.txt	251	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	252	ho yy al haideri m mazzone vogel presley jf sturley sl deckelbaum rj
0.3207539.15509658.html.plaintext.txt	253	endogenously expressed apolipoprotein e different effect cell lipid metabolism compared exogenous apolipoprotein e carried triglyceride rich particle
0.3207539.15509658.html.plaintext.txt	254	biochemistry num num num num
0.3207539.15509658.html.plaintext.txt	255	ho yy deckelbaum rj chen y vogel talmage da
0.3207539.15509658.html.plaintext.txt	256	apolipoprotein e inhibits serum stimulated cell proliferation enhances serum independent cell proliferation
0.3207539.15509658.html.plaintext.txt	257	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	258	huang zh lin cy oram jf mazzone
0.3207539.15509658.html.plaintext.txt	259	sterol efflux mediated endogenous macrophage apoe expression independent abcanum
0.3207539.15509658.html.plaintext.txt	260	arterioscler thromb vasc biol num num num num
0.3207539.15509658.html.plaintext.txt	261	ji z pita re mahley rw
0.3207539.15509658.html.plaintext.txt	262	differential cellular accumulationretention apolipoprotein e mediated cell surface heparan sulfate proteoglycans
0.3207539.15509658.html.plaintext.txt	263	apolipoproteins enum enum greater enum
0.3207539.15509658.html.plaintext.txt	264	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	265	lauffenburger da oehrtman gt walker l wiley h
0.3207539.15509658.html.plaintext.txt	266	real time quantitative measurement autocrine ligand binding indicates autocrine loop spatially localized
0.3207539.15509658.html.plaintext.txt	267	proc natl acad sci usa num num num num
0.3207539.15509658.html.plaintext.txt	268	apolipoprotein e dependent cholesterol efflux macrophage kinetic study divergent mechanism endogenous versus exogenous apolipoprotein e
0.3207539.15509658.html.plaintext.txt	269	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	270	lin cy huang zh mazzone
0.3207539.15509658.html.plaintext.txt	271	interaction proteoglycans enhances sterol efflux produced endogenous expression macrophage apoe
0.3207539.15509658.html.plaintext.txt	272	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	273	lin cy lucas m mazzone
0.3207539.15509658.html.plaintext.txt	274	endogenous apoe expression modulates hdlnum binding macrophage
0.3207539.15509658.html.plaintext.txt	275	j lipid re num num num num
0.3207539.15509658.html.plaintext.txt	276	linton mf atkinson jb fazio
0.3207539.15509658.html.plaintext.txt	277	prevention atherosclerosis apolipoprotein e deficient mouse bone marrow transplantation
0.3207539.15509658.html.plaintext.txt	278	science num num num num
0.3207539.15509658.html.plaintext.txt	279	lowry oh rosebrough nj farr al randall rj
0.3207539.15509658.html.plaintext.txt	280	protein measurement folin phenol reagent
0.3207539.15509658.html.plaintext.txt	281	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	282	mazzone gump h diller p getz g
0.3207539.15509658.html.plaintext.txt	283	macrophage free cholesterol content regulates apolipoprotein e synthesis
0.3207539.15509658.html.plaintext.txt	284	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	285	moran ec kamiguti cawley jc pettitt ar
0.3207539.15509658.html.plaintext.txt	286	cytoprotective antioxidant activity serum albumin autocrine catalase chronic lymphocytic leukaemia
0.3207539.15509658.html.plaintext.txt	287	br j haematol num num num num
0.3207539.15509658.html.plaintext.txt	288	mukherjee zha x tabas maxfield fr
0.3207539.15509658.html.plaintext.txt	289	cholesterol distribution living cell fluorescence imaging using dehydroergosterol fluorescent cholesterol analog
0.3207539.15509658.html.plaintext.txt	290	biophys j num num num num
0.3207539.15509658.html.plaintext.txt	291	oehrtman gt wiley h lauffenburger da
0.3207539.15509658.html.plaintext.txt	292	escape autocrine ligand extracellular medium experimental test theoretical model prediction
0.3207539.15509658.html.plaintext.txt	293	biotechnol bioeng num num num num
0.3207539.15509658.html.plaintext.txt	294	conum dlinktypedoi crossrefisimedline
0.3207539.15509658.html.plaintext.txt	295	emerging issue cellular biology cardiovascular system
0.3207539.15509658.html.plaintext.txt	296	j cardiol num numg numg num
0.3207539.15509658.html.plaintext.txt	297	origin intracrine hormone action
0.3207539.15509658.html.plaintext.txt	298	j med sci num num num num
0.3207539.15509658.html.plaintext.txt	299	shvartsman sy wiley h deen wm lauffenburger da
0.3207539.15509658.html.plaintext.txt	300	spatial range autocrine signaling modeling computational analysis
0.3207539.15509658.html.plaintext.txt	301	biophys j num num num num
0.3207539.15509658.html.plaintext.txt	302	autocrine secretion num year later
0.3207539.15509658.html.plaintext.txt	303	ann intern med num num num num
0.3207539.15509658.html.plaintext.txt	304	steck tl kezdy fj lange y
0.3207539.15509658.html.plaintext.txt	305	activation collision mechanism cholesterol transfer membrane
0.3207539.15509658.html.plaintext.txt	306	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	307	swift ll farkas mh major valyi nagy k linton mf fazio
0.3207539.15509658.html.plaintext.txt	308	recycling pathway resecretion internalized apolipoprotein e liver cell
0.3207539.15509658.html.plaintext.txt	309	j biol chem num num num num
0.3207539.15509658.html.plaintext.txt	310	warner gj stoudt g bamberger m johnson wj rothblat gh
0.3207539.15509658.html.plaintext.txt	311	cell toxicity induced inhibition acyl coenzyme acholesterol acyltransferase accumulation unesterified cholesterol
0.3207539.15509658.html.plaintext.txt	312	j biol chem num num num num
0.32282493.12501252.html.plaintext.txt	0	novel role apolipoprotein e central nervous system modulation sulfatide content xianlin han hua cheng john d
0.32282493.12501252.html.plaintext.txt	1	division bioorganic chemistry molecular pharmacology department internal medicine department neurology department molecular biology pharmacology center study nervous system injury washington university school medicine st
0.32282493.12501252.html.plaintext.txt	2	received publication december num num revised form december num num
0.32282493.12501252.html.plaintext.txt	3	human apolipoprotein e apoe protein apoe genenum num kda protein coded gene chromosome num play prominent role transport metabolism plasma cholesterol triacylglycerides ability interact low density lipoprotein ldl receptor ldl receptor related protein num num
0.32282493.12501252.html.plaintext.txt	4	postulated apoe may also play important role redistribution cholesterol phospholipid within central nervous system cns num apoe expressed mainly astrocyte num num
0.32282493.12501252.html.plaintext.txt	5	vitro vivo data suggest apoe play role neurite outgrowth sprouting num num num however whether due effect cholesterol lipid metabolism unclear
0.32282493.12501252.html.plaintext.txt	6	addition role plasma lipid transport protein apoe participates pathobiological process including alzheimers disease ad num
0.32282493.12501252.html.plaintext.txt	7	effect apoe ad likely occur least part via interaction amyloid peptide see ref
0.32282493.12501252.html.plaintext.txt	8	date mechanism apoe involved biological process completely clarified
0.32282493.12501252.html.plaintext.txt	9	three common isoforms human apoe differ amino acid position num num num
0.32282493.12501252.html.plaintext.txt	10	common isoform apoenum cysteine position num arginine num whereas apoenum cysteine position apoenum contains arginine position
0.32282493.12501252.html.plaintext.txt	11	isoforms encoded three allele gene locus
0.32282493.12501252.html.plaintext.txt	12	apoenum shown risk factor ad cerebral amyloid angiopathy num
0.32282493.12501252.html.plaintext.txt	13	although role apoe pathogenesis ad entirely clear study suggest apoe influence deposition toxicity brain num num
0.32282493.12501252.html.plaintext.txt	14	sulfatides st represent class sulfated galactocerebrosides differ composition fatty acid residue acylates amino group sphingosine
0.32282493.12501252.html.plaintext.txt	15	sulfatides mediate diverse biological process including regulation cell growth protein trafficking signal transduction cell adhesion neuronal plasticity cell morphogenesis see ref
0.32282493.12501252.html.plaintext.txt	16	sulfatides almost exclusively synthesized oligodendrocyte cns present predominantly myelin sheath surrounding axon thus present white matter gray matter num
0.32282493.12501252.html.plaintext.txt	17	altered level st human brain tissue involved pathogenesis various human disease
0.32282493.12501252.html.plaintext.txt	18	accumulation st due sulfatidase deficiency responsible metachromatic leukodystrophy encephalopathy long tract sign degeneration myelin cns num
0.32282493.12501252.html.plaintext.txt	19	contrast recent study demonstrated substantial st deficiency occurs earliest stage ad although one cause deficiency remain unclear num
0.32282493.12501252.html.plaintext.txt	20	mouse deficient st galactocerebrosides galc generated knocking ceramide galactosyltransferase generally die num month age demonstrate several abnormality including abnormal axonal function dysmyelinosis loss axonal conduction velocity num num
0.32282493.12501252.html.plaintext.txt	21	material synthetic heptadecanoyl ceramide nnumnum cer phospholipid including numnum dimyristoleoyl num phosphatidylcholine numnum numnum ptdcho numnum dipentadecanoyl num phosphatidylethanolamine numnum numnum ptdetn num myristoyl num palmitoyl num phosphadylglycerol numnum numnum ptdgro purchased avanti polar lipid inc
0.32282493.12501252.html.plaintext.txt	22	semisynthetic n palmitoyl sulfatide nnumnum st perdeuterated n stearoyl galactocerebroside dnum nnumnum galc obtained matreya inc
0.32282493.12501252.html.plaintext.txt	23	amplex red cholesterol assay kit obtained molecular probe inc
0.32282493.12501252.html.plaintext.txt	24	human recombinant apoe rhapoe isoforms rhapoenum rhapoenum rhapoenum purchased calbiochem novabiochem corp
0.32282493.12501252.html.plaintext.txt	25	rhapoe isoforms determined st free electrospray ionization mass spectrometry esims
0.32282493.12501252.html.plaintext.txt	26	cell culture supply invitrogen new york ny unless specified
0.32282493.12501252.html.plaintext.txt	27	goat anti apoe anti apoj antibody purchased biodesign saco
0.32282493.12501252.html.plaintext.txt	28	goat igg control antibody purchased sigma st
0.32282493.12501252.html.plaintext.txt	29	protein g sepharose obtained pierce rockford il
0.32282493.12501252.html.plaintext.txt	30	mouse brain tissue wild type
0.32282493.12501252.html.plaintext.txt	31	apoe apoe transgenic mouse study cnumblnum background
0.32282493.12501252.html.plaintext.txt	32	transgenic mouse hemizygous gfap apoenum gfap apoenum transgene mouse apoe background produced described previously num
0.32282493.12501252.html.plaintext.txt	33	gfap refers glial fibrillary acidic protein promoter
0.32282493.12501252.html.plaintext.txt	34	gfap apoenum apoenum mouse express apoe level
0.32282493.12501252.html.plaintext.txt	35	indicated age mouse anesthetized intraperitoneal pentobarbital num mgkg perfused transcardially num
0.32282493.12501252.html.plaintext.txt	36	num m phosphate buffered saline ph num
0.32282493.12501252.html.plaintext.txt	37	brain region immediately dissected frozen powdered dry ice analysis
0.32282493.12501252.html.plaintext.txt	38	human cerebrospinal fluid astrocyte secreted lipoprotein human lumbar csf sample collected previously described num
0.32282493.12501252.html.plaintext.txt	39	freshly frozen csf sample num degree c num
0.32282493.12501252.html.plaintext.txt	40	num num ml subject used study st content
0.32282493.12501252.html.plaintext.txt	41	lumbar csf sample obtained cognitively normal subject clinical dementia rating score num non demented num
0.32282493.12501252.html.plaintext.txt	42	clinical dementia rating score assigned subject experienced clinician based extensive clinical neuropsychological evaluation described num
0.32282493.12501252.html.plaintext.txt	43	subject genotype apoe kindly provided laboratory dr
0.32282493.12501252.html.plaintext.txt	44	goate washington university school medicine
0.32282493.12501252.html.plaintext.txt	45	total num subject participated study apoenumenum n num apoenumenum n num apoenumenum n num overall average age num
0.32282493.12501252.html.plaintext.txt	46	astrocyte secreted apoenum apoenum lipoprotein purified using immunoaffinity column described num
0.32282493.12501252.html.plaintext.txt	47	briefly primary culture forebrain astrocyte num pure prepared neonatal num num day old wild type cnumblnum apoe gfap apoenum transgenic gfap apoenum transgenic mouse grown confluence num num day tnum flask
0.32282493.12501252.html.plaintext.txt	48	culture incubated num ml serum free dulbeccos modified eagle mediumhams f num numnum medium containing nnum supplement invitrogen additional num h
0.32282493.12501252.html.plaintext.txt	49	conditioned medium collected apoenum apoenum lipoprotein purified corresponding conditioned medium anti apoe immunoaffinity column
0.32282493.12501252.html.plaintext.txt	50	preparation quantitation lipid mouse brain tissue human csf astrocyte secreted lipoprotein lipid individual mouse brain tissue prepared presence numnum numnum ptdcho num nmolmg protein numnum numnum ptdetn num nmolmg protein numnum numnum ptdgro num nmolmg protein dnum nnumnum galc num nmolmg protein nnumnum cer num nmolmg protein used internal standard quantification choline containing phospholipid ethanolamine containing phospholipid anionic lipid including ptdgro phosphatidylinositol ptdins phosphatidylserine ptdser st galc cer respectively similarly prepared described previously num num num
0.32282493.12501252.html.plaintext.txt	51	lipid similarly extracted human csf astrocyte secreted lipoprotein presence nnumnum st num pmolmg csf protein num nmolmg apoe respectively used internal standard quantification st
0.32282493.12501252.html.plaintext.txt	52	esims analysis lipid performed utilizing finnigan tsq num spectrometer equipped electrospray ion source described num num num
0.32282493.12501252.html.plaintext.txt	53	molecular specie directly quantitated comparison individual ion peak intensity properly selected internal standard e
0.32282493.12501252.html.plaintext.txt	54	numnum numnum ptdgro anionic lipid including ptdins ptdser correction numc isotope effect num
0.32282493.12501252.html.plaintext.txt	55	quantification cholesterol brain tissue sample tissue num mg homogenized num
0.32282493.12501252.html.plaintext.txt	56	num ml phosphate buffered saline
0.32282493.12501252.html.plaintext.txt	57	cholesterol mass homogenate quantitated using enzymatic methodology amplex red cholesterol assay kit molecular probe inc
0.32282493.12501252.html.plaintext.txt	58	hydrolysis assay sulfatide mediated human recombinant apoe isoforms hydrolysis st mediated rhapoes performed modification n sulfatidase assay described previously num
0.32282493.12501252.html.plaintext.txt	59	briefly rhapoe isoforms num microg incubated num ml final assay buffer num mm imidazole ph num
0.32282493.12501252.html.plaintext.txt	60	num micromol dissolved num microl menumso injected assay solution
0.32282493.12501252.html.plaintext.txt	61	num num num num h num degree c aliquot num microl assay mixture pipetted lipid mixture immediately extracted modified bligh dyer technique num presence nnumnum cer num nmol dnum nnumnum galc num nmol internal standard used quantitation cer galc two product st hydrolysis
0.32282493.12501252.html.plaintext.txt	62	mass cer galc quantitated esims described previously num num
0.32282493.12501252.html.plaintext.txt	63	fractionation immunoprecipitation assay human csf human csf obtained fasted healthy subject via lumbar puncture lnumlnum trained neurologist d
0.32282493.12501252.html.plaintext.txt	64	blood contamination
0.32282493.12501252.html.plaintext.txt	65	csf centrifuged num min num x g num degree c pellet cellular element
0.32282493.12501252.html.plaintext.txt	66	twenty milliliter csf concentrated num ml num degree c using centriplus num concentrators num kda molecular mass millipore bedford ma prior fractionation via gel filtration chromatography biologic system bio rad hercules ca using tandem superose num hr numnum column amersham bioscience piscataway nj condition physiological ph ph num
0.32282493.12501252.html.plaintext.txt	67	seventy fraction num microl collected
0.32282493.12501252.html.plaintext.txt	68	lipid individual fraction extracted presence nnumnum st num pmolfraction used internal standard st quantitation using modified method bligh dyer num st content fraction analyzed esims described
0.32282493.12501252.html.plaintext.txt	69	immunoprecipitation initiated incubating num
0.32282493.12501252.html.plaintext.txt	70	num ml pooled human csf individual antibody final concentration num microgml num microl num protein g sepharose slurry num h room temperature
0.32282493.12501252.html.plaintext.txt	71	immunoprecipitation complex pelleted briefly rinsed three time gently ice cooled phosphate buffered saline
0.32282493.12501252.html.plaintext.txt	72	lipid extracted final immunoprecipitation pellet supernatant using modified bligh dyer method st content lipid extract analyzed esims described
0.32282493.12501252.html.plaintext.txt	73	altered mass sulfatides examined lipid brain apoe mouse examine effect apoe mouse brain lipid homeostasis molecular specie mass lipid including choline glycerophospholipids pc ethanolamine glycerophospholipids pe phosphatidylglycerol ptdgro phosphatidylinositol ptdins phosphatidylserine ptdser sphingomyelin sm galactocerebroside galc st cholesterol apoe apoe mouse brain region analyzed either esims fluorometric assay
0.32282493.12501252.html.plaintext.txt	74	negative ion esims analysis chloroform extract wild type cnumblnum mouse apoe mouse hippocampus num month age demonstrated multiple abundant ion peak corresponding pe molecular specie indicated fig
0.32282493.12501252.html.plaintext.txt	75	pe molecular specie account total mass num
0.32282493.12501252.html.plaintext.txt	76	num nmolmg protein including num
0.32282493.12501252.html.plaintext.txt	77	num nmolmg protein ethanolamine plasmalogen
0.32282493.12501252.html.plaintext.txt	78	numb illustrates positive ion esims spectrum identical lipid extract apoe mouse hippocampus num month age pc sm galc molecular specie identified quantitated
0.32282493.12501252.html.plaintext.txt	79	num nmolmg protein pc sm galc respectively obtained table
0.32282493.12501252.html.plaintext.txt	80	negative ion esims analysis identical chloroform extract apoe mouse hippocampus without addition lioh demonstrated multiple abundant ion peak corresponding ptdins ptdser st anionic lipid molecular specie indicated fig
0.32282493.12501252.html.plaintext.txt	81	numa total mass specie tabulated table
0.32282493.12501252.html.plaintext.txt	82	num nmolmg protein cholesterol hippocampus obtained using enzymatic methodology amplex red cholesterol assay kit
0.32282493.12501252.html.plaintext.txt	83	esims analysis fluorometric assay lipid apoe mouse cortex cerebellum also performed result tabulated table
0.32282493.12501252.html.plaintext.txt	84	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	85	representative esi mass spectrum lipid extract wild type mouse hippocampus
0.32282493.12501252.html.plaintext.txt	86	apoe mouse hippocampus num month age extracted modified method bligh dyer described experimental procedure
0.32282493.12501252.html.plaintext.txt	87	negative ion positive ion b esims lipid extract performed presence trace amount lioh experimental procedure
0.32282493.12501252.html.plaintext.txt	88	major individual molecular specie indicated identified using tandem mass spectrometry
0.32282493.12501252.html.plaintext.txt	89	view table table lipid content brain region wild type apoe human apoenum transgenic mouse num month age mouse brain tissue lipid extracted bligh dyer method num
0.32282493.12501252.html.plaintext.txt	90	phospholipid sphingolipids analyzed directly esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	91	lipid molecular specie identified esi tandem mass spectrometry quantitated comparison individual ion peak intensity properly selected internal standard correction numc isotope effect
0.32282493.12501252.html.plaintext.txt	92	cholesterol content determined flurometric technique
0.32282493.12501252.html.plaintext.txt	93	result expressed nmolmg protein represent mean plus minus
0.32282493.12501252.html.plaintext.txt	94	least three separate animal
0.32282493.12501252.html.plaintext.txt	95	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	96	representative negative ion esi mass spectrum lipid extract wild type apoe knockout mouse hippocampus
0.32282493.12501252.html.plaintext.txt	97	apoe panel apoe knockout
0.32282493.12501252.html.plaintext.txt	98	apoe panel b mouse hippocampus num month age extracted modified method bligh dyer negative ion esims lipid extract without presence lioh performed experimental procedure
0.32282493.12501252.html.plaintext.txt	99	major individual molecular specie indicated identified using tandem mass spectrometry
0.32282493.12501252.html.plaintext.txt	100	asterisk indicate lower abundant ion peak sulfatide molecular specie present lipid extract
0.32282493.12501252.html.plaintext.txt	101	numoh nnumnum st represents num hydroxy nnumnum st molecular specie
0.32282493.12501252.html.plaintext.txt	102	examination mass various lipid molecular specie hippocampus cortex cerebellum apoe mouse esims analysis fluorometric assay demonstrated significant difference pc pe ptdins ptdser sm galc cholesterol comparison obtained corresponding region apoe mouse fig
0.32282493.12501252.html.plaintext.txt	103	interestingly mass content st hippocampus cortex cerebellum apoe mouse increased num num num mol respectively relative found apoe mouse age num month fig
0.32282493.12501252.html.plaintext.txt	104	result indicate apoe way regulates st content cns
0.32282493.12501252.html.plaintext.txt	105	alteration sulfatide content mediated apoe dependence apoe isoform age examine effect human apoe isoforms modulation st content mouse brain st molecular specie mass lipid extract different brain region transgenic mouse expressing human apoenum apoenum specifically brain astrocyte compared apoe mouse esims analysis fig
0.32282493.12501252.html.plaintext.txt	106	importantly level apoenum apoenum expression hemizygous transgenic mouse indistinguishable num level mouse apoe wild type mouse num num
0.32282493.12501252.html.plaintext.txt	107	level st mass hippocampus cortex apoenum transgenic mouse num month age num num mol respectively found apoe mouse statistically lower found apoe mouse fig
0.32282493.12501252.html.plaintext.txt	108	level st mass cortex hippocampus apoenum transgenic mouse num num mol respectively counterpart apoe mouse tissue num num mol respectively found corresponding apoe mouse tissue num month age fig
0.32282493.12501252.html.plaintext.txt	109	st mass level brain region apoenum transgenic mouse significantly lower found corresponding apoenum transgenic mouse tissue p num
0.32282493.12501252.html.plaintext.txt	110	num demonstrating isoform specific regulation st mass level apoe
0.32282493.12501252.html.plaintext.txt	111	apoe mouse significantly higher st content thalamus striatum septum compared present apoe mouse even num month age fig
0.32282493.12501252.html.plaintext.txt	112	contrast significantly lower st content brain region demonstrated apoenum transgenic mouse relative wild type apoe mouse fig
0.32282493.12501252.html.plaintext.txt	113	fact human apoe transgenic mouse express apoe brain lower level sulfatide wild type mouse demonstrates regulation brain sulfatide level via apoe produced brain
0.32282493.12501252.html.plaintext.txt	114	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	115	comparison sulfatide mass level hippocampus cortex wild type apoe human apoenum apoenum transgenic mouse num month age
0.32282493.12501252.html.plaintext.txt	116	sulfatide mass lipid extract hippocampus cortex b wild type apoe apoenum apoenum transgenic mouse num month age determined using negative ion esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	117	data represent mean plus minus
0.32282493.12501252.html.plaintext.txt	118	least three separate animal
0.32282493.12501252.html.plaintext.txt	119	num relative apoe mouse
0.32282493.12501252.html.plaintext.txt	120	also significant difference human apoenum apoenum transgenic mouse p num
0.32282493.12501252.html.plaintext.txt	121	num hippocampus cortex
0.32282493.12501252.html.plaintext.txt	122	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	123	absence apoe result increase sulfatide mass level several brain region num month age
0.32282493.12501252.html.plaintext.txt	124	total mass sulfatides lipid extract thalamus striatum septum apoe unfilled apoe dot filled human apoenum transgenic black filled mouse num month age determined using negative ion esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	125	num relative apoe mouse
0.32282493.12501252.html.plaintext.txt	126	experiment performed examine effect age alteration st content mediated mouse human apoe
0.32282493.12501252.html.plaintext.txt	127	overall st content brain region wild type apoe mouse relatively unchanged num month age fig
0.32282493.12501252.html.plaintext.txt	128	however level st mass apoe mouse num num month age substantially increased relative apoe mouse advanced age fig
0.32282493.12501252.html.plaintext.txt	129	contrast st content examined region apoenum transgenic mouse substantially lower compared found apoe mouse age num month older although st content two type mouse almost identical num month age fig
0.32282493.12501252.html.plaintext.txt	130	also found alteration st mass mediated apoe smaller cerebellum found cortex hippocampus early age fig
0.32282493.12501252.html.plaintext.txt	131	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	132	age dependent regulation sulfatide mass level hippocampus cortex cerebellum wild type apoe human apoenum transgenic mouse
0.32282493.12501252.html.plaintext.txt	133	sulfatide mass level lipid extract hippocampus cortex b cerebellum c apoe apoe human apoenum transgenic mouse determined using negative ion esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	134	error bar within symbol
0.32282493.12501252.html.plaintext.txt	135	sulfatide content cultured astrocyte secreted apoe particle human csf investigate possible mechanism apoe mediated alteration st content cns two experiment performed
0.32282493.12501252.html.plaintext.txt	136	first purified astrocyte secreted lipoprotein containing either apoenum apoenum prepared cultured astrocyte described experimental procedure
0.32282493.12501252.html.plaintext.txt	137	st content particle quantitated esims
0.32282493.12501252.html.plaintext.txt	138	found st content particle negligible although apoenum particle contained st mass found apoenum particle num plus minus num versus num plus minus num pmolmg apoe respectively
0.32282493.12501252.html.plaintext.txt	139	second csf contains cns produced apoe containing lipoprotein particle sample collected age matched cognitively normal human subject
0.32282493.12501252.html.plaintext.txt	140	st content csf sample analyzed esims
0.32282493.12501252.html.plaintext.txt	141	st mass nmolmg apoe apoenumenum homozygous subject num
0.32282493.12501252.html.plaintext.txt	142	num whereas level significantly higher subject one two allele apoenum num
0.32282493.12501252.html.plaintext.txt	143	noted st content csf sample subject either heterozygous homozygous apoenum numnum numnum indistinguishable study
0.32282493.12501252.html.plaintext.txt	144	therefore concluded human csf contains significant amount st mass level st human csf apoe isoform dependent
0.32282493.12501252.html.plaintext.txt	145	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	146	relationship sulfatide mass human cerebrospinal fluid apoe genotype subject
0.32282493.12501252.html.plaintext.txt	147	cerebrospinal fluid sample collected age matched num
0.32282493.12501252.html.plaintext.txt	148	num year cognitively normal human subject lipid extracted modified method bligh dyer described experimental procedure
0.32282493.12501252.html.plaintext.txt	149	mass st lipid extract human cerebrospinal fluid subject homozygous apoenum denotes average level sulfatide mass homozygous heterozygous apoenum denotes average level sulfatide mass determined using negative ion esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	150	identification st carrier human csf examination mass level st cultured astrocyte secreted apoe particle human csf see last subsection suggests two possibility
0.32282493.12501252.html.plaintext.txt	151	first st molecule acquired directly associate apoe particle cns apoe particle secreted astrocyte
0.32282493.12501252.html.plaintext.txt	152	alternatively st molecule may influenced apoe indirect fashion directly associate interact apoe containing lipoprotein
0.32282493.12501252.html.plaintext.txt	153	therefore understand one mechanism apoe mediated alteration st content cns necessary identify carrier carrier st molecule
0.32282493.12501252.html.plaintext.txt	154	location st molecule first investigated analyzing st content human csf fraction gel filtration chromatography
0.32282493.12501252.html.plaintext.txt	155	found sulfatides co localized exactly hdl like lipoprotein present human csf fig
0.32282493.12501252.html.plaintext.txt	156	two abundant apolipoproteins produced cns apoe apoj well several apolipoproteins present human csf
0.32282493.12501252.html.plaintext.txt	157	therefore experiment performed identify specific carrier st human csf immunoprecipitation see inset fig
0.32282493.12501252.html.plaintext.txt	158	numb western blot followed esims quantitation st content supernatant pellet
0.32282493.12501252.html.plaintext.txt	159	found num mol st molecule immunoprecipitated anti apoe antibody whereas st molecule specifically immunoprecipitated anti apoj antibody fig
0.32282493.12501252.html.plaintext.txt	160	result clearly demonstrated st molecule specifically associated apoe containing hdl like lipoprotein csf suggested apoe particle mainly acquired st cns secretion astrocyte
0.32282493.12501252.html.plaintext.txt	161	view larger version numk fig
0.32282493.12501252.html.plaintext.txt	162	identification sulfatide carrier human cerebrospinal fluid
0.32282493.12501252.html.plaintext.txt	163	quantitation sulfatide content human cerebrospinal fluid fraction gel filtration chromatography
0.32282493.12501252.html.plaintext.txt	164	human cerebrospinal fluid fractionated employing tandem superose num column described experimental procedure
0.32282493.12501252.html.plaintext.txt	165	seventy fraction num microl collected
0.32282493.12501252.html.plaintext.txt	166	lipid individual fraction extracted presence n palmitoyl sulfatide num pmolfraction used internal standard sulfatide quantitation using modified bligh dyer method
0.32282493.12501252.html.plaintext.txt	167	sulfatide content fraction quantitated esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	168	x axis indicates fraction number known elution profile csf lipoprotein reported previously num
0.32282493.12501252.html.plaintext.txt	169	quantitation sulfatide content immunoprecipitated lipoprotein particle b supernatant immunoprecipitation c initiated incubating num
0.32282493.12501252.html.plaintext.txt	170	num ml pooled human cerebrospinal fluid individual antibody indicated described experimental procedure
0.32282493.12501252.html.plaintext.txt	171	lipid immunoprecipitation pellet extracted presence n palmitoyl sulfatide num pmol
0.32282493.12501252.html.plaintext.txt	172	sulfatide content lipid extract quantitated esims described experimental procedure
0.32282493.12501252.html.plaintext.txt	173	data represent mean plus minus
0.32282493.12501252.html.plaintext.txt	174	least three separate experiment
0.32282493.12501252.html.plaintext.txt	175	inset b show typical western blot using anti apoe anti apoj antibody analyze apoe apoj content csf sample prior pre ip immunoprecipitation following post ip
0.32282493.12501252.html.plaintext.txt	176	following immunoprecipitation csf pellet also analyzed apoe apoj
0.32282493.12501252.html.plaintext.txt	177	involvement apoe metabolism phospholipid cholesterol plasma well known num num
0.32282493.12501252.html.plaintext.txt	178	investigate whether apoe influence mass distribution brain lipid systematically quantified distribution lipid including multiple phospholipid sphingolipids cholesterol different brain region wild type apoe human apoe transgenic mouse
0.32282493.12501252.html.plaintext.txt	179	found significant effect apoe content examined lipid exception st level dramatically altered apoe knockout human apoe transgenic mouse
0.32282493.12501252.html.plaintext.txt	180	furthermore apoe mediated alteration st content cns regulated aging well apoe produced brain human apoe transgenic mouse express apoe brain still markedly elevated plasma cholesterol num
0.32282493.12501252.html.plaintext.txt	181	result examination st content astrocyte secreted apoe particle indicate apoe acquire small amount st directly cell secrete apoe
0.32282493.12501252.html.plaintext.txt	182	however brain st produced oligodendrocyte located myelin cns likely majority st apoe particle cns acquired myelin apoe secretion expressed cell
0.32282493.12501252.html.plaintext.txt	183	major effect mouse human apoe appears keeping st level brain lower level present absence apoe
0.32282493.12501252.html.plaintext.txt	184	effect probably due apoe containing lipoprotein facilitating cellular clearance st
0.32282493.12501252.html.plaintext.txt	185	although hydrolysis st directly catalyzed apoe observed study apoe associated st hydrolysis vivo completely excluded
0.32282493.12501252.html.plaintext.txt	186	showed st directly associate apoe containing lipoprotein csf likely transport st apoe particle brain interstitial fluid csf endocytotic recycling apoe particle ldl receptor ldl receptor family member ldl receptor related protein num major pathway apoe mediates st metabolism cns
0.32282493.12501252.html.plaintext.txt	187	num allele apoe strong genetic risk factor ad cerebral amyloid angiopathy whereas num allele protective
0.32282493.12501252.html.plaintext.txt	188	although several possible mechanism association exist strong evidence suggest interaction apoe play important role effect apoe ad see ref
0.32282493.12501252.html.plaintext.txt	189	example transgenic animal model develop ad like amyloidosis neuritic plaque lack apoe result little fibrillar amyloid formation neuritic dystrophy num num expression human apoe result isoform specific deposition amyloid within neuritic plaque effect order apoenum enum enum num num
0.32282493.12501252.html.plaintext.txt	190	effect apoe likely mediated interaction apoe containing hdl form apoe brain
0.32282493.12501252.html.plaintext.txt	191	given issue way sulfatide association apoe containing lipoprotein may involved apoe interaction
0.32282493.12501252.html.plaintext.txt	192	shown apoe interaction markedly influenced presence lipid num num
0.32282493.12501252.html.plaintext.txt	193	however previous work num data presented shown quantitative difference amount phospholipid cholesterol present brain csf lipoprotein presence absence apoe apoe isoforms
0.32282493.12501252.html.plaintext.txt	194	contrast observed significant isoform specific difference st level enum enum human csf lipoprotein
0.32282493.12501252.html.plaintext.txt	195	although yet explored whether sulfatide level apoe particle influence interaction shown portion co elutes apoe containing hdl particle shown also contain st human csf num
0.32282493.12501252.html.plaintext.txt	196	addition effect apoe apoe isoform risk ad substantial evidence apoenum also risk factor poor outcome following certain cns injury head trauma multiple sclerosis possibly stroke see ref
0.32282493.12501252.html.plaintext.txt	197	apoe play role process remains unclear
0.32282493.12501252.html.plaintext.txt	198	possible effect via isoform specific difference regeneration shown vitro vivo model see ref
0.32282493.12501252.html.plaintext.txt	199	also possible particularly case multiple sclerosis possibly stroke apoe somehow regulating cns inflammatory process cytokine production seen model e
0.32282493.12501252.html.plaintext.txt	200	interestingly numerous study shown sulfatides ligand family receptor protein called selectins located activated vascular endothelial cell leukocyte activated platelet num num
0.32282493.12501252.html.plaintext.txt	201	although relationship role apoe immunoregulation sulfatide ligand selectins unclear shown sulfatides potent anti inflammatory agent num
0.32282493.12501252.html.plaintext.txt	202	potential relationship likely indicates possible role st apoe particle anti inflammatory immunomodulatory molecule
0.32282493.12501252.html.plaintext.txt	203	grateful washington university mass spectrometer facility center use electrospray ionization mass spectrometer
0.32282493.12501252.html.plaintext.txt	204	thank clinical core washington university alzheimers disease research center providing subject evaluation clinical dementia rating washington university general clinical research center providing lumbar csf sample
0.32282493.12501252.html.plaintext.txt	205	also give special thanks maia parsadanian skillful assistance mouse brain dissection
0.32282493.12501252.html.plaintext.txt	206	work supported nia national institute health nih grant pnum agnum nih grant ag num nih grant mnum rrnum alzheimers disease related disorder program university missouri system
0.32282493.12501252.html.plaintext.txt	207	cost publication article defrayed part payment page charge
0.32282493.12501252.html.plaintext.txt	208	article must therefore hereby marked advertisement accordance num u
0.32282493.12501252.html.plaintext.txt	209	section num solely indicate fact
0.32282493.12501252.html.plaintext.txt	210	correspondence addressed division bioorganic chemistry molecular pharmacology dept
0.32282493.12501252.html.plaintext.txt	211	internal medicine washington university school medicine box num num
0.32282493.12501252.html.plaintext.txt	212	num num num fax num num num e mail xianlinpcg
0.32282493.12501252.html.plaintext.txt	213	published jbc paper press december num num doi num
0.32282493.12501252.html.plaintext.txt	214	abbreviation used apoe apolipoprotein e apoenum apoenum human apoe isoforms apoj apolipoprotein j ad alzheimers disease cer ceramides cns central nervous system csf cerebrospinal fluid esims electrospray ionization mass spectrometry galc galactocerebrosides hdl high density lipoprotein ldl low density lipoprotein mn acyl chain containing m carbon n double bond nmn acyl amide m carbon n double bond pc choline glycerophospholipids pe ethanolamine glycerophospholipids ptdcho phosphatidylcholine ptdetn phosphatidylethanolamine ptdgro phosphatidylglycerols ptdins phosphatidylinositols ptdser phosphatidylserines rhapoe human recombinant apoe sm sphingomyelins st sulfatides amyloid peptide gfap glial fibrillary acidic protein
0.32282493.12501252.html.plaintext.txt	215	copyright num american society biochemistry molecular biology inc
0.3345159.16033878.html.plaintext.txt	0	large meta analysis establishes ace insertion deletion polymorphism marker alzheimers disease donald j
0.3345159.16033878.html.plaintext.txt	1	lehmannnum mario cortina borjanum donald r
0.3345159.16033878.html.plaintext.txt	2	david smithnum kristel sleegersnum jonathan
0.3345159.16033878.html.plaintext.txt	3	num oxford project investigate memory ageing optimum department pharmacology university oxford oxford united kingdom num centre paediatric epidemiology biostatistics institute child health university college london london united kingdom num department epidemiology biostatistics erasmus mc rotterdam netherlands num center genomics bioinformatics karolinska institute stockholm sweden num care elderly department clinical science north bristol university bristol frenchay hospital bristol united kingdom
0.3345159.16033878.html.plaintext.txt	4	lehmann university department pharmacology mansfield road oxford oxnum numqt united kingdom e mail donald
0.3345159.16033878.html.plaintext.txt	5	received publication january num num
0.3345159.16033878.html.plaintext.txt	6	accepted publication march num num
0.3345159.16033878.html.plaintext.txt	7	alzheimer disease heterogeneity meta analysis
0.3345159.16033878.html.plaintext.txt	8	abbreviation ace angiotensin converting enzyme protein ace angiotensin converting enzyme gene apoenum apolipoprotein e num allele
0.3345159.16033878.html.plaintext.txt	9	since potential association examined num sample num num table num around world
0.3345159.16033878.html.plaintext.txt	10	several study replicated report increased risk positive contradicted many found association alzheimers disease
0.3345159.16033878.html.plaintext.txt	11	one study suggested effect age association num another proposed influence gender num
0.3345159.16033878.html.plaintext.txt	12	association onset age alzheimers disease also proposed num
0.3345159.16033878.html.plaintext.txt	13	cohort used meta analysis ace insertion deletion polymorphism alzheimers disease
0.3345159.16033878.html.plaintext.txt	14	association recently studied longitudinal observational cohort oxford project investigate memory ageing optimum rotterdam study num
0.3345159.16033878.html.plaintext.txt	15	group found suggestion gender difference result consistent previous report num
0.3345159.16033878.html.plaintext.txt	16	therefore undertook meta analysis study association ace indel alzheimers disease stratified gender age ethnic group apolipoprotein e num allele apoenum carrier status using mainly primary data supplied author
0.3345159.16033878.html.plaintext.txt	17	although three previous meta analysis ace study reported num num subsequent study made data available
0.3345159.16033878.html.plaintext.txt	18	compared even latest meta analysis num num sample eight study available u num num num study oxford project investigate memory ageing
0.3345159.16033878.html.plaintext.txt	19	addition previous meta analysis based published data largely unstratified thus limited interpretation allowed
0.3345159.16033878.html.plaintext.txt	20	using primary data able explore deeply searching source heterogeneity
0.3345159.16033878.html.plaintext.txt	21	two previous stratified meta analysis alzheimers disease gene num num based primary data deepened understanding
0.3345159.16033878.html.plaintext.txt	22	num stressed need examine source heterogeneity meta analysis case control study
0.3345159.16033878.html.plaintext.txt	23	therefore divided analysis two phase first broad overall analysis second detailed examination source heterogeneity
0.3345159.16033878.html.plaintext.txt	24	aimed discover whether ace indel associated alzheimers disease nature association
0.3345159.16033878.html.plaintext.txt	25	phase num examination heterogeneity examined six possible source heterogeneity
0.3345159.16033878.html.plaintext.txt	26	performed analysis stratified age gender apoenum status
0.3345159.16033878.html.plaintext.txt	27	age stratification num year num num year num year divided sample two group according age case defined example onset first group examination death second group
0.3345159.16033878.html.plaintext.txt	28	also conducted analysis restricted control diagnosis probable definite alzheimers disease according criterion consortium establish registry alzheimers disease cerad num national institute neurological communicative disorder stroke alzheimers disease related disorder association nincds adrda num num full sample two part sample
0.3345159.16033878.html.plaintext.txt	29	separate analysis excluded eight sample hardy weinberg analysis genotyping method compatible mistyping
0.3345159.16033878.html.plaintext.txt	30	underreporting heterozygote may occur unless either num percent dimethyl sulfoxide included polymerase chain reaction num dd genotype confirmed insertion specific second amplification num
0.3345159.16033878.html.plaintext.txt	31	analysis sample placed possible num num sample one three ethnic group north european num sample south caucasian num sample defined mediterranean middle east east asian four sample china japan
0.3345159.16033878.html.plaintext.txt	32	data analysis statistical method three method commonly used produce odds ratio genetic association study method num allelic
0.3345159.16033878.html.plaintext.txt	33	case method num comparing genotype one turn e
0.3345159.16033878.html.plaintext.txt	34	di method num comparing genotype turn two combined
0.3345159.16033878.html.plaintext.txt	35	three method subject bias degree bias depending imperfectly model fit reality
0.3345159.16033878.html.plaintext.txt	36	instance method num best suited testing codominant model allelic dose effect e
0.3345159.16033878.html.plaintext.txt	37	method num hand may used test either dominantd recessive d dominanti recessive model
0.3345159.16033878.html.plaintext.txt	38	chose follow hypothesis generating study num using method num partly preliminary examination subsequent study shown evidence codominance
0.3345159.16033878.html.plaintext.txt	39	also used method num num examine heterosis heterozygote greater lesser risk either homozygote
0.3345159.16033878.html.plaintext.txt	40	main approach method num give estimate risk associated genotype compared rest population
0.3345159.16033878.html.plaintext.txt	41	pooled odds ratio calculated three time fixed effect method mantel haenszel num random effect method dersimonian laird num bayesian random effect method warn et al
0.3345159.16033878.html.plaintext.txt	42	however result three method similar first two shown table num
0.3345159.16033878.html.plaintext.txt	43	method meta analysis permit accumulation result across independent study even number subject ratio case control varies considerably cohort sleegers et al
0.3345159.16033878.html.plaintext.txt	44	heterogeneity test method armitage num
0.3345159.16033878.html.plaintext.txt	45	logistic regression analysis used compare odds ratio among ethnic group
0.3345159.16033878.html.plaintext.txt	46	funnel plot num cumulative meta analysis num used investigate bias
0.3345159.16033878.html.plaintext.txt	47	analysis performed using r num package rmeta thomas lumley httpwww
0.3345159.16033878.html.plaintext.txt	48	orgsrccontribdescriptionsrmeta
0.3345159.16033878.html.plaintext.txt	49	test significance two sided
0.3345159.16033878.html.plaintext.txt	50	bonferroni correction factor num applied p value genotype
0.3345159.16033878.html.plaintext.txt	51	odds ratio alzheimers disease ace genotype versus two meta analysis
0.3345159.16033878.html.plaintext.txt	52	view larger version numk figure num
0.3345159.16033878.html.plaintext.txt	53	funnel plot angiotensin converting enzyme gene ace study d homozygote versus di ii p num
0.3345159.16033878.html.plaintext.txt	54	num b homozygote versus di dd p num
0.3345159.16033878.html.plaintext.txt	55	d represents deletion allele represents insertion allele
0.3345159.16033878.html.plaintext.txt	56	horizontal line num confidence interval dashed vertical line summary log odds ratio
0.3345159.16033878.html.plaintext.txt	57	view larger version numk figure num
0.3345159.16033878.html.plaintext.txt	58	cumulative meta analysis odds ratio alzheimers disease aced homozygote versus positive
0.3345159.16033878.html.plaintext.txt	59	d represents deletion allele represents insertion allele
0.3345159.16033878.html.plaintext.txt	60	horizontal line num confidence interval vertical dotted line summary odds ratio
0.3345159.16033878.html.plaintext.txt	61	optimum oxford project investigate memory ageing ace angiotensin converting enzyme gene
0.3345159.16033878.html.plaintext.txt	62	additional study information given table num
0.3345159.16033878.html.plaintext.txt	63	risk alzheimers disease genotype
0.3345159.16033878.html.plaintext.txt	64	odds ratio genotype versus two shown figure num num num summarized table num
0.3345159.16033878.html.plaintext.txt	65	d homozygote reduced risk alzheimers disease overall odds ratio num
0.3345159.16033878.html.plaintext.txt	66	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	67	num method dersimonian laird num
0.3345159.16033878.html.plaintext.txt	68	heterozygote increased risk alzheimers disease overall odds ratio num
0.3345159.16033878.html.plaintext.txt	69	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	70	odds ratio alzheimers disease homozygote versus d positive differ significantly num
0.3345159.16033878.html.plaintext.txt	71	two three result heterogeneous
0.3345159.16033878.html.plaintext.txt	72	view larger version numk figure num
0.3345159.16033878.html.plaintext.txt	73	odds ratio alzheimers disease aced homozygote versus positive
0.3345159.16033878.html.plaintext.txt	74	d represents deletion allele represents insertion allele
0.3345159.16033878.html.plaintext.txt	75	horizontal line num confidence interval
0.3345159.16033878.html.plaintext.txt	76	optimum oxford project investigate memory ageing ace angiotensin converting enzyme gene
0.3345159.16033878.html.plaintext.txt	77	additional study information given table num
0.3345159.16033878.html.plaintext.txt	78	view larger version numk figure num
0.3345159.16033878.html.plaintext.txt	79	odds ratio alzheimers disease ace heterozygote versus homozygote
0.3345159.16033878.html.plaintext.txt	80	horizontal line num confidence interval
0.3345159.16033878.html.plaintext.txt	81	optimum oxford project investigate memory ageing ace angiotensin converting enzyme gene
0.3345159.16033878.html.plaintext.txt	82	additional study information given table num
0.3345159.16033878.html.plaintext.txt	83	view larger version numk figure num
0.3345159.16033878.html.plaintext.txt	84	odds ratio alzheimers disease acei homozygote versus d positive
0.3345159.16033878.html.plaintext.txt	85	d represents deletion allele represents insertion allele
0.3345159.16033878.html.plaintext.txt	86	horizontal line num confidence interval
0.3345159.16033878.html.plaintext.txt	87	optimum oxford project investigate memory ageing ace angiotensin converting enzyme gene
0.3345159.16033878.html.plaintext.txt	88	additional study information given table num
0.3345159.16033878.html.plaintext.txt	89	onset age alzheimers disease
0.3345159.16033878.html.plaintext.txt	90	onset age data available num sample comprising numnum case alzheimers disease
0.3345159.16033878.html.plaintext.txt	91	stratified analysis linear regression analysis performed data also subset num north european sample comprising numnum case alzheimers disease
0.3345159.16033878.html.plaintext.txt	92	effect acei carrier status onset age alzheimers disease surprisingly modest effect apoenum carrier status onset age seen data shown
0.3345159.16033878.html.plaintext.txt	93	phase num examination heterogeneity examined six potential source heterogeneity age gender race apoenum status misdiagnosis mistyping
0.3345159.16033878.html.plaintext.txt	94	stratification gender apoenum status
0.3345159.16033878.html.plaintext.txt	95	significant effect seen gender apoenum status association alzheimers disease stratification either two factor remove heterogeneity data shown
0.3345159.16033878.html.plaintext.txt	96	calculated odds ratio alzheimers disease aced homozygote versus positive stratified age num year num num year num year
0.3345159.16033878.html.plaintext.txt	97	rather little effect age seen association d homozygote alzheimers disease data shown reduction heterogeneity stratification age
0.3345159.16033878.html.plaintext.txt	98	repeated overall analysis three genotype restricting data num sample could limited rigorous diagnosis probable definite alzheimers disease according criterion consortium establish registry alzheimers disease num national institute neurological communicative disorder stroke alzheimers disease related disorder association num
0.3345159.16033878.html.plaintext.txt	99	odds ratio similar shown table num significant odds ratio method dersimonian laird num num
0.3345159.16033878.html.plaintext.txt	100	num heterozygote nonsignificant odds ratio num
0.3345159.16033878.html.plaintext.txt	101	heterogeneity remained d homozygote p num
0.3345159.16033878.html.plaintext.txt	102	num longer significant p num
0.3345159.16033878.html.plaintext.txt	103	num instance hardy weinberg disequilibrium individual study four six group pooled case control analyzed race table num
0.3345159.16033878.html.plaintext.txt	104	therefore excluded eight sample mistyping considered possible underreporting heterozygote taking account genotyping method hardy weinberg analysis
0.3345159.16033878.html.plaintext.txt	105	repeated overall analysis remaining num sample
0.3345159.16033878.html.plaintext.txt	106	odds ratio similar table num significant odds ratio num
0.3345159.16033878.html.plaintext.txt	107	num heterozygote nonsignificant odds ratio num
0.3345159.16033878.html.plaintext.txt	108	heterogeneity remained homozygote p num
0.3345159.16033878.html.plaintext.txt	109	num longer significant d homozygote p num
0.3345159.16033878.html.plaintext.txt	110	odds ratio alzheimers disease ace genotype meta analysis ethnic group
0.3345159.16033878.html.plaintext.txt	111	sample divided three ethnic group possible north european num sample south caucasian mediterranean middle eastern num sample east asian chinese japanese four sample
0.3345159.16033878.html.plaintext.txt	112	removed nearly heterogeneity table num
0.3345159.16033878.html.plaintext.txt	113	table num show clear difference among three ethnic group
0.3345159.16033878.html.plaintext.txt	114	overlap whatsoever allelic frequency among three group
0.3345159.16033878.html.plaintext.txt	115	north european east asian differed odds ratio d homozygote versus positive p num
0.3345159.16033878.html.plaintext.txt	116	num homozygote versus d positive p num
0.3345159.16033878.html.plaintext.txt	117	south caucasian also differed east asian odds ratio d homozygote versus positive p num
0.3345159.16033878.html.plaintext.txt	118	d homozygote reduced risk group particularly east asian
0.3345159.16033878.html.plaintext.txt	119	heterozygote increased risk north european
0.3345159.16033878.html.plaintext.txt	120	homozygote higher risk east asian except bayesian analysis
0.3345159.16033878.html.plaintext.txt	121	examined heterosis heterozygote greater risk north european comparing di dd ii turn
0.3345159.16033878.html.plaintext.txt	122	found heterozygote higher risk d homozygote odds ratio num
0.3345159.16033878.html.plaintext.txt	123	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	124	num significantly higher homozygote odds ratio num
0.3345159.16033878.html.plaintext.txt	125	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	126	aced homozygote reduced risk alzheimers disease table num three main ethnic group examined table num
0.3345159.16033878.html.plaintext.txt	127	homozygote neutral regard alzheimers disease risk table num except east asian homozygote may higher risk table num
0.3345159.16033878.html.plaintext.txt	128	heterozygote increased risk alzheimers disease overall table num mainly north european table num
0.3345159.16033878.html.plaintext.txt	129	example heterosis discussed
0.3345159.16033878.html.plaintext.txt	130	similar result achieved three method fixed effect random effect bayesian random effect refer material method table num
0.3345159.16033878.html.plaintext.txt	131	genotypic comparison made refer material method showed allelic dose effect except east asian table num thus allelic comparison would proved le informative
0.3345159.16033878.html.plaintext.txt	132	finding odds ratio close num even though significantly different num table num num suggest either linkage disequilibrium true risk factor confounding hidden interaction
0.3345159.16033878.html.plaintext.txt	133	second possibility discussed
0.3345159.16033878.html.plaintext.txt	134	regarding former kehoe et al
0.3345159.16033878.html.plaintext.txt	135	num study ace haplotype gave evidence indel may actual risk factor rather linkage disequilibrium nearby functional polymorphism true risk factor
0.3345159.16033878.html.plaintext.txt	136	ace haplotype analysis also proved value phenotype enzyme level num insulin level myocardial infarction obesity num
0.3345159.16033878.html.plaintext.txt	137	future alzheimers disease study may better examine polymorphism regulatory region rather indel
0.3345159.16033878.html.plaintext.txt	138	overall result consistent kehoe et al
0.3345159.16033878.html.plaintext.txt	139	num num also recent meta analysis kehoe et al
0.3345159.16033878.html.plaintext.txt	140	num num elkins et al
0.3345159.16033878.html.plaintext.txt	141	latter report num also suggested age difference however although actual age available mean cohort age take account different way defining case age refer material method strongly confounding factor
0.3345159.16033878.html.plaintext.txt	142	latter problem exclude possibility association might stronger younger case example aged le num year onset le num year death
0.3345159.16033878.html.plaintext.txt	143	heterogeneity overall result showed heterogeneity table num
0.3345159.16033878.html.plaintext.txt	144	heterogeneity may due difference sample selection e
0.3345159.16033878.html.plaintext.txt	145	age gender diagnosis method e
0.3345159.16033878.html.plaintext.txt	146	genotyping may due real difference population e
0.3345159.16033878.html.plaintext.txt	147	race interaction risk factor e
0.3345159.16033878.html.plaintext.txt	148	examined potential source heterogeneity
0.3345159.16033878.html.plaintext.txt	149	found little effect age gender apoenum status thus confounding initial hypothesis
0.3345159.16033878.html.plaintext.txt	150	diagnostic genotyping difference contributed heterogeneity
0.3345159.16033878.html.plaintext.txt	151	former mainly due diagnosis possible alzheimers disease reported poor record confirmation autopsy num
0.3345159.16033878.html.plaintext.txt	152	latter largely due certain genotyping method may lead underreporting heterozygote num num shown hardy weinberg analysis
0.3345159.16033878.html.plaintext.txt	153	however greatest source heterogeneity ethnic difference
0.3345159.16033878.html.plaintext.txt	154	ethnic stratification removed nearly heterogeneity table num
0.3345159.16033878.html.plaintext.txt	155	clear contrast among three ethnic group examined north european south caucasian east asian allelic frequency odds ratio table num
0.3345159.16033878.html.plaintext.txt	156	latter might due difference linkage disequilibrium true risk polymorphism see
0.3345159.16033878.html.plaintext.txt	157	ethnic difference previously pointed panza et al
0.3345159.16033878.html.plaintext.txt	158	contrast highlight danger combining ethnic group within single cohort even north south european indicated panza et al
0.3345159.16033878.html.plaintext.txt	159	unfortunately one cohort african origin united state num
0.3345159.16033878.html.plaintext.txt	160	thus conclusion could drawn african
0.3345159.16033878.html.plaintext.txt	161	heterosis deviation hardy weinberg equilibrium common study ace indel previously pointed bus et al
0.3345159.16033878.html.plaintext.txt	162	may due either mistyping heterosis
0.3345159.16033878.html.plaintext.txt	163	several case disequilibrium indeed compatible mistyping
0.3345159.16033878.html.plaintext.txt	164	example disequilibrium north european however excess heterozygote alzheimers disease requires another explanation
0.3345159.16033878.html.plaintext.txt	165	believe explanation heterosis
0.3345159.16033878.html.plaintext.txt	166	heterosis occurs heterozygote show either greater lesser association given trait either group homozygote
0.3345159.16033878.html.plaintext.txt	167	case north european excess heterozygote alzheimers disease association heterozygote alzheimers disease found
0.3345159.16033878.html.plaintext.txt	168	coming macmurray num suggested three explanation heterosis second applied
0.3345159.16033878.html.plaintext.txt	169	proposes heterosis may follow inadvertent combination two unlike subset due hidden interaction another unknown risk factor
0.3345159.16033878.html.plaintext.txt	170	test proposal constructed mathematical model two equal subset based median split unknown factor x table num
0.3345159.16033878.html.plaintext.txt	171	model illustrates although heterozygote may intermediate odds ratio subset emerge highest odds ratio subset combined
0.3345159.16033878.html.plaintext.txt	172	overall result illustrative model table num close present meta analysis table num
0.3345159.16033878.html.plaintext.txt	173	stress however heterosis found north european
0.3345159.16033878.html.plaintext.txt	174	moreover although heterozygote greater risk d homozygote odds ratio num
0.3345159.16033878.html.plaintext.txt	175	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	176	num significantly higher risk homozygote odds ratio num
0.3345159.16033878.html.plaintext.txt	177	num num percent confidence interval num
0.3345159.16033878.html.plaintext.txt	178	thus partial heterosis better describes case
0.3345159.16033878.html.plaintext.txt	179	model show heterosis may follow combination two unlike subset
0.3345159.16033878.html.plaintext.txt	180	hidden interaction partial heterosis north european suggests interaction another risk factor alzheimers disease another potential source heterogeneity
0.3345159.16033878.html.plaintext.txt	181	candidate include cardiovascular risk factor since many also contribute alzheimers disease risk since ace indel associated cardiovascular risk num num
0.3345159.16033878.html.plaintext.txt	182	biologic background full discussion biologic basis association outside scope mainly analytical study
0.3345159.16033878.html.plaintext.txt	183	however note association ace indel nearby polymorphism various phenotype including cardiovascular risk num num num
0.3345159.16033878.html.plaintext.txt	184	addition ace protein level raised certain brain region alzheimers disease num num enzyme reported modify s amyloid aggregation num ace inhibitor reported maintain memory aged rat num human patient num brain penetrating ace inhibitor associated reduced incidence alzheimers disease elderly hypertensive patient num le cognitive decline case mild moderate alzheimers disease num
0.3345159.16033878.html.plaintext.txt	185	num recently provided evidence magnetic resonance imaging increased atrophy hippocampus amygdala nondemented woman homozygous acei allele together modest significant increase risk alzheimers disease independent vascular factor
0.3345159.16033878.html.plaintext.txt	186	d allele associated raised plasma level ace num association thought due linkage disequilibrium nearby polymorphism num num
0.3345159.16033878.html.plaintext.txt	187	apparent conflict benefit ace inhibitor therapy association indel alzheimers disease risk pathology plasma level ace
0.3345159.16033878.html.plaintext.txt	188	however influence ace polymorphism brain level enzyme yet known assumed reflect level plasma
0.3345159.16033878.html.plaintext.txt	189	subject warrant fuller discussion possible
0.3345159.16033878.html.plaintext.txt	190	detailed discussion given kehoe num although need reconsidered perhaps revised light interacting factor factor may emerge future study
0.3345159.16033878.html.plaintext.txt	191	limitation meta analysis lack information author limitation obtained full data num percent subject
0.3345159.16033878.html.plaintext.txt	192	quality diagnosis genotyping varied among study overall result changed question taken account
0.3345159.16033878.html.plaintext.txt	193	considerable heterogeneity initial result
0.3345159.16033878.html.plaintext.txt	194	however found main source heterogeneity able remove
0.3345159.16033878.html.plaintext.txt	195	since cardiovascular factor strong candidate potential interaction ace variant lack data available u factor limitation hope overcome future study
0.3345159.16033878.html.plaintext.txt	196	cardiovascular factor might also influenced result selective mortality
0.3345159.16033878.html.plaintext.txt	197	however d homozygote slightly increased risk cardiovascular complication num num num little evidence association reduced life span num num
0.3345159.16033878.html.plaintext.txt	198	thus influence selective mortality likely small enough provide alternative explanation finding
0.3345159.16033878.html.plaintext.txt	199	conclusion suggest large study established ace indel marker alzheimers disease risk since found evidence bias found removed main source heterogeneity excluded various potential interaction significant result remained three ethnic group examined
0.3345159.16033878.html.plaintext.txt	200	indel however probably linkage disequilibrium true risk polymorphism num
0.3345159.16033878.html.plaintext.txt	201	marked contrast among three ethnic group studied table num
0.3345159.16033878.html.plaintext.txt	202	also found evidence interaction another risk factor north european
0.3345159.16033878.html.plaintext.txt	203	potential interaction factor age gender apoenum status examined particularly interaction cardiovascular risk factor
0.3345159.16033878.html.plaintext.txt	204	acknowledgment financial support received bristol myers squibb phytopharm plc medical research council norman collisson foundation takayama foundation
0.3345159.16033878.html.plaintext.txt	205	kehoe supported gestetner foundation fellowship
0.3345159.16033878.html.plaintext.txt	206	author thank group undertaken acealzheimers disease association study thereby providing data analysis
0.3345159.16033878.html.plaintext.txt	207	especially thank author generously responded request primary data dr
0.3345159.16033878.html.plaintext.txt	208	author particularly grateful dr
0.3345159.16033878.html.plaintext.txt	209	finkh colleague highlighting issue hardy weinberg disequilibrium ace study num dr
0.3345159.16033878.html.plaintext.txt	210	capurso colleague num num pointing ethnic difference ace indel frequency
0.3345159.16033878.html.plaintext.txt	211	author also warmly thank dr
0.3345159.16033878.html.plaintext.txt	212	pembrey advice genetics dr
0.3345159.16033878.html.plaintext.txt	213	marchini advice statistic c
0.3345159.16033878.html.plaintext.txt	214	aldridge administrative support m
0.3345159.16033878.html.plaintext.txt	215	lehmann help mathematical calculation dr
0.3345159.16033878.html.plaintext.txt	216	conflict interest none declared
0.3345159.16033878.html.plaintext.txt	217	note added proof two association study published since submission article kolsch et al
0.3345159.16033878.html.plaintext.txt	218	neurosci lett numnumnum num zhang et al
0.3345159.16033878.html.plaintext.txt	219	dement geriatr cogn disord numnumnum num
0.3375625.15328426.html.plaintext.txt	0	presence apolipoprotein e num allele predisposes early onset primary sjogrens syndrome m
0.3375625.15328426.html.plaintext.txt	1	tampere university hospital num university tampere medical school tampere university hospital tampere finland
0.3375625.15328426.html.plaintext.txt	2	pertovaara department internal medicine section rheumatology tampere university hospital p
0.3375625.15328426.html.plaintext.txt	3	box num fin num tampere finland
0.3375625.15328426.html.plaintext.txt	4	establish whether polymorphism apoe gene affect susceptibility primary sjogrens syndrome ps degree inflammation age onset ps
0.3375625.15328426.html.plaintext.txt	5	apoe genotype distribution allelic frequency analysed using pcr taqman system num finnish caucasian patient ps num healthy control matched sex ethnic origin area residence
0.3375625.15328426.html.plaintext.txt	6	clinical immunological data ps patient analysed relation apoe genotype
0.3375625.15328426.html.plaintext.txt	7	difference ps patient control apoe genotype allelic frequency
0.3375625.15328426.html.plaintext.txt	8	apoe num allele significantly associated early onset ps entire population female patient kaplan meier log rank test p num
0.3375625.15328426.html.plaintext.txt	9	average age plus minus
0.3375625.15328426.html.plaintext.txt	10	onset ps apoe num allele carrier num plus minus num genotype num plus minus num yr p num
0.3375625.15328426.html.plaintext.txt	11	apoe polymorphism associated sign inflammation evaluated marker concentration plasma crp plasma interleukin num plasma tnf immunoglobulin g haemoglobin leucocyte count esr
0.3375625.15328426.html.plaintext.txt	12	apoe polymorphism affect susceptibility ps level plasma inflammatory index patient ps
0.3375625.15328426.html.plaintext.txt	13	however clear association prevails apoe num early onset ps
0.3375625.15328426.html.plaintext.txt	14	key word apolipoprotein e gene polymorphism primary sjogrens syndrome age disease onset
0.3375625.15328426.html.plaintext.txt	15	apolipoprotein e apoe gene polymorphism play significant role lipid metabolism addition recently also suggested regulate inflammation measured level c reactive protein num
0.3375625.15328426.html.plaintext.txt	16	gene apoe polymorphic presenting three common allele num num num single gene locus chromosome num
0.3375625.15328426.html.plaintext.txt	17	allele form six genotype enumnum enumnum enumnum enumnum enumnum enumnum enumnum commonest enumnum second commonest population
0.3375625.15328426.html.plaintext.txt	18	presence apoe num allele associated increased risk coronary heart disease alzheimers disease reviewed num
0.3375625.15328426.html.plaintext.txt	19	circulating testosterone dehydroepiandrosterone dhea level recently found associated apoe genotype woman carrying apoe num allele thus susceptible development disease associated menopause num
0.3375625.15328426.html.plaintext.txt	20	sjogrens syndrome present characteristically middle aged woman
0.3375625.15328426.html.plaintext.txt	21	hypothesized apoe could candidate gene susceptibility ps genetic polymorphism apoe could exert effect marker inflammation patient ps
0.3375625.15328426.html.plaintext.txt	22	hence aim present study investigate well characterized group finnish caucasian patient ps effect polymorphism apoe gene susceptibility severity ps particularly marker inflammation age onset ps
0.3375625.15328426.html.plaintext.txt	23	clinical method careful clinical examination together depth interview patient covering previous disease duration sicca symptom existence recurrent salivary gland swelling recently conducted patient num
0.3375625.15328426.html.plaintext.txt	24	special emphasis laid possible extraglandular symptom ps dermatological endocrine gastrointestinal lymphoproliferative musculoskeletal neurological renal respiratory vascular symptom
0.3375625.15328426.html.plaintext.txt	25	standard laboratory test standard laboratory test included blood cell count erythrocyte sedimentation rate esr plasma c reactive protein crp
0.3375625.15328426.html.plaintext.txt	26	anti s anti s b antibody determined enzyme immunoassay
0.3375625.15328426.html.plaintext.txt	27	serum concentration immunoglobulin g igg measured laser nephelometry serum ssnum microglobulin radioimmunoassay pharmacia beta num micro ria kit pharmacia diagnostics uppsala sweden
0.3375625.15328426.html.plaintext.txt	28	plasma il num tnf concentration determined using commercially available elisa pelikine human il num elisa kit pelikine compact human tnf elisa kit clb amsterdam netherlands
0.3375625.15328426.html.plaintext.txt	29	optical density individual well determined multiscan biochromatic num spectrophotometer thermo labsystems helsinki finland
0.3375625.15328426.html.plaintext.txt	30	detection limit il num assay num
0.3375625.15328426.html.plaintext.txt	31	num pgml tnf assay num
0.3375625.15328426.html.plaintext.txt	32	normal control sixty four healthy finnish red cross transfusion service blood donor matched sex num female two male ethnic origin finnish caucasian area residence tampere finland served control group dna study ps patient
0.3375625.15328426.html.plaintext.txt	33	mean age control subject num plus minus num yr
0.3375625.15328426.html.plaintext.txt	34	apolipoprotein e genotyping genomic dna extracted peripheral blood leucocyte using commercially available kit qiagen hilden germany
0.3375625.15328426.html.plaintext.txt	35	apoe num genotyping fluorogenic allele specific taqman probe primer used previously described num
0.3375625.15328426.html.plaintext.txt	36	apoe num genotype determined using allele specific fluorogenic probe conjugated minor groove binder mgb group
0.3375625.15328426.html.plaintext.txt	37	nucleotide sequence apoe num primer probe used pcr deduced published sequence deposited genbank database chosen synthesized conjunction applied biosystems foster city ca usa using assay design tool
0.3375625.15328426.html.plaintext.txt	38	dna sample genotyped mean num nuclease assay allelic discrimination using abi prism num sequence detection system applied biosystems
0.3375625.15328426.html.plaintext.txt	39	polymerase chain reaction pcr reaction containing genomic dna num x universal pcr master mix num nm primer num nm probe performed num well plate using standard protocol total volume num microl
0.3375625.15328426.html.plaintext.txt	40	water control known control sample previously typed restriction fragment length polymorphism pcr analysis run parallel unknown dna sample
0.3375625.15328426.html.plaintext.txt	41	cycling end point fluorescence measured genotype calling carried using allelic discrimination analysis module
0.3375625.15328426.html.plaintext.txt	42	statistical analysis unpaired student test num test used comparison continuous dichotomous variable respectively
0.3375625.15328426.html.plaintext.txt	43	association num allele age onset ps analysed kaplan meier log rank test
0.3375625.15328426.html.plaintext.txt	44	finding considered statistically significant p num
0.3375625.15328426.html.plaintext.txt	45	statistical analysis performed spss num
0.3375625.15328426.html.plaintext.txt	46	num window spss chicago il usa
0.3375625.15328426.html.plaintext.txt	47	ethical approval study protocol approved ethical committee tampere university hospital
0.3375625.15328426.html.plaintext.txt	48	apolipoprotein e apoe genotype allelic frequency patient primary sjogrens syndrome ps healthy subject
0.3375625.15328426.html.plaintext.txt	49	view larger version numk fig
0.3375625.15328426.html.plaintext.txt	50	kaplan meier plot showing earlier age onset female male patient primary sjogrens syndrome ps carrying num allele apolipoprotein e gene p num
0.3375625.15328426.html.plaintext.txt	51	num log rank test b female patient ps carrying num allele apolipoprotein e gene p num
0.3375625.15328426.html.plaintext.txt	52	apoe polymorphism marker inflammation mean concentration plasma crp ps patient num
0.3375625.15328426.html.plaintext.txt	53	num pgml plasma tnf num
0.3375625.15328426.html.plaintext.txt	54	statistically significant difference marker inflammation plasma crp level num
0.3375625.15328426.html.plaintext.txt	55	num pgml plasma tnf concentration num
0.3375625.15328426.html.plaintext.txt	56	num pgml ps patient carrying apoe num allele carrying allele
0.3375625.15328426.html.plaintext.txt	57	haemoglobin concentration num plus minus num v num plus minus num gl leukocyte count num
0.3375625.15328426.html.plaintext.txt	58	num x numl esr num plus minus num v num plus minus num mmh serum igg num
0.3375625.15328426.html.plaintext.txt	59	num gl serum ssnum microglobulin concentration num
0.3375625.15328426.html.plaintext.txt	60	num mgl differ patient group
0.3375625.15328426.html.plaintext.txt	61	neither anti ssa num plus minus num v num plus minus num iul anti ssb antibody titre num plus minus num v num plus minus num iul differ apoe num carrier non carrier
0.3375625.15328426.html.plaintext.txt	62	apoe polymorphism clinical feature ps difference observed frequency extraglandular manifestation ps history arthralgia arthritis salivary gland swelling raynauds symptom purpura lymphadenopathy pleuritis alveolitis pulmonary fibrosis peripheral central nervous system symptom patient without apoe num allele
0.3375625.15328426.html.plaintext.txt	63	number diagnostic criterion ps differ patient group data shown
0.3375625.15328426.html.plaintext.txt	64	histological grade labial salivary gland biopsy lower apoe num carrier non carrier grade num num num v num p num
0.3375625.15328426.html.plaintext.txt	65	discussion genetic variation apoe gene influence susceptibility coronary heart disease sporadic alzheimers disease apoe num allele strong association
0.3375625.15328426.html.plaintext.txt	66	recently genetic variation apoe gene also found affect degree inflammation influencing serum crp level dyslipidaemic middle aged men num
0.3375625.15328426.html.plaintext.txt	67	surprisingly however patient carrying apoe num allele known associated inflammation found lower crp level others num
0.3375625.15328426.html.plaintext.txt	68	patient ps chronic inflammation present shown markedly elevated esr level pronounced hypergammaglobulinaemia elevated il num level
0.3375625.15328426.html.plaintext.txt	69	therefore hypothesized genetic polymorphism apoe could effect marker inflammation patient ps
0.3375625.15328426.html.plaintext.txt	70	however proved case first difference found apoe genotype allele frequency ps patient healthy control
0.3375625.15328426.html.plaintext.txt	71	moreover apoe num allele influence level crp patient ps
0.3375625.15328426.html.plaintext.txt	72	finding might explained fact ps known belong group autoimmune disease modest even absent crp reaction num
0.3375625.15328426.html.plaintext.txt	73	however addition lack difference crp level difference emerged well established marker inflammatory activity including plasma il num tnf igg apoe num carrier non carrier
0.3375625.15328426.html.plaintext.txt	74	apoe num carrier state also associated clinical feature disease
0.3375625.15328426.html.plaintext.txt	75	labial salivary gland histology marker severity inflammation ps even milder apoe num allele carrier compared non carrier
0.3375625.15328426.html.plaintext.txt	76	found age disease onset significantly lower ps patient apoe num allele without allele
0.3375625.15328426.html.plaintext.txt	77	similarly noted effect apoe num allele coronary atherosclerosis num alzheimers disease num age dependent
0.3375625.15328426.html.plaintext.txt	78	moreover recent study apoe polymorphism also found affect age onset infectious disease num num
0.3375625.15328426.html.plaintext.txt	79	apoe polymorphism found affect age becoming infected plasmodium falciparum child ghana num possible role protection early stage malaria num
0.3375625.15328426.html.plaintext.txt	80	epstein barr cytomegalovirus retrovirus infection proposed act triggering agent development ps genetically susceptible subject num
0.3375625.15328426.html.plaintext.txt	81	data apoe polymorphism susceptibility age disease onset related infection
0.3375625.15328426.html.plaintext.txt	82	know background significant association apoe num earlier disease onset ps
0.3375625.15328426.html.plaintext.txt	83	one might speculate however association could mediated example possible effect time point triggering viral infection
0.3375625.15328426.html.plaintext.txt	84	speculative explanation earlier age onset ps particularly female subject carrying apoe num allele might relation hormonal factor view strong female predominance among patient ps also believed involved pathogenesis ps num
0.3375625.15328426.html.plaintext.txt	85	gender bias concomitant characteristic late age disease onset ps difficult interpret oestrogen considered favour autoimmunity androgen protect
0.3375625.15328426.html.plaintext.txt	86	carrier apoe num held susceptible development disease associated menopause found higher serum dhea testosterone level woman carrying allele num
0.3375625.15328426.html.plaintext.txt	87	furthermore interaction oestrogen apoe alzheimers disease process observed recent study apoe polymorphism influenced binding oestrogen receptor altered transcriptional activity response oestrogen num
0.3375625.15328426.html.plaintext.txt	88	demonstrated apoe polymorphism affect susceptibility ps plasma inflammatory index patient ps clear association apoe num allele early onset ps
0.3375625.15328426.html.plaintext.txt	89	acknowledgment study supported medical research fund tampere university hospital tampere finland maud kuistilas foundation
0.3375625.15328426.html.plaintext.txt	90	author declared conflict interest
0.33803913.15066991.html.plaintext.txt	0	apolipoprotein stimulated apolipoprotein e secretion human macrophage independent cholesterol efflux maaike kockxa kerry anne ryeb katharina gausa carmel m
0.33803913.15066991.html.plaintext.txt	1	quinna janelle wrighta timothy sloanea dimitri sviridovc ying fuc david sullivand john r
0.33803913.15066991.html.plaintext.txt	2	burnette stephan rustf gerd assmannf g
0.33803913.15066991.html.plaintext.txt	3	palgunacharig sissel lund katzh michael c
0.33803913.15066991.html.plaintext.txt	4	deani wendy jessupa leonard kritharidesabjk
0.33803913.15066991.html.plaintext.txt	5	macrophage biology group centre vascular research university new south wale sydney num australia b heart research institute sydney num australia c baker heart research institute melbourne num australia d department clinical biochemistry royal prince alfred hospital university sydney sydney num australia e department core clinical pathology biochemistry royal perth hospital school medicine pharmacology university western australia perth num australia f institut fur arterioskleroseforschung der westfalischen wilhelms universitat munster munster num germany g university alabama birmingham medical center birmingham alabama num hchildrens hospital philadelphia stokes research institute philadelphia pennsylvania num num university canberra australian capital territory num australia j department cardiology concord hospital university sydney sydney num australia
0.33803913.15066991.html.plaintext.txt	6	received publication february num num revised form march num num
0.33803913.15066991.html.plaintext.txt	7	lipid removal apoa involves camp inducible active transport pathway num known mediated atp binding cassette transporter num abcanumabc num num
0.33803913.15066991.html.plaintext.txt	8	transporter membrane protein utilize atp hydrolysis transport substrate across membrane num
0.33803913.15066991.html.plaintext.txt	9	mutation abcanumabc num cause tangier disease td severe hdl deficiency syndrome characterized low plasma level hdl apoa accumulation cholesterol tissue macrophage predisposition atherosclerosis num num
0.33803913.15066991.html.plaintext.txt	10	fibroblast subject tangier disease show impaired cholesterol phospholipid release lipid free apolipoproteins num
0.33803913.15066991.html.plaintext.txt	11	addition inhibition abcanum expression activity inhibits lipid efflux apoa normal fibroblast num num
0.33803913.15066991.html.plaintext.txt	12	property additional induction cholesterol efflux may contribute anti atherogenic effect apoa num
0.33803913.15066991.html.plaintext.txt	13	human atherosclerotic lesion contain apoe protein mrna especially association macrophage foam cell num
0.33803913.15066991.html.plaintext.txt	14	secretion apoe macrophage may protect atherosclerosis indicated effect transplantation apoe expressing bone marrow apoe null mouse num num
0.33803913.15066991.html.plaintext.txt	15	may depend upon enhanced local clearance cellular lipid andor inhibition local inflammatory response addition lowering plasma concentration atherogenic plasma lipoprotein
0.33803913.15066991.html.plaintext.txt	16	recent study demonstrated apoa stimulates apoe secretion cholesterol efflux human mouse foam cell macrophage num num
0.33803913.15066991.html.plaintext.txt	17	stimulation apoe secretion apoa hdl likely post transcriptionally regulated observed endogenous apoe macrophage recycled apoe hepatocytes num num
0.33803913.15066991.html.plaintext.txt	18	recent study indicate abcanum may involved basal apoe secretion num
0.33803913.15066991.html.plaintext.txt	19	however requirement abcanum activity apoa induced apoe secretion never reported
0.33803913.15066991.html.plaintext.txt	20	study provide evidence apoa stimulated apoe secretion mechanistically distinct stimulation abcanum mediated cholesterol efflux
0.33803913.15066991.html.plaintext.txt	21	demonstrate apoa promotes secretion mobile pool apoe otherwise destined intracellular degradation process require interaction c terminus apoa plasma membrane occurs normally macrophage patient tangier disease implying independence abcanum activity
0.33803913.15066991.html.plaintext.txt	22	apolipoproteins human apoa apoa ii isolated hdl ultracentrifugation anion exchange chromatography num num
0.33803913.15066991.html.plaintext.txt	23	human apoa iv isolated density num
0.33803913.15066991.html.plaintext.txt	24	num gml fraction plasma adsorption onto synthetic triglyceride rich microemulsions
0.33803913.15066991.html.plaintext.txt	25	microemulsions delipidated apoa iv purified anion exchange chromatography q sepharose fast flow column num num
0.33803913.15066991.html.plaintext.txt	26	human apoenum apoenum apoenum expressed blnum escherichia coli provided dr
0.33803913.15066991.html.plaintext.txt	27	karl weisgraber gladstone institute purified gel filtration chromatography
0.33803913.15066991.html.plaintext.txt	28	apoa peptide recombinant protein pure peptide representing peptide apoa synthesized using automated solid phase peptide synthesizer described previously num num
0.33803913.15066991.html.plaintext.txt	29	promote helical stability peptide molecule n c terminus acetylated amidated except peptide num num respectively num
0.33803913.15066991.html.plaintext.txt	30	truncated apoa propeptide mutant expressed e
0.33803913.15066991.html.plaintext.txt	31	colipgex expression system num
0.33803913.15066991.html.plaintext.txt	32	cholesterol efflux protein previously published num
0.33803913.15066991.html.plaintext.txt	33	apoa deletion mutant constructed described previously num num
0.33803913.15066991.html.plaintext.txt	34	wild type apoa engineered variant apoa expressed expression host e
0.33803913.15066991.html.plaintext.txt	35	coli strain blnum denum isolated gel filtration anion exchange chromatography num
0.33803913.15066991.html.plaintext.txt	36	identical stimulation apoe secretion human macrophage foam cell observed control experiment using recombinant wild type apoa human apoa prepared human plasma
0.33803913.15066991.html.plaintext.txt	37	previous study established num num microgml apoa saturating cholesterol efflux apoe secretion human murine macrophage num
0.33803913.15066991.html.plaintext.txt	38	present study peptide protein added cell final concentration num microgml culture medium first establishing excess saturating concentration induction apoe secretion molecule
0.33803913.15066991.html.plaintext.txt	39	preparation phospholipid apoa phospholipid apoa ii disc disc prepared described previously num using cholate dialysis method num
0.33803913.15066991.html.plaintext.txt	40	preparation disc dialyzed extensively num
0.33803913.15066991.html.plaintext.txt	41	num m tris buffered saline containing num
0.33803913.15066991.html.plaintext.txt	42	num wv edta nanum numnum wv nannum stored argon
0.33803913.15066991.html.plaintext.txt	43	lipid free apoa apoa ii present preparation judged electrophoresis non denaturing num num gradient gel
0.33803913.15066991.html.plaintext.txt	44	phospholipid composition varied altering proportion phospholipid added time preparation
0.33803913.15066991.html.plaintext.txt	45	chemical analysis reconstituted particle carried rochehitachi num analyzer roche diagnostics zurich switzerland
0.33803913.15066991.html.plaintext.txt	46	phospholipid concentration determined enzymatically num num
0.33803913.15066991.html.plaintext.txt	47	stokes diameter surface charge particle measured non denaturing page agarose gel electrophoresis num num
0.33803913.15066991.html.plaintext.txt	48	experiment cell efflux incubation medium containing apoa phospholipid apoa ii phospholipid disc underwent non denaturing polyacrylamide gel electrophoresis followed electrophoretic transfer nitrocellulose membrane immunoblotting apoe apoa apoa ii investigate possible association apoe phospholipid containing particle
0.33803913.15066991.html.plaintext.txt	49	isolation culture human monocyte derived macrophage hmdm human monocyte apoenumenum phenotype isolated white cell concentrate healthy donor using centrifugal elutriation described num
0.33803913.15066991.html.plaintext.txt	50	genotyping completed taq polymerase chain reaction amplification num base pair fragment apoe gene followed cutting restriction endonuclease cfonum department biochemistry royal prince alfred hospital
0.33803913.15066991.html.plaintext.txt	51	white cell buffy coat concentrate num h ex vivo human serum provided new south wale red cross blood transfusion service sydney australia
0.33803913.15066991.html.plaintext.txt	52	purified monocyte num purity nonspecific esterase staining differentiated plating num
0.33803913.15066991.html.plaintext.txt	53	num x num cell per num mm diameter culture dish costar rpmi num containing penicillin g streptomycin num unitsml num microgml respectively l glutamine num mm num vv heat inactivated whole human serum num day
0.33803913.15066991.html.plaintext.txt	54	following differentiation cell washed enriched unesterified cholesterol fc cholesteryl ester ce incubation rpmi num containing num lpds vv acldl num microg proteinml num day num
0.33803913.15066991.html.plaintext.txt	55	mononuclear cell individual donor tangier disease subject control isolated minor modification previously described density separation method num num using optipreptm solution density num
0.33803913.15066991.html.plaintext.txt	56	num gml solution density num
0.33803913.15066991.html.plaintext.txt	57	num gml remove platelet lymphocyte respectively
0.33803913.15066991.html.plaintext.txt	58	total cell plated density num x num cellsnum mm diameter culture well falcon
0.33803913.15066991.html.plaintext.txt	59	cell differentiated macrophage rpmi num containing antibiotic glutamine num ngml m csf num heat inactivated whole human serum num num num day
0.33803913.15066991.html.plaintext.txt	60	time cell washed prior cholesterol enrichment see
0.33803913.15066991.html.plaintext.txt	61	direct comparison hmdm isolated normal donor density centrifugation centrifugal elutriation confirmed identical cholesterol efflux apoe secretion either method
0.33803913.15066991.html.plaintext.txt	62	lipid efflux apoe secretion achieve cholesterol loading macrophage num microciml numhcholesterol ethanol incorporated acldl incubating cell num day described num
0.33803913.15066991.html.plaintext.txt	63	triplicate culture harvested loading confirm efficient enrichment fc ce hplc
0.33803913.15066991.html.plaintext.txt	64	cell subsequently washed equilibrated overnight rpmi num containing num
0.33803913.15066991.html.plaintext.txt	65	num wv bovine serum albumin allow equilibration numhcholesterol fc ce pool
0.33803913.15066991.html.plaintext.txt	66	experiment cell loaded acldl without numhcholesterol phospholipid labeled end num day cholesterol loading period incubating cell rpmi num containing num microciml numhcholine chloride ethanol final num vv num
0.33803913.15066991.html.plaintext.txt	67	num bovine serum albumin wv num h followed equilibration num h rpmi num containing num
0.33803913.15066991.html.plaintext.txt	68	equilibrated cholesterol enriched cell washed warm pb incubated num
0.33803913.15066991.html.plaintext.txt	69	num ml efflux medium comprising rpmi num without num microgml apoa appropriate addition
0.33803913.15066991.html.plaintext.txt	70	num num h medium removed mixed complete protease inhibitor roche applied science num
0.33803913.15066991.html.plaintext.txt	71	num tiu aprotinin sigma spun num min numnum x g remove detached cell
0.33803913.15066991.html.plaintext.txt	72	culture washed twice ice cold pb scraped num
0.33803913.15066991.html.plaintext.txt	73	num ml cold pb containing complete protease inhibitor aprotinin
0.33803913.15066991.html.plaintext.txt	74	quantitation cholesterol cholesteryl ester cell medium num microl medium aliquot num microl cell aliquot analyzed scintillation counting quantify efflux numhcholesterol
0.33803913.15066991.html.plaintext.txt	75	proportion label cell numhfc numhce determined separation tlc heptaneethyl acetate numnum vv
0.33803913.15066991.html.plaintext.txt	76	standard fc ce identified charring num degree c num cusonum num
0.33803913.15066991.html.plaintext.txt	77	mass fc ce cell medium determined reverse phase hplc extraction methanolhexane num num
0.33803913.15066991.html.plaintext.txt	78	radiochemical equilibrium determined calculating specific activity free esterified cholesterol dpm per nmol num reproducibly achieved num day cholesterol enrichment overnight equilibration
0.33803913.15066991.html.plaintext.txt	79	quantitation phospholipid cell medium phospholipid extracted num microl aliquot cell lysates medium sample using method bligh dyer including two backwash methanolwater numnum vv described previously num
0.33803913.15066991.html.plaintext.txt	80	evaporation chloroform phase lipid dissolved num microl chloroformmethanol numnum vv num microl aliquot counted scintillation counting determine phospholipid efflux
0.33803913.15066991.html.plaintext.txt	81	total phospholipid mass determined using modification bartlett assay described num used determine specific activity dpm per nmol phospholipid
0.33803913.15066991.html.plaintext.txt	82	quantitation apoe cell lysates efflux medium western blot elisa aliquot num microl cell culture medium mixed sample buffer num
0.33803913.15066991.html.plaintext.txt	83	num microl containing num mm dithiothreitol heated num degree c num min separated sd page using num stacking gel num
0.33803913.15066991.html.plaintext.txt	84	num polyacrylamide resolving gel reducing condition tris glycine buffer described num
0.33803913.15066991.html.plaintext.txt	85	electrophoretic western blot transfer onto num
0.33803913.15066991.html.plaintext.txt	86	num microm nitrocellulose membrane performed trisglycine buffer num h num num v blocked incubating primary antibody apoe goat anti human polyclonal numnum dilution washing incubating numnum dilution secondary antibody rabbit anti goat igg conjugated horseradish peroxidase num
0.33803913.15066991.html.plaintext.txt	87	membrane chemiluminescence signal quantified using kodak digital science numd expressed arbitrary unit au per mg cell protein
0.33803913.15066991.html.plaintext.txt	88	experiment serial dilution authentic human apoe standard sample buffer separated blotted parallel allow calculation secreted apoe mass microgram per culture microg per mg cell protein
0.33803913.15066991.html.plaintext.txt	89	linear response range chemiluminescence signal mass authentic human apoe standard defined western blot experiment
0.33803913.15066991.html.plaintext.txt	90	addition apoe secretion measured experiment using elisa
0.33803913.15066991.html.plaintext.txt	91	nunc num well immunoplates coated num
0.33803913.15066991.html.plaintext.txt	92	num microgml mouse monoclonal anti human apoe antibody biodesign num
0.33803913.15066991.html.plaintext.txt	93	standard prepared purified human apoe biodesign whereas antibody used western analysis used tagging antibody goat anti human polyclonal numnum rabbit antigoat horseradish peroxidase numnum
0.33803913.15066991.html.plaintext.txt	94	metabolic labeling cell protein numsmethioninecysteine study fate newly synthesized apoe cholesterol enriched hmdm labeled methionine free medium invitrogen containing num microciml numstran label num cimmol icn num h washed chased rpmi num medium containing num mm methionine sigma cysteine sigma
0.33803913.15066991.html.plaintext.txt	95	nums labeled apoe cell lysates culture medium determined immunoprecipitation using numnumnum dilution polyclonal goat antibody human apoe protein sepharose amersham bioscience separation sd page quantified phosphorimaging photostimulated luminescence fujix ba num expressed au apoemg cell protein num
0.33803913.15066991.html.plaintext.txt	96	indicated experiment detecting small amount secreted apoe requiring increased sensitivity immunoprecipitated nums labeled apoe directly quantified radiometric detection confirming single band sd page phosphorimaging
0.33803913.15066991.html.plaintext.txt	97	numsmethioninecysteine labeling also used discriminate cell derived secreted exogenous apoe experiment investigating secretion apoe recombinant apoenum enum enum
0.33803913.15066991.html.plaintext.txt	98	biotinylation isolation biotinylated apoe cholesterol enriched hmdm incubated num microciml numstran label methionine free dulbeccos modified eagle medium dmem containing num dmem num h
0.33803913.15066991.html.plaintext.txt	99	surface protein biotinylated placing cell ice num min followed incubation num mgml sulfo nh s biotin pierce pb num degree c num min
0.33803913.15066991.html.plaintext.txt	100	cell washed twice ice cold pb subsequently incubated without num microgml apoa num min num degree c
0.33803913.15066991.html.plaintext.txt	101	apoe immunoprecipitated described biotinylated apoe separated total immunoprecipitated apoe described num
0.33803913.15066991.html.plaintext.txt	102	short total apoe released protein sepharose bead boiling num microl hepes buffered saline containing num sd num degree c num min
0.33803913.15066991.html.plaintext.txt	103	biotinylated apoe separated unbiotinylated apoe using immunopure immobilized streptavidin pierce quantified using scintillation counting sd pagephosphorimaging
0.33803913.15066991.html.plaintext.txt	104	biotinylated apoe quantified au apoemg cell protein percent total immunoprecipitated secreted apoe
0.33803913.15066991.html.plaintext.txt	105	num total cellular apoe biotinylated num
0.33803913.15066991.html.plaintext.txt	106	num cellular apoe protein plasma membrane fraction isolated sucrose density gradient num
0.33803913.15066991.html.plaintext.txt	107	cell surface protein biotinylated num degree c num estimated num
0.33803913.15066991.html.plaintext.txt	108	num plasma membrane pool apoe biotinylated experiment
0.33803913.15066991.html.plaintext.txt	109	analysis apoe mrna real time pcr cell harvested total rna using tri reagent sigma according manufacturer instruction exception num bromo num chloropropane sigma substituted chloroform
0.33803913.15066991.html.plaintext.txt	110	reverse transcription reaction num microg total rna reverse transcribed using oligodt primer invitrogen superscript ii reverse transcriptase invitrogen
0.33803913.15066991.html.plaintext.txt	111	relative real time rt pcr performed using iq sybr green supermix bio rad abi num sequence detector pe biosystems analyzed using abi prism sequence detector software vnum
0.33803913.15066991.html.plaintext.txt	112	gene specific primer used follows apoe num ctgctcagctcccaggtcacccagg numforward num cttctgcaggtcatcggcatcgcgg numreverse annealing num degree c num cycle product size num base pair
0.33803913.15066991.html.plaintext.txt	113	abcanum num gcactgaggaagatgctgaaa numforward num agttcctggaaggtcttgttcac num reverse annealing num degree c num cycle product size num base pair
0.33803913.15066991.html.plaintext.txt	114	result normalized housekeeping gene pbgd num gagtgattcgcgtgggtacc num forward num ggctccgatggtgaagcc num reverse annealing num num degree c
0.33803913.15066991.html.plaintext.txt	115	melting curve analysis performed confirm production single product reaction
0.33803913.15066991.html.plaintext.txt	116	result exposure apoa related without apoa rpmi num medium control experiment result three experiment averaged
0.33803913.15066991.html.plaintext.txt	117	sucrose density ultracentrifugation determine buoyant density secreted apoe medium sample subjected sucrose density ultracentrifugation using minor modification published protocol num
0.33803913.15066991.html.plaintext.txt	118	following efflux num microl aliquot medium centrifuged numnum x g num min remove cellular debris supernatant underlayed
0.33803913.15066991.html.plaintext.txt	119	underlay completed using num ml num
0.33803913.15066991.html.plaintext.txt	120	num ml num sucrose solution num
0.33803913.15066991.html.plaintext.txt	121	num ml num sucrose solution num
0.33803913.15066991.html.plaintext.txt	122	num ml beckman quick seal tube sample centrifuged numnum rpm numnum x g num h num degree c using tlnum
0.33803913.15066991.html.plaintext.txt	123	num rotor beckman tlx ultracentrifuge
0.33803913.15066991.html.plaintext.txt	124	num x num microl aliquot taken analyzed numhcholesterol apoe western blot
0.33803913.15066991.html.plaintext.txt	125	tangier disease patient tdnum tdnum previously unreported num year old male clinical feature consistent tangier disease tdnum identified
0.33803913.15066991.html.plaintext.txt	126	patient premature coronary artery disease low plasma hdl cholesterol num
0.33803913.15066991.html.plaintext.txt	127	num mgdl normal range num num mgdl apoa concentration num
0.33803913.15066991.html.plaintext.txt	128	num mgdl normal num num mgdl low total cholesterol num
0.33803913.15066991.html.plaintext.txt	129	num mgdl normal range num num mgdl ldl cholesterol num
0.33803913.15066991.html.plaintext.txt	130	num mgdl normal range num num mgdl level
0.33803913.15066991.html.plaintext.txt	131	also elevated plasma triglyceride num
0.33803913.15066991.html.plaintext.txt	132	num mgdl normal num mgdl bilateral cataract hepatomegaly
0.33803913.15066991.html.plaintext.txt	133	splenomegaly tonsil removed childhood
0.33803913.15066991.html.plaintext.txt	134	assmann institut fur arterioskleroseforschung der westfalischen wilhelms universitat munster germany
0.33803913.15066991.html.plaintext.txt	135	two novel amino acid mutation within abcanum gene found cnumr exon num c
0.33803913.15066991.html.plaintext.txt	136	numc deletion three nucleotide exon num c
0.33803913.15066991.html.plaintext.txt	137	num numdeltct different allele shown segregation analysis numbering follows recommendation international nomenclature working group
0.33803913.15066991.html.plaintext.txt	138	mutation affect amino acid conserved human mouse
0.33803913.15066991.html.plaintext.txt	139	neither mutation previously described
0.33803913.15066991.html.plaintext.txt	140	healthy subject normal lipoprotein profile history vascular disease used source control macrophage hcnum
0.33803913.15066991.html.plaintext.txt	141	since completion study tdnum died
0.33803913.15066991.html.plaintext.txt	142	second td patient tdnum healthy normal brother hcnum heterozygous parent hznuma mother hznumb father previously described num num
0.33803913.15066991.html.plaintext.txt	143	abcanum mutation td patient published missense mutation exon num anumd frameshift mutation exon num numinsa anum xnum num
0.33803913.15066991.html.plaintext.txt	144	using current nomenclature respectively equivalent missense mutation exon num c
0.33803913.15066991.html.plaintext.txt	145	numc anumd frameshift mutation exon num c
0.33803913.15066991.html.plaintext.txt	146	num numinsa anum f xnum
0.33803913.15066991.html.plaintext.txt	147	hcnum neither abcanum mutation hznuma hznumb contain numinsa anumd mutation respectively
0.33803913.15066991.html.plaintext.txt	148	plasma hdl cholesterol concentration hcnum tdnum hznuma hznumb respectively num
0.33803913.15066991.html.plaintext.txt	149	num mgdl apoa level respectively num num
0.33803913.15066991.html.plaintext.txt	150	plasma triglyceride concentration elevated subject num
0.33803913.15066991.html.plaintext.txt	151	protein estimation protein content ldl sample cell lysates determined duplicate triplicate sample measured using bca method bovine serum albumin standard num
0.33803913.15066991.html.plaintext.txt	152	cell viability cell viability following various treatment routinely assessed light microscopic morphology estimation cell protein measuring leakage lactate dehydrogenase medium num
0.33803913.15066991.html.plaintext.txt	153	cell viability routinely num num incubation efflux medium
0.33803913.15066991.html.plaintext.txt	154	data analysis degradation secretion cellular apoe pulse chase experiment simultaneously fitted first order rate equation knum knum describing rate constant secretion degradation respectively
0.33803913.15066991.html.plaintext.txt	155	first order rate equation shown equation num
0.33803913.15066991.html.plaintext.txt	156	num fitted experimental secretion degradation data using non linear least square fitting program solver microsoft excel
0.33803913.15066991.html.plaintext.txt	157	quality fit evaluated error function previously described num
0.33803913.15066991.html.plaintext.txt	158	efflux calculated numhlipids e
0.33803913.15066991.html.plaintext.txt	159	cholesterol phospholipid released medium expressed percentage total numh cellular lipid tnum num num
0.33803913.15066991.html.plaintext.txt	160	unless otherwise stated data presented mean plus minus
0.33803913.15066991.html.plaintext.txt	161	triplicate culture single experiment representative least num num independent experiment
0.33803913.15066991.html.plaintext.txt	162	significance result assessed unpaired student test simple comparison two group one way analysis variance using tukeys test post hoc correction multiple comparison
0.33803913.15066991.html.plaintext.txt	163	difference considered significant p num
0.33803913.15066991.html.plaintext.txt	164	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	165	post transcriptional stimulation apoe secretion apoa
0.33803913.15066991.html.plaintext.txt	166	hmdm incubated num day num microgml acldl washed incubated time indicated rpmi num apoa without control num microgml apoa
0.33803913.15066991.html.plaintext.txt	167	apoe protein determined western blotting num h three independent cell culture medium cell lysates elisa variable time b
0.33803913.15066991.html.plaintext.txt	168	apoe mrna level c determined num h real time rt pcr relative housekeeping gene pbgd described experimental procedure
0.33803913.15066991.html.plaintext.txt	169	determine effect apoa secretion degradation preformed apoe absence ongoing de novo synthesis pulse chase experiment performed
0.33803913.15066991.html.plaintext.txt	170	pulse incubation first incorporated numsmethionine cellular apoe chased without apoa absence label fig
0.33803913.15066991.html.plaintext.txt	171	apoa rapidly stimulated secretion numsapoe difference apoa containing control medium apparent within num min incubation
0.33803913.15066991.html.plaintext.txt	172	analysis residual cell nums labeled apoe chase incubation demonstrated rapid nearly identical decline cell associated apoe without apoa
0.33803913.15066991.html.plaintext.txt	173	net degradation apoe cell plus medium lower apoa containing culture relative control condition matched increased secretion apoe apoa containing medium
0.33803913.15066991.html.plaintext.txt	174	identical rate decline cell associated apoe control apoa exposed condition suggests apoa diverts apoe secretion cellular pool apoe otherwise degraded
0.33803913.15066991.html.plaintext.txt	175	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	176	apoa stimulates secretion preformed apoe decrease net apoe degradation
0.33803913.15066991.html.plaintext.txt	177	hmdm incubated num day num microgml acldl washed incubated methionine free dulbeccos modified eagle medium num microciml numsmethioninecysteine num h
0.33803913.15066991.html.plaintext.txt	178	cell washed chased without num microgml apoa
0.33803913.15066991.html.plaintext.txt	179	indicated time nums labeled apoe immunoprecipitated medium cell lysates separated detected sd page phosphorimaging single num kda band measured scintillation counting excised band described experimental procedure
0.33803913.15066991.html.plaintext.txt	180	start chase tnum total apoe num
0.33803913.15066991.html.plaintext.txt	181	secreted apoe b cell associated apoe c net degradation apoe calculated subtracting residual apoe cell medium apoe cell tnum
0.33803913.15066991.html.plaintext.txt	182	data expressed percent total apoe tnum
0.33803913.15066991.html.plaintext.txt	183	investigate pool apoe mobilized apoa degradation secretion cellular apoe simultaneously fitted first order rate equation knum describing rate constant secretion knum degradation
0.33803913.15066991.html.plaintext.txt	184	previously described boundary condition accepting modeling experimental data error function erf num
0.33803913.15066991.html.plaintext.txt	185	initial model assumed de novo synthesized apoe equally susceptible degradation secretion net degradation secretion proceeded constant rate independent
0.33803913.15066991.html.plaintext.txt	186	however comparison experimental calculated data using model identified erf excessive fulfill boundary condition erf control num
0.33803913.15066991.html.plaintext.txt	187	second model simultaneously fitted degradation secretion nums labeled cellular apoe first order rate equation described experimental procedure
0.33803913.15066991.html.plaintext.txt	188	cellular labeled apoe start chase divided two pool larger mobile pool apoe em num smaller stable pool e num neither degraded secreted duration experiment
0.33803913.15066991.html.plaintext.txt	189	presence e apparent residual pool undegraded cell associated apoe presence stable pool previously identified surface hepgnum cell num
0.33803913.15066991.html.plaintext.txt	190	using model secretion degradation apoe mutually dependent boundary condition goodness fit fulfilled fig
0.33803913.15066991.html.plaintext.txt	191	apoa increased rate constant secretion knum decreased rate constant degradation knum relative control condition substantially alter size e em
0.33803913.15066991.html.plaintext.txt	192	thus apoa stimulated secretion mobile pool apoe otherwise fated intracellular degradation
0.33803913.15066991.html.plaintext.txt	193	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	194	apoa diverts apoe degradation secretion
0.33803913.15066991.html.plaintext.txt	195	degradation secretion nums labeled cellular apoe pulse chase experiment simultaneously fitted first order rate equation described experimental procedure
0.33803913.15066991.html.plaintext.txt	196	model apoe turnover e em representing stable mobile cellular apoe pool respectively knum knum respectively describing rate constant secretion degradation
0.33803913.15066991.html.plaintext.txt	197	b experimental open symbol dashed line calculated closed symbol solid line kinetic data secreted cellular degraded apoe presence apoa
0.33803913.15066991.html.plaintext.txt	198	c summary modeling parameter e representing percent cellular apoe stable pool erf representing error function modeling parameter
0.33803913.15066991.html.plaintext.txt	199	considered cell surface apoe might contribute mobile pool apoe secreted apoa apoe mobilized surface cell num
0.33803913.15066991.html.plaintext.txt	200	investigate numsmethionine labeled hmdm incubated num degree c biotin label cell surface protein cell exposed control medium apoa num min num degree c allow apoe secretion fig
0.33803913.15066991.html.plaintext.txt	201	cell medium sample sequentially immunoprecipitated first using antibody apoe biotin
0.33803913.15066991.html.plaintext.txt	202	apoa stimulated secretion biotin labeled apoe num fold relative control medium indicating cell surface apoe contribute secreted apoe
0.33803913.15066991.html.plaintext.txt	203	however biotin labeled apoe represented num secreted apoe control num
0.33803913.15066991.html.plaintext.txt	204	num condition num min much le estimated proportion plasma membrane apoe biotinylated num
0.33803913.15066991.html.plaintext.txt	205	num see experimental procedure
0.33803913.15066991.html.plaintext.txt	206	data indicated net contribution cell surface pool overall apoe secretion minor
0.33803913.15066991.html.plaintext.txt	207	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	208	apoa stimulates release cell surface pool apoe
0.33803913.15066991.html.plaintext.txt	209	hmdm cholesterol enriched acldl radiolabeled nums methioninecysteine num h
0.33803913.15066991.html.plaintext.txt	210	numsmethionine labeled hmdm placed ice num degree c cell surface protein biotinylated described experimental procedure
0.33803913.15066991.html.plaintext.txt	211	cell incubated medium without control num microgml apoa apoa num min num degree c
0.33803913.15066991.html.plaintext.txt	212	total nums labeled apoe immunoprecipitated biotinylated pool immunoprecipitated pool quantified
0.33803913.15066991.html.plaintext.txt	213	total nums labeled apoe immunoprecipitated cell culture tnum numnum plus minus numnum dpmmg cell protein
0.33803913.15066991.html.plaintext.txt	214	b numsmethionine labeled hmdm placed ice incubated without apoa num min num degree c
0.33803913.15066991.html.plaintext.txt	215	nums labeled apoe released medium immunoprecipitated quantified represented num
0.33803913.15066991.html.plaintext.txt	216	num total cellular apoe tnum control apoa respectively
0.33803913.15066991.html.plaintext.txt	217	significantly different versus control p num
0.33803913.15066991.html.plaintext.txt	218	cell surface apoe re endocytosed num pool biotin labeled apoe secreted apoa could represent apoe directly mobilized cell surface apoe re internalized re secreted although little recycling would expected num min
0.33803913.15066991.html.plaintext.txt	219	confirm apoa directly mobilizes cell surface apoe numsmethionine labeled hmdm precooled num degree c incubated control medium apoa num degree c num min fig
0.33803913.15066991.html.plaintext.txt	220	apoa approximately doubled release cell surface apoe num degree c num
0.33803913.15066991.html.plaintext.txt	221	num total cell apoe present tnum indicating cell surface apoe contribute directly mobile pool apoe released apoa although overall remains minor proportion total apoe released
0.33803913.15066991.html.plaintext.txt	222	c terminal truncation pro apoa differentially affect cholesterol efflux apoe secretion previous study indicated c terminus apoa particularly important stimulation cholesterol efflux binding apoa cell surface num related lipid binding ability c terminus num num
0.33803913.15066991.html.plaintext.txt	223	investigated role c terminus inducing apoe secretion primary human foam cell macrophage using recombinant pro apoa num num truncation c terminus num num num num fig
0.33803913.15066991.html.plaintext.txt	224	initial study confirmed pro apoa native human apoa induced similar cholesterol efflux apoe secretion data shown
0.33803913.15066991.html.plaintext.txt	225	consistent previous study hepgnum cell num deletion c terminal num amino acid num num decreased cholesterol efflux relative whole apoa num num whereas deletion c terminal num amino acid num num effect
0.33803913.15066991.html.plaintext.txt	226	correlated relative ability protein stimulate phospholipid efflux fig
0.33803913.15066991.html.plaintext.txt	227	contrast c terminal deletion increased apoe secretion relative full length pro apoa
0.33803913.15066991.html.plaintext.txt	228	discrepant effect c terminal deletion lipid efflux apoe secretion suggest induction apoe secretion linked apoa lipid affinity stimulation cholesterol efflux via abcanum
0.33803913.15066991.html.plaintext.txt	229	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	230	truncation c terminal domain recombinant pro apoa increase apoe secretion human macrophage
0.33803913.15066991.html.plaintext.txt	231	monocyte differentiated incubated num day num microgml acldl numhcholesterol acldl numhcholine b described experimental procedure
0.33803913.15066991.html.plaintext.txt	232	cell washed equilibrated incubated rpmi num control num microgml indicated recombinant whole pro apoa num num pro apoa varying c terminal truncation num num num num
0.33803913.15066991.html.plaintext.txt	233	aliquot medium removed num h cholesterol efflux phospholipid efflux b apoe secretion c western blot inset measured described experimental procedure
0.33803913.15066991.html.plaintext.txt	234	lipid composition loading tnum fc num
0.33803913.15066991.html.plaintext.txt	235	num nmolmg cell protein specific activity fc num plus minus num dpmnmol specific activity ce num plus minus num dpmnmol
0.33803913.15066991.html.plaintext.txt	236	b specific activity pl num plus minus num dpmnmol
0.33803913.15066991.html.plaintext.txt	237	significantly different versus control value p num
0.33803913.15066991.html.plaintext.txt	238	num significantly different versus num num pro apoa p num
0.33803913.15066991.html.plaintext.txt	239	selected deletion point mutation recombinant modulate stimulation apoe secretion num amino acid residue n terminal prosegment pro apoa interfere cholesterol efflux apoa num
0.33803913.15066991.html.plaintext.txt	240	however structural requirement apoe secretion cholesterol efflux appeared dissociated studied second series recombinant apoa molecule lacking propeptide
0.33803913.15066991.html.plaintext.txt	241	role c terminus n terminus central protein lcat activation domain dnum num mediating apoa stimulated apoe secretion cholesterol efflux determined fig
0.33803913.15066991.html.plaintext.txt	242	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	243	recombinant apoa selected deletion differentially promote apoe secretion human macrophage
0.33803913.15066991.html.plaintext.txt	244	monocyte differentiated cholesterol enriched incubated rpmi num control num microgml whole apoa num microgml recombinant apoa protein deletion c terminal dnum num n terminal dnum num central dnum num domain
0.33803913.15066991.html.plaintext.txt	245	aliquot medium removed num h cholesterol efflux apoe secretion b measured described experimental procedure
0.33803913.15066991.html.plaintext.txt	246	lipid composition loading num fc num
0.33803913.15066991.html.plaintext.txt	247	num nmolmg cell protein ce num
0.33803913.15066991.html.plaintext.txt	248	num nmolmg cell protein specific activity fc num plus minus num dpmnmol specific activity ce num plus minus num dpmnmol
0.33803913.15066991.html.plaintext.txt	249	recombinant whole apoa isolated human apoa induced identical apoe secretion cholesterol efflux data shown
0.33803913.15066991.html.plaintext.txt	250	significantly different versus apoa p num
0.33803913.15066991.html.plaintext.txt	251	deletion major domain within n terminal segment dnum num central protein segment dnum num stimulated equivalent cholesterol efflux whole apoa whereas recombinant apoa c terminal deletion dnum num significantly le effective intact apoa fig
0.33803913.15066991.html.plaintext.txt	252	numa consistent previous report num
0.33803913.15066991.html.plaintext.txt	253	although dnum num caused much le cholesterol efflux induced significantly apoe secretion native intact apoa
0.33803913.15066991.html.plaintext.txt	254	significantly deletion central region apoa domain dnum num important stimulation apoe secretion absence domain halved apoe secretion relative whole apoa effect cholesterol efflux
0.33803913.15066991.html.plaintext.txt	255	consistent important role apoa flexibility recently described num contributing apoe secretion
0.33803913.15066991.html.plaintext.txt	256	data also support finding experiment using pro apoa indicating c terminal membrane binding lipid efflux rate limiting apoa mediated apoe secretion
0.33803913.15066991.html.plaintext.txt	257	synthetic peptide representing helical segment apoa induce apoe secretion apoa contains num helical segment num num amino acid length num
0.33803913.15066991.html.plaintext.txt	258	peptide representing segment induce cholesterol efflux approximately proportion lipid bilayer binding lipid affinity segment num
0.33803913.15066991.html.plaintext.txt	259	investigate whether apparent difference recombinant apoa molecule stimulation apoe secretion attributable specific helical domain within apoa particularly n terminal central domain compared apoe secretion num num mer helical peptide representing specific amphipathic helical segment apoa table
0.33803913.15066991.html.plaintext.txt	260	c terminal peptide num num stimulated cholesterol efflux significantly basal control medium level
0.33803913.15066991.html.plaintext.txt	261	although significant cholesterol efflux peptide num num le intact apoa num
0.33803913.15066991.html.plaintext.txt	262	num consistent previous literature num
0.33803913.15066991.html.plaintext.txt	263	contrast cholesterol efflux helical peptide stimulated apoe secretion
0.33803913.15066991.html.plaintext.txt	264	num fold control medium many peptide achieved stimulation apoe secretion equivalent achieved apoa e
0.33803913.15066991.html.plaintext.txt	265	peptide num num num num num num num num num num
0.33803913.15066991.html.plaintext.txt	266	correlation known helical content peptide num stimulation apoe secretion rnum num
0.33803913.15066991.html.plaintext.txt	267	peptide studied represent segment n terminus central region c terminus apoa many display low lipid affinity num
0.33803913.15066991.html.plaintext.txt	268	indicates stimulation apoe secretion whole apoa recombinant apoa molecule attributable individual helical segment isolated domain within apoa
0.33803913.15066991.html.plaintext.txt	269	view table table cholesterol efflux apoe secretion helical segment apoa
0.33803913.15066991.html.plaintext.txt	270	hmdm incubated num h rpmi num medium alone control control medium containing num microgml apoa control medium containing num microgml helical peptide representing segment apoa
0.33803913.15066991.html.plaintext.txt	271	value mean plus minus
0.33803913.15066991.html.plaintext.txt	272	triplicate culture one experiment representative three experiment
0.33803913.15066991.html.plaintext.txt	273	percent cholesterol efflux calculated dividing numhcholesterol released medium total numhcholesterol cell equilibration tnum apoe determined western blotting
0.33803913.15066991.html.plaintext.txt	274	buoyant density apoe secreted response apoa previous study shown secreted apoe predominantly lipidated density num
0.33803913.15066991.html.plaintext.txt	275	num gml num num proportion secreted apoe cell surface apoe lipid poor num num
0.33803913.15066991.html.plaintext.txt	276	apoa mediated apoe secretion appeared independent apoa lipid affinity apoa mediated lipid efflux investigated whether apoa induced secretion non lipidated non buoyant apoe fig
0.33803913.15066991.html.plaintext.txt	277	basal condition without apoa secreted apoe found buoyant density range num
0.33803913.15066991.html.plaintext.txt	278	num gml predominant density num
0.33803913.15066991.html.plaintext.txt	279	addition apoa stimulated increase apoe across density range num
0.33803913.15066991.html.plaintext.txt	280	num gml although proportion present le buoyant fraction density num
0.33803913.15066991.html.plaintext.txt	281	num gml much greater control
0.33803913.15066991.html.plaintext.txt	282	density distribution cell derived cholesterol medium basal stimulated condition num
0.33803913.15066991.html.plaintext.txt	283	num gml corresponding buoyant apoe fraction
0.33803913.15066991.html.plaintext.txt	284	thus apoe secreted control stimulated condition buoyant however presence apoa significant proportion dense cholesterol containing particle medium
0.33803913.15066991.html.plaintext.txt	285	observation consistent independent regulation apoe secretion cholesterol efflux apoa exposure suggest apoa induces pathway apoe secretion distinct involved basal apoe secretion
0.33803913.15066991.html.plaintext.txt	286	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	287	density secreted apoe without stimulation apoa
0.33803913.15066991.html.plaintext.txt	288	monocyte differentiated loaded num day num microgml acldl numhcholesterol washed equilibrated incubated control medium plus minus num microgml apoa
0.33803913.15066991.html.plaintext.txt	289	aliquot medium subjected ultracentrifugation num
0.33803913.15066991.html.plaintext.txt	290	num num sucrose gradient analyzed numhcholesterol apoe described experimental procedure
0.33803913.15066991.html.plaintext.txt	291	cholesterol efflux without open circle apoa closed circle b apoe secretion without open circle apoa closed circle
0.33803913.15066991.html.plaintext.txt	292	density fraction indicated open diamond
0.33803913.15066991.html.plaintext.txt	293	total cholesterol efflux control apoa num
0.33803913.15066991.html.plaintext.txt	294	num respectively total apoe secretion control apoa num
0.33803913.15066991.html.plaintext.txt	295	c fraction analyzed western blot diluting medium culture exposed apoa num
0.33803913.15066991.html.plaintext.txt	296	num fold facilitate comparison relative distribution apoe among fraction
0.33803913.15066991.html.plaintext.txt	297	data representative three independent experiment
0.33803913.15066991.html.plaintext.txt	298	stimulation apoe secretion induced helix containing apolipoproteins broad specificity stimulation apoe secretion helical peptide apoa suggested amphiphathic containing apolipoproteins might induce apoe secretion
0.33803913.15066991.html.plaintext.txt	299	apolipoproteins specifically apoa ii apoa iv num also stimulate cholesterol phospholipid efflux cell num vary markedly total helical content hydrophobicity num
0.33803913.15066991.html.plaintext.txt	300	incubated apolipoproteins hmdm saturating condition num microgml found human apoa apoa ii apoa iv stimulated apoe secretion equally effectively fig
0.33803913.15066991.html.plaintext.txt	301	also induced similar modest cholesterol efflux primary human macrophage ranging num num num h num num fold control medium significant difference apolipoproteins induction cholesterol efflux multiple independent experiment
0.33803913.15066991.html.plaintext.txt	302	view larger version numk fig
0.33803913.15066991.html.plaintext.txt	303	apoe secretion stimulated apolipoproteins apoa
0.33803913.15066991.html.plaintext.txt	304	monocyte differentiated cholesterol enriched acldl radiolabeled numsmethionine incubation num microgml indicated apolipoprotein
0.33803913.15066991.html.plaintext.txt	305	aliquot medium removed num h apoe immunoprecipitated secretion medium containing apoa apoa ii apoa iv apoenum determined au numsapoe per mg cell protein phosphorimaging num kda band described experimental procedure
0.33803913.15066991.html.plaintext.txt	306	apoe secretion apoa ii iv confirmed western blot well phosphorimaging
0.33803913.15066991.html.plaintext.txt	307	b data expressed au numsmethionine labeled apoe secretedmg cell protein
0.33803913.15066991.html.plaintext.txt	308	cholesterol efflux apolipoproteins num num fold control differ apolipoproteins data shown
0.33803913.15066991.html.plaintext.txt	309	significantly different versus apoenum p num
0.33803913.15066991.html.plaintext.txt	310	apoe also hdl associated contains helix extracellular apoe stimulate secretion apoe macrophage may mediate potentially anti atherogenic autocrine loop artery wall
0.33803913.15066991.html.plaintext.txt	311	apoe stimulate secretion de novo synthesized nums labeled apoe comparable efficiency apoa apoa ii apoa iv
0.33803913.15066991.html.plaintext.txt	312	enum enum enum differ effect risk atherosclerosis differ substantially helix organization n c terminal domain organization num respective lipid binding property c terminus num
0.33803913.15066991.html.plaintext.txt	313	therefore investigated whether structural difference affected stimulation apoe secretion
0.33803913.15066991.html.plaintext.txt	314	three isoforms stimulated macrophage apoe secretion basal level
0.33803913.15066991.html.plaintext.txt	315	however apoenum stimulated apoe secretion apoenum p num
0.33803913.15066991.html.plaintext.txt	316	contrast cholesterol efflux three apoe isoforms differ data shown consistent previous study num
0.33803913.15066991.html.plaintext.txt	317	non reducing sd page apoenum enum contain one two cysteine molecule respectively self associated trimer tetramers reducible dithiothreitol whereas apoenum data shown
0.33803913.15066991.html.plaintext.txt	318	thus possible either n c terminal organization exogenous apoenum lesser self association may contribute lesser apoe secretion isoform
0.33803913.15066991.html.plaintext.txt	319	apoa maintains ability stimulate apoe secretion lipid bound conformation complexed phospholipid e
0.33803913.15066991.html.plaintext.txt	320	nascent hdl disc apoa undergoes conformational change increase helicity molecule num num potentially increase exposure polar residue cell surface
0.33803913.15066991.html.plaintext.txt	321	change may affect efficacy apoa mediated apoe secretion lipidated particle
0.33803913.15066991.html.plaintext.txt	322	apoe secretion may thus diminished critical domain apoa obscured lipidation may enhanced greater exposure polar domain enhances apoe secretion
0.33803913.15066991.html.plaintext.txt	323	also potential synergy phospholipid apoa previous study identified lipid soluble pool apoe associated extracellular matrix hepgnum cell macrophage num num num num
0.33803913.15066991.html.plaintext.txt	324	apoa phospholipid disc containing popc popc popcspm popcspm compared popc liposome lipid free apoa ability induce cholesterol efflux apoe secretion table ii
0.33803913.15066991.html.plaintext.txt	325	acceptor added concentration matched apoa content allow accurate comparison efficiency stimulating apoe secretion
0.33803913.15066991.html.plaintext.txt	326	lipidation apoa popc significantly increased apoe secretion num num fold relative apoa alone whereas popc alone significantly stimulate apoe secretion
0.33803913.15066991.html.plaintext.txt	327	data suggest lipidation apoa promotes apoe secretion might caused secondary conformational change increased exposure polar residue apoa cell surface
0.33803913.15066991.html.plaintext.txt	328	view table table ii lipidation enhances apoe secretion apoa apoa ii
0.33803913.15066991.html.plaintext.txt	329	pre hdl important initial acceptor cell cholesterol num represent dynamic pool apoa may play role stimulating apoe secretion artery wall
0.33803913.15066991.html.plaintext.txt	330	pre hdl contain increased concentration spm relative mature hdl num investigated whether spm modulated ability apoa stimulate apoe secretion whether cholesterol efflux modulated parallel table ii
0.33803913.15066991.html.plaintext.txt	331	popcspm particle containing num spm num popc achieved num
0.33803913.15066991.html.plaintext.txt	332	num cholesterol efflux achieved popc increase apoe secretion relative popc
0.33803913.15066991.html.plaintext.txt	333	indicates synergistic interaction apoa phospholipid inducing apoe secretion independent variation phospholipid subtype
0.33803913.15066991.html.plaintext.txt	334	apoa ii higher average residue hydrophobicity apoa num
0.33803913.15066991.html.plaintext.txt	335	consequently conformation popc disc may differ apoa
0.33803913.15066991.html.plaintext.txt	336	unlike secretion apoa apoa ii stimulated apoe secretion increased significantly lipidation popc even though cholesterol efflux enhanced table ii part b
0.33803913.15066991.html.plaintext.txt	337	suggests relatively specific conformation change apoa seen apoa ii important enhanced stimulation apoe secretion apoa following lipidation
0.33803913.15066991.html.plaintext.txt	338	investigate whether secreted apoe associated apoa popc particle density gradient analysis non denaturing gel electrophoresis performed efflux medium
0.33803913.15066991.html.plaintext.txt	339	apoe shared buoyant density effluxed cholesterol apoa medium containing apoa popc disc density range num
0.33803913.15066991.html.plaintext.txt	340	differed medium containing lipid free apoa effluxed cholesterol buoyant density secreted apoe consistent possibility apoe associated apoa popc disc
0.33803913.15066991.html.plaintext.txt	341	directly investigated non denaturing gel electrophoresis medium containing apoa popc apoa ii popc disc followed electrophoretic transfer nitrocellulose membrane immunoblotting apoa apoa ii apoe num
0.33803913.15066991.html.plaintext.txt	342	efflux apoa apoa ii migrated popc disc num
0.33803913.15066991.html.plaintext.txt	343	num nm diameter respectively without evidence displacement lipid free apoa apoa ii disc data shown
0.33803913.15066991.html.plaintext.txt	344	secreted apoe migrated large diameter num
0.33803913.15066991.html.plaintext.txt	345	num nm particle small proportion migrated particle diameter apoa apoa ii popc containing disc num
0.33803913.15066991.html.plaintext.txt	346	association apoe apoa popc apoa ii popc disc would expected increase size particle
0.33803913.15066991.html.plaintext.txt	347	size apoa popc apoa ii popc particle unaltered secretion apoe data suggest secreted apoe significantly associate apoa apoa ii popc disc displace apoa apoa ii particle
0.33803913.15066991.html.plaintext.txt	348	result also imply amount apoe secreted apoa popc apoa ii popc particle explained differential displacement apoa apoa ii popc particle
0.33803913.15066991.html.plaintext.txt	349	apoa mediated apoe secretion independent abcanum activity apoa mediated cholesterol efflux known critically dependent upon abcanum activity
0.33803913.15066991.html.plaintext.txt	350	data dissociating structural requirement apoa stimulated apoe secretion cholesterol efflux imply apoa mediated apoe secretion may independent abcanum
0.33803913.15066991.html.plaintext.txt	351	patient tangier disease impaired abcanum activity although previous study indicated basal apoe secretion impaired td macrophage num apoa stimulated apoe secretion investigated
0.33803913.15066991.html.plaintext.txt	352	directly investigate role abcanum apoe secretion human macrophage studied macrophage two unrelated patient molecular clinical cellular phenotype td
0.33803913.15066991.html.plaintext.txt	353	first subject td tdnum see experimental procedure compound heterozygote novel abcanum mutation cnumr exon num deletion three nucleotide c
0.33803913.15066991.html.plaintext.txt	354	num num deltct exon num tdnum hmdm
0.33803913.15066991.html.plaintext.txt	355	apoa mediated cholesterol efflux tdnum hmdm severely impaired relative unrelated healthy control hcnum hmdm confirming cellular td phenotype table iii
0.33803913.15066991.html.plaintext.txt	356	basal apoe secretion lower tdnum hmdm hcnum macrophage consistent earlier study num
0.33803913.15066991.html.plaintext.txt	357	however apoa strongly stimulated apoe secretion tdnum hmdm num fold increase p num
0.33803913.15066991.html.plaintext.txt	358	num relative control medium control hmdm num
0.33803913.15066991.html.plaintext.txt	359	num relative control medium achieving total apoe secretion tdnum hmdm hcnum hmdm
0.33803913.15066991.html.plaintext.txt	360	thus despite severely impaired abca num mediated cholesterol efflux apoa stimulated apoe secretion normally td macrophage
0.33803913.15066991.html.plaintext.txt	361	view table table iii apoa induced apoe secretion normal hmdm subject tangier disease
0.33803913.15066991.html.plaintext.txt	362	note apoa stimulated apoe secretion significantly differ subject panel b
0.33803913.15066991.html.plaintext.txt	363	cellular data mean plus minus
0.33803913.15066991.html.plaintext.txt	364	three cell culture subject
0.33803913.15066991.html.plaintext.txt	365	exclude mutation specific effect macrophage second unrelated tangier patient tdnum hmdm see experimental procedure studied
0.33803913.15066991.html.plaintext.txt	366	cell tdnum compound heterozygote mutation anumd c
0.33803913.15066991.html.plaintext.txt	367	num numinsa compared healthy brother known free abcanum mutation hcnum hmdm heterozygous parent mutation numinsa hznuma hmdm anumd hznumb hmdm num num table iii b
0.33803913.15066991.html.plaintext.txt	368	basal cholesterol efflux similar four subject num
0.33803913.15066991.html.plaintext.txt	369	apoa mediated cholesterol efflux tdnum cell severely impaired relative family member confirming dysfunctional abcanum
0.33803913.15066991.html.plaintext.txt	370	despite apoa strongly equally increased apoe secretion macrophage including tdnum hmdm
0.33803913.15066991.html.plaintext.txt	371	finding support structural study clearly dissociate apoa induced cholesterol efflux via abcanum apoa induced apoe secretion
0.33803913.15066991.html.plaintext.txt	372	previous study including secretion apoe exposure cell hdl apoa concurrent efflux cholesterol num numnum
0.33803913.15066991.html.plaintext.txt	373	however cyclodextrin stimulated cholesterol efflux induce apoe secretion acute inhibition apoe synthesis secretion cycloheximide inhibit cholesterol efflux apoa num
0.33803913.15066991.html.plaintext.txt	374	latter observation dissociate stimulation apoa mediated cholesterol efflux apoe secretion
0.33803913.15066991.html.plaintext.txt	375	similar dissociation earlier reported hdl mediated cholesterol efflux apoe secretion num
0.33803913.15066991.html.plaintext.txt	376	investigated detail structural functional requirement apoa induced apoe secretion identify quite distinct required apoa induced cholesterol efflux
0.33803913.15066991.html.plaintext.txt	377	apoa increase macrophage apoe mrna level pulse chase experiment demonstrate apoa stimulates secretion newly synthesized apoe confirming apoa stimulates apoe secretion post transcriptionally
0.33803913.15066991.html.plaintext.txt	378	modeling pulse chase data indicated human macrophage contain larger mobile pool apoe em lesser stable pool apoe e
0.33803913.15066991.html.plaintext.txt	379	previous study indicate heterogeneous pool apoe may include apoe cell surface num
0.33803913.15066991.html.plaintext.txt	380	pronase treatment human macrophage experimental condition indicates small proportion e cell surface
0.33803913.15066991.html.plaintext.txt	381	num em basis biotin labeling num degree c displacement study part derived cell surface pool apoe apoa increase secretion concurrently diminishes degradation apoe pool
0.33803913.15066991.html.plaintext.txt	382	however biotin labeled pool represents minor proportion total apoe secreted num quantitative significance unclear
0.33803913.15066991.html.plaintext.txt	383	data consistent either continual displacement apoe cell surface recycling ongoing replenishment intracellular pool num consistent two source secreted apoe smaller cell surface pool larger intracellular pool mobilized apoa
0.33803913.15066991.html.plaintext.txt	384	clear structural requirement apoa mediated apoe secretion distinct required cholesterol efflux
0.33803913.15066991.html.plaintext.txt	385	study recombinant pro apoa molecule demonstrate deletion c terminus apoa enhances apoe secretion whereas impairs cholesterol efflux phospholipid efflux
0.33803913.15066991.html.plaintext.txt	386	remarkable previous study apoa function emphasized importance lipid binding c terminal domain functional integrity binding extracellular matrix cell surface num
0.33803913.15066991.html.plaintext.txt	387	c terminal deletion enhances apoe secretion suggests apoa bind extracellular matrix achieve num
0.33803913.15066991.html.plaintext.txt	388	consistent previous study indicating heparinase pretreatment inhibit apoa mediated apoe secretion primary macrophage num
0.33803913.15066991.html.plaintext.txt	389	central domain apoa regulates lcat activity num hdl mediated inhibition macrophage homing atherosclerotic plaque num
0.33803913.15066991.html.plaintext.txt	390	deletion central region apoa dnum num modification decreased stimulation apoe secretion apoa
0.33803913.15066991.html.plaintext.txt	391	domain affect apoa flexibility num suggests whole apoa flexibility important lipid affinity inducing apoe secretion
0.33803913.15066991.html.plaintext.txt	392	unlikely contain epitope specific apoa induced apoe secretion given helical peptide away domain apolipoproteins also induced apoe secretion
0.33803913.15066991.html.plaintext.txt	393	whether apolipoprotein flexibility also important apolipoproteins e
0.33803913.15066991.html.plaintext.txt	394	apoa ii apoa iv apoes unknown
0.33803913.15066991.html.plaintext.txt	395	systematic comparison individual helical peptide apoa identified c terminal helical peptide capable independently inducing cholesterol efflux primary human macrophage consistent earlier study num
0.33803913.15066991.html.plaintext.txt	396	contrast helical peptide stimulated apoe secretion
0.33803913.15066991.html.plaintext.txt	397	cholesterol efflux peptide related lipid affinity num property appear determine induction apoe secretion
0.33803913.15066991.html.plaintext.txt	398	stimulation apoe secretion appears general structural property helical protein peptide case whole apoa enhanced overall protein flexibility inhibited lipid binding plasma membrane
0.33803913.15066991.html.plaintext.txt	399	one striking observation enhanced secretion apoe apoa popc disc relative apoa
0.33803913.15066991.html.plaintext.txt	400	observed apoa ii stimulated apoe secretion extent free lipid bound state
0.33803913.15066991.html.plaintext.txt	401	difference response lipidation apoa apoa ii interesting given cholesterol efflux apolipoproteins increased lipidation
0.33803913.15066991.html.plaintext.txt	402	apolipoprotein mediated apoe secretion may allow subsequent binding secreted apoe exogenous phospholipid could explain apparent synergy apoa popc
0.33803913.15066991.html.plaintext.txt	403	however association apoe apoa apoa ii popc disc would expected require displacement apoa apoa ii andor increase apparent size popc containing particle neither found non denaturing gel electrophoresis
0.33803913.15066991.html.plaintext.txt	404	absence synergy apoa ii popc therefore suggests conformational change unique apoa occur lipidation
0.33803913.15066991.html.plaintext.txt	405	suggest apoa expose polar non lipid bound residue popc disc apoa ii enhances interaction exposed residue apoe cell surface undefined plasma membrane site critical stimulating vesicular trafficking apoe cell surface
0.33803913.15066991.html.plaintext.txt	406	apoa ii iv enum apolipoprotein phospholipid disc stimulated apoe secretion efficiently indicating stimulation apoe secretion broad relevance vivo
0.33803913.15066991.html.plaintext.txt	407	ability apoe stimulate apoe secretion highly significant local autocrine secretion apoe artery wall could mediate apoe secretion neighboring cell independently requirement plasma derived hdl specie
0.33803913.15066991.html.plaintext.txt	408	apoenum increase risk atherosclerosis alzheimers disease relative apoenum num
0.33803913.15066991.html.plaintext.txt	409	reduced local stimulation apoe secretion apoenum artery cns might contribute disease state associated apoenum phenotype
0.33803913.15066991.html.plaintext.txt	410	apoenum differs apoenum single amino acid substitution arginine instead cysteine position num
0.33803913.15066991.html.plaintext.txt	411	confers positive apoe charge cause conformational change n terminal helix apoenum salt bridge form argnum glunum alters conformation argnum interacts glunum num
0.33803913.15066991.html.plaintext.txt	412	enum also differs enum enum lacking potential disulfide formation self association
0.33803913.15066991.html.plaintext.txt	413	previous study smith et al
0.33803913.15066991.html.plaintext.txt	414	num identified binding enum enum enum raw macrophage cholesterol efflux induced isoforms
0.33803913.15066991.html.plaintext.txt	415	study confirmed similar efflux various apoe isoforms supporting difference inducible apoe secretion explained altered efflux binding
0.33803913.15066991.html.plaintext.txt	416	recent study indicates apoenum higher lipid affinity apoe isoforms num respect data support observation c terminal deletion apoa diminish lipid affinity enhance ability induce apoe secretion
0.33803913.15066991.html.plaintext.txt	417	apoa mediated cholesterol efflux apoe secretion independently regulated directly confirmed apoa stimulated apoe secretion two unrelated subject clinical molecular cellular phenotype tangier disease
0.33803913.15066991.html.plaintext.txt	418	despite impaired abcanum mediated cholesterol efflux severely reduced basal apoe secretion apoa stimulated apoe secretion normally
0.33803913.15066991.html.plaintext.txt	419	recent study shown apoa mediated cholesterol efflux via abcanum linked accelerated secretory vesicular transport golgi plasma membrane absent tangier disease fibroblast num
0.33803913.15066991.html.plaintext.txt	420	apoa stimulated apoe secretion normally tangier disease macrophage conclude apoa must stimulate distinct pathway apoe secretion unrelated interaction abcanum stimulation cholesterol efflux
0.33803913.15066991.html.plaintext.txt	421	apoe secretion induced apoa severalfold greater basal apoe secretion abcanum independent secretion likely quantitatively important related abcanum activity
0.33803913.15066991.html.plaintext.txt	422	knowledge finding represent first reported non abcanum mediated cellular process mediated apoa
0.33803913.15066991.html.plaintext.txt	423	unlikely apoa stimulates apoe secretion directly inhibiting lysosomal proteasomal degradation apoe
0.33803913.15066991.html.plaintext.txt	424	apoe degraded lysosomal proteasomal compartment num num although direct inhibition lysosomal cysteine protease inhibit apoe degradation increase apoe secretion num
0.33803913.15066991.html.plaintext.txt	425	possibility apoa exchange cellular apoe apoa degraded place apoe also seems unlikely mass apoa degraded corresponds num mass apoe secreted human macrophage time course experiment
0.33803913.15066991.html.plaintext.txt	426	num likely apoa promotes apoe secretion inhibiting trafficking degradatory compartment lysosome proteasome stimulating vesicular traffic plasma membrane analogous effect described fibroblast num
0.33803913.15066991.html.plaintext.txt	427	although hdl stimulates range protein kinase c dependent independent signaling pathway necessarily activated apoa num mechanism apoa regulates vesicle traffic general protein secretion particular require investigation
0.33803913.15066991.html.plaintext.txt	428	conclude apoa mediated apoe secretion structural requirement distinct regulating stimulation cholesterol efflux facilitated central hinge region apoa inhibited c terminal domain independent macrophage abcanum activity
0.33803913.15066991.html.plaintext.txt	429	represents novel abca num independent positive feedback process secretion anti atherogenic cholesterol efflux inducing apoe helix containing molecule
0.33803913.15066991.html.plaintext.txt	430	footnote work supported grant aid w
0.33803913.15066991.html.plaintext.txt	431	national health medical research council australia national institute health grant hlnum hlnum national heart foundation australia australian research council k
0.33803913.15066991.html.plaintext.txt	432	cost publication article defrayed part payment page charge
0.33803913.15066991.html.plaintext.txt	433	article must therefore hereby marked advertisement accordance num u
0.33803913.15066991.html.plaintext.txt	434	section num solely indicate fact
0.33803913.15066991.html.plaintext.txt	435	k correspondence addressed macrophage biology group centre vascular research numth floor wallace wurth bldg
0.33803913.15066991.html.plaintext.txt	436	university new south wale unsw sydney nsw num australia
0.33803913.15066991.html.plaintext.txt	437	num num num fax num num num e mail l
0.33803913.15066991.html.plaintext.txt	438	num abbreviation used hdl high density lipoprotein plv phospholipid vesicle apoa apolipoprotein abcanum atp binding cassette transporter spm sphingomyelin pc phosphatidylcholine td tangier disease ldl low density lipoprotein apo apolipoprotein abcanum atp binding cassette transporter anum rct reverse cholesterol transport acldl acetylated ldl hmdm human primary monocyte derived macrophage popc num palmitoyl num oleoyl phosphatidylcholine spm egg yolk sphingomyelin bca bicinchoninic acid pb phosphate buffered saline au arbitrary unit rt pcr reverse transcriptase pcr
0.33803913.15066991.html.plaintext.txt	439	kritharides unpublished observation
0.33803913.15066991.html.plaintext.txt	440	kritharides unpublished observation
0.3392243.12502505.html.plaintext.txt	0	apolipoprotein e influence aspect intellectual ability type num diabetes stewart c
0.3392243.12502505.html.plaintext.txt	1	evansnum sian ellardnum andrew
0.3392243.12502505.html.plaintext.txt	2	num department diabetes royal infirmary edinburgh edinburgh scotland u
0.3392243.12502505.html.plaintext.txt	3	num department psychology university edinburgh edinburgh scotland u
0.3392243.12502505.html.plaintext.txt	4	num centre molecular genetics exeter university exeter england u
0.3392243.12502505.html.plaintext.txt	5	permanent cognitive impairment rare consequence insulin induced hypoglycemia
0.3392243.12502505.html.plaintext.txt	6	insulin treated diabetes severe hypoglycemia common annual prevalence num type num diabetes higher incidence people impaired awareness hypoglycemia strict glycemic control num
0.3392243.12502505.html.plaintext.txt	7	whether recurrent exposure severe hypoglycemia promotes long term cognitive sequela unresolved
0.3392243.12502505.html.plaintext.txt	8	retrospective cross sectional study indicated people type num diabetes suffer modest cognitive decrement num finding replicated prospective observation num year numnum
0.3392243.12502505.html.plaintext.txt	9	cross sectional study reported individual difference cognitive decrement exposed severe hypoglycemia num suggesting factor neuroglycopenia may influence risk developing subsequent cognitive impairment
0.3392243.12502505.html.plaintext.txt	10	chronological age diabetes duration coexistent microvascular macrovascular complication proposed potential mediator susceptibility hypoglycemia induced cognitive impairment num whereas genetic susceptibility examined
0.3392243.12502505.html.plaintext.txt	11	genetic factor influence cognitive aging polymorphism gene apolipoprotein e apoe important genetic determinant late onset alzheimer disease num
0.3392243.12502505.html.plaintext.txt	12	apoe gene three common allele num num num coding three protein isoforms designated enum enum enum
0.3392243.12502505.html.plaintext.txt	13	apolipoprotein e apoe mediates central nervous system cholesterol transport isoform specific manner num
0.3392243.12502505.html.plaintext.txt	14	apoe activity important neuronal repair maintenance least active enum isoform confers survival disadvantage injured neuron num
0.3392243.12502505.html.plaintext.txt	15	apoe polymorphism influence cognitive ability health disease apparently healthy middle aged adult possessing num allele average relatively low learning memory ability num num allele associated poorer cognitive neurological outcome head injury demyelinating disease intracerebral hemorrhage cardiopulmonary bypass surgery num
0.3392243.12502505.html.plaintext.txt	16	aim present study examine whether possession apoe num allele associated cognitive disadvantage people type num diabetes secondly determine whether magnitude difference cognitive ability modified preceding exposure recurrent severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	17	assessment neuropsychological function
0.3392243.12502505.html.plaintext.txt	18	neuropsychological test battery chosen sensitive cognitive decrement across diverse cognitive ability
0.3392243.12502505.html.plaintext.txt	19	assessor blinded diabetes characteristic apoe genotype participant administered neuropsychological test fixed order
0.3392243.12502505.html.plaintext.txt	20	incipient hypoglycemia hypoglycemia within preceding num h excluded neuropsychological assessment
0.3392243.12502505.html.plaintext.txt	21	evidence biochemical blood glucose num
0.3392243.12502505.html.plaintext.txt	22	num mmoll symptomatic hypoglycemia resulted rescheduling neuropsychological session
0.3392243.12502505.html.plaintext.txt	23	psychometric instrument used follows
0.3392243.12502505.html.plaintext.txt	24	hospital anxiety depression scale num evaluated potential confounding effect low mood anxiety
0.3392243.12502505.html.plaintext.txt	25	wechsler adult intelligence scale revised wais r num us performance subtests measure current intellectual performance fluid nonverbal intelligence sensitive disruption organic brain disease
0.3392243.12502505.html.plaintext.txt	26	four performance subtests utilized picture completion object assembly block design digit symbol test
0.3392243.12502505.html.plaintext.txt	27	national adult reading test nart num relatively resistant effect age type organic brain disease
0.3392243.12502505.html.plaintext.txt	28	nart performance correlate closely premorbid iq demographic variable used control confounding effect prior intellectual ability premorbid iq crystallized intelligence present study
0.3392243.12502505.html.plaintext.txt	29	inspection time num used ass visual perceptual speed component information processing ability
0.3392243.12502505.html.plaintext.txt	30	participant discriminated spatial position left right longer two briefly presented vertical line
0.3392243.12502505.html.plaintext.txt	31	stimulus backward masked presentation duration varied duration time required reliably distinguish stimulus num correct termed inspection time
0.3392243.12502505.html.plaintext.txt	32	choice reaction time num used ass psychomotor speed completed test information processing ability numnumnumnum numnumnumnum choice reaction time examined
0.3392243.12502505.html.plaintext.txt	33	borkowski verbal fluency test controlled association num thought ass frontal lobe executive function
0.3392243.12502505.html.plaintext.txt	34	participant num state many word possible beginning letter alphabet specified assessor
0.3392243.12502505.html.plaintext.txt	35	paced auditory serial addition task num used ass ability sustain attention concentration
0.3392243.12502505.html.plaintext.txt	36	participant listened number list required add together according given rule
0.3392243.12502505.html.plaintext.txt	37	practice two consecutive num number trial performed num num successive digit respectively
0.3392243.12502505.html.plaintext.txt	38	assessment severe hypoglycemia exposure
0.3392243.12502505.html.plaintext.txt	39	severe hypoglycemia defined episode requiring external assistance facilitate recovery num exposure assessed retrospectively using validated formatted hypoglycemia questionnaire num
0.3392243.12502505.html.plaintext.txt	40	participant asked discus history severe hypoglycemia family partner friend completing questionnaire improve accuracy estimate
0.3392243.12502505.html.plaintext.txt	41	total number lifetime episode frequency episode total number hypoglycemic seizure coma episode requiring medical intervention recorded
0.3392243.12502505.html.plaintext.txt	42	dna extracted venous blood subject using standard method
0.3392243.12502505.html.plaintext.txt	43	apoe genotyping performed using pcr restriction fragment length polymorphism assay described wenham et al
0.3392243.12502505.html.plaintext.txt	44	num spss chicago il used statistical analysis
0.3392243.12502505.html.plaintext.txt	45	demographic factor influencing neuropsychological performance age sex duration diabetes premorbid intellectual ability nart grouping interest severe hypoglycemia category apoe genotype evaluated multivariate general linear modeling multiple analysis covariance mancova
0.3392243.12502505.html.plaintext.txt	46	severe hypoglycemia dichotomized two group group num naive severe hypoglycemia group num previously exposed severe hypoglycemia based upon total number previous episode
0.3392243.12502505.html.plaintext.txt	47	apoe genotype categorized two group num num
0.3392243.12502505.html.plaintext.txt	48	mancova used determine significance p magnitude etanum variable effect cognitive performance
0.3392243.12502505.html.plaintext.txt	49	clinical characteristic participant shown table num
0.3392243.12502505.html.plaintext.txt	50	data glycemic control included laboratory reference range methodology estimating glycated hemoglobin changed across two time frame data participant collated
0.3392243.12502505.html.plaintext.txt	51	view table table num characteristic participant subdivided presence apoe num allele
0.3392243.12502505.html.plaintext.txt	52	subdivision participant apoe num produced two group num n num num n num
0.3392243.12502505.html.plaintext.txt	53	clinical characteristic shown table num
0.3392243.12502505.html.plaintext.txt	54	subgroup similar premorbid intellectual ability nart similar exposure severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	55	possessing num slightly older p num
0.3392243.12502505.html.plaintext.txt	56	num test tended diabetes longer duration p num
0.3392243.12502505.html.plaintext.txt	57	view table table num effect severe hypoglycemia cognitive ability interaction apoe
0.3392243.12502505.html.plaintext.txt	58	apoe num neuropsychological performance
0.3392243.12502505.html.plaintext.txt	59	apoe num allele associated disadvantage current intellectual performance wais r performance test score p num
0.3392243.12502505.html.plaintext.txt	60	num trend toward poorer frontal lobe executive function borkowski verbal fluency p num
0.3392243.12502505.html.plaintext.txt	61	num consideration age sex duration diabetes preceding severe hypoglycemia premorbid intellectual ability table num
0.3392243.12502505.html.plaintext.txt	62	relative disadvantage associated apoe num appeared sex specific apoe x sex interaction f num
0.3392243.12502505.html.plaintext.txt	63	sex specificity mancova thereafter performed separately men woman using similar model excluding sex subject factor
0.3392243.12502505.html.plaintext.txt	64	apoe genotype significantly influenced cognitive ability woman men table num
0.3392243.12502505.html.plaintext.txt	65	woman apoe num exhibited significant cognitive disadvantage affecting current intellectual performance wais r performance test score p num
0.3392243.12502505.html.plaintext.txt	66	num frontal lobe executive function borkowski verbal fluency p num
0.3392243.12502505.html.plaintext.txt	67	difference ability associated possession apoe num woman moderate large etanum
0.3392243.12502505.html.plaintext.txt	68	view table table num effect apoe num num age premorbid intellectual ability nart cognitive performance
0.3392243.12502505.html.plaintext.txt	69	view table table num apoe allele cognition sex
0.3392243.12502505.html.plaintext.txt	70	apolipoprotein e genotype severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	71	statistical evidence detrimental interaction apoe genotype previous exposure severe hypoglycemia cognitive ability apoe x severe hypoglycemia interaction f num
0.3392243.12502505.html.plaintext.txt	72	cognitive ability subject apoe num allele subdivided exposed previously severe hypoglycemia n num naive severe hypoglycemia n num shown table num
0.3392243.12502505.html.plaintext.txt	73	significant difference cognitive ability demonstrated subgroup although number subject analysis small confident nonsignificant difference table num
0.3392243.12502505.html.plaintext.txt	74	laboratory clinical evidence support concept num associated premature cognitive aging diabetes
0.3392243.12502505.html.plaintext.txt	75	elderly people type num diabetes num allele exhibit greater cognitive decrement num accelerated cognitive decline num compared age matched num healthy control subject apoe people diabetes irreversibly glycated exhibit le vitro bioactivity num compared nondiabetic control subject
0.3392243.12502505.html.plaintext.txt	76	apoe bioactivity appears clinical relevance outcome variety cerebral pathology poorer individual possessing least biologically active enum isoform num
0.3392243.12502505.html.plaintext.txt	77	present study include healthy comparator group notion apoe num associated premature cognitive aging type num diabetes speculative present whereas demonstrated type num diabetes numnum
0.3392243.12502505.html.plaintext.txt	78	present study support hypothesis polymorphism apoe gene may contribute susceptibility hypoglycemia induced cognitive decrement people type num diabetes
0.3392243.12502505.html.plaintext.txt	79	number subject num subgroup n num previous severe hypoglycemia v
0.3392243.12502505.html.plaintext.txt	80	n num hypoglycemia naive give sufficient power allow definitive conclusion appropriately powered investigation required evaluate hypothesis
0.3392243.12502505.html.plaintext.txt	81	irrespective influence apoe allele cognitive performance unaffected severe hypoglycemia per se consistent conclusion diabetes control complication trial num stockholm diabetes intervention study num many participant type num diabetes relatively short duration conflicting retrospective cross sectional study num examined older subject diabetes long duration
0.3392243.12502505.html.plaintext.txt	82	conclusion data modestly powered study suggest apoe num confers cognitive disadvantage young woman type num diabetes
0.3392243.12502505.html.plaintext.txt	83	investigation required verify finding determine whether apoe num allele associated premature accelerated cognitive aging people type num diabetes diabetes specific factor may mediating disadvantage possible interaction sex
0.3392243.12502505.html.plaintext.txt	84	supported funding eli lilly company ltd
0.3392243.12502505.html.plaintext.txt	85	study supported royal infirmary edinburgh nh trust
0.3392243.12502505.html.plaintext.txt	86	received millhayes scholarship exeter university
0.3392243.12502505.html.plaintext.txt	87	recipient royal society wolfson research merit award
0.3392243.12502505.html.plaintext.txt	88	footnote address correspondence reprint request prof
0.3392243.12502505.html.plaintext.txt	89	deary department psychology university edinburgh num george square edinburgh ehnum numjz scotland
0.3392243.12502505.html.plaintext.txt	90	received publication num may num accepted revised form num october num
0.3392243.12502505.html.plaintext.txt	91	apoe apolipoprotein e mancova multiple analysis covariance nart national adult reading test wais r wechsler adult intelligence scale revised
0.3398514.15583000.html.plaintext.txt	0	two step mechanism binding apolipoprotein e heparin implication kinetics apolipoprotein e heparan sulfate proteoglycan complex formation cell surface miho futamura padmaja dhanasekaran tetsurou handa michael c
0.3398514.15583000.html.plaintext.txt	1	phillips sissel lund katz hiroyuki saito
0.3398514.15583000.html.plaintext.txt	2	lipid research group childrens hospital philadelphia university pennsylvania school medicine philadelphia pennsylvania num num graduate school pharmaceutical science kyoto university kyoto num num japan
0.3398514.15583000.html.plaintext.txt	3	received publication october num num
0.3398514.15583000.html.plaintext.txt	4	apoe comprises single polypeptide chain num amino acid residue contains two independently folded functional domain num kda n terminal domain residue num num num kda c terminal domain residue num num num num
0.3398514.15583000.html.plaintext.txt	5	n terminal domain folded four helix bundle amphipathic helix contains ldlr binding region around residue num num helix num num num
0.3398514.15583000.html.plaintext.txt	6	c terminal domain also contains amphipathic helix involved binding lipoprotein particle num num num
0.3398514.15583000.html.plaintext.txt	7	n c terminal domain contain heparin binding site num num
0.3398514.15583000.html.plaintext.txt	8	n terminal domain site located residue num num overlapping ldlr binding region num num whereas c terminal site involves basic residue around lysine num num
0.3398514.15583000.html.plaintext.txt	9	although site functional separated fragment n terminal site available interaction lipid free lipidated state intact apoe molecule num
0.3398514.15583000.html.plaintext.txt	10	human apoe polymorphic protein three major isoforms apoenum apoenum apoenum differing cysteine arginine position num num num
0.3398514.15583000.html.plaintext.txt	11	apoenum common form contains cysteine arginine position respectively whereas apoenum contains cysteine apoenum contains arginine site
0.3398514.15583000.html.plaintext.txt	12	apoenum apoenum bind equally high affinity ldlr apoenum defective binding ldlr associated type iii hyperlipoproteinemia num
0.3398514.15583000.html.plaintext.txt	13	apoenum associated increased risk coronary artery disease major risk factor alzheimers disease num num num
0.3398514.15583000.html.plaintext.txt	14	cluster arginine lysine residue located polar face fourth amphipathic helix n terminal bundle represents binding site cell surface receptor num
0.3398514.15583000.html.plaintext.txt	15	despite apparent accessibility basic residue interaction apoe lipid necessary high affinity binding ldlr num
0.3398514.15583000.html.plaintext.txt	16	recent study indicate lipid binding induces opening helix bundle n terminal domain num num increase exposure lysine num num aqueous phase thereby enhances interaction acidic element ldlr num
0.3398514.15583000.html.plaintext.txt	17	disruption amphipathic helix spanning residue num num abolishes ldlr binding indicating structural motif apoe critical function num
0.3398514.15583000.html.plaintext.txt	18	contrast binding ldlr stringency binding apoe lrp hspg appears le severe
0.3398514.15583000.html.plaintext.txt	19	lipid association apoe required binding lrp num hspg num num although apoe domain spanning residue num num involved binding num num
0.3398514.15583000.html.plaintext.txt	20	apoenum highly defective ldlr binding activity num normal apoenum activity significant binding activity lrp num num apoenum num hspg num num apoenum num
0.3398514.15583000.html.plaintext.txt	21	detailed molecular feature control high affinity binding apoe lrp hspg yet defined fully
0.3398514.15583000.html.plaintext.txt	22	previously characterized effect point mutation basic residue present heparin binding site equilibrium parameter defining interaction apoe heparin num
0.3398514.15583000.html.plaintext.txt	23	predict distribution apoe different receptor ldlr lrp hspg however also important establish kinetics apoe receptor association dissociation receptorligand interaction cell surface occur equilibrium
0.3398514.15583000.html.plaintext.txt	24	study surface plasmon resonance spr measurement employed determine affinity kinetics interaction engineered apoe molecule lipid free lipidated state heparin
0.3398514.15583000.html.plaintext.txt	25	using approach provide novel insight mechanism apoeheparin interaction
0.3398514.15583000.html.plaintext.txt	26	expression purification protein full length human apoenum apoenum apoenum num kda num kda num kda fragment expressed purified described previously num
0.3398514.15583000.html.plaintext.txt	27	mutant apoe made using quikchange site directed mutagenesis kit stratagene la jolla ca
0.3398514.15583000.html.plaintext.txt	28	cdna ligated thioredoxin fusion expression vector petnuma novagen madison wi transformed escherichia coli strain blnum star denum invitrogen
0.3398514.15583000.html.plaintext.txt	29	resulting thioredoxin apoe fusion protein expressed purified described previously num
0.3398514.15583000.html.plaintext.txt	30	apoenum num kda lnumkknumlknumllnumk mutant expressed insoluble protein protein solubilized cell pellet using num m urea num
0.3398514.15583000.html.plaintext.txt	31	apoe preparation least num pure assessed sd page
0.3398514.15583000.html.plaintext.txt	32	experiment apoe sample freshly dialyzed num mercaptoethanol num m guanidine hcl solution tris buffer num mm tris hcl num mm nacl num
0.3398514.15583000.html.plaintext.txt	33	disulfide linked apoenum num kda mutant dialyzed num m guanidine hcl solution maintain interhelical disulfide bonding num
0.3398514.15583000.html.plaintext.txt	34	dmpc complex apoenum num kda variant prepared described previously num
0.3398514.15583000.html.plaintext.txt	35	spr measurement experiment performed biacore x num spr instrument biacore inc
0.3398514.15583000.html.plaintext.txt	36	streptavidin sa sensor chip pretreated three consecutive num microl injection num mm naoh num m nacl remove nonspecifically bound contaminant
0.3398514.15583000.html.plaintext.txt	37	immobilization heparin sa chip injection biotinylated heparin num microgml tris buffer made flow rate num microlmin followed num microl injection num m nacl
0.3398514.15583000.html.plaintext.txt	38	typically num num resonance unit heparin immobilized effect mass transport significant low surface density ligand num
0.3398514.15583000.html.plaintext.txt	39	untreated flow cell used control
0.3398514.15583000.html.plaintext.txt	40	kinetic measurement apoe interaction heparin num microl injection apoe sample passed sensor surface flow rate num microlmin
0.3398514.15583000.html.plaintext.txt	41	end sample plug buffer passed sensor surface facilitate dissociation
0.3398514.15583000.html.plaintext.txt	42	num min dissociation time sensor surface regenerated next sample using num microl pulse num m nacl
0.3398514.15583000.html.plaintext.txt	43	resultant sensorgrams analyzed using biaevaluation software version num
0.3398514.15583000.html.plaintext.txt	44	response curve various analyte concentration globally fitted either numnum langmuir model two state binding model described following equation numnum
0.3398514.15583000.html.plaintext.txt	45	num equilibrium constant binding step knum kanumkdnum knum kanumkdnum overall equilibrium binding constant calculated ka knumnum knum kd numka
0.3398514.15583000.html.plaintext.txt	46	model analyte bind ligand b form initial complex ab undergoes subsequent binding conformational change form stable complex abx
0.3398514.15583000.html.plaintext.txt	47	apoe num num kda fragment binding response steady state region sensorgrams req also plotted analyte concentration c determine overall equilibrium binding affinity
0.3398514.15583000.html.plaintext.txt	48	data subjected nonlinear regression fitting according following equation
0.3398514.15583000.html.plaintext.txt	49	num rmax maximum binding response kd dissociation constant
0.3398514.15583000.html.plaintext.txt	50	circular dichroism cd spectroscopy far uv cd spectrum recorded num num nm num degree c using jasco j num spectropolarimeter
0.3398514.15583000.html.plaintext.txt	51	dialyzing num mercaptoethanol num m guanidine hcl solution apoe sample diluted num microgml tris buffer ph num
0.3398514.15583000.html.plaintext.txt	52	apoeheparin mixture sample apoe mixed heparin apoeheparin ratio num
0.3398514.15583000.html.plaintext.txt	53	num num ww prior measurement
0.3398514.15583000.html.plaintext.txt	54	result corrected subtracting buffer base line blank sample containing identical concentration heparin
0.3398514.15583000.html.plaintext.txt	55	helix content calculated molar ellipticity num nm num according following equation numnum
0.3398514.15583000.html.plaintext.txt	56	analytical procedure protein concentration determined either lowry procedure num absorbance coefficient num nm
0.3398514.15583000.html.plaintext.txt	57	phospholipid concentration determined enzymatic assay kit wako chemical richmond va
0.3398514.15583000.html.plaintext.txt	58	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	59	comparison use spr sensor chip heparin sepharose gel determine apoeheparin interaction
0.3398514.15583000.html.plaintext.txt	60	spr sensorgrams interaction apoe num kda num kda knumq mutant b num kda fragment c num microgml heparin immobilized sa sensor chip
0.3398514.15583000.html.plaintext.txt	61	b steady state affinity analysis spr data
0.3398514.15583000.html.plaintext.txt	62	c binding isotherm apoe num kda fragment num kda knumq mutant b num kda fragment c heparin sepharose gel replotted ref
0.3398514.15583000.html.plaintext.txt	63	kinetic analysis heparin binding full length apoenum num num kda fragment fig
0.3398514.15583000.html.plaintext.txt	64	num show typical sensorgram binding full length apoe heparin
0.3398514.15583000.html.plaintext.txt	65	kinetic data fitted well numnum langmuir binding model indicated large value goodness fit num num fig
0.3398514.15583000.html.plaintext.txt	66	however significantly improved fit num num
0.3398514.15583000.html.plaintext.txt	67	num obtained using two state binding model indicating binding apoe heparin involves either sequential two step process conformational change num num
0.3398514.15583000.html.plaintext.txt	68	response curve heparin binding apoenum num kda fragment also showed two state binding kinetics fig
0.3398514.15583000.html.plaintext.txt	69	changing injection time revealed dissociation rate progressively decreased longer injection contact time fig
0.3398514.15583000.html.plaintext.txt	70	numa inset indicating stability initial apoe heparin complex increase time num num
0.3398514.15583000.html.plaintext.txt	71	effect contact time dissociation rate seen apoe num kda binding heparin contribution second binding step overall process small fig
0.3398514.15583000.html.plaintext.txt	72	table summarizes kinetic rate constant derived affinity constant full length apoenum num num kda fragment obtained using two state binding model
0.3398514.15583000.html.plaintext.txt	73	good agreement kd value full length apoenum data previous report num discrepancy apoenum num kda fragment num previous study applied numnum langmuir binding model kinetic data
0.3398514.15583000.html.plaintext.txt	74	addition kd value num kda fragment table num microgml similar obtained steady state analysis num microgml fig
0.3398514.15583000.html.plaintext.txt	75	numb validating two state binding model
0.3398514.15583000.html.plaintext.txt	76	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	77	two state binding apoe heparin detected spr measurement kinetics association dissociation
0.3398514.15583000.html.plaintext.txt	78	sensorgram binding full length apoenum num microgml immobilized heparin
0.3398514.15583000.html.plaintext.txt	79	experimental data fitted two state binding model b ab abx see experimental procedure
0.3398514.15583000.html.plaintext.txt	80	simulated curve displaying initial binding ab subsequent binding conformational change abx additive component fitted curve
0.3398514.15583000.html.plaintext.txt	81	inset show result fitting numnum langmuir binding model dashed line
0.3398514.15583000.html.plaintext.txt	82	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	83	spr sensorgrams binding apoenum num kda num kda b fragment num microgml heparin
0.3398514.15583000.html.plaintext.txt	84	experimental binding data fitted two state binding model
0.3398514.15583000.html.plaintext.txt	85	component shown initial complex ab transferred complex ab
0.3398514.15583000.html.plaintext.txt	86	inset show effect increased injection time stability apoe heparin complex
0.3398514.15583000.html.plaintext.txt	87	anums bnums c num d num
0.3398514.15583000.html.plaintext.txt	88	view table table kinetic parameter binding lipid free apoenum fragment heparin
0.3398514.15583000.html.plaintext.txt	89	effect heparin binding secondary tertiary structure apoe examine possibility conformational change apoe occurs binding heparin far uv cd measurement employed evaluate secondary structure apoe
0.3398514.15583000.html.plaintext.txt	90	num change spectrum apoe num kda fragment observed absence presence heparin
0.3398514.15583000.html.plaintext.txt	91	helix content derived molar ellipticity num nm range num num heparin apoe weight ratio num fig
0.3398514.15583000.html.plaintext.txt	92	num inset indicating change secondary structure apoe upon heparin binding
0.3398514.15583000.html.plaintext.txt	93	four helix bundle apoe num kda fragment known open upon lipid binding num num
0.3398514.15583000.html.plaintext.txt	94	confirm conformational change apoe involved two state binding heparin tested heparin binding triple interhelical disulfide linked apoenum num kda mutant opening four helix bundle completely restricted num
0.3398514.15583000.html.plaintext.txt	95	spr sensorgrams heparin binding mutant still exhibited two state binding kinetics data shown indicating conformational change opening helix bundle involved two state binding apoeheparin interaction
0.3398514.15583000.html.plaintext.txt	96	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	97	far uv cd spectrum apoenum num kda alone incubated heparin broken line
0.3398514.15583000.html.plaintext.txt	98	protein heparin concentration num microgml
0.3398514.15583000.html.plaintext.txt	99	inset show change helix content apoenum num kda function weight ratio heparin protein protein concentration num microgml
0.3398514.15583000.html.plaintext.txt	100	effect lysine mutation heparin binding site apoe binding kinetics explore molecular mechanism two state heparin binding apoe used mutant substitution lysine num num residue located n c terminal heparin binding site respectively contribute ionic interaction heparin num num
0.3398514.15583000.html.plaintext.txt	101	num large decrease binding response observed apoenum knume mutant whereas apoenum knume mutant exhibited response similar wild type wt consistent previous observation using heparin sepharose gel lys num play dominant role heparin binding full length apoe num
0.3398514.15583000.html.plaintext.txt	102	numa summarizes relative change rate constant mutant well mutant knumq knumq
0.3398514.15583000.html.plaintext.txt	103	replacement lysine significantly affected first association rate effect rate constant second step
0.3398514.15583000.html.plaintext.txt	104	relative contribution step overall free energy binding estimated affinity constant two individual step fig
0.3398514.15583000.html.plaintext.txt	105	although first binding step contributes largest part free energy binding protein significant decrease favorable free energy binding first step observed knumq knume mutant without change second step
0.3398514.15583000.html.plaintext.txt	106	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	107	spr sensorgrams binding wt knume b knume c mutant full length apoenum heparin
0.3398514.15583000.html.plaintext.txt	108	experimental binding data fitted two state binding model dashed line
0.3398514.15583000.html.plaintext.txt	109	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	110	spr rate constant free energy binding interaction apoenum mutant heparin
0.3398514.15583000.html.plaintext.txt	111	relative change spr rate constant binding step apoe mutant heparin
0.3398514.15583000.html.plaintext.txt	112	b free energy binding step apoe mutant heparin
0.3398514.15583000.html.plaintext.txt	113	free energy calculated according g rt ln k using binding constant step knum knum
0.3398514.15583000.html.plaintext.txt	114	effect apoe isoform binding kinetics heparin compared association dissociation rate constant equilibrium dissociation constant binding apoe isoforms heparin
0.3398514.15583000.html.plaintext.txt	115	previous spr study indicated three full length apoe isoforms similar affinity heparin num
0.3398514.15583000.html.plaintext.txt	116	numa full length apoenum exhibited somewhat slower first association rate higher kd value full length apoenum
0.3398514.15583000.html.plaintext.txt	117	regarding num kda fragment although apoenum displayed slower rate apoenum faster rate first association phase compared apoenum kd value similar among three isoforms fig
0.3398514.15583000.html.plaintext.txt	118	overall result indicate apoenum tends bind heparin somewhat le affinity apoenum apoenum slower first binding step
0.3398514.15583000.html.plaintext.txt	119	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	120	comparison spr rate constant interaction apoe isoforms heparin
0.3398514.15583000.html.plaintext.txt	121	full length apoe apoe num kda fragment b
0.3398514.15583000.html.plaintext.txt	122	effect substitution basic residue disruption helical structure n terminal heparin binding site binding kinetics lipidated apoe previously determined structural requirement apoe receptor binding domain effective binding ldlr substituting basic residue disrupting helical structure region num
0.3398514.15583000.html.plaintext.txt	123	examine possibility similar requirement necessary heparin binding used two apoenum num kda mutant spr measurement
0.3398514.15583000.html.plaintext.txt	124	first knumrknumr mutant conservative substitution two lysine arginine decrease affinity ldlr num wt value
0.3398514.15583000.html.plaintext.txt	125	second lnumkknumlknumllnumk mutant exchange lysine leucine disrupts helical structure spanning residue num num without altering net charge eliminates binding ldlr num
0.3398514.15583000.html.plaintext.txt	126	lipid association required high affinity binding apoe ldlr num used discoidal complex apoe num kda fragment spr measurement compare ldlr binding ability
0.3398514.15583000.html.plaintext.txt	127	apoenum num kda fragment dmpc discoidal complex displayed second order higher first association rate constant lipid free protein resulting much higher affinity binding heparin cf
0.3398514.15583000.html.plaintext.txt	128	among apoe isoforms complexed dmpc significant difference association dissociation rate constant equilibrium affinity table ii
0.3398514.15583000.html.plaintext.txt	129	mutation knumrknumr effect kinetics affinity binding heparin indicating charge specificity basic residue required effective binding heparin
0.3398514.15583000.html.plaintext.txt	130	contrast lnumkknumlknumllnumk mutant exhibited much lower response heparin binding wt apoenum num kda fragment lipidated state fig
0.3398514.15583000.html.plaintext.txt	131	num suggesting amphipathic nature helix spanning residue num num critical heparin binding apoe
0.3398514.15583000.html.plaintext.txt	132	interestingly mutation led increased favorable free energy binding second step well decrease free energy first step fig
0.3398514.15583000.html.plaintext.txt	133	num overall kd value significantly different wt table ii
0.3398514.15583000.html.plaintext.txt	134	view table table ii kinetic parameter binding apoe num kda dmpc disc heparin
0.3398514.15583000.html.plaintext.txt	135	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	136	spr sensorgrams binding dmpc discoidal complex apoenum num kda fragment lnumkknumlknumllnumk mutant b heparin
0.3398514.15583000.html.plaintext.txt	137	experimental binding data fitted two state binding model dashed line
0.3398514.15583000.html.plaintext.txt	138	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	139	comparison free energy heparin binding dmpc discoidal complex apoenum mutant
0.3398514.15583000.html.plaintext.txt	140	free energy calculated according g rt ln k using binding constant step
0.3398514.15583000.html.plaintext.txt	141	num compared apoenum num kda fragment dmpc complex
0.3398514.15583000.html.plaintext.txt	142	two step mechanism binding apoe heparin spr data indicate binding apoe heparin two state process involving sequential binding andor conformational change
0.3398514.15583000.html.plaintext.txt	143	known protein bind heparin induce change conformation within heparin andor protein num
0.3398514.15583000.html.plaintext.txt	144	interaction antithrombin heparin initial interaction induces conformational change antithrombin enables additional interaction antithrombin heparin resulting stronger binding num
0.3398514.15583000.html.plaintext.txt	145	also evidence relatively flexible num sulfoiduronic acid residue heparin change conformation upon protein binding resulting better fit enhanced binding num
0.3398514.15583000.html.plaintext.txt	146	however cd measurement apoeheparin mixture demonstrated heparin binding induce change secondary structure apoe fig
0.3398514.15583000.html.plaintext.txt	147	taken together spr data triple interhelical disulfide linked apoenum num kda mutant showing two state binding heparin appears two state apoeheparin interaction observed spr measurement due major conformational change apoe upon heparin binding
0.3398514.15583000.html.plaintext.txt	148	dominant type interaction heparin protein ionic cluster basic residue protein form ion pair spatially defined acidic group heparin num
0.3398514.15583000.html.plaintext.txt	149	fact molecular modeling interaction heparin binding site apoe heparin fragment suggested eight polar residue including lys num directly contact sulfate carboxyl group heparin chain num
0.3398514.15583000.html.plaintext.txt	150	thus large reduction association rate favorable free energy first binding step lys num mutant fig
0.3398514.15583000.html.plaintext.txt	151	num consistent first step involving fast electrostatic interaction basic residue apoe acidic group heparin
0.3398514.15583000.html.plaintext.txt	152	addition analysis dependence kd value sodium chloride concentration data shown using proteinpolyelectrolyte interaction theory num indicated num
0.3398514.15583000.html.plaintext.txt	153	num charged residue respectively involved electrostatic component overall first binding process apoeheparin interaction
0.3398514.15583000.html.plaintext.txt	154	similarity two value also support idea electrostatic interaction involved first binding step
0.3398514.15583000.html.plaintext.txt	155	besides ionic interaction known significant contribution binding heparin nonionic interaction hydrogen bonding hydrophobic interaction case num
0.3398514.15583000.html.plaintext.txt	156	fact molecular modeling apoeheparin interaction predicts formation hydrogen bonding residue lys num apoe heparin also hydrophobic interaction shallow groove helix apoe saccharide chain heparin num
0.3398514.15583000.html.plaintext.txt	157	regard significant increase contribution second step free energy binding observed lnumkknumlknumllnumk mutant fig
0.3398514.15583000.html.plaintext.txt	158	num disruption amphipathic helix heparin binding region destabilizes n terminal helix bundle expose hydrophobic surface num implies hydrophobic interaction apoe heparin contributes second binding step
0.3398514.15583000.html.plaintext.txt	159	addition found spr data interaction brain natriuretic peptide heparin major contribution free energy binding come hydrogen bonding interaction num displayed two state binding first binding step contributed overall free energy binding data shown
0.3398514.15583000.html.plaintext.txt	160	suggests hydrogen bonding may involved mostly first binding step
0.3398514.15583000.html.plaintext.txt	161	structural requirement receptor binding region apoe heparin interaction although lipid association required high affinity binding apoe ldlr num lipid free apoe bind effectively heparin table
0.3398514.15583000.html.plaintext.txt	162	addition apoenum highly defective ldlr binding num exhibited similar heparin binding activity apoenum lipid free lipidated state fig
0.3398514.15583000.html.plaintext.txt	163	result consistent previous observation requirement high affinity binding apoe hspgheparin le stringent binding ldlr num
0.3398514.15583000.html.plaintext.txt	164	suggested multiple basic residue receptor binding region residue num num apoe required particular orientation optimal binding ldlr num
0.3398514.15583000.html.plaintext.txt	165	indeed comparison structure residue num num lipid free lipid associated apoe showed significantly different curvature basic residue le scattered forming better aligned elongated hydrophilic surface lipidated form num num
0.3398514.15583000.html.plaintext.txt	166	addition nuclear magnetic resonance study num num demonstrated lipid interaction increase positive electrostatic potential around lysine num num effect much le apoenum
0.3398514.15583000.html.plaintext.txt	167	taken together appears enhanced electrostatic potential around residue num num apoe required interaction ldlr necessary high affinity binding heparin
0.3398514.15583000.html.plaintext.txt	168	previous study relative strength heparin binding arginine lysine demonstrated former bind num
0.3398514.15583000.html.plaintext.txt	169	indeed found spr measurement lipid free substitution mutant knumrknumr displayed num
0.3398514.15583000.html.plaintext.txt	170	num time higher affinity heparin wt data shown
0.3398514.15583000.html.plaintext.txt	171	however shown table ii double substitution lysine arginine effect kinetics affinity binding lipidated apoe heparin although mutant exhibit much reduced binding affinity ldlr num
0.3398514.15583000.html.plaintext.txt	172	follows preference lysine arginine position heparin binding lipid associated apoe
0.3398514.15583000.html.plaintext.txt	173	disruption helical structure region num num mutation lnumkknumlknumllnumk greatly affected kinetics binding heparin fig
0.3398514.15583000.html.plaintext.txt	174	num table ii mutant still displayed overall heparin binding affinity similar wt table ii
0.3398514.15583000.html.plaintext.txt	175	suggests amphipathic helical structural motif receptor binding region apoe critical effective binding heparin contrast situation ldlr binding
0.3398514.15583000.html.plaintext.txt	176	somewhat surprising result may arise appropriate arrangement basic residue required interaction heparin still maintained discoidal complex mutant
0.3398514.15583000.html.plaintext.txt	177	presumably cooperative binding multiple copy heparin binding site apoe molecule important determining heparin binding ability apoe bound lipid particle num
0.3398514.15583000.html.plaintext.txt	178	implication sequestration role hspg remnant lipoprotein metabolism spr kinetic data apoeheparin interaction provide novel insight mechanism hspg lrp pathway remnant lipoprotein uptake cell fig
0.3398514.15583000.html.plaintext.txt	179	pathway apoe postulated interact initially cell surface hspg transfer lrp internalization num
0.3398514.15583000.html.plaintext.txt	180	limited kinetic parameter apoelrp interaction available num compare kinetic parameter binding lipidated apoe heparin related ldlr num num
0.3398514.15583000.html.plaintext.txt	181	fast association lipidated apoe first binding step heparin long range nondirectional ionic interaction table ii follows apoe enriched remnant particle captured rapidly abundant hspg cell surface
0.3398514.15583000.html.plaintext.txt	182	fast dissociation step likely allow rapid transfer remnant particle lrp associated closely hspg num
0.3398514.15583000.html.plaintext.txt	183	lrp could retain remnant particle cell surface endocytosis occurs slow dissociation rate apoe receptor complex num num num num
0.3398514.15583000.html.plaintext.txt	184	process would efficient direct binding remnant particle solution lrp remnant particle concentrated cell surface could diffuse two dimension rapidly exchanging hspg binding site collide lrp form lrp remnant particle complex
0.3398514.15583000.html.plaintext.txt	185	lateral diffusion cell surface reminiscent scooting mode proposed interfacial reaction phospholipases num
0.3398514.15583000.html.plaintext.txt	186	also possible initial complex hspg remnant particle would undergo second binding step forming stable complex internalization without lrp involvement
0.3398514.15583000.html.plaintext.txt	187	view larger version numk fig
0.3398514.15583000.html.plaintext.txt	188	model two step kinetics remnant lipoprotein uptake hspg lrp pathway
0.3398514.15583000.html.plaintext.txt	189	apoe enriched remnant lipoprotein first captured fast association apoe cell surface hspg
0.3398514.15583000.html.plaintext.txt	190	fast dissociation rate interaction remnant lipoprotein rapidly transferred lrp form stable complex characterized slow dissociation endocytosis
0.3398514.15583000.html.plaintext.txt	191	initial complex hspg remnant particle would undergo second binding step forming stable complex internalization
0.3398514.15583000.html.plaintext.txt	192	summary characterized kinetics affinity interaction apoe heparin using spr
0.3398514.15583000.html.plaintext.txt	193	data show binding apoe heparin two step process fast initial binding involving polar interaction followed relatively slow nonpolar interaction
0.3398514.15583000.html.plaintext.txt	194	propose fast association dissociation process apoehspg interaction play role hspg lrp pathway remnant lipoprotein rapidly captured hspg transferred lrp form stable complex internalization
0.3398514.15583000.html.plaintext.txt	195	footnote work supported national institute health grant hlnum grant aid num num scientific research japan society promotion science
0.3398514.15583000.html.plaintext.txt	196	cost publication article defrayed part payment page charge
0.3398514.15583000.html.plaintext.txt	197	article must therefore hereby marked advertisement accordance num u
0.3398514.15583000.html.plaintext.txt	198	section num solely indicate fact
0.3398514.15583000.html.plaintext.txt	199	correspondence addressed childrens hospital philadelphia abramson research bldg
0.3398514.15583000.html.plaintext.txt	200	suite num num civic center blvd
0.3398514.15583000.html.plaintext.txt	201	num num num fax num num num e mail katzatemail
0.3398514.15583000.html.plaintext.txt	202	num abbreviation used apoe apolipoprotein e dmpc numnum dimyristoyl phosphatidylcholine hspg heparan sulfate proteoglycan ldlr low density lipoprotein receptor lrp ldlr related protein spr surface plasmon resonance wt wild type cd circular dichroism
0.3398514.15583000.html.plaintext.txt	203	acknowledgment thank dr
0.3398514.15583000.html.plaintext.txt	204	masashi hyuga national institute health science tokyo japan kaori morimoto biacore k
0.3398514.15583000.html.plaintext.txt	205	tokyo japan valuable suggestion spr measurement
0.3398514.15583000.html.plaintext.txt	206	home help feedback subscription archive search table content asbmb journal molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright num american society biochemistry molecular biology
0.34268814.15576362.html.plaintext.txt	0	generation recombinant apolipoprotein e variant improved biological function hydrophobic residue leu num trp num phe num leu num val num apoe account apoe induced hypertriglyceridemia kyriakos e
0.34268814.15576362.html.plaintext.txt	1	molecular genetics department medicine boston university school medicine boston massachusetts num department human genetics leiden university medical center numal leiden netherlands department general internal medicine leiden university medical center numal leiden netherlands tno preventie en gezondheid prevention health gaubius laboratory leiden numck netherlands department cardiology leiden university medical center numal leiden netherlands department biochemistry institute molecular biology biotechnology university crete medical school heraklion crete num greece
0.34268814.15576362.html.plaintext.txt	2	received publication november num num
0.34268814.15576362.html.plaintext.txt	3	series recent study used adenovirus expressing full length truncated genomic apoe sequence correct high cholesterol profile apoe deficient apoe mouse
0.34268814.15576362.html.plaintext.txt	4	shown overexpression full length apoe infection mouse num num x num pfu correct high cholesterol level apoe mouse contrast increased vldl triglyceride secretion induced hypertriglyceridemia num num
0.34268814.15576362.html.plaintext.txt	5	overexpression apoenum apoenum also aggravated hypercholesterolemia apoenum knock mouse num
0.34268814.15576362.html.plaintext.txt	6	however high cholesterol profile apoe mouse apoenum knock mouse corrected infection truncated apoe form lacking different segment carboxyl terminal domain num num
0.34268814.15576362.html.plaintext.txt	7	hypertriglyceridemia induced full length apoe independent apoe phenotype mouse strain could corrected overexpression lipoprotein lipase num
0.34268814.15576362.html.plaintext.txt	8	normal cnumblnum mouse overexpression full length apoe induced combined hyperlipidemia characterized high cholesterol high triglyceride level whereas truncated apoe form change plasma lipid lipoprotein level mouse num
0.34268814.15576362.html.plaintext.txt	9	finally truncated apoe form could correct high cholesterol profile apoe x ldlr double deficient mouse induce hypertriglyceridemia indicating carboxyl terminal region apoe responsible hypertriglyceridemia num num
0.34268814.15576362.html.plaintext.txt	10	use series apoe deletion mutant extending amino acid num amino acid num num num num mapped region responsible hypertriglyceridemia amino acid num num apoe num num
0.34268814.15576362.html.plaintext.txt	11	region contains two hydrophobic stretch amino acid residue num num num num
0.34268814.15576362.html.plaintext.txt	12	present study hydrophobic residue region mutated alanine function mutant apoe form studied vivo using adenovirus mediated gene transfer
0.34268814.15576362.html.plaintext.txt	13	analysis showed residue leu num trp num phe num leu num ala num account apoe induced hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	14	furthermore num num apoe sequence responsible displacing apoa hdl region leading reduction plasma apoa hdl level
0.34268814.15576362.html.plaintext.txt	15	recombinant adenovirus constructed described num using ad easy num system adenovirus construct generated bacteria bj num cell num
0.34268814.15576362.html.plaintext.txt	16	correct clone propagated reca dhnum cell
0.34268814.15576362.html.plaintext.txt	17	recombinant adenoviral vector linearized paci used infect num cell num
0.34268814.15576362.html.plaintext.txt	18	following large scale infection human embryonic kidney num cell culture recombinant adenovirus purified two consecutive cscl ultracentrifugation step dialyzed titrated num
0.34268814.15576362.html.plaintext.txt	19	usually titer num num x num pfuml obtained
0.34268814.15576362.html.plaintext.txt	20	cell culture study human htbnum cell swnum human astrocytoma grown confluence medium containing num fetal calf serum infected adgfp enum adenovirus expressing mutant apoe form adgfp enum mutnum adgfp enum mutnum multiplicity infection num
0.34268814.15576362.html.plaintext.txt	21	twenty four hour postinfection cell washed twice phosphate buffered saline fresh serum free medium added
0.34268814.15576362.html.plaintext.txt	22	num h incubation medium collected analyzed enzyme linked immunosorbent assay elisa sd page apoe expression
0.34268814.15576362.html.plaintext.txt	23	animal study female apoe deficient mouse num num week old used study
0.34268814.15576362.html.plaintext.txt	24	group num num female mouse injected intravenously tail vein dose num x num pfu
0.34268814.15576362.html.plaintext.txt	25	blood obtained tail vein num h fast preceding adenoviral injection num num num num num day postinfection
0.34268814.15576362.html.plaintext.txt	26	aliquot plasma stored num num degree c
0.34268814.15576362.html.plaintext.txt	27	rna analysis ass expression apoenum apoenum mutnum apoenum mutnum infected mouse least num mouse group sacrificed num day postinfection
0.34268814.15576362.html.plaintext.txt	28	liver collected individual animal frozen liquid nitrogen stored num degree c
0.34268814.15576362.html.plaintext.txt	29	total rna isolated liver analyzed apoe mrna expression northern blotting quantitated phosphorimaging num
0.34268814.15576362.html.plaintext.txt	30	fplc analysis lipid determination fplc analysis serum sample num microl serum diluted numnum phosphate buffered saline loaded onto superose num column smart micro fplc system amersham bioscience eluted phosphate buffered saline
0.34268814.15576362.html.plaintext.txt	31	total num fraction num microl volume collected analysis
0.34268814.15576362.html.plaintext.txt	32	triglyceride cholesterol determined using gpo trinder kit sigma chol mprnum kit roche applied science according manufacturer instruction
0.34268814.15576362.html.plaintext.txt	33	triglyceride cholesterol concentration serum fplc fraction determined spectrophotometrically num num nm respectively described previously num
0.34268814.15576362.html.plaintext.txt	34	quantification human apoe human apoe concentration measured using sandwich elisa num num
0.34268814.15576362.html.plaintext.txt	35	rate vldl triglyceride production cnumblnum mouse infected different apoe form vldl triglyceride secretion determined following infection cnumblnum mouse num x num pfu adenovirus expressing either wt apoenum apoenum mutnum control adgfp adenovirus
0.34268814.15576362.html.plaintext.txt	36	four day postinfection mouse fasted num h injected triton wr num dose num mgkg body weight using num solution wv num
0.34268814.15576362.html.plaintext.txt	37	num nacl triton wr num shown completely inhibit vldl catabolism num
0.34268814.15576362.html.plaintext.txt	38	serum sample isolated num num num num min injection triton wr num
0.34268814.15576362.html.plaintext.txt	39	serum triglyceride measured rate vldl triglyceride secretion expressed mgdlmin determined described num
0.34268814.15576362.html.plaintext.txt	40	statistical analysis comparison data two group mouse performed using student test
0.34268814.15576362.html.plaintext.txt	41	density gradient ultracentrifugation ass ability wt mutant apoe form associate different lipoprotein num
0.34268814.15576362.html.plaintext.txt	42	num ml serum mouse infected either control adenovirus adgfp adenovirus expressing wt apoenum apoenum mutnum apoenum mutnum brought volume num
0.34268814.15576362.html.plaintext.txt	43	num ml phosphate buffered saline adjusted density num
0.34268814.15576362.html.plaintext.txt	44	solution overlaid num ml num
0.34268814.15576362.html.plaintext.txt	45	mixture centrifuged num h sw num rotor numnum rpm
0.34268814.15576362.html.plaintext.txt	46	following ultracentrifugation num fraction num
0.34268814.15576362.html.plaintext.txt	47	num ml collected analyzed sd page
0.34268814.15576362.html.plaintext.txt	48	electron microscopy aliquot fraction equilibrium density gradient centrifugation dialysis ammonium acetate carbonate buffer stained sodium phosphotungstate visualized phillips cm num electron microscopy phillips electron optic eindhoven netherlands photographed described previously num
0.34268814.15576362.html.plaintext.txt	49	photomicrograph taken xnumnum magnification enlarged three time
0.34268814.15576362.html.plaintext.txt	50	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	51	sd page analysis culture medium htb num cell infected control adenovirus adenovirus expressing wt apoenum apoenum mutnum apoenum mutnum
0.34268814.15576362.html.plaintext.txt	52	m indicates protein marker different molecular mass new england biolabs
0.34268814.15576362.html.plaintext.txt	53	apoe level assessed comparison intensity band sample containing num
0.34268814.15576362.html.plaintext.txt	54	num num microg bovine serum albumin
0.34268814.15576362.html.plaintext.txt	55	residue leu num trp num phe num leu num val num responsible apoe induced hypertriglyceridemia used adenovirus mediated gene transfer apoe mouse ass effect wild type apoenum two mutant apoenum mutnum apoenum mutnum form induction hyperlipidemia vivo
0.34268814.15576362.html.plaintext.txt	56	apoe mouse infected either control adenovirus adgfp recombinant adenovirus expressing wild type apoenum mutant form apoenum mutnum contains point mutation lnuma wnuma fnuma lnuma vnuma apoenum mutnum contains point mutation wnuma lnuma vnuma vnuma blood sample collected num num day postinfection analyzed plasma lipid level
0.34268814.15576362.html.plaintext.txt	57	analysis showed infection mouse num x num pfu recombinant adenovirus expressing apoenum apoenum mutnum alter significantly plasma cholesterol level num num day postinfection induced hypertriglyceridemia compared mouse infected control virus fig
0.34268814.15576362.html.plaintext.txt	58	num non infected mouse data shown
0.34268814.15576362.html.plaintext.txt	59	apoenum mutnum overexpression resulted mild hypertriglyceridemia compared wild type apoenum fig
0.34268814.15576362.html.plaintext.txt	60	contrast infection mouse recombinant adenovirus expressing apoenum mutnum dose num x num greatly reduced plasma cholesterol level num num day postinfection cause hypertriglyceridemia fig
0.34268814.15576362.html.plaintext.txt	61	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	62	plasma cholesterol triglyceride apoe level apoe mouse infected recombinant adenovirus expressing apoenum apoenum mutnum apoenum mutnum control adgfp virus
0.34268814.15576362.html.plaintext.txt	63	mouse infected least triplicate indicated dos recombinant virus serum sample isolated analyzed cholesterol triglyceride level b indicated day postinfection described experimental procedure
0.34268814.15576362.html.plaintext.txt	64	apoe level determined day num postinfection
0.34268814.15576362.html.plaintext.txt	65	expression apoenum apoenum mutnum apoenum mutnum assessed mouse group num day postinfection northern blotting apoe mrna quantitated phosphorimaging
0.34268814.15576362.html.plaintext.txt	66	analysis showed apoe mrna level three group similar fig
0.34268814.15576362.html.plaintext.txt	67	however apoenum mutnum cleared efficiently cholesterol apoe deficient mouse without induction hypertriglyceridemia whereas full length apoenum apoenum mutnum correct cholesterol level apoe mouse induced hypertriglyceridemia fig
0.34268814.15576362.html.plaintext.txt	68	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	69	steady state hepatic apoe mrna level liver individual mouse infected adenovirus expressing apoenum apoenum mutnum apoenum mutnum
0.34268814.15576362.html.plaintext.txt	70	total rna isolated liver infected mouse num day postinfection analyzed northern blotting phosphorimaging expression apoe glyceraldehyde num phosphate dehydrogenase gapdh mrna
0.34268814.15576362.html.plaintext.txt	71	representative autoradiograms northern blot analysis total rna isolated liver individual mouse infected indicated dose recombinant adenovirus expressing apoenum num apoenum mutnum wt apoenum
0.34268814.15576362.html.plaintext.txt	72	b apoe mrna level quantified phosphorimager using imagequant program version num
0.34268814.15576362.html.plaintext.txt	73	numa normalized glyceraldehyde num phosphate dehydrogenase mrna level reported format bar graph mouse
0.34268814.15576362.html.plaintext.txt	74	apoenum apoenum mutnum overexpression result accumulation triglyceride rich vldl particle whereas overexpression apoenum mutnum clear vldl fplc analysis plasma adenovirus infected mouse showed mouse expressing apoenum apoenum mutnum num day postinfection cholesterol triglyceride level high distributed predominantly vldl region fig
0.34268814.15576362.html.plaintext.txt	75	contrast mouse infected adgfp enum mutnum cholesterol triglyceride low distributed lipoprotein fraction fig
0.34268814.15576362.html.plaintext.txt	76	additional control infection mouse num x num pfu control virus adgfp result change cholesterol triglyceride profile apoe mouse data shown
0.34268814.15576362.html.plaintext.txt	77	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	78	fplc profile serum cholesterol c triglyceride d f adenovirus infected mouse
0.34268814.15576362.html.plaintext.txt	79	serum sample obtained uninfected apoe deficient mouse mouse infected num x num pfu recombinant adenovirus expressing wt apo enum d apoenum mutnum b e apoenum mutnum c f num day postinfection fractionated fplc
0.34268814.15576362.html.plaintext.txt	80	cholesterol level c triglyceride level d f fplc fraction determined described experimental procedure
0.34268814.15576362.html.plaintext.txt	81	apoenum mutnum apoenum mutnum modest effect rate hepatic vldl triglyceride secretion rate hepatic vldl triglyceride secretion plasma determined following injection triton wr num num day infection recombinant adenovirus
0.34268814.15576362.html.plaintext.txt	82	found consistent previous finding num num rate triglyceride secretion increased num
0.34268814.15576362.html.plaintext.txt	83	num fold mouse infected adenovirus expressing wt apoenum compared mouse infected adgfp control
0.34268814.15576362.html.plaintext.txt	84	mouse infected adenovirus expressing either apoe mutnum apoenum mutnum rate vldl triglyceride secretion increased num
0.34268814.15576362.html.plaintext.txt	85	num fold compared mouse infected control adenovirus num rate vldl secretion observed mouse infected apoenum expressing adenovirus fig
0.34268814.15576362.html.plaintext.txt	86	finding suggest residue leu num trp num phe num leu num val num residue trp num leu num val num val num human apoe major effect secretion hepatic triglyceride altered le hydrophobic alanine rate triglyceride secretion diminished
0.34268814.15576362.html.plaintext.txt	87	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	88	hepatic vldl triglyceride tg secretion analysis mouse infected either control adgfp adenovirus recombinant adenovirus expressing wt apoenum apoenum mutnum apoenum mutnum
0.34268814.15576362.html.plaintext.txt	89	triton wr num num mgkg body weight injected num fasted micevirus group
0.34268814.15576362.html.plaintext.txt	90	serum sample collected num num num num min injection detergent
0.34268814.15576362.html.plaintext.txt	91	control serum sample isolated num min immediately injection detergent
0.34268814.15576362.html.plaintext.txt	92	serum triglyceride level determined linear graph serum triglyceride concentration versus time generated
0.34268814.15576362.html.plaintext.txt	93	rate vldl triglyceride secretion expressed mgdlmin calculated slope linear graph individual mouse
0.34268814.15576362.html.plaintext.txt	94	individual rate vldl triglyceride secretionvirus group presented form bar graph
0.34268814.15576362.html.plaintext.txt	95	co expression full length apoenum apoenum mutnum lipoprotein lipase normalizes lipid level apoe mouse test potential insufficiency activity lipoprotein lipase induction hypertriglyceridemia apoe mouse co infected num x num pfu adenovirus expressing apoenum apoenum mutnum apoenum mutnum num x num pfu adenovirus expressing human lipoprotein lipase
0.34268814.15576362.html.plaintext.txt	96	treatment corrected hypertriglyceridemia hypercholesterolemia occurs mouse treated apoenum apoenum mutnum alone fig
0.34268814.15576362.html.plaintext.txt	97	co infection apoenum mutnum adenovirus expressing human lipoprotein lipase decreased slightly plasma cholesterol level significant effect plasma triglyceride level fig
0.34268814.15576362.html.plaintext.txt	98	finding indicated condition overexpression apoenum apoenum mutnum endogenous lipoprotein lipase activity rate limiting lipolysis clearance vldl
0.34268814.15576362.html.plaintext.txt	99	num d e suggest apoenum mutnum reduces plasma lipid level apoe mouse affect significantly hepatic vldl triglyceride secretion negative effect activity lipoprotein lipase
0.34268814.15576362.html.plaintext.txt	100	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	101	plasma cholesterol triglyceride apoe level apoe mouse infected recombinant adenovirus expressing either full length apoenum apoenum mutnum apoenum mutnum alone mixture apoenum apoenum mutnum apoenum mutnum human lipoprotein lipase determined num num day postinfection
0.34268814.15576362.html.plaintext.txt	102	mouse infected indicated dos recombinant adenovirus serum sample isolated analyzed plasma cholesterol d g triglyceride b e h apoe level c f day num num num num num num postinfection described experimental procedure
0.34268814.15576362.html.plaintext.txt	103	effect overexpression lipoprotein lipase plasma apoe level mouse infected adenovirus expressing apoenum apoenum mutnum apoenum mutnum lipoprotein lipase treatment different effect plasma apoe level mouse treated apoenum compared mouse treated either apoenum mutnum apoenum mutnum fig
0.34268814.15576362.html.plaintext.txt	104	thus apoe level reduced average value num mgdl mouse infected apoenum expressing adenovirus num num day postinfection average value num mgdl mouse infected apoenum lipoprotein lipase expressing adenovirus fig
0.34268814.15576362.html.plaintext.txt	105	lipoprotein lipase treatment reduced apoe level average value num mgdl mouse treated apoenum mutnum alone average value num mgdl mouse treated apoenum mutnum lipoprotein lipase fig
0.34268814.15576362.html.plaintext.txt	106	interesting greatest level apoe day num num postinfection apoenum mutnum expressing adenovirus associated mild hypertriglyceridemia fig
0.34268814.15576362.html.plaintext.txt	107	contrast apoe level apoenum mutnum remained high average value num mgdl without treatment lpl expressing adenovirus fig
0.34268814.15576362.html.plaintext.txt	108	apoenum apoenum mutnum apoenum mutnum displace apoa hdl region promote formation discoidal hdl particle establish ability apoenum apoenum mutnum apoenum mutnum associate different lipoprotein num microl serum mouse infected either recombinant adenovirus expressing apoenum apoenum mutnum apoenum mutnum fractionated density gradient ultracentrifugation
0.34268814.15576362.html.plaintext.txt	109	fraction different density isolated analyzed sd page followed either staining coomassie brilliant blue stain western blotting using anti apoe antibody
0.34268814.15576362.html.plaintext.txt	110	found full length apoenum apoenum mutnum apoenum mutnum mutant associate lipoprotein float hdl region lesser extent particle ldl idl vldl region
0.34268814.15576362.html.plaintext.txt	111	remarkably however overexpression wt apoenum apoenum mutnum resulted displacement apoa hdl whereas overexpression apoenum mutnum displace apoa hdl density region fig
0.34268814.15576362.html.plaintext.txt	112	estimated based sd page analysis apoa level mouse infected apoenum mutnum appear similar apoe mouse num apoa found hdl following density gradient ultracentrifugation fig
0.34268814.15576362.html.plaintext.txt	113	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	114	distribution apoe different lipoprotein fraction following density gradient ultracentrifugation
0.34268814.15576362.html.plaintext.txt	115	plasma obtained apoe mouse expressing wt apoenum apoenum mutnum apoenum mutnum mouse infected control adenovirus fractionated density gradient ultracentrifugation analyzed sd page described experimental procedure
0.34268814.15576362.html.plaintext.txt	116	analysis plasma obtained mouse infected control adenovirus adgfp
0.34268814.15576362.html.plaintext.txt	117	b c analysis plasma obtained apoe mouse infected wt apoenum
0.34268814.15576362.html.plaintext.txt	118	concentration plasma apoe e mouse analyzed b c num num mgdl respectively
0.34268814.15576362.html.plaintext.txt	119	fraction number density fraction position apoa apoe shown panel
0.34268814.15576362.html.plaintext.txt	120	m indicates protein marker different mr
0.34268814.15576362.html.plaintext.txt	121	note depending level apoe expression apoa ai either drastically reduced b totally displaced c hdl
0.34268814.15576362.html.plaintext.txt	122	d e analysis apoe mouse infected apoenum mutnum apoenum mutnum respectively
0.34268814.15576362.html.plaintext.txt	123	electron microscopy analysis fraction num num containing apoa showed overexpression wt apoenum apoenum mutnum associated formation discoidal hdl particle whereas expression apoenum mutnum similar level associated formation spherical hdl particle fig
0.34268814.15576362.html.plaintext.txt	124	difference biogenesis catabolism vldl hdl apoe mouse overexpress apoenum apoenum mutnum apoenummutnum summarized fig
0.34268814.15576362.html.plaintext.txt	125	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	126	electron microscopy analysis hdl fraction obtained plasma mouse infected control adenovirus adgfp adenovirus expressing wt apoenum b apoenum mutnum c apoenum mutnum d
0.34268814.15576362.html.plaintext.txt	127	pooled hdl fraction num num shown fig
0.34268814.15576362.html.plaintext.txt	128	num c d e used electron microscopy analysis
0.34268814.15576362.html.plaintext.txt	129	view larger version numk fig
0.34268814.15576362.html.plaintext.txt	130	schematic representation summarizing difference biosynthesis catabolism vldl hdl apoe mouse overexpressing wt apoenum two mutant apoenum mutnum b apoenum mutnum c
0.34268814.15576362.html.plaintext.txt	131	apoe ldl receptor interaction control plasma cholesterol level confer protection atherosclerosis num
0.34268814.15576362.html.plaintext.txt	132	contribution receptor ldl receptor clearance apoe containing lipoprotein remnant previously assessed study apoe x ldlr double deficient mouse num
0.34268814.15576362.html.plaintext.txt	133	study shown neither full length apoenum apoenum truncated apoenum num apoenum num corrected high cholesterol profile apoe x ldlr double deficient mouse num
0.34268814.15576362.html.plaintext.txt	134	data observation full length apoenum suggest strongly apoe mediated lipoprotein clearance mouse carried mainly ldl receptor num
0.34268814.15576362.html.plaintext.txt	135	absence receptor lipoprotein receptor related protein apoe recognizing lipoprotein receptor heparan sulfate proteoglycans num num sufficient clear lipoprotein remnant accumulate plasma double deficient mouse num
0.34268814.15576362.html.plaintext.txt	136	addition role apoe cholesterol homeostasis circulation plasma apoe level correlate plasma triglyceride level human num
0.34268814.15576362.html.plaintext.txt	137	hypertriglyceridemia also induced mouse overexpression human apoe num num num
0.34268814.15576362.html.plaintext.txt	138	however recent study shown hypertriglyceridemia occur mouse infected adenovirus expressing truncated apoe form lacking num num carboxyl terminal domain num num
0.34268814.15576362.html.plaintext.txt	139	set experiment also showed truncated apoe form co expressed full length apoe form dominant effect normalized cholesterol level apoe mouse num
0.34268814.15576362.html.plaintext.txt	140	finding suggested full length apoe bound triglyceride rich vldl particle receptor binding domain may masked thus preventing direct apoe mediated clearance vldl particle prior lipolysis
0.34268814.15576362.html.plaintext.txt	141	contrast truncated apoe bound triglyceride rich vldl particle receptor binding domain may exposed may allow direct clearance vldl particle num
0.34268814.15576362.html.plaintext.txt	142	current study designed map residue carboxyl terminal region apoe responsible hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	143	rationale identification residue may lead generation recombinant apoe form improved biological function
0.34268814.15576362.html.plaintext.txt	144	focused two region apoe residue num num contain hydrophobic amino acid
0.34268814.15576362.html.plaintext.txt	145	first region includes amino acid leu num trp num phe num leu num val num second region includes amino acid trp num leu num val num val num
0.34268814.15576362.html.plaintext.txt	146	blast search ncbi data base www
0.34268814.15576362.html.plaintext.txt	147	gov showed region highly conserved among mammalian specie
0.34268814.15576362.html.plaintext.txt	148	vivo adenovirus mediated gene transfer two apoe mutant established unequivocally hydrophobic residue apoe amino acid num num account large extent induction hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	149	hypertriglyceridemia occur mouse infected adenovirus expressing apoenum mutnum residue changed alanine
0.34268814.15576362.html.plaintext.txt	150	contrast infection mouse adenovirus expressing apoenum mutnum hydrophobic residue amino acid num num substituted alanine resulted milder hypertriglyceridemia compared mouse infected apoenum expressing adenovirus
0.34268814.15576362.html.plaintext.txt	151	appears hydrophobic residue within num num well num num region affect secretion vldl triglyceride
0.34268814.15576362.html.plaintext.txt	152	mutation residue alanine reduced rate hepatic vldl triglyceride secretion num caused wild type apoenum
0.34268814.15576362.html.plaintext.txt	153	data also showed increase level plasma lipoprotein lipase co infection recombinant adenovirus expressing human lipoprotein lipase corrected apoe induced dyslipidemia apoe mouse overexpress full length apoenum
0.34268814.15576362.html.plaintext.txt	154	finding suggests condition apoe overexpression activity lipoprotein lipase becomes rate limiting clearance hypertriglyceridemic vldl
0.34268814.15576362.html.plaintext.txt	155	substantial le severe hypertriglyceridemia also observed overexpression apoenum mutnum also corrected co infection lipoprotein lipase expressing adenovirus
0.34268814.15576362.html.plaintext.txt	156	difference severity hypertriglyceridemia wt apoenum apoenum mutnum may related increased vldl triglyceride secretion caused wt apoenum
0.34268814.15576362.html.plaintext.txt	157	important clue nature hypertriglyceridemic lipoprotein particle accumulate plasma mouse provided clearance apoe mouse co infected wild type mutant form apoe lpl expressing adenovirus
0.34268814.15576362.html.plaintext.txt	158	apoe cleared mouse treated apoenum lpl partially cleared mouse treated apoenum mutnum lpl unaffected mouse treated apoenum mutnum lpl
0.34268814.15576362.html.plaintext.txt	159	average apoe level without treatment lipoprotein lipase num num day postinfection changed num mgdl num mgdl apoenum num mgdl num mgdl apoenum mutnum remained num mgdl apoenum mutnum
0.34268814.15576362.html.plaintext.txt	160	finding indicate wild type apoenum resides triglyceride rich lipoprotein particle following hydrolysis triglyceride particle lpl apoenum recognized cleared component remnant particle ldl receptor
0.34268814.15576362.html.plaintext.txt	161	appears majority mutant apoenum mutnum may reside another population triglyceride poor particle cleared ldl receptor
0.34268814.15576362.html.plaintext.txt	162	finally apoenum mutnum may partitioned triglyceride rich particle processed lpl cleared ldl receptor triglyceride poor particle cleared ldl receptor
0.34268814.15576362.html.plaintext.txt	163	possible mutation introduced apoenum mutnum lesser extent apoenum mutnum may promoted formation triglyceride poor apoe containing lipoprotein particle accumulate hdl region mouse
0.34268814.15576362.html.plaintext.txt	164	significant finding study apoenum apoenum mutnum wnuma lnuma vnuma vnuma displaced apoa hdl promoted formation discoidal hdl
0.34268814.15576362.html.plaintext.txt	165	contrast apoe mutnum lnuma wnuma fnuma lnuma vnuma displace apoa hdl region affect formation spherical hdl particle
0.34268814.15576362.html.plaintext.txt	166	finding suggest wt apoenum apoenum mutnum overexpressed may influence formation stability hdl
0.34268814.15576362.html.plaintext.txt	167	effect apoe mutation biosynthesis catabolism vldl hdl summarized fig
0.34268814.15576362.html.plaintext.txt	168	present time clear whether apoe overexpression interferes biogenesis hdl pathway involves abcanum transporter whether affect stability displacing apoa surface hdl
0.34268814.15576362.html.plaintext.txt	169	process expected reduce level hdl
0.34268814.15576362.html.plaintext.txt	170	undesirable property wt apoe reduce plasma hdl level overcome recombinant apoenum mutnum hydrophobic residue num num region mutated alanine
0.34268814.15576362.html.plaintext.txt	171	ability recombinant apoe form apoenum mutnum clear cholesterol without inducing hypertriglyceridemia interfering formation spherical hdl make attractive therapeutic agent correct remnant removal disorder
0.34268814.15576362.html.plaintext.txt	172	therapeutic form apoe may involve pure recombinant protein associated liposome potential gene therapy future
0.34268814.15576362.html.plaintext.txt	173	footnote work supported grant hlnum national institute health ko pharmaceutical grant lst
0.34268814.15576362.html.plaintext.txt	174	grant mcif num num european union fifth framework program k
0.34268814.15576362.html.plaintext.txt	175	cost publication article defrayed part payment page charge
0.34268814.15576362.html.plaintext.txt	176	article must therefore hereby marked advertisement accordance num u
0.34268814.15576362.html.plaintext.txt	177	section num solely indicate fact
0.34268814.15576362.html.plaintext.txt	178	correspondence addressed section molecular genetics whitaker cardiovascular institute dept
0.34268814.15576362.html.plaintext.txt	179	medicine boston university school medicine num albany st
0.34268814.15576362.html.plaintext.txt	180	w num boston massachusetts num
0.34268814.15576362.html.plaintext.txt	181	num num num fax num num num e mail vzannisatbu
0.34268814.15576362.html.plaintext.txt	182	num abbreviation used apoe apolipoprotein e apoa apolipoprotein ad adenovirus elisa enzyme linked immunosorbent assay fplc fast pressure liquid chromatography gfp green fluorescence protein hdl high density lipoprotein vldl low density lipoprotein lpl lipoprotein lipase pfu plaque forming unit wt wild type idl intermediate density lipoprotein apoe apoe deficient ldlr ldl receptor deficient
0.34268814.15576362.html.plaintext.txt	183	zannis unpublished observation
0.34268814.15576362.html.plaintext.txt	184	acknowledgment thank anne plunkett manuscript preparation adelina shkodrani gayle forbes andre van der zee technical assistance course experiment
0.34592706.9302273.html.plaintext.txt	0	synergy gene butyrylcholinesterase k variant apolipoprotein enum late onset confirmed alzheimers disease synergy gene butyrylcholinesterase k variant apolipoprotein enum late onset confirmed alzheimers disease d
0.34592706.9302273.html.plaintext.txt	1	oxford project investigate memory ageing optimum university department pharmacology mansfield rd oxford oxnum numqt uk radcliffe infirmary woodstock rd oxford oxnum numhe uk
0.34592706.9302273.html.plaintext.txt	2	received july num num revised accepted july num num
0.34592706.9302273.html.plaintext.txt	3	allelic frequency gene k variant butyrylcholinesterase bche k num
0.34592706.9302273.html.plaintext.txt	4	num num subject late onset age num year histopathologically diagnosed alzheimers disease ad higher frequency num elderly control subject num
0.34592706.9302273.html.plaintext.txt	5	num num early onset case confirmed ad num
0.34592706.9302273.html.plaintext.txt	6	num num confirmed case dementia num
0.34592706.9302273.html.plaintext.txt	7	association bche k late onset ad limited carrier epsilonnum allele apolipoprotein e gene apoe among presence bche k gave odds ratio confirmed late onset ad num
0.34592706.9302273.html.plaintext.txt	8	num num subject num year num
0.34592706.9302273.html.plaintext.txt	9	apoeepsilonnum carrier num year numnum control compared numnum confirmed late onset ad case bche k
0.34592706.9302273.html.plaintext.txt	10	suggest bche k nearby gene chromosome num act synergy apoeepsilonnum susceptibility gene late onset ad
0.34592706.9302273.html.plaintext.txt	11	butyrylcholinesterase bche expressed human tissue num yet function unknown
0.34592706.9302273.html.plaintext.txt	12	bche activity brain increase age num year elevated alzheimers disease ad num num
0.34592706.9302273.html.plaintext.txt	13	histochemically reactive bche associated amyloid plaque neurofibrillary tangle amyloid angiopathy ad num num
0.34592706.9302273.html.plaintext.txt	14	looked possible association ad two common human variant gene bche bche atypical allele k variant bche k
0.34592706.9302273.html.plaintext.txt	15	latter point mutation nucleotide num gca aca change alanum threonine catalytic activity reduced third num
0.34592706.9302273.html.plaintext.txt	16	bche k thought allelic frequency num
0.34592706.9302273.html.plaintext.txt	17	num subject genotyped three control subject num three ad case num identified heterozygote atypical bche allele
0.34592706.9302273.html.plaintext.txt	18	thus association found histopathologically confirmed ad atypical allele bche
0.34592706.9302273.html.plaintext.txt	19	two six atypical bche heterozygote carrier bche k
0.34592706.9302273.html.plaintext.txt	20	altogether num caucasian subject genotyped bche k apoe allele
0.34592706.9302273.html.plaintext.txt	21	bche k common late onset ad case early onset ad case dementia control table num
0.34592706.9302273.html.plaintext.txt	22	subject aged num allelic frequency bche k num
0.34592706.9302273.html.plaintext.txt	23	num num confirmed ad case giving odds ratio ad num
0.34592706.9302273.html.plaintext.txt	24	association appeared due subject num year old frequency bche k num
0.34592706.9302273.html.plaintext.txt	25	num num confirmed ad case chinum yates correction num
0.34592706.9302273.html.plaintext.txt	26	num giving odds ratio ad num
0.34592706.9302273.html.plaintext.txt	27	insufficient case trend age reach significance nevertheless thought helpful show data num year subgroup well subject num year table num
0.34592706.9302273.html.plaintext.txt	28	taking account individual carrier status apoe epsilonnum produced striking result
0.34592706.9302273.html.plaintext.txt	29	subject num year without apoe epsilonnum allelic frequency bche k num
0.34592706.9302273.html.plaintext.txt	30	num num confirmed ad case num
0.34592706.9302273.html.plaintext.txt	31	thus association bche k late onset ad subject lacking apoe epsilonnum allele
0.34592706.9302273.html.plaintext.txt	32	apoe epsilonnum carrier however bche k allelic frequency subject aged num year num
0.34592706.9302273.html.plaintext.txt	33	num num confirmed ad case num
0.34592706.9302273.html.plaintext.txt	34	num num control subject aged num year frequency num
0.34592706.9302273.html.plaintext.txt	35	num num confirmed ad case num
0.34592706.9302273.html.plaintext.txt	36	result gave odds ratio confirmed ad num
0.34592706.9302273.html.plaintext.txt	37	num bche k apoe epsilonnum carrier aged num year num year respectively table num
0.34592706.9302273.html.plaintext.txt	38	comparison give table num odds ratio confirmed ad apoe epsilonnum bche k carrier
0.34592706.9302273.html.plaintext.txt	39	seen individual bche k status markedly influence strength effect apoe epsilonnum
0.34592706.9302273.html.plaintext.txt	40	table num show striking difference case control proportion subject carry bche k apoe epsilonnum allele
0.34592706.9302273.html.plaintext.txt	41	finding indicated interaction bche k apoe epsilonnum confirmed logistic regression analysis
0.34592706.9302273.html.plaintext.txt	42	fitted several logistic regression model data found parsimonious model apoe epsilonnum bche k interaction gave adequate fit residual deviance num
0.34592706.9302273.html.plaintext.txt	43	model apoe epsilonnum interaction bche k significantly associated ad bche k
0.34592706.9302273.html.plaintext.txt	44	table num allelic frequency bche k apoe epsilonnum
0.34592706.9302273.html.plaintext.txt	45	bche k allele frequency apoe epsilonnum allelefrequency control num year num num
0.34592706.9302273.html.plaintext.txt	46	num confirmed dementia num num
0.34592706.9302273.html.plaintext.txt	47	num load eoad respectively late onset num year early onsetalzheimers disease
0.34592706.9302273.html.plaintext.txt	48	bche k group exact hardy weinberg equilibrium
0.34592706.9302273.html.plaintext.txt	49	num chinum yates correction versus control
0.34592706.9302273.html.plaintext.txt	50	aages death status confirmed last clinical assessment living subject
0.34592706.9302273.html.plaintext.txt	51	table num odds ratio confirmed late onset alzheimers disease bche k allele subject control case odds ratioa num c
0.34592706.9302273.html.plaintext.txt	52	num apoe epsilonnum carrier num year num num num
0.34592706.9302273.html.plaintext.txt	53	num num apoe epsilonnum carrier num year num num num
0.34592706.9302273.html.plaintext.txt	54	num num age table num num onset late onset ad case control death confirmed last clinical assessment living
0.34592706.9302273.html.plaintext.txt	55	athese odds ratio based allele
0.34592706.9302273.html.plaintext.txt	56	equivalent odds ratio bche k based carrier num
0.34592706.9302273.html.plaintext.txt	57	table num odds ratio confirmed late onset alzheimers disease apoe epsilonnum allele subject control case odds ratio num c
0.34592706.9302273.html.plaintext.txt	58	num bche k carrier num year num num num
0.34592706.9302273.html.plaintext.txt	59	num num bche k carrier num year num num num
0.34592706.9302273.html.plaintext.txt	60	table num proportion control confirmed late onset ad case bche k apoe epsilonnum allele subject proportion allele control case p num year numnum num numnum num num
0.34592706.9302273.html.plaintext.txt	61	num num year numnum num numnum num num
0.34592706.9302273.html.plaintext.txt	62	num apoe epsilonnum carrier num year numnum num numnum num num
0.34592706.9302273.html.plaintext.txt	63	num apoe epsilonnum carrier num year numnum num numnum num num
0.34592706.9302273.html.plaintext.txt	64	num chinum yates correction
0.34592706.9302273.html.plaintext.txt	65	table num odds ratio confirmed late onset ad taking subject neither apoe epsilonnum bche k reference apoe epsilonnum bche k control case odds ratio num ci age num year num num reference num num num
0.34592706.9302273.html.plaintext.txt	66	num num age num year num num reference num num num
0.34592706.9302273.html.plaintext.txt	67	order examine strength interaction bche k apoe epsilonnum give table num odds ratio confirmed ad subject different combination two gene taking subject neither gene reference
0.34592706.9302273.html.plaintext.txt	68	subject num year odds ratio carry bche k num
0.34592706.9302273.html.plaintext.txt	69	num apoe epsilonnum num
0.34592706.9302273.html.plaintext.txt	70	gave predicted odds ratio num
0.34592706.9302273.html.plaintext.txt	71	num subject gene assumption independent effect two gene compared observed value num
0.34592706.9302273.html.plaintext.txt	72	subject num year predicted odds ratio num
0.34592706.9302273.html.plaintext.txt	73	num observed odds ratio num
0.34592706.9302273.html.plaintext.txt	74	therefore suggest strong synergy two allele late onset ad
0.34592706.9302273.html.plaintext.txt	75	apoe epsilonnum risk factor ad well established num num
0.34592706.9302273.html.plaintext.txt	76	result consistent hypothesis bche k associated increase risk late onset ad apoe epsilonnum carrier
0.34592706.9302273.html.plaintext.txt	77	effect could due linkage disequilibrium another gene chromosome num conceivably transferrin whose cnum variant reported common num clinically diagnosed ad case general population num
0.34592706.9302273.html.plaintext.txt	78	num num gene transferrin numqnum qnum num
0.34592706.9302273.html.plaintext.txt	79	hand effect late onset ad might mediated bche k
0.34592706.9302273.html.plaintext.txt	80	various potential interaction bche apolipoprotein e apoe
0.34592706.9302273.html.plaintext.txt	81	protein produced quantity liver secreted circulation num num
0.34592706.9302273.html.plaintext.txt	82	apoe probably also bche interact lipoprotein num num
0.34592706.9302273.html.plaintext.txt	83	protein found astrocyte num num glia bche oligodendrocyte num apoe microglia num
0.34592706.9302273.html.plaintext.txt	84	protein occur ad plaque intra extracellular neurofibrillary tangle association amyloid angiopathy num num num num
0.34592706.9302273.html.plaintext.txt	85	furthermore bche apoe implicated certain model neurite growth num num
0.34592706.9302273.html.plaintext.txt	86	case apoe difference enum enum isoforms num num case bche suggested nature attached sugar residue may important num num
0.34592706.9302273.html.plaintext.txt	87	noted k variant bche additional threonine residue position num whether potential o glycosylation site indeed phosphorylation site remains shown
0.34592706.9302273.html.plaintext.txt	88	furthermore threonine residue high propensity beta sheet formation num
0.34592706.9302273.html.plaintext.txt	89	lysozyme conversion isoleucine residue threonine cause amyloidosis num conversion alanine residue threonine transthyretin num
0.34592706.9302273.html.plaintext.txt	90	evidence cited provides pointer future work test hypothesis bche apoe may interact interaction influenced allelic variant
0.34592706.9302273.html.plaintext.txt	91	implication clinical genetics
0.34592706.9302273.html.plaintext.txt	92	replication finding particularly important since num caucasian population carry bche k apoe epsilonnum assuming respective allelic frequency num
0.34592706.9302273.html.plaintext.txt	93	thus subject confirmation result several million elderly carry gene high risk developing ad especially aged num year
0.34592706.9302273.html.plaintext.txt	94	pointed rose num ability identify risk individual major social ethical implication
0.34592706.9302273.html.plaintext.txt	95	since apoe epsilonnum established risk factor cardiovascular disease important see whether carrier also bche k greater risk cardiovascular disease
0.34592706.9302273.html.plaintext.txt	96	study would clinical relevance could also increase understanding role vascular risk factor num aetiology ad
0.34592706.9302273.html.plaintext.txt	97	num change brain cholinesterase senile dementia alzheimer type
0.34592706.9302273.html.plaintext.txt	98	num cholinergic system old age alzheimers disease
0.34592706.9302273.html.plaintext.txt	99	num electron microscopic localization cholinesterase activity alzheimer brain tissue
0.34592706.9302273.html.plaintext.txt	100	num cholinesterase amyloid angiopathy alzheimers disease
0.34592706.9302273.html.plaintext.txt	101	num butyrylcholinesterase reactivity differentiates amyloid plaque aging dementia
0.34592706.9302273.html.plaintext.txt	102	num cholinesterase pathology alzheimer disease
0.34592706.9302273.html.plaintext.txt	103	num ultrastructural localization butyrylcholinesterase neurofibrillary degeneration site brain aged alzheimers disease patient
0.34592706.9302273.html.plaintext.txt	104	num dna mutation associated human butyrylcholinesterase k variant linkage atypical variant mutation polymorphic site
0.34592706.9302273.html.plaintext.txt	105	num identification frequency j k cholinesterase phenotype caucasian population
0.34592706.9302273.html.plaintext.txt	106	num plasma cholinesterase variant
0.34592706.9302273.html.plaintext.txt	107	family study enumk gene
0.34592706.9302273.html.plaintext.txt	108	num association apolipoprotein e allele epsilonnum late onset familial sporadic alzheimers disease
0.34592706.9302273.html.plaintext.txt	109	num apolipoprotein e allele risk factor alzheimers disease
0.34592706.9302273.html.plaintext.txt	110	num increased frequency transferrin cnum subtype alzheimers disease
0.34592706.9302273.html.plaintext.txt	111	num refinement localization human butyrylcholinesterase chromosome numqnum
0.34592706.9302273.html.plaintext.txt	112	num human transferrin cdna characterization chromosomal localization
0.34592706.9302273.html.plaintext.txt	113	num apolipoprotein e cholesterol transport protein expanding role cell biology
0.34592706.9302273.html.plaintext.txt	114	num enzymatic activity related human serum beta lipoprotein histochemical immunoelectrophoretic quantitative study
0.34592706.9302273.html.plaintext.txt	115	num interrelationship serum beta lipoprotein cholinesterase
0.34592706.9302273.html.plaintext.txt	116	num neuroglial cholinesterase normal brain alzheimers disease relationship plaque tangle pattern selective vulnerability
0.34592706.9302273.html.plaintext.txt	117	num neuropathological change scrapie alzheimers disease associated increased expression apolipoprotein e cathepsin d astrocyte
0.34592706.9302273.html.plaintext.txt	118	num change butyryl cholinesterase activity reactive glia
0.34592706.9302273.html.plaintext.txt	119	num lipoprotein neurobiology alzheimers disease structure function apolipoprotein e
0.34592706.9302273.html.plaintext.txt	120	num apolipoprotein e immunoreactivity cerebral amyloid deposit neurofibrillary tangle alzheimers disease kuru plaque amyloid creutzfeldt jakob disease
0.34592706.9302273.html.plaintext.txt	121	num apolipoprotein e sporadic alzheimers disease allelic variation receptor interaction
0.34592706.9302273.html.plaintext.txt	122	num cranial nerve growth bird preceded cholinesterase expression neural crest cell migration formation hnk num scaffold
0.34592706.9302273.html.plaintext.txt	123	num cholinesterase regulate neurite growth chick nerve cell vitro mean non enzymatic mechanism
0.34592706.9302273.html.plaintext.txt	124	num novel function cholinesterase development physiology disease
0.34592706.9302273.html.plaintext.txt	125	num differential effect apolipoproteins enum enum neuronal growth vitro
0.34592706.9302273.html.plaintext.txt	126	num low density lipoprotein receptor related protein mediates apolipoprotein e dependent neurite outgrowth central nervous system derived neuronal cell line
0.34592706.9302273.html.plaintext.txt	127	num inhibitory effect apolipoprotein enum neurite outgrowth associated microtubule depolymerization
0.34592706.9302273.html.plaintext.txt	128	num measurement beta sheet forming propensity amino acid
0.34592706.9302273.html.plaintext.txt	129	num human lysozyme gene mutation cause hereditary systemic amyloidosis
0.34592706.9302273.html.plaintext.txt	130	num new transthyretin mutation associated amyloid cardiomyopathy
0.34592706.9302273.html.plaintext.txt	131	num genetic control human apolipoprotein e polymorphism comparison one two dimensional technique isoprotein analysis
0.34592706.9302273.html.plaintext.txt	132	num model susceptibility polymorphism complex disease apolipoprotein e alzheimer disease
0.34592706.9302273.html.plaintext.txt	133	num atherosclerosis apolipoprotein e prevalence dementia alzheimers disease rotterdam study
0.34592706.9302273.html.plaintext.txt	134	num detection life confirmed alzheimers disease using simple measurement medial temporal lobe atrophy computed tomography
0.34592706.9302273.html.plaintext.txt	135	num consortium establish registry alzheimers disease cerad
0.34592706.9302273.html.plaintext.txt	136	standardization neuropathologic assessment alzheimers disease
0.34592706.9302273.html.plaintext.txt	137	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.34592706.9302273.html.plaintext.txt	138	num camdex cambridge examination mental disorder elderly
0.34592706.9302273.html.plaintext.txt	139	cambridge university press cambridge
0.34592706.9302273.html.plaintext.txt	140	num detection plasma cholinesterase k variant pcr using amplification created restriction site
0.34592706.9302273.html.plaintext.txt	141	num apolipoprotein e genotyping one stage pcr
0.34592706.9302273.html.plaintext.txt	142	correspondence addressed
0.34592706.9302273.html.plaintext.txt	143	tel num num num fax num num num email david
0.3494895.15385439.html.plaintext.txt	0	allelic expression apoe human brain effect epsilon status promoter haplotype nicholas j
0.3494895.15385439.html.plaintext.txt	1	braynum luke jehunum valentina moskvinanum joseph d
0.3494895.15385439.html.plaintext.txt	2	buxbaumnum stella drachevanum vahram haroutuniannumnum julie williamsnumnum paul r
0.3494895.15385439.html.plaintext.txt	3	numdepartment psychological medicine numbiostatistics bioinformatics unit school medicine cardiff university cardiff cfnum numxn uk numdepartment psychiatry mount sinai school medicine new york ny num usa nummental illness research education clinical centre mirecc bronx veteran affair medical centre bronx new york ny num usa
0.3494895.15385439.html.plaintext.txt	4	received august num num accepted september num num
0.3494895.15385439.html.plaintext.txt	5	possession num allele apoe gene encoding apoenum undisputed genetic risk factor common late onset form alzheimers disease load increasing risk dose dependent manner numnum
0.3494895.15385439.html.plaintext.txt	6	however num allele neither necessary sufficient expression disease large proportion num homozygote surviving num year show cognitive impairment num
0.3494895.15385439.html.plaintext.txt	7	num allele encoding apoenum confers protective effect num
0.3494895.15385439.html.plaintext.txt	8	postulated addition structural change apoe ci acting variation within apoe regulatory sequence might also contribute disease susceptibility influencing gene expression
0.3494895.15385439.html.plaintext.txt	9	transgenic mouse model indicate apoe dosage significantly influence pathological hallmark human alzheimers disease including amyloid deposition neuritic degeneration numnum
0.3494895.15385439.html.plaintext.txt	10	furthermore ci acting regulatory variant human apoe potential influence load susceptibilty suggested study variation quantitative measure peripheral lipid metabolism better explained considering genotype data additional polymorphic site vicinity apoe rather num num status alone num
0.3494895.15385439.html.plaintext.txt	11	however noted implication study alzheimers disease unknown unclear aspect apoe function indexed peripheral lipid metabolism relevant load pathogenesis
0.3494895.15385439.html.plaintext.txt	12	moreover extent ci acting influence apoe expression human brain also currently unclear
0.3494895.15385439.html.plaintext.txt	13	powerful method investigating ci acting influence gene expression involves comparing relative level mrna transcript individual heterozygous expressed polymorphism
0.3494895.15385439.html.plaintext.txt	14	within subject approach allow detection genuine ci acting effect whilst controlling trans acting factor confound measure total expression sample
0.3494895.15385439.html.plaintext.txt	15	one study using rflp based assay reported evidence intrinsic effect epsilon status apoe mrna expression brain num expression greatly increased relative num num heterozygote num
0.3494895.15385439.html.plaintext.txt	16	elevated num expression observed load case control although former magnitude difference smaller
0.3494895.15385439.html.plaintext.txt	17	however finding replicated subsequent study potential methodological shortcoming rflp based assay clearly demonstrated num
0.3494895.15385439.html.plaintext.txt	18	molecular genetic study provide support association load two polymorphism promoter apoe denoted numa numg also known thnumenumcs num num
0.3494895.15385439.html.plaintext.txt	19	polymorphism shown influence apoe expression vitro num raising possibility association direct result ci acting effect gene expression rather virtue linkage disequilibrium ld
0.3494895.15385439.html.plaintext.txt	20	given importance apoe risk factor load potential importance variation apoe expression undertaken thorough investigation allelic expression apoe human brain using highly quantitative measure allele discrimination numnum large series heterozygous sample
0.3494895.15385439.html.plaintext.txt	21	objective establish whether epsilon status influence apoe expression brain determine extent apoe expression subject ci acting influence particular effect promoter polymorphism current interest alzheimers disease research
0.3494895.15385439.html.plaintext.txt	22	observed allele frequency genotyped polymorphism sample group measure apoe allele specific expression performed using expressed snp numt c numc
0.3494895.15385439.html.plaintext.txt	23	num allele determined haplotype numt numc num allele numt numt num allele numc numc
0.3494895.15385439.html.plaintext.txt	24	use polymorphism within mrna sequence permit discrimination allele transcribed chromosome
0.3494895.15385439.html.plaintext.txt	25	corrected cdna ratio num num heterozygote shown table num
0.3494895.15385439.html.plaintext.txt	26	analysis corrected cdna ratio initial sample num num heterozygote showed small significant elevation c allele snp numt c num relative allele num three replication experiment
0.3494895.15385439.html.plaintext.txt	27	repeat assay showed good reproducibility individual cdna allele ratio average co efficient variation sdmean num
0.3494895.15385439.html.plaintext.txt	28	combining data num individual across experiment expression num allele increased cdna average num relative num allele mean corrected rationum
0.3494895.15385439.html.plaintext.txt	29	num individual ratio ranging num num relative increase fig
0.3494895.15385439.html.plaintext.txt	30	comparison corrected genomic cdna ratio assayed snp numt c num subject
0.3494895.15385439.html.plaintext.txt	31	individual c allele determines num allele determines num
0.3494895.15385439.html.plaintext.txt	32	ratio therefore expressed level numnum
0.3494895.15385439.html.plaintext.txt	33	column num show cdna data point non ad case nnum column num show cdna data point confirmed load case nnum
0.3494895.15385439.html.plaintext.txt	34	data genomic dna average two measurement individual sample
0.3494895.15385439.html.plaintext.txt	35	data cdna average six estimate individual sample
0.3494895.15385439.html.plaintext.txt	36	non ad load case level num significantly greater num cdna p num
0.3494895.15385439.html.plaintext.txt	37	difference observed extent allelic distortion non ad load case pnum
0.3494895.15385439.html.plaintext.txt	38	expression ratio derived num num heterozygote load sample yielded similar pattern average num relative increase num compared num expression p num
0.3494895.15385439.html.plaintext.txt	39	good reproducibility individual cdna ratio across assay sdmeannum
0.3494895.15385439.html.plaintext.txt	40	num averaged increase ranging num num fig
0.3494895.15385439.html.plaintext.txt	41	significant difference observed ratio derived initial sample load case pnum
0.3494895.15385439.html.plaintext.txt	42	ratio obtained additional num num heterozygote tissue banum banum available showed significant increase expression num allele banum mean increasenum p num
0.3494895.15385439.html.plaintext.txt	43	num banum mean increasenum p num
0.3494895.15385439.html.plaintext.txt	44	within subject comparison two brain region indicated significant difference extent allelic imbalance paired test pnum
0.3494895.15385439.html.plaintext.txt	45	smaller difference observed relative expression num num allele snp numc initial sample num num heterozygote fig
0.3494895.15385439.html.plaintext.txt	46	average increase numc num allele numt num allele across experiment num rationum
0.3494895.15385439.html.plaintext.txt	47	num ranging equal expression rationum num relative increase num allele rationum
0.3494895.15385439.html.plaintext.txt	48	although meet conventional criterion significance pnum
0.3494895.15385439.html.plaintext.txt	49	num increase relative num expression observed four num heterozygote usa sample tissue derived either banum banum mean ratiosnum
0.3494895.15385439.html.plaintext.txt	50	combining data num sample frontal cortex yielded mean numnum ratio num
0.3494895.15385439.html.plaintext.txt	51	view larger version numk figure num
0.3494895.15385439.html.plaintext.txt	52	comparison corrected genomic cdna ratio assayed snp numc non ad num subject nnum
0.3494895.15385439.html.plaintext.txt	53	individual c allele determines num allele determines num
0.3494895.15385439.html.plaintext.txt	54	ratio therefore expressed level numnum
0.3494895.15385439.html.plaintext.txt	55	data genomic dna average two measurement individual sample
0.3494895.15385439.html.plaintext.txt	56	data cdna average six estimate individual sample
0.3494895.15385439.html.plaintext.txt	57	level num allele slightly higher num cdna pnum
0.3494895.15385439.html.plaintext.txt	58	two initial num sample num heterozygote therefore heterozygous snp numt c numc
0.3494895.15385439.html.plaintext.txt	59	allowed comparison allele ratio derived two separate assay absence alternative splicing comparable despite amplified assayed using different primer set
0.3494895.15385439.html.plaintext.txt	60	cdna ratio corrected average genomic assay num
0.3494895.15385439.html.plaintext.txt	61	num sample snp numt c numc respectively
0.3494895.15385439.html.plaintext.txt	62	thus case calculated ratio differed num two independent assay
0.3494895.15385439.html.plaintext.txt	63	sample small statistical analysis expected observation relative expression num num num num allele expressed higher level num case
0.3494895.15385439.html.plaintext.txt	64	investigate influence known promoter polymorphism allelic expression num unrelated caucasian num caucasian load case genotyped promoter snp numa numg observed allele frequency presented table num
0.3494895.15385439.html.plaintext.txt	65	although variant potential regulatory significance exist e
0.3494895.15385439.html.plaintext.txt	66	numt c numg c particular polymorphism selected basis strongest prior evidence association load num
0.3494895.15385439.html.plaintext.txt	67	sample used within subject comparison brain region included analysis ethnically heterogeneous
0.3494895.15385439.html.plaintext.txt	68	use sample different genetic background potentially problematic calculating conditional diplotype probability diplotypes le likely follow hardy weinberg expectation
0.3494895.15385439.html.plaintext.txt	69	determine variance relative num expression attributable heterozygosity promoter site corrected cdna ratio obtained analysis num heterozygote snpnumt c stratified according whether individual heterozygous homozygous two promoter locus
0.3494895.15385439.html.plaintext.txt	70	ratio derived num numg heterozygote num numg homozygote compared using two factorial anova load diagnosis included factor
0.3494895.15385439.html.plaintext.txt	71	num numg homozygote nine homozygous numt allele four homozygous numg allele
0.3494895.15385439.html.plaintext.txt	72	average increase num allele relative num num numg heterozygote range num num compared num numg homozygote range num num fig
0.3494895.15385439.html.plaintext.txt	73	significant main effect heterozygosity versus homozygosity numg polymorphism observed pnum
0.3494895.15385439.html.plaintext.txt	74	num significant effect load diagnosis pnum
0.3494895.15385439.html.plaintext.txt	75	knowledge phase required allow inference direction effect numg allele
0.3494895.15385439.html.plaintext.txt	76	diplotypes unambiguous respect individual homozygous promoter polymorphism heterozygous assayed site
0.3494895.15385439.html.plaintext.txt	77	however given observed haplotype frequency numg tnumt c double heterozygote probability numg nucleotide phase numt num numt nucleotide phase numc num num
0.3494895.15385439.html.plaintext.txt	78	numg heterozygote showed reduced relative increase num expression compared numg homozygote case heterozygote numt allele predicted phase num allele num case infer numt allele associated reduced apoe expression compared numg allele
0.3494895.15385439.html.plaintext.txt	79	view larger version numk figure num
0.3494895.15385439.html.plaintext.txt	80	comparison corrected numnum cdna ratio numg homozygote numg heterozygote assayed snp numt c
0.3494895.15385439.html.plaintext.txt	81	ratio derived num heterozygote also heterozygous snp numg show lower ratio numnum expression num heterozygote homozygous snp numg pnum
0.3494895.15385439.html.plaintext.txt	82	num num heterozygote included analysis six heterozygous numa polymorphism one homozygous numt allele num homozygous numa allele
0.3494895.15385439.html.plaintext.txt	83	average increase num allele relative num num numa heterozygote range num num compared num numa homozygote range num num fig
0.3494895.15385439.html.plaintext.txt	84	difference allele ratio approach statistical significance pnum
0.3494895.15385439.html.plaintext.txt	85	significant effect load diagnosis pnum
0.3494895.15385439.html.plaintext.txt	86	however given individual genotype snp numt c numg four six numa heterozygote probability numt nucleotide phase numt num allele numa nucleotide phase numc num allele num
0.3494895.15385439.html.plaintext.txt	87	phase probability much greater chance likely phase reversed proportion case distorting directional effect num expression
0.3494895.15385439.html.plaintext.txt	88	numa heterozygote greatest phase certainty pnum
0.3494895.15385439.html.plaintext.txt	89	num predicted posse numa nucleotide phase numg numc num numt nucleotide phase numg numt num
0.3494895.15385439.html.plaintext.txt	90	sample individual homozygous high expression numg allele whereas heterozygous numa polymorphism showed greatest elevation relative numc num expression assayed sample num
0.3494895.15385439.html.plaintext.txt	91	view larger version numk figure num
0.3494895.15385439.html.plaintext.txt	92	comparison corrected numnum cdna ratio numa homozygote numa heterozygote assayed snp numt c
0.3494895.15385439.html.plaintext.txt	93	significant difference observed two group pnum
0.3494895.15385439.html.plaintext.txt	94	found increased expression num allele num allele num heterozygote finding replicated two additional sample load subject mixed population subject neuropsychiatric disorder
0.3494895.15385439.html.plaintext.txt	95	also observed small increase relative num expression num individual finding replicate small number neuropsychiatric patient genotype observed
0.3494895.15385439.html.plaintext.txt	96	although comprehensive survey different brain region analysis frontal temporal cortex yielded evidence difference neuroanatomical region
0.3494895.15385439.html.plaintext.txt	97	relatively small difference allele ratio observed num heterozygote study stark contrast finding previous study num rflp based design used
0.3494895.15385439.html.plaintext.txt	98	study large increase observed level num relative num mrna control load sample although smaller difference seen load group
0.3494895.15385439.html.plaintext.txt	99	data compatible subsequent study num major difference expression two allele found either control load num heterozygote
0.3494895.15385439.html.plaintext.txt	100	also notable subsequent study num average num relative increase num expression found maximum num
0.3494895.15385439.html.plaintext.txt	101	using rflp based design similar previous study also showed estimation allele ratio using method critically dependent number pcr cycle due digestion resistant heteroduplex formation suggesting former result due artefact
0.3494895.15385439.html.plaintext.txt	102	primer extension method used present study unaffected problem thus present data likely provide accurate estimate relative allelic expression brain apoe
0.3494895.15385439.html.plaintext.txt	103	small increase num expression observed study could possibly reflect intrinsic effect allele transcription efficiency rna stability
0.3494895.15385439.html.plaintext.txt	104	alternatively finding may reflect strong ld num num conferring haplotype untested regulatory variant may many num
0.3494895.15385439.html.plaintext.txt	105	increased representation num allele unlikely resulted difference pcr primer extension efficiency controlled corrected concurrent assay genomic dna condition
0.3494895.15385439.html.plaintext.txt	106	although genomic control applied limit potential confounding differential rt efficiency neither phenomenon likely explain observed difference num heterozygote inter individual difference ratio largely preserved separate rt reaction
0.3494895.15385439.html.plaintext.txt	107	finding increased expression num allele rna level consistent recent study encoded apoenum isoform found account elevated proportion total apoe protein csf num heterozygote num
0.3494895.15385439.html.plaintext.txt	108	finding contrast measure apoenum plasma numnum associated lower protein expression suggesting important allele specific difference cns periphery control synthesis andor degradation apoe
0.3494895.15385439.html.plaintext.txt	109	magnitude num expression found virtually identical initial sample sample confirmed load case
0.3494895.15385439.html.plaintext.txt	110	initial sample selected specific control group load sample although contain individual diagnosis ad possible individual might developed disease survived old age
0.3494895.15385439.html.plaintext.txt	111	however difference observed sample confirmed load case consistent previous comparison using age matched control group term relative num rna expression num relative level apoenum protein num suggesting common risk factor load influence risk disease altering apoe expression selectively interact markedly increase expression specific apoe mrna specie
0.3494895.15385439.html.plaintext.txt	112	though significant influence ci acting polymorphism steady state level apoe mrna cerebral cortex small maximum relative difference expression observed study num
0.3494895.15385439.html.plaintext.txt	113	num apoe heterozygote assayed study provided num power detect effect distinct regulatory variant occurring general population frequency num
0.3494895.15385439.html.plaintext.txt	114	num almost num power detect effect one present frequency num
0.3494895.15385439.html.plaintext.txt	115	degree power effectively excludes existence even fairly rare polymorphism around apoe exerting large direct effect net apoe mrna expression
0.3494895.15385439.html.plaintext.txt	116	third objective study determine apoe mrna level vivo influenced polymorphism affect transcription activity vitro several study associated load
0.3494895.15385439.html.plaintext.txt	117	stratification observed numnum allele ratio according heterozygosity promoter polymorphism indicated small statistically significant effect numg polymorphism allelic expression consistent functional effect brain
0.3494895.15385439.html.plaintext.txt	118	numt allele previously associated reduced transcriptional activity vitro num reduced plasma apoe vivo num
0.3494895.15385439.html.plaintext.txt	119	present finding reduced ratio numnum expression probability num allele phase numt allele num allele phase numg allele suggests numt allele also decrease apoe expression brain
0.3494895.15385439.html.plaintext.txt	120	measure total expression data allow u distinguish direct indirect association consistency finding vitro study suggests direct effect
0.3494895.15385439.html.plaintext.txt	121	conditional probability diplotypes suggest num numg heterozygote
0.3494895.15385439.html.plaintext.txt	122	two num higher expression numg allele phase num num individual
0.3494895.15385439.html.plaintext.txt	123	know individual diplotypes analysis misclassified accurately ass impact estimate magnitude effect
0.3494895.15385439.html.plaintext.txt	124	however assume two heterozygote displaying least reduction numnum ratio misclassified obtain estimate maximum possible size effect
0.3494895.15385439.html.plaintext.txt	125	excluding analysis reveals mean net effect numt allele num reduction relative num expression
0.3494895.15385439.html.plaintext.txt	126	stress analysis provides guide maximum effect conclude effect size compelling case exclude single individual analysis
0.3494895.15385439.html.plaintext.txt	127	numa allele numa g promoter polymorphism reported show higher transcriptional activity vitro num associated increased measure total apoe expression plasma num brain num
0.3494895.15385439.html.plaintext.txt	128	present study heterozygosity site significantly influence relative num expression one direction
0.3494895.15385439.html.plaintext.txt	129	noted however power detect small directional effect would diminished small sample size low predicted consistency phase
0.3494895.15385439.html.plaintext.txt	130	interestingly although single observation assayed sample one showing greatest elevation relative numc num expression num also sample high probability num
0.3494895.15385439.html.plaintext.txt	131	num numa high expression predicted vitro nucleotide phase numg high expression vitro study numc high expression study
0.3494895.15385439.html.plaintext.txt	132	study illustrates importance complementing vivo vitro work
0.3494895.15385439.html.plaintext.txt	133	vitro work requires analysis effect variant alien genomic cellular context therefore finding must examined compatibility vivo
0.3494895.15385439.html.plaintext.txt	134	nevertheless without vitro work association observed impossible attribute vivo effect expression specific variant
0.3494895.15385439.html.plaintext.txt	135	would require effect ci acting variant haplotype controlled effectively impossible task relevant variant could legion distributed across large genomic sequence
0.3494895.15385439.html.plaintext.txt	136	summarize using relatively large series brain sample demonstrated common influence apoe expression attributable ci acting polymorphism small
0.3494895.15385439.html.plaintext.txt	137	also effectively excluded existence even fairly rare ci acting haplotype large effect
0.3494895.15385439.html.plaintext.txt	138	variance occur accounted num haplotype num allele apoe expressed significantly higher level num
0.3494895.15385439.html.plaintext.txt	139	highly reproducible appears independent ad status
0.3494895.15385439.html.plaintext.txt	140	also shown numg promoter allele associated higher expression apoe mrna vivo finding compatible previous vitro study
0.3494895.15385439.html.plaintext.txt	141	study provides important functional vivo plausibility existing body association data suggesting numt promoter polymorphism may modulate risk ad independent apoe epsilon status num
0.3494895.15385439.html.plaintext.txt	142	however though demonstration functionality enhances case strong genetic support sample larger currently available single group required force conclusion extremely small effect observed relevant load susceptibility
0.3494895.15385439.html.plaintext.txt	143	genotyping genotyping apoe numnumnum performed using rflp based assay described previously num
0.3494895.15385439.html.plaintext.txt	144	genotyping snp numa performed using snapshot primer extension amplification primer num gcctagccccactttctttt num num cacagtgggcgaatcactta num extension primer num cgaatcacttaaggtcaggag num
0.3494895.15385439.html.plaintext.txt	145	snp numg genotyped using primer num agaatggaggagggtgtccg num num actcaaggatcccagacttg num followed restriction digestion hpaii econnum
0.3494895.15385439.html.plaintext.txt	146	allele expression assay genomic dna subject initially genotyped described order identify heterozygote snp numt c num heterozygote numc num heterozygote
0.3494895.15385439.html.plaintext.txt	147	individual allelic expression experiment cdna heterozygote assayed two separate rt reaction alongside duplicate corresponding genomic dna sample
0.3494895.15385439.html.plaintext.txt	148	experiment repeated two separate occasion
0.3494895.15385439.html.plaintext.txt	149	dnase treated rna sample yield detectable product absence rt step
0.3494895.15385439.html.plaintext.txt	150	assay relative num expression num bp fragment containing snp numt c amplified cdna genomic dna using primer num gcctacaaatcggaactgga num num agctcctcggtgctctgg num
0.3494895.15385439.html.plaintext.txt	151	assay relative num expression num bp fragment containing snp numc amplified cdna genomic dna using primer num ctgcgtaagcggctcctc num num ccccggcctggtacactg num
0.3494895.15385439.html.plaintext.txt	152	pcrs carried total reaction volume num microl containing either cdna genomic dna template numxpcr buffer dntps num
0.3494895.15385439.html.plaintext.txt	153	num u hot star taq polymerase qiagen num dmso num cycle annealing temperature num degree c
0.3494895.15385439.html.plaintext.txt	154	amplified sample incubated num u shrimp alkaline phosphatase amersham num u exonuclease amersham num min num degree c num min num degree c prior primer extension reaction
0.3494895.15385439.html.plaintext.txt	155	primer extension carried using snapshot multiplex kit applied biosystems
0.3494895.15385439.html.plaintext.txt	156	extension primer snp numt c num gcgcggacatggaggacgtg num
0.3494895.15385439.html.plaintext.txt	157	extension primer snp numc num ccgatgacctgcagaag num
0.3494895.15385439.html.plaintext.txt	158	primer extension reaction performed total volume num microl containing num microl treated pcr product num
0.3494895.15385439.html.plaintext.txt	159	num microl water num pm extension primer
0.3494895.15385439.html.plaintext.txt	160	primer extension thermocycling condition consisted initial step num degree c num min followed num cycle num degree c num num degree c num num degree c num
0.3494895.15385439.html.plaintext.txt	161	following primer extension reaction product treated num
0.3494895.15385439.html.plaintext.txt	162	num u shrimp alkaline phosphatase amersham num min num degree c num min num degree c
0.3494895.15385439.html.plaintext.txt	163	aliquot num microl snapshot reaction product combined num microl hi di formamide loaded onto num dna sequencer applied biosystems
0.3494895.15385439.html.plaintext.txt	164	product electrophoresed num cm capillary array num degree c data processed using genescan analysis version num
0.3494895.15385439.html.plaintext.txt	165	num software applied biosystems
0.3494895.15385439.html.plaintext.txt	166	peak height allele specific extended primer determined using genotyper version num
0.3494895.15385439.html.plaintext.txt	167	num software applied biosystems ratio used index relative expression two allele individual sample
0.3494895.15385439.html.plaintext.txt	168	analytic condition used genomic dna cdna average ratio observed genomic dna experiment representing num num ratio two allele could used correct allelic ratio obtained cdna analysis inequality allelic representation specific assay num
0.3494895.15385439.html.plaintext.txt	169	statistical analysis difference allelic expression tested comparing genomic ratio cdna ratio heterozygous sample
0.3494895.15385439.html.plaintext.txt	170	group comparison analyzed test two tailed diagnosis included factor two factorial anova
0.3494895.15385439.html.plaintext.txt	171	predicted haplotype frequency calculated using eh plus num formed basis calculation individual diplotype probability
0.3494895.15385439.html.plaintext.txt	172	calculate probability individual carry specific diplotype first reconstructing possible combination diplotypes individual given observed genotype locus
0.3494895.15385439.html.plaintext.txt	173	use expected distribution diplotype frequency given observed haplotype frequency within specific sample identify probable diplotype individual
0.3494895.15385439.html.plaintext.txt	174	probability diplotype within individual frequency diplotype divided sum frequency possible diplotypes
0.3494895.15385439.html.plaintext.txt	175	calculation power detect effect unknown regulatory variant based binomial distribution hardy weinberg equilibrium regulatory snp ld marker snp
0.3494895.15385439.html.plaintext.txt	176	probability individual homozygous putative regulatory locus allele hardy weinberg equilibrium pnumqnum p q two allele frequency
0.3494895.15385439.html.plaintext.txt	177	probability n individual homozygous therefore undetected assay regulatory polymorphism pnumqnumn
0.3494895.15385439.html.plaintext.txt	178	also applies n individual selected heterozygosity marker locus relationship
0.3494895.15385439.html.plaintext.txt	179	ld genotype locus
0.3494895.15385439.html.plaintext.txt	180	power detect least one heterozygote num pnumqnumn
0.3494895.15385439.html.plaintext.txt	181	marker regulatory snp ld higher proportion people selected heterozygosity marker also heterozygous regulatory snp power increased
0.3494895.15385439.html.plaintext.txt	182	footnote correspondence addressed
0.3494895.15385439.html.plaintext.txt	183	tel num num fax num num email odonovanmcatcardiff
0.3494895.15385439.html.plaintext.txt	184	num simultaneous effect apolipoprotein e polymorphism apolipoprotein e apolipoprotein b cholesterol metabolism
0.3494895.15385439.html.plaintext.txt	185	num differential effect apolipoproteins enum enum neuronal growth vitro
0.3494895.15385439.html.plaintext.txt	186	num apolipoprotein e sporadic alzheimers disease allelic variation receptor interaction
0.3494895.15385439.html.plaintext.txt	187	num apolipoprotein e high avidity binding beta amyloid increased frequency type num allele late onset familial alzheimer disease
0.3494895.15385439.html.plaintext.txt	188	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.3494895.15385439.html.plaintext.txt	189	num apolipoprotein e cognitive change elderly population
0.3494895.15385439.html.plaintext.txt	190	num protection alzheimers disease apoe epsilon num
0.3494895.15385439.html.plaintext.txt	191	num lack apolipoprotein e dramatically reduces amyloid beta peptide deposition
0.3494895.15385439.html.plaintext.txt	192	num apolipoprotein e isoform dependent amyloid deposition neuritic degeneration mouse model alzheimers disease
0.3494895.15385439.html.plaintext.txt	193	num contribution num additional dna sequence variation gene encoding apolipoprotein e explaining variation quantitative measure lipid metabolism
0.3494895.15385439.html.plaintext.txt	194	num distortion allelic expression apolipoprotein e alzheimers disease
0.3494895.15385439.html.plaintext.txt	195	num lack allelic imbalance apoe epsilonnumnum brain mrna expression alzheimers disease
0.3494895.15385439.html.plaintext.txt	196	num polymorphism regulatory region apoe associated risk alzheimers dementia
0.3494895.15385439.html.plaintext.txt	197	num new polymorphism apoe promoter associated risk developing alzheimers disease
0.3494895.15385439.html.plaintext.txt	198	num contribution apoe promoter polymorphism alzheimers disease risk
0.3494895.15385439.html.plaintext.txt	199	num allelic polymorphism transcriptional regulatory region apolipoprotein e gene
0.3494895.15385439.html.plaintext.txt	200	num allelic variation human gene expression
0.3494895.15385439.html.plaintext.txt	201	num haplotype implicated schizophrenia susceptibility associated reduced comt expression human brain
0.3494895.15385439.html.plaintext.txt	202	num high expression apolipoprotein e mrna brain sporadic alzheimers disease
0.3494895.15385439.html.plaintext.txt	203	num apoe epsilon numepsilon num heterozygote elevated proportion apolipoprotein enum cerebrospinal fluid relative plasma independent alzheimers disease diagnosis
0.3494895.15385439.html.plaintext.txt	204	num independent association apoe gene promoter polymorphism increased risk myocardial infarction decreased apoe plasma concentration ectim study
0.3494895.15385439.html.plaintext.txt	205	num numaa polymorphism apoe gene associated increased plasma apoe level alzheimers disease
0.3494895.15385439.html.plaintext.txt	206	num variation apoe num promoter locus associated altered brain level apolipoprotein e
0.3494895.15385439.html.plaintext.txt	207	num restriction isotyping human apolipoprotein e gene amplification cleavage hhanum
0.3494895.15385439.html.plaintext.txt	208	num cheap accurate rapid allele frequency estimation single nucleotide polymorphism primer extension dhplc dna pool
0.3494895.15385439.html.plaintext.txt	209	num model free analysis permutation test allelic association
0.36174858.15888448.html.plaintext.txt	0	low density lipoprotein receptor regulates level central nervous system human murine apolipoprotein e modify amyloid plaque pathology pdapp mouse john d
0.36174858.15888448.html.plaintext.txt	1	sullivanf maia parsadaniana guojun bucg david m
0.36174858.15888448.html.plaintext.txt	2	department aneurologyh molecular biology pharmacologyc pediatrics gcell biology physiology ihope center neurological disorder washington university school medicine st
0.36174858.15888448.html.plaintext.txt	3	louis missouri num bneuroscience discovery research eli lilly co
0.36174858.15888448.html.plaintext.txt	4	lilly research laboratory indianapolis indiana num department ofd pharmacology toxicology ande psychiatry indiana university school medicine indianapolis indiana num fbryan alzheimers disease research center division neurology department medicine duke university medical center durham north carolina num
0.36174858.15888448.html.plaintext.txt	5	received publication february num num revised form april num num
0.36174858.15888448.html.plaintext.txt	6	num num allele apoe found genetic risk factor common form ad late onset ad well cerebral amyloid angiopathy whereas num allele shown protective num
0.36174858.15888448.html.plaintext.txt	7	abundant data suggest apoe linked ad cerebral amyloid angiopathy due ability act chaperone num influence metabolism
0.36174858.15888448.html.plaintext.txt	8	acting binding molecule apoe influence amount deposition conformation aggregate well clearance toxicity vivo num num
0.36174858.15888448.html.plaintext.txt	9	furthermore level apoe brain directly influence aforementioned process num num
0.36174858.15888448.html.plaintext.txt	10	example app transgenic mouse lacking apoe develop le deposition virtually fibrillar deposit num num num
0.36174858.15888448.html.plaintext.txt	11	thus understanding cellular event receptor regulate apoe level brain may give important insight ad pathogenesis
0.36174858.15888448.html.plaintext.txt	12	apoe expressed high level liver central nervous system cns present lipoprotein particle
0.36174858.15888448.html.plaintext.txt	13	furthermore apoe cns derived within cns plasma num
0.36174858.15888448.html.plaintext.txt	14	however cns apoe containing lipoprotein differ found periphery amount sialation perhaps importantly type lipoprotein particle associate num
0.36174858.15888448.html.plaintext.txt	15	plasma apoe low density lipoprotein vldl subset high density lipoprotein also contain apoproteins
0.36174858.15888448.html.plaintext.txt	16	contrast cns apoe high density lipoprotein like lipoprotein secreted primarily astrocyte released cell contain apoe sole apolipoprotein constituent num num
0.36174858.15888448.html.plaintext.txt	17	despite information whether specific apoe receptor regulate level apoe brain mediate apoe dependent clearance apoe binding protein unknown
0.36174858.15888448.html.plaintext.txt	18	nearly num year ago brown goldstein num elucidated role low density lipoprotein receptor ldlr receptor mediated endocytosis lipoprotein plasma including apoe
0.36174858.15888448.html.plaintext.txt	19	subsequently member ldlr family identified
0.36174858.15888448.html.plaintext.txt	20	many expressed brain shown vitro bind endocytose lipid rich lipoprotein contain apoe num
0.36174858.15888448.html.plaintext.txt	21	determine whether ldlr family member influence level cns apoe metabolism ad mouse model recently bred mouse lacking num kda receptor associated protein rap num
0.36174858.15888448.html.plaintext.txt	22	increase aggregation deposition found mouse
0.36174858.15888448.html.plaintext.txt	23	rap endoplasmic reticulum chaperone protein known influence folding level ldlr family member study level ldlr related protein lrp ldlr examined found reduced brain mouse lacking rap num
0.36174858.15888448.html.plaintext.txt	24	additionally overexpression functional lrp mini receptor pdapp model led increase level soluble advanced stage deposition detectable change deposition measured histologically num
0.36174858.15888448.html.plaintext.txt	25	thus whether ldlr family member responsible brain apoe metabolism whether play role regulating level vivo remains unclear
0.36174858.15888448.html.plaintext.txt	26	herein investigate role ldlr regulation cns derived apoe well brain level mouse model ad
0.36174858.15888448.html.plaintext.txt	27	animal tissue preparation analysis tissue plasma cholesterol csf apoe num month old ldlr ldlr mouse identical cnumblnumj background used num
0.36174858.15888448.html.plaintext.txt	28	analysis human apoe isoforms ldlr mouse first bred wild type sjl mouse generate ldlr mouse mixed cnumblnumj x sjl background
0.36174858.15888448.html.plaintext.txt	29	mouse bred human apoe expressing mouse num maintained cnumblnumj x sjl background mouse analyzed human apoe experiment identical background
0.36174858.15888448.html.plaintext.txt	30	analysis utilized pdapp mouse overexpress human appnum familial ad mutation position num appvnumf control neuron specific platelet derived growth factor promoter num
0.36174858.15888448.html.plaintext.txt	31	crossed pdapp ldlr mouse ldlr mouse generate pdapp ldlr pdapp ldlr mouse littermates mixed genetic background described previously num
0.36174858.15888448.html.plaintext.txt	32	hereafter mouse referred pdapp study hemizygous pdapp transgene pdapp
0.36174858.15888448.html.plaintext.txt	33	animal anesthetized pentobarbital num mgkg intraperitoneal perfused transcardially num
0.36174858.15888448.html.plaintext.txt	34	num m pb containing heparin num unitsml ph num
0.36174858.15888448.html.plaintext.txt	35	one hemibrain immersion fixed pb containing num paraformaldehyde overnight num degree c
0.36174858.15888448.html.plaintext.txt	36	fixation brain cryoprotected pb containing num sucrose num degree c
0.36174858.15888448.html.plaintext.txt	37	brain region hemisphere dissected frozen powdered dry ice analysis
0.36174858.15888448.html.plaintext.txt	38	complete protease inhibitor roche applied science used indicated
0.36174858.15888448.html.plaintext.txt	39	pb soluble analysis tissue first dounce homogenized ice cold pb protease inhibitor immediately spun num min numnum x g
0.36174858.15888448.html.plaintext.txt	40	carbonate soluble analysis pb insoluble pellet homogenized ice cold num mm carbonate num mm nacl ph num
0.36174858.15888448.html.plaintext.txt	41	num protease inhibitor immediately spun num min numnum x g
0.36174858.15888448.html.plaintext.txt	42	carbonate insoluble analysis carbonate insoluble pellet lysed num h rotation num m guanidine num mm tris protease inhibitor
0.36174858.15888448.html.plaintext.txt	43	experimental protocol approved animal study committee washington university
0.36174858.15888448.html.plaintext.txt	44	biochemical histological analysis anum anum quantified enzyme linked immunosorbent assay described previously num
0.36174858.15888448.html.plaintext.txt	45	deposition assessed immunostaining numdnum antibody recognizing amino acid num num stereological analysis previously described num
0.36174858.15888448.html.plaintext.txt	46	apoe measured cortical tissue dounce homogenized briefly pb protease inhibitor spun immediately numnum x g num min
0.36174858.15888448.html.plaintext.txt	47	murine apoe quantified using sandwich enzyme linked immunosorbent assay pooled cnumblnumj plasma serving standard apoe set num microgml num sensitivity num ngml
0.36174858.15888448.html.plaintext.txt	48	human apoe quantified using enzyme linked immunosorbent assay protocol except standard used purified apoe isolated human vldl biodesign sako
0.36174858.15888448.html.plaintext.txt	49	num well microtiter plate coated overnight num degree c num microgml monoclonal anti apoe antibody wuenum num
0.36174858.15888448.html.plaintext.txt	50	wash performed num timeswell pb standard microplate washer
0.36174858.15888448.html.plaintext.txt	51	plate washed blocked num dry milk pb num min num degree c
0.36174858.15888448.html.plaintext.txt	52	plate washed sample standard loaded num
0.36174858.15888448.html.plaintext.txt	53	num bovine serum albumin pb num
0.36174858.15888448.html.plaintext.txt	54	num tween num containing protease inhibitor incubated num min num degree c
0.36174858.15888448.html.plaintext.txt	55	plate washed incubated goat anti apoe antiserum calbiochem numnum dilution num
0.36174858.15888448.html.plaintext.txt	56	num bovine serum albumin pb num
0.36174858.15888448.html.plaintext.txt	57	num tween num num min num degree c
0.36174858.15888448.html.plaintext.txt	58	plate washed horseradish peroxidase conjugated horse anti goat antibody numnum dilution vector laboratory burlingame ca incubated num min room temperature
0.36174858.15888448.html.plaintext.txt	59	plate washed tetramethylbenzidine substrate sigma added absorbance monitored num nm
0.36174858.15888448.html.plaintext.txt	60	amplex red kit molecular probe eugene used measure total cholesterol content
0.36174858.15888448.html.plaintext.txt	61	western blotting tissue sample homogenized radioimmune precipitation assay buffer num mm nacl num mm tris num
0.36174858.15888448.html.plaintext.txt	62	num sd ph num protease inhibitor passed num time num gauge needle incubated num h room temperature rotation
0.36174858.15888448.html.plaintext.txt	63	insoluble material pelleted centrifugation numnum x g
0.36174858.15888448.html.plaintext.txt	64	protein content supernatant quantified using bca kit pierce protein num microglane run sd page gel transferred nitrocellulose western blotting using standard technique
0.36174858.15888448.html.plaintext.txt	65	detect full length app c terminal fragment app blot probed ctnum generous gift dr
0.36174858.15888448.html.plaintext.txt	66	ed koo university california san diego ca rabbit polyclonal antibody raised c terminal num amino acid app num
0.36174858.15888448.html.plaintext.txt	67	detect lrp blot probed rabbit anti lrp antibody num
0.36174858.15888448.html.plaintext.txt	68	image captured using kodak imagestation numcf densitometric analysis band performed using kodak numd image analysis software eastman kodak co
0.36174858.15888448.html.plaintext.txt	69	statistical analysis data reported mean plus minus
0.36174858.15888448.html.plaintext.txt	70	analyzed using prism version num
0.36174858.15888448.html.plaintext.txt	71	num software graphpad san diego ca
0.36174858.15888448.html.plaintext.txt	72	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	73	ldlr regulates cellular uptake astrocyte secreted apoe
0.36174858.15888448.html.plaintext.txt	74	dii labeled astrocyte secreted apoenum containing lipoprotein particle readily endocytosed wild type lrp mouse embryonic fibroblast cell ldlr double null ldlr lrp mouse embryonic fibroblast cell
0.36174858.15888448.html.plaintext.txt	75	b astrocyte secreted apoe lipoprotein particle labeled numi applied chinese hamster ovary lrp null cell overexpressing ldlr family member
0.36174858.15888448.html.plaintext.txt	76	rap inhibitable binding numi labeled apoenum calculated presented percentage pcdnanum
0.36174858.15888448.html.plaintext.txt	77	cell overexpressing ldlr able endocytose degrade apoe evidenced trichloroacetic acid soluble count cell culture supernatant percentage control p num
0.36174858.15888448.html.plaintext.txt	78	num analysis variance post hoc tukey test
0.36174858.15888448.html.plaintext.txt	79	determine potential role ldlr brain apoe metabolism vivo used sandwich enzyme linked immunosorbent assay measure level murine apoe extracellular space brain csf wild type ldlr ldlr knock ldlr mouse
0.36174858.15888448.html.plaintext.txt	80	apoe secreted brain extracellular space expected receptor ldlr involved endocytosis absent extracellular level would elevated
0.36174858.15888448.html.plaintext.txt	81	example apoe elevated severalfold plasma ldlr mouse num well human familial hypercholesterolemia resulting reduced ldlr expression andor function num num
0.36174858.15888448.html.plaintext.txt	82	found ldlr mouse num increase csf level apoe relative ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	83	furthermore found apoe level cortical tissue homogenized pb reflection extracellular pool apoe significantly increased num ldlr mouse compared ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	84	together vitro vivo data suggest ldlr play important role apoe receptor mediates uptake degradation level apoe brain
0.36174858.15888448.html.plaintext.txt	85	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	86	ldlr regulates level apoe cns
0.36174858.15888448.html.plaintext.txt	87	level endogenous apoe csf num month old mouse num
0.36174858.15888448.html.plaintext.txt	88	num microgml ldlr mouse n num versus num
0.36174858.15888448.html.plaintext.txt	89	num microgml ldlr mouse n num p num
0.36174858.15888448.html.plaintext.txt	90	num unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	91	b level endogenous apoe cortical pb homogenate num
0.36174858.15888448.html.plaintext.txt	92	num microgmg ldlr mouse n num versus num
0.36174858.15888448.html.plaintext.txt	93	num microgmg ldlr mouse n num p num
0.36174858.15888448.html.plaintext.txt	94	num unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	95	ldlr mouse elevated extracellular level apoe brain apoe act chaperone soluble insoluble wanted determine effect ldlr deposition vivo
0.36174858.15888448.html.plaintext.txt	96	determine whether ldlr direct effect aggregation deposition vivo used pdapp mouse model ad generate pdapp ldlr pdapp ldlr mouse littermates
0.36174858.15888448.html.plaintext.txt	97	pdapp mouse express human app transgene containing familial ad mutation amino acid num overproduce particularly anum
0.36174858.15888448.html.plaintext.txt	98	hippocampus mouse amount soluble insoluble increase age dependent manner beginning num num month age plaque begin deposit num num
0.36174858.15888448.html.plaintext.txt	99	first examined level anum anum young pdapp ldlr pdapp ldlr mouse num month age well deposition begin
0.36174858.15888448.html.plaintext.txt	100	pb soluble level anum anum hippocampus significantly different two genotype fig
0.36174858.15888448.html.plaintext.txt	101	carbonate soluble level anum anum hippocampus also significantly different two genotype fig
0.36174858.15888448.html.plaintext.txt	102	next examined pdapp ldlr pdapp ldlr mouse num month age determine effect ldlr deposition
0.36174858.15888448.html.plaintext.txt	103	area hippocampus covered immunoreactive deposit tissue section num higher num month old pdapp ldlr mouse compared pdapp ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	104	numa increase statistically significant
0.36174858.15888448.html.plaintext.txt	105	similar result found thioflavine positive fibrillar deposit comparable result found cortex data shown
0.36174858.15888448.html.plaintext.txt	106	biochemical analysis carbonate soluble level hippocampus revealed slight nonsignificant increase anum num anum num num month old pdapp ldlr mouse compared pdapp ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	107	carbonate insoluble level hippocampus also revealed slight nonsignificant increase anum num anum num num month old pdapp ldlr mouse compared pdapp ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	108	whereas ldlr mouse increase plasma cholesterol num compared wild type ldlr mouse fig
0.36174858.15888448.html.plaintext.txt	109	numa difference either brain csf cholesterol fig
0.36174858.15888448.html.plaintext.txt	110	also evidence processing app fig
0.36174858.15888448.html.plaintext.txt	111	numd level total app protein data shown different genotype
0.36174858.15888448.html.plaintext.txt	112	additionally hippocampal lrp level altered absence ldlr data shown
0.36174858.15888448.html.plaintext.txt	113	thus although level murine apoe elevated num extracellular cns pool ldlr mouse data suggest degree change level apoe sufficiently increased significantly affect level young age early stage deposition pdapp transgenic mouse
0.36174858.15888448.html.plaintext.txt	114	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	115	ldlr affect level hippocampus young pdapp mouse
0.36174858.15888448.html.plaintext.txt	116	level pb soluble anum significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	117	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	118	level pb soluble anum also significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	119	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	120	b level carbonate soluble anum significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	121	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	122	level carbonate soluble anum also significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	123	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	124	explore possibility ldlr may differentially regulate level human apoe isoforms cns compared murine apoe bred human apoenum apoenum apoenum targeted replacement mouse knock onto ldlr mouse background
0.36174858.15888448.html.plaintext.txt	125	confirm previous finding noted mouse num assessed plasma cholesterol apoe found significantly elevated absence ldlr genotype data shown
0.36174858.15888448.html.plaintext.txt	126	determine extent ldlr regulates human apoe level extracellular space cns measured apoe level csf
0.36174858.15888448.html.plaintext.txt	127	found level human apoenum human apoenum csf significantly higher num num respectively absence ldlr fig
0.36174858.15888448.html.plaintext.txt	128	level human apoenum csf significantly altered presence absence ldlr fig
0.36174858.15888448.html.plaintext.txt	129	numa expected human apoenum isoform exhibit num binding ldlr num
0.36174858.15888448.html.plaintext.txt	130	however interesting note level human apoenum substantially higher apoenum apoenum csf fig
0.36174858.15888448.html.plaintext.txt	131	despite increase human apoe level absence ldlr significant increase level brain cholesterol mouse fig
0.36174858.15888448.html.plaintext.txt	132	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	133	ldlr affect deposition pdapp mouse num month age
0.36174858.15888448.html.plaintext.txt	134	percentage cross sectional area hippocampus covered immunoreactive deposit significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	135	num compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	136	b level carbonate soluble anum significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	137	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	138	level carbonate soluble anum also significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	139	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	140	c level carbonate insoluble anum significantly different pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	141	num ngmg compared pdapp ldlr mouse num
0.36174858.15888448.html.plaintext.txt	142	level carbonate soluble anum also significantly different pdapp ldlr mouse num plus minus num ngmg compared pdapp ldlr mouse num plus minus num ngmg
0.36174858.15888448.html.plaintext.txt	143	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	144	ldlr influence level plasma cholesterol effect hippocampal csf cholesterol app processing
0.36174858.15888448.html.plaintext.txt	145	level total plasma cholesterol num
0.36174858.15888448.html.plaintext.txt	146	num mgdl ldlr mouse n num compared num plus minus num
0.36174858.15888448.html.plaintext.txt	147	num mgdl ldlr mouse n num p num
0.36174858.15888448.html.plaintext.txt	148	num unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	149	level total cholesterol hippocampus b csf c app processing assessed semiquantitative western blotting c terminal fragment ctf d significantly different genotype n num numgroup
0.36174858.15888448.html.plaintext.txt	150	view larger version numk fig
0.36174858.15888448.html.plaintext.txt	151	ldlr influence level human apoenum apoenum apoenum cerebrospinal fluid
0.36174858.15888448.html.plaintext.txt	152	level apoe cerebrospinal fluid measured human apoenum apoenum itsup apoenum targeted replacement mouse knock presence ldlr absence ldlr endogenous ldlr
0.36174858.15888448.html.plaintext.txt	153	level human apoe significantly higher apoenum mouse num
0.36174858.15888448.html.plaintext.txt	154	num microgml compared apoenum num
0.36174858.15888448.html.plaintext.txt	155	num microgml mouse p num
0.36174858.15888448.html.plaintext.txt	156	num analysis variance post hoc tukey test
0.36174858.15888448.html.plaintext.txt	157	expected previous study level human apoe significantly different apoenum ldlr apoenum ldlr mouse
0.36174858.15888448.html.plaintext.txt	158	level human apoe significantly higher apoenum ldlr mouse num
0.36174858.15888448.html.plaintext.txt	159	num microgml compared apoenum ldlr mouse num
0.36174858.15888448.html.plaintext.txt	160	num analysis variance post hoc tukey test
0.36174858.15888448.html.plaintext.txt	161	level human apoe also significantly higher apoenum ldlr mouse num
0.36174858.15888448.html.plaintext.txt	162	num microgml compared apoenum ldlr mouse num
0.36174858.15888448.html.plaintext.txt	163	num analysis variance post hoc tukey test
0.36174858.15888448.html.plaintext.txt	164	b level total cholesterol cortex increased human apoenum apoenum apoenum knock mouse absence ldlr
0.36174858.15888448.html.plaintext.txt	165	interestingly human apoenum slight significant decrease level cholesterol cortex absence ldlr p num
0.36174858.15888448.html.plaintext.txt	166	vitro data indicate ldlr family member including lrp vldl receptor apoernum able appreciably internalize degrade astrocyte secreted apoe containing lipoprotein
0.36174858.15888448.html.plaintext.txt	167	previous work clearly demonstrated ldlr family member able efficiently bind endocytose apoe reconstituted large cholesterol rich lipoprotein particle termed vldl num
0.36174858.15888448.html.plaintext.txt	168	however vldl particle differ astrocyte secreted apoe lipid composition presence apoproteins amount sialation num
0.36174858.15888448.html.plaintext.txt	169	apolipoprotein lipidation state alter receptor binding characteristic
0.36174858.15888448.html.plaintext.txt	170	example previous study shown recombinant apoe absence lipid prefers binding lrp ldlr num
0.36174858.15888448.html.plaintext.txt	171	form apoe shown present physiological condition
0.36174858.15888448.html.plaintext.txt	172	together result indicate lipid content form apoe lipoprotein particle alter receptor binding specificity
0.36174858.15888448.html.plaintext.txt	173	also demonstrate ldlr important apoe receptor regulates human murine apoe endocytosis level brain
0.36174858.15888448.html.plaintext.txt	174	although result study rule ldlr family member contribute way level apoe brain clearly show ldlr play important role brain apoe metabolism
0.36174858.15888448.html.plaintext.txt	175	recent study shown increasing decreasing cellular cholesterol influence cellular secretion num
0.36174858.15888448.html.plaintext.txt	176	although ldlr mouse elevated plasma cholesterol level found level brain cholesterol unaffected mouse previously reported num
0.36174858.15888448.html.plaintext.txt	177	exact mechanism apoe affect ad pathogenesis unclear
0.36174858.15888448.html.plaintext.txt	178	however large body evidence suggests one mechanism influence age onset ad acting chaperone soluble insoluble thereby influencing clearance fibrillogenesis num num num num
0.36174858.15888448.html.plaintext.txt	179	current result suggest although ldlr regulates extracellular level apoe brain num increase level murine apoe endogenous level sufficient alter level young age early stage deposition pdapp mouse num month age
0.36174858.15888448.html.plaintext.txt	180	may represent ceiling effect level murine apoe indicate larger increase level murine apoe may necessary effect change level model
0.36174858.15888448.html.plaintext.txt	181	alternatively pathway apoe mediated clearance play much larger role metabolism lrp bulk flow along interstitial fluid drainage pathway
0.36174858.15888448.html.plaintext.txt	182	unfortunately lrp mouse die early embryonic stage thus effect endogenous lrp brain apoe level difficult ass shown study
0.36174858.15888448.html.plaintext.txt	183	additionally ldlr may play role deposition later stage deposition found lrp pdapp mouse num
0.36174858.15888448.html.plaintext.txt	184	also possible ldlr may differentially regulate human apoe isoforms cns greater extent murine apoe therefore influence level deposition
0.36174858.15888448.html.plaintext.txt	185	interesting independent effect ldlr level apoe csf human apoenum mouse significantly higher apoenum apoenum mouse
0.36174858.15888448.html.plaintext.txt	186	suggests human ldlr may play important role regulating cns apoe level ad pathogenesis
0.36174858.15888448.html.plaintext.txt	187	study human csf reported significant difference level human apoe individual expressing apoenum apoenum allele level csf apoe apoenumnum homozygous individual assessed knowledge
0.36174858.15888448.html.plaintext.txt	188	given apoenum associated decreased risk developing ad intriguing possibility absolute level apoe present brain individual could account decrease risk
0.36174858.15888448.html.plaintext.txt	189	human murine apoe differ num amino acid level human apoe isoforms murine apoe isolated vldl shown differentially bind ldlr num
0.36174858.15888448.html.plaintext.txt	190	using pdapp mouse model previous study group shown expression human apoe isoforms control glial fibrillary acidic protein promoter result significant delay deposition compared mouse expressing endogenous murine apoe num num
0.36174858.15888448.html.plaintext.txt	191	recently human apoe knock mouse used study crossed pdapp mouse delay deposition isoform dependent effect deposition enum enum enum found num
0.36174858.15888448.html.plaintext.txt	192	additionally recently replicated result appsw mouse model ad utilizing apoenum apoenum knock mouse used study num
0.36174858.15888448.html.plaintext.txt	193	clearly human apoe isoforms affect metabolism deposition differently murine apoe whether due altered clearance andor structure vivo remains determined
0.36174858.15888448.html.plaintext.txt	194	determining role ldlr receptor clearance pathway brain also involved regulating apoe level central understanding apoe influence metabolism ad pathogenesis
0.36174858.15888448.html.plaintext.txt	195	footnote work supported national institute health grant agnum pnum agnum agnum metlife foundation eli lilly co
0.36174858.15888448.html.plaintext.txt	196	cost publication article defrayed part payment page charge
0.36174858.15888448.html.plaintext.txt	197	article must therefore hereby marked advertisement accordance num u
0.36174858.15888448.html.plaintext.txt	198	section num solely indicate fact
0.36174858.15888448.html.plaintext.txt	199	j correspondence addressed dept
0.36174858.15888448.html.plaintext.txt	200	neurology campus box num num
0.36174858.15888448.html.plaintext.txt	201	num num num fax num num num e mail holtzmanatwustl
0.36174858.15888448.html.plaintext.txt	202	num abbreviation used ad alzheimer disease ldlr low density lipoprotein receptor apoe apolipoprotein e app amyloid precursor protein amyloid lrp low density lipoprotein receptor related protein csf cerebrospinal fluid cns central nervous system vldl low density lipoprotein rap receptor associated protein pb phosphate buffered saline
0.36494276.15269217.html.plaintext.txt	0	abcanum required normal central nervous system apoe level lipidation astrocyte secreted apoe suzanne e
0.36494276.15269217.html.plaintext.txt	1	wahrle hong jiang maia parsadanian justin legleiter xianlin han john d
0.36494276.15269217.html.plaintext.txt	2	fryer tomasz kowalewski david m
0.36494276.15269217.html.plaintext.txt	3	program neuroscience department neurology department medicine department molecular biology pharmacology center study nervous system injury alzheimers disease research center washington university st
0.36494276.15269217.html.plaintext.txt	4	louis missouri num department chemistry carnegie mellon university pittsburgh pennsylvania num
0.36494276.15269217.html.plaintext.txt	5	received publication july num num
0.36494276.15269217.html.plaintext.txt	6	abcanum transport cellular cholesterol phospholipid cell onto high density lipoprotein hdl plasma num num
0.36494276.15269217.html.plaintext.txt	7	human loss function mutation abcanum cause tangier disease num num characterized accumulation cholesterol lymphatic tissue increased catabolism abnormally lipidated hdl resulting low level plasma hdl hdl associated apolipoproteins apoa ii apoa ii num num
0.36494276.15269217.html.plaintext.txt	8	abcanum knock mouse abcanum produced mouse similar phenotype patient tangier disease num
0.36494276.15269217.html.plaintext.txt	9	however neither tangier disease patient abcanum mouse examined determine whether abcanum play role lipidation metabolism lipoprotein central nervous system cns
0.36494276.15269217.html.plaintext.txt	10	abundant apolipoprotein cns apolipoprotein e apoe produced within cns primarily astrocyte extent microglia num num
0.36494276.15269217.html.plaintext.txt	11	apoe present brain tissue cerebrospinal fluid csf present hdl like particle num num
0.36494276.15269217.html.plaintext.txt	12	analyzing brain tissue csf plasma primary astrocyte culture abcanum mouse determined deletion abcanum markedly affect metabolism apoe cholesterol cns nascent lipoprotein particle secreted cultured astrocyte
0.36494276.15269217.html.plaintext.txt	13	finding implication neurological disease involving apoe alzheimers disease
0.36494276.15269217.html.plaintext.txt	14	apoe elisa sandwich elisa mouse apoe developed sensitivity num ngml
0.36494276.15269217.html.plaintext.txt	15	num well plate coated overnight num
0.36494276.15269217.html.plaintext.txt	16	num microgwell mouse monoclonal antibody wu e num raised apoe num washed pb blocked num milk pb washed
0.36494276.15269217.html.plaintext.txt	17	brain sample sonicated num
0.36494276.15269217.html.plaintext.txt	18	num tween pb numx complete protease inhibitor mixture numx protease inhibitor roche applied science debris pelleted numnum x g x num min spin supernatant diluted num
0.36494276.15269217.html.plaintext.txt	19	conditioned medium plasma csf diluted directly num
0.36494276.15269217.html.plaintext.txt	20	standard based pooled plasma cnumblnum mouse containing num microgml apoe reported previously num
0.36494276.15269217.html.plaintext.txt	21	following sample incubation plate washed num microgwell biotinylated goat anti apoe added
0.36494276.15269217.html.plaintext.txt	22	antibody calbiochem catalog number num biotinylated using biotin maleimide reagent vector laboratory burlingame ca
0.36494276.15269217.html.plaintext.txt	23	incubation secondary antibody plate washed poly horseradish peroxidase streptavidin pierce added numnum incubated
0.36494276.15269217.html.plaintext.txt	24	plate washed developed tetramethylbenzidine sigma read num nm biotek num plate reader bio tek instrument winooski vt
0.36494276.15269217.html.plaintext.txt	25	real time rt pcr mouse apoe following perfusion animal sample cortex placed rnalater ambion austin tx stored num degree c
0.36494276.15269217.html.plaintext.txt	26	rna extracted using rneasy lipid tissue kit qiagen valencia ca column dnase digestion
0.36494276.15269217.html.plaintext.txt	27	rna quantified bio rad smartspec num bio rad
0.36494276.15269217.html.plaintext.txt	28	forward primer used mouse apoe num ccgtgctgttggtcacattgctgacaggat num reverse primer num gttcttgtgtgacttgggagctctgcagct num
0.36494276.15269217.html.plaintext.txt	29	num primerprobe reagent used normalization rna level abi foster city ca
0.36494276.15269217.html.plaintext.txt	30	brilliant sybr green qrt pcr master mix kit num step stratagene la jolla ca used reverse transcription rt pcr reaction
0.36494276.15269217.html.plaintext.txt	31	master mix rtrnase block mix added num microm forward reverse primer num
0.36494276.15269217.html.plaintext.txt	32	apoe num rt pcr sample cycled abi prism num sequence detection system following temperature num num degree c num min num num degree c num min num num degree c num
0.36494276.15269217.html.plaintext.txt	33	num num degree c num min num num degree c num min num repeat step num num num time
0.36494276.15269217.html.plaintext.txt	34	standard curve critical threshold versus log concentration plotted rna wild type mouse cortex relative transcript level calculated using abi software accompanied prism num
0.36494276.15269217.html.plaintext.txt	35	apoj western blot sample cortex sonicated numx radioimmune precipitation buffer numx protease inhibitor
0.36494276.15269217.html.plaintext.txt	36	radioimmune precipitation buffer insoluble material removed spinning numnum x g x num min
0.36494276.15269217.html.plaintext.txt	37	num microg total proteinwell run num bi tris gel invitrogen transferred onto nitrocellulose membrane
0.36494276.15269217.html.plaintext.txt	38	blot probed rabbit anti apoj antibody developed laboratory num washed probed anti rabbit igg linked horseradish peroxidase amersham bioscience
0.36494276.15269217.html.plaintext.txt	39	band visualized enhanced chemiluminescence pierce imaged kodak image station eastman kodak co
0.36494276.15269217.html.plaintext.txt	40	cholesterol phospholipid analysis brain sample prepared cholesterol analysis sonication pb
0.36494276.15269217.html.plaintext.txt	41	homogenized whole brain suspension subjected enzymatic analysis total cholesterol using amplex red cholesterol kit molecular probe eugene
0.36494276.15269217.html.plaintext.txt	42	result using homogenized brain suspension identical using chloroform extracted lipid brain data shown
0.36494276.15269217.html.plaintext.txt	43	csf astrocyte conditioned medium diluted reaction buffer assayed
0.36494276.15269217.html.plaintext.txt	44	free cholesterol measured using kit omitting cholesterol esterase enzyme
0.36494276.15269217.html.plaintext.txt	45	esterified cholesterol calculated total cholesterol minus free cholesterol
0.36494276.15269217.html.plaintext.txt	46	quantification phospholipid specie performed electrospray ionization mass spectrometry described previously num
0.36494276.15269217.html.plaintext.txt	47	histological analysis tissue section cut coronal plane num microm freezing sliding microtome mounted superfrost plus slide fisher
0.36494276.15269217.html.plaintext.txt	48	oil red o staining neutral fat slide dipped consecutively num ethanol num immersed num min num oil red o sigma num ethanol num acetone
0.36494276.15269217.html.plaintext.txt	49	slide washed water counterstained num min harris hematoxylin sigma washed water
0.36494276.15269217.html.plaintext.txt	50	slide dipped ammonia water num
0.36494276.15269217.html.plaintext.txt	51	num ammonium hydroxide blue washed mounted
0.36494276.15269217.html.plaintext.txt	52	staining cresyl violet nucleus luxol fast blue identify myelin performed described previously num num
0.36494276.15269217.html.plaintext.txt	53	non denaturing gradient gel electrophoresis sample csf astrocyte conditioned medium acm mixed numnum native sample buffer electrophoresed num num tris glycine gel invitrogen
0.36494276.15269217.html.plaintext.txt	54	protein known hydrated diameter used size standard amersham bioscience catalog number num protein transferred nitrocellulose membrane
0.36494276.15269217.html.plaintext.txt	55	apoe immunoblotting membrane probed goat anti mouse apoe antibody numnum m num santa cruz biotechnology santa cruz ca washed probed horse anti goat igg linked horseradish peroxidase numnum vector laboratory
0.36494276.15269217.html.plaintext.txt	56	apoa immunoblotting membrane probed rabbit anti mouse apoa antibody numnum biodesign saco washed probed goat anti rabbit igg linked horseradish peroxidase numnum bio rad
0.36494276.15269217.html.plaintext.txt	57	band visualized enhanced chemiluminescence sigma imaged kodak image station kodak
0.36494276.15269217.html.plaintext.txt	58	primary astrocyte culture primary culture forebrain astrocyte num pure prepared individual neonatal num num day old mouse described previously num
0.36494276.15269217.html.plaintext.txt	59	astrocyte grown dulbeccos modified eagle mediumf num containing num fetal bovine serum num heat inactivated horse serum num mm sodium pyruvate num unitsml penicillin num microgml streptomycin num ngml fungizone num ngml epidermal growth factor sigma
0.36494276.15269217.html.plaintext.txt	60	obtain acm confluent astrocyte culture washed twice sterile pb
0.36494276.15269217.html.plaintext.txt	61	serum free medium added dulbeccos modified eagle mediumf num num nnum supplement invitrogen num mm sodium pyruvate num unitsml penicillin num microgml streptomycin num ngml fungizone cell incubated num day
0.36494276.15269217.html.plaintext.txt	62	medium collected spun numnum x g x num min remove cellular debris
0.36494276.15269217.html.plaintext.txt	63	num sodium azide numx protease inhibitor added acm stored num degree c analysis
0.36494276.15269217.html.plaintext.txt	64	following harvesting acm astrocyte scraped flask washed pb pelleted sonicated pb
0.36494276.15269217.html.plaintext.txt	65	fractionation acm acm concentrated num fold num kda molecular mass cut spin concentrator millipore billerica ma
0.36494276.15269217.html.plaintext.txt	66	num ml concentrated acm subjected gel filtration chromatography using biologic system bio rad tandem superose num hr numnum column amersham bioscience num
0.36494276.15269217.html.plaintext.txt	67	num sodium azide described previously num
0.36494276.15269217.html.plaintext.txt	68	atomic force microscopy afm fraction num abcanum acm fraction num abcanum stored num degree c afm analysis
0.36494276.15269217.html.plaintext.txt	69	sample analyzed situ afm described previously num
0.36494276.15269217.html.plaintext.txt	70	view larger version numk fig
0.36494276.15269217.html.plaintext.txt	71	level apoe apoj abcanum mouse
0.36494276.15269217.html.plaintext.txt	72	c apoe level plasma csf cortex measured elisa
0.36494276.15269217.html.plaintext.txt	73	cortical apoe level normalized total protein tp
0.36494276.15269217.html.plaintext.txt	74	d relative mrna level apoe determined real time rt pcr normalized num rna
0.36494276.15269217.html.plaintext.txt	75	relative mrna level apoe cortex num
0.36494276.15269217.html.plaintext.txt	76	d n num mouse per genotype
0.36494276.15269217.html.plaintext.txt	77	e level apoj cortex determined western blotting num microg total protein mouse n num abcanum n num abcanum
0.36494276.15269217.html.plaintext.txt	78	band visible cortical homogenate apoj mouse
0.36494276.15269217.html.plaintext.txt	79	unlike plasma contains variety lipoprotein class apoa major apoprotein constituent hdl csf hdl like lipoprotein apoe abundant apoprotein
0.36494276.15269217.html.plaintext.txt	80	apoe csf derived cns plasma num
0.36494276.15269217.html.plaintext.txt	81	determine whether abcanum play role cns apoe metabolism measured apoe level csf brain abcanum deficient mouse
0.36494276.15269217.html.plaintext.txt	82	interestingly apoe level csf reduced similar extent plasma abcanum mouse num abcanum mouse num reduction apoe level relative wild type littermates fig
0.36494276.15269217.html.plaintext.txt	83	brain tissue apoe level cortex reduced num num abcanum mouse respectively compared wild type littermates fig
0.36494276.15269217.html.plaintext.txt	84	real time rt pcr apoe mrna performed cortex abcanum mouse determine whether difference apoe protein level related gene expression
0.36494276.15269217.html.plaintext.txt	85	difference apoe mrna level three genotype fig
0.36494276.15269217.html.plaintext.txt	86	numd suggesting abcanum affect apoe level post transcriptionally cns
0.36494276.15269217.html.plaintext.txt	87	second abundant apoprotein produced cns apolipoprotein j clusterin present hdl like particle csf num
0.36494276.15269217.html.plaintext.txt	88	determine whether abcanum play role metabolism apoj similar manner apoe measured apoj level plasma csf cortex found significant difference among different abcanum genotype fig
0.36494276.15269217.html.plaintext.txt	89	apoa major component plasma hdl synthesized primarily periphery enters cns small quantity relation high plasma concentration num
0.36494276.15269217.html.plaintext.txt	90	level greatly decreased csf cortex abcanum mouse see fig
0.36494276.15269217.html.plaintext.txt	91	since apoa level plasma abcanum mouse near zero num cns apoa derived mostly plasma expected result
0.36494276.15269217.html.plaintext.txt	92	view larger version numk fig
0.36494276.15269217.html.plaintext.txt	93	determination lipoprotein size csf acm run non denaturing gradient gel probed apoe c apoa b
0.36494276.15269217.html.plaintext.txt	94	num microl csf abcanum mouse loaded lane num microl abcanum apoe csf loaded
0.36494276.15269217.html.plaintext.txt	95	b num microl csf abcanum apoa num microl csf abcanum mouse loaded run lane
0.36494276.15269217.html.plaintext.txt	96	c num microl acm abcanum astrocyte loaded run lane
0.36494276.15269217.html.plaintext.txt	97	apoe acm control band data shown
0.36494276.15269217.html.plaintext.txt	98	d e apoe total cholesterol tc acm measured elisa enzymatic assay respectively normalized total protein tp astrocyte cell lysates
0.36494276.15269217.html.plaintext.txt	99	lipid csf cortex abcanum mouse since major function abcanum outside cns transport cholesterol phospholipid onto hdl examined whether abcanum deficiency altered level cholesterol phospholipid within cns
0.36494276.15269217.html.plaintext.txt	100	found total cholesterol csf reduced num abcanum mouse compared wild type littermates fig
0.36494276.15269217.html.plaintext.txt	101	likely abcanum deficiency result decreased level hdl lipoprotein class normally carry proportion cholesterol csf
0.36494276.15269217.html.plaintext.txt	102	contrast csf total cholesterol level brain tissue cortex significantly different abcanum mouse fig
0.36494276.15269217.html.plaintext.txt	103	cholesterol ester cortex represented le num total cholesterol also significantly different data shown
0.36494276.15269217.html.plaintext.txt	104	anionic phospholipid choline glycerophospholipids sphingomyelins ethanolamine glycerophospholipids measured cortex electrospray ionization mass spectrometry vary significantly abcanum mouse n num group data shown
0.36494276.15269217.html.plaintext.txt	105	view larger version numk fig
0.36494276.15269217.html.plaintext.txt	106	lipid cns abcanum mouse
0.36494276.15269217.html.plaintext.txt	107	b total cholesterol tc level measured csf cortex enzymatic assay normalized total protein level cortex
0.36494276.15269217.html.plaintext.txt	108	c image brain section stained oil red o
0.36494276.15269217.html.plaintext.txt	109	determine whether lipid buildup brain stained num month old abcanum brain section oil red o
0.36494276.15269217.html.plaintext.txt	110	evidence abnormal lipid deposition abcanum mouse fig
0.36494276.15269217.html.plaintext.txt	111	standard histological staining method including cresyl violet nucleus luxol fast blue myelin also revealed abnormality brain abcanum mouse data shown
0.36494276.15269217.html.plaintext.txt	112	lipoprotein particle csf astrocyte conditioned medium abcanum mouse addition evaluating effect abcanum deficiency level lipid apoe cns vivo studied apoe apoa containing lipoprotein csf nascent apoe containing lipoprotein produced astrocyte examine abcanum deficiency affected property
0.36494276.15269217.html.plaintext.txt	113	determined size distribution apoe apoa containing lipoprotein mouse csf non denaturing gradient gel electrophoresis
0.36494276.15269217.html.plaintext.txt	114	described previously num apoe csf wild type mouse hdl like particle num num nm diameter abundant size num num nm fig
0.36494276.15269217.html.plaintext.txt	115	apoe particle abcanum csf similar size wild type
0.36494276.15269217.html.plaintext.txt	116	however addition apoe level csf abcanum markedly reduced apoe present within particle size distribution different wild type mouse
0.36494276.15269217.html.plaintext.txt	117	addition population particle num num nm diameter csf abcanum mouse also population smaller apoe containing particle num num nm diameter suggesting poorly lipidated
0.36494276.15269217.html.plaintext.txt	118	apoa also greatly reduced csf abcanum mouse small amount present particle num
0.36494276.15269217.html.plaintext.txt	119	num nm compared particle num num nm csf abcanum mouse fig
0.36494276.15269217.html.plaintext.txt	120	abcanum mouse low csf apoe level altered particle size distribution led u investigate whether primary alteration nascently produced apoe containing hdl astrocyte cell produce majority apoe cns
0.36494276.15269217.html.plaintext.txt	121	compared total cholesterol apoe acm derived primary astrocyte culture abcanum mouse found total level apoe acm vary abcanum genotype fig
0.36494276.15269217.html.plaintext.txt	122	however level total cholesterol significantly lower abcanum acm fig
0.36494276.15269217.html.plaintext.txt	123	suggests apoe secreted normal level abcanum astrocyte apoe normally lipidated absence abcanum
0.36494276.15269217.html.plaintext.txt	124	examine extent lipidation apoe containing particle acm subjected size analysis non denaturing gradient gel electrophoresis followed western blotting apoe
0.36494276.15269217.html.plaintext.txt	125	demonstrated apoe containing lipoprotein population num num num nm acm abcanum mouse much smaller lipoprotein acm abcanum mouse num
0.36494276.15269217.html.plaintext.txt	126	data suggested apoe containing particle abcanum acm likely lipid poor
0.36494276.15269217.html.plaintext.txt	127	analyze lipid composition astrocyte secreted lipoprotein acm fractionated size exclusion chromatography
0.36494276.15269217.html.plaintext.txt	128	apoe elisa cholesterol assay different fraction demonstrated lipoprotein abcanum acm contain le apoe smaller markedly le cholesterol abcanum acm fig
0.36494276.15269217.html.plaintext.txt	129	lipoprotein associated apoe reduced abcanum acm num compared abcanum acm
0.36494276.15269217.html.plaintext.txt	130	expected num apoe abcanum acm fraction num num corresponding hdl size range
0.36494276.15269217.html.plaintext.txt	131	however num lipoprotein associated apoe abcanum acm fraction num num corresponds much smaller particle
0.36494276.15269217.html.plaintext.txt	132	smaller lipoprotein particle derived abcanum astrocyte cholesterol poor compared abcanum particle num
0.36494276.15269217.html.plaintext.txt	133	num microg total cholesterol microg apoe abcanum versus num
0.36494276.15269217.html.plaintext.txt	134	num microg total cholesterol microg apoe abcanum
0.36494276.15269217.html.plaintext.txt	135	view larger version numk fig
0.36494276.15269217.html.plaintext.txt	136	fractionation size analysis lipoprotein acm
0.36494276.15269217.html.plaintext.txt	137	following size exclusion gel filtration fraction subjected analysis
0.36494276.15269217.html.plaintext.txt	138	apoe total cholesterol tc acm measured elisa enzymatic assay respectively normalized total protein tp astrocyte cell lysates b
0.36494276.15269217.html.plaintext.txt	139	num abcanum acm fraction num fr
0.36494276.15269217.html.plaintext.txt	140	num abcanum acm subjected atomic force microscopy determine appearance size lipoprotein particle c
0.36494276.15269217.html.plaintext.txt	141	volume lipoprotein particle obtained afm corrected finite size tip
0.36494276.15269217.html.plaintext.txt	142	confirm size shape abnormal abcanum particle afm performed size exclusion chromatography fraction abcanum abcanum acm highest apoe level
0.36494276.15269217.html.plaintext.txt	143	afm tool choice allows characterization three dimensional shape nanoparticles nearly physiological condition
0.36494276.15269217.html.plaintext.txt	144	use study lipoprotein particle protocol needed obtain reliable volume measurement recently described elsewhere num
0.36494276.15269217.html.plaintext.txt	145	afm image obtained demonstrate abundant apoe containing particle abcanum acm significantly smaller abcanum acm fig
0.36494276.15269217.html.plaintext.txt	146	although alteration cns apoe level profound difference total cns lipid subtle present csf
0.36494276.15269217.html.plaintext.txt	147	brain tissue abcanum mouse difference free cholesterol esterified cholesterol phospholipid showed evidence lipid deposition histological staining
0.36494276.15269217.html.plaintext.txt	148	result suggest abcanum play major role regulating global cellular lipid level brain tissue vivo regulation performed additional molecule
0.36494276.15269217.html.plaintext.txt	149	however csf abcanum mouse significantly reduced cholesterol showing abcanum important regulating extracellular lipid level cns
0.36494276.15269217.html.plaintext.txt	150	conditioned medium collected primary culture astrocyte derived abcanum mouse showed although total level apoe secreted astrocyte affected abcanum genotype secretion cholesterol medium markedly reduced abcanum culture consistent abcanum role transporting astrocyte derived cellular cholesterol onto lipoprotein
0.36494276.15269217.html.plaintext.txt	151	function may occur astrocyte secretory pathway extracellularly
0.36494276.15269217.html.plaintext.txt	152	analysis nascent lipoprotein particle isolated conditioned medium primary astrocyte culture demonstrated abcanum astrocyte secrete apoe containing particle markedly smaller size reduced cholesterol apoe demonstrating abcanum required main cellular producer apoe cns normally lipidate apoe
0.36494276.15269217.html.plaintext.txt	153	apoe produced cns cell astrocyte reach csf abcanum mouse fraction particle present also abnormally small although normal size
0.36494276.15269217.html.plaintext.txt	154	thus appears mechanism require abcanum lipidate apoe reach csf
0.36494276.15269217.html.plaintext.txt	155	however fact csf apoe level abcanum num normal suggests non abcanum mediated pathway inefficient apoe particle produced absence abcanum mediated lipidation rapidly metabolized cns
0.36494276.15269217.html.plaintext.txt	156	apoe apoj two major apoproteins produced astrocyte secreted unique apoe apoj containing particle num
0.36494276.15269217.html.plaintext.txt	157	apoe secreted astrocyte present particle contain approximately equal mass apoe cholesterol phospholipid num
0.36494276.15269217.html.plaintext.txt	158	furthermore virtually cholesterol phospholipid secreted astrocyte associated apoe num
0.36494276.15269217.html.plaintext.txt	159	contrast apoj secreted astrocyte little associated cholesterol phospholipid num found present normal level brain abcanum mouse
0.36494276.15269217.html.plaintext.txt	160	thus apoj particle stable absence abcanum possibly normally lipid poor require extensive lipidation stability
0.36494276.15269217.html.plaintext.txt	161	data demonstrate complete loss abcanum profoundly affect apoe level cns
0.36494276.15269217.html.plaintext.txt	162	additionally since abcanum mouse intermediate apoe level subtle alteration abcanum gene dosage andor functionality may affect apoe metabolism
0.36494276.15269217.html.plaintext.txt	163	apoe genotype major risk factor alzheimers disease ad cerebral amyloid angiopathy caa num num
0.36494276.15269217.html.plaintext.txt	164	apoe genotype may also influence neurologic prognosis intracerebral hemorrhage num traumatic brain injury num multiple sclerosis num
0.36494276.15269217.html.plaintext.txt	165	effect apoe ad caa likely mediated large part role apoe role amyloid chaperone influence clearance fibrillogenesis num
0.36494276.15269217.html.plaintext.txt	166	amyloid precursor protein transgenic mouse develop many pathological change seen ad caa level apoe regardless specie genotype markedly influence time onset conformation amount peptide accumulates brain age num num
0.36494276.15269217.html.plaintext.txt	167	example amyloid precursor protein transgenic mouse crossed apoe mouse animal lacking apoe almost fibrillar deposition neuritic plaque caa apoe mouse le num much related pathology apoe mouse num num
0.36494276.15269217.html.plaintext.txt	168	result show alteration cns apoe level little num massive effect ad like pathology cns
0.36494276.15269217.html.plaintext.txt	169	since abcanum regulates level apoe well state lipidation modulation abcanum level function likely directly influence apoea interaction along deposition negative consequence brain
0.36494276.15269217.html.plaintext.txt	170	addition effect abcanum apoe recent study also suggest abcanum influence cellular production num num
0.36494276.15269217.html.plaintext.txt	171	effect likely independent apoe since alteration abcanum expression level affect cell type express apoe
0.36494276.15269217.html.plaintext.txt	172	several study also suggest direct link abcanum polymorphism risk ad num num num
0.36494276.15269217.html.plaintext.txt	173	summary shown abcanum required normal cns apoe level vivo well production normally lipidated apoe containing lipoprotein astrocyte
0.36494276.15269217.html.plaintext.txt	174	since apoe level cns profoundly influence ad caa pathology vivo modulation abcanum function level may novel therapeutic target ad caa disease cns
0.36494276.15269217.html.plaintext.txt	175	footnote work supported national institute health grant agnum pnum agnum nsnum d
0.36494276.15269217.html.plaintext.txt	176	cost publication article defrayed part payment page charge
0.36494276.15269217.html.plaintext.txt	177	article must therefore hereby marked advertisement accordance num u
0.36494276.15269217.html.plaintext.txt	178	section num solely indicate fact
0.36494276.15269217.html.plaintext.txt	179	correspondence addressed washington university school medicine dept
0.36494276.15269217.html.plaintext.txt	180	num num num fax num num num e mail holtzmanatneuro
0.36494276.15269217.html.plaintext.txt	181	num abbreviation used abc atp binding cassette amyloid peptide acm astrocyte conditioned medium afm atomic force microscopy ad alzheimers disease caa cerebral amyloid angiopathy cns central nervous system csf cerebrospinal fluid hdl high density lipoprotein rt reverse transcription elisa enzyme linked immunosorbent assay pb phosphate buffered saline apoe apolipoprotein e bi tris num bisnum hydroxyethylamino num hydroxy methylpropane numnum diol
0.36494276.15269217.html.plaintext.txt	182	acknowledgment thank ravi rajaram kirsten jansen mike spinner dr
0.36494276.15269217.html.plaintext.txt	183	anne fagan hua cheng technical assistance helpful advice
0.3697104.9700208.html.plaintext.txt	0	pronounced impact thnumenumcs mutation compared num mutation neural apoe gene expression risk developing alzheimers disease
0.3697104.9700208.html.plaintext.txt	1	jean charles lambert claudine berrnum florence pasquiernum andre delacourtenum bernard frigardnum dominique cottel jordi perez turnum vincent mouroux michel mohrnum danielle cecyrenum douglas galaskonum corinne lendonnum jude poiriernum john hardynum david mannnum philippe amouyel marie christine chartier harlin
0.3697104.9700208.html.plaintext.txt	2	inserm cjfnum num institut pasteur de lille num rue du professeur calmette bp num num lille cedex france numinserm unum hopital de la salpetriere num paris cedex num france numchr et u de lille clinique neurologique centre de la memoire hopital salengro num lille cedex france numinserm unum place de verdun num lille cedex france numcentre de geriatrie de wasquehal rue salvador allende bp num num wasquehal france numbirdsall building mayo clinic jacksonville num san pablo road jacksonville fl num usa numinstitut de pathologie num place de lhopital bp num num strasbourg cedex france nummcgill centre study aging num la salle boulevard verdun quebec canada hnumh numrnum numdepartment neuroscience university california san diego num la jolla village drive san diego ca num usa numdepartments psychiatry neurology genetics washington university school medicine st louis mo num usa numdepartment pathological science stopford building university manchester oxford road manchester mnum numpt uk
0.3697104.9700208.html.plaintext.txt	3	received june num num revised accepted july num num
0.3697104.9700208.html.plaintext.txt	4	possession apolipoprotein e apoe epsisnum allele frequently associated genetic susceptibility factor alzheimers disease ad
0.3697104.9700208.html.plaintext.txt	5	recently new polymorphism regulatory region apoe gene described
0.3697104.9700208.html.plaintext.txt	6	analysed effect three mutation num num ct thnumenumcs disease risk large case control study tested impact apoe allelic expression brain tissue
0.3697104.9700208.html.plaintext.txt	7	thnumenumcs allele associated increased risk occurrence ad num allele associated decreased risk independently apoe epsisnumepsisnumepsisnum polymorphism effect
0.3697104.9700208.html.plaintext.txt	8	however impact thnumenumcs mutation strongest
0.3697104.9700208.html.plaintext.txt	9	num ct polymorphism associated disease
0.3697104.9700208.html.plaintext.txt	10	ad subject heterozygous epsisnum allele analysis allelic expression showed relative expression level epsisnum allele higher corresponding control
0.3697104.9700208.html.plaintext.txt	11	consistent epidemiological data relative level expression epsisnum allele modified accordingly presence absence two main promoter polymorphism indicating vivo deleterious effect thnumenumcs allele protective effect num allele population
0.3697104.9700208.html.plaintext.txt	12	data indicate addition qualitative effect apoe epsisnumepsisnumepsisnum polymorphism ad occurrence quantitative variation expression allele due functional apoe promoter mutation key determinant ad development
0.3697104.9700208.html.plaintext.txt	13	presence least one apolipoprotein e apoe epsisnum allele major genetic susceptibility factor late onset familial sporadic alzheimers disease ad
0.3697104.9700208.html.plaintext.txt	14	risk factor account num num case num
0.3697104.9700208.html.plaintext.txt	15	indeed epsisnum allele associated increased risk ad allele dose dependant manner numnum
0.3697104.9700208.html.plaintext.txt	16	conversely epsisnum allele protects disease numnum
0.3697104.9700208.html.plaintext.txt	17	mechanism apoe isoforms implicated human nervous system physiology influence pathogenesis ad fully understood numnum num
0.3697104.9700208.html.plaintext.txt	18	effect apoe epsisnumepsisnumepsisnum allele may due intrinsic biochemical property isoforms coded allele
0.3697104.9700208.html.plaintext.txt	19	genetic variant influencing apoe allele expression may account increase decrease level risk ad
0.3697104.9700208.html.plaintext.txt	20	hypothesis supported firstly preliminary observation relative overexpression epsisnum allele compared epsisnum allele brain patient ad compared control num
0.3697104.9700208.html.plaintext.txt	21	secondly thnumenumcs num polymorphism located apoe promoter described associated ad risk numnum
0.3697104.9700208.html.plaintext.txt	22	moreover effect two polymorphism ad occurrence described separately case control study
0.3697104.9700208.html.plaintext.txt	23	prompted u analyse relative contribution two promoter polymorphism also third located position num apoe promoter together epsisnumepsisnumepsisnum allele towards ad risk large case control study num control num ad case
0.3697104.9700208.html.plaintext.txt	24	furthermore investigated possible influence two main polymorphism apoe epsisnumepsisnumepsisnum allelic relative expression brain tissue approach vivo functionality brain sample num ad case num control
0.3697104.9700208.html.plaintext.txt	25	expected possession epsisnum allele strongly associated ad odds ratio num
0.3697104.9700208.html.plaintext.txt	26	num num confidence interval ci num
0.3697104.9700208.html.plaintext.txt	27	num presence epsisnum allele exhibited protective effect num
0.3697104.9700208.html.plaintext.txt	28	frequency thnumenumcs allele increased ad case compared control chinum num
0.3697104.9700208.html.plaintext.txt	29	risk developing ad carrier least one allele num
0.3697104.9700208.html.plaintext.txt	30	conversely frequency num allele decreased patient compared control chinum num
0.3697104.9700208.html.plaintext.txt	31	genotype allele frequency num polymorphism similar observed north american population differed spanish sample num
0.3697104.9700208.html.plaintext.txt	32	develop ad subject bearing least one num allele num
0.3697104.9700208.html.plaintext.txt	33	association disease detected num ct polymorphism
0.3697104.9700208.html.plaintext.txt	34	eliminate possible confounding effect apoe epsisnum allele association thnumenumcs num polymorphism ad controlled effect allele using logistic regression adjusted presence absence epsisnum allele
0.3697104.9700208.html.plaintext.txt	35	adjustment risk associated possession least one thnumenumcs allele persisted num
0.3697104.9700208.html.plaintext.txt	36	num risk associated num allele num
0.3697104.9700208.html.plaintext.txt	37	observation suggested effect thnumenumcs allele independent epsisnum allele num allele
0.3697104.9700208.html.plaintext.txt	38	however since thnumenumcs g epsisnum allele complete disequilibrium table num also performed logistic regression including protective deleterious effect epsisnum epsisnum allele respectively
0.3697104.9700208.html.plaintext.txt	39	risk associated thnumenumcs allele still persisted num
0.3697104.9700208.html.plaintext.txt	40	assume level expression apoe allele increased decreased due ci mutation promoter region hypothesis two major implication promoter mutation may modulate expression apoe allele leading increase decrease deleterious protective risk associated epsisnum epsisnum allele respectively ii given determines risk importance relative level expression allele apoe suggested preliminary data num promoter mutation differential effect detectable mainly apoe epsisnumepsisnumepsisnum heterozygous individual
0.3697104.9700208.html.plaintext.txt	41	verify assumption studied developing ad apoe heterozygous homozygous individual using logistic regression adjusted age sex presence least one num one thnumenum allele
0.3697104.9700208.html.plaintext.txt	42	apoe epsisnumepsisnumepsisnum homozygote effect found num
0.3697104.9700208.html.plaintext.txt	43	num thnumenum num allele respectively
0.3697104.9700208.html.plaintext.txt	44	conversely apoe epsisnumepsisnumepsisnum heterozygote individual bearing least one thnumenum allele increased risk developing ad num
0.3697104.9700208.html.plaintext.txt	45	num individual bearing least one num allele exhibited protective effect num
0.3697104.9700208.html.plaintext.txt	46	num consistent initial hypothesis
0.3697104.9700208.html.plaintext.txt	47	apoe thnumenumcs num allele genotype distribution allele genotype apoe epsisnum epsisnum epsisnum epsisnumepsisnuma epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum control num num
0.3697104.9700208.html.plaintext.txt	48	num thnumegrnumcs g gga gt tt control num num
0.3697104.9700208.html.plaintext.txt	49	num num tcb c tt tc cc control num num
0.3697104.9700208.html.plaintext.txt	50	num num aac tt control num num
0.3697104.9700208.html.plaintext.txt	51	num allele genotype number frequency presented
0.3697104.9700208.html.plaintext.txt	52	genotypic distribution control population hardy weinberg equilibrium
0.3697104.9700208.html.plaintext.txt	53	combination num thnumenumcs apoe polymorphism allele control ad case apoe thnumenumcs polymorphism combination n epsisnumepsisnuma epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum ad case gg num num num num num num gt num num num num num num tt num num num num n num num num num num num control case gg num num num num num gt num num num num num num tt num num num num n num num num num num num apoe num polymorphism combination n epsisnumepsisnuma epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum ad case aa num num num num num num num num num num num num tt num num num num num n num num num num num num control case aa num num num num num num num num num num num num tt num num num num n num num num num num num thnumenumcs num polymorphism combination n agragr agrsigma sigmasigma ad case gg num num num num gt num num num num tt num num num num n num num num num control case gg num num num num gt num num num num tt num num num num n num num num num athree individual epsisnumepsisnum control
0.3697104.9700208.html.plaintext.txt	54	num epsisnum allele present degree linkage disequilibrium num num control ad population respectively
0.3697104.9700208.html.plaintext.txt	55	thnumenumcs g epsisnum allele complete linkage disequilibrium population thnumenumcs epsisnum allele show linkage disequilibrium num population
0.3697104.9700208.html.plaintext.txt	56	linkage disequilibrium found num thnumenumcs polymorphism
0.3697104.9700208.html.plaintext.txt	57	location polymorphism within regulatory region apoe gene potential effect vitro reported hepatoma cell suggested polymorphism may play role control apoe expression level brain
0.3697104.9700208.html.plaintext.txt	58	order test hypothesis obtained num ad control brain tissue heterozygous apoe measured percentage expression level three apoe allele
0.3697104.9700208.html.plaintext.txt	59	control epsisnum allele strongly underexpressed compared epsisnum epsisnum allele epsisnumepsisnum epsisnumepsisnum brain sample respectively epsisnum epsisnum expression almost similar epsisnumepsisnum sample fig
0.3697104.9700208.html.plaintext.txt	60	suggested preliminary data num clear consistent increase relative epsisnum allelic expression epsisnumepsisnum patient epsisnumepsisnum control num
0.3697104.9700208.html.plaintext.txt	61	significant decrease relative epsisnum expression demonstrated epsisnumepsisnum ad brain compared epsisnumepsisnum control num
0.3697104.9700208.html.plaintext.txt	62	increased expression epsisnum allele also detected epsisnumepsisnum ad control num
0.3697104.9700208.html.plaintext.txt	63	measured value epsisnumepsisnum ad case control corresponded expected value estimated genotype reinforcing observation see material method arrow fig
0.3697104.9700208.html.plaintext.txt	64	differential expression apoe mrna three heterozygous genotype ad control case
0.3697104.9700208.html.plaintext.txt	65	average level expression indicated bold line category
0.3697104.9700208.html.plaintext.txt	66	brain sample rt pcr semi quantitation repeated least twice
0.3697104.9700208.html.plaintext.txt	67	bold arrow indicate expected value epsisnum allele percentage epsisnumepsisnum sample calculated epsisnum epsisnum percentage epsisnumepsisnum epsisnumepsisnum ad control case respectively
0.3697104.9700208.html.plaintext.txt	68	previous epidemiological data suggest num polymorphism thnumenumcs polymorphism may good candidate mediate allelic distortion
0.3697104.9700208.html.plaintext.txt	69	particular estimation associated combination epsisnum thnumenumcs allele chromosome indicate estimated increased risk num
0.3697104.9700208.html.plaintext.txt	70	num heterozygous epsisnumepsisnum individual presenting haplotype described previously num
0.3697104.9700208.html.plaintext.txt	71	thus epsisnum allele associated thnumenumcs allele chromosome epsisnum allele associated thnumenumcs g allele relative epsisnumepsisnum mrna ratio significantly increased associated ad
0.3697104.9700208.html.plaintext.txt	72	conversely epsisnum epsisnum allele control thnumenumcs allele either g level expression similar
0.3697104.9700208.html.plaintext.txt	73	thus expected stronger distortion thnumenumcs heterozygote homozygote
0.3697104.9700208.html.plaintext.txt	74	argument clearly illustrated experimental data table num
0.3697104.9700208.html.plaintext.txt	75	approach valid num mutation
0.3697104.9700208.html.plaintext.txt	76	influence polymorphism relative mrna expression level could observed case fig
0.3697104.9700208.html.plaintext.txt	77	affected patient carrying thnumenumcs gt num genotype highest lowest relative level expression epsisnum expression respectively fig
0.3697104.9700208.html.plaintext.txt	78	difference level expression case pronounced thnumenumcs gt bearer num bearer num
0.3697104.9700208.html.plaintext.txt	79	differential expression epsisnum allele epsisnumepsisnum ad control case according thnumenumcs genotype
0.3697104.9700208.html.plaintext.txt	80	ad case denoted triangle control circle
0.3697104.9700208.html.plaintext.txt	81	closed symbol open symbol correspond num aa genotype respectively
0.3697104.9700208.html.plaintext.txt	82	deleterious effect thnumenumcs allele protective effect num allele described recently numnum confirmed large case control study
0.3697104.9700208.html.plaintext.txt	83	effect obvious apoe heterozygous population homozygous population
0.3697104.9700208.html.plaintext.txt	84	data surprising two reason would expect apoe epsisnum homozygote high expressing promoter allele chromosome higher risk developing ad epsisnum homozygote low expressing promoter allele
0.3697104.9700208.html.plaintext.txt	85	however small size epsisnumepsisnum control population allow impact brought forward ii consequence measured epsisnumepsisnumepsisnum homozygous individual mainly depended epsisnumepsisnum population
0.3697104.9700208.html.plaintext.txt	86	effect found latter population whatever studied promoter polymorphism
0.3697104.9700208.html.plaintext.txt	87	furthermore apoenum isoform considered isoform lesser effect ad pathology
0.3697104.9700208.html.plaintext.txt	88	relative epsisnum allele expression according thnumenumcs num polymorphism ad control brain sample n ad n controlsa thnumenumcs gg num num
0.3697104.9700208.html.plaintext.txt	89	confirm deleterious effect num aa genotype described epsisnumepsisnum spanish population num
0.3697104.9700208.html.plaintext.txt	90	discrepancy may explained significant difference num genotype distribution observed spanish french american control population
0.3697104.9700208.html.plaintext.txt	91	since ad genotypic frequency similar three studied population deleterious effect aa genotype epsisnumepsisnum group may due distribution spanish control population
0.3697104.9700208.html.plaintext.txt	92	impact two promoter polymorphism apoe epsisnum allele studied simultaneously multiple logistic regression model demonstrated thnumenumcs allele modified risk developing ad independently epsisnum allele suggesting num polymorphism may play weaker role compared thnumenumcs development ad
0.3697104.9700208.html.plaintext.txt	93	location polymorphism regulatory region apoe gene effect transcriptional activity hepatoma cell num impact ad population prompted u test hypothesis may modulate apoe expression level brain therefore partly responsible marked allelic distortion apoe mrna observed ad brain compared control heterozygous genotype
0.3697104.9700208.html.plaintext.txt	94	indeed epsisnum allele overexpressed epsisnumepsisnum epsisnumepsisnum ad case epsisnum allele underexpressed epsisnumepsisnum ad case compared respective control
0.3697104.9700208.html.plaintext.txt	95	consistent effect deduced case control study epsisnum allele expression ad brain also correlated polymorphism regulatory region apoe fig
0.3697104.9700208.html.plaintext.txt	96	num thnumenumcs allele may increase relative expression epsisnum allele ad num allele may decrease
0.3697104.9700208.html.plaintext.txt	97	numerous study reported contradictory finding brain cerebrospinal fluid csf concerning apoe protein level difficult speculate link apoe mrna apoe protein level num num
0.3697104.9700208.html.plaintext.txt	98	however suggested yamada et al
0.3697104.9700208.html.plaintext.txt	99	apoe expression may decreased epsisnum gene dosage ad epsisnum homozygous ad case expressed apoe mrna epsisnumepsisnum ad case epsisnumepsisnum presenting intermediate mrna level num
0.3697104.9700208.html.plaintext.txt	100	similar trend found protein ad brain num plasma j
0.3697104.9700208.html.plaintext.txt	101	poirier personal communication indicating protein mrna level may directly correlated disease
0.3697104.9700208.html.plaintext.txt	102	underlining importance apoe level apoe expression shown correlate abeta peptide deposition transgenic mouse numnum
0.3697104.9700208.html.plaintext.txt	103	observation may important since previous report showed apoe gene expression increased num num fold ad brain compared control regardless apoe genotype numnum
0.3697104.9700208.html.plaintext.txt	104	epsisnumepsisnum ad case epsisnum epsisnum allele would overexpressed epsisnum allele due promoter mutation still overexpressed epsisnum allele
0.3697104.9700208.html.plaintext.txt	105	exacerbation apoe epsisnum expression level may foster intrinsic deleterious effect apoenum isoform ad instance promoting abeta aggregation numnumnum
0.3697104.9700208.html.plaintext.txt	106	expression level modulation may intended neurodegenerative disease also neural development
0.3697104.9700208.html.plaintext.txt	107	indeed observed strong underexpression epsisnum allele compared epsisnum allele control
0.3697104.9700208.html.plaintext.txt	108	although role apoe maturation ageing completely understood yet fact apoe deficient homozygous mouse exhibit reversible dendritic alteration significant learning deficit morris water maze suggests neurotrophic capability apoe num num
0.3697104.9700208.html.plaintext.txt	109	however ability isoform may different since apoenum isoform effect apoenum isoform neurite outgrowth num
0.3697104.9700208.html.plaintext.txt	110	instance apoenum apoenum may stabilize neuronal cytoskeleton num
0.3697104.9700208.html.plaintext.txt	111	global assessment modulation apoe expression difficult
0.3697104.9700208.html.plaintext.txt	112	indeed date five polymorphism described apoe promoter region numnum
0.3697104.9700208.html.plaintext.txt	113	two three polymorphism studied seem play role ad
0.3697104.9700208.html.plaintext.txt	114	two remaining allelic frequency num num therefore explain effect observed case control mrna study
0.3697104.9700208.html.plaintext.txt	115	however remains possible unknown polymorphism modulate apoe mrna level
0.3697104.9700208.html.plaintext.txt	116	new mutation may far away promoter polymorphism instance brain tissue specific element numnum
0.3697104.9700208.html.plaintext.txt	117	interaction putative polymorphism modifying apoe expression difficult model
0.3697104.9700208.html.plaintext.txt	118	various combination different mutation may confer large apoe expression heterogeneity two level absolute level apoe expression ii percentage expression one allele compared heterozygous individual adding complexity association apoe ad
0.3697104.9700208.html.plaintext.txt	119	therefore variation apoe expression induced apoe promoter polymorphism may partly explain heterogeneity impact epsisnum allele different ethnic group numnum
0.3697104.9700208.html.plaintext.txt	120	material method population
0.3697104.9700208.html.plaintext.txt	121	ad control sample caucasian originating france
0.3697104.9700208.html.plaintext.txt	122	diagnosis probable ad established according dsm iii r nindcs adrda criterion n num age num
0.3697104.9700208.html.plaintext.txt	123	caucasian control defined subject without dm iii r dementia criterion integrity cognitive function n num age num
0.3697104.9700208.html.plaintext.txt	124	individual relative signed informed consent
0.3697104.9700208.html.plaintext.txt	125	consisted num control age num
0.3697104.9700208.html.plaintext.txt	126	num men num late onset ad case age num
0.3697104.9700208.html.plaintext.txt	127	num men selected according apoe genotype
0.3697104.9700208.html.plaintext.txt	128	eighty eight sample extracted frontal cortex six occipital cortex difference relative expression observed region
0.3697104.9700208.html.plaintext.txt	129	num year ad case genotyped epsisnumepsisnum num
0.3697104.9700208.html.plaintext.txt	130	diagnosis confirmed neuropathological examination
0.3697104.9700208.html.plaintext.txt	131	num num ct thnumenumcs apoe genotype produced pcr followed restriction enzyme digestion amplified dna described num numnum
0.3697104.9700208.html.plaintext.txt	132	total rna extraction brain tissue heterozygous apoe genotype performed described num using rneasy mini kit qiagen germany digested dnase eurogentec belgium
0.3697104.9700208.html.plaintext.txt	133	dna contamination observed dnase digestion detected pcr digested product
0.3697104.9700208.html.plaintext.txt	134	apoe mrna amplified rt pcr allele quantitation performed described previously num measuring ratio expression two allele heterozygote order avoid problem due post mortem delay agonal state cell population density
0.3697104.9700208.html.plaintext.txt	135	num used sa institute cary nc
0.3697104.9700208.html.plaintext.txt	136	univariate analysis performed using pearsons chinum test
0.3697104.9700208.html.plaintext.txt	137	multivariate analysis coded genotype subject dummy variable according tested hypothesis least one thnumenumcs allele tttggg least one num allele ttataa least one epsisnum allele
0.3697104.9700208.html.plaintext.txt	138	effect variable disease assessed multiple logistic regression model adjusted age gender
0.3697104.9700208.html.plaintext.txt	139	comparison allelic expression performed using wilcoxon test
0.3697104.9700208.html.plaintext.txt	140	calculated expected range value epsisnum percentage epsisnumepsisnum ad control individual using extreme value obtained epsisnum epsisnum percentage epsisnumepsisnum epsisnumepsisnum ad control sample respectively epsisnum allele used reference
0.3697104.9700208.html.plaintext.txt	141	recipient ministere de lenseignement superieur et de la recherche mesr
0.3697104.9700208.html.plaintext.txt	142	work supported institut national pour la sante et la recherche medicale inserm institut pasteur de lille conseil regional du nord pa de calais axe regional de recherche sur le malady neurodegeneratives et le vieillissement cerebral m
0.3697104.9700208.html.plaintext.txt	143	fondation pour la recherche medicale
0.3697104.9700208.html.plaintext.txt	144	num binding human apolipoprotein e synthetic amyloid beta peptide isoform specific effect implication late onset alzheimer disease
0.3697104.9700208.html.plaintext.txt	145	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.3697104.9700208.html.plaintext.txt	146	num apolipoprotein e epsisnum allele major risk factor sporadic early late onset form alzheimers disease analysis numqnum
0.3697104.9700208.html.plaintext.txt	147	num protective effect apolipoprotein e type num late onset alzheimers disease
0.3697104.9700208.html.plaintext.txt	148	num apolipoprotein e kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment alzheimers disease
0.3697104.9700208.html.plaintext.txt	149	num apolipoprotein e allele specific antioxidant activity effect cytotoxicity oxidative insult beta amyloid peptide
0.3697104.9700208.html.plaintext.txt	150	num hypotesis microtubule instability paired helical filament formation alzheimer disease related apolipoprotein e genotype
0.3697104.9700208.html.plaintext.txt	151	num distortion allelic expression apolipoprotein e alzheimers disease
0.3697104.9700208.html.plaintext.txt	152	num new polymorphism apoe promoter associated risk developing alzheimers disease
0.3697104.9700208.html.plaintext.txt	153	num polymorphism regulatory region apoe associated risk alzheimers dementia
0.3697104.9700208.html.plaintext.txt	154	num allelic polymorphism transcriptional regulatory region apolipoprotein e gene
0.3697104.9700208.html.plaintext.txt	155	num relevance quantification apolipoprotein e cerebrospinal fluid alzheimers disease
0.3697104.9700208.html.plaintext.txt	156	num association apolipoprotein e genotype brain level apolipoprotein e apolipoprotein j clusterin alzheimer disease
0.3697104.9700208.html.plaintext.txt	157	num brain expression apolipoprotein e j alzheimers disease
0.3697104.9700208.html.plaintext.txt	158	num apolipoprotein e apoe polymorphism influence apoe concentration cerebrospinal fluid finnish patient alzheimers disease
0.3697104.9700208.html.plaintext.txt	159	num cerebrospinal fluid apolipoprotein e level increased late onset alzheimers disease
0.3697104.9700208.html.plaintext.txt	160	num apolipoprotein e mrna brain patient alzheimers disease
0.3697104.9700208.html.plaintext.txt	161	num lack apolipoprotein e dramatically reduces amyloid beta peptide deposition
0.3697104.9700208.html.plaintext.txt	162	num apolipoprotein e accumulates progression beta deposition transgenic mouse
0.3697104.9700208.html.plaintext.txt	163	num neuropathological change scrapie alzheimers disease associated increased expression apolipoprotein e cathepsin d astrocyte
0.3697104.9700208.html.plaintext.txt	164	num apolipoprotein e allele epsilon num linked increased deposition amyloid beta peptide beta case without alzheimers disease
0.3697104.9700208.html.plaintext.txt	165	num neurodegeneration central nervous system apoe deficient mouse
0.3697104.9700208.html.plaintext.txt	166	num memory deficit cholinergic impairment apolipoprotein e deficient mouse
0.3697104.9700208.html.plaintext.txt	167	num neurodegeneration cognitive impairment apoe deficient mouse ameliorated infusion recombinant apoe
0.3697104.9700208.html.plaintext.txt	168	num apolipoprotein e containing high density lipoprotein promotes neurite outgrowth ligand low density lipoprotein receptor related protein
0.3697104.9700208.html.plaintext.txt	169	num multiple tissue specific element control apolipoprotein ec gene locus transgenic mouse
0.3697104.9700208.html.plaintext.txt	170	num apolipoprotein e gene complex biological interaction aging brain
0.3697104.9700208.html.plaintext.txt	171	num apoe epsisnum allele risk alzheimer disease among african american white hispanic
0.3697104.9700208.html.plaintext.txt	172	american psychiatric association num diagnostic statistical manual mental disorder
0.3697104.9700208.html.plaintext.txt	173	third edition revised dsm iii r american psychatric association washington dc
0.3697104.9700208.html.plaintext.txt	174	num clinical diagnosis alzheimers disease report nincds adrda work group neurology num num num
0.3697104.9700208.html.plaintext.txt	175	num restriction isotyping human apolipoprotein e gene amplification cleavage hhai
0.3697104.9700208.html.plaintext.txt	176	num biosynthesis protamine trout testis
0.3697104.9700208.html.plaintext.txt	177	correspondence addressed
0.3697104.9700208.html.plaintext.txt	178	tel num num num num num num fax num num num num num num email marie christine
0.3697104.9700208.html.plaintext.txt	179	fr u d page run oxford university press great clarendon street oxford oxnum numdp part oup journal comment feedback www adminatoup
0.3697104.9700208.html.plaintext.txt	180	uk u d last modification num aug num copyright oxford university press num
0.37081465.15229191.html.plaintext.txt	0	independent effect apoe cholesterol metabolism brain as level alzheimer disease mouse model karen m
0.37081465.15229191.html.plaintext.txt	1	thorngatenum yuko katoh fukuinum hiroki hamanakanum david l
0.37081465.15229191.html.plaintext.txt	2	williamsnum shinobu fujitanum bruce
0.37081465.15229191.html.plaintext.txt	3	numdepartment genetics case western reserve university cleveland oh num usa numcenter human genetics university memory aging center ireland cancer center university hospital cleveland cleveland oh num usa numdepartment pharmacological science university medical center stony brook university stony brook ny num usa numdepartment developmental biology national institute basic biology myodaiji cho okazaki num num japan numcenter neural science new york university new york ny num num usa nummitsubishi kagaku institute life science machida tokyo japan
0.37081465.15229191.html.plaintext.txt	4	received march num num accepted june num num
0.37081465.15229191.html.plaintext.txt	5	apoe num first shown association study genetic risk factor cardiovascular disease presumably role conferring high circulating cholesterol level mainly form ldl individual one copy allele numnum
0.37081465.15229191.html.plaintext.txt	6	subsequently apoe num found associated increased risk late onset alzheimers disease load numnum
0.37081465.15229191.html.plaintext.txt	7	furthermore presence one num allele decrease age disease onset much num year num
0.37081465.15229191.html.plaintext.txt	8	one hypothesis link apoe genotype cardiovascular disease ad involves contribution cholesterol homeostasis disease role apoe process
0.37081465.15229191.html.plaintext.txt	9	several study implicated role cholesterol production as primary constituent senile plaque ad brain num num
0.37081465.15229191.html.plaintext.txt	10	high serum cholesterol level mouse transgenic app precursor protein as peptide correlate increased brain as level severe plaque load numnum
0.37081465.15229191.html.plaintext.txt	11	retrospective epidemiological study demonstrated decreased ad risk human population statin therapy lower cholesterol level reviewed num although effect may indirect several study shown statin alter as level serum numnum
0.37081465.15229191.html.plaintext.txt	12	several study reported association elevated serum cholesterol level ad risk level as numnum independent apoe genotype
0.37081465.15229191.html.plaintext.txt	13	study however failed demonstrate correlation serum cholesterol level ad development num
0.37081465.15229191.html.plaintext.txt	14	apoe num may affect ad risk conferring high cholesterol level thereby increasing as production
0.37081465.15229191.html.plaintext.txt	15	ad patient num allele increased level assnum num brain csf extensive plaque pathology numnum
0.37081465.15229191.html.plaintext.txt	16	interestingly num allele confers low cholesterol level also considered protective ad development num
0.37081465.15229191.html.plaintext.txt	17	several apoe transgenic mouse model generated effort gain insight role apoe ad num num
0.37081465.15229191.html.plaintext.txt	18	model utilize various promoter drive expression human apoe cdna neuron glia
0.37081465.15229191.html.plaintext.txt	19	approach several limitation concerning regulation apoe brain periphery
0.37081465.15229191.html.plaintext.txt	20	first apoe transgenic study attempted normalize apoe level apoe num num transgenic line respect num endogenous level num
0.37081465.15229191.html.plaintext.txt	21	however several human study suggest level apoe vary genotype may impact ad pathogenesis
0.37081465.15229191.html.plaintext.txt	22	second apoe transgenic line bred onto apoe null background confers high circulating cholesterol level
0.37081465.15229191.html.plaintext.txt	23	given role apoe peripheral cholesterol metabolism growing evidence cholesterol level influencing brain as metabolism unclear absence apoe affect ad pathology animal
0.37081465.15229191.html.plaintext.txt	24	importantly consensus impact apoe genotype ad pathogenesis study perhaps owing complication different promoter altered level apoe brain combined complication mixed genetic background model
0.37081465.15229191.html.plaintext.txt	25	apoe knock ki mouse provide unique model understanding apoe allele behaves development alzheimers disease
0.37081465.15229191.html.plaintext.txt	26	obtained mouse previously published hamanaka et al
0.37081465.15229191.html.plaintext.txt	27	num order characterize behavior human apoe allele defined genetic background
0.37081465.15229191.html.plaintext.txt	28	present apoe protein abundance cholesterol lipoprotein data young animal expressing apoe num num num defined cnumblnumj background
0.37081465.15229191.html.plaintext.txt	29	demonstrate significant difference protein abundance mirror human data well significant difference serum cholesterol level absence effect app processing
0.37081465.15229191.html.plaintext.txt	30	presence apoe significantly increase level as cholesterol brain irrespective allele
0.37081465.15229191.html.plaintext.txt	31	genomic based mouse model provides evidence neither cholesterol level apoe abundance alone sufficient influence as metabolism young animal
0.37081465.15229191.html.plaintext.txt	32	protein abundance apoe ki mouse level steady state apoe brain liver serum three ki mouse line determined western blot analysis using human specific apoe antibody
0.37081465.15229191.html.plaintext.txt	33	parallel western blot recombinant enum enum enum serial dilution num
0.37081465.15229191.html.plaintext.txt	34	num num num microg protein run determine affinity antibody isoform
0.37081465.15229191.html.plaintext.txt	35	standard curve fluorescent unit isoform revealed little difference detection
0.37081465.15229191.html.plaintext.txt	36	enum appeared detected slightly le well data shown
0.37081465.15229191.html.plaintext.txt	37	level apoe protein ki animal compared standard homogenate serum standard homozygous num ki animal
0.37081465.15229191.html.plaintext.txt	38	figure num illustrates difference apoe level compared across line ratio steady state level sample relative standard
0.37081465.15229191.html.plaintext.txt	39	apoe num ki animal average num fold higher steady state level apoe brain fasted liver compared num ki num ki animal fig
0.37081465.15229191.html.plaintext.txt	40	three line significantly different level apoe brain
0.37081465.15229191.html.plaintext.txt	41	level steady state apoe brain confirmed human specific apoe elisa using standard curve recombinant enum enum enum quantitate level isoform
0.37081465.15229191.html.plaintext.txt	42	num ki animal demonstrated num fold increase level brain apoe method well p num
0.37081465.15229191.html.plaintext.txt	43	num although enum enum significantly different
0.37081465.15229191.html.plaintext.txt	44	difference shown western blotting num num line may explained slightly lower affinity antibody recombinant enum
0.37081465.15229191.html.plaintext.txt	45	level apoe fasted serum num ki animal also significantly higher found num ki num ki animal western blotting fig
0.37081465.15229191.html.plaintext.txt	46	relationship genotype apoe level ki mouse recapitulates observed human serum num num
0.37081465.15229191.html.plaintext.txt	47	view larger version numk figure num
0.37081465.15229191.html.plaintext.txt	48	analysis apoe abundance apoe ki animal
0.37081465.15229191.html.plaintext.txt	49	relative level apoe brain fasted liver fasted serum apoe ki line assayed male female num num week age
0.37081465.15229191.html.plaintext.txt	50	protein extract brain fasted liver made num chap protease inhibitor
0.37081465.15229191.html.plaintext.txt	51	apoe level brain nnum fasted liver b nnum fasted serum d nnum assayed western blot analysis using human specific apoe antibody calbiochem
0.37081465.15229191.html.plaintext.txt	52	apoe quantitation expressed ratio apoe abundance sample relative standard total protein concentration
0.37081465.15229191.html.plaintext.txt	53	num ki apoe level significantly increased brain fasted liver b p num
0.37081465.15229191.html.plaintext.txt	54	num one factor anova post tukey compared num ki num ki level
0.37081465.15229191.html.plaintext.txt	55	num ki apoe level also significantly increased fasted serum d p num
0.37081465.15229191.html.plaintext.txt	56	num one factor anova followed dunns post test
0.37081465.15229191.html.plaintext.txt	57	num ki level brain significantly increased num ki level p num
0.37081465.15229191.html.plaintext.txt	58	num one factor anova post tukey
0.37081465.15229191.html.plaintext.txt	59	representative western blot apoe abundance brain fasted liver c demonstrates relative num fold increase apoe liver versus brain num fold higher level num ki homogenate compared num ki num ki homogenate
0.37081465.15229191.html.plaintext.txt	60	apoe brain level also measured human specific elisa e num ki level significantly increased num ki num ki level p num
0.37081465.15229191.html.plaintext.txt	61	num one factor anova post tukey
0.37081465.15229191.html.plaintext.txt	62	cholesterol metabolism apoe ki mouse examine allele affect cholesterol metabolism mouse serum cholesterol triglyceride level measured num h fast using enzymatic assay
0.37081465.15229191.html.plaintext.txt	63	analysis cholesterol level num animal genotype mixed sex demonstrated inverse relationship genotype phenotype relative human data
0.37081465.15229191.html.plaintext.txt	64	num ki animal highest cholesterol mean num mgdl triglyceride mean num mgdl
0.37081465.15229191.html.plaintext.txt	65	contrast num ki animal lowest cholesterol mean num mgdl whereas num ki animal significantly differ bnum wild type animal table num
0.37081465.15229191.html.plaintext.txt	66	triglyceride level num ki num ki bnum animal statistically indistinguishable
0.37081465.15229191.html.plaintext.txt	67	fasted serum cholesterol triglyceride level apoe genotype understand different apoe isoforms participate peripheral cholesterol metabolism mouse generated lipoprotein profile fplc ki line
0.37081465.15229191.html.plaintext.txt	68	distribution apoe cholesterol analyzed profile
0.37081465.15229191.html.plaintext.txt	69	fasted serum three animal sex pooled analysis genotype sex difference apparent data shown
0.37081465.15229191.html.plaintext.txt	70	profile genotype shown figure num
0.37081465.15229191.html.plaintext.txt	71	apoe num ki num ki profile differ bnum wild type animal majority circulating cholesterol found hdl fraction whereas vldl ldlidl fraction minimal
0.37081465.15229191.html.plaintext.txt	72	contrast num ki profile demonstrated although level hdl cholesterol remained equal found line cholesterol distribution extended ldlidl fraction highest level vldl fraction
0.37081465.15229191.html.plaintext.txt	73	thus increased total cholesterol level num ki mouse due increase vldl ldlidl cholesterol
0.37081465.15229191.html.plaintext.txt	74	view larger version numk figure num
0.37081465.15229191.html.plaintext.txt	75	fplc analysis lipoprotein profile apoe ki animal
0.37081465.15229191.html.plaintext.txt	76	fasted serum three animal sex apoe line pooled fractionated fplc superose num column
0.37081465.15229191.html.plaintext.txt	77	fplc profile generated male female line two separate experiment representative result shown figure
0.37081465.15229191.html.plaintext.txt	78	vldl peak around num min bnum endogenous apoe apoewt b num ki c num ki profile contains little cholesterol compared vldl fraction d num ki profile
0.37081465.15229191.html.plaintext.txt	79	large peak num min represents hdl fraction cholesterol level four group relatively equal fraction
0.37081465.15229191.html.plaintext.txt	80	e distribution apoe lipoprotein fraction analyzed western blot analysis using human specific apoe antibody calbiochem
0.37081465.15229191.html.plaintext.txt	81	five fraction lipoprotein peak pooled equal volume combined fraction loaded lane representative western blot apoe abundance shown
0.37081465.15229191.html.plaintext.txt	82	absence apoe vldl fraction apoewt num ki num ki distinct compared abundance apoe num ki profile
0.37081465.15229191.html.plaintext.txt	83	majority apoe num ki profile found hdl fraction contrast num ki apoewt profile show majority apoe apoe ldlidl fraction
0.37081465.15229191.html.plaintext.txt	84	distribution apoe protein lipoprotein fraction determined western blot analysis
0.37081465.15229191.html.plaintext.txt	85	five fraction lipoprotein class including peak fraction pooled run condition apoe quantitation tissue
0.37081465.15229191.html.plaintext.txt	86	resulting data shown figure nume
0.37081465.15229191.html.plaintext.txt	87	apoe detected vldl fraction num ki num ki non transgenic control profile reflected low level cholesterol fraction
0.37081465.15229191.html.plaintext.txt	88	level apoe highest ldlidl fraction followed hdl fraction
0.37081465.15229191.html.plaintext.txt	89	num ki profile demonstrated highest level apoe hdl fraction
0.37081465.15229191.html.plaintext.txt	90	may reflect preferential binding enum larger lipoprotein mouse plasma enriched large apoe rich hdl absent normal human plasma num
0.37081465.15229191.html.plaintext.txt	91	contrast profile high level apoe observed fraction num ki profile consistent high level cholesterol found distributed fraction
0.37081465.15229191.html.plaintext.txt	92	app processing as metabolism brain cholesterol apoe ki mouse examine effect different apoe allele app biochemistry apoe ki mouse crossed rnum
0.37081465.15229191.html.plaintext.txt	93	num app transgenic line congenic bnum background
0.37081465.15229191.html.plaintext.txt	94	num line yac based transgenic model ad express appswe proper spatial temporal manner num
0.37081465.15229191.html.plaintext.txt	95	num transgenic animal display as deposition num
0.37081465.15229191.html.plaintext.txt	96	apoe ki animal crossed rnum
0.37081465.15229191.html.plaintext.txt	97	num transgenic animal generate animal homozygous apoe allele hemizygous app
0.37081465.15229191.html.plaintext.txt	98	brain num day old apoeapoe rnum
0.37081465.15229191.html.plaintext.txt	99	num animal subsequently denoted apoernum
0.37081465.15229191.html.plaintext.txt	100	utilized examine level app processing intermediate as
0.37081465.15229191.html.plaintext.txt	101	level app holo protein c terminal fragment ctfs determined using num app c terminal antibody
0.37081465.15229191.html.plaintext.txt	102	difference holo app observed line fig
0.37081465.15229191.html.plaintext.txt	103	addition relative amount app ctfs expressed ratio ctfsstotal ctfs determined apoernum
0.37081465.15229191.html.plaintext.txt	104	num animal endogenous apoe fig
0.37081465.15229191.html.plaintext.txt	105	despite significant difference serum cholesterol among three apoernum
0.37081465.15229191.html.plaintext.txt	106	numa difference ratio ctfsstotal ctfs
0.37081465.15229191.html.plaintext.txt	107	likewise app ctf ratio unchanged presence apoe apoe animal num day age
0.37081465.15229191.html.plaintext.txt	108	view larger version numk figure num
0.37081465.15229191.html.plaintext.txt	109	app processing product analyzed num m urea homogenate half brain apoernum
0.37081465.15229191.html.plaintext.txt	110	western blotting app antibody num used assay level holo app ctfs apoernum
0.37081465.15229191.html.plaintext.txt	111	num line nnum line well rnum
0.37081465.15229191.html.plaintext.txt	112	num animal endogenous apoe nnum
0.37081465.15229191.html.plaintext.txt	113	representative western blot shown
0.37081465.15229191.html.plaintext.txt	114	app quantitation b expressed ratio app abundance sample relative endogenous level wild type extract total protein concentration
0.37081465.15229191.html.plaintext.txt	115	analysis holo app level demonstrated difference line p num
0.37081465.15229191.html.plaintext.txt	116	relative ratio ctfss total app ctfs c unaffected apoe genotype p num
0.37081465.15229191.html.plaintext.txt	117	num one factor anova four five animal per group
0.37081465.15229191.html.plaintext.txt	118	view larger version numk figure num
0.37081465.15229191.html.plaintext.txt	119	total cholesterol brain assnum num level apoernum
0.37081465.15229191.html.plaintext.txt	120	measurement total cholesterol serum brain brain as level obtained animal num day age
0.37081465.15229191.html.plaintext.txt	121	serum cholesterol assayed apoernum
0.37081465.15229191.html.plaintext.txt	122	num animal endogenous apoe colorimetric assay thermotrace
0.37081465.15229191.html.plaintext.txt	123	result confirmed app transgene affect serum cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	124	num animal num fold higher level total cholesterol numrnum
0.37081465.15229191.html.plaintext.txt	125	num one factor anova followed post tukey
0.37081465.15229191.html.plaintext.txt	126	b level total brain cholesterol measured num m urea homogenate half brain colorimetic assay thermotrace
0.37081465.15229191.html.plaintext.txt	127	presence human apoenum num significantly increase brain cholesterol rnum
0.37081465.15229191.html.plaintext.txt	128	num brain cholesterol level also elevated compared bnum
0.37081465.15229191.html.plaintext.txt	129	num animal although significant p num
0.37081465.15229191.html.plaintext.txt	130	c level assnum num brain measured num m guanidine extract half brain elisa biosource significantly different apoernum
0.37081465.15229191.html.plaintext.txt	131	num one factor anova nnum line
0.37081465.15229191.html.plaintext.txt	132	num line significantly increased assnum num level compared bnum
0.37081465.15229191.html.plaintext.txt	133	num enum versus bnum one factor anova post tukey
0.37081465.15229191.html.plaintext.txt	134	level serum cholesterol apoernum
0.37081465.15229191.html.plaintext.txt	135	num line nnum backcross generation determined previously mentioned
0.37081465.15229191.html.plaintext.txt	136	similar result absence rnum
0.37081465.15229191.html.plaintext.txt	137	num mouse significantly higher cholesterol level compared line
0.37081465.15229191.html.plaintext.txt	138	num animal slightly higher level cholesterol relative num
0.37081465.15229191.html.plaintext.txt	139	num animal endogenous apoe fig
0.37081465.15229191.html.plaintext.txt	140	difference compared data table num nnum generation likely illustrates genetic background effect cholesterol metabolism num ki mouse
0.37081465.15229191.html.plaintext.txt	141	level steady state assnum num assessed elisa half brain extract
0.37081465.15229191.html.plaintext.txt	142	given increased serum cholesterol conferred diet effectively increase assnum num brain num expectation num
0.37081465.15229191.html.plaintext.txt	143	num animal serum cholesterol level nearly twice num
0.37081465.15229191.html.plaintext.txt	144	num animal would greatest amount assnum num
0.37081465.15229191.html.plaintext.txt	145	however significant difference assnum num level three apoernum
0.37081465.15229191.html.plaintext.txt	146	data suggest fundamental distinction genetic dietary control cholesterol level effect assnum num metabolism
0.37081465.15229191.html.plaintext.txt	147	interestingly three apoernum
0.37081465.15229191.html.plaintext.txt	148	num line demonstrated significantly increased level assnum num relative bnum
0.37081465.15229191.html.plaintext.txt	149	num animal endogenous apoe
0.37081465.15229191.html.plaintext.txt	150	thus presence human apoe rnum
0.37081465.15229191.html.plaintext.txt	151	num line led increased assnum num steady state level num day age
0.37081465.15229191.html.plaintext.txt	152	level total brain cholesterol measured enzymatic assay normalized concentration protein extracted mg cholesterolmg protein
0.37081465.15229191.html.plaintext.txt	153	average level brain cholesterol num
0.37081465.15229191.html.plaintext.txt	154	num animal higher average brain cholesterol rnum
0.37081465.15229191.html.plaintext.txt	155	num animal endogenous apoe fig
0.37081465.15229191.html.plaintext.txt	156	increase brain cholesterol apoernum
0.37081465.15229191.html.plaintext.txt	157	num animal appeared coincide increased assnum num level suggesting link apoe brain cholesterol as metabolism
0.37081465.15229191.html.plaintext.txt	158	despite high level serum cholesterol num
0.37081465.15229191.html.plaintext.txt	159	num animal brain cholesterol level indistinguishable num
0.37081465.15229191.html.plaintext.txt	160	cholesterol data lend evidence hypothesis peripheral brain cholesterol level independently regulated
0.37081465.15229191.html.plaintext.txt	161	apoe abundance much known apoe biology human particularly role lipid metabolism
0.37081465.15229191.html.plaintext.txt	162	apoe primarily synthesized liver brain additional site include adrenal gland kidney numnum
0.37081465.15229191.html.plaintext.txt	163	apoe genotype shown correlate apoe abundance periphery numnum num num allele confers high apoe whereas num allele confers low apoe respect num level
0.37081465.15229191.html.plaintext.txt	164	effect apoe allele apoe abundance brain csf le clear owing conflicting report many study concentrating abundance apoe ad brain relative control irrespective apoe genotype numnumnum
0.37081465.15229191.html.plaintext.txt	165	demonstrate western blot analysis elisa steady state level apoe tissue serum three ki line genotype dependent reflect human data serum apoe level
0.37081465.15229191.html.plaintext.txt	166	num ki animal significantly higher level apoe tissue examined p num
0.37081465.15229191.html.plaintext.txt	167	finding particularly data brain illustrate innate difference behavior three human apoe allele mouse arguing relevance genomic based apoe model understanding apoe function
0.37081465.15229191.html.plaintext.txt	168	difference brain apoe level ki mouse may important implication apoe influence pathology development ad mouse model
0.37081465.15229191.html.plaintext.txt	169	recent report sullivan et al
0.37081465.15229191.html.plaintext.txt	170	num showing brain apoe level genotype independent different set apoe ki animal contradicts data
0.37081465.15229191.html.plaintext.txt	171	however reported apoe line contain neo cassette targeted allele may affect protein expression
0.37081465.15229191.html.plaintext.txt	172	additional difference inclusion human apoe intron num targeted allele mouse may contain additional endo genous regulatory element
0.37081465.15229191.html.plaintext.txt	173	comparison mouse necessary determine innate difference two model
0.37081465.15229191.html.plaintext.txt	174	apoe cholesterol metabolism mouse addition protein level show apoe genotype also impact cholesterol level periphery
0.37081465.15229191.html.plaintext.txt	175	num ki animal fasted cholesterol level slightly bnum wild type animal whereas num ki animal num fold higher cholesterol level
0.37081465.15229191.html.plaintext.txt	176	num ki bnum wild type cholesterol level significantly differ
0.37081465.15229191.html.plaintext.txt	177	data recapitulate shown apoe ki model num num opposite finding human num allele associated high num low cholesterol level
0.37081465.15229191.html.plaintext.txt	178	data highlight innate difference mouse human cholesterol metabolism include utilization different lipoprotein transport cholesterol
0.37081465.15229191.html.plaintext.txt	179	data also contrast initial report num ki mouse hamanaka et al
0.37081465.15229191.html.plaintext.txt	180	num fold increase level circulating cholesterol relative wild type control
0.37081465.15229191.html.plaintext.txt	181	discrepancy data may attributed several factor
0.37081465.15229191.html.plaintext.txt	182	first perhaps notable difference genetic background two study
0.37081465.15229191.html.plaintext.txt	183	several line evidence demonstrate strong genetic component cholesterol metabolism mouse num num
0.37081465.15229191.html.plaintext.txt	184	complex trait involves gene work additive manner well epistatically num
0.37081465.15229191.html.plaintext.txt	185	analysis cholesterol ki mouse subsequent backcrosses argues background effect demonstrated comparing cholesterol level num
0.37081465.15229191.html.plaintext.txt	186	num animal nnum backcross generation table num versus fig
0.37081465.15229191.html.plaintext.txt	187	second ki mouse report longer transmit neo cassette targeted allele
0.37081465.15229191.html.plaintext.txt	188	although direct evidence suggest presence neo affect function apoe cholesterol metabolism mouse ruled
0.37081465.15229191.html.plaintext.txt	189	finally difference diet methodology two study may also impact reported cholesterol level
0.37081465.15229191.html.plaintext.txt	190	characterization lipoprotein profile reported num num ki mouse demonstrated majority cholesterol distributed hdl fraction similar bnum wild type animal
0.37081465.15229191.html.plaintext.txt	191	data suggest presence human apoe num num disrupt mouse cholesterol metabolism observation also made maeda colleague num num
0.37081465.15229191.html.plaintext.txt	192	comparison profile published hamanaka et al
0.37081465.15229191.html.plaintext.txt	193	highlight distinction num ki model characterized
0.37081465.15229191.html.plaintext.txt	194	contrast data hamanaka et al
0.37081465.15229191.html.plaintext.txt	195	showed cholesterol distributed lipoprotein class num ki mouse including vldl ldl
0.37081465.15229191.html.plaintext.txt	196	profile actually similar num ki animal presented
0.37081465.15229191.html.plaintext.txt	197	animal significantly higher cholesterol level appear transport excess circulating cholesterol vldl ldl fraction suggesting impaired cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	198	noted increase triglyceride level num ki animal also suggests development type iii hyperlipoproteinemia complex disorder characterized high cholesterol triglyceride level affect num human homozygous num allele num
0.37081465.15229191.html.plaintext.txt	199	suggested sullivan et al
0.37081465.15229191.html.plaintext.txt	200	others numnum condition manifest num ki mouse owing presence additional genetic factor mouse genome interact num allele
0.37081465.15229191.html.plaintext.txt	201	qualitative western blot analysis num num ki fplc profile demonstrated behavior enum mouse maintained low cholesterol diet follows endogenous apoe found mainly idlldl hdl fraction enum appears enriched hdl fraction
0.37081465.15229191.html.plaintext.txt	202	observation may reflect another difference mouse human cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	203	enum isoform greater affinity large lipoprotein human chylomicron vldl
0.37081465.15229191.html.plaintext.txt	204	enum enum hand prefer smaller lipoprotein primarily found associated hdl smallest lipoprotein class
0.37081465.15229191.html.plaintext.txt	205	importantly mouse plasma enriched large apoe rich hdl absent normal human plasma num
0.37081465.15229191.html.plaintext.txt	206	may enum preference particle two isoforms
0.37081465.15229191.html.plaintext.txt	207	mouse show enrichment apoe vldl observed maeda colleague
0.37081465.15229191.html.plaintext.txt	208	discrepancy data may explained difference genetic background diet
0.37081465.15229191.html.plaintext.txt	209	comparison two set apoe ki model including level protein required thoroughly explain result
0.37081465.15229191.html.plaintext.txt	210	cholesterol app processing order identify effect apoe allele app processing as production particularly regard cholesterol metabolism apoe abundance crossed apoe ki animal rnum
0.37081465.15229191.html.plaintext.txt	211	several study established link cholesterol app processing numnumnum
0.37081465.15229191.html.plaintext.txt	212	num demonstrated cholesterol influence cleavage app beta secretase vivo hypercholesterolemia increasing ctfss level
0.37081465.15229191.html.plaintext.txt	213	however neither level holo app ctfs altered apoernum
0.37081465.15229191.html.plaintext.txt	214	lack effect app processing num ki animal unexpected considering high serum cholesterol level
0.37081465.15229191.html.plaintext.txt	215	analysis assnum num level animal provided evidence serum cholesterol alone enough affect app processing young age
0.37081465.15229191.html.plaintext.txt	216	given strong evidence high cholesterol level increasing as production num predicted num ki animal num fold increase total serum cholesterol would demonstrate much higher level as num ki num ki mouse
0.37081465.15229191.html.plaintext.txt	217	however similar ctf data level assnum num brain indistinguishable across line
0.37081465.15229191.html.plaintext.txt	218	several possible explanation result
0.37081465.15229191.html.plaintext.txt	219	first data present come num day old animal age post weaning prior sexual maturity
0.37081465.15229191.html.plaintext.txt	220	possible ability cholesterol affect app processing as metabolism time age dependent
0.37081465.15229191.html.plaintext.txt	221	successful diet study chronically fed mouse high cholesterol diet several week numnum
0.37081465.15229191.html.plaintext.txt	222	chronic exposure high serum cholesterol level several week month may required affect as metabolism apoernum animal
0.37081465.15229191.html.plaintext.txt	223	assaying level assnum num older animal useful understand age component cholesterol effect apoe app processing
0.37081465.15229191.html.plaintext.txt	224	second show peripheral cholesterol metabolism affect cns cholesterol regulation
0.37081465.15229191.html.plaintext.txt	225	despite difference serum cholesterol three apoernum
0.37081465.15229191.html.plaintext.txt	226	num line described manuscript brain cholesterol level indistinguishable animal
0.37081465.15229191.html.plaintext.txt	227	finding supported large body evidence demonstrating cholesterol metabolism periphery fundamentally different independent central nervous system involving different lipoprotein apolipoproteins num num
0.37081465.15229191.html.plaintext.txt	228	argues effect peripheral cholesterol process brain
0.37081465.15229191.html.plaintext.txt	229	num animal demonstrate significantly increased brain cholesterol level rnum
0.37081465.15229191.html.plaintext.txt	230	num animal endogenous apoe brain cholesterol level enum
0.37081465.15229191.html.plaintext.txt	231	rnum animal also greater rnum
0.37081465.15229191.html.plaintext.txt	232	num although trend statistically significant
0.37081465.15229191.html.plaintext.txt	233	data correspond significant increase brain assnum num level apoernum
0.37081465.15229191.html.plaintext.txt	234	num animal suggesting brain cholesterol level particular may significant impact as production
0.37081465.15229191.html.plaintext.txt	235	notably one diet study increased brain cholesterol addition as level num
0.37081465.15229191.html.plaintext.txt	236	data argue independent role apoe peripheral cns cholesterol metabolism furthermore suggest distinction apoe endogenous apoe effect murine brain cholesterol metabolism steady state as level
0.37081465.15229191.html.plaintext.txt	237	apoe alzheimers disease manuscript highlight first report apoe mouse model utilizes endogenous regulation study native apoe level cholesterol metabolism relation alzheimers disease
0.37081465.15229191.html.plaintext.txt	238	importantly correlation apoe genotype apoe steady state level cholesterol metabolism observed human uncoupled ki mouse
0.37081465.15229191.html.plaintext.txt	239	allows u dissect two aspect apoe function may impact development ad cholesterol metabolism as clearance
0.37081465.15229191.html.plaintext.txt	240	apoe abundance brain num ki animal low animal normal serum cholesterol level
0.37081465.15229191.html.plaintext.txt	241	animal allow u study effect low apoe level absence high cholesterol often observed human inherit num allele
0.37081465.15229191.html.plaintext.txt	242	likewise num ki animal high serum cholesterol high brain apoe level
0.37081465.15229191.html.plaintext.txt	243	animal useful determine effect high cholesterol independent low apoe level
0.37081465.15229191.html.plaintext.txt	244	future experiment ass effect age diet apoernum
0.37081465.15229191.html.plaintext.txt	245	num line cholesterol metabolism particularly brain apoe abundance well as metabolism amyloid deposition
0.37081465.15229191.html.plaintext.txt	246	cholesterol triglyceride measurement serum cholesterol triglyceride measurement obtained animal fasted num h retro ortbital sinus bleed
0.37081465.15229191.html.plaintext.txt	247	measurement obtained using infinity cholesterol reagent infinity triglyceride reagent respectively thermotrace arlington tx usa according manufacturer instruction
0.37081465.15229191.html.plaintext.txt	248	brain cholesterol hemisphere extracted homogenization num m urea buffer num m urea num mm tris ph num
0.37081465.15229191.html.plaintext.txt	249	num m aebsf num sd reported levin allerhand et al
0.37081465.15229191.html.plaintext.txt	250	brain cholesterol measured using inifinity cholesterol reagent thermotrace diluting homogenate num num pb
0.37081465.15229191.html.plaintext.txt	251	brain cholesterol concentration expressed mg cholesterol relative mg protein measured bca assay pierce rockford il usa
0.37081465.15229191.html.plaintext.txt	252	fplc analysis lipoprotein profile cholesterol distribution apoe ki animal fasted serum three animal genotype sex pooled fractionation superose num column pharmacia kalamazoo mi usa previously described num
0.37081465.15229191.html.plaintext.txt	253	western blot analysis analysis apoe level tissue brain liver homogenate prepared num chap protease inhibitor num microm pepstatin num
0.37081465.15229191.html.plaintext.txt	254	num microgml leupeptin num microgml aprotinin num mm aebsf
0.37081465.15229191.html.plaintext.txt	255	brain fasted liver homogenate run num num bi tris gradient gel invitrogen carlsbad ca usa reducing condition according manufacturer instruction
0.37081465.15229191.html.plaintext.txt	256	equal concentration protein determined bca assay loaded every gel
0.37081465.15229191.html.plaintext.txt	257	linear standard curve serially diluted control num ki known concentration run every gel normalize across gel rnum
0.37081465.15229191.html.plaintext.txt	258	protein transferred immobilon p membrane millipore bedford ma usa probed anti human polyclonal apoe antibody calbiochem lajolla ca usa followed hrp conjugated secondary antibody detected using ecl pierce film
0.37081465.15229191.html.plaintext.txt	259	apoe antibody used extensively detect human apoe mouse immunohistochemistry western blotting elisa numnumnumnum
0.37081465.15229191.html.plaintext.txt	260	apoe protein level serum tissue quantitated calculating intensity sample relative standard concentration
0.37081465.15229191.html.plaintext.txt	261	imagequant software used analysis protein abundance
0.37081465.15229191.html.plaintext.txt	262	level apoe unfractionated serum determined loading equal concentration protein fasted serum sample diluted pb onto bi tris gel non reducing condition following analytical paradigm tissue
0.37081465.15229191.html.plaintext.txt	263	apoe serum fractionated fplc analyzed qualitatively combining equal volume peak fraction num volume lipoprotein class
0.37081465.15229191.html.plaintext.txt	264	apoe detected using human specific apoe antibody visualized ecl using film
0.37081465.15229191.html.plaintext.txt	265	relative level holo app determined using brain homogenate prepared num m urea mentioned earlier
0.37081465.15229191.html.plaintext.txt	266	equal concentration protein every sample loaded onto num tris acetate gel invitrogen run according manufacturer instruction
0.37081465.15229191.html.plaintext.txt	267	linear standard curve serially diluted homogenate bnum non transgenic animal run every gel normalize across gel rnum
0.37081465.15229191.html.plaintext.txt	268	protein transferred mentioned earlier membrane probed c terminal antibody human app num gift sam gandy thomas jefferson university
0.37081465.15229191.html.plaintext.txt	269	intensity app protein band determined ecl detected using fluor max imaging machine biorad hercules ca usa quantitated quantity one software biorad
0.37081465.15229191.html.plaintext.txt	270	app ctfs determined extract run num num bi tris gradient gel mentioned earlier using num antibody
0.37081465.15229191.html.plaintext.txt	271	quantitation carried film mentioned earlier
0.37081465.15229191.html.plaintext.txt	272	elisa level human apoe brain measured human specific apoe elisa mbl international according manufacturer instruction
0.37081465.15229191.html.plaintext.txt	273	homogenate made num chap mentioned earlier run duplicate detected using pan apoe antibody
0.37081465.15229191.html.plaintext.txt	274	standard curve recombinant enum enum enum run duplicate plate
0.37081465.15229191.html.plaintext.txt	275	level apoe determined using standard curve respective isoform
0.37081465.15229191.html.plaintext.txt	276	level assnum num measured human specific assnum num elisa biosource international according manufacturer instruction
0.37081465.15229191.html.plaintext.txt	277	half brain homogenized num m guanidine num mm tris ph num
0.37081465.15229191.html.plaintext.txt	278	num incubated room temperature num
0.37081465.15229191.html.plaintext.txt	279	num num h ensure complete protein extraction
0.37081465.15229191.html.plaintext.txt	280	sample diluted standardsample buffer centrifuged loaded triplicate onto elisa plate
0.37081465.15229191.html.plaintext.txt	281	statistic statistical analysis carried using prism graphpad software san diego ca usa
0.37081465.15229191.html.plaintext.txt	282	specific test used analysis indicated appropriate figure legend
0.37081465.15229191.html.plaintext.txt	283	footnote correspondence addressed department genetics case western reserve university num euclid avenue cleveland oh num num usa
0.37081465.15229191.html.plaintext.txt	284	tel num num fax num num email btlatcwru
0.37081465.15229191.html.plaintext.txt	285	num novel mechanism defective receptor binding apolipoprotein enum type iii hyperlipoproteinemia
0.37081465.15229191.html.plaintext.txt	286	num apolipoprotein e polymorphism coronary artery disease
0.37081465.15229191.html.plaintext.txt	287	arteriosclerosis num num num
0.37081465.15229191.html.plaintext.txt	288	num apolipoprotein e polymorphism predicts death coronary heart disease longitudinal study elderly finnish men
0.37081465.15229191.html.plaintext.txt	289	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.37081465.15229191.html.plaintext.txt	290	num apolipoprotein e high avidity binding beta amyloid increased frequency type num allele late onset familial alzheimer disease
0.37081465.15229191.html.plaintext.txt	291	num protective effect apolipoprotein e type num allele late onset alzheimer disease
0.37081465.15229191.html.plaintext.txt	292	num cholesterol modulates alpha secretase cleavage amyloid precursor protein
0.37081465.15229191.html.plaintext.txt	293	num role cholesterol biosynthesis beta amyloid
0.37081465.15229191.html.plaintext.txt	294	num cholesterol depletion inhibits generation beta amyloid hippocampal neuron
0.37081465.15229191.html.plaintext.txt	295	num inhibition intracellular cholesterol transport alters presenilin localization amyloid precursor protein processing neuronal cell
0.37081465.15229191.html.plaintext.txt	296	num cholesterol dependent gamma secretase activity buoyant cholesterol rich membrane microdomains
0.37081465.15229191.html.plaintext.txt	297	num hypercholesterolemia accelerates alzheimers amyloid pathology transgenic mouse model
0.37081465.15229191.html.plaintext.txt	298	num increased amyloid level appswe transgenic mouse treated chronically physiological high fat high cholesterol diet
0.37081465.15229191.html.plaintext.txt	299	num relation cholesterol level statin alzheimers disease human population
0.37081465.15229191.html.plaintext.txt	300	num pravastatin num mgday decrease plasma level either amyloid beta abeta num abeta num human
0.37081465.15229191.html.plaintext.txt	301	num plasma level amyloid beta protein differ subject taking statin taking statin
0.37081465.15229191.html.plaintext.txt	302	num mild hypercholesterolemia early risk factor development alzheimer amyloid pathology
0.37081465.15229191.html.plaintext.txt	303	num elevated low density lipoprotein alzheimers disease correlate brain abeta num num level
0.37081465.15229191.html.plaintext.txt	304	num plasma total cholesterol level risk factor alzheimer disease framingham study
0.37081465.15229191.html.plaintext.txt	305	num preferential deposition amyloid beta protein abeta form abetanum alzheimers disease associated gene dosage effect apolipoprotein e enum allele
0.37081465.15229191.html.plaintext.txt	306	num effect apolipoprotein e allele epsilonnum initial phase amyloid beta protein accumulation human brain
0.37081465.15229191.html.plaintext.txt	307	num human apolipoprotein enum accelerates beta amyloid deposition appsw transgenic mouse brain
0.37081465.15229191.html.plaintext.txt	308	num expression human apolipoprotein e reduces amyloid beta deposition mouse model alzheimers disease
0.37081465.15229191.html.plaintext.txt	309	num hyper expression human apolipoprotein enum astroglia neuron enhance amyloid deposition transgenic mouse
0.37081465.15229191.html.plaintext.txt	310	num glial fibrillary acidic protein apolipoprotein e apoe transgenic mouse astrocyte specific expression differing biological effect astrocyte secreted apoenum apoenum lipoprotein
0.37081465.15229191.html.plaintext.txt	311	num altered cholesterol metabolism human apolipoprotein enum knock mouse
0.37081465.15229191.html.plaintext.txt	312	num genetic background regulates beta amyloid precursor protein processing beta amyloid deposition mouse
0.37081465.15229191.html.plaintext.txt	313	num direct removal mouse floxed neo gene three loxp conditional knockout allele two novel approach
0.37081465.15229191.html.plaintext.txt	314	num graded reduction pafahnumbnum lisnum activity result neuronal migration defect early embryonic lethality
0.37081465.15229191.html.plaintext.txt	315	num expression cre recombinase mouse oocyte mean study maternal effect gene
0.37081465.15229191.html.plaintext.txt	316	conum numlinktypedoi crossrefisimedline
0.37081465.15229191.html.plaintext.txt	317	mouse genetics concept application
0.37081465.15229191.html.plaintext.txt	318	oxford university press new york pp
0.37081465.15229191.html.plaintext.txt	319	num role apolipoprotein e polymorphism determining normal plasma lipid lipoprotein variation
0.37081465.15229191.html.plaintext.txt	320	num apolipoprotein e beta amyloid level hippocampus frontal cortex alzheimers disease subject disease related apolipoprotein e genotype dependent
0.37081465.15229191.html.plaintext.txt	321	num association apolipoprotein e genotype brain level apolipoprotein e apolipoprotein j clusterin alzheimer disease
0.37081465.15229191.html.plaintext.txt	322	num identification apolipoprotein b num low density lipoprotein apolipoprotein b num remnant apolipoprotein e rich high density lipoprotein mouse
0.37081465.15229191.html.plaintext.txt	323	num altered metabolism familial alzheimers disease linked amyloid precursor protein variant yeast artificial chromosome transgenic mouse
0.37081465.15229191.html.plaintext.txt	324	num apolipoprotein e mrna abundant brain adrenal well liver present peripheral tissue rat marmoset
0.37081465.15229191.html.plaintext.txt	325	num apolipoprotein e synthesis human kidney adrenal gland liver
0.37081465.15229191.html.plaintext.txt	326	jr num apolipoprotein e metabolism normolipoproteinemic human subject
0.37081465.15229191.html.plaintext.txt	327	jr num abnormal vivo metabolism apolipoprotein enum human
0.37081465.15229191.html.plaintext.txt	328	num association apolipoprotein apoe genotype plasma apo e level
0.37081465.15229191.html.plaintext.txt	329	atherosclerosis num num num
0.37081465.15229191.html.plaintext.txt	330	num apolipoprotein e apoe level brain alzheimer disease patient control
0.37081465.15229191.html.plaintext.txt	331	num risk alzheimers disease correlate transcriptional activity apoe gene
0.37081465.15229191.html.plaintext.txt	332	num marked regional difference brain human apolipoprotein e expression targeted replacement mouse
0.37081465.15229191.html.plaintext.txt	333	num variation susceptibility atherosclerosis among inbred strain mouse
0.37081465.15229191.html.plaintext.txt	334	num quantitative trait locus determine lipoprotein cholesterol level dbanumj castei inbred mouse
0.37081465.15229191.html.plaintext.txt	335	num gene variation cholesterol fat intake serum lipid
0.37081465.15229191.html.plaintext.txt	336	num quantitative trait locus analysis plasma hdl cholesterol concentration atherosclerosis susceptibility inbred mouse strain cnumblnumj numsnumsvimj
0.37081465.15229191.html.plaintext.txt	337	num targeted replacement mouse apolipoprotein e gene common human apoenum allele enhances diet induced hypercholesterolemia atherosclerosis
0.37081465.15229191.html.plaintext.txt	338	num type iii hyperlipoproteinemia spontaneous atherosclerosis mouse resulting gene replacement mouse apoe human apoenum
0.37081465.15229191.html.plaintext.txt	339	num apo e structure determines vldl clearance atherosclerosis risk mouse
0.37081465.15229191.html.plaintext.txt	340	jr num pathogenesis type iii hyperlipoproteinemia dysbetalipoproteinemia
0.37081465.15229191.html.plaintext.txt	341	question quandary paradox
0.37081465.15229191.html.plaintext.txt	342	num genetic factor precipitating type iii hyperlipoproteinemia hypolipidemic transgenic mouse expressing human apolipoprotein enum
0.37081465.15229191.html.plaintext.txt	343	num amyloidogenic processing alzheimer beta amyloid precursor protein depends lipid raft
0.37081465.15229191.html.plaintext.txt	344	num low cholesterol stimulates nonamyloidogenic pathway effect alpha secretase adam num
0.37081465.15229191.html.plaintext.txt	345	num characterization four lipoprotein class human cerebrospinal fluid
0.37081465.15229191.html.plaintext.txt	346	num lipoprotein receptor central nervous system
0.37081465.15229191.html.plaintext.txt	347	characterization lipoprotein cerebrospinal fluid identification apolipoprotein beldl receptor brain
0.37081465.15229191.html.plaintext.txt	348	num apolipoproteins human cerebrospinal fluid
0.37081465.15229191.html.plaintext.txt	349	num low level extrahepatic nonmacrophage apoe inhibit atherosclerosis without correcting hypercholesterolemia apoe deficient mouse
0.37081465.15229191.html.plaintext.txt	350	article abstract free full text pdf version article numnumnum recent ddhnumvnum alert article cited alert correction posted service email article friend similar article journal similar article isi web science similar article pubmed alert new issue journal add personal archive download citation manager search citing article isi web science num request permission google scholar article mann k
0.37081465.15229191.html.plaintext.txt	351	pubmed pubmed citation article mann k
0.37081465.15229191.html.plaintext.txt	352	online issn num num print issn num num copyright num oxford university press oxford journal oxford university press site map term condition privacy policy frequently asked question oxford university press site oxford university press american national biography bookseller information service childrens fiction poetry childrens reference corporate special sale dictionary dictionary national biography digital reference english language teaching higher education textbook humanity international education unit law medicine music online product oxford english dictionary reference right permission science school book social science short introduction world classic
0.37510666.12551940.html.plaintext.txt	0	hepatocyte derived apoe effective non hepatocyte derived apoe remnant lipoprotein clearance robert l
0.37510666.12551940.html.plaintext.txt	1	hasty yuwei wang shelley e
0.37510666.12551940.html.plaintext.txt	2	linton sergio fazio karl h
0.37510666.12551940.html.plaintext.txt	3	gladstone institute cardiovascular disease neurological disease san francisco california num num cardiovascular research institute department pathology university california san francisco california num department medicine vanderbilt university nashville tennessee num
0.37510666.12551940.html.plaintext.txt	4	received publication december num num revised form january num num
0.37510666.12551940.html.plaintext.txt	5	plasma remnant lipoprotein metabolic end product intestine derived chylomicron hepatocyte derived low density lipoprotein num num
0.37510666.12551940.html.plaintext.txt	6	apolipoprotein aponum e mediates uptake remnant liver binding ldl receptor ldlr ldlr related protein lrp heparan sulfate proteoglycans hspg num num
0.37510666.12551940.html.plaintext.txt	7	inefficient clearance lead accumulation remnant plasma contributes premature atherosclerosis num num
0.37510666.12551940.html.plaintext.txt	8	liver major source plasma apoe extrahepatic tissue primarily macrophage contribute num plasma level num
0.37510666.12551940.html.plaintext.txt	9	hepatocyte derived apoe proposed promote remnant clearance uptake two step process referred secretion capture num num num
0.37510666.12551940.html.plaintext.txt	10	first step portion newly secreted apoe interacts hspg remains bound hepatocyte cell surface remainder released space disse serf enrich lipoprotein num num
0.37510666.12551940.html.plaintext.txt	11	presence apoe hepatocytes thought promote trapping sequestration remnant num num
0.37510666.12551940.html.plaintext.txt	12	support mechanism distinct dynamic pool apoe hepatocyte cell surface recently reported vitro num
0.37510666.12551940.html.plaintext.txt	13	second step sequestered remnant enriched hepatocyte derived apoe internalized hepatocytes process mediated receptor including ldlr lrp num num num interaction hspg alone num num num
0.37510666.12551940.html.plaintext.txt	14	apoehspg interaction disrupted vivo intravenous heparinase infusion remnant clearance severely inhibited supporting importance secretion capture role apoe remnant clearance num num
0.37510666.12551940.html.plaintext.txt	15	importance hepatically synthesized localized apoe thus secretion capture role apoe recently questioned num
0.37510666.12551940.html.plaintext.txt	16	moreover evidence mouse model expressing apoe exclusively extrahepatic source suggests hepatic apoe expression absolutely required remnant clearance normal plasma cholesterol level num num
0.37510666.12551940.html.plaintext.txt	17	finally clear whether hepatic apoe expression required remnant clearance mouse lacking ldlr num num num
0.37510666.12551940.html.plaintext.txt	18	previously reported num generation hypomorphic apoe hypoe mouse express reduced level arg num apoe similar human apoenum display apoenum domain interaction
0.37510666.12551940.html.plaintext.txt	19	reduction apoe level caused neomycin neo cassette flanked loxp site apoe intron num
0.37510666.12551940.html.plaintext.txt	20	however expression pattern hypomorphic allele remains normal liver producing majority apoe mouse num
0.37510666.12551940.html.plaintext.txt	21	excision neo cassette cre mediated gene repair restores normal expression allele tissue num
0.37510666.12551940.html.plaintext.txt	22	despite num num wild type plasma apoe level hypoe mouse display nearly normal lipoprotein profile
0.37510666.12551940.html.plaintext.txt	23	however apoe mouse similar plasma apoe level transplantation varying amount wild type bone marrow remnant accumulate num
0.37510666.12551940.html.plaintext.txt	24	plasma apoe level exceeded num wild type level remnant level approached normal
0.37510666.12551940.html.plaintext.txt	25	efficient remnant clearance hypoe mouse suggests importance hepatocyte derived apoe secretion capture role apoe
0.37510666.12551940.html.plaintext.txt	26	hepatocyte derived apoe mouse model generation hypoe mouse hepatocyte derived apoe model previously described num
0.37510666.12551940.html.plaintext.txt	27	briefly neo cassette flanked loxp site inserted apoe intron num gene targeting embryonic stem cell help follow replacement human equivalent thr num arginine aimed creating model apoenum num
0.37510666.12551940.html.plaintext.txt	28	presence neo cassette apoe intron num result reduced apoe mrna level tissue organ num
0.37510666.12551940.html.plaintext.txt	29	apoe mrna level liver brain spleen targeted mouse num wild type mouse resulting plasma apoe level equal num
0.37510666.12551940.html.plaintext.txt	30	num mgdl num num wild type level determined western blot analysis using mouse apoe standard liver remaining primary source apoe
0.37510666.12551940.html.plaintext.txt	31	however following cre mediated excision neo cassette targeted mouse normal expression arg num apoe allele restored
0.37510666.12551940.html.plaintext.txt	32	mouse weaned num day age housed barrier facility num h lightnum h dark cycle fed chow diet containing num
0.37510666.12551940.html.plaintext.txt	33	non hepatocyte derived apoe mouse model mouse expressing arg num apoe primarily peripheral source generated transplanting cre deleted arg num mouse bone marrow lethally irradiated apoe mouse
0.37510666.12551940.html.plaintext.txt	34	bone marrow collected flushing femur tibia rpmi num containing num fetal bovine serum num unitsml heparin sigma
0.37510666.12551940.html.plaintext.txt	35	cell washed counted resuspended rpmi used immediately transplantation lethally irradiated apoe recipient mouse
0.37510666.12551940.html.plaintext.txt	36	cell num x num volume num microl injected tail vein num h irradiation num rad cesium gamma source
0.37510666.12551940.html.plaintext.txt	37	immunohistochemistry mouse fasted num h anesthetized avertin flush perfused pb ph num
0.37510666.12551940.html.plaintext.txt	38	num num paraformaldehyde pb ph num
0.37510666.12551940.html.plaintext.txt	39	num room temperature num min
0.37510666.12551940.html.plaintext.txt	40	hardened liver lobe cut slice num num mm thick fixed overnight immersion num paraformaldehyde pb ph num
0.37510666.12551940.html.plaintext.txt	41	slice briefly washed pb ph num
0.37510666.12551940.html.plaintext.txt	42	num drained placed mold tissue tek compound sakura finetek torrance ca frozen liquid nitrogen
0.37510666.12551940.html.plaintext.txt	43	block held num degree c cut num num microm thick section leica frigocut num cryostat mounted glass slide
0.37510666.12551940.html.plaintext.txt	44	slide immunostained follows room temperature unless otherwise indicated
0.37510666.12551940.html.plaintext.txt	45	section incubated sequence rabbit polyclonal anti mouse apoe antiserum num numnum overnight num degree c biotinylated goat anti rabbit igg zymed laboratory inc
0.37510666.12551940.html.plaintext.txt	46	south san francisco ca num
0.37510666.12551940.html.plaintext.txt	47	num microgml streptavidin horseradish peroxidase conjugate tyramide signal amplification kit tsa fluorescein system nel num perkinelmer life science numnum finally fluorescein tyramide kit numnum
0.37510666.12551940.html.plaintext.txt	48	slide coverslipped application vectashield anti fade mounting medium vector h num vector laboratory burlingame ca imaged epifluorescence using nikon enum microscope equipped spot num digital camera diagnostic instrument sterling height mi
0.37510666.12551940.html.plaintext.txt	49	lipid lipoprotein determination lipid lipoprotein measured age matched male mouse fasted num h anesthetized bled retro orbital puncture
0.37510666.12551940.html.plaintext.txt	50	lipoprotein fractionated fast performance liquid chromatography fplc superose num column amersham bioscience plasma lipoprotein fraction examined agarose gel electrophoresis universal gelnum helena laboratory beaumont tx
0.37510666.12551940.html.plaintext.txt	51	cholesterol triglyceride level plasma fplc fraction determined colorimetric assay spectrum abbott irving tx triglyceride roche molecular biochemicals respectively
0.37510666.12551940.html.plaintext.txt	52	statistical significance difference lipid level determined student test
0.37510666.12551940.html.plaintext.txt	53	apoe apob quantitation fasted mouse plasma subjected sd page num num num num gel transferred nitrocellulose
0.37510666.12551940.html.plaintext.txt	54	western blotting performed rabbit antiserum mouse apoe num apob num
0.37510666.12551940.html.plaintext.txt	55	western blot incubated primary antibody numnum bound primary antibody detected horseradish peroxidase conjugated anti rabbit antibody invitrogen
0.37510666.12551940.html.plaintext.txt	56	signal generated incubating membrane chemiluminescent reagent amersham bioscience exposing x ray film kodak rochester ny
0.37510666.12551940.html.plaintext.txt	57	signal quantified phosphorimaging quantification software quantity one bio rad
0.37510666.12551940.html.plaintext.txt	58	detection apoe hepatocyte cell surface liver impact tissue source apoe remnant clearance assessed studying two mouse model expressing low level plasma apoe derived primarily liver hepatocytes primarily peripheral source
0.37510666.12551940.html.plaintext.txt	59	first examined liver associated apoe mouse model
0.37510666.12551940.html.plaintext.txt	60	like wild type mouse hepatocyte derived apoe model detectable level apoe bound hepatic sinusoidal surface although reduced level fig
0.37510666.12551940.html.plaintext.txt	61	contrast similar apoe mouse non hepatocyte derived apoe model little detectable apoe bound hepatic sinusoidal surface
0.37510666.12551940.html.plaintext.txt	62	however unlike apoe mouse non hepatocyte derived apoe model apoe immunoreactive cell liver section likely represent macrophage derived kupfer cell expressing apoe cell taken apoe circulation
0.37510666.12551940.html.plaintext.txt	63	thus enrichment apoe hepatic sinusoidal surface required local apoe expression present hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	64	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	65	localization apoe mouse liver
0.37510666.12551940.html.plaintext.txt	66	liver wild type hepatocyte derived apoe model non hepatocyte derived apoe model apoe mouse perfused saline fixed paraformadehyde prepared cryosectioning
0.37510666.12551940.html.plaintext.txt	67	apoe detected immunofluorescence viewed inverted light microscope
0.37510666.12551940.html.plaintext.txt	68	plasma apoe level hepatocyte derived non hepatocyte derived apoe model despite different level liver associated apoe hepatocyte derived non hepatocyte derived apoe model expressed similarly low level apoe plasma corresponding num num wild type apoe level hepatocyte derived apoe model num fold non hepatocyte derived apoe model fig
0.37510666.12551940.html.plaintext.txt	69	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	70	relative level apoe mouse plasma
0.37510666.12551940.html.plaintext.txt	71	plasma num microl fasted mouse resolved sd page apoe detected western blotting
0.37510666.12551940.html.plaintext.txt	72	lane num recombinant mouse apoe lane num num plasma two hepatocyte derived apoe mouse lane num num plasma two non hepatocyte derived apoe mouse
0.37510666.12551940.html.plaintext.txt	73	plasma lipid lipoprotein level hepatocyte derived non hepatocyte derived apoe model tissue source apoe resulted marked difference plasma lipid lipoprotein level
0.37510666.12551940.html.plaintext.txt	74	plasma cholesterol level non hepatocyte derived apoe model num fold higher hepatocyte derived apoe model num plus minus num versus num plus minus num mgdl n num p num
0.37510666.12551940.html.plaintext.txt	75	num plasma triglyceride level num fold higher non hepatocyte derived apoe model hepatocyte derived apoe model num plus minus num versus num plus minus num mgdl n num p num
0.37510666.12551940.html.plaintext.txt	76	fractionation mouse plasma showed marked difference lipoprotein profile fig
0.37510666.12551940.html.plaintext.txt	77	non hepatocyte derived apoe mouse transported num num plasma cholesterol remnant lipoprotein
0.37510666.12551940.html.plaintext.txt	78	contrast hepatocyte derived apoe mouse transported num num plasma cholesterol remnant lipoprotein num like wild type mouse transport majority plasma cholesterol high density lipoprotein num
0.37510666.12551940.html.plaintext.txt	79	thus non hepatocyte derived apoe model transport num num fold remnant lipoprotein associated cholesterol le high density lipoprotein cholesterol hepatocyte derived model
0.37510666.12551940.html.plaintext.txt	80	agarose gel electrophoresis mouse plasma confirmed normal lipoprotein profile hepatocyte derived apoe model accumulation remnant non hepatocyte derived model data shown
0.37510666.12551940.html.plaintext.txt	81	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	82	plasma lipoprotein profile hepatocyte derived non hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	83	plasma num microl four fasted mouse pooled fractionated fplc
0.37510666.12551940.html.plaintext.txt	84	fraction corresponding remnant high density lipoprotein distribution plasma cholesterol level indicated
0.37510666.12551940.html.plaintext.txt	85	distribution apoe among class plasma lipoprotein mouse model determined pooling plasma fplc fraction lipoprotein class followed western blotting
0.37510666.12551940.html.plaintext.txt	86	num apoe present remnant fraction mouse model demonstrates distribution pattern apoe among plasma lipoprotein class mouse model identical
0.37510666.12551940.html.plaintext.txt	87	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	88	distribution apoe various lipoprotein class hepatocyte derived non hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	89	plasma num microl four fasted mouse pooled separated lipoprotein class fplc low density lipoprotein fraction num num intermediate density lipoprotein idl fraction num num ldl fraction num num hdl fraction num num see fig
0.37510666.12551940.html.plaintext.txt	90	apoe detected sd page western blotting
0.37510666.12551940.html.plaintext.txt	91	sd page western blot analysis mouse plasma demonstrated model accumulate apobnum
0.37510666.12551940.html.plaintext.txt	92	non hepatocyte derived apoe model num fold plasma apobnum hepatocyte derived apoe model model similar level plasma apobnum lower wild type mouse fig
0.37510666.12551940.html.plaintext.txt	93	result consistent rapid removal apobnum containing remnant hepatocyte derived apoe model non hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	94	taken together result demonstrate remnant clearance effective hepatocyte derived apoe model non hepatocyte derived model due hepatically derived localized apoe
0.37510666.12551940.html.plaintext.txt	95	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	96	relative level apobnum apobnum mouse plasma
0.37510666.12551940.html.plaintext.txt	97	plasma num microl fasted mouse resolved sd page apob detected western blotting
0.37510666.12551940.html.plaintext.txt	98	lane num wild type mouse plasma lane num apoe mouse plasma lane num num plasma two hepatocyte derived apoe mouse lane num num plasma three non hepatocyte derived apoe mouse
0.37510666.12551940.html.plaintext.txt	99	uptake inum labeled remnant lipoprotein mouse importance source apoe synthesis remnant uptake assessed measuring plasma clearance liver uptake numi labeled apoe deficient mouse remnant fig
0.37510666.12551940.html.plaintext.txt	100	although hepatocyte derived apoe model non hepatocyte derived apoe model overall delay remnant clearance relative wild type mouse hepatocyte derived apoe model reached wild type level num h
0.37510666.12551940.html.plaintext.txt	101	moreover liver hepatocyte derived apoe model n num contained num plus minus num total radioactivity found wild type mouse liver whereas liver non hepatocyte derived apoe model n num contained num plus minus num num h
0.37510666.12551940.html.plaintext.txt	102	view larger version numk fig
0.37510666.12551940.html.plaintext.txt	103	clearance apoe deficient remnant mouse
0.37510666.12551940.html.plaintext.txt	104	numi labeled apoe deficient mouse remnant injected mouse via tail vein blood sample collected various time point
0.37510666.12551940.html.plaintext.txt	105	presence remnant plasma presented percentage injected dose remaining plasma
0.37510666.12551940.html.plaintext.txt	106	value represent mean plus minus
0.37510666.12551940.html.plaintext.txt	107	three mouse time point
0.37510666.12551940.html.plaintext.txt	108	b experiment performed hepatocyte derived apoe model well apoe wild type mouse
0.37510666.12551940.html.plaintext.txt	109	study present vivo evidence demonstrates site apoe synthesis significantly influence remnant clearance consequently plasma cholesterol triglyceride level mouse
0.37510666.12551940.html.plaintext.txt	110	hepatically derived localized apoe hepatocyte derived apoe model found effective macrophage derived apoe non hepatocyte derived apoe model promoting plasma clearance liver uptake apobnum containing remnant
0.37510666.12551940.html.plaintext.txt	111	moreover low level hepatically derived localized apoe hepatocyte derived apoe model influenced late initial part remnant clearance
0.37510666.12551940.html.plaintext.txt	112	hepatocyte derived apoe model express arg num apoe non hepatocyte derived apoe model generated using cre deleted arg num bone marrow allow direct comparison hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	113	mouse cre mediated excision neo cassette apoe intron num result normal apoe expression level tissue including macrophage num
0.37510666.12551940.html.plaintext.txt	114	normal lipid lipoprotein level cre deleted arg num mouse suggest arg num apoe wild type apoe equally effective remnant clearance num
0.37510666.12551940.html.plaintext.txt	115	immunohistochemical analysis liver section demonstrated hepatocyte derived apoe model contained significant level hepatically localized apoe whereas non hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	116	hepatically localized apoe hepatocyte derived apoe model likely originated mostly hepatocytes expression pattern hypomorphic apoe allele hepatocyte derived apoe model normal liver producing majority apoe mouse num
0.37510666.12551940.html.plaintext.txt	117	however exclude possibility hepatically localized apoe hepatocyte derived apoe model originated periphery
0.37510666.12551940.html.plaintext.txt	118	higher plasma lipid lipoprotein level non hepatocyte derived apoe model relative hepatocyte derived apoe model despite similarly low apoe plasma level consistent efficient clearance remnant hepatocyte derived model
0.37510666.12551940.html.plaintext.txt	119	non hepatocyte derived apoe model accumulated num fold plasma cholesterol num fold plasma triglyceride hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	120	num fold greater accumulation apobnum containing remnant non hepatocyte derived apoe model also consistent site apoe synthesis influencing remnant clearance despite model similar level plasma apoe
0.37510666.12551940.html.plaintext.txt	121	hepatocyte derived apoe model low level hepatic apoe synthesis overcome significant degree deficiency remnant clearance seen non hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	122	contrast wild type mouse similar apoe mouse model equally low level plasma apobnum
0.37510666.12551940.html.plaintext.txt	123	low level plasma apoe two model apparently failed sufficiently enrich apobnum containing remnant apoe causing become poor competitor apobnum containing ldl binding ldlr
0.37510666.12551940.html.plaintext.txt	124	alternatively reduced level apobnum model may result decreased apobnum secretion liver
0.37510666.12551940.html.plaintext.txt	125	however hepatic apoe expression reported influence production rate apobnum apobnum mouse num
0.37510666.12551940.html.plaintext.txt	126	finding level apobnum far greater non hepatocyte derived apoe model hepatocyte derived apoe model emphasizes importance hepatically derived localized apoe remnant clearance non hepatocyte derived apoe model likely secretes reduced level apobnum similar apoe mouse num
0.37510666.12551940.html.plaintext.txt	127	thus direct assessment apob secretion rate model necessary confirm possibility
0.37510666.12551940.html.plaintext.txt	128	lastly remnant clearance model may influenced recently described recycling pathway apoe liver hepatocytes num
0.37510666.12551940.html.plaintext.txt	129	however num internalized apoe reported re secreted hepatocytes pathway likely play minor role mediating remnant clearance model low level plasma apoe
0.37510666.12551940.html.plaintext.txt	130	directly comparing remnant clearance hepatocyte derived non hepatocyte derived apoe model confirmed conclusion drawn steady state plasma lipid lipoprotein level indicate hepatocyte derived apoe effective non hepatocyte derived apoe remnant clearance
0.37510666.12551940.html.plaintext.txt	131	compared wild type mouse initial phase remnant clearance similarly reduced mouse model comparable apoe null mouse
0.37510666.12551940.html.plaintext.txt	132	initial phase likely reflects binding sequestration remnant hepatocyte cell surface space disse level apoe molecule per remnant well level hepatically localized apoe hepatocyte derived apoe model appear contribute significantly process
0.37510666.12551940.html.plaintext.txt	133	moreover difference lipoprotein pool size model affect rapid initial clearance remnant
0.37510666.12551940.html.plaintext.txt	134	however near normal level remnant clearance num h hepatocyte derived apoe model suggests hepatically derived localized apoe contribute substantially slower component remnant clearance likely represents liver uptake
0.37510666.12551940.html.plaintext.txt	135	indeed liver hepatocyte derived apoe model contained num plus minus num normal numi level whereas liver non hepatocyte derived apoe model contained num plus minus num
0.37510666.12551940.html.plaintext.txt	136	hepatocyte derived apoe model apoe poor remnant sequestered hepatocytes likely become enriched newly secreted apoe space disse passive exchange existing hepatically localized apoe allowing accelerated receptor mediated internalization ldlr lrp hspg alone
0.37510666.12551940.html.plaintext.txt	137	however non hepatocyte derived apoe model large proportion sequestered apoe poor remnant likely redistribute accumulate circulation due absence apoe enrichment space disse inefficient receptor mediated uptake
0.37510666.12551940.html.plaintext.txt	138	study remnant clearance isolated mouse liver perfusion model recently questioned importance hepatic synthesis localization apoe thus importance secretion capture role apoe remnant clearance num
0.37510666.12551940.html.plaintext.txt	139	liver apoe mouse cleared infused bolus apoe containing rat chylomicron remnant efficiently wild type mouse unlike liver apoe mouse abundant level apoe localized hepatocyte cell surface num
0.37510666.12551940.html.plaintext.txt	140	recent data model suggested apoehspg interaction hepatocyte cell surface required efficient remnant uptake num
0.37510666.12551940.html.plaintext.txt	141	rather apoelrp interaction proposed mediate direct sequestration internalization remnant
0.37510666.12551940.html.plaintext.txt	142	interestingly parallel result observed mouse liver perfusion model num absence hepatically localized apoe non hepatocyte derived apoe model apoe mouse influence early phase remnant clearance relative hepatocyte derived apoe model
0.37510666.12551940.html.plaintext.txt	143	indeed three mouse model displayed similarly delayed initial rate remnant clearance relative wild type mouse
0.37510666.12551940.html.plaintext.txt	144	however shortcoming liver perfusion model result necessarily extrapolated explain steady state level remnant mouse
0.37510666.12551940.html.plaintext.txt	145	example apoe null mouse perfused liver effectively cleared infused bolus remnant whereas steady state mouse accumulate remnant plasma
0.37510666.12551940.html.plaintext.txt	146	contrast vivo model directly focus steady state level remnant mouse
0.37510666.12551940.html.plaintext.txt	147	also thank dale newland help histological analysis brian auerbach manuscript preparation gary howard stephen ordway editorial assistance jack hull john carroll graphic
0.37510666.12551940.html.plaintext.txt	148	work supported part nih grant hlnum k
0.37510666.12551940.html.plaintext.txt	149	grant numkt num university california tobacco related disease research program fellowship heart stroke foundation canada r
0.37510666.12551940.html.plaintext.txt	150	nih grant num
0.37510666.12551940.html.plaintext.txt	151	cost publication article defrayed part payment page charge
0.37510666.12551940.html.plaintext.txt	152	article must therefore hereby marked advertisement accordance num u
0.37510666.12551940.html.plaintext.txt	153	section num solely indicate fact
0.37510666.12551940.html.plaintext.txt	154	correspondence addressed gladstone inst
0.37510666.12551940.html.plaintext.txt	155	box num san francisco ca num num
0.37510666.12551940.html.plaintext.txt	156	num num num fax num num num e mail kweisgrabergladstone
0.37510666.12551940.html.plaintext.txt	157	published jbc paper press january num num doi num
0.37510666.12551940.html.plaintext.txt	158	abbreviation used apo apolipoprotein hypoe hypomorphic apoe neo neomycin fplc fast performance liquid chromatography hspg heparan sulfate proteoglycans ldl low density lipoprotein ldlr ldl receptor lrp ldlr related protein pb phosphate buffered saline
0.37510666.12551940.html.plaintext.txt	159	copyright num american society biochemistry molecular biology inc
0.38120866.16091415.html.plaintext.txt	0	sense antisense transcript apolipoprotein e gene normal apoe knockout mouse expression spinal cord injury corresponding human transcript alexander seitz dmitri gourevitch xiang ming zhang lise clark pan chen maja kragol natasha levenkova john rux stefan samulewicz ellen heber katz
0.38120866.16091415.html.plaintext.txt	1	wistar institute philadelphia pa num usa
0.38120866.16091415.html.plaintext.txt	2	correspondence addressed
0.38120866.16091415.html.plaintext.txt	3	tel num num fax num num email heberkatzatwistar
0.38120866.16091415.html.plaintext.txt	4	received june num num revised july num num accepted august num num
0.38120866.16091415.html.plaintext.txt	5	apoe also synthesized secreted tissue including cns spleen kidney adrenal gland large intestine lung numnum associated cardiovascular cns disease use different allele gene num num
0.38120866.16091415.html.plaintext.txt	6	cns num apoe allelic form identified shown associated alzheimers disease num
0.38120866.16091415.html.plaintext.txt	7	apoe thought important normal functioning neural tissue response injury although exact mechanism clear
0.38120866.16091415.html.plaintext.txt	8	shown synthesized secreted astrocyte numnum monocyte numnum
0.38120866.16091415.html.plaintext.txt	9	finding apoe neuron brain num explained presence apoe receptor reflect uptake molecule num
0.38120866.16091415.html.plaintext.txt	10	using spinal cord injury model num previously showed apoe mrna protein level upregulated spinal cord injury mouse num
0.38120866.16091415.html.plaintext.txt	11	effect knocking apoe gene studied mouse num
0.38120866.16091415.html.plaintext.txt	12	creation knockout involved insertion neomycin resistance gene homologous recombination place exon num part intron num apoe gene
0.38120866.16091415.html.plaintext.txt	13	mouse heterozygous knockout gene reported healthy num month age produce homozygous knockout expected frequency
0.38120866.16091415.html.plaintext.txt	14	homozygous knockout progeny appear healthy despite absence apoe plasma
0.38120866.16091415.html.plaintext.txt	15	present study show evidence two additional mouse sense transcript generated apoe gene could transmembrane protein antisense transcript open reading frame exon num conserved mouse human
0.38120866.16091415.html.plaintext.txt	16	antisense protein fall within region epsilon num allele linked familial onset form alzheimers disease numnum
0.38120866.16091415.html.plaintext.txt	17	also demonstrate expression one sense antisense apoe transcript apoe knockout mouse
0.38120866.16091415.html.plaintext.txt	18	furthermore show transcript upregulated bnum mouse spinal cord injury follow upregulation apoe
0.38120866.16091415.html.plaintext.txt	19	finally find one additional sense transcript antisense transcript corresponding rna exist human
0.38120866.16091415.html.plaintext.txt	20	genenumest blast server num used align est mouse human rat genomic sequence corresponding apoe gene
0.38120866.16091415.html.plaintext.txt	21	num mapping visualized artemis num
0.38120866.16091415.html.plaintext.txt	22	search well rt pcr sequencing effort uncovered several new transcript relative original known transcript
0.38120866.16091415.html.plaintext.txt	23	current model mouse apoe gene including sense antisense transcript well primer rna probe location used subsequent experiment represented figure num
0.38120866.16091415.html.plaintext.txt	24	positional information made reference genomic sequence apoe dnum corrected two deletion discussed subsequently
0.38120866.16091415.html.plaintext.txt	25	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	26	representation apoe gene mouse accession
0.38120866.16091415.html.plaintext.txt	27	num two correction made deletion c position num tg c ctc c num tgg c ccc
0.38120866.16091415.html.plaintext.txt	28	known transcript named apoe snum
0.38120866.16091415.html.plaintext.txt	29	start stop site translation indicated black line bar predicted transmembrane region shown solid black rectangle
0.38120866.16091415.html.plaintext.txt	30	apoe snum snum use frame apoe snum us different frame
0.38120866.16091415.html.plaintext.txt	31	apoe asnum translates protein antisense direction gene
0.38120866.16091415.html.plaintext.txt	32	primer shown num location
0.38120866.16091415.html.plaintext.txt	33	also shown location neo insert apoe knockout mouse cnumblnumj apoetmnumunc jackson num
0.38120866.16091415.html.plaintext.txt	34	b representation human apoe gene accession
0.38120866.16091415.html.plaintext.txt	35	apoe snum corresponds mouse transcript however protein translated identical apoe snum
0.38120866.16091415.html.plaintext.txt	36	antisense trancript highly conserved human mouse
0.38120866.16091415.html.plaintext.txt	37	two alternative stop codon shown asnum molecule one num open one allelic variation table num
0.38120866.16091415.html.plaintext.txt	38	apoe snum est accession no ainum bfnum ainum aanum lack exon num translation start site atg num base upstream apoe snum exon num
0.38120866.16091415.html.plaintext.txt	39	thereafter amino acid sequence identical apoe snum
0.38120866.16091415.html.plaintext.txt	40	starting transcription manner upstream exon num transforms secretory signal peptide transmembrane helix
0.38120866.16091415.html.plaintext.txt	41	thus apoe snum could encode num amino acid protein molecular weight num
0.38120866.16091415.html.plaintext.txt	42	num kda transmembrane helix amino acid num num sosui num
0.38120866.16091415.html.plaintext.txt	43	blastp similarity search apoe snum ncbis non redundant protein sequence database nr return hit
0.38120866.16091415.html.plaintext.txt	44	third transcript apoe snum est accession no aanum ainum code transmembrane protein well
0.38120866.16091415.html.plaintext.txt	45	using published sequence mouse gene dnum
0.38120866.16091415.html.plaintext.txt	46	num predicted translational start atg num base apoe snum exon num using reading frame apoe snum within exon num
0.38120866.16091415.html.plaintext.txt	47	however sequencing could account two base published sequence dnum
0.38120866.16091415.html.plaintext.txt	48	num c position num ttg c ctc c num tgg c ccc
0.38120866.16091415.html.plaintext.txt	49	confirmed genomic mrna level
0.38120866.16091415.html.plaintext.txt	50	corrected sequence apoe snum still predicts open reading frame however resulting amino acid sequence entirely different apoe snum even shared part exon num apoe snum using different reading frame
0.38120866.16091415.html.plaintext.txt	51	apoe snum translated num amino acid long molecular weight num
0.38120866.16091415.html.plaintext.txt	52	num kda predicted transmembrane helix sosui num amino acid num num
0.38120866.16091415.html.plaintext.txt	53	antisense transcript apoe asnum complimentary apoe snum fig
0.38120866.16091415.html.plaintext.txt	54	translational start site near stop codon apoe snum frame open throughout exon num polya signal num
0.38120866.16091415.html.plaintext.txt	55	encodes num amino acid long soluble protein molecular weight num
0.38120866.16091415.html.plaintext.txt	56	conserved domain database search return hit num
0.38120866.16091415.html.plaintext.txt	57	ncbi blastp protein search uncovered low level similarity protein last num amino acid class helical cytokine receptor member num tetraodon nigroviridis accession
0.38120866.16091415.html.plaintext.txt	58	num highest score num
0.38120866.16091415.html.plaintext.txt	59	used neural network promoter prediction software num predict promoter transcriptional start site apoe snum apoe snum apoe asnum
0.38120866.16091415.html.plaintext.txt	60	appropriate target found
0.38120866.16091415.html.plaintext.txt	61	program however predict correct promoter transcriptional start apoe snum
0.38120866.16091415.html.plaintext.txt	62	expression new apoe derived transcript mouse expression predicted form apoe initially tested rt pcr
0.38120866.16091415.html.plaintext.txt	63	reverse transcription reaction rna variety tissue primed oligo dt amplified transcript specific pair pcr primer fig
0.38120866.16091415.html.plaintext.txt	64	although approach could differentiate sense antisense transcript illustrate tissue specific expression pattern different apoe transcript
0.38120866.16091415.html.plaintext.txt	65	apoe snum present tissue tested
0.38120866.16091415.html.plaintext.txt	66	apoe snum expressed almost exclusively liver marginal level expression cerebellum parotis kidney lung thymus
0.38120866.16091415.html.plaintext.txt	67	apoe snum antisense apoe asnum found liver thymus lower level lung parotis heart small intestine
0.38120866.16091415.html.plaintext.txt	68	marginal level appear skeletal muscle cerebellum brainstem
0.38120866.16091415.html.plaintext.txt	69	rest organ brain ear spleen adrenal gland bone marrow fat negative
0.38120866.16091415.html.plaintext.txt	70	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	71	rt pcr showing expression level different transcript variety tissue
0.38120866.16091415.html.plaintext.txt	72	primer used apoe snum numf numr apoe snum numf numr apoe snumasnum numf numr gapdh numf numr
0.38120866.16091415.html.plaintext.txt	73	control sample omitted enzyme rt reaction included primer pair negative data shown
0.38120866.16091415.html.plaintext.txt	74	b c directional specific rt pcr demonstrating presence sense apoe snum antisense transcript apoe asnum liver
0.38120866.16091415.html.plaintext.txt	75	b apoe snum rt primer used numr pcr numf numr
0.38120866.16091415.html.plaintext.txt	76	c apoe asnum rt primer used numf pcr numf numr lane num num numf numr lane num num numf numr lane num num
0.38120866.16091415.html.plaintext.txt	77	lane num num rt lane num num rt
0.38120866.16091415.html.plaintext.txt	78	product gel purified sequence verified
0.38120866.16091415.html.plaintext.txt	79	distinguish apoe snumasnum rt pcr performed liver rna using rt subsequent pcr primer specifically amplify apoe snum apoe asnum fig
0.38120866.16091415.html.plaintext.txt	80	presence apoe snum apoe snum apoe snum apoe asnum also confirmed northern analysis fig
0.38120866.16091415.html.plaintext.txt	81	probe designed hybridize specific target
0.38120866.16091415.html.plaintext.txt	82	addition binding sense probe
0.38120866.16091415.html.plaintext.txt	83	num apoe asnum also hybridized sense probe
0.38120866.16091415.html.plaintext.txt	84	num cnumblnum liver data shown confirming antisense transcript least extends start stop codon
0.38120866.16091415.html.plaintext.txt	85	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	86	northern blot analysis demonstrating expression apoe transcript normal knockout mouse using nump labeled rna probe specific message
0.38120866.16091415.html.plaintext.txt	87	probe location see figure num
0.38120866.16091415.html.plaintext.txt	88	apoe snum antisense probe
0.38120866.16091415.html.plaintext.txt	89	num b apoe snum antisense probe
0.38120866.16091415.html.plaintext.txt	90	num show signal arrow normal signal knockout
0.38120866.16091415.html.plaintext.txt	91	c apoe snum antisense probe
0.38120866.16091415.html.plaintext.txt	92	num d apoe asnum sense probe
0.38120866.16091415.html.plaintext.txt	93	num found liver mouse strain however much lower level knockout
0.38120866.16091415.html.plaintext.txt	94	expression new apoe derived transcript apoe knockout mouse apoe knockout mouse important tool determining role apoe variety system
0.38120866.16091415.html.plaintext.txt	95	therefore wanted investigate effect knocking gene expression apoe transcript
0.38120866.16091415.html.plaintext.txt	96	knockout mouse used study apoe gene disrupted upstream exon num fig
0.38120866.16091415.html.plaintext.txt	97	employed oligo dt primed rt pcr transcript specific pcr primer investigate whether apoe transcript could detected apoe knockout mouse
0.38120866.16091415.html.plaintext.txt	98	apoe snumasnum could amplified method fig
0.38120866.16091415.html.plaintext.txt	99	furthermore expression profile differed wild type apoe snumasnum could amplified normal brain spleen fig
0.38120866.16091415.html.plaintext.txt	100	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	101	rt pcr apoe knockout tissue
0.38120866.16091415.html.plaintext.txt	102	rt primed oligo dt primer used figure num
0.38120866.16091415.html.plaintext.txt	103	product seen row num demonstrates existence sense apoe snum andor antisense apoe asnum transcript apoe knockout mouse cnumblnumj apoetmnumunc jackson
0.38120866.16091415.html.plaintext.txt	104	control used sample omitted enzyme rt reaction included primer pair negative data shown
0.38120866.16091415.html.plaintext.txt	105	b demonstration specific sense antisense transcript liver
0.38120866.16091415.html.plaintext.txt	106	snum lane num num rt carried using primer numr
0.38120866.16091415.html.plaintext.txt	107	asnum lane num num rt carried using primer numf
0.38120866.16091415.html.plaintext.txt	108	rt reaction pcr amplified using primer numf numr
0.38120866.16091415.html.plaintext.txt	109	control reaction performed absence rt
0.38120866.16091415.html.plaintext.txt	110	use specific rt pcr primer revealed apoe snum apoe asnum expressed liver knockout fig
0.38120866.16091415.html.plaintext.txt	111	northern blot analysis also demonstrates presence apoe asnum knockout mouse
0.38120866.16091415.html.plaintext.txt	112	although knockout seems affect transcription level apoe snum almost detection limit technique fig
0.38120866.16091415.html.plaintext.txt	113	numd present knockout wild type mouse
0.38120866.16091415.html.plaintext.txt	114	functional expression new apoe transcript follow previous study showing apoe expression following spinal cord injury cnumblnum mouse num examined expression various transcript apoe gene spinal cord injury
0.38120866.16091415.html.plaintext.txt	115	apoe snum could demonstrated brain marginal level cerebellum fig
0.38120866.16091415.html.plaintext.txt	116	using rt pcr apoe snum also could detected uninjured injured spinal cord data shown
0.38120866.16091415.html.plaintext.txt	117	however northern blot analysis show expression two newly identified product gene apoe snum apoe asnum within week injury fig
0.38120866.16091415.html.plaintext.txt	118	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	119	expression profile apoe transcript spinal cord injury
0.38120866.16091415.html.plaintext.txt	120	upper panel showing northern blot analysis
0.38120866.16091415.html.plaintext.txt	121	apoe snum antisense probe
0.38120866.16091415.html.plaintext.txt	122	num b apoe asnum sense probe
0.38120866.16091415.html.plaintext.txt	123	num upregulation spinal cord injury
0.38120866.16091415.html.plaintext.txt	124	animal injured transection thnum num followed num num num day
0.38120866.16091415.html.plaintext.txt	125	lower box showing level gapdh
0.38120866.16091415.html.plaintext.txt	126	c f real time rt pcr showing expression level different transcript spinal cord injury
0.38120866.16091415.html.plaintext.txt	127	rt designed exclusively amplify transcript shown
0.38120866.16091415.html.plaintext.txt	128	c d rt primed numr
0.38120866.16091415.html.plaintext.txt	129	pcr shown c carried primer pair numf numr show level apoe snum d numf numr apoe snum
0.38120866.16091415.html.plaintext.txt	130	e rt primed numf amplified numf numr demonstrating level expression apoe asnum
0.38120866.16091415.html.plaintext.txt	131	normalize included gene specific primer gapdh numr rt reaction background correction level obtained amplifying gapdh numf numr
0.38120866.16091415.html.plaintext.txt	132	f exclude level seen due different level genomic background included experiment sample lacked enzyme rt reaction amplifying genomic apoe gapdh
0.38120866.16091415.html.plaintext.txt	133	real time rt pcr rna extracted injured cnumblnum mouse actually reveals increase expression specie early num day post injury maximal expression around num week fig
0.38120866.16091415.html.plaintext.txt	134	highest level apoe snum apoe snum num fold upregulated compared normal level
0.38120866.16091415.html.plaintext.txt	135	contrast apoe asnum num fold upregulated
0.38120866.16091415.html.plaintext.txt	136	detection apoe snum protein western blot analysis apoe snum protein includes apoe snum protein sequence antibody apoe snum also bind apoe snum
0.38120866.16091415.html.plaintext.txt	137	therefore western blot exposed apoe antiserum
0.38120866.16091415.html.plaintext.txt	138	addition num kda band depicting apoe snum mouse liver serum fig
0.38120866.16091415.html.plaintext.txt	139	numa b mouse serum antibody bound protein num kda arrow fig
0.38120866.16091415.html.plaintext.txt	140	numb size predicted apoe snum
0.38120866.16091415.html.plaintext.txt	141	apoe snum protein present apoe knockout specificity demonstrated including knockout sample negative control blot
0.38120866.16091415.html.plaintext.txt	142	binding num num kda protein absent apoe knockout mouse demonstrating specificity
0.38120866.16091415.html.plaintext.txt	143	even though apoe snum protein could detected liver western blot analysis likely secreted liver apoe snum message almost exclusively expressed liver organ investigated
0.38120866.16091415.html.plaintext.txt	144	one however rule another organ represented figure num source protein
0.38120866.16091415.html.plaintext.txt	145	possible protein level liver detection limit western blot analysis though protein secreted blood accumulates detected
0.38120866.16091415.html.plaintext.txt	146	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	147	western blot demonstrating apoe snum protein liver b serum lower band apoe snum protein upper bandarrow b serum
0.38120866.16091415.html.plaintext.txt	148	knockout sample included negative control
0.38120866.16091415.html.plaintext.txt	149	transcript human gene finally investigate whether corresponding transcript mouse apoe snum snum asnum transcript also present human rt pcr analysis carried human liver rna
0.38120866.16091415.html.plaintext.txt	150	resulting model human gene transcription product shown figure numb
0.38120866.16091415.html.plaintext.txt	151	human apoe snum could amplified rt primed oligo numr subsequent pcr primed either numf numr lane num fig
0.38120866.16091415.html.plaintext.txt	152	human apoe snum sequence also backed est accession
0.38120866.16091415.html.plaintext.txt	153	contrast mouse human protein translated apoe snum apoe snum
0.38120866.16091415.html.plaintext.txt	154	view larger version numk figure num
0.38120866.16091415.html.plaintext.txt	155	rt pcr human liver sample
0.38120866.16091415.html.plaintext.txt	156	apoe snum expression rt primed numr pcr numf numr lane num num numf numr lane num num
0.38120866.16091415.html.plaintext.txt	157	b apoe asnum expression rt primed numf pcr numf numr
0.38120866.16091415.html.plaintext.txt	158	lower band lane num asnum upper band apoe gene transcript
0.38120866.16091415.html.plaintext.txt	159	product gel purified sequence verified
0.38120866.16091415.html.plaintext.txt	160	human sequence corresponding apoe snum could amplified
0.38120866.16091415.html.plaintext.txt	161	rt using numr subsequent pcr primer combination numf numr numf numr numf numr yield product transcribed apoe gene
0.38120866.16091415.html.plaintext.txt	162	presence human apoe asnum demonstrated rt primed numf followed pcr primer numf numr lane num fig
0.38120866.16091415.html.plaintext.txt	163	two product amplified reaction sequencing lower band confirmed originating apoe asnum message
0.38120866.16091415.html.plaintext.txt	164	upper band product apoe gene
0.38120866.16091415.html.plaintext.txt	165	translated human mouse protein highly conserved
0.38120866.16091415.html.plaintext.txt	166	one set apoe transcript identified code putative transmembrane protein one frame shifted antisense rna
0.38120866.16091415.html.plaintext.txt	167	sense antisense message sequence recognized translation start site therefore could exist protein
0.38120866.16091415.html.plaintext.txt	168	example demonstrating expression antisense message shown variety gene reviewed num num including urocortin num cardiac troponin num basic fibroblast growth factor bfgf num
0.38120866.16091415.html.plaintext.txt	169	scenario describe apoe closely resembles bfgf expression
0.38120866.16091415.html.plaintext.txt	170	bfgf gene locus known transcribed multiple mrna product including least one antisense transcript
0.38120866.16091415.html.plaintext.txt	171	antisense transcript may involved regulating gene expression hybridizing sense transcript still nucleus perhaps affecting developmental pattern tissue differentiation num
0.38120866.16091415.html.plaintext.txt	172	bfgf transcript isolated xenopus could also however translated num kda protein yet unknown function num
0.38120866.16091415.html.plaintext.txt	173	point unclear whether newly identified apoe transcript including antisense transcript fact translated except apoe snum protein found serum
0.38120866.16091415.html.plaintext.txt	174	beyond translated protein transcript could participate regulating others level process like rnai
0.38120866.16091415.html.plaintext.txt	175	marking yet another similarity bfgf antisense transcript present human mouse num
0.38120866.16091415.html.plaintext.txt	176	apoe antisense transcript say reading frame also open human consequently possibility antisense message actually translated protein
0.38120866.16091415.html.plaintext.txt	177	protein predicted sequence mnum num amino acid signal peptide predicted signalp num
0.38120866.16091415.html.plaintext.txt	178	num hmm program num probability num
0.38120866.16091415.html.plaintext.txt	179	contrast mouse asnum protein program predicts signal peptide probability num
0.38120866.16091415.html.plaintext.txt	180	even deleting first num amino acid mouse protein human protein lack increase probability num
0.38120866.16091415.html.plaintext.txt	181	therefore even though human sequence probably enters secretory pathway mouse sequence seems lack signal peptide
0.38120866.16091415.html.plaintext.txt	182	num hmm focusing prediction classical signal peptide one exclude presence signal motif mouse protein
0.38120866.16091415.html.plaintext.txt	183	apoe antisense protein encoded exon num exon account three major allelic variant human
0.38120866.16091415.html.plaintext.txt	184	allelic variation sense protein defined substitution arginine positively charged polar amino acid cysteine non polar amino acid position num num protein numnum
0.38120866.16091415.html.plaintext.txt	185	putative antisense protein arginine substituted histidine positively charged polar amino acid
0.38120866.16091415.html.plaintext.txt	186	therefore two variant probably affecting function antisense protein le sense protein therefore conservative antisense direction
0.38120866.16091415.html.plaintext.txt	187	however study allelic variation implication disease always conducted reference sense protein prominent variation table num might lead functional relevant change
0.38120866.16091415.html.plaintext.txt	188	one dramatic change variation position num num sequence position reference mnum
0.38120866.16091415.html.plaintext.txt	189	substitution tag gct antisense strand open reading frame translation continue another num amino acid
0.38120866.16091415.html.plaintext.txt	190	enum allele published paik et al
0.38120866.16091415.html.plaintext.txt	191	num contains stop codon position num num
0.38120866.16091415.html.plaintext.txt	192	however point clear allelic variation open reading frame linked major allelic form like enum enum enum genotype observed haplotype see table num num relative frequency apoe sequence variant within enum enum enum genotype see table num num
0.38120866.16091415.html.plaintext.txt	193	therefore involvement putative antisense protein disease correlated allelic variant excluded
0.38120866.16091415.html.plaintext.txt	194	example alzheimers disease specific molecular pathway apoe modifies expression disease remains elusive num
0.38120866.16091415.html.plaintext.txt	195	furthermore sequence variation different allele num conservative sense direction might lead amino acid substitution even stop signal antisense direction
0.38120866.16091415.html.plaintext.txt	196	sequence variation human apoe gene accession
0.38120866.16091415.html.plaintext.txt	197	mnum relation apoe snum asnum protein intron num exon num even though sequence work thus far suggests human apoe snum translated protein apoe snum allelic variation might cause open reading frame similar one seen cnumblnum mouse leading presence transmembrane version apoe
0.38120866.16091415.html.plaintext.txt	198	knockout organism created investigate phenotypic change may take place organism absence gene
0.38120866.16091415.html.plaintext.txt	199	data suggest genetic manipulation used generate apoe knockout eliminated expression apoe snum apoe snum transcript
0.38120866.16091415.html.plaintext.txt	200	found apoe snum putative transmembrane protein sequence completely different known apoe protein apoe asnum protein potentially produced antisense transcript still expressed knockout
0.38120866.16091415.html.plaintext.txt	201	possible region gene responsible transcript particular exon num disrupted insertion neo gene knockout
0.38120866.16091415.html.plaintext.txt	202	role transcript currently unknown
0.38120866.16091415.html.plaintext.txt	203	addition work must done determine whether translated vivo
0.38120866.16091415.html.plaintext.txt	204	indication potentially important role apoe snum apoe asnum antisense message cns disease come data mouse spinal cord injury model numnum
0.38120866.16091415.html.plaintext.txt	205	response spinal injury transcript upregulated follow expression pattern apoe snum
0.38120866.16091415.html.plaintext.txt	206	however apoe asnum num fold upregulated either apoe snum snum might also involved influencing translation
0.38120866.16091415.html.plaintext.txt	207	would useful know either alternate mrna translated response spinal injury
0.38120866.16091415.html.plaintext.txt	208	apoe lipoprotein class protein responsible carrying cholesterol fat bloodstream little package essential normal breakdown molecule
0.38120866.16091415.html.plaintext.txt	209	particular apoe major component specific lipoprotein called low density lipoprotein vldl
0.38120866.16091415.html.plaintext.txt	210	major function vldl remove excess cholesterol blood carry liver processing
0.38120866.16091415.html.plaintext.txt	211	maintaining normal level cholesterol essential prevention cardiovascular disease including heart attack stroke
0.38120866.16091415.html.plaintext.txt	212	least three slightly different version apoe gene
0.38120866.16091415.html.plaintext.txt	213	major version allele called num num num
0.38120866.16091415.html.plaintext.txt	214	common allele num found half population
0.38120866.16091415.html.plaintext.txt	215	researcher found people familial hypercholesterolemia condition cause high level cholesterol increased risk heart attack stroke two copy num allele
0.38120866.16091415.html.plaintext.txt	216	allele seems one several genetic factor play part disorder
0.38120866.16091415.html.plaintext.txt	217	addition apoe allelic version num risk factor coronary artery disease
0.38120866.16091415.html.plaintext.txt	218	people inherit least one copy apoe num allele increased risk developing type num alzheimers disease first appears later life
0.38120866.16091415.html.plaintext.txt	219	study shown people inherit two copy apoe num highest chance developing disease
0.38120866.16091415.html.plaintext.txt	220	yet known allele affect person risk alzheimers disease however found increase number amyloid plaque characteristic disease numnum
0.38120866.16091415.html.plaintext.txt	221	finally est evidence apoe alternative splice variant human exist num
0.38120866.16091415.html.plaintext.txt	222	one est corresponds last exon different apoe snum snum
0.38120866.16091415.html.plaintext.txt	223	validated rt pcr showed expressed lung cancer strongly normal tissue
0.38120866.16091415.html.plaintext.txt	224	conclusion apoe protein may play vital role occurrence diverse group malady
0.38120866.16091415.html.plaintext.txt	225	appears apoe gene characterized complex expression pattern multiple start site sense antisense direction
0.38120866.16091415.html.plaintext.txt	226	open reading frame transcript may translated protein
0.38120866.16091415.html.plaintext.txt	227	work must done determine whether antisense transcript involved regulating expression post transcriptionally translated novel protein
0.38120866.16091415.html.plaintext.txt	228	addition given significance exon num various allelic version apoe knockout exon may give insight role
0.38120866.16091415.html.plaintext.txt	229	primer mouse apoe genbank accession
0.38120866.16091415.html.plaintext.txt	230	num mouse gapdh mnum human apoe mnum rt pcr human human liver rna obtained stratagene catalog
0.38120866.16091415.html.plaintext.txt	231	enzymatic reaction carried described earlier
0.38120866.16091415.html.plaintext.txt	232	apoe snum rt carried primer numr pcr primer numf numr numf numr
0.38120866.16091415.html.plaintext.txt	233	apoe asnum rt carried primer numf pcr primer numf numr fig
0.38120866.16091415.html.plaintext.txt	234	gene sense antisense specific reverse transcription mouse rna extracted either exsanguinated liver spinal cord trizol treated dnase re extracted phenolchloroform precipitated alcohol
0.38120866.16091415.html.plaintext.txt	235	sample time point pooled equally according odnum reverse transcription carried num
0.38120866.16091415.html.plaintext.txt	236	num microg time point num microl reaction described earlier exception gene specific primer used
0.38120866.16091415.html.plaintext.txt	237	selectively amplify apoe exon num sense strand used primer numr numr gapdh control ii antisense used primer numf numr gapdh control
0.38120866.16091415.html.plaintext.txt	238	control reaction omitted reverse transcriptase
0.38120866.16091415.html.plaintext.txt	239	reverse transcription carried num degree c num h
0.38120866.16091415.html.plaintext.txt	240	sample brought num microl hnumo passed though chroma spin num size exclusion column clontech exclude unused primer re extracted phenolchloroform precipitated alcohol
0.38120866.16091415.html.plaintext.txt	241	real time rt pcr mouse real time rt pcr mouse num carried lightcycler roche num determine amount apoe snum rt primed numr pcr primer numf numr antisense exon num rt primed numf pcr primer numf numr well apoe snum rt primed numr pcr primer numf numr
0.38120866.16091415.html.plaintext.txt	242	reaction set using faststart dna master sybr green kit roche according instruction num microl cocktail magnesium concentration num mm
0.38120866.16091415.html.plaintext.txt	243	period num min num degree c used denature inactivate taq start antibody
0.38120866.16091415.html.plaintext.txt	244	cycling carried num time using num degree c num num degree c num num degree c num acquisition temperature set num degree c num
0.38120866.16091415.html.plaintext.txt	245	level quantified basis fluorescence intercalated syber green dye dsdna cycle
0.38120866.16091415.html.plaintext.txt	246	quality control includes exponential curve melting product analysis ensure amplification one template well size analysis gel electrophoresis
0.38120866.16091415.html.plaintext.txt	247	northern hybridization mouse total rna extracted trizol treated dnase num microg run denaturing num
0.38120866.16091415.html.plaintext.txt	248	num polyacrylamide urea num m gel numxtbe buffer
0.38120866.16091415.html.plaintext.txt	249	electroblotting done onto hydrobond n amersham pharmacia num
0.38120866.16091415.html.plaintext.txt	250	rna checked uv light integrity evenness transfer
0.38120866.16091415.html.plaintext.txt	251	rna immobilized onto membrane backing vacuum num degree c num min
0.38120866.16091415.html.plaintext.txt	252	sense antisense specific rna probe synthesized tnum tnum polymerase using epicintres riboscribe kit
0.38120866.16091415.html.plaintext.txt	253	gel purified pcr product generated gene specific primer table num included either tnum tnum promoter served template generating probe
0.38120866.16091415.html.plaintext.txt	254	location probe indicated figure num
0.38120866.16091415.html.plaintext.txt	255	tnum tnum reaction num microlnum microg template atp gtp ctp num
0.38120866.16091415.html.plaintext.txt	256	num mm num microm utp num mm dtt num microci microl numputp polymerase num
0.38120866.16091415.html.plaintext.txt	257	num u microl carried num degree c num h followed num min dnase treatment num degree c
0.38120866.16091415.html.plaintext.txt	258	probe purified chroma spin num size exclusion column clontech aliquot run num agarose checking size labeling
0.38120866.16091415.html.plaintext.txt	259	hybridization carried ultrahyb ambion hybridization buffer overnight num degree c num h blocking rotating chamber
0.38120866.16091415.html.plaintext.txt	260	membrane washed numxnum min num degree c numxssc num
0.38120866.16091415.html.plaintext.txt	261	num sd followed numxnum min num degree c num
0.38120866.16091415.html.plaintext.txt	262	signal collected phosphor screen scanned storm scanner molecular dynamic
0.38120866.16091415.html.plaintext.txt	263	primer rt pcr primer designed using software primer numwww
0.38120866.16091415.html.plaintext.txt	264	num num applied apoe genomic sequence genbank accession
0.38120866.16091415.html.plaintext.txt	265	specificity determined size sequence verification product
0.38120866.16091415.html.plaintext.txt	266	location primer pair seen figure num
0.38120866.16091415.html.plaintext.txt	267	primer sequence shown table num
0.38120866.16091415.html.plaintext.txt	268	used amplify template vitro transcription rna probe tnum num taatacgactcactataggg num tnum num aattaaccctcactaaaggg num promoter added
0.38120866.16091415.html.plaintext.txt	269	primer synthesized desalted integrated dna technology coralville ia usa
0.38120866.16091415.html.plaintext.txt	270	spinal cord injury experiment female cnumblnum mouse jackson laboratory used age num num week
0.38120866.16091415.html.plaintext.txt	271	animal injured using previously described surgical model complete spinal cord transection including meninges cut dura model numnum
0.38120866.16091415.html.plaintext.txt	272	short animal anesthetized ketamine xylazine num num mgkg
0.38120866.16091415.html.plaintext.txt	273	skin surgically scrubbed chlorohexadine hair surgical field removed
0.38120866.16091415.html.plaintext.txt	274	complete transection cord carried level thnum num using microscalpel num mm blade depth num degree catalog
0.38120866.16091415.html.plaintext.txt	275	num num roboz surgical instrument
0.38120866.16091415.html.plaintext.txt	276	two sham two unoperated control three animal per time point used real time rt pcr analysis injury site thnum num
0.38120866.16091415.html.plaintext.txt	277	northern analysis num microg dnase treated trizol extracted total rna one animal per time point used
0.38120866.16091415.html.plaintext.txt	278	dissected spinal cord tissue stored num degree c use
0.38120866.16091415.html.plaintext.txt	279	western blot mouse liver serum sample collected cnumblnum apoe ko mouse jackson laboratory age num num month
0.38120866.16091415.html.plaintext.txt	280	serum blood collected tail vein left coagulate num h num degree c separation
0.38120866.16091415.html.plaintext.txt	281	liver collected wet ice homogenized glass homogenizer mixed lysis buffer containing proteinase inhibitor cocktail completetm boehringer mannheim numxpbs num
0.38120866.16091415.html.plaintext.txt	282	total protein concentration serum liver sample determined using standard lowry protein assay procedure dc protein assay kit biorad laboratory catalog
0.38120866.16091415.html.plaintext.txt	283	num num equilibrated total protein concentration num mgml
0.38120866.16091415.html.plaintext.txt	284	protein sample mixed numxsds gel loading buffer boiled num min loaded onto num sd page liver sample num num microg per well lane loaded onto num gel serum sample num num microgwell
0.38120866.16091415.html.plaintext.txt	285	gel electroblotted immobilon p millipore num mm tris oh num mm glycine num methanol num v num ma overnight
0.38120866.16091415.html.plaintext.txt	286	blot blocked pb tween num num
0.38120866.16091415.html.plaintext.txt	287	detect apoe snum apoe snum blot incubated goat anti apoe antibody numnum sc num santa cruz biotechnology overnight num degree c
0.38120866.16091415.html.plaintext.txt	288	secondary antibody hrp labeled mouse monoclonal anti goatsheep antibody used sigma num num h rt following concentration liver numnum serum numnum
0.38120866.16091415.html.plaintext.txt	289	blot developed using chemiluminescence kit boehringer mannheim
0.38120866.16091415.html.plaintext.txt	290	chemiluminescent signal scanned digitalized
0.38120866.16091415.html.plaintext.txt	291	num three dimensional structure ldl receptor binding domain human apolipoprotein e
0.38120866.16091415.html.plaintext.txt	292	num human apolipoprotein enum aqueous solution
0.38120866.16091415.html.plaintext.txt	293	evidence two structural domain
0.38120866.16091415.html.plaintext.txt	294	num human apolipoprotein enum aqueous solution
0.38120866.16091415.html.plaintext.txt	295	property amino carboxyl terminal domain
0.38120866.16091415.html.plaintext.txt	296	num extrahepatic synthesis apolipoprotein e
0.38120866.16091415.html.plaintext.txt	297	num apolipoprotein e mrna abundant brain adrenal well liver present peripheral tissue rat marmoset
0.38120866.16091415.html.plaintext.txt	298	num cognitive change apoe epsilon num allele
0.38120866.16091415.html.plaintext.txt	299	num apolipoprotein e cns response injury
0.38120866.16091415.html.plaintext.txt	300	num apolipoprotein e high avidity binding beta amyloid increased frequency type num allele late onset familial alzheimer disease
0.38120866.16091415.html.plaintext.txt	301	num polymorphism apolipoprotein e occurrence dysbetalipoproteinaemia man
0.38120866.16091415.html.plaintext.txt	302	num apolipoprotein e associated astrocytic glia central nervous system nonmyelinating glia peripheral nervous system
0.38120866.16091415.html.plaintext.txt	303	num expression apolipoprotein e mrna rat microglia
0.38120866.16091415.html.plaintext.txt	304	num astrocyte microglia respond estrogen increased apoe mrna vivo vitro
0.38120866.16091415.html.plaintext.txt	305	num neuron human frontal cortex display apolipoprotein e immunoreactivity implication alzheimers disease
0.38120866.16091415.html.plaintext.txt	306	num astrocyte lipoprotein effect apoe neuronal function role apoe amyloid beta deposition vivo
0.38120866.16091415.html.plaintext.txt	307	conum clinktypedoi crossref
0.38120866.16091415.html.plaintext.txt	308	num recovery spinal cord injury new transection model cnumblnum mouse
0.38120866.16091415.html.plaintext.txt	309	num apo e expression spinal cord injury mouse
0.38120866.16091415.html.plaintext.txt	310	num generation mouse carrying mutant apolipoprotein e gene inactivated gene targeting embryonic stem cell
0.38120866.16091415.html.plaintext.txt	311	num apolipoprotein e alzheimers disease
0.38120866.16091415.html.plaintext.txt	312	num continuous fluorescence monitoring rapid cycle dna amplification
0.38120866.16091415.html.plaintext.txt	313	num lightcycler microvolume multi sample fluorimeter rapid temperature control
0.38120866.16091415.html.plaintext.txt	314	edugenomesoftwareotherprimernum
0.38120866.16091415.html.plaintext.txt	315	num sosui classification secondary structure prediction system membrane protein
0.38120866.16091415.html.plaintext.txt	316	bioinformatics num num num
0.38120866.16091415.html.plaintext.txt	317	num cdd curated entrez database conserved domain alignment
0.38120866.16091415.html.plaintext.txt	318	num large scale sequencing specific neural network promoter splice site recognition
0.38120866.16091415.html.plaintext.txt	319	ed biocomputing proceeding num pacific symposium
0.38120866.16091415.html.plaintext.txt	320	world scientific publishing co
0.38120866.16091415.html.plaintext.txt	321	num widespread occurrence antisense transcription human genome
0.38120866.16091415.html.plaintext.txt	322	num num human transcript might form sense antisense pair
0.38120866.16091415.html.plaintext.txt	323	num antisense rna function fate duplex rna cell higher eukaryote
0.38120866.16091415.html.plaintext.txt	324	num natural antisense transcript make sense eukaryote gene num num num
0.38120866.16091415.html.plaintext.txt	325	num identification urocortin mrna antisense transcript rat tissue
0.38120866.16091415.html.plaintext.txt	326	num cardiac troponin sense antisense rna duplex myocardium
0.38120866.16091415.html.plaintext.txt	327	num characterization tissue specific expression rat basic fibroblast growth factor antisense mrna protein
0.38120866.16091415.html.plaintext.txt	328	num antisense transcript xenopus laevis bfgf gene coding evolutionarily conserved num kda protein
0.38120866.16091415.html.plaintext.txt	329	num improved prediction signal peptide signalp num
0.38120866.16091415.html.plaintext.txt	330	num nucleotide sequence structure human apolipoprotein e gene
0.38120866.16091415.html.plaintext.txt	331	num genotyping sequence analysis apolipoprotein e isoforms
0.38120866.16091415.html.plaintext.txt	332	num apolipoprotein e variation sequence haplotype level implication origin maintenance major human polymorphism
0.38120866.16091415.html.plaintext.txt	333	num sequence diversity large scale typing snp human apolipoprotein e gene
0.38120866.16091415.html.plaintext.txt	334	num genenumest blastnum server searching expressed sequence tag est database eukaryotic gene sized query
0.38120866.16091415.html.plaintext.txt	335	num artemis sequence visualisation annotation
0.38120866.16091415.html.plaintext.txt	336	bioinformatics num num num
0.38120866.16091415.html.plaintext.txt	337	identification alternatively spliced mrna variant related cancer genome wide est alignment
0.38120866.16091415.html.plaintext.txt	338	article abstract full text pdf version article numnumnum recent ddinumvnum alert article cited alert correction posted service email article friend similar article journal similar article pubmed alert new issue journal add personal archive download citation manager request permission google scholar article seitz
0.38120866.16091415.html.plaintext.txt	339	pubmed pubmed citation article seitz
0.38120866.16091415.html.plaintext.txt	340	online issn num num print issn num num copyright num oxford university press oxford journal oxford university press site map term condition privacy policy frequently asked question oxford university press site oxford university press american national biography bookseller information service childrens fiction poetry childrens reference corporate special sale dictionary dictionary national biography digital reference english language teaching higher education textbook humanity international education unit law medicine music online product oxford english dictionary reference right permission science school book social science short introduction world classic
0.4035247.9467014.html.plaintext.txt	0	new polymorphism apoe promoter associated risk developing alzheimers disease
0.4035247.9467014.html.plaintext.txt	1	jean charles lambertnum florence pasquiernum dominique cottelnum bernard frigardnum philippe amouyelnum marie christine chartier harlinnum
0.4035247.9467014.html.plaintext.txt	2	numinserm cjfnum num institut pasteur de lille num rue du professeur calmette num lille cedex france numchr et u de lille clinique neurologique centre de la memoire hopital salengro num lille cedex france numcentre de geriartrie de wasquehal molinel rue salvador allende b
0.4035247.9467014.html.plaintext.txt	3	received october num num revised accepted december num num
0.4035247.9467014.html.plaintext.txt	4	epsisnum allele apolipoprotein e gene apoe one main allele apoe polymorphism major risk factor development alzheimers disease
0.4035247.9467014.html.plaintext.txt	5	however several data suggest genetic factor within apoe locus may also modulate risk associated polymorphism
0.4035247.9467014.html.plaintext.txt	6	look new mutation apoe promoter susceptible modify risk associated apoe epsisnum allele
0.4035247.9467014.html.plaintext.txt	7	characterised grarrt mutation num bp apoe gene tata box named thnumenumcs
0.4035247.9467014.html.plaintext.txt	8	new polymorphism located consensus sequence potential transcriptional thnumenum factor binding site
0.4035247.9467014.html.plaintext.txt	9	studied impact new polymorphism marker apoe locus large case control study observed thnumenumcs modulated influence apoe epsisnum allele risk alzheimers disease
0.4035247.9467014.html.plaintext.txt	10	apolipoprotein e gene apoe key player lipid transport exists three main allele general population epsisnum epsisnum epsisnum
0.4035247.9467014.html.plaintext.txt	11	polymorphism correspond mutation coding sequence apoe gene resulting amino acid substitution arg cys position num num protein
0.4035247.9467014.html.plaintext.txt	12	gene located chromosome num position qnum
0.4035247.9467014.html.plaintext.txt	13	implication chromosome num alzheimers disease ad suspected least three occasion num num report association late onset ad apoe epsisnum allele num
0.4035247.9467014.html.plaintext.txt	14	numerous study confirmed finding extended observation early onset ad num num
0.4035247.9467014.html.plaintext.txt	15	established carrying epsisnum allele increase risk ad allele dose dependent manner shift age onset disease earlier age num
0.4035247.9467014.html.plaintext.txt	16	conversely bearing epsisnum allele confers protection disease numnumnum
0.4035247.9467014.html.plaintext.txt	17	thus apoe genotype appears important biological marker ad susceptibility accounting num num ad genetic variability
0.4035247.9467014.html.plaintext.txt	18	several biological mechanism proposed underlie association
0.4035247.9467014.html.plaintext.txt	19	enum isoform would facilitate limit amyloid substance deposition numnum
0.4035247.9467014.html.plaintext.txt	20	isoform may protect oxidative stress contrast enum isoform num
0.4035247.9467014.html.plaintext.txt	21	also suggested enum enum isoforms would prevent aggregation tau protein limiting abnormal phosphorylation leading constitution paired helical filament enum isoform would num
0.4035247.9467014.html.plaintext.txt	22	however none hypothesis fully explained many num homozygous subject survive num year develop ad
0.4035247.9467014.html.plaintext.txt	23	observation suggests factor influence apoe associated risk
0.4035247.9467014.html.plaintext.txt	24	indeed genetic environmental factor family history gender smoking oestrogen cholesterol level polymorphism located apoe receptor gene instance num num may modify apoe associated risk
0.4035247.9467014.html.plaintext.txt	25	however recent report suggest additional genetic factor within apoe locus may also modulate risk
0.4035247.9467014.html.plaintext.txt	26	firstly genetic study marker vicinity apoe locus demonstrated combination three polymorphism increase estimation apoe associated risk ad compared apoe polymorphism alone num
0.4035247.9467014.html.plaintext.txt	27	secondly distortion allelic expression apoe gene observed brain affected patient indeed relative expression epsisnum allele increased num
0.4035247.9467014.html.plaintext.txt	28	num fold epsisnumepsisnum bearer ad patient compared epsisnumepsisnum bearer control num
0.4035247.9467014.html.plaintext.txt	29	together data suggest potential existence one additional genetic susceptibility factor apoe sequence modifying risk associated apoe epsisnum allele occurrence ad
0.4035247.9467014.html.plaintext.txt	30	detailed sequence analysis study apoe locus needed characterise additional genetic factor
0.4035247.9467014.html.plaintext.txt	31	reported polymorphism numenum first intron apoe gene strong linkage disequilibrium apoe epsisnum allele num
0.4035247.9467014.html.plaintext.txt	32	go hunt polymorphism sequenced num bp upstream apoe tata box detected new polymorphism whose impact ad risk together apoe epsisnum allele investigated large case control study
0.4035247.9467014.html.plaintext.txt	33	sequencing num bp upstream tata box apoe found grarrt polymorphism position num tata box located potential consensus binding sequence thnumenum heterodimer transcriptional factor fig
0.4035247.9467014.html.plaintext.txt	34	location named thnumenumcs polymorphism thnumenum consensus sequence polymorphism
0.4035247.9467014.html.plaintext.txt	35	autoradiograph sequencing gel part apoe promoter heterozygous thnumenumcs individual showing grarrt base pair change
0.4035247.9467014.html.plaintext.txt	36	b comparison apoe promoter sequence including thnumenumcs polymorphism consensus sequence predicted binding site thnumenumcs heterodimer num
0.4035247.9467014.html.plaintext.txt	37	predicted position thnum enum binding site indicated top based known half site specificity enum predicted thnum
0.4035247.9467014.html.plaintext.txt	38	grarrt mutation boxed located half site specificity enum
0.4035247.9467014.html.plaintext.txt	39	nucleotide position numbered relative canonical e box sequence
0.4035247.9467014.html.plaintext.txt	40	studied association thnumenumcs polymorphism ad large case control study num case age num
0.4035247.9467014.html.plaintext.txt	41	num year num control age num
0.4035247.9467014.html.plaintext.txt	42	analysed thnumenumcs polymorphism together apoe numenum dnumsnum repeat polymorphism
0.4035247.9467014.html.plaintext.txt	43	distribution polymorphism presented table num
0.4035247.9467014.html.plaintext.txt	44	deviation hardy weinberg equilibrium observed polymorphism
0.4035247.9467014.html.plaintext.txt	45	expected epsisnum allele strongly associated ad num
0.4035247.9467014.html.plaintext.txt	46	num epsisnum allele exhibited protective effect num
0.4035247.9467014.html.plaintext.txt	47	control population thnumenumcs g allele common one num
0.4035247.9467014.html.plaintext.txt	48	num contrast ad population num
0.4035247.9467014.html.plaintext.txt	49	allelic genotypic distribution significantly different ad case compared control case p num
0.4035247.9467014.html.plaintext.txt	50	thnumenumcs allele associated increased risk developing ad num
0.4035247.9467014.html.plaintext.txt	51	num individual bearing least one allele
0.4035247.9467014.html.plaintext.txt	52	numenum polymorphism allelic genotypic distribution similar one reported mui et al
0.4035247.9467014.html.plaintext.txt	53	num significantly different ad control population p num
0.4035247.9467014.html.plaintext.txt	54	numenum c allele associated decreased risk developing ad num
0.4035247.9467014.html.plaintext.txt	55	difference allelic genotypic distribution dnumsnum repeat allele observed p num
0.4035247.9467014.html.plaintext.txt	56	calculated pairwise linkage disequilibrium dnumsnum thnumenumcs numenum apoe polymorphism table num
0.4035247.9467014.html.plaintext.txt	57	expected significant linkage disequilibrium existed thnumenumcs numenum apoe polymorphism
0.4035247.9467014.html.plaintext.txt	58	dnumsnum independent polymorphism although weak linkage disequilibrium existed apoe control population
0.4035247.9467014.html.plaintext.txt	59	estimated haplotype generated four polymorphism using myriad haplotype algorithm
0.4035247.9467014.html.plaintext.txt	60	among num theoretical haplotype num observed table numa
0.4035247.9467014.html.plaintext.txt	61	haplotype observed ad case three no num num num represented control
0.4035247.9467014.html.plaintext.txt	62	difference distribution estimated haplotype frequency case control tested likelihood ratio test num degree freedom chinum num
0.4035247.9467014.html.plaintext.txt	63	take account strong association apoe epsisnum allele ad compared estimated haplotype distribution epsisnumepsisnum epsisnumepsisnum ad control subgroup table numb c
0.4035247.9467014.html.plaintext.txt	64	subgroup epsisnumepsisnum epsisnumepsisnum genotype bearer respectively estimated haplotype distribution significantly different ad control subject likelihood test chinum num df num chinum num df num respectively suggesting potential independent effect polymorphism
0.4035247.9467014.html.plaintext.txt	65	distribution combination different polymorphism allele control ad case allele frequency genotype frequency apoea n epsisnum epsisnum epsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum control case num num
0.4035247.9467014.html.plaintext.txt	66	num thnumenumcs n gb ggc gt tt control case num num
0.4035247.9467014.html.plaintext.txt	67	num numenum n gd c gge gc cc control case num num
0.4035247.9467014.html.plaintext.txt	68	num dnumsnumf n l ll l s control case num num
0.4035247.9467014.html.plaintext.txt	69	num n epsisnumepsisnumg epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum apoe numenum polymorphism combination ad case cc num num num num gc num num num num gg num num num num num num total num num num num num num control case cc num num num num gc num num num num gg num num num num num num total num num num num num num apoe thnumenumcs polymorphism combination ad case gg num num num num num num gt num num num num num num tt num num num num total num num num num num num control case gg num num num num num gt num num num num num num tt num num num num num total num num num num num num ap num
0.4035247.9467014.html.plaintext.txt	70	num fns gone individual epsisnumepsisnum control case
0.4035247.9467014.html.plaintext.txt	71	pairwise linkage disequilibrium numqnum
0.4035247.9467014.html.plaintext.txt	72	num chromosomal region dnumsnum thnumenumcs numenum apoe ad case dnumsnum num
0.4035247.9467014.html.plaintext.txt	73	num apoe num num num control dnumsnum num
0.4035247.9467014.html.plaintext.txt	74	num apoe num num apoe polymorphism analysed biallelic marker
0.4035247.9467014.html.plaintext.txt	75	allele num versus allele num num
0.4035247.9467014.html.plaintext.txt	76	diagonal delta standardised linkage disequilibrium coefficient
0.4035247.9467014.html.plaintext.txt	77	diagonal dprime percentage linkage disequilibrium coefficient maximum possible value given allele frequency
0.4035247.9467014.html.plaintext.txt	78	polymorphism haplotype estimation along numq
0.4035247.9467014.html.plaintext.txt	79	num chromosomal region haplotype polymorphism estimated haplotype frequency
0.4035247.9467014.html.plaintext.txt	80	dnumsnum thnumenumcs numenum apoe ad case control expected control general population num g epsisnum num
0.4035247.9467014.html.plaintext.txt	81	numa number chromosome num num b population genotyped epsisnumepsisnum num g num
0.4035247.9467014.html.plaintext.txt	82	numa number chromosome num num c population genotyped epsisnumepsisnum num g num
0.4035247.9467014.html.plaintext.txt	83	num number chromosome num num ap num
0.4035247.9467014.html.plaintext.txt	84	whole population ad num control num estimated developing ad subject least one allele genotype polymorphism separately table num
0.4035247.9467014.html.plaintext.txt	85	expected significant effect observed except dnumsnum
0.4035247.9467014.html.plaintext.txt	86	determine effect thnumenumcs numenum polymorphism due linkage disequilibrium existing apoe polymorphism performed multivariate logistic regression taking account age gender four polymorphism model
0.4035247.9467014.html.plaintext.txt	87	effect thnumenumcs numenum polymorphism persisted even increased reinforcing hypothesis several genetic susceptibility factor within apoe locus
0.4035247.9467014.html.plaintext.txt	88	adjusted odds ratio estimated multiple logistic regression num ci dnumsnumss lsll thnumenumcstt gtgg numenumcc gcgg apoewith epsisnumwithout epsisnum non adjusted num
0.4035247.9467014.html.plaintext.txt	89	num adjusted gender age num
0.4035247.9467014.html.plaintext.txt	90	num polymorphism p num
0.4035247.9467014.html.plaintext.txt	91	assume level expression apoe allele increased due ci mutation promoter region hypothesis three major implication promoter mutation may modulate expression apoe allele leading increased deleterious risk epsisnum increased protective effect epsisnum ii given determines risk importance relative level expression allele apoe promoter mutation differential effect apoe heterozygous homozygous genotype iii effect ci mutation heterozygous individual depend phase polymorphism apoe epsis allele
0.4035247.9467014.html.plaintext.txt	92	heterozygous thnumenumcs apoe epsisnum genotype bearer epsisnum allele may combined either thnumenumcs g allele
0.4035247.9467014.html.plaintext.txt	93	one combination may increase relative expression level epsisnum allele decrease relative expression level epsisnum allele combination inverse influence
0.4035247.9467014.html.plaintext.txt	94	thus epsisnumepsisnum genotype bearer risk developing ad different thnumenumcs heterozygous homozygous individual
0.4035247.9467014.html.plaintext.txt	95	test assumption studied gender age adjusted developing ad thnumenumcs heterozygous genotype bearer compared homozygous thnumenumcs individual
0.4035247.9467014.html.plaintext.txt	96	thnumenumcs heterozygous genotype associated increased risk developing ad heterozygous apoe individual num
0.4035247.9467014.html.plaintext.txt	97	num homozygous apoe individual num
0.4035247.9467014.html.plaintext.txt	98	particular epsisnumepsisnum sub population table num risk developing ad heterozygous thnumenumcs individual increased compared homozygous thnumenumcs individual num
0.4035247.9467014.html.plaintext.txt	99	num ad num control num
0.4035247.9467014.html.plaintext.txt	100	increased risk became significant larger epsisnumepsisnum population num
0.4035247.9467014.html.plaintext.txt	101	num ad num control num
0.4035247.9467014.html.plaintext.txt	102	however risk obtained heterozygous numenum individual significant compared homozygous numenum individual num
0.4035247.9467014.html.plaintext.txt	103	ass contribution polymorphism risk developing ad epsisnumepsisnum population performed multiple logistic regression
0.4035247.9467014.html.plaintext.txt	104	detected increased risk tendency developing ad heterozygous thnumenumcs num
0.4035247.9467014.html.plaintext.txt	105	num heterozygous numenum bearer num
0.4035247.9467014.html.plaintext.txt	106	altogether data suggest thnumenumcs polymorphism could modify relative level expression apoe allele
0.4035247.9467014.html.plaintext.txt	107	distribution numenum thnumenumcs genotype larger epsisnumepsisnum population numenum polymorphisma thnumenumcs polymorphismb n gg gc gg gt tt control case num num num num num num ad case num num num num num num ap num
0.4035247.9467014.html.plaintext.txt	108	order approach influence phase thnumenumcs apoe polymorphism ad risk estimated frequency haplotype thnumenumcs g allele associated epsisnum allele ad control epsisnumepsisnum bearer population described material method
0.4035247.9467014.html.plaintext.txt	109	apoe epsisnumepsisnum thnumenumcs gt bearer num
0.4035247.9467014.html.plaintext.txt	110	num control estimated epsisnum allele chromosome proportion num
0.4035247.9467014.html.plaintext.txt	111	num case group leading estimated num
0.4035247.9467014.html.plaintext.txt	112	recently hypothesis others mutation nearby apoe gene fuelled new physiological data difference allelic expression apoe gene observed num suggesting non coding polymorphism regulatory region apoe gene could modify risk developing ad
0.4035247.9467014.html.plaintext.txt	113	looking new polymorphism found grarrt polymorphism located position num degenerative e box consensus fig
0.4035247.9467014.html.plaintext.txt	114	num num influenced effect apoe polymorphism ad expected way
0.4035247.9467014.html.plaintext.txt	115	thnumenumcs numenum polymorphism associated ad studied separately
0.4035247.9467014.html.plaintext.txt	116	although strong linkage disequilibrium existed epsisnum thnumenumcs numenum g allele effect polymorphism persisted introduced logistic regression model
0.4035247.9467014.html.plaintext.txt	117	observation suggested risk associated apoe epsis allele may modulated according combination polymorphism
0.4035247.9467014.html.plaintext.txt	118	least one thnumenumcs numenum c allele significantly modified risk developing ad whole population
0.4035247.9467014.html.plaintext.txt	119	furthermore impact epsisnum allele seemed decreased suggesting part effect may attributed promoter polymorphism
0.4035247.9467014.html.plaintext.txt	120	another argument brought forward estimating risk associated phase
0.4035247.9467014.html.plaintext.txt	121	estimated risk developing disease epsisnumepsisnum genotype bearer similar according combination thnumenumcs apoe epsis allele chromosome
0.4035247.9467014.html.plaintext.txt	122	result accordance previous data suggest epsisnumepsisnum individual preferentially develop ad expressed epsisnum allele greater level
0.4035247.9467014.html.plaintext.txt	123	thus ci mutation apoe promoter may favour relative expression level epsisnum allele potentially deleterious action enum isoform
0.4035247.9467014.html.plaintext.txt	124	thnumenumcs polymorphism characterised binding site basic helix loop helix transcription factor enum
0.4035247.9467014.html.plaintext.txt	125	factor enum belongs class protein ubiquitously expressed form combinatorial interaction class b protein control tissue specific gene expression num
0.4035247.9467014.html.plaintext.txt	126	particular enum expressed brain associated multiple class b protein implicated development maintenance mammalian nervous system num num
0.4035247.9467014.html.plaintext.txt	127	little known thnum factor
0.4035247.9467014.html.plaintext.txt	128	identified screen mouse embryo cdna library
0.4035247.9467014.html.plaintext.txt	129	homologous protein drosophila partner drosophila class protein daughterless expression essential neurogenesis num
0.4035247.9467014.html.plaintext.txt	130	nevertheless essential determine vitro vivo functionality transcriptional factor sequence binding
0.4035247.9467014.html.plaintext.txt	131	furthermore effect new polymorphism susceptible modulate risk associated apoe allele must confirmed epidemiological study profound analysis performed determine haplotype
0.4035247.9467014.html.plaintext.txt	132	conclusion thnumenumcs polymorphism located within putative regulatory element apoe promoter could contribute apoe expression level polymorphism regulatory sequence gene may exist extended screening regulatory region need developed
0.4035247.9467014.html.plaintext.txt	133	regulation apoe gene could important deciphering mechanism involvement apoe allele particular better define subject higher risk developing ad
0.4035247.9467014.html.plaintext.txt	134	population method population
0.4035247.9467014.html.plaintext.txt	135	ad control sample caucasian originating france
0.4035247.9467014.html.plaintext.txt	136	sixteen case european country
0.4035247.9467014.html.plaintext.txt	137	different ethnic origin influence genotype distribution
0.4035247.9467014.html.plaintext.txt	138	diagnosis probable ad established according dsm iii r nincs adrda criterion n num age num
0.4035247.9467014.html.plaintext.txt	139	num range num num age onset num
0.4035247.9467014.html.plaintext.txt	140	caucasian control defined subject without dm iii r dementia criterion integrity cognitive function n num age num
0.4035247.9467014.html.plaintext.txt	141	individual relative signed informed consent
0.4035247.9467014.html.plaintext.txt	142	number subject tested different polymorphism varied followed thnumenumcs study num ad case num control numenum study num ad case num control dnumsnum study num ad case num control
0.4035247.9467014.html.plaintext.txt	143	order increase statistical power study analysis heterozygous individual increased number individual epsisnumepsisnum genotype adding new epsisnumepsisnum subject independent population total num ad num control case num
0.4035247.9467014.html.plaintext.txt	144	direct sequencing performed num sequenase version num
0.4035247.9467014.html.plaintext.txt	145	num dna sequencing kit amersham life science using gamma numsdatp
0.4035247.9467014.html.plaintext.txt	146	apoe pcr product obtained described aso technique see
0.4035247.9467014.html.plaintext.txt	147	reaction run num acrylamidenum m urea gel num num h num w
0.4035247.9467014.html.plaintext.txt	148	gel exposed x ray film
0.4035247.9467014.html.plaintext.txt	149	genomic dna extracted white blood cell
0.4035247.9467014.html.plaintext.txt	150	analysed thnumenumcs polymorphism distribution together two polymorphism located numqnum
0.4035247.9467014.html.plaintext.txt	151	num chromosomal region flanking thnumenumcs polymorphism numenum polymorphism located num
0.4035247.9467014.html.plaintext.txt	152	num kb downstream thnumenumcs polymorphism anonymous repeat dna marker dnumsnum located num
0.4035247.9467014.html.plaintext.txt	153	frequency dnumsnum repeat allele dichotomised long num short allele num
0.4035247.9467014.html.plaintext.txt	154	four marker amplified polymerase chain reaction perkin elmer cetus thermal cycler
0.4035247.9467014.html.plaintext.txt	155	anonymous repeat dna marker dnumsnum numenum polymorphism apoe polymorphism tested previously described numnumnum
0.4035247.9467014.html.plaintext.txt	156	thnumenumcs polymorphism create destroy restriction enzyme site two technique used confirm result
0.4035247.9467014.html.plaintext.txt	157	first one consisted designing mismatch primer contained one mismatched base pair four base away numprime end forward primer five base polymorphism
0.4035247.9467014.html.plaintext.txt	158	incorporated pcr product primer produced bstn cut site g present cut site present polymorphic site
0.4035247.9467014.html.plaintext.txt	159	briefly pcr step performed num cycle num min num degree c num min num num degree c num min num degree c cycle forward primer numprime agaatggaggagggtgcctg numprime reverse primer numprime actcaaggatcccagacttg numprime total volume num microl containing num
0.4035247.9467014.html.plaintext.txt	160	num mm dntp num dmso num
0.4035247.9467014.html.plaintext.txt	161	twenty five microl pcr product digested num u bstn num degree c overnight
0.4035247.9467014.html.plaintext.txt	162	digestion product visualised num polyacrylamide gel
0.4035247.9467014.html.plaintext.txt	163	thnumenumcs allele characterised num bp fragment g allele num bp fragment
0.4035247.9467014.html.plaintext.txt	164	second technique consisted performing allele specific oligonucleotide aso hybridisation
0.4035247.9467014.html.plaintext.txt	165	num bp fragment containing thnumenumcs polymorphism amplified using forward primer numprime tactttctttctgggatccagg numprime reverse primer numprime actcaaggatcccagacttg numprime
0.4035247.9467014.html.plaintext.txt	166	pcr performed total volume num microl num cycle num min num degree c num min num degree c num min num degree c cycle containing num
0.4035247.9467014.html.plaintext.txt	167	num mm dntp num mm mgclnum
0.4035247.9467014.html.plaintext.txt	168	two primer numprime gcccagtaatccagacaccc numprime numprime gcccagtaatacagacaccc numprime g allele detection respectively numprime end labelled dig boerhinger mannheim
0.4035247.9467014.html.plaintext.txt	169	allele specific hybridisation obtained washing num min num
0.4035247.9467014.html.plaintext.txt	170	num x ssc solution num degree c num degree c g allele hybridisation respectively
0.4035247.9467014.html.plaintext.txt	171	detection realised described supplier boerhinger mannheim
0.4035247.9467014.html.plaintext.txt	172	univariate analysis performed using pearsons chinum test fisher exact test necessary
0.4035247.9467014.html.plaintext.txt	173	since impact epsisnum allele pronounced range num num year numnum since significant difference observed distribution different marker according age cut num year tested analysed different polymorphism without performing distinction early late onset
0.4035247.9467014.html.plaintext.txt	174	deviation hardy weinberg equilibrium hypothesis tested
0.4035247.9467014.html.plaintext.txt	175	pairwise linkage disequilibrium measured collapsed data estimation two marker haplotype frequency maximum likelihood procedure dnumsnum thnumenumcs numenum apoe coded biallelic marker
0.4035247.9467014.html.plaintext.txt	176	allele epsisnum versus allele epsisnum epsisnum num
0.4035247.9467014.html.plaintext.txt	177	standardised disequilibrium delta percent maximum possible value disequilibrium computed outlined thompson et al
0.4035247.9467014.html.plaintext.txt	178	statistical significance linkage disequilibrium considered p num
0.4035247.9467014.html.plaintext.txt	179	num level since multiple non independent pairwise comparison performed
0.4035247.9467014.html.plaintext.txt	180	extended haplotype frequency four marker estimated collapsed data using myriad haplotype algorithm described mclean morton num implemented computer program cox et al
0.4035247.9467014.html.plaintext.txt	181	comparison haplotype frequency case control tested likelihood ratio test
0.4035247.9467014.html.plaintext.txt	182	estimated frequency compared expected basis equilibrium pearsons chinum fisher exact test necessary num
0.4035247.9467014.html.plaintext.txt	183	multivariate analysis coded genotype subject dummy variable according tested hypothesis least one dnumsnum short allele sssl versus ll least one thnumenumcs allele tttg versus gg least one numenum c allele ccgc versus gg least one epsisnum allele
0.4035247.9467014.html.plaintext.txt	184	effect variable disease tested multiple logistic regression model adjusted age gender
0.4035247.9467014.html.plaintext.txt	185	estimation risk developing ad according combination thnumenumcs epsisnum allele epsisnumepsisnum subgroup
0.4035247.9467014.html.plaintext.txt	186	according three polymorphism presented table numc defined epsisnumepsisnum sub population fi xi yi num fi frequency haplotype num num defined table numc xi frequency epsisnum allele found haplotype yi frequency epsisnum allele found haplotype
0.4035247.9467014.html.plaintext.txt	187	estimation performed epsisnumepsisnum sub population equal total proportion epsisnum epsisnum allele num
0.4035247.9467014.html.plaintext.txt	188	given numenum c allele strong linkage disequilibrium apoe epsis polymorphism table num num associated epsisnum allele ynum ynum ynum ynum num
0.4035247.9467014.html.plaintext.txt	189	thus xnum xnum xnum xnum value directly obtained table numc fi xi
0.4035247.9467014.html.plaintext.txt	190	equation num obtain num
0.4035247.9467014.html.plaintext.txt	191	xi directly approached haplotype distribution estimated epsisnumepsisnum subgroup
0.4035247.9467014.html.plaintext.txt	192	xiprime frequency haplotype epsisnumepsisnum ad control subgroup xi value estimated follows num equation num num
0.4035247.9467014.html.plaintext.txt	193	num linkage study familial alzheimer disease evidence chromosome num linkage
0.4035247.9467014.html.plaintext.txt	194	num genetic association linkage analysis apolipoprotein e cii locus familial alzheimers disease
0.4035247.9467014.html.plaintext.txt	195	num apolipoprotein e high avidity binding beta amyloid increased frequency type num allele late onset familial alzheimers disease
0.4035247.9467014.html.plaintext.txt	196	num apolipoprotein e epsisnum allele major risk factor sporadic early late onset form alzheimers disease analysis numqnum
0.4035247.9467014.html.plaintext.txt	197	num reduced survival patient early onset alzheimers disease carry apolipoprotein enum allele
0.4035247.9467014.html.plaintext.txt	198	french alzheimers disease collaborative group num evidence apolipoprotein e epsisnum association early onset alzheimers patient late onset relative
0.4035247.9467014.html.plaintext.txt	199	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.4035247.9467014.html.plaintext.txt	200	num protective effect apolipoprotein e type num late onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	201	num protection alzheimers disease apoe epsisnum
0.4035247.9467014.html.plaintext.txt	202	num binding human apolipoprotein e synthetic amyloid beta peptide isoform specific effect implication late onset alzheimer disease
0.4035247.9467014.html.plaintext.txt	203	num apolipoprotein e kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment alzheimers disease
0.4035247.9467014.html.plaintext.txt	204	num apolipoprotein e allele specific antioxidant activity effect cytotoxicity oxidative insult beta amyloid peptide
0.4035247.9467014.html.plaintext.txt	205	num hypothesis microtubule instability paired helical filament formation alzheimer disease related apolipoprotein e genotype
0.4035247.9467014.html.plaintext.txt	206	num apolipoprotein enum allele population based study early onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	207	num alzheimers disease apolipoprotein enum gender
0.4035247.9467014.html.plaintext.txt	208	num apolipoprotein e genotype association smoking early onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	209	num interaction apolipoprotein e genotype total cholesterol level age sex prediction alzheimers disease case control study
0.4035247.9467014.html.plaintext.txt	210	num association low density lipoprotein related receptor protein lrp alzheimers disease
0.4035247.9467014.html.plaintext.txt	211	num low density lipoprotein vldl receptor genetic susceptibility factor alzheimers disease european caucasian population alzheimers disease related disorder press
0.4035247.9467014.html.plaintext.txt	212	num distortion allelic expression apolipoprotein e alzheimers disease
0.4035247.9467014.html.plaintext.txt	213	num newly identified polymorphism apolipoprotein e enhancer gene region associated ad strongly epsisnum allele
0.4035247.9467014.html.plaintext.txt	214	num identification new family tissue specific basic helix loop helix protein two hybrid system
0.4035247.9467014.html.plaintext.txt	215	num new dna binding dimerization motif immunoglobulin enhancer binding daughterless myod myc protein
0.4035247.9467014.html.plaintext.txt	216	num math num mammalian helix loop helix factor structurally related product drosophilia proneuronal gene atonal specifically expressed nervous system
0.4035247.9467014.html.plaintext.txt	217	kageyamar num mammalian helix loop helix factor structurally related product drosophilia proneuronal gene atonal positive transcriptional regulator expressed developing nervous system
0.4035247.9467014.html.plaintext.txt	218	num betanum novel helix loop helix protein act negative regulator betanum myod responsive gene
0.4035247.9467014.html.plaintext.txt	219	num daughterless drosophilia gene essential neurogenesis sex determination sequence similarity myc achaete scute complex
0.4035247.9467014.html.plaintext.txt	220	american psychiatric association num diagnostic statistical manual mental disorder
0.4035247.9467014.html.plaintext.txt	221	third edition revised dm iii r american psychatric association ed
0.4035247.9467014.html.plaintext.txt	222	num clinical diagnosis alzheimers disease report nincds adra work group
0.4035247.9467014.html.plaintext.txt	223	num restriction isotyping human apolipoprotein e gene amplification cleavage hhai
0.4035247.9467014.html.plaintext.txt	224	num apolipoprotrein e alzheimer disease genotype specific risk age sex
0.4035247.9467014.html.plaintext.txt	225	apoe alzheimer disease meta analysis consortium num effect age gender ethnicity association apolipoprotein e genotype alzheimer disease
0.4035247.9467014.html.plaintext.txt	226	num test association gene frequency several locus random mating diploid population
0.4035247.9467014.html.plaintext.txt	227	num detection linkage disequilibrium closely marker rflps ai ciii apolipoprotein gene
0.4035247.9467014.html.plaintext.txt	228	num efficiency lod score representing multiple locus linkage data
0.4035247.9467014.html.plaintext.txt	229	num linkage disequilibrium human insulininsulin like growth factor ii region human chromosome ii
0.4035247.9467014.html.plaintext.txt	230	num extended haplotype linkage disequilibrium ii marker apoai cnum cnum anum gene cluster chromosome ii
0.4035247.9467014.html.plaintext.txt	231	correspondence addressed
0.4035247.9467014.html.plaintext.txt	232	tel num num num num num num fax num num num num num num email philippe
0.4035247.9467014.html.plaintext.txt	233	fr page run oxford university press great clarendon street oxford oxnum numdp part oup journalscomments feedback www adminatoup
0.4035247.9467014.html.plaintext.txt	234	uk u d last modification num feb numcopyright oxford university press num
0.407656.9328480.html.plaintext.txt	0	distortion allelic expression apolipoprotein e alzheimers disease
0.407656.9328480.html.plaintext.txt	1	jean charles lambertnumnum jordi perez turnumnum marie joelle dupirenum douglas galaskonum david mannnum philippe amouyelnum john hardynum andre delacourtenum marie christine chartier harlinnumnum
0.407656.9328480.html.plaintext.txt	2	numinserm unite num place de verdun num lille cedex france numinserm cjfnum num institut pasteur de lille num rue de calmette num lille cedex france numbirdsall building mayo clinic jacksonville num san pablo road jacksonville fl num usa numucsd medical centre pulman ambulatory care centre num campus point drive la jolla ca num usa numdepartment pathological science stopford building university manchester oxford road manchester mnum numpt uk
0.407656.9328480.html.plaintext.txt	3	received july num num revised accepted august num num
0.407656.9328480.html.plaintext.txt	4	apoe epsisnum allele strong genetic susceptibility factor alzheimers disease
0.407656.9328480.html.plaintext.txt	5	interaction biological factor may modulate effect apoe isoforms
0.407656.9328480.html.plaintext.txt	6	however previous work suggested genetic variability within apoe locus influencing effect epsisnum allele may exist
0.407656.9328480.html.plaintext.txt	7	variability could modify expression apoe gene particular level expression apoe allele could important determinant disease pathogenesis
0.407656.9328480.html.plaintext.txt	8	test hypothesis examined level expression apoe heterozygote ad control using new method semi quantitation
0.407656.9328480.html.plaintext.txt	9	report relative epsisnum mrna expression increased ad compared control suggest genetic variability neural expression apoe contributes disease risk
0.407656.9328480.html.plaintext.txt	10	epsisnum allele apoe gene major risk factor late onset alzheimers disease load num also implicated risk factor early onset disease population numnum
0.407656.9328480.html.plaintext.txt	11	previous study described epsisnum homozygote higher risk developing disease epsisnumepsisnum heterozygote
0.407656.9328480.html.plaintext.txt	12	however individual bearing one two epsisnum allele inevitably develop disease
0.407656.9328480.html.plaintext.txt	13	detailed genetic analysis around apoe locus suggested existence genetic variability region could contribute disease risk num
0.407656.9328480.html.plaintext.txt	14	two possible explanation observation another genetically variable locus vicinity apoe gene involved pathogenesis disease ii genetic variability control expression apoe gene num
0.407656.9328480.html.plaintext.txt	15	little examination mrna expression apoe ad numnum
0.407656.9328480.html.plaintext.txt	16	available evidence suggests apoe expression increased neuronal damage numnum bulk expression occurs astrocyte num
0.407656.9328480.html.plaintext.txt	17	expression believed part compensatory mechanism aimed aiding reafferentation reactive synaptogenesis num
0.407656.9328480.html.plaintext.txt	18	study examined expression apoe protein ad case control relative apoe genotype numnum
0.407656.9328480.html.plaintext.txt	19	suggested amount apoe protein could inversely correlated number epsisnum allele carried subject higher level observed epsisnum homozygote lower epsisnum homozygote intermediate level epsisnumepsisnum heterozygote num
0.407656.9328480.html.plaintext.txt	20	hypothesised since epsisnum homozygote higher risk developing disease epsisnumepsisnum heterozygote high proportion individual latter genotype reach greater age without developing ad likely explanation genetic variability neural expression apoe locus epsisnumepsisnum heterozygote individual high epsisnum expressors andor low epsisnum expressors likely develop ad individual high epsisnum expressors andor low epsisnum expressors
0.407656.9328480.html.plaintext.txt	21	identification apoe allele transcription product easily achieved rt pcr using restriction fragment length polymorphism
0.407656.9328480.html.plaintext.txt	22	developed semi quantitative assay measure allelic expression apoe mrna rt pcr using silver staining num
0.407656.9328480.html.plaintext.txt	23	method quantitation applied brain heterozygote subject collected various centre used ass percentage epsisnum mrna expression epsisnumepsisnum epsisnumepsisnum subject epsisnum mrna expression epsisnumepsisnum individual
0.407656.9328480.html.plaintext.txt	24	carried ad case control
0.407656.9328480.html.plaintext.txt	25	selected series epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum ad case n num control n num order measure relative level expression apoe allele frontal cortex fig
0.407656.9328480.html.plaintext.txt	26	observed epsisnum mrna expression consistently greater epsisnum mrna expression case fig
0.407656.9328480.html.plaintext.txt	27	addition clear consistent difference epsisnum allelic expression ratio ad case control fig
0.407656.9328480.html.plaintext.txt	28	num ad case showing higher relative expression epsisnum mrna control num
0.407656.9328480.html.plaintext.txt	29	regarding heterozygous genotype small size group prevented u reaching definite conclusion
0.407656.9328480.html.plaintext.txt	30	nevertheless trend towards situation observed epsisnumepsisnum group could noted increase expression epsisnum allele epsisnumepsisnum group num
0.407656.9328480.html.plaintext.txt	31	num control whereas nothing apparent epsisnumepsisnum group num
0.407656.9328480.html.plaintext.txt	32	num ad case versus num
0.407656.9328480.html.plaintext.txt	33	furthermore difference allelic expression ratio epsisnumepsisnum epsisnumepsisnum ad case observed since epsisnumepsisnum patient showed num
0.407656.9328480.html.plaintext.txt	34	num fold increase epsisnum allele ratio p num
0.407656.9328480.html.plaintext.txt	35	figure num semi quantitation epsisnum allele ratio control case
0.407656.9328480.html.plaintext.txt	36	final epsisnum allele ratio calculated data num
0.407656.9328480.html.plaintext.txt	37	figure num differential expression apoe mrna three heterozygote genotype alzheimers disease case control
0.407656.9328480.html.plaintext.txt	38	epsisnum mrna percentage measured epsisnumepsisnum population epsisnum mrna percentage epsisnumepsisnum epsisnumepsisnum population
0.407656.9328480.html.plaintext.txt	39	average level expression indicated bold line category
0.407656.9328480.html.plaintext.txt	40	brain sample rt pcr semi quantitation repeated three time
0.407656.9328480.html.plaintext.txt	41	important note measurement ratio expression two allele heterozygote likely much robust measurement determination absolute level mrna expression tissue since latter profoundly affected post mortem delay agonal state cell population density
0.407656.9328480.html.plaintext.txt	42	seen figure num level expression epsisnum allele consistently higher epsisnum allele ad group well control group
0.407656.9328480.html.plaintext.txt	43	data suggest either differential stability different mrna specie genetic variability expression two allele disequilibrium coding polymorphism
0.407656.9328480.html.plaintext.txt	44	however addition clear consistent difference epsisnum allelic expression ratio ad case control
0.407656.9328480.html.plaintext.txt	45	result consistent notion part least genetic risk developing ad encoded apoe locus relates expression protein brain
0.407656.9328480.html.plaintext.txt	46	would seem heterozygote individual express relatively high proportion epsisnum allele greater risk developing disease expressing relatively low proportion
0.407656.9328480.html.plaintext.txt	47	observation different allele apoe equally expressed may importance formulation hypothesis relating role apoe pathogenesis ad general
0.407656.9328480.html.plaintext.txt	48	present much speculation experimentation designed determine nature role different allele apoe pathogenesis ad
0.407656.9328480.html.plaintext.txt	49	previously suggested enum isoform may facilitate num limit num amyloid substance deposition
0.407656.9328480.html.plaintext.txt	50	isoform would protect oxidative stress conversely enum isoform num
0.407656.9328480.html.plaintext.txt	51	finally suggested enum enum isoforms may prevent aggregation tau protein enum isoform may prevent paired helical filament formation num
0.407656.9328480.html.plaintext.txt	52	however hypothesis based premise apoe allele isoforms equally expressed present similar concentration brain
0.407656.9328480.html.plaintext.txt	53	isoform specific difference could enhanced different representation isoform individual
0.407656.9328480.html.plaintext.txt	54	date seems difficult link apoe mrna apoe protein level
0.407656.9328480.html.plaintext.txt	55	several study explored issue reporting contradictory finding brain numnum cerebrospinal fluid numnum plasma num
0.407656.9328480.html.plaintext.txt	56	even apoe level tested according apoe genotype none previous study able determine relative ratio different isoforms thus result comparable
0.407656.9328480.html.plaintext.txt	57	development isoform specific monoclonal antibody would help determine whether variation observed population also present protein level num
0.407656.9328480.html.plaintext.txt	58	two major finding work
0.407656.9328480.html.plaintext.txt	59	first expression epsisnum allele consistently higher expression epsisnum allele
0.407656.9328480.html.plaintext.txt	60	second expression epsisnum allele beyond certain level seems greatly influence vulnerability individual alzheimers disease
0.407656.9328480.html.plaintext.txt	61	interesting note apoe regulated consequence insult
0.407656.9328480.html.plaintext.txt	62	showed increase level expression apoe mrna rat lesioning cerebral cortex num
0.407656.9328480.html.plaintext.txt	63	showed apoe mrna increased ad brain num
0.407656.9328480.html.plaintext.txt	64	together result support event may lead increase apoe mrna parallel distortion allelic expression
0.407656.9328480.html.plaintext.txt	65	distortion allelic expression may specific brain possibly restricted certain area num
0.407656.9328480.html.plaintext.txt	66	suggests neural genetic susceptibility ad associated apoe gene
0.407656.9328480.html.plaintext.txt	67	interestingly templeton reached similar conclusion using cladistic analysis previously reported genetic data num
0.407656.9328480.html.plaintext.txt	68	using haplotype data marker surrounding apoe locus including apoe polymorphism templeton showed coding polymorphism apoe gene sufficient explain increased risk ad num
0.407656.9328480.html.plaintext.txt	69	data suggest influence non coding polymorphism apoe expression may supply rest answer
0.407656.9328480.html.plaintext.txt	70	material method rna extraction
0.407656.9328480.html.plaintext.txt	71	fourteen late onset ad case caucasian origin mean age num
0.407656.9328480.html.plaintext.txt	72	num year five male nine female num control mean age num
0.407656.9328480.html.plaintext.txt	73	num year five male seven female selected function apoe genotype num
0.407656.9328480.html.plaintext.txt	74	mean age sampling num
0.407656.9328480.html.plaintext.txt	75	num year ad case genotyped epsisnumepsisnum num
0.407656.9328480.html.plaintext.txt	76	num year control genotyped epsisnumepsisnum
0.407656.9328480.html.plaintext.txt	77	diagnosis confirmed neuropathological examination
0.407656.9328480.html.plaintext.txt	78	total rna extraction performed frontal lobe sample described gilmour et al
0.407656.9328480.html.plaintext.txt	79	num digested dnase eurogentec
0.407656.9328480.html.plaintext.txt	80	dna contamination observed dnase digestion detected pcr digested product
0.407656.9328480.html.plaintext.txt	81	rt pcr amplification apoe mrna
0.407656.9328480.html.plaintext.txt	82	rt reaction performed num h num min num degree c using fnum primer numprime acagaattcgccccggcctggta numprime num pmol num mug total rna template m mlv reverse transcriptase following condition described supplier gibcobrl
0.407656.9328480.html.plaintext.txt	83	pcr step carried fnum primer numprime taagcttggcacggctgtccaagga numprime num pmol final volume num mul num cycle num min num degree c num min num degree c num min num degree c cycle remain linear range reaction
0.407656.9328480.html.plaintext.txt	84	briefly pcr performed total volume num mul containing num
0.407656.9328480.html.plaintext.txt	85	num mm dntp num mm dtt num
0.407656.9328480.html.plaintext.txt	86	num triton x num num vv glycerol using whole rt reaction template
0.407656.9328480.html.plaintext.txt	87	rt pcr dna digested num u cfoi endonuclease promega dna fragment resolved num polyacrylamide gel acrylamidebisacrylamide numnum num h num vcm
0.407656.9328480.html.plaintext.txt	88	num mul rt pcr product loaded
0.407656.9328480.html.plaintext.txt	89	gel fixed num min num vv ethanol num
0.407656.9328480.html.plaintext.txt	90	two washing deionised water gel placed silver nitrate solution num mgml num min
0.407656.9328480.html.plaintext.txt	91	gel washed twice deionised water
0.407656.9328480.html.plaintext.txt	92	dna polymorphism fragment stained num min num
0.407656.9328480.html.plaintext.txt	93	num formaldehyde vv hydroxyde nitrate num mgml
0.407656.9328480.html.plaintext.txt	94	finally reaction stopped sodium carbonate solution num mgml
0.407656.9328480.html.plaintext.txt	95	developer silver nitrate solution prepared extemporaneously
0.407656.9328480.html.plaintext.txt	96	gel digitalised sharp jx num high resolution colour scanner fragment intensity measured using image master software pharmacia appropriate background subtract
0.407656.9328480.html.plaintext.txt	97	percentage epsisnum allele calculated equation described ref
0.407656.9328480.html.plaintext.txt	98	roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman n o sup epsilon roman num o r epsilon roman num m r n roman alpha sup prime epsilon roman num m r n roman alpha sup prime epsilon roman num m r n alpha sup prime epsilon roman num o r epsilon roman num m r n
0.407656.9328480.html.plaintext.txt	99	noepsisnum mrna noepsisnum mrna initial number epsisnum epsisnum mrna
0.407656.9328480.html.plaintext.txt	100	alphaprimeepsisnum mrna alphaprimeepsisnum epsisnum mrna coefficient allowing silver staining phenomenon saturation due staining integrated normalised
0.407656.9328480.html.plaintext.txt	101	coefficient proportionality correcting length difference restriction fragment
0.407656.9328480.html.plaintext.txt	102	digestion cfoi epsisnum epsisnum epsisnum allele characterised num num num bp fragment respectively
0.407656.9328480.html.plaintext.txt	103	coefficient therefore calculated numnum epsisnumepsisnum individual numnum epsisnumepsisnum individual numnum epsisnumepsisnum population
0.407656.9328480.html.plaintext.txt	104	epsisnum epsisnum allele give restriction length fragment num bp aodepsisnum mrna odepsisnum mrna odnum bp
0.407656.9328480.html.plaintext.txt	105	initial epsisnum allele percentage epsisnumepsisnum population calculated
0.407656.9328480.html.plaintext.txt	106	roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman alpha sup roman prime epsilon roman num m r n alpha prime sup num num roman b p
0.407656.9328480.html.plaintext.txt	107	detail calculation modelling method described ref
0.407656.9328480.html.plaintext.txt	108	tested viability approach apoe allele using genomic dna template different parameter initial concentration dna template initial percentage allele compared another num
0.407656.9328480.html.plaintext.txt	109	num reduced survival patient early onset alzheimers disease carry apolipoprotein egrnum allele
0.407656.9328480.html.plaintext.txt	110	french alzheimers disease collaborative group num evidence apolipoprotein e epsisnum association early onset alzheimers patient late onset relative
0.407656.9328480.html.plaintext.txt	111	num apolipoprotein e epsisnum allele major risk factor sporadic early late onset form alzheimers disease analysis numqnum
0.407656.9328480.html.plaintext.txt	112	num neuropathological change scrapie alzheimers disease associated increased expression apolipoprotein e cathepsin d astrocyte
0.407656.9328480.html.plaintext.txt	113	num astrocytic apolipoprotein e mrna gfap mrna hippocampus entorhinal cortex lesioning
0.407656.9328480.html.plaintext.txt	114	num apolipoprotrein e cholesterol transport protein expanding role cell biology
0.407656.9328480.html.plaintext.txt	115	num regulation apolipoprotein e gene expression injury rat sciatic nerve
0.407656.9328480.html.plaintext.txt	116	num low density lipoprotein pathway central nervous system apolipoprotein e isoform specific difference
0.407656.9328480.html.plaintext.txt	117	iqbal mortimer winblad wisniewski ed research advance alzheimers disease related disorder
0.407656.9328480.html.plaintext.txt	118	num association apolipoprotein e genotype brain level apolipoprotein e apolipoprotein j clusterin alzheimer disease
0.407656.9328480.html.plaintext.txt	119	num overcoming normalisation signal saturation due silver staining way quantify allele specific rt pcr product
0.407656.9328480.html.plaintext.txt	120	num binding human apolipoprotein e synthetic amyloid beta peptide isoform specific effect implication late onset alzheimer disease
0.407656.9328480.html.plaintext.txt	121	num apolipoprotein e kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment alzheimers disease
0.407656.9328480.html.plaintext.txt	122	num apolipoprotein e allele specific antioxidant activity effect cytotoxicity oxidative insult beta amyloid peptide
0.407656.9328480.html.plaintext.txt	123	num hypothesis microtubule instability paired helical filament formation alzheimer disease related apolipoprotein e genotype
0.407656.9328480.html.plaintext.txt	124	num brain expression apolipoprotein e j alzheimers disease
0.407656.9328480.html.plaintext.txt	125	num apolipoprotein e apoe polymorphism influence apoe concentration cerebrospinal fluid finnish patient alzheimers disease
0.407656.9328480.html.plaintext.txt	126	num relevance quantification apolipoprotein e cerebrospinal fluid alzheimers disease
0.407656.9328480.html.plaintext.txt	127	num increased plasma apolipoprotein e apoe level alzheimers disease
0.407656.9328480.html.plaintext.txt	128	num monoclonal antibody polymorphic site distinguishes apolipoprotein egrnum isoforms
0.407656.9328480.html.plaintext.txt	129	num accumulation apolipoprotein e b amyloid like protein trace hippocampal canum pyramidal cell layer ischaemic delayed neuronal death neuroreport num num num
0.407656.9328480.html.plaintext.txt	130	num cladistic analysis phenotypic association haplotype inferred restriction endonuclease mapping dna sequencing
0.407656.9328480.html.plaintext.txt	131	analysis casecontrol sampling design alzheimers disease apolipoprotein e locus
0.407656.9328480.html.plaintext.txt	132	num restriction isotyping human apolipoprotein e gene amplification cleavage hhai
0.407656.9328480.html.plaintext.txt	133	num biosynthesis protamine trout testis
0.407656.9328480.html.plaintext.txt	134	correspondence addressed inserm cjfnum num institut pasteur de lille num rue de calmette num lille cedex france
0.407656.9328480.html.plaintext.txt	135	tel num num num num num num fax num num num num num num email marie christine
0.407656.9328480.html.plaintext.txt	136	fr page maintained oup admin
0.407656.9328480.html.plaintext.txt	137	last updated sat oct num numnumnum bst num
0.407656.9328480.html.plaintext.txt	138	part oup journal world wide web service
0.407656.9328480.html.plaintext.txt	139	copyright oxford university press num
0.42286012.9811931.html.plaintext.txt	0	risk alzheimers disease correlate transcriptional activity apoe gene
0.42286012.9811931.html.plaintext.txt	1	departamento de biologia molecular centro de biologia molecular severo ochoa csic uam universidad autonoma de madrid cantoblanco num madrid spain numservicio de neurologia hospital universitario la paz uam num madrid spain numdepartments psychiatry neurology genetics washington university school medicine st louis mo num usa
0.42286012.9811931.html.plaintext.txt	2	received may num num revised accepted august num num
0.42286012.9811931.html.plaintext.txt	3	epsisnum allele apolipoprotein e apoe gene apoe protein widely accepted major genetic risk factor late onset form alzheimers disease ad recent evidence point variation apoe level another important factor
0.42286012.9811931.html.plaintext.txt	4	previously reported common variant regulatory region apoe numa associated risk late onset ad
0.42286012.9811931.html.plaintext.txt	5	report analyze association another apoe promoter polymorphism numtc ad two case control clinical sample demonstrate correlation apoe promoter transcriptional activity risk ad
0.42286012.9811931.html.plaintext.txt	6	association study show allelic variant numc haplotype numa numc apoe promoter associated increased risk ad
0.42286012.9811931.html.plaintext.txt	7	study transcriptional activity common haplotype defined combination num num allele indicated risk late onset ad positively correlate transcriptional activity apoe gene suggesting increase local expression apoe could responsible association apoe promoter polymorphism ad
0.42286012.9811931.html.plaintext.txt	8	alzheimers disease ad common cause dementia elderly exists familial sporadic form
0.42286012.9811931.html.plaintext.txt	9	genetic study led identification three gene beta amyloid precursor protein app num presenilin num num presenilin num num mutated cause autosomal dominant form familial ad
0.42286012.9811931.html.plaintext.txt	10	however mutation three gene responsible small fraction ad case vast majority patient ad present late age onset show non mendelian inheritance
0.42286012.9811931.html.plaintext.txt	11	absence mendelian inheritance indicates late onset ad complex disease genetic non genetic factor likely interacting
0.42286012.9811931.html.plaintext.txt	12	epsisnum allele apolipoprotein e apoe gene apoe protein associated increased risk developing ad num
0.42286012.9811931.html.plaintext.txt	13	however many ad case apoe epsisnum allele
0.42286012.9811931.html.plaintext.txt	14	thus likely additional ad risk factor genetic environmental still identified
0.42286012.9811931.html.plaintext.txt	15	screened genetic variability proximal promoter region apoe nt num num observed three new polymorphic site num num num num previously described one num num within region
0.42286012.9811931.html.plaintext.txt	16	recently reported one variant numa associated risk ad num
0.42286012.9811931.html.plaintext.txt	17	report allelic variant numc apoe promoter also associated ad whereas found significant association num num polymorphism risk ad
0.42286012.9811931.html.plaintext.txt	18	result others suggested num polymorphism act modifier apoenum associated risk num
0.42286012.9811931.html.plaintext.txt	19	study transcriptional activity haplotype defined combination num num allele indicates risk late onset ad correlate transcriptional activity apoe gene
0.42286012.9811931.html.plaintext.txt	20	screening transcriptional regulatory region apoe gene novel polymorphic site numtc identified num
0.42286012.9811931.html.plaintext.txt	21	possible genetic association polymorphism risk ad studied spanish case control sample previously observed association polymorphism position num apoe promoter risk ad num
0.42286012.9811931.html.plaintext.txt	22	genotype allele distribution numtc polymorphism shown table num
0.42286012.9811931.html.plaintext.txt	23	tc genotype c allele frequent although difference achieved statistical significance ad group control suggesting associated increased risk ad odds ratio num
0.42286012.9811931.html.plaintext.txt	24	num num confidence interval ci num
0.42286012.9811931.html.plaintext.txt	25	num tc genotype num
0.42286012.9811931.html.plaintext.txt	26	apoe numtc genotype allele frequency f spain age onset num year apoenum status genotype n f allele n f tt tc cc c whole sample case num num
0.42286012.9811931.html.plaintext.txt	27	num apoenum non carrier case num num
0.42286012.9811931.html.plaintext.txt	28	num carrier case num num
0.42286012.9811931.html.plaintext.txt	29	num num x num chinum test compare tt tc genotype frequency ad versus control performed whole sample p num
0.42286012.9811931.html.plaintext.txt	30	order determine whether variation risk ad associated numtc polymorphism independent risk conferred apoenum sample stratified basis absence presence apoenum allele table num
0.42286012.9811931.html.plaintext.txt	31	difference frequency numc allele numtc genotype observed ad patient control bearing one two apoenum allele numc allele clearly associated increased risk ad individual bearing apoenum allele num
0.42286012.9811931.html.plaintext.txt	32	similarly numtc genotype associated num fold increase risk ad subpopulation num
0.42286012.9811931.html.plaintext.txt	33	num indicating variation risk ad conferred numtc polymorphism apparent individual carrying apoenum allele
0.42286012.9811931.html.plaintext.txt	34	trend observed u group individual bearing apoenum allele num
0.42286012.9811931.html.plaintext.txt	35	num tc genotype although difference allelic frequency achieve statistical significance population
0.42286012.9811931.html.plaintext.txt	36	since numtc numat polymorphism located close within proximal numprime flanking region apoe gene appeared associated risk developing ad analyzed effect ad risk combined haplotype
0.42286012.9811931.html.plaintext.txt	37	first analyzed num num haplotype distribution spanish u sample
0.42286012.9811931.html.plaintext.txt	38	combined digestion apoe fragment spanning nt num num drai alui performed allowed identification four haplotype num genotype defined combination num num allele
0.42286012.9811931.html.plaintext.txt	39	haplotype num num common followed c
0.42286012.9811931.html.plaintext.txt	40	subject c haplotype found either sample
0.42286012.9811931.html.plaintext.txt	41	distribution haplotype genotype close expected hardy weinberg equilibrium chinum test p num
0.42286012.9811931.html.plaintext.txt	42	furthermore statistically significant evidence linkage disequilibrium polymorphism detected chinum test p num
0.42286012.9811931.html.plaintext.txt	43	frequent genotype ta followed tt ta c three genotype accounted num spanish st louis control population
0.42286012.9811931.html.plaintext.txt	44	frequency genotype tt ct num frequency genotype ranged num num
0.42286012.9811931.html.plaintext.txt	45	distribution major haplotype genotype spanish st louis sample shown table num
0.42286012.9811931.html.plaintext.txt	46	since previous study revealed difference transcription associated num polymorphism numnum examined functional characteristic major num num haplotype present population
0.42286012.9811931.html.plaintext.txt	47	apoe proximal promoter activity three haplotype c measured unum human astrocytoma cell using luciferase based transient transfection system employed previous study numnumnum
0.42286012.9811931.html.plaintext.txt	48	shown figure num transcriptional activity haplotype c increased num num respectively haplotype suggesting presence allele conferring increased risk ad numa numc associated increased constitutive level apoe promoter activity human astrocytoma cell
0.42286012.9811931.html.plaintext.txt	49	three haplotype c thus named minus even x plus respectively according transcriptional activity
0.42286012.9811931.html.plaintext.txt	50	additional information obtained using oligonucleotide probe corresponding num num allelic form electrophoretic mobility shift assay freshly prepared nuclear extract unum cell
0.42286012.9811931.html.plaintext.txt	51	shown figure num one three specific band shift detected numt probe arrow detected numc probe suggesting c substitution hinders binding probe nuclear protein
0.42286012.9811931.html.plaintext.txt	52	finding agreement data obtained previous work using num probe num strongly suggests differential transcriptional activity three num num haplotype encountered astrocytoma cell consequence differential binding nuclear protein present cell
0.42286012.9811931.html.plaintext.txt	53	apoe num num major genotype haplotype frequency f age onset num year genotype n f haplotype n f ta tt ta c c spain madrid case num num
0.42286012.9811931.html.plaintext.txt	54	num usa st louis case num num
0.42286012.9811931.html.plaintext.txt	55	num num x num chinum test ta c versus tt spain p num
0.42286012.9811931.html.plaintext.txt	56	num x num chinum test ta versus tt spain p num
0.42286012.9811931.html.plaintext.txt	57	transcriptional activity num num haplotype apoe promoter
0.42286012.9811931.html.plaintext.txt	58	luciferasebeta galactosidase activity ratio pxpnum construct containing x c apoe haplotype transfected unum astrocytoma cell expressed percentage activity construct
0.42286012.9811931.html.plaintext.txt	59	data mean plus minus sem six determination representative five experiment
0.42286012.9811931.html.plaintext.txt	60	protein binding numtc allelic form apoe promoter
0.42286012.9811931.html.plaintext.txt	61	nump labeled numt numc probe incubated unum nuclear extract ne subjected electrophoretic mobility shift assay
0.42286012.9811931.html.plaintext.txt	62	competition experiment performed pre incubating nuclear extract num fold excess unlabeled oligonucleotide addition probe
0.42286012.9811931.html.plaintext.txt	63	arrow specific shift band asterisk non specific band
0.42286012.9811931.html.plaintext.txt	64	result representative four independent experiment
0.42286012.9811931.html.plaintext.txt	65	association apoe promoter activity risk ad analyzed spanish population stratified according apoe status table num
0.42286012.9811931.html.plaintext.txt	66	strong association ad risk promoter activity three predominant genotype x xx x observed spanish non apoenum individual taking reference x individual risk ad found increase num num fold xx x individual respectively
0.42286012.9811931.html.plaintext.txt	67	statistical significance data evaluated logistic regression model
0.42286012.9811931.html.plaintext.txt	68	analysis subgroup non enum carrier showed highly significant association ad risk promoter activity p num num yielded predicted or num
0.42286012.9811931.html.plaintext.txt	69	num num num ci num num genotype xx x respectively fig
0.42286012.9811931.html.plaintext.txt	70	association risk ad apoe promoter genotype spanish b u non apoenum subpopulation
0.42286012.9811931.html.plaintext.txt	71	risk represented log odds scale taking reference genotype x bear weakest expressing haplotype
0.42286012.9811931.html.plaintext.txt	72	bar represent calculated or
0.42286012.9811931.html.plaintext.txt	73	superimposed line represents or estimated logistic regression model error bar indicate num ci
0.42286012.9811931.html.plaintext.txt	74	finally hypothesis ad risk increase promoter transcriptional activity measured transfection assay tested st louis population
0.42286012.9811931.html.plaintext.txt	75	although association le impressive encountered spanish population similar dependence developing ad promoter activity three predominant genotype detected non enum subpopulation table num
0.42286012.9811931.html.plaintext.txt	76	logistic regression analysis indicated highly statistically significant association ad risk promoter activity p num num or num
0.42286012.9811931.html.plaintext.txt	77	num genotype xx x respectively fig
0.42286012.9811931.html.plaintext.txt	78	paper report association polymorphism proximal region apoe promoter risk ad
0.42286012.9811931.html.plaintext.txt	79	previously reported association homozygosity numa allele risk ad num
0.42286012.9811931.html.plaintext.txt	80	show numc allele also associated risk ad
0.42286012.9811931.html.plaintext.txt	81	furthermore combination two allele numa numc haplotype generates high risk ad particular spanish population individual bearing apoenum allele
0.42286012.9811931.html.plaintext.txt	82	effect observed st louis sample although relative risk lower spanish sample
0.42286012.9811931.html.plaintext.txt	83	difference relative risk probably attributable difference frequency apoe promoter haplotype two control population since two ad sample show similar frequency promoter haplotype
0.42286012.9811931.html.plaintext.txt	84	well documented population based difference apoenum allele frequency numnum give rise population difference relative risk ad associated allele
0.42286012.9811931.html.plaintext.txt	85	consistently sample associated apoenum spanish population num
0.42286012.9811931.html.plaintext.txt	86	num double st louis sample num
0.42286012.9811931.html.plaintext.txt	87	based data anticipate wide variation relative risk ad associated apoe promoter polymorphism different population already noted apoenum allele num
0.42286012.9811931.html.plaintext.txt	88	dividing sample basis presence absence apoenum revealed promoter polymorphism apoenum independent risk factor
0.42286012.9811931.html.plaintext.txt	89	indeed risk due promoter polymorphism prominent individual without apoenum allele
0.42286012.9811931.html.plaintext.txt	90	apoe num num major genotype distribution apoe epsisnum carrier non carrier age onset num year apoenum status spain madrid n f usa st louis n f ta tt ta c ta tt ta c case num num
0.42286012.9811931.html.plaintext.txt	91	num num x num chinum test ta c versus tt apoenum non carrier spain p num
0.42286012.9811931.html.plaintext.txt	92	num x num chinum test ta versus tt apoenum non carrier spain p num
0.42286012.9811931.html.plaintext.txt	93	p value apoenum carrier num
0.42286012.9811931.html.plaintext.txt	94	num significant sample
0.42286012.9811931.html.plaintext.txt	95	apoe expression regulated complex interaction developmental hormonal dietary factor num num
0.42286012.9811931.html.plaintext.txt	96	regulation apoe expression investigated thoroughly hepatoma cell shown element required efficient expression located numprime proximal region first intron num num
0.42286012.9811931.html.plaintext.txt	97	recently demonstrated region also drive efficient expression apoe astrocytoma cell num
0.42286012.9811931.html.plaintext.txt	98	data presented report strongly suggest allelic polymorphism transcriptional regulatory region apoe may contribute difference level apoe synthesis astrocyte
0.42286012.9811931.html.plaintext.txt	99	specifically data indicate single base substitution corresponding num num apoe polymorphic site produce difference transcriptional activity apoe promoter due differential binding nuclear protein
0.42286012.9811931.html.plaintext.txt	100	well documented single nucleotide change within promoter region dramatically affect transcriptional activity mediated transcription factor num num
0.42286012.9811931.html.plaintext.txt	101	data presented strongly suggest existence direct correlation risk ad apoe promoter activity astrocytic cell
0.42286012.9811931.html.plaintext.txt	102	higher expression apoe higher risk ad
0.42286012.9811931.html.plaintext.txt	103	increasing evidence suggesting increased level apoe associated ad pathogenesis
0.42286012.9811931.html.plaintext.txt	104	several study reported apoe level elevated brain plasma ad patient num num
0.42286012.9811931.html.plaintext.txt	105	intracellular accumulation apoe also correlated neuronal cell death intracellular abeta stabilization num
0.42286012.9811931.html.plaintext.txt	106	recent study also demonstrated level apoe expression modify cytotoxic effect apoe propensity abeta deposit murine brain
0.42286012.9811931.html.plaintext.txt	107	apoe concentration found cerebrospinal fluid protects neuronal cell abeta peptide higher apoe concentration could lead neuronal cell death num
0.42286012.9811931.html.plaintext.txt	108	crossing apoe knockout mouse mouse overexpressing human mutant app gene indicates abeta deposition correlate positively apoe dose suggests apoe may facilitate abeta peptide deposition vivo num
0.42286012.9811931.html.plaintext.txt	109	despite evidence implicating apoenum single important genetic determinant susceptibility late onset ad pathogenic role well understood
0.42286012.9811931.html.plaintext.txt	110	amino acid substitution associated enum enum enum apoe isoforms lead difference predicted three dimensional structure apoe likely alter functional property molecule
0.42286012.9811931.html.plaintext.txt	111	several potential mechanism action apoenum ad risk proposed based apoe isoform specific difference observed several assay developed brain cell num num
0.42286012.9811931.html.plaintext.txt	112	however date adequate explanation variation risk ad associated different apoe isoforms
0.42286012.9811931.html.plaintext.txt	113	based upon data presented elsewhere suggest two independent mechanism ad risk modified apoe gene
0.42286012.9811931.html.plaintext.txt	114	first involves variant coding region alter functional property apoe molecule second involves promoter region variant result quantitative difference apoe expression
0.42286012.9811931.html.plaintext.txt	115	two factor associated ad risk independently
0.42286012.9811931.html.plaintext.txt	116	one produce risk may interact resulting overall risk individual bearing apoenum high expressing apoe promoter form would depend relative contribution two risk factor
0.42286012.9811931.html.plaintext.txt	117	summary data strongly suggest risk ad associated apoe promoter polymorphism directly correlate transcriptional activity gene
0.42286012.9811931.html.plaintext.txt	118	speculate increase local expression apoe due apoe promoter polymorphism could lead enhanced deposition abeta peptide brain thus explaining increased risk ad
0.42286012.9811931.html.plaintext.txt	119	correct drug either control apoe synthesis inhibit abeta production deposition may useful treatment ad
0.42286012.9811931.html.plaintext.txt	120	material method study subject
0.42286012.9811931.html.plaintext.txt	121	test sample consisted num healthy control age onset num plus minus num year mean plus minus sd num late onset sporadic ad case num plus minus num year madrid region spain recruited neurology service hospital la paz madrid
0.42286012.9811931.html.plaintext.txt	122	replication sample composed num healthy control num plus minus num year num ad numnum case num plus minus num year st louis metropolitan region usa recruited alzheimers disease research center washington university
0.42286012.9811931.html.plaintext.txt	123	sample included individual caucasian origin
0.42286012.9811931.html.plaintext.txt	124	genotyping numat numtc apoe polymorphism
0.42286012.9811931.html.plaintext.txt	125	apoe region num num amplified nested pcr using mismatched primer generate drai site specific numa allele
0.42286012.9811931.html.plaintext.txt	126	briefly pcr used amplify num bp fragment transcriptional regulatory region spanning num num relative transcriptional start site num
0.42286012.9811931.html.plaintext.txt	127	primer numprime caaggtcacacagctggcaac numprime numprime tccaatcgacggctagctacc numprime used amplify whole transcriptional regulatory region
0.42286012.9811931.html.plaintext.txt	128	nested pcr used difficulty reliably amplifying num num fragment directly genomic dna
0.42286012.9811931.html.plaintext.txt	129	num bp pcr product therefore used template following reaction
0.42286012.9811931.html.plaintext.txt	130	forward mismatched primer numprime tgttggccaggctggttttaa numprime reverse primer numprime cctcctttcctgaccctgtcc numprime
0.42286012.9811931.html.plaintext.txt	131	analyze num num genotype well num num haplotype product digested drai alui restriction enzyme together
0.42286012.9811931.html.plaintext.txt	132	apoe isoform genotyping performed described numnum
0.42286012.9811931.html.plaintext.txt	133	numprime region position num num apoe gene cloned pxpnum luciferase reporter plasmid described num
0.42286012.9811931.html.plaintext.txt	134	pcr based site directed mutagenesis used replace num c num using modification described method num
0.42286012.9811931.html.plaintext.txt	135	construct transfected unum human astrocytoma cell luciferase beta galactosidase activity extract determined described num
0.42286012.9811931.html.plaintext.txt	136	electrophoretic mobility shift assay emsa
0.42286012.9811931.html.plaintext.txt	137	emsa oligonucleotide probe unum nuclear extract performed described numnum
0.42286012.9811931.html.plaintext.txt	138	oligonucleotides numprime gctggtctcaaatctcctgaccttaa numprime numprime acaggcgtgagctcaccgcccccagc numprime used study nuclear protein binding num num site respectively
0.42286012.9811931.html.plaintext.txt	139	genotype allelehaplotype distribution analyzed num x num chinum test
0.42286012.9811931.html.plaintext.txt	140	relative risk or num ci calculated described num
0.42286012.9811931.html.plaintext.txt	141	logistic regression model used estimate relative risk ad major apoe promoter genotype function transcriptional activity
0.42286012.9811931.html.plaintext.txt	142	alonso hospital ramon y cajal madrid kind collaboration sample collection p
0.42286012.9811931.html.plaintext.txt	143	diez tejedor hospital la paz madrid advice clinical work faculty staff washington university alzheimers disease research center patient evaluation sample collection
0.42286012.9811931.html.plaintext.txt	144	baty washington university division biostatistics advice statistical analysis
0.42286012.9811931.html.plaintext.txt	145	mayor continuous encouragement help
0.42286012.9811931.html.plaintext.txt	146	thank patient healthy individual participated research
0.42286012.9811931.html.plaintext.txt	147	work supported boehringer ingelheim espana fondo de investigacion sanitarium grant
0.42286012.9811931.html.plaintext.txt	148	num num nih agnum agnum alzheimers association nettie rebecca brown foundation metropolitan life foundation
0.42286012.9811931.html.plaintext.txt	149	institutional grant fundacion ramon areces cbmso acknowledged
0.42286012.9811931.html.plaintext.txt	150	recipient fellowship fondo de investigacion sanitarium
0.42286012.9811931.html.plaintext.txt	151	recipient fellowship spanish ministerio de educacion y ciencia
0.42286012.9811931.html.plaintext.txt	152	post doctoral fellow washington university alzheimers disease research center
0.42286012.9811931.html.plaintext.txt	153	recipient nih career development award agnum
0.42286012.9811931.html.plaintext.txt	154	ad alzheimers disease apoe apolipoprotein e apoe apolipoprotein e gene app beta amyloid precursor protein ci confidence interval odds ratio
0.42286012.9811931.html.plaintext.txt	155	num cloning gene bearing missense mutation early onset familial alzheimers disease
0.42286012.9811931.html.plaintext.txt	156	num candidate gene chromosome num familial alzheimers disease locus
0.42286012.9811931.html.plaintext.txt	157	num gene dose apolipoprotein e type num allele risk ad late onset family
0.42286012.9811931.html.plaintext.txt	158	num allelic polymorphism transcriptional regulatory region apolipoprotein e gene
0.42286012.9811931.html.plaintext.txt	159	num newly identified polymorphism apolipoprotein e enhancer gene region associated alzheimers disease strongly epsisnum allele
0.42286012.9811931.html.plaintext.txt	160	num polymorphism regulatory region apoe associated risk alzheimers dementia
0.42286012.9811931.html.plaintext.txt	161	num new polymorphism apoe promoter associated risk developing alzheimers dementia
0.42286012.9811931.html.plaintext.txt	162	num apolipoprotein e polymorphism danish population compared finding num study population around world
0.42286012.9811931.html.plaintext.txt	163	num pattern gradient apolipoprotein e allele num frequency western europe
0.42286012.9811931.html.plaintext.txt	164	num effect age sex ethnicity association apolipoprotein e genotype alzheimer disease
0.42286012.9811931.html.plaintext.txt	165	apoe alzheimer disease meta analysis consortium
0.42286012.9811931.html.plaintext.txt	166	num effect atherogenic diet apolipoprotein e biosynthesis rat
0.42286012.9811931.html.plaintext.txt	167	num cloning regulation messenger rna mouse apolipoprotein e
0.42286012.9811931.html.plaintext.txt	168	num apolipoprotein e mrna abundant brain adrenal well liver present peripheral tissue rat marmoset
0.42286012.9811931.html.plaintext.txt	169	num secretion apolipoprotein e human monocyte derived macrophage
0.42286012.9811931.html.plaintext.txt	170	num identification characterization transcriptional regulatory region associated expression human apolipoprotein e gene
0.42286012.9811931.html.plaintext.txt	171	num expression human apolipoprotein e gene regulated multiple positive negative element
0.42286012.9811931.html.plaintext.txt	172	num human apolipoprotein e gene negatively regulated human liver hepgnum cell transcription factor bef num
0.42286012.9811931.html.plaintext.txt	173	num transcriptional factor ap num regulates human apolipoprotein e gene expression astrocytoma cell
0.42286012.9811931.html.plaintext.txt	174	num single base pair substitution within hla dra gene promoter separate function xnum xnum box
0.42286012.9811931.html.plaintext.txt	175	num polymorphism g transition num position apolipoprotein promoter increase transcription efficiency
0.42286012.9811931.html.plaintext.txt	176	num polymorphism human apolipoprotein num gene promoter region
0.42286012.9811931.html.plaintext.txt	177	association minor allele decreased production rate vivo promoter activity vitro
0.42286012.9811931.html.plaintext.txt	178	num apolipoprotein e mrna brain patient alzheimers disease
0.42286012.9811931.html.plaintext.txt	179	num distortion allelic expression apolipoprotein e alzheimers disease
0.42286012.9811931.html.plaintext.txt	180	num increased plasma apolipoprotein e apoe level alzheimers disease
0.42286012.9811931.html.plaintext.txt	181	num neuronal cell death alzheimers disease correlate apoe uptake intracellular abeta stabilization
0.42286012.9811931.html.plaintext.txt	182	num apolipoprotein e allele specific antioxidant activity effect cytotoxicity oxidative insult beta amyloid peptide
0.42286012.9811931.html.plaintext.txt	183	num lack apolipoprotein e dramatically reduces amyloid beta peptide deposition
0.42286012.9811931.html.plaintext.txt	184	num alteration apolipoprotein e expression aging neurodegeneration
0.42286012.9811931.html.plaintext.txt	185	num role apolipoprotein e apolipoprotein low density lipoprotein receptor cholesterol transport regeneration remyelination rat sciatic nerve
0.42286012.9811931.html.plaintext.txt	186	num apolipoprotein e impact cytoskeletal stability neuron relationship alzheimers disease
0.42286012.9811931.html.plaintext.txt	187	num interaction apolipoprotein e laminin increase neuronal adhesion alters neurite morphology
0.42286012.9811931.html.plaintext.txt	188	num apolipoprotein e cholesterol affect neuronal calcium signalling possible relationship beta amyloid neurotoxicity
0.42286012.9811931.html.plaintext.txt	189	num glial fibrillary acidic protein apolipoprotein e apoe transgenic mouse astrocyte specific expression differing biological effect astrocyte secreted apoenum apoenum lipoprotein
0.42286012.9811931.html.plaintext.txt	190	num differential cellular accumulationretention apolipoprotein e mediated cell surface heparan sulfate proteoglicans
0.42286012.9811931.html.plaintext.txt	191	apolipoproteins enum enum greater enum
0.42286012.9811931.html.plaintext.txt	192	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.42286012.9811931.html.plaintext.txt	193	num restriction isotyping human apolipoprotein e gene amplification cleavage hhai
0.42286012.9811931.html.plaintext.txt	194	num protection alzheimers disease apoe epsilon num
0.42286012.9811931.html.plaintext.txt	195	academic press new york ny pp
0.42286012.9811931.html.plaintext.txt	196	num calculating confidence interval relative risk odds ratio standardised ratio rate
0.42286012.9811931.html.plaintext.txt	197	correspondence addressed
0.42286012.9811931.html.plaintext.txt	198	tel num num num num num fax num num num num num email fvaldiviesoat cbm
0.42286012.9811931.html.plaintext.txt	199	e u d first two author contributed equally work page run oxford university press great clarendon street oxford oxnum numdp part oup journal comment feedback www adminatoup
0.42286012.9811931.html.plaintext.txt	200	uk u d last modification num nov num copyright oxford university press num
0.5179277.15126630.html.plaintext.txt	0	cathepsin d involved regulation transglutaminase num epidermal differentiation friederike egbertsnum michael heinrichnum jens michael jensennum supandi winoto morbachnum stephan pfeiffernum marc wickelnum michael schuncknum judith steudenum paul saftignum ehrhardt prokschnum stefan schutzenum
0.5179277.15126630.html.plaintext.txt	1	num department dermatology university hospital schleswig holstein campus kiel num kiel germany num institute immunology university hospital schleswig holstein campus kiel num kiel germany num central microscopy centrum biology university kiel num kiel germany num department biochemistry university kiel num kiel germany
0.5179277.15126630.html.plaintext.txt	2	author correspondence e mail schuetzeatimmunologie
0.5179277.15126630.html.plaintext.txt	3	key word barrier function cathepsin d cornified envelope epidermal differentiation involucrin loricrin filaggrin keratin sphingomyelinase transglutaminase
0.5179277.15126630.html.plaintext.txt	4	insoluble protein envelope located beneath plasma membrane keratinocytes cross linked cellular transglutaminase num tgnum terminal differentiation epidermis
0.5179277.15126630.html.plaintext.txt	5	involucrin early marker terminal differentiation soluble protein precursor cross linked cornified envelope ce synthesized keratinocytes upper spinous layer watt num eckert et al
0.5179277.15126630.html.plaintext.txt	6	num rice green num steinert marekov num
0.5179277.15126630.html.plaintext.txt	7	hyperproliferative disease like psoriasis premature expression involucrin found lower spinous layer thewes et al
0.5179277.15126630.html.plaintext.txt	8	another main component ce loricrin
0.5179277.15126630.html.plaintext.txt	9	expressed later stage differentiation watt num cross linked epidermal protein cystatin elafin filaggrin
0.5179277.15126630.html.plaintext.txt	10	extracellular lipid barrier predominantly ceramides synthesized keratinocytes stored epidermal lamellar body secreted intercellular space stratum corneum elia num
0.5179277.15126630.html.plaintext.txt	11	beside structural role ceramide known important intracellular signal mediator various cytokine particular tumor necrosis factor tnf liu et al
0.5179277.15126630.html.plaintext.txt	12	num perry hannun num
0.5179277.15126630.html.plaintext.txt	13	tnf binding pnum tnf receptor tnf rnum result activation endolysosomal acid sphingomyelinase wiegmann et al
0.5179277.15126630.html.plaintext.txt	14	increase intracellular ceramide level followed different cellular response depending cell type degree activation differentiation proliferation programmed cell death apoptosis kronke et al
0.5179277.15126630.html.plaintext.txt	15	num kolesnick golde num geilen et al
0.5179277.15126630.html.plaintext.txt	16	suggested functional role tnf ceramide derived acid sphingomyelinase cutaneous permeability barrier repair experimentally induced injury skin
0.5179277.15126630.html.plaintext.txt	17	detected high level sphingomyelinase ceramides barrier disruption well significant delay barrier repair tnf rnum deficient mouse jensen et al
0.5179277.15126630.html.plaintext.txt	18	understanding various biological effect ceramides important know direct intracellular target
0.5179277.15126630.html.plaintext.txt	19	recently found aspartatic protease cathepsin d ctsd novel specific intracellular binding protein ceramide derived acid sphingomyelinase heinrich et al
0.5179277.15126630.html.plaintext.txt	20	ceramide enhances proteolytic activity ctsd
0.5179277.15126630.html.plaintext.txt	21	ctsd main aspartatic protease endolysosomes
0.5179277.15126630.html.plaintext.txt	22	synthesized translocated endoplasmic reticulum inactive pre proenzyme num kda processed enzymatically active intermediate proenzyme num kda finally converted mature form num kda lysosome fujita et al
0.5179277.15126630.html.plaintext.txt	23	ctsd involved proteolytic activation well proteolytic degradation intracellular protein diment et al
0.5179277.15126630.html.plaintext.txt	24	increased level ctsd correlated tumor cell invasion metastasis malignant melanoma squamous cell carcinoma human breast cancer kageshita et al
0.5179277.15126630.html.plaintext.txt	25	report suggest ctsd may play role metastasizing process malignant cell destructive effect extracellular matrix
0.5179277.15126630.html.plaintext.txt	26	therefore ctsd activity used predict recurrence breast cancer tandon et al
0.5179277.15126630.html.plaintext.txt	27	hela cell culture ctsd mediator programmed cell death induced various cytokine
0.5179277.15126630.html.plaintext.txt	28	overexpression ctsd induced cell death without external stimulus ctsd inhibitor pepstatin suppressed cell death system deiss et al
0.5179277.15126630.html.plaintext.txt	29	finding supported vivo study ctsd deficient mouse generated gene targeting
0.5179277.15126630.html.plaintext.txt	30	mouse developed normally first num week
0.5179277.15126630.html.plaintext.txt	31	afterwards exhibited progressive atrophy intestinal mucosa followed massive intestinal necrosis profound destruction lymphoid cell
0.5179277.15126630.html.plaintext.txt	32	mouse died state anorexia age num week though lysosomal bulk proteolysis maintained possibly due compensatory activation related lysosomal protease saftig et al
0.5179277.15126630.html.plaintext.txt	33	skin ctsd play role extracellular intracellular catabolism
0.5179277.15126630.html.plaintext.txt	34	hyperproliferative skin disorder psoriasis increased expression mature form ctsd reported returning normal resolution psoriasis psoralen long wave ultraviolet radiation puva light treatment kawada et al
0.5179277.15126630.html.plaintext.txt	35	suggested ctsd may involved control cell differentiation normal development
0.5179277.15126630.html.plaintext.txt	36	found increased expression increased activity ctsd isoforms skin depending stage epidermal differentiation horikoshi et al
0.5179277.15126630.html.plaintext.txt	37	ctsd enzyme active acid ph maximum ph num may work transition stratum granulosum stratum corneum stratum corneum produce acid environment ph num
0.5179277.15126630.html.plaintext.txt	38	despite result function cellular substrate ctsd epidermal differentiation still unknown
0.5179277.15126630.html.plaintext.txt	39	present study explored functional role ctsd skin permeability barrier repair epidermal differentiation using keratinocyte cell culture wild type ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	40	particular examined functional role ctsd activation keratinocyte tgnum key enzyme processing ce protein involucrin loricrin filaggrin epidermal differentiation
0.5179277.15126630.html.plaintext.txt	41	permeability barrier disruption disruption permeability barrier induced hairless mouse tape stripping tesafilm beiersdorf hamburg germany remove cell stratum corneum resulting superficial wound num num fold increase transepidermal water loss tewl marker barrier disruption achieved meeco electronic water analyzer meeco inc
0.5179277.15126630.html.plaintext.txt	42	warrington pa spruit malten num grubauer et al
0.5179277.15126630.html.plaintext.txt	43	barrier recovery calculated follows barrier recovery num xh baselinenumnumh baseline
0.5179277.15126630.html.plaintext.txt	44	xhtewl x hour barrier disruption ohtewl directly barrier disruption baselinenormal tewl skin without barrier disruption
0.5179277.15126630.html.plaintext.txt	45	hairy ctsd deficient mouse fur carefully removed shaving prior barrier disruption
0.5179277.15126630.html.plaintext.txt	46	shaving result irritation barrier disruption
0.5179277.15126630.html.plaintext.txt	47	experiment least three animal treated least three animal served control
0.5179277.15126630.html.plaintext.txt	48	different time barrier disruption num num hour tewl marker barrier repair measured skin sample num cmnum obtained
0.5179277.15126630.html.plaintext.txt	49	measurement basal tewl measurement basal tewl performed using tewameter courage khazaka germany described previously jensen et al
0.5179277.15126630.html.plaintext.txt	50	sensitivity tewameter small change tewl seen basal condition higher meeco water analyzer
0.5179277.15126630.html.plaintext.txt	51	topical application pepstatin normal mouse skin immediately barrier disruption num microl pepstatin num
0.5179277.15126630.html.plaintext.txt	52	num propylene glycolisopropanol numnum vv applied topically
0.5179277.15126630.html.plaintext.txt	53	vehicle application served control
0.5179277.15126630.html.plaintext.txt	54	tewl determined different time point barrier disruption num num hour skin sample num cmnum taken
0.5179277.15126630.html.plaintext.txt	55	isolation epidermal sample acute barrier disruption flank skin treated untreated site excised immediately placed epidermal side onto covered petri dish containing crushed ice
0.5179277.15126630.html.plaintext.txt	56	skin piece scraped scalpel blade remove subcutaneous fat immersed num degree c num minute num mm edta calcium magnesium free phosphate buffered saline pb
0.5179277.15126630.html.plaintext.txt	57	thereafter epidermis peeled dermis gentle scraping scalpel blade
0.5179277.15126630.html.plaintext.txt	58	num num mg epidermis disrupted num ml buffer h num mm kcl num mm naf num mm phenylmethylsulfonylfluoride num microm pepstatin num microm leupeptin num microm antipain boehringer complete numnum hepes ph num
0.5179277.15126630.html.plaintext.txt	59	num electric glass homogenizer potter braun melsungen germany num rpm num minute
0.5179277.15126630.html.plaintext.txt	60	cell homogenized passing num g needle followed sonication three time num second
0.5179277.15126630.html.plaintext.txt	61	analyze involucrin loricrin expression entire skin sample excised subcutaneous fat removed skin disrupted ultrathurrax ika labortechnik staufen germany tris buffer num mm nacl num mm tris ph num
0.5179277.15126630.html.plaintext.txt	62	num homogenized potter described
0.5179277.15126630.html.plaintext.txt	63	subsequently probe boiled num minute lysates cleared centrifugation num minute numnum g
0.5179277.15126630.html.plaintext.txt	64	isolation culture cell keratinocyte culture cell harvested incubation trypsin edta scraped pb pelleted centrifugation num minute num g homogenized buffer h sonicated
0.5179277.15126630.html.plaintext.txt	65	centrifugation supernatant stored num degree c
0.5179277.15126630.html.plaintext.txt	66	determination ctsd tgnum involucrin loricrin protein concentration measured bicinchoninic acid protein assay pierce rockford usa
0.5179277.15126630.html.plaintext.txt	67	equal protein sample electrophoresed num
0.5179277.15126630.html.plaintext.txt	68	num polyacrylamide gel transferred onto nitrocellulose filter num v num minute mini transblot biorad munich germany
0.5179277.15126630.html.plaintext.txt	69	ctsd cell culture detected incubation num hour room temperature polyclonal rabbit anti human ctsd antibody dilution numnum tbst calbiochem oncogene science usa ctsd mouse detected rabbit anti mouse ctsd antibody kindly provided r
0.5179277.15126630.html.plaintext.txt	70	pohlmann university munster germany tgnum goat anti human polyclonal antibody kindly provided
0.5179277.15126630.html.plaintext.txt	71	steinert nih bethesda md see kim et al
0.5179277.15126630.html.plaintext.txt	72	num involucrin loricrin detected rabbit anti mouse antibody prb numc prb nump respectively covance inc
0.5179277.15126630.html.plaintext.txt	73	ca usa distributed hiss diagnostics freiburg germany
0.5179277.15126630.html.plaintext.txt	74	secondary antibody complex visualized using chemiluminescent detection system ecl amersham braunschweig germany quantified densitometry pc ba tina software
0.5179277.15126630.html.plaintext.txt	75	ctsd assay estimate activity cellular ctsd assay performed using parathyroid hormone pth specific substrate previously described heinrich et al
0.5179277.15126630.html.plaintext.txt	76	digestion pth result cleavage hormone phenum valnum yielding pth num num pth num num fragment
0.5179277.15126630.html.plaintext.txt	77	pth proteolysis detected immunoblotting using monoclonal antibody could blocked aspartate protease inhibitor pepstatin selective inhibitor ctsd
0.5179277.15126630.html.plaintext.txt	78	num microg lysate protein incubated indicated time num ng pth num degree c volume num microl acidic buffer num mm sodium acetate num mm kcl ph num
0.5179277.15126630.html.plaintext.txt	79	demonstrate ctsd specificity reaction num
0.5179277.15126630.html.plaintext.txt	80	num microm pepstatin added assay indicated
0.5179277.15126630.html.plaintext.txt	81	one sample containing pth acidic buffer without lysate served control
0.5179277.15126630.html.plaintext.txt	82	reaction stopped boiling sample num minute tris tricine sd sample buffer num s mercaptoethanol num glycerol num mm tris ph num
0.5179277.15126630.html.plaintext.txt	83	num num sodium dodecyl sulfate num
0.5179277.15126630.html.plaintext.txt	84	protein separated num sd page transferred onto nitrocellulose filter
0.5179277.15126630.html.plaintext.txt	85	immunoblotting performed using anti pth mouse antibody specific fragment num num biogenesis anti mouse secondary horseradish peroxidase conjugate
0.5179277.15126630.html.plaintext.txt	86	blot developed using ecl detection reagent amersham
0.5179277.15126630.html.plaintext.txt	87	tgnum assay mouse epidermis disrupted ultrathurrax ika labortechnik staufen germany homogenized potter described buffer containing num mm sodium phosphate ph num
0.5179277.15126630.html.plaintext.txt	88	num mm edta num mm dithiothreitol num microgml phenylmethylsulfonylfluoride
0.5179277.15126630.html.plaintext.txt	89	epidermal cell lysed buffer sonication
0.5179277.15126630.html.plaintext.txt	90	epidermal tgnum activity measured described previously hohl et al
0.5179277.15126630.html.plaintext.txt	91	briefly num microg tissue extract added num microl solution containing num
0.5179277.15126630.html.plaintext.txt	92	num m sodium borate ph num num microl num mm edta ph num num microl num mm caclnum num microl dimethylcasein num mgml num
0.5179277.15126630.html.plaintext.txt	93	num microl num triton x num num
0.5179277.15126630.html.plaintext.txt	94	num microl num m dithiotreitol num
0.5179277.15126630.html.plaintext.txt	95	num microl num microm putrescine num microl numnum n numh putrescine dihydrochloride num mciml num num cimmol nen num
0.5179277.15126630.html.plaintext.txt	96	incubation num degree c num minute num microl applied cellulose filter paper whatman washed sequentially num tca num
0.5179277.15126630.html.plaintext.txt	97	radioactivity determined liquid scintillation counting
0.5179277.15126630.html.plaintext.txt	98	tgnum activity expressed pmol numhputrescine incorporated dimethylcaseine per hour mg protein
0.5179277.15126630.html.plaintext.txt	99	evaluation effect ctsd tgnum activity membrane fraction prepared lysates homogenate centrifuged numnum g num degree c num minute
0.5179277.15126630.html.plaintext.txt	100	pellet re extracted sonication buffer supplemented num triton x num
0.5179277.15126630.html.plaintext.txt	101	num minute incubation num degree c lysate centrifuged supernatant membrane fraction collected
0.5179277.15126630.html.plaintext.txt	102	tgnum activity membrane fraction measured described whole tissue extract
0.5179277.15126630.html.plaintext.txt	103	skin histology chemical fixation embedding light electron microscopy follows
0.5179277.15126630.html.plaintext.txt	104	skin sample prefixed overnight modified karnovskys medium elia friend num num degree c washed twice num
0.5179277.15126630.html.plaintext.txt	105	num m sodium cacodylate buffer num minute postfixed num wv osonum num
0.5179277.15126630.html.plaintext.txt	106	num m sodium cacodylate buffer containing num
0.5179277.15126630.html.plaintext.txt	107	num wv knumfecnnum num degree c num minute
0.5179277.15126630.html.plaintext.txt	108	subsequently specimen dehydrated ethanol series embedded epon num luft num
0.5179277.15126630.html.plaintext.txt	109	polymerization carried overnight num degree c
0.5179277.15126630.html.plaintext.txt	110	semi thin section cut ultra microtome leica uct leica bensheim germany staining investigated zeiss axioskop num zeiss gottingen germany transmission mode
0.5179277.15126630.html.plaintext.txt	111	electron microscopy ultra thin section cut post stained according method reynolds reynolds num subsequently investigated philip cm num electron microscope
0.5179277.15126630.html.plaintext.txt	112	immunohistochemistry skin sample fixed formaldehyde embedded paraffin
0.5179277.15126630.html.plaintext.txt	113	num microm section incubated num hnumonum num minute block endogenous peroxidase activity rinsed microwave irradiated num w antigen detection according method hazelbag et al
0.5179277.15126630.html.plaintext.txt	114	blocking unspecific antibody binding incubation num pig serum dako germany primary antibody applied num minute room temperature
0.5179277.15126630.html.plaintext.txt	115	primary antibody anti keratin knum numnum anti keratin knum numnum anti keratin knum numnum anti involucrin numnum anti loricrin numnum anti filaggrin numnum hohl num rosenthal et al
0.5179277.15126630.html.plaintext.txt	116	primary antibody purchased hiss diagnostics germany
0.5179277.15126630.html.plaintext.txt	117	strep ab complexhrp used third antibody followed incubation diaminobenzidine substrate peroxidase
0.5179277.15126630.html.plaintext.txt	118	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	119	increase protein expression activity ctsd differentiated keratinocyte culture
0.5179277.15126630.html.plaintext.txt	120	protein expression ctsd isoforms primary differentiated keratinocytes determined cell lysates western blotting using anti ctsd antibody
0.5179277.15126630.html.plaintext.txt	121	increase prepro enzymatically active pro form differentiated keratinocytes
0.5179277.15126630.html.plaintext.txt	122	b ctsd activity measured vitro enzyme assay keratinocyte lysates using parathyroid hormone pth ctsd specific substrate
0.5179277.15126630.html.plaintext.txt	123	amount pth absence sample protein used control
0.5179277.15126630.html.plaintext.txt	124	level pth protein determined western blotting using anti pth mab peptide num num quantified two dimensional laser scanning densitometry molecular dynamic personal densitometer
0.5179277.15126630.html.plaintext.txt	125	ctsd activity calculated amount pth cleavedhour increased differentiated keratinocytes
0.5179277.15126630.html.plaintext.txt	126	enzymatic activity ctsd primary differentiated keratinocytes correlated amount ctsd protein significantly enhanced num day stratified culture estimated cleavage ctsd specific substrate pth num amino acid polypeptide heinrich et al
0.5179277.15126630.html.plaintext.txt	127	num resulting generation num amino acid fragment amount pth decreased upper part fig
0.5179277.15126630.html.plaintext.txt	128	numb ctsd activity calculated amount pth cleavedhour increased differentiated keratinocytes fig
0.5179277.15126630.html.plaintext.txt	129	result indicate ctsd protein enzymatic activity correlate stage keratinocyte differentiation vitro
0.5179277.15126630.html.plaintext.txt	130	increased epidermal expression increased activity ctsd experimental injury skin hairless mouse evaluate possible role ctsd skin epidermal differentiation vivo determined protein level activity ctsd epidermal barrier repair following experimental barrier disruption tape stripping
0.5179277.15126630.html.plaintext.txt	131	following experimental skin injury expression active intermediate num kda proenzyme fig
0.5179277.15126630.html.plaintext.txt	132	numa black bar mature num kda form fig
0.5179277.15126630.html.plaintext.txt	133	numb black bar significantly increased num hour num hour num num p num
0.5179277.15126630.html.plaintext.txt	134	num nnum num kda form num num p num
0.5179277.15126630.html.plaintext.txt	135	num nnum num kda form respectively estimated western blotting
0.5179277.15126630.html.plaintext.txt	136	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	137	increased epidermal expression ctsd experimental skin injury
0.5179277.15126630.html.plaintext.txt	138	acute disruption permeability barrier induced tape stripping
0.5179277.15126630.html.plaintext.txt	139	immediately pepstatin carrier solution applied skin sample obtained different time
0.5179277.15126630.html.plaintext.txt	140	expression active intermediate mature form b ctsd examined sd page western blotting using polyclonal anti ctsd antibody quantified two dimensional laser scanning densitometry
0.5179277.15126630.html.plaintext.txt	141	inhibition ctsd topical application ctsd inhibitor pepstatin suppressed increase amount intermediate mature enzyme barrier disruption fig
0.5179277.15126630.html.plaintext.txt	142	increase ctsd protein paralleled enhanced ctsd enzyme activity num hour num hour skin injury determined pth cleavage assay fig
0.5179277.15126630.html.plaintext.txt	143	topical application pepstatin resulted decrease enzymatic activity num hour treatment data shown
0.5179277.15126630.html.plaintext.txt	144	together data demonstrate increased protein expression increased enzyme activity ctsd skin repair epidermal differentiation
0.5179277.15126630.html.plaintext.txt	145	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	146	increased activity ctsd experimental skin injury
0.5179277.15126630.html.plaintext.txt	147	acute disruption permeability barrier induced tape stripping
0.5179277.15126630.html.plaintext.txt	148	immediately barrier disruption pepstatin carrier solution applied skin sample obtained directly tape stripping num hour num num hour
0.5179277.15126630.html.plaintext.txt	149	ctsd activity measured specific parathyroid hormone pth enzyme assay
0.5179277.15126630.html.plaintext.txt	150	level pth protein determined western blotting using anti pth mab peptide num num
0.5179277.15126630.html.plaintext.txt	151	amount pth assay starting point used control ctsd activity calculated amount pth cleavedhour
0.5179277.15126630.html.plaintext.txt	152	tgnum activity stimulated exogenous ctsd keratinocytes culture epidermal differentiation ce protein involucrin loricrin filaggrin cross linked formation glutamyllysine isodipeptide bond catalyzed tgnum kim et al
0.5179277.15126630.html.plaintext.txt	153	addition described tgnum catalyzes covalent ester binding hydroxyceramide involucrin nemes et al
0.5179277.15126630.html.plaintext.txt	154	thus enzyme mediates key function epidermal differentiation
0.5179277.15126630.html.plaintext.txt	155	since ctsd may involved regulation activity tgnum negi et al
0.5179277.15126630.html.plaintext.txt	156	num investigated possible direct involvement ctsd proteolytic activation tgnum
0.5179277.15126630.html.plaintext.txt	157	since high molecular mass tgnum precursor protein membrane bound chakravarty rice num steinert et al
0.5179277.15126630.html.plaintext.txt	158	numb upon terminal differentiation keratinocytes tgnum cleaved two site leading active form rice et al
0.5179277.15126630.html.plaintext.txt	159	numb prepared membrane fraction lysates hacat cell starting material
0.5179277.15126630.html.plaintext.txt	160	enzymatic activity tgnum measured membrane preparation addition exogenous ctsd absence presence pepstatin vitro tgnum assay based cross linking numhputrescine dimethylcasein substrate hohl et al
0.5179277.15126630.html.plaintext.txt	161	num tgnum activity increased exogenous ctsd enzymatic activation blocked pepstatin
0.5179277.15126630.html.plaintext.txt	162	result suggests ctsd mediated proteolytic activation membrane bound tgnum precursor molecule leading enzymatically active tgnum fragment
0.5179277.15126630.html.plaintext.txt	163	observation support functional link ctsd tgnum activity
0.5179277.15126630.html.plaintext.txt	164	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	165	ctsd stimulates transglutaminase num tgnum activity primary keratinocytes vitro
0.5179277.15126630.html.plaintext.txt	166	isolated membrane hacat cell left untreated black square treated pepstatin black circle purified ctsd absence black triangle presence pepstatin white triangle num minute subsequently measured tgnum enzymatic activity vitro enzyme assay using dimethylcasein numnumn numh putrescine substrate
0.5179277.15126630.html.plaintext.txt	167	result three experiment performed triplicate shown mean plus minus
0.5179277.15126630.html.plaintext.txt	168	topical application ctsd inhibitor pepstatin tg inhibitor monodansyl cadaverin significantly delayed permeability barrier repair investigate physiological significance ctsd epidermal differentiation next examined barrier recovery following experimental skin injury topical application ctsd inhibitor pepstatin
0.5179277.15126630.html.plaintext.txt	169	different time barrier disruption tape stripping num num hour tewl marker barrier repair measured grubauer et al
0.5179277.15126630.html.plaintext.txt	170	experimental barrier disruption endogenous barrier repair commenced
0.5179277.15126630.html.plaintext.txt	171	rapid decrease tewl leading num barrier recovery occurred hairless mouse within num hour
0.5179277.15126630.html.plaintext.txt	172	followed slower kinetics barrier recovery within next num hour
0.5179277.15126630.html.plaintext.txt	173	topically application ctsd inhibitor pepstatin immediately barrier disruption led significant delay barrier repair num num num num num hour treatment fig
0.5179277.15126630.html.plaintext.txt	174	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	175	topical application ctsd inhibitor pepstatin tg inhibitor monodansyl cadaverin mdc b significantly delay permeability barrier repair
0.5179277.15126630.html.plaintext.txt	176	acute disruption permeability barrier induced tape stripping num num fold increase tewl transepidermal water losstranscutaneous water loss occurred
0.5179277.15126630.html.plaintext.txt	177	immediately barrier disruption pepstatin monodansyl cadaverin carrier solution applied recovery tewl determined different time treatment
0.5179277.15126630.html.plaintext.txt	178	result three experiment performed triplicate shown
0.5179277.15126630.html.plaintext.txt	179	addition functional role tgnum cutaneous differentiation permeability barrier repair examined topical application tgnum inhibitor monodansyl cadaverin experimental skin injury
0.5179277.15126630.html.plaintext.txt	180	different time barrier disruption tape stripping tewl determined marker barrier repair
0.5179277.15126630.html.plaintext.txt	181	application monodansyl cadaverin found significant delay barrier repair num num num num num hour treatment fig
0.5179277.15126630.html.plaintext.txt	182	result show inhibition ctsd tgnum activity influence epidermal differentiation delay permeability barrier repair
0.5179277.15126630.html.plaintext.txt	183	reduced tgnum enzymatic activity defective tg processing ctsd deficient mouse based observation ctsd able activate tgnum vitro fig
0.5179277.15126630.html.plaintext.txt	184	num next explored possible role ctsd regulation tgnum expression ctsd deficient mouse vivo
0.5179277.15126630.html.plaintext.txt	185	using specific tgnum enzyme assay found significantly decreased tgnum activity epidermis heterozygous ctsd mouse reduced homozygous ctsd mouse fig
0.5179277.15126630.html.plaintext.txt	186	order investigate whether decreased tgnum activity ctsd mouse caused defective processing tgnum precursor molecule analyzed distribution tgnum protein western blotting using specific anti tgnum antibody
0.5179277.15126630.html.plaintext.txt	187	strongly band approximately num kda detected epidermis wild type mouse band significantly decreased skin ctsd deficient heterozygous even homozygous mouse fig
0.5179277.15126630.html.plaintext.txt	188	ctsd mouse num kda protein strongly expressed instead also seen ctsd mouse completely absent wild type mouse
0.5179277.15126630.html.plaintext.txt	189	finding suggest defective processing num kda tgnum precursor protein epidermis ctsd deficient mouse point functional role ctsd maturation num kda tgnum precursor enzymatic active num kda form vivo
0.5179277.15126630.html.plaintext.txt	190	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	191	reduced transglutaminase num tgnum activity ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	192	tgnum enzymatic activity determined epidermal lysates wild type heterozygous ctsd deficient mouse vitro assay using dimethylcasein numnumn numh putrescine substrate
0.5179277.15126630.html.plaintext.txt	193	result three experiment performed triplicate shown mean plus minus
0.5179277.15126630.html.plaintext.txt	194	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	195	absence num kda tgnum protein ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	196	tgnum protein level determined epidermal sample wild type heterozygous homozygous ctsd deficient mouse western blotting using anti tgnum antibody quantified densitometry
0.5179277.15126630.html.plaintext.txt	197	reduced level involucrin loricrin ctsd deficient mouse next investigated whether ctsd deficiency also result change expression involucrin early marker loricrin late marker epidermal differentiation watt num yoneda et al
0.5179277.15126630.html.plaintext.txt	198	num steinert marekov num
0.5179277.15126630.html.plaintext.txt	199	epidermal sample wild type mouse involucrin fig
0.5179277.15126630.html.plaintext.txt	200	numb expressed num kda num kda protein respectively estimated western blotting
0.5179277.15126630.html.plaintext.txt	201	ctsd mouse level protein clearly reduced ctsd mouse completely absent suggesting crucial function ctsd appearance num kda involucrin num kda loricrin epidermis
0.5179277.15126630.html.plaintext.txt	202	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	203	reduced ce protein expression ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	204	skin section wild type heterozygous homozygous ctsd deficient mouse obtained
0.5179277.15126630.html.plaintext.txt	205	expression involucrin loricrin b determined epidermal sample western blotting using anti involucrin anti loricrin antibody
0.5179277.15126630.html.plaintext.txt	206	change immunohistology differentiation related protein ctsd mouse examine protein expression localization differentiation related epidermal protein performed immunohistology using specific antibody
0.5179277.15126630.html.plaintext.txt	207	num keratin knum staining healthy skin found suprabasal layer epidermis whereas keratin knum expressed epidermal basal cell
0.5179277.15126630.html.plaintext.txt	208	ctsd mouse focal extension knum staining basal layer
0.5179277.15126630.html.plaintext.txt	209	staining knum focally extended upper epidermal layer ctsd mouse entire nucleated epidermis stained ctsd mouse
0.5179277.15126630.html.plaintext.txt	210	also thickness epidermis stratum granulosum stratum spinosum stratum basale reduced whereas thickening stratum corneum hyperkeratosis evident ctsd mouse
0.5179277.15126630.html.plaintext.txt	211	result show change protein expression basal differentiation related keratin ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	212	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	213	immunohistology revealed distinct change expression keratin ce protein ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	214	keratin knum staining healthy skin found suprabasal layer epidermis whereas keratin knum expressed epidermal basal cell
0.5179277.15126630.html.plaintext.txt	215	ctsd mouse focal extension knum staining basal layer focal extension knum upper epidermal layer
0.5179277.15126630.html.plaintext.txt	216	keratin knum faintly stained normal mouse skin ctsd ctsd mouse skin
0.5179277.15126630.html.plaintext.txt	217	involucrin filaggrin antibody showed strong staining upper stratum spinosum stratum granulosum whereas loricrin antibody showed staining stratum granulosum solely wild type mouse skin
0.5179277.15126630.html.plaintext.txt	218	three antibody staining intensity reduced ctsd mouse even reduced ctsd mouse
0.5179277.15126630.html.plaintext.txt	219	keratin knum known involved proliferation show faint probably unspecific staining normal mouse skin
0.5179277.15126630.html.plaintext.txt	220	staining found heterozygous homozygous mouse skin
0.5179277.15126630.html.plaintext.txt	221	reveals abnormal cornification seen light microscopy ctsd mouse related hyperproliferation
0.5179277.15126630.html.plaintext.txt	222	involucrin antibody showed strong continuous staining upper stratum spinosum stratum granulosum wild type mouse
0.5179277.15126630.html.plaintext.txt	223	ctsd ctsd mouse involucrin staining markedly reduced band like staining locally interrupted
0.5179277.15126630.html.plaintext.txt	224	loricrin antibody produced strong staining stratum granulosum
0.5179277.15126630.html.plaintext.txt	225	ctsd ctsd mouse found focally reduced staining
0.5179277.15126630.html.plaintext.txt	226	filaggrin similar involucrin stained strongly upper stratum spinosum stratum granulosum wild type mouse
0.5179277.15126630.html.plaintext.txt	227	slight reduction staining intensity found ctsd mouse
0.5179277.15126630.html.plaintext.txt	228	staining intensity clearly reduced staining focally absent ctsd mouse
0.5179277.15126630.html.plaintext.txt	229	reveals reduced expression ce protein
0.5179277.15126630.html.plaintext.txt	230	study show functional link ctsd activity expression epidermal differentiation related protein
0.5179277.15126630.html.plaintext.txt	231	structural change stratum corneum transition stratum granulosum stratum corneum change tewl ctsd deficient mouse biological consequence ctsd deficiency reduction tgnum activity alteration ce protein level analyzed histological examination semi thin skin section derived wild type ctsd mouse
0.5179277.15126630.html.plaintext.txt	232	epidermis wild type heterozygous mouse data shown exhibited well known regular arrangement corneocytes stratum corneum
0.5179277.15126630.html.plaintext.txt	233	contrast stratum corneum ctsd mouse irregular structure
0.5179277.15126630.html.plaintext.txt	234	different layer stratum corneum disrupted singular corneocytes undulated
0.5179277.15126630.html.plaintext.txt	235	furthermore stratum corneum layer fig
0.5179277.15126630.html.plaintext.txt	236	part change also evident fig
0.5179277.15126630.html.plaintext.txt	237	ultrastructure epidermis analyzed electron microscopy revealing distinct change morphology stratum corneum transition stratum granulosum stratum corneum ctsd mouse
0.5179277.15126630.html.plaintext.txt	238	wild type mouse found normal distance stratum corneum layer normal ce seen dark line around corneocytes fig
0.5179277.15126630.html.plaintext.txt	239	ctsd mouse distance stratum corneum layer broader faint staining ce thickened corneocytes axial direction fig
0.5179277.15126630.html.plaintext.txt	240	measurement tewl basal condition mouse age num day ctsd mouse life expectancy num day tewameter revealed small increase significant tewl ctsd mouse num ctsd mouse num wild type mouse tewl num
0.5179277.15126630.html.plaintext.txt	241	num gm numh nnum ctsd tewl num
0.5179277.15126630.html.plaintext.txt	242	num gm numh nnum ctsd tewl num
0.5179277.15126630.html.plaintext.txt	243	together result show increase thickness number stratum corneum layer ultrastructural change ctsd mouse
0.5179277.15126630.html.plaintext.txt	244	ichthyotic skin phenotype ctsd mouse largely compensates defect protein expression shown small increase basal tewl
0.5179277.15126630.html.plaintext.txt	245	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	246	ctsd deficient mouse exhibited impaired stratum corneum morphology
0.5179277.15126630.html.plaintext.txt	247	microscopic analysis semi thin skin section ctsd wild type mouse revealed normal stratum corneum morphology
0.5179277.15126630.html.plaintext.txt	248	ctsd deficient mouse b disrupted stratum corneum increased number corneocyte layer
0.5179277.15126630.html.plaintext.txt	249	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	250	ultrastructural change stratum corneum transition stratum granulosum stratum corneum ctsd mouse
0.5179277.15126630.html.plaintext.txt	251	electron microscopy show wild type mouse cornified envelope ce clearly visible dark line around corneocytes arrow
0.5179277.15126630.html.plaintext.txt	252	ctsd mouse b broadening intercellular space stratum corneum sc faint staining ce arrow corneocytes thickened axial direction
0.5179277.15126630.html.plaintext.txt	253	examined role specific target ctsd epidermal differentiation
0.5179277.15126630.html.plaintext.txt	254	first performed vitro study determining protein expression activity ctsd primary differentiated stratified organotypic cultured keratinocytes
0.5179277.15126630.html.plaintext.txt	255	found significant increase ctsd protein level increase enzymatic activity ctsd differentiated compared primary keratinocytes suggesting function ctsd epidermal differentiation vitro
0.5179277.15126630.html.plaintext.txt	256	explore possible link ctsd epidermal differentiation vivo investigated epidermal expression enzymatic activity ctsd experimental skin injury permeability barrier repair wild type mouse
0.5179277.15126630.html.plaintext.txt	257	found significantly increased epidermal expression active intermediate well mature form ctsd num hour num hour permeability barrier disruption caused increased processing increased synthesis enzyme
0.5179277.15126630.html.plaintext.txt	258	accordance noted significant increase epidermal ctsd enzyme activity different time skin injury
0.5179277.15126630.html.plaintext.txt	259	topical application pepstatin inhibitor ctsd heinrich et al
0.5179277.15126630.html.plaintext.txt	260	num prevented increase protein expression activity ctsd significantly delayed permeability barrier repair experimental disruption
0.5179277.15126630.html.plaintext.txt	261	result clearly show involvement ctsd epidermal repair process injury
0.5179277.15126630.html.plaintext.txt	262	kinetics ctsd processing activation demonstrated increased expression num num hour treatment corresponded activation sphingomyelinase amount epidermal ceramides barrier perturbation jensen et al
0.5179277.15126630.html.plaintext.txt	263	previous study significant increase acid sphingomyelinase activation elevated epidermal ceramide content num num hour barrier disruption demonstrated jensen et al
0.5179277.15126630.html.plaintext.txt	264	num thus acid sphingomyelinase derived ceramide may linked ctsd activity permeability barrier repair
0.5179277.15126630.html.plaintext.txt	265	epidermis follows programmed transformation keratinocytes proliferating basal cell spinous granular horny layer permeability barrier resides finally desquamation occurs
0.5179277.15126630.html.plaintext.txt	266	starting granular layer aspartatic proteinase ctsd activated lysosome participate massive degradation process accompanying cornification
0.5179277.15126630.html.plaintext.txt	267	recent observation identified ctsd located lamellar body within keratinocytes ishida yamamoto et al
0.5179277.15126630.html.plaintext.txt	268	involucrin loricrin cross linked tgnum form insoluble rigid ce steinert marekov num
0.5179277.15126630.html.plaintext.txt	269	ctsd reported activate tgnum thereby contribute enzymatic process cornification negi et al
0.5179277.15126630.html.plaintext.txt	270	finding supported extended vitro vivo result found ctsd dependent activation tgnum keratinocyte membrane preparation furthermore activity tgnum severely diminished epidermis ctsd mouse compared wild type mouse
0.5179277.15126630.html.plaintext.txt	271	enzymatic activity tgnum correlated expression num kda protein wild type mouse detected immunoblotting
0.5179277.15126630.html.plaintext.txt	272	num kda protein undetectable epidermis ctsd mouse observed expression num kda tgnum protein instead
0.5179277.15126630.html.plaintext.txt	273	le protein ctsd mouse none wild type control mouse
0.5179277.15126630.html.plaintext.txt	274	observation suggest involvement ctsd processing higher molecular weight precursor generate enzymatically active num kda tgnum form see model fig
0.5179277.15126630.html.plaintext.txt	275	recent report iizuka et al
0.5179277.15126630.html.plaintext.txt	276	num studied proteolytically activated tgnum epidermis using cleavage site directed antibody
0.5179277.15126630.html.plaintext.txt	277	num kda fragment identified western blotting mainly found cytosol keratinocytes differentiated cell stratum corneum skin iizuka et al
0.5179277.15126630.html.plaintext.txt	278	second fragment resided plasma membrane keratinocytes region skin including suprabasal layer spinous layer granular layer stratum corneum
0.5179277.15126630.html.plaintext.txt	279	differentiation related num kda tgnum fragment study could protein num kda fragment detected ctsd mouse ctsd mouse
0.5179277.15126630.html.plaintext.txt	280	view larger version numk fig
0.5179277.15126630.html.plaintext.txt	281	model role ctsd epidermal differentiation
0.5179277.15126630.html.plaintext.txt	282	epidermal differentiation aspartate protease ctsd stratum granulosum sg activated cleaves membrane bound num kda precursor transglutaminase num tgnum producing active num kda form
0.5179277.15126630.html.plaintext.txt	283	tgnum turn mediates cross linking cornified envelope ce protein involucrin loricrin ce
0.5179277.15126630.html.plaintext.txt	284	sc stratum corneum s stratum spinosum sb stratum basale
0.5179277.15126630.html.plaintext.txt	285	functional significance tgnum epidermal homeostasis demonstrated delay permeability barrier repair inhibition tgnum monodansyl cadaverin
0.5179277.15126630.html.plaintext.txt	286	similar effect observed inhibition ctsd pepstatin inhibition acid sphingomyelinase imipramine jensen et al
0.5179277.15126630.html.plaintext.txt	287	num suggesting importance possible associated function three enzyme barrier formation differentiation
0.5179277.15126630.html.plaintext.txt	288	epidermal differentiation including formation ce protein involucrin loricrin crucially involved permeability barrier repair ekanayake mudiyanselage et al
0.5179277.15126630.html.plaintext.txt	289	soluble ce protein involucrin expressed spinous layer early stage keratinocyte differentiation
0.5179277.15126630.html.plaintext.txt	290	loricrin insoluble ce precursor expressed later differentiation process intracellular granule
0.5179277.15126630.html.plaintext.txt	291	link ctsd dependent activation keratinocyte tgnum expression ce protein confirmed ctsd mouse
0.5179277.15126630.html.plaintext.txt	292	mouse found significantly reduced involucrin loricrin protein level experimental skin injury parallel reduced activity tgnum
0.5179277.15126630.html.plaintext.txt	293	result agreement effect observed application ctsd inhibitor pepstatin data shown
0.5179277.15126630.html.plaintext.txt	294	since high molecular mass tgnum precursor protein present ctsd wild type mouse ctsd appears mediate proteolysis enzymatically inactive tgnum active enzyme
0.5179277.15126630.html.plaintext.txt	295	thus deficient mouse also reveal functional link ctsd expression maturation activation tgnum appearance involucrin loricrin epidermis
0.5179277.15126630.html.plaintext.txt	296	morphologically ctsd mouse exhibited epidermal hyperkeratosis sign disturbed epidermal differentiation
0.5179277.15126630.html.plaintext.txt	297	skin symptom may explained diminished ability corneocytes bind intercellular lipid caused reduced expression involucrin loricrin stratum corneum
0.5179277.15126630.html.plaintext.txt	298	previously shown ce protein particular involucrin covalently bind hydroxy ceramides
0.5179277.15126630.html.plaintext.txt	299	ceramides form scaffold attachment free ceramides cholesterol free fatty acid provides stratum corneum lipid bilayers permeability barrier function downing num steinert marekov num
0.5179277.15126630.html.plaintext.txt	300	morphological disruption corneocyte layer found ctsd mouse fig
0.5179277.15126630.html.plaintext.txt	301	disruption started interface stratum granulosumstratum corneum place normally lipid bilayers extrude lipid intercellular space
0.5179277.15126630.html.plaintext.txt	302	ultrastructural analysis epidermis ctsd mouse revealed broadening distance sc layer faint staining ce thickened corneocytes axial direction
0.5179277.15126630.html.plaintext.txt	303	demonstrates influence ctsd corneocytes possibly lipid organization stratum corneum
0.5179277.15126630.html.plaintext.txt	304	together morphological finding suggest important role ctsd epidermal differentiation
0.5179277.15126630.html.plaintext.txt	305	evaluate consequence ctsd deficiency reduced tgnum activity detail analyzed distribution various epidermal keratin ce protein immunohistology
0.5179277.15126630.html.plaintext.txt	306	extended expression basal differentiation related keratin knum knum sign disturbed differentiation found ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	307	previous study found expression differentiation marker knum disturbed acute tape stripping chronic metabolic essential fatty acid deficient diet efad barrier disruption
0.5179277.15126630.html.plaintext.txt	308	however model also found increase expression proliferation associated keratin knum also knum ekanayake mudiyanselage et al
0.5179277.15126630.html.plaintext.txt	309	expression knum besides change basal differentiation related keratin also known psoriasis hagemann proksch num
0.5179277.15126630.html.plaintext.txt	310	ctsd mouse knum absent though thickening horny layer clearly visible
0.5179277.15126630.html.plaintext.txt	311	therefore ctsd mouse may similarity called retention hyperkeratosis ichthyosis called hyperproliferation associated keratosis psoriasis
0.5179277.15126630.html.plaintext.txt	312	accordance mouse heterozygous truncated keratin knum model ichthyosis called epidermolytic hyperkeratosis caused point mutation suprabasal knum knum cheng et al
0.5179277.15126630.html.plaintext.txt	313	num show knumknum protein expression flank skin porter et al
0.5179277.15126630.html.plaintext.txt	314	ichthyosis group skin disorder different cause showing disturbed epidermal differentiation variable effect permeability barrier lavrijsen et al
0.5179277.15126630.html.plaintext.txt	315	expression involucrin loricrin well filaggrin significantly reduced heterozygote homozygote epidermis ctsd deficient mouse
0.5179277.15126630.html.plaintext.txt	316	filaggrin deficiency well known ichthyosis vulgaris gunzel et al
0.5179277.15126630.html.plaintext.txt	317	defective interaction keratin filaggrin also seen epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	318	abnormal distribution loricrin detected genetic disease involving loricrin loricrin keratoderma vohwinkels syndrome maestrini et al
0.5179277.15126630.html.plaintext.txt	319	loricrin mutation vohwinkels keratoderma unique variant ichthyosis korge et al
0.5179277.15126630.html.plaintext.txt	320	defect cross linking loricrin detected tgnum deficient mouse animal model lamellar ichthyosis matsuki et al
0.5179277.15126630.html.plaintext.txt	321	evaluation barrier function ctsd mouse measurement tewl revealed constitutive defect
0.5179277.15126630.html.plaintext.txt	322	suggest development ichthyosiform skin compensates defective stratum corneum morphology deficiency differentiation related protein
0.5179277.15126630.html.plaintext.txt	323	recently similar result reported mouse lacking tgnum matsuki et al
0.5179277.15126630.html.plaintext.txt	324	skin tgnum deficient mouse die neonate lack normal insoluble ce impaired barrier function
0.5179277.15126630.html.plaintext.txt	325	neonatal tgnum mouse skin taut erythrodermic transplanted tgnum mouse skin resembled seen severe ichthyosis epidermal hyperplasia marked hyperkeratosis
0.5179277.15126630.html.plaintext.txt	326	abnormality barrier structure remained tewl decreased control level ichthyosiform skin
0.5179277.15126630.html.plaintext.txt	327	author suggested ichthyosiform skin phenotype tgnum deficiency develops massive hyperkeratosis physical compensation defective cutaneous permeability barrier kuramoto et al
0.5179277.15126630.html.plaintext.txt	328	compensatory mechanism maintaining skin barrier function absence major ce protein also described loricrin deficient mouse model koch et al
0.5179277.15126630.html.plaintext.txt	329	also targeted ablation murine involucrin gene show defect barrier function
0.5179277.15126630.html.plaintext.txt	330	mouse developed normally possessed apparently normal epidermis hair follicle generated ce could distinguished wild type mouse djian et al
0.5179277.15126630.html.plaintext.txt	331	complexity redundancy epithelial barrier function discussed steinert steinert num
0.5179277.15126630.html.plaintext.txt	332	ctsd mouse model broader impact skin morphology either involucrin loricrin deficiency
0.5179277.15126630.html.plaintext.txt	333	notably similarity skin ctsd mouse skin tgnum mouse human skin disease lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	334	lamellar ichthyosis mutation tgnum gene resulting reduction epidermal involucrin described hohl et al
0.5179277.15126630.html.plaintext.txt	335	similarity explained strongly reduced tgnum expression skin ctsd mouse
0.5179277.15126630.html.plaintext.txt	336	initial characterization ctsd deficient mouse atopic change ileal mucosa leading insufficient mucosal barrier observed
0.5179277.15126630.html.plaintext.txt	337	limit epithelium central connective tissue normally formed basement membrane undetectable mouse saftig et al
0.5179277.15126630.html.plaintext.txt	338	together result prove importance ctsd barrier function epithelial differentiation different organ
0.5179277.15126630.html.plaintext.txt	339	summary vitro vivo result suggest crucial involvement aspartate protease ctsd activation keratinocyte tgnum regulation ce protein expression epidermal differentiation summarized model shown fig
0.5179277.15126630.html.plaintext.txt	340	finding may important development new treatment modality skin disease altered epidermal differentiation pattern
0.5179277.15126630.html.plaintext.txt	341	acknowledgment greatly appreciate assistance andrea hethke claudia neumann dr xu ping wang
0.5179277.15126630.html.plaintext.txt	342	work supported deutsche forschungsgemeinschaft sonderforschungsbereich sfb num granted e
0.5179277.15126630.html.plaintext.txt	343	wish thank katherine houghton reviewing text article
0.5179277.15126630.html.plaintext.txt	344	tumor necrosis factor development last decade
0.5179277.15126630.html.plaintext.txt	345	human epidermis reconstructed culture normal j
0.5179277.15126630.html.plaintext.txt	346	normal keratinization spontaneously immortalized aneuploid human keratinocyte cell line
0.5179277.15126630.html.plaintext.txt	347	acylation keratinocyte transglutaminase pamitic myristic acid membrane anchorage region
0.5179277.15126630.html.plaintext.txt	348	genetic basis epidermolytic hyperkeratosis disorder differentiation specific epidermal keratin gene
0.5179277.15126630.html.plaintext.txt	349	response keratinocytes normal psoriatic epidermis interferon differs expression zinc num glycoprotein cathepsin d
0.5179277.15126630.html.plaintext.txt	350	leucine proline mutation hnum subdomain keratin num cause epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	351	cathepsin d protease mediates programmed cell death induced interferon gamma fasapo num tnf alpha
0.5179277.15126630.html.plaintext.txt	352	targeted ablation murine involucrin gene
0.5179277.15126630.html.plaintext.txt	353	lipid protein structure permeability barrier mammalian epidermis
0.5179277.15126630.html.plaintext.txt	354	cathepsin d membrane associated macrophage endosomes
0.5179277.15126630.html.plaintext.txt	355	involucrin structure role envelope assembly
0.5179277.15126630.html.plaintext.txt	356	expression epidermal keratin cornified envelope protein involucrin influenced permeability barrier disruption
0.5179277.15126630.html.plaintext.txt	357	permeability barrier mammalian epidermis
0.5179277.15126630.html.plaintext.txt	358	epidermal lipid barrier function desquamation
0.5179277.15126630.html.plaintext.txt	359	isolation sequencing cdna clone encoding rat liver lysosomal cathepsin d structure three form mature enzyme
0.5179277.15126630.html.plaintext.txt	360	ceramide signalling regulatory role cell proliferation differentiation apoptosis human epidermis
0.5179277.15126630.html.plaintext.txt	361	transepidermal water loss signal recovery barrier structure function
0.5179277.15126630.html.plaintext.txt	362	keratohyalin granule heterogeneous ridged non ridged human skin evidence anti filaggrin immunogold labelling normal skin skin autosomal dominant ichthyosis vulgaris patient
0.5179277.15126630.html.plaintext.txt	363	topical treatment urea reduces epidermal hyperproliferation induces differentiation psoriasis
0.5179277.15126630.html.plaintext.txt	364	immunostaining chain specific keratin formalin fixed paraffin embedded tissue comparison various antigen retrieval system using microwave heating proteolytic pre treatment
0.5179277.15126630.html.plaintext.txt	365	cathepsin d targeted acid sphingomyelinase derived ceramide
0.5179277.15126630.html.plaintext.txt	366	expression pattern loricrin dermatological disorder
0.5179277.15126630.html.plaintext.txt	367	vitro rapid situ transglutaminase assay congenital ichthyoses
0.5179277.15126630.html.plaintext.txt	368	analysis cornified cell envelope lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	369	isoforms cathepsin d human epidermal differentiation
0.5179277.15126630.html.plaintext.txt	370	role endogenous cathepsin d like chymotrypsin like proteolysis human epidermal desquamation
0.5179277.15126630.html.plaintext.txt	371	mutation keratinocyte transglutaminase lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	372	novel approach detection proteolytically activated transglutaminase num epidermis using cleavage site directed antibody
0.5179277.15126630.html.plaintext.txt	373	decreased deiminated keratin knum psoriatic hyperproliferative epidermis
0.5179277.15126630.html.plaintext.txt	374	epidermal lamellar granule part branched tubular structure transport different cargo distinct aggregate
0.5179277.15126630.html.plaintext.txt	375	induction apoptotic dna damage cell death activation sphingomyelin pathway
0.5179277.15126630.html.plaintext.txt	376	role tumor necrosis factor receptor pnum sphingomyelinase cutaneous permeability barrier repair
0.5179277.15126630.html.plaintext.txt	377	disturbed permeability barrier function transgenic involucrin deficient mouse
0.5179277.15126630.html.plaintext.txt	378	impaired cutaneous permeability barrier funcion skin hydration sphingomyelinase activity keratin num deficient mouse
0.5179277.15126630.html.plaintext.txt	379	biochemical immunohistochemical analysis cathepsins b h l d human melanocytic tumor
0.5179277.15126630.html.plaintext.txt	380	involucrin expression keratinization disorder skin preliminary study
0.5179277.15126630.html.plaintext.txt	381	expression cathepsin d b invasion metastasis squamous cell carcinoma
0.5179277.15126630.html.plaintext.txt	382	expression transglutaminase num human epidermis
0.5179277.15126630.html.plaintext.txt	383	lesson loricrin deficient mouse compensatory mechanism maintaining skin barrier function absence major cornified envelope protein
0.5179277.15126630.html.plaintext.txt	384	sphingomyelin pathway tumor necrosis factor interleukin num signaling
0.5179277.15126630.html.plaintext.txt	385	loricrin mutation vohwinkels keratoderma unique variant ichthyosis
0.5179277.15126630.html.plaintext.txt	386	sphingomyelinases tnf induced apoptosis
0.5179277.15126630.html.plaintext.txt	387	development ichthyosiform skin compensates defective permeability barrier function mouse lacking transglutaminase num
0.5179277.15126630.html.plaintext.txt	388	barrier function parameter various keratinization disorder transepidermal water loss vascular response hexyl nicotinate
0.5179277.15126630.html.plaintext.txt	389	cathepsin d rabbit skin immunoenzymic study
0.5179277.15126630.html.plaintext.txt	390	sphingomyelinases cell regulation
0.5179277.15126630.html.plaintext.txt	391	improvement epoxy resin embedding method
0.5179277.15126630.html.plaintext.txt	392	molecular defect loricrin major component cornified cell envelope underlies vohwinkels syndrome
0.5179277.15126630.html.plaintext.txt	393	defective stratum corneum early neonatal death mouse lacking gene transglutaminase num keratinocyte transglutaminase
0.5179277.15126630.html.plaintext.txt	394	detection neutrophil activating peptide napil num napil num mrna human recombinant il num alpha human recombinant tumor necrosis factor alpha stimulated human dermal fibroblast
0.5179277.15126630.html.plaintext.txt	395	immunocytochemical fluorescent situ hybridization study
0.5179277.15126630.html.plaintext.txt	396	novel function transglutaminase num attatchment long chain omega hydroxyceramides involucrin ester bond formation
0.5179277.15126630.html.plaintext.txt	397	mechanism human epidermal transglutaminase
0.5179277.15126630.html.plaintext.txt	398	mechanism regulation human epidermal transglutaminase
0.5179277.15126630.html.plaintext.txt	399	vivo study concerning ph gradient human stratum corneum upper epidermis
0.5179277.15126630.html.plaintext.txt	400	role ceramide cell signaling
0.5179277.15126630.html.plaintext.txt	401	cdna cloning expression assembly characteristic mouse keratin num
0.5179277.15126630.html.plaintext.txt	402	use lead citrate high ph electron opaque stain electron microscopy
0.5179277.15126630.html.plaintext.txt	403	presence human epidermal cell soluble protein precursor cross linked envelope activation cross linking calcium ion
0.5179277.15126630.html.plaintext.txt	404	proteolytic release keratinocyte transglutaminase
0.5179277.15126630.html.plaintext.txt	405	acute chronic topical retinoic acid treatment human skin vivo alters expression epidermal transglutaminase loricrin involucrin filaggrin keratin num num keratin num num num
0.5179277.15126630.html.plaintext.txt	406	mutation rod domain keratin num num epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	407	mouse deficient lysosomal proteinase cathepsin d exhibit progressive atrophy intestinal mucosa profound destruction lymphoid cell
0.5179277.15126630.html.plaintext.txt	408	immunocytochemical localization lysosomal cysteine aspartatic proteinase ubiquitin rat epidermis
0.5179277.15126630.html.plaintext.txt	409	regeneration rate water vapour loss heavily damaged skin
0.5179277.15126630.html.plaintext.txt	410	complexity redundancy epithelial barrier function
0.5179277.15126630.html.plaintext.txt	411	inactive zymogen highly active proteolytically processed membrane bound form transglutaminase num enzyme human epidermal keratinocytes
0.5179277.15126630.html.plaintext.txt	412	transglutaminase num enzyme variably acylated myristate palmitate differentiation epidermal keratinocytes
0.5179277.15126630.html.plaintext.txt	413	direct evidence involucrin major early isopeptide cross linked keratinocyte cornified cell envelope
0.5179277.15126630.html.plaintext.txt	414	interleukin num stimulated secretion interleukin num growth related oncogene alpha demonstrates greatly enhanced keratinocyte growth human raft cultured epidermis
0.5179277.15126630.html.plaintext.txt	415	novel helix termination mutation keratin num annular epidermolytic ichthyosis variant bullous congenital ichthyosiform erythroderma
0.5179277.15126630.html.plaintext.txt	416	transgenic mouse expressing mutant form loricrin reveal molecular basis skin disease vohwinkel syndrome progressive symmetric erythrokeratoderma
0.5179277.15126630.html.plaintext.txt	417	cathepsin d prognosis breast cancer
0.5179277.15126630.html.plaintext.txt	418	normal psoriatic epidermis expression hyperproliferation associated keratin
0.5179277.15126630.html.plaintext.txt	419	keratinocyte differentiation induced cell permeant ceramides proliferation promoted sphingosine
0.5179277.15126630.html.plaintext.txt	420	involucrin marker keratinocyte terminal differentiation
0.5179277.15126630.html.plaintext.txt	421	functional dichotomy neutral acidic spingomyelinases tumor necrosis factor signaling
0.5179277.15126630.html.plaintext.txt	422	alanine proline mutation numa rod domain keratin num chain epidermolytic hyperkeratosis
0.54427505.15198969.html.plaintext.txt	0	estrogen alzheimer disease apolipoprotein connection neil j
0.54427505.15198969.html.plaintext.txt	1	center reproductive science columbia university medical center new york new york num
0.54427505.15198969.html.plaintext.txt	2	address correspondence request reprint dr
0.54427505.15198969.html.plaintext.txt	3	maclusky center reproductive science columbia university medical center num west numth street new york new york num
0.54427505.15198969.html.plaintext.txt	4	contribution estrogen prevention neurodegenerative disorder attracted considerable attention last year result conflicting data clinical trial shown protective effect postmenopausal estrogen based hormone replacement therapy hrt whereas others including recently concluded woman health initiative trial revealed significant benefit
0.54427505.15198969.html.plaintext.txt	5	although reason apparently discrepant result remains subject heated debate growing body evidence suggests individual woman may exhibit variable neuroprotective response hrt part interaction known risk factor neurodegenerative disease
0.54427505.15198969.html.plaintext.txt	6	one risk factor modulates effect hrt rate cognitive decline aging woman expression pattern allelic variant apolipoprotein e apoe
0.54427505.15198969.html.plaintext.txt	7	num issue endocrinology indicates may case
0.54427505.15198969.html.plaintext.txt	8	trophic effect natural ovarian estrogen estradiol numss neurite growth cultured mouse cerebral cortical neuron reported critically dependent apoe expression
0.54427505.15198969.html.plaintext.txt	9	moreover response estradiol numss shown dependent type apoe present whereas estradiol numss neurotrophic presence human apoe num apoe num apoe num variant associated progression late onset alzheimer disease support response
0.54427505.15198969.html.plaintext.txt	10	concept hrt might beneficial effect aging brain evolved initially study laboratory animal
0.54427505.15198969.html.plaintext.txt	11	almost num decade ago estradiol numss shown exert neurotrophic effect tissue explants derived developing mouse hypothalamus preoptic area num
0.54427505.15198969.html.plaintext.txt	12	synaptogenic effect estradiol numss later demonstrated occur adult brain including region brain hippocampus important cognitive function num num
0.54427505.15198969.html.plaintext.txt	13	various model neuronal damage natural synthetic estrogen reported enhance cell survival num whereas estradiol numss treatment shown enhance nonamyloidogenic processing alzheimer amyloid precursor protein num
0.54427505.15198969.html.plaintext.txt	14	estradiol numss also found positive effect maintenance neurotransmitter system undergo degeneration alzheimer disease num parkinson disease num
0.54427505.15198969.html.plaintext.txt	15	taken together observation provided strong mechanistic support concept postmenopausal hrt might slow prevent neurodegenerative process
0.54427505.15198969.html.plaintext.txt	16	clinical trial general provided mixed support hypothesis simultaneously highlighting potential health risk long term postmenopausal hrt use num num num num
0.54427505.15198969.html.plaintext.txt	17	part problem appears human being unlike laboratory animal effect hrt may confounded variety factor modulate oppose action hormone
0.54427505.15198969.html.plaintext.txt	18	one particularly important genetic factor appears expression pattern apoe
0.54427505.15198969.html.plaintext.txt	19	expression different apoe allele previously demonstrated affect risk atherosclerosis num well rate progression several human neurodegenerative disease num num including alzheimer dementia num
0.54427505.15198969.html.plaintext.txt	20	intriguingly pattern apoe expression also found significantly influence response hrt num
0.54427505.15198969.html.plaintext.txt	21	mechanism underlying interaction remained uncertain
0.54427505.15198969.html.plaintext.txt	22	one possibility might reflect known effect apoe expression atherosclerotic process num cerebral vascular compromise secondarily affecting rate cognitive decline num
0.54427505.15198969.html.plaintext.txt	23	alternative hypothesis however suggested study aimed elucidating effect estradiol numss apoe expression nerve cell
0.54427505.15198969.html.plaintext.txt	24	study mouse demonstrated expression apoe different brain region varied stage female reproductive cycle num consistent hypothesis estradiol numss might induce apoe expression brain already demonstrated apoe blood num
0.54427505.15198969.html.plaintext.txt	25	addition apoe num found produce effect like estradiol numss cultured neuron num
0.54427505.15198969.html.plaintext.txt	26	moreover neuroprotective effect estradiol numss abolished transgenic mouse homozygous deletion apoe gene num
0.54427505.15198969.html.plaintext.txt	27	observation raised possibility apoe might represent integral component mechanism mediating trophic response neuron estrogen exposure
0.54427505.15198969.html.plaintext.txt	28	num demonstrate indeed case
0.54427505.15198969.html.plaintext.txt	29	growth promoting effect estradiol numss depend expression apoe also highly dependent nature apoe subtype
0.54427505.15198969.html.plaintext.txt	30	cultured cell adult mouse cerebral cortex estradiol numss increased apoe level neurite outgrowth
0.54427505.15198969.html.plaintext.txt	31	hormone effect neurite outgrowth mouse lacking apoe gene apoe num exogenously supplied
0.54427505.15198969.html.plaintext.txt	32	apoe num apoe variant associated reduced risk alzheimer disease increased age onset increased neurite length apoe num presence estradiol numss
0.54427505.15198969.html.plaintext.txt	33	culture mouse transgenic human apoe num capable responding estradiol numss whereas mouse expressing apoe num relatively insensitive
0.54427505.15198969.html.plaintext.txt	34	similarly apoe num accumulated neuron greater extent apoe num effective facilitating neuronal uptake fatty acid
0.54427505.15198969.html.plaintext.txt	35	data consistent hypothesis apoe may play integral role supporting neurotrophic effect estradiol numss pattern apoe expression may profound impact sensitivity brain estrogen action
0.54427505.15198969.html.plaintext.txt	36	observation important implication future study effect hrt
0.54427505.15198969.html.plaintext.txt	37	expression specific apoe allele required estrogen exert neurotrophic neuroprotective effect pattern apoe allele expression likely important determining effectiveness estrogen based hrt
0.54427505.15198969.html.plaintext.txt	38	synergism apoe subtype expression effect hrt already demonstrated respect progression atherosclerosis postmenopausal woman estrogen use appears particularly beneficial patient apoe num allele num
0.54427505.15198969.html.plaintext.txt	39	situation may well true effect neurodegenerative process
0.54427505.15198969.html.plaintext.txt	40	num administered cognitive function test number year woman either taking estrogen based hrt taken hrt time past never used hrt
0.54427505.15198969.html.plaintext.txt	41	woman express apoe num variant postmenopausal estrogen use reduced risk age related cognitive impairment almost num compared woman never used estrogen
0.54427505.15198969.html.plaintext.txt	42	contrast apoe num positive woman show significant estrogen response num
0.54427505.15198969.html.plaintext.txt	43	data consistent hypothesis analysis apoe variant expression may predictive whether hrt likely long term beneficial cognitive effect
0.54427505.15198969.html.plaintext.txt	44	one key question remains answered extent data presented nathan et al
0.54427505.15198969.html.plaintext.txt	45	num extrapolated normal brain
0.54427505.15198969.html.plaintext.txt	46	used culture dispersed neuronal glial cell adult mouse cerebral cortex
0.54427505.15198969.html.plaintext.txt	47	important future determine whether effect estrogen aging brain involve comparable apoe dependent mechanism
0.54427505.15198969.html.plaintext.txt	48	published evidence consistent view effect estradiol numss recovery mature brain injury require apoe
0.54427505.15198969.html.plaintext.txt	49	thus mouse enhancement synaptic sprouting estradiol numss response entorhinal cortex lesion dependent apoe expression num
0.54427505.15198969.html.plaintext.txt	50	however neuronal damage perhaps including cellular damage inevitably incurred preparation primary cell culture may result reexpression estrogen receptor mechanism normally expressed development num
0.54427505.15198969.html.plaintext.txt	51	hence remains established whether finding extrapolated regulation neuronal growth survival uninjured brain
0.54427505.15198969.html.plaintext.txt	52	num dementia trauma degeneration repair may dynamic balance cognitive decline occurring degenerative process predominate
0.54427505.15198969.html.plaintext.txt	53	however significant trophic response estradiol numss also observed condition neurodegeneration probably minimal num num
0.54427505.15198969.html.plaintext.txt	54	response may contribute effect estrogen cognitive performance num
0.54427505.15198969.html.plaintext.txt	55	remains determined whether apoe involved trophic action estradiol numss normal physiological opposed pathological condition
0.54427505.15198969.html.plaintext.txt	56	second question apoe regulated steroid estradiol numss
0.54427505.15198969.html.plaintext.txt	57	wide range estrogen progestin used hrt postmenopausal woman num num
0.54427505.15198969.html.plaintext.txt	58	remains determined different steroid affect apoe expression
0.54427505.15198969.html.plaintext.txt	59	question specificity apoe response critical possibility combination hormonal agent could abrogate beneficial effect natural estrogen
0.54427505.15198969.html.plaintext.txt	60	example nilsen brinton num reported whereas progesterone num norprogesterone potentiate neuroprotective effect estradiol numss opposite effect observed medroxyprogesterone acetate synthetic progestin used woman health initiative trial
0.54427505.15198969.html.plaintext.txt	61	whether apoe expression affected steroid also important fact estradiol numss hormonal steroid neuroprotective neurotrophic property
0.54427505.15198969.html.plaintext.txt	62	recent work suggests androgen may confer protection neurodegenerative process
0.54427505.15198969.html.plaintext.txt	63	men higher free testosterone level appear lower risk developing alzheimer disease num whereas reduced level principal adrenal androgen dehydroepiandrosterone reported alzheimer disease patient num
0.54427505.15198969.html.plaintext.txt	64	laboratory study androgen progestin reported elicit neurotrophic neuroprotective effect variety experimental condition num num num
0.54427505.15198969.html.plaintext.txt	65	although case effect may involve either interaction estrogen intermediate estrogen biosynthesis others clearly num
0.54427505.15198969.html.plaintext.txt	66	intriguing hypothesis future study apoe expression may represent common link steroid activated neurotrophic response
0.54427505.15198969.html.plaintext.txt	67	effect androgen like estrogen may influenced apoe genotype
0.54427505.15198969.html.plaintext.txt	68	interestingly possibility already raised preliminary clinical study demonstrated interaction testosterone apoe num expression men alzheimer disease well association apoe num circulating testosterone level men without disease num
0.54427505.15198969.html.plaintext.txt	69	observation raise possibility relationship apoe expression gonadal steroid may multifactorial apoe num allele directly affecting risk neurodegenerative disease via effect neuronal growth survival well indirectly via reduction testicular androgen secretion
0.54427505.15198969.html.plaintext.txt	70	perhaps intriguing aspect observation nathan et al
0.54427505.15198969.html.plaintext.txt	71	num however potential development novel strategy replacement therapy designed directly target regulation neural apoe expression
0.54427505.15198969.html.plaintext.txt	72	adverse effect conventional hrt primarily associated response involve brain including alteration coagulation factor enhancing risk stroke well trophic effect reproductive organ resulting increased risk breast endometrial cancer num num
0.54427505.15198969.html.plaintext.txt	73	regulation apoe expression indeed critical component mechanism mediating neuroprotective response estradiol numss direct targeting apoe regulation brain might mimic beneficial central effect hormone without adverse risk associated conventional hrt
0.54427505.15198969.html.plaintext.txt	74	approach seems least potentially feasible receptor system mediating effect estrogen central apoe synthesis may well different found nonneural estrogen target organ
0.54427505.15198969.html.plaintext.txt	75	thus estradiol num estrogen weak systemic hormonal activity fully capable inducing apoe synthesis release mouse cerebral cortex cultured glial cell num num
0.54427505.15198969.html.plaintext.txt	76	better understanding molecular mechanism underlying effect estrogen apoe expression evolves may possible identify agent selectively regulate apoe expression brain significant adverse effect tissue elsewhere body
0.54427505.15198969.html.plaintext.txt	77	footnote abbreviation apoe apolipoprotein e hrt hormone replacement therapy
0.54427505.15198969.html.plaintext.txt	78	accepted publication april num num
0.976726.15003956.html.plaintext.txt	0	meta analysis association cathepsin d alanumval gene polymorphism risk alzheimer disease huge gene disease association review christos ntaisnum anastasia polycarpounum john p
0.976726.15003956.html.plaintext.txt	1	num clinical molecular epidemiology unit department hygiene epidemiology university ioannina school medicine ioannina greece
0.976726.15003956.html.plaintext.txt	2	num biomedical research institute foundation research technology hellas ioannina greece
0.976726.15003956.html.plaintext.txt	3	num institute clinical research health policy study department medicine tuft new england medical center tuft university school medicine boston ma
0.976726.15003956.html.plaintext.txt	4	received publication august num num accepted publication october num num
0.976726.15003956.html.plaintext.txt	5	alzheimer disease cathepsin d ctsd epidemiology genetics meta analysis polymorphism genetics
0.976726.15003956.html.plaintext.txt	6	abbreviation abbreviation ci confidence interval odds ratio
0.976726.15003956.html.plaintext.txt	7	molecular epidemiologic study presented seemingly contradictory result concerning potential role ctsd polymorphism alzheimer disease num num
0.976726.15003956.html.plaintext.txt	8	also controversy whether polymorphism may interact apolipoprotein e num allele apoenum best known genetic determinant sporadic alzhei mer disease num
0.976726.15003956.html.plaintext.txt	9	single study may underpowered detect interaction even overall effect
0.976726.15003956.html.plaintext.txt	10	given amount accumulated data deemed important perform quantitative synthesis evidence using rigorous method
0.976726.15003956.html.plaintext.txt	11	thus conducted comprehensive meta analysis available study relating ctsd polymorphism risk alzheimer disease
0.976726.15003956.html.plaintext.txt	12	case control study eligible determined distribution ctsd genotype alzheimer disease case regardless age onset concurrent control group dementia free subject using molecular method genotyping
0.976726.15003956.html.plaintext.txt	13	case alzheimer disease eligible regardless whether family history alzhei mer disease
0.976726.15003956.html.plaintext.txt	14	however excluded family based study pedigree several affected case per family analysis based linkage consideration
0.976726.15003956.html.plaintext.txt	15	data extraction two investigator independently extracted data reached consensus item
0.976726.15003956.html.plaintext.txt	16	following information sought report author journal year publication country origin selection characteristic alzheimer disease case control demographic ethnic group study population eligible genotyped case control number case control ctsd genotype
0.976726.15003956.html.plaintext.txt	17	study including subject different ethnic group data extracted separately ethnicity whenever possible
0.976726.15003956.html.plaintext.txt	18	furthermore examined whether matching used whether specific mention blinding personnel performed genotyping clinical status subject whether genotyping method validated
0.976726.15003956.html.plaintext.txt	19	meta analysis primary analysis compared alzheimer disease case control contrast versus c allele
0.976726.15003956.html.plaintext.txt	20	analysis aim detect overall difference
0.976726.15003956.html.plaintext.txt	21	also examined contrast extreme homozygote tt versus cc
0.976726.15003956.html.plaintext.txt	22	finally examined contrast tt versus ct cc contrast ct tt versus cc
0.976726.15003956.html.plaintext.txt	23	contrast correspond recessive dominant effect respectively allele
0.976726.15003956.html.plaintext.txt	24	odds ratio used metric choice
0.976726.15003956.html.plaintext.txt	25	genetic contrast estimated study heterogeneity across eligible comparison using chi square based q statistic num
0.976726.15003956.html.plaintext.txt	26	heterogeneity considered significant p num
0.976726.15003956.html.plaintext.txt	27	data combined using fixed effect mantel haenszel random effect dersimonian laird model num
0.976726.15003956.html.plaintext.txt	28	random effect incorporate estimate study variance tend provide wider confidence interval result constituent study differ among
0.976726.15003956.html.plaintext.txt	29	absence study heterogeneity two method provide identical result
0.976726.15003956.html.plaintext.txt	30	random effect appropriate heterogeneity present num
0.976726.15003956.html.plaintext.txt	31	also performed cumulative meta analysis num recursive cumulative meta analysis num num evaluate whether summary odds ratio versus c contrast changed time data accumulated whether strength association changed first hypothesis generating study excluded calculation num
0.976726.15003956.html.plaintext.txt	32	inverted funnel plot begg mazumdar publication bias diagnostic nonparametric correlation coefficient num evaluated whether magnitude observed association related variance study whether large study gave different result compared smaller one num
0.976726.15003956.html.plaintext.txt	33	finally evaluated whether summary result different analysis limited study intensive effort exclude alzheimer disease control clearly performed neuropsychological testing control
0.976726.15003956.html.plaintext.txt	34	previous investigation alluded possibility allele may interact apoenum allele conferring susceptibility alzheimer disease num num
0.976726.15003956.html.plaintext.txt	35	thus also evaluated effect allele carriage risk alzheimer disease separately apoenum positive apoenum negative subject
0.976726.15003956.html.plaintext.txt	36	moreover evaluated genetic effect conferred presence apoenum separately subject carrying allele carrying allele
0.976726.15003956.html.plaintext.txt	37	odds ratio combined fixed random effect model described
0.976726.15003956.html.plaintext.txt	38	data reported communicated primary investigator obtain information whenever possible
0.976726.15003956.html.plaintext.txt	39	analysis performed spss num
0.976726.15003956.html.plaintext.txt	40	chicago illinois meta analyst joseph lau boston massachusetts software
0.976726.15003956.html.plaintext.txt	41	whenever num value num x num table added num
0.976726.15003956.html.plaintext.txt	42	num four cell odds ratio could calculated
0.976726.15003956.html.plaintext.txt	43	characteristic study included meta analysis specific matching age described five study num num num
0.976726.15003956.html.plaintext.txt	44	one study also matched sex num
0.976726.15003956.html.plaintext.txt	45	one study num specifically mentioned blinding personnel performed genotyping
0.976726.15003956.html.plaintext.txt	46	appropriate molecular method genotyping used
0.976726.15003956.html.plaintext.txt	47	study used polymerase chain reaction two study num num also used dynamic allele specific hybridization
0.976726.15003956.html.plaintext.txt	48	meta analysis database eligible study summarized table num included total numnum case alzheimer disease numnum control numnum numnum respectively genotype data
0.976726.15003956.html.plaintext.txt	49	allele highly represented among control american descent overall prevalence num
0.976726.15003956.html.plaintext.txt	50	num percent num percent confidence interval ci num
0.976726.15003956.html.plaintext.txt	51	num control european num
0.976726.15003956.html.plaintext.txt	52	significant heterogeneity prevalence rate allele even across control subject european descent rate num
0.976726.15003956.html.plaintext.txt	53	num percent among hispanic american num
0.976726.15003956.html.plaintext.txt	54	num percent spain lower rate northern european country num
0.976726.15003956.html.plaintext.txt	55	num percent united kingdom num
0.976726.15003956.html.plaintext.txt	56	num percent germany lowest prevalence rate num
0.976726.15003956.html.plaintext.txt	57	num percent polish population
0.976726.15003956.html.plaintext.txt	58	overall prevalence tt homozygosity num
0.976726.15003956.html.plaintext.txt	59	num percent control subject american european asian descent respectively
0.976726.15003956.html.plaintext.txt	60	respective prevalence rate ct heterozygosity num
0.976726.15003956.html.plaintext.txt	61	num percent respective rate cc homozygosity num
0.976726.15003956.html.plaintext.txt	62	distribution genotype control group consistent hardy weinberg equilibrium study
0.976726.15003956.html.plaintext.txt	63	distribution ctsd allele among alzheimer disease case control included study overall effect trend suggesting allele may confer increased susceptibility alzheimer disease figure num
0.976726.15003956.html.plaintext.txt	64	shown table num summary odds ratio num
0.976726.15003956.html.plaintext.txt	65	num significant heterogeneity among num study comparison p num
0.976726.15003956.html.plaintext.txt	66	found evidence association tt genotype risk alzheimer disease relative cc genotype
0.976726.15003956.html.plaintext.txt	67	significant study heterogeneity
0.976726.15003956.html.plaintext.txt	68	evidence association alzhei mer disease discerned also recessive model examined effect trend association seen dominant model random effect num
0.976726.15003956.html.plaintext.txt	69	study heterogeneity recessive model contrast significant heterogeneity p num
0.976726.15003956.html.plaintext.txt	70	num still seen dominant model contrast
0.976726.15003956.html.plaintext.txt	71	subgroup analysis study case control european descent yielded similar result num comparison numnum allele num
0.976726.15003956.html.plaintext.txt	72	view larger version numk figure num
0.976726.15003956.html.plaintext.txt	73	meta analysis effect allele versus c allele risk alzheimer disease
0.976726.15003956.html.plaintext.txt	74	comparison presented name first author year publication
0.976726.15003956.html.plaintext.txt	75	h signifies hispanic subject j signifies japanese subject
0.976726.15003956.html.plaintext.txt	76	comparison point estimate odds ratio accompanying num confidence interval ci shown
0.976726.15003956.html.plaintext.txt	77	represents summary random effect estimate comparison along respective num confidence interval
0.976726.15003956.html.plaintext.txt	78	value num denote increased risk alzheimer disease allele
0.976726.15003956.html.plaintext.txt	79	summary odds ratio various contrast bias diagnostics cumulative meta analysis recursive cumulative meta analysis magnitude summary odds ratio stable time changed considerably per year apparent dissipation postulated effect random effect summary v
0.976726.15003956.html.plaintext.txt	80	excluding first hypothesis generating study num found summary odds ratio became num
0.976726.15003956.html.plaintext.txt	81	num significant study heterogeneity p num
0.976726.15003956.html.plaintext.txt	82	num evidence association even comparison homozygote tt v
0.976726.15003956.html.plaintext.txt	83	num study heterogeneity
0.976726.15003956.html.plaintext.txt	84	relation effect size variance study suggesting larger study agreed result smaller study
0.976726.15003956.html.plaintext.txt	85	analysis limited study intensive effort exclude alzheimer disease control yielded similar result num comparison numnum allele num
0.976726.15003956.html.plaintext.txt	86	interaction apoe genotype nine study num num num num num num obtained data ctsd apoe genotype
0.976726.15003956.html.plaintext.txt	87	one study num separating male female subject num comparison became available
0.976726.15003956.html.plaintext.txt	88	nine comparative study tended gave slightly inflated effect allele compared full meta analysis num comparison summary random effect num
0.976726.15003956.html.plaintext.txt	89	num complete meta analysis thus inference cautious
0.976726.15003956.html.plaintext.txt	90	among carrier high risk apoenum allele allele carrier random effect odds ratio num
0.976726.15003956.html.plaintext.txt	91	num alzheimer disease compared subject carrying allele
0.976726.15003956.html.plaintext.txt	92	among subject carrying apoenum allele respective odds ratio num
0.976726.15003956.html.plaintext.txt	93	significant study heterogeneity apoenum positive group p num
0.976726.15003956.html.plaintext.txt	94	two effect size overlapped widely
0.976726.15003956.html.plaintext.txt	95	among carrier allele presence apoenum increased risk alzheimer disease num
0.976726.15003956.html.plaintext.txt	96	num study heterogeneity
0.976726.15003956.html.plaintext.txt	97	among subject without allele presence apoenum increased risk alzheimer disease num
0.976726.15003956.html.plaintext.txt	98	num significant study heterogeneity p num
0.976726.15003956.html.plaintext.txt	99	two estimate overlapped widely individual study overall typically odds ratio larger group allele carrier figure num
0.976726.15003956.html.plaintext.txt	100	meta analysis finding may interpreted postulated biologic context ctsd polymorphism
0.976726.15003956.html.plaintext.txt	101	cathepsin d intracellular acid protease beta secretase activity vitro num num cleave amyloid precursor protein tau protein generate fragment intact microtubule binding domain num might play role pathogenesis paired helical filament
0.976726.15003956.html.plaintext.txt	102	one study shown ctsd polymorphism associated increased secretion altered intracellular maturation procathepsin d num
0.976726.15003956.html.plaintext.txt	103	noted clear whether ctsd polymorphism functional consequence mature form enzyme
0.976726.15003956.html.plaintext.txt	104	although exclude biologic effect ctsd polymorphism finding accordance result recent full genome scan showing significant linkage alzheimer disease short arm chromosome num region ctsd gene located num num
0.976726.15003956.html.plaintext.txt	105	attention given design individual study
0.976726.15003956.html.plaintext.txt	106	result meta analysis may affected methodological problem potential bias design constituent study
0.976726.15003956.html.plaintext.txt	107	nondifferential misclassification error may dilute strength observed association
0.976726.15003956.html.plaintext.txt	108	alzheimer disease case generally selected according appropriate criterion
0.976726.15003956.html.plaintext.txt	109	however young control subject may developed alzheimer disease older age
0.976726.15003956.html.plaintext.txt	110	choice appropriate age window assessing postulated genetic risk factor alzheimer disease difficult
0.976726.15003956.html.plaintext.txt	111	study younger subject may suitable identifying risk factor result early onset alzhei mer disease
0.976726.15003956.html.plaintext.txt	112	conversely selection younger subject may le appropriate influence postulated genetic risk factor important late onset alzhei mer disease
0.976726.15003956.html.plaintext.txt	113	subgroup effect effect modification e
0.976726.15003956.html.plaintext.txt	114	differential effect genetic polymorphism early v
0.976726.15003956.html.plaintext.txt	115	late onset alzheimer disease case familial v
0.976726.15003956.html.plaintext.txt	116	sporadic disease complex interaction gene may also need considered num
0.976726.15003956.html.plaintext.txt	117	analysis addressed interaction apoenum major known genetic determinant alzhei mer disease
0.976726.15003956.html.plaintext.txt	118	interaction genetic environmental factor studied
0.976726.15003956.html.plaintext.txt	119	trend stronger effect apoenum presence allele carriage interesting light data suggesting carriage may affect general intelligence num
0.976726.15003956.html.plaintext.txt	120	however subgroup interaction analysis interpreted cautiously since difference subgroup may occur chance num validation would require study even larger sample size several thousand included meta analysis
0.976726.15003956.html.plaintext.txt	121	finally population stratification may theoretically affected result constituent study meta analysis num since documented frequency allele varied considerably among different ethnic group even among different ethnic group european descent
0.976726.15003956.html.plaintext.txt	122	however study strictly ethnically defined population stratification effect unlikely considerable magnitude
0.976726.15003956.html.plaintext.txt	123	increasing prevalence alzheimer disease worldwide crucial identify genetic risk factor neurodegenerative disease
0.976726.15003956.html.plaintext.txt	124	thus list identified polymorphism may influence risk alzheimer disease continuously expanding num num reported association candidate gene date remain nonreplicated least controversial subsequent investigation
0.976726.15003956.html.plaintext.txt	125	early small genetic association study may come spurious finding num num num
0.976726.15003956.html.plaintext.txt	126	even genetic association replicated usually major public health impact would lead screening recommendation num
0.976726.15003956.html.plaintext.txt	127	nevertheless knowledge could improve understanding pathogenesis complex disease alzheimer disease
0.976726.15003956.html.plaintext.txt	128	acknowledgment author thank jonathan
0.976726.15003956.html.plaintext.txt	129	prince patrizia mecocci anthony j
0.976726.15003956.html.plaintext.txt	130	brooke providing additional data study
0.976726.15003956.html.plaintext.txt	131	note correspondence dr
0.976726.15003956.html.plaintext.txt	132	ioannidis department hygiene epidemiology university ioannina school medicine ioannina num greece e mail jioannidatcc
